,Unnamed: 0,Title,Status,Interventions,Gender,Age,Phases,Enrollment,Start.Date,Completion.Date,Last.Update.Posted,Locations,URL,MapCountry,Drugonly,Month,Completion.Year,day_of_week
0,1,Duvelisib to Combat COVID-19,Recruiting,Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,28.0,"October 12, 2020",2022-04-30,"November 9, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04372602,United States,Duvelisib|Placebo,4.0,2022,Saturday
1,2,Observational Cohort of COVID-19 Patients at Raymond-Poincare,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"May 7, 2020",2020-06-01,"May 14, 2020","Department of Infectiology, Raymond Poincaré Hospital, APHP, Garches, France",https://ClinicalTrials.gov/show/NCT04364698,France,,6.0,2020,Monday
2,3,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Recruiting,Drug: Decitabine|Other: Placebo Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"September 14, 2020",2021-07-01,"September 25, 2020","Johns Hopkins University, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04482621,United States,Decitabine,7.0,2021,Thursday
3,4,COVID-19 Surveillance Based on Smart Wearable Device,Not yet recruiting,,All,"18 Years to 75 Years   (Adult, Older Adult)",,200.0,"July 1, 2020",2021-03-10,"July 7, 2020","Peking University First Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04459637,China,,3.0,2021,Wednesday
4,5,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Recruiting,Drug: Infliximab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,17.0,"June 1, 2020",2020-12-01,"June 11, 2020","Tufts Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04425538,United States,Infliximab,12.0,2020,Tuesday
5,6,Safety & Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19,Not yet recruiting,Device: Seraph 100,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,42.0,"December 15, 2020",2021-04-15,"November 27, 2020","Carla Kikken-Jussen, Vaals, Limburg, Netherlands",https://ClinicalTrials.gov/show/NCT04547257,Netherlands,,4.0,2021,Thursday
6,7,Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients,Not yet recruiting,Drug: Tramadol|Other: Standard care delivered in the isolation hospitals.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,100.0,July 2020,2020-10-01,"July 2, 2020",,https://ClinicalTrials.gov/show/NCT04454307,Undefined,Tramadol,10.0,2020,Thursday
7,8,Safety and Efficacy of C21 in Subjects With COVID-19,Completed,Drug: C21|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,106.0,"July 21, 2020",2020-10-13,"October 20, 2020","Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India|Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India|Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India|First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India|Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India|Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India|Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India|Respiratory Medicine, University College Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04452435,India,C21|Placebo,10.0,2020,Tuesday
8,9,Application of Desferal to Treat COVID-19,Recruiting,Drug: Deferoxamine,All,"3 Years to 99 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,50.0,April 2020,2021-03-01,"May 4, 2020","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04333550,"Iran, Islamic Republic of",Deferoxamine,3.0,2021,Monday
9,10,Dornase Alpha for the Treatment of COVID-19,Recruiting,Drug: Pulmozyme,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 25, 2020",2020-09-25,"June 16, 2020","Acıbadem Altunizade Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04432987,Turkey,Pulmozyme,9.0,2020,Friday
10,11,Impact of COVID-19 Outbreak on Non-COVID-19 Patients,Enrolling by invitation,,All,"16 Years and older   (Child, Adult, Older Adult)",,40000.0,"March 1, 2020",2020-10-31,"September 7, 2020","Geneva University Hospital, Geneva, Canton De Genève, Switzerland",https://ClinicalTrials.gov/show/NCT04537559,Switzerland,,10.0,2020,Saturday
11,12,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Not yet recruiting,Drug: Nafamostat Mesilate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"November 20, 2020",2021-06-30,"November 13, 2020",,https://ClinicalTrials.gov/show/NCT04628143,Undefined,Nafamostat Mesilate,6.0,2021,Wednesday
12,13,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"Active, not recruiting",Drug: Favipiravir|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100.0,"March 25, 2020",2020-07-01,"April 8, 2020","Asst Fatebenefratelli Sacco, Milano, Italy",https://ClinicalTrials.gov/show/NCT04336904,Italy,Favipiravir,7.0,2020,Wednesday
13,14,Study of AZD1222 for the Prevention of COVID-19 in Japan,"Active, not recruiting",Drug: AZD1222|Drug: 0.9% (w/v) saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,256.0,"August 23, 2020",2021-11-10,"December 3, 2020","Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Toshima-ku, Japan",https://ClinicalTrials.gov/show/NCT04568031,Japan,AZD1222|0.9% (w/v) saline,11.0,2021,Wednesday
14,15,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,Recruiting,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"May 22, 2020",2020-08-22,"June 24, 2020","Hospital Universitario de Cabueñes, Gijón, Asturias, Spain|Hospital Universitario Central Asturias, Oviedo, Asturias, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Sant Joan de Déu de Manresa, Manresa, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Hospital Universitario Marqués Valdecilla, Santander, Cantabria, Spain|Hospital Público General del Tomelloso, Tomelloso, Ciudad Real, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera, Cádiz, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Nuestra Señora del Prado, Talavera De La Reina, Toledo, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Clínic i Provincial Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital San Pedro Alcántara, Cáceres, Spain|Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitario Clínico San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Poliectenic La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT04445272,China,Tocilizumab,8.0,2020,Saturday
15,16,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,Recruiting,Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,131.0,"May 11, 2020",2023-05-01,"May 13, 2020","Froedtert Hospital, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04354831,United States,,5.0,2023,Monday
16,17,PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US,Not yet recruiting,Drug: Remdesivir,Female,"Child, Adult, Older Adult",,40.0,"October 15, 2020",2022-01-15,"October 9, 2020","USC/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States|University California, San Diego (CRS 4601), San Diego, California, United States|Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States|University of Florida (5051), Jacksonville, Florida, United States|Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Ann & Robert H Lurie Children's Hospital of Chicago (4001), Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|University of Puerto Rico Pediatric HIV/AIDS CRS (6601), San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04582266,Georgia,Remdesivir,1.0,2022,Saturday
17,18,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,Recruiting,Diagnostic Test: Lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",,180.0,"May 11, 2020",2021-01-20,"December 4, 2020","Derriford Hospital, Plymouth, Devon, United Kingdom",https://ClinicalTrials.gov/show/NCT04351802,United Kingdom,,1.0,2021,Wednesday
18,19,AZD1222 Vaccine for the Prevention of COVID-19,Suspended,Biological: AZD1222,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,100.0,"September 2, 2020",2021-03-12,"November 16, 2020","Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04540393,Russian Federation,,3.0,2021,Friday
19,20,Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,Not yet recruiting,Drug: Tocilizumab|Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310.0,"April 15, 2020",2020-10-31,"April 14, 2020","University Malaya Medical Centre, Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04345445,Malaysia,Tocilizumab|Methylprednisolone,10.0,2020,Saturday
20,21,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1200.0,"August 18, 2020",2021-02-28,"September 30, 2020","Clinica santa Maria del lago, Bogota, DC, Colombia|Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",https://ClinicalTrials.gov/show/NCT04359095,Colombia,Emtricitabine/tenofovir|Colchicine Pill|Rosuvastatin,2.0,2021,Sunday
21,22,Long-term Outcomes in Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,900.0,"August 10, 2020",2021-08-31,"October 23, 2020","Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong, Shanghai, China",https://ClinicalTrials.gov/show/NCT04508712,China,,8.0,2021,Tuesday
22,23,Isotretinoin in Treatment of COVID-19,Not yet recruiting,Drug: Isotretinoin Only Product in Oral Dose Form,All,18 Years to 40 Years   (Adult),Phase 3,300.0,"December 1, 2020",2021-12-01,"September 23, 2020",,https://ClinicalTrials.gov/show/NCT04361422,Undefined,Isotretinoin Only Product in Oral Dose Form,12.0,2021,Wednesday
23,24,Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic,Not yet recruiting,Drug: Convalescent Plasma Transfusion|Drug: Hydroxychloroquine|Drug: DAS181|Drug: Ivermectin|Drug: Interferon Beta-1A,All,"1 Year and older   (Child, Adult, Older Adult)",,200.0,"July 25, 2020",2020-09-20,"July 7, 2020",,https://ClinicalTrials.gov/show/NCT04460547,Undefined,Convalescent Plasma Transfusion|Hydroxychloroquine|DAS181|Ivermectin|Interferon Beta-1A,9.0,2020,Sunday
24,25,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",Completed,Other: Exposure,All,"18 Years and older   (Adult, Older Adult)",,115.0,"April 20, 2020",2020-07-16,"August 25, 2020","Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário São João, Oporto, Portugal",https://ClinicalTrials.gov/show/NCT04355741,Portugal,,7.0,2020,Thursday
25,26,Inhaled Nitric Oxide for Preventing Progression in COVID-19,Recruiting,Drug: Nitric Oxide,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,42.0,"May 12, 2020",2021-07-31,"May 18, 2020","Tufts Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04388683,United States,Nitric Oxide,7.0,2021,Saturday
26,27,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",Recruiting,Drug: AZD7442|Drug: Placebo,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,1125.0,"December 2, 2020",2022-01-04,"December 10, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Guntersville, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Corona, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Modesto, California, United States|Research Site, Sacramento, California, United States|Research Site, Coral Springs, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Buford, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Oak Park, Illinois, United States|Research Site, Greenwood, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Arlington, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Waxahachie, Texas, United States|Research Site, Riverton, Utah, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Hull, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Wakefield, United Kingdom",https://ClinicalTrials.gov/show/NCT04625972,Georgia,AZD7442|Placebo,1.0,2022,Tuesday
27,28,Developement and Evaluation of Serological Assays for COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"July 15, 2020",2020-12-01,"August 19, 2020","Laboratory of microbiology of hospital hygiene, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France",https://ClinicalTrials.gov/show/NCT04377763,France,,12.0,2020,Tuesday
28,29,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Recruiting,Dietary Supplement: Quercetin Phytosome,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"October 29, 2020",2021-06-28,"October 30, 2020","Liaquat University Hospital, Jāmshoro, Sindh, Pakistan",https://ClinicalTrials.gov/show/NCT04578158,Pakistan,,6.0,2021,Monday
29,30,Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19,Not yet recruiting,Drug: Lactoferrin,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,150.0,June 2020,2020-11-01,"June 9, 2020",,https://ClinicalTrials.gov/show/NCT04421534,Undefined,Lactoferrin,11.0,2020,Sunday
30,31,A Trial of NT-I7 in COVID-19 (SPESELPIS),Recruiting,Drug: Double-Blind NT-I7|Drug: Double-Blind Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,30.0,August 2020,2021-12-01,"August 6, 2020","Nih/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",https://ClinicalTrials.gov/show/NCT04501796,United States,Double-Blind NT-I7|Double-Blind Placebo,12.0,2021,Wednesday
31,32,Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19,Not yet recruiting,Biological: autologous adipose-derived stem cells,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"January 10, 2021",2024-01-10,"November 9, 2020",,https://ClinicalTrials.gov/show/NCT04428801,Undefined,,1.0,2024,Wednesday
32,33,COVID-19 Symptom Tracker,Recruiting,Other: No Intervention,All,"18 Years and older   (Adult, Older Adult)",,10000000.0,"March 23, 2020",2022-03-23,"April 7, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04331509,United Kingdom,,3.0,2022,Wednesday
33,34,Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,Recruiting,Device: olfactory device,All,"18 Years and older   (Adult, Older Adult)",,250.0,"June 15, 2020",2020-10-01,"August 4, 2020","Yale New Haven Hospital, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04431908,United States,,10.0,2020,Thursday
34,35,COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics),Completed,Diagnostic Test: ELISA|Diagnostic Test: RT-PCR,All,"18 Years and older   (Adult, Older Adult)",,340.0,"June 8, 2020",2020-08-25,"September 14, 2020","Boston IVF Fertility Clinic, Boston, Massachusetts, United States|Utah Fertility Clinic, Pleasant Grove, Utah, United States",https://ClinicalTrials.gov/show/NCT04466644,United States,,8.0,2020,Tuesday
35,36,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,Not yet recruiting,Device: Hyperbaric Oxygen Therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48.0,April 2020,2020-06-01,"April 13, 2020","Ochsner Medical Center, New Orleans, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04343183,United States,,6.0,2020,Monday
36,37,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",Recruiting,Drug: AZD7442|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,5000.0,"November 21, 2020",2022-02-03,"December 10, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Cerritos, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fresno, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Lancaster, California, United States|Research Site, Modesto, California, United States|Research Site, Victorville, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Middlebury, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Wesley Chapel, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Noblesville, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Jamaica, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Alken, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozée, Belgium|Research Site, Namur, Belgium|Research Site, Wetteren, Belgium|Research Site, Clermont-Ferrand cedex, France|Research Site, Dijon cedex, France|Research Site, La Roche S/ Yon Cedex 9, France|Research Site, Lille, France|Research Site, Limoges cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Nimes, France|Research Site, Paris cedex 10, France|Research Site, Paris cedex 14, France|Research Site, Saint Etienne Cedex 2, France|Research Site, Tours cedex 9, France|Research Site, Alcobendas, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella (Málaga), Spain|Research Site, Pozuelo de Alarcón, Spain|Research Site, Enfield, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, London, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Rochdale, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Torpoint, United Kingdom|Research Site, Wakefield, United Kingdom",https://ClinicalTrials.gov/show/NCT04625725,Belgium,AZD7442|Placebo,2.0,2022,Thursday
37,38,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,Recruiting,Drug: Clevudine|Drug: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 6, 2020",2020-12-31,"June 30, 2020","Korea University Guro Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04347915,"Korea, Republic of",Clevudine|Placebo,12.0,2020,Thursday
38,39,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,3170.0,"April 3, 2020",2021-03-30,"April 9, 2020","Charing Cross Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04333407,United Kingdom,Aspirin 75mg|Clopidogrel 75mg|Rivaroxaban 2.5 MG|Atorvastatin 40mg|Omeprazole 20mg,3.0,2021,Tuesday
39,40,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),Recruiting,Drug: Aprepitant injectable emulsion|Drug: Saline Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"July 20, 2020",2021-03-01,"November 12, 2020","Helen Keller Hospital, Sheffield, Alabama, United States|University of California, Irvine Medical Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States|Ponce Medical School Foundation, Ponce, Puerto Rico",https://ClinicalTrials.gov/show/NCT04470622,Puerto Rico,Aprepitant injectable emulsion|Saline Placebo,3.0,2021,Monday
40,41,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Not yet recruiting,Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"August 15, 2020",2021-02-01,"July 31, 2020","Ohio State University, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04452669,United States,VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),2.0,2021,Monday
41,42,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),Recruiting,Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban,All,"18 Years and older   (Adult, Older Adult)",Phase 4,186.0,"October 13, 2020",2021-06-01,"October 20, 2020","Weill Cornell Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04406389,United States,Enoxaparin sodium|Unfractionated heparin|Fondapariniux|Argatroban,6.0,2021,Tuesday
42,43,The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19,Not yet recruiting,Drug: Huaier Granule,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,550.0,"April 1, 2020",2020-09-01,"March 17, 2020",,https://ClinicalTrials.gov/show/NCT04291053,Undefined,Huaier Granule,9.0,2020,Tuesday
43,44,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Completed,,All,"Child, Adult, Older Adult",,74.0,"May 14, 2020",2020-10-12,"October 30, 2020","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",https://ClinicalTrials.gov/show/NCT04610554,Italy,,10.0,2020,Monday
44,45,COVID-19 Endoscopy Survey,Completed,Other: Practice details,All,"30 Years to 70 Years   (Adult, Older Adult)",,163.0,"April 10, 2020",2020-05-01,"May 20, 2020","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04342637,Egypt,,5.0,2020,Friday
45,46,COVID-19 Convalescent Plasma (CCP) Transfusion,Recruiting,Biological: COVID Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,100.0,"June 1, 2020",2022-05-31,"July 2, 2020","University of Mississippi Medical Center, Jackson, Mississippi, United States",https://ClinicalTrials.gov/show/NCT04412486,United States,,5.0,2022,Tuesday
46,47,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,"Active, not recruiting",Biological: Ad5-nCoV,All,"18 Years and older   (Adult, Older Adult)",Phase 1,149.0,"September 29, 2020",2021-06-30,"December 7, 2020","Zhongnan Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04552366,China,,6.0,2021,Wednesday
47,48,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Recruiting,Device: oxyhydrogen|Device: Oxygen,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,100.0,"February 15, 2020",2020-08-01,"April 7, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04336462,China,,8.0,2020,Saturday
48,49,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Recruiting,Drug: Lambda 180 mcg S.C,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"August 5, 2020",2021-12-31,"September 1, 2020","Soroka UMC, Be'er Sheva, Israel",https://ClinicalTrials.gov/show/NCT04534673,Israel,Lambda 180 mcg S.C,12.0,2021,Friday
49,50,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Recruiting,Drug: ABX464|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1034.0,"May 1, 2020",2021-04-30,"July 20, 2020","Centre hospitalier Saint Pierre, Brussels, Belgium|Hôpital Erasme, Brussels, Belgium|UZ Gent, Gent, Belgium|Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema, Manaus, Amazonas, Brazil|Centro Oncológico de Roraima - CECOR - NAP, Boa Vista, Roraima, Brazil|Hospital das Clinicas da FMUSP, São Paulo, Sao Paulo, Brazil|Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro, Rio De Janeiro, Brazil|Conjunto Hospitalar do Mandaqui, Sao Paulo, Brazil|Hôpital Nord, Amiens, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|Centre Hospitalier Universitaire de Nice, Nice, France|Hôpital Saint-Antoine, Paris, France|Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid, Mannheim, Baden-Württemberg, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases, Milano, Lombardia, Italy|Ospedale San Paolo, Milano, Lombardia, Italy|Ospedale Luigi Sacco, AO-PU, Milano, Lombardia, Italy|Ospedale di Vittorio Veneto - Medecina generale, Vittorio Veneto, Treviso, Italy|Ospedale A. Manzonidi Lecco - ASST Lecco, Lecco, Italy|Ospedale Niguarda, Milano, Italy|Consultorio médico, Mérida, Yucatan, Mexico|Centro de Prevención y Rehabilitación de Enfermedades Pulmon, Nuevo León, Mexico|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|H.G.U. Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Royal Free Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04393038,Belgium,ABX464|Placebo,4.0,2021,Friday
50,51,Setting up a COVID-19 Care Facility at a Prison in Pakistan,Completed,Other: COVID-19 FACILITY,All,"Child, Adult, Older Adult",,69.0,"March 27, 2020",2020-05-02,"May 29, 2020","Camp Jail / COVID-19 CARE FACILITY/ SIMS, Lahore, Pakistan",https://ClinicalTrials.gov/show/NCT04404179,Pakistan,,5.0,2020,Saturday
51,52,Serological Surveillance for COVID-19 in Central North Carolina,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"August 24, 2020",2022-06-01,"December 7, 2020","NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04490174,United States,,6.0,2022,Wednesday
52,53,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Drug: Melatonin|Other: Placebo (Methylcellulose) capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"November 6, 2020",2021-03-31,"November 10, 2020","University at Buffalo, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT04474483,United States,Melatonin,3.0,2021,Wednesday
53,54,The Role of Resistant Starch in COVID-19 Infection,Recruiting,Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch,All,"19 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"June 3, 2020",2021-06-01,"June 17, 2020","Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04342689,United States,Dietary Supplement containing resistant starch,6.0,2021,Tuesday
54,55,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,Recruiting,Drug: Tocilizumab|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,332.0,"September 10, 2020",2021-03-01,"September 23, 2020","University of Chicago Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04479358,United States,Tocilizumab,3.0,2021,Monday
55,56,Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),Completed,,All,"Child, Adult, Older Adult",,1526.0,"May 7, 2020",2020-08-25,"October 9, 2020","Igenomix, Paterna, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04389658,Spain,,8.0,2020,Tuesday
56,57,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,Recruiting,Drug: FT516,All,"18 Years to 76 Years   (Adult, Older Adult)",Phase 1,12.0,"May 14, 2020",2022-01-01,"May 18, 2020","University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04363346,United States,FT516,1.0,2022,Saturday
57,58,C5a Receptor Expression - COVID-19 (C5-COV),Recruiting,Other: draw blood,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"March 31, 2020",2020-11-01,"May 4, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04369820,France,,11.0,2020,Sunday
58,59,TXA127 for the Treatment of Severe COVID-19,Recruiting,Drug: TXA127|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,August 2020,2021-12-01,"August 20, 2020","Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04401423,United States,TXA127|Placebo,12.0,2021,Wednesday
59,60,Relation Between Lab Finding and COVID-19 Severity,Not yet recruiting,"Diagnostic Test: D-dimer,CBC.ESR,CRP,|Diagnostic Test: Liver function tests ,serum ferritin and PCR for COVID-19 .",All,"Child, Adult, Older Adult",,100.0,"July 15, 2020",2020-12-01,"July 14, 2020",,https://ClinicalTrials.gov/show/NCT04470557,Undefined,,12.0,2020,Tuesday
60,61,Genosvid Diagnostic Test for Early Detection of COVID-19,Recruiting,Other: exhaled breath sampling,All,"4 Years and older   (Child, Adult, Older Adult)",Not Applicable,1543.0,"April 1, 2020",2020-12-31,"December 9, 2020","RS Bhayangkara Tk I R.Said Soekanto, Jakarta, Indonesia|RST Tk II Dr Soejono, Magelang, Indonesia|Saiful Anwar, Malang, Indonesia|Dr Sardjito Hospital, Yogyakarta, Indonesia|Bambanglipuro Hospital, Yogyakarta, Indonesia|Bhayangkara Tk III Polda DIY, Yogyakarta, Indonesia|RS Akademik UGM, Yogyakarta, Indonesia|RSPAU Hardjolukito, Yogyakarta, Indonesia|RST Tk III Dr Soetarto, Yogyakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04558372,Indonesia,,12.0,2020,Thursday
61,62,Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19,Not yet recruiting,Drug: Placebo|Drug: Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,51.0,"October 20, 2020",2021-06-20,"August 14, 2020","Hospital San José, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04514302,Mexico,Placebo|Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS),6.0,2021,Sunday
62,63,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Recruiting,Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,200.0,"April 1, 2020",2020-11-01,"November 3, 2020","Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04392141,"Iran, Islamic Republic of",Standard Treatment|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,11.0,2020,Sunday
63,64,Online Learning of Veterinary Anatomy During COVID-19 Pandemic,Recruiting,Other: survey,All,"17 Years to 35 Years   (Child, Adult)",,400.0,"June 5, 2020",2020-11-05,"October 20, 2020","South Valley University, Qinā, Egypt",https://ClinicalTrials.gov/show/NCT04418284,Egypt,,11.0,2020,Thursday
64,65,Vitamin D Supplementation in Patients With COVID-19,Completed,Dietary Supplement: Vitamin D|Dietary Supplement: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240.0,"June 1, 2020",2020-10-07,"November 17, 2020","Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04449718,Brazil,,10.0,2020,Wednesday
65,66,DAS181 for Severe COVID-19: Compassionate Use,Completed,Drug: DAS181,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,4.0,"March 6, 2020",2020-04-30,"May 5, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04324489,China,DAS181,4.0,2020,Thursday
66,67,Multi-site Adaptive Trials for COVID-19,Completed,Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,233.0,"April 7, 2020",2020-09-07,"December 11, 2020","Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States",https://ClinicalTrials.gov/show/NCT04370262,United States,SOC + Intravenous Famotidine|SOC + Placebo,9.0,2020,Monday
67,68,VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 22, 2020",2023-05-20,"October 14, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04587323,United States,,5.0,2023,Saturday
68,69,"A Prospective ""Universal"" Observational Database for COVID-19",Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"March 27, 2020",2021-04-01,"April 24, 2020","Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04347993,Jersey,,4.0,2021,Thursday
69,70,Expanded Access to Convalescent Plasma for Treatment of COVID-19,Available,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",,,,,"September 1, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04472572,Jersey,,,n,
70,71,Genetic Bases of COVID-19 Clinical Variability,Recruiting,Genetic: Massive parallel sequencing of host genome,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"April 8, 2020",2026-04-08,"September 17, 2020","University of Siena, Siena, Italy",https://ClinicalTrials.gov/show/NCT04549831,Italy,,4.0,2026,Wednesday
71,72,COVID-19 Infection in Healthcare Workers,Not yet recruiting,Other: Cohort,All,"18 Years and older   (Adult, Older Adult)",,6000.0,May 2020,2020-10-01,"May 13, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",https://ClinicalTrials.gov/show/NCT04386759,France,,10.0,2020,Thursday
72,73,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,Not yet recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"August 20, 2020",2020-12-31,"August 12, 2020","Hospital Nacional Hipolito Unanue, Lima, Peru",https://ClinicalTrials.gov/show/NCT04497324,Peru,,12.0,2020,Thursday
73,74,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Not yet recruiting,Drug: Standard of care|Drug: Apremilast|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,700.0,"November 30, 2020",2021-08-15,"November 27, 2020",,https://ClinicalTrials.gov/show/NCT04590586,Undefined,Standard of care|Apremilast|Placebo,8.0,2021,Sunday
74,75,Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children,Not yet recruiting,,All,up to 17 Years   (Child),,20.0,June 2020,2020-12-01,"June 9, 2020","Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Armand Trousseau, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Robert Debré, Paris, France",https://ClinicalTrials.gov/show/NCT04420468,France,,12.0,2020,Tuesday
75,76,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Recruiting,Dietary Supplement: Oral supplement enriched in antioxidants|Dietary Supplement: cellulose-containing placebo capsules,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,40.0,"September 1, 2020",2020-12-30,"September 22, 2020","Prince Mohamed BinAbdulaziz Hospital, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04323228,Saudi Arabia,,12.0,2020,Wednesday
76,77,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,15.0,"May 20, 2020",2020-09-01,"July 9, 2020","Ain Shams University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04376788,Egypt,Methylene Blue 5 MG/ML,9.0,2020,Tuesday
77,78,Impact of COVID-19 on Marshallese Communities in the U.S.,Enrolling by invitation,Other: Assessing impact of COVID19,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"July 27, 2020",2020-12-15,"November 24, 2020","University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04474496,United States,,12.0,2020,Tuesday
78,79,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),"Active, not recruiting","Drug: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60.0,"February 6, 2020",2021-01-31,"December 11, 2020","Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT04664010,China,"Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment",1.0,2021,Sunday
79,80,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,Procedure: CT-scan with minimal invasive autopsy,All,"Child, Adult, Older Adult",Not Applicable,45.0,"April 14, 2020",2020-12-01,"April 29, 2020","Jessa Hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04366882,Belgium,,12.0,2020,Tuesday
80,81,Study of Open Label Losartan in COVID-19,Completed,Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,"April 4, 2020",2020-08-17,"November 3, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",https://ClinicalTrials.gov/show/NCT04335123,United States,Losartan,8.0,2020,Monday
81,82,Ivermectin and Nitazoxanide Combination Therapy for COVID-19,Not yet recruiting,Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,May 2020,2020-12-01,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04360356,Undefined,,12.0,2020,Tuesday
82,83,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,Not yet recruiting,Drug: FSD201|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,350.0,"November 15, 2020",2021-12-05,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04619706,Undefined,FSD201|Placebo,12.0,2021,Sunday
83,84,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Active, not recruiting",Drug: Favipiravir|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,330.0,"April 23, 2020",2020-07-01,"June 16, 2020","Republican Clinical Hospital, Makhachkala, Russian Federation|""K+31"" Clinic, Moscow, Russian Federation|""Khaven"" Llc, Moscow, Russian Federation|Central Clinical Hospital with Polyclinic, Moscow, Russian Federation|Central Research Institute of Epidemiology, Moscow, Russian Federation|City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital named after S.S. Yudin, Moscow, Russian Federation|City Clinical Hospital No. 24, Moscow, Russian Federation|City Clinical Hospital No. 51, Moscow, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow State University n.a. M. V. Lomonosov, Moscow, Russian Federation|National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russian Federation|City Hospital № 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Ryazan State Medical University named after I.P. Pavlov, Ryazan, Russian Federation|Military Medical Academy named after S.M. Kirova, Saint Petersburg, Russian Federation|Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation|Clinical hospital No.1, Smolensk, Russian Federation|Regional Clinic Hospital, Tver, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yakutsk City Clinical Hospital, Yakutsk, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04434248,Russian Federation,Favipiravir|Standard of Care,7.0,2020,Wednesday
84,85,Dapagliflozin in Respiratory Failure in Patients With COVID-19,Recruiting,Drug: Dapagliflozin 10 MG|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900.0,"April 22, 2020",2020-12-01,"August 27, 2020","Heart Group of the Eastern Shore, Fairhope, Alabama, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Centro de Pesquisa Dr. Marco Mota, Maceió, Alagoas, Brazil|Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Hospital de Messejana dr Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil|Hospital Coração do Brasil, Brasília, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espírito Santo, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Clínica do Coração, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, São Paulo, Brazil|Centro Integrado de Pesquisas, São José do Rio Preto, São Paulo, Brazil|Fundação Pio XII, Barretos, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04350593,Brazil,Dapagliflozin 10 MG|Placebo,12.0,2020,Tuesday
85,86,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Recruiting,Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,80.0,"September 14, 2020",2021-06-01,"October 26, 2020","HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Bégin, Saint-Mandé, France|HIA Sainte Anne, Toulon, France",https://ClinicalTrials.gov/show/NCT04372979,France,Transfusion of SARS-CoV-2 Convalescent Plasma.|Transfusion of standard Plasma.,6.0,2021,Tuesday
86,87,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Recruiting,Biological: Convalescent Plasma|Other: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,306.0,"November 6, 2020",2021-11-01,"November 20, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04456413,Jersey,,11.0,2021,Monday
87,88,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Recruiting,Drug: CPI-006|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,"July 1, 2020",2021-08-31,"October 19, 2020","El Centro Regional Medical Center, El Centro, California, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04464395,United States,CPI-006,8.0,2021,Tuesday
88,89,"Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19",Withdrawn,Drug: anti-SARS-CoV-2 plasma|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,October 2020,2021-12-01,"October 22, 2020",,https://ClinicalTrials.gov/show/NCT04467151,Undefined,anti-SARS-CoV-2 plasma,12.0,2021,Wednesday
89,90,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,"April 9, 2020",2021-04-01,"December 1, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04343755,Jersey,,4.0,2021,Thursday
90,91,CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - A Registry From Germany,Recruiting,,All,"Child, Adult, Older Adult",,4000.0,"March 26, 2020",2021-07-01,"December 10, 2020","Asklepios Fachkliniken München-Gauting, Gauting, Bavaria, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Wandsbek, Hamburg, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Asklepios Kliniken GmbH & Co. KGaA, Hamburg, Germany|Asklepios Klinik Nord, Hamburg, Germany|Asklepios Westklinikum Hamburg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany",https://ClinicalTrials.gov/show/NCT04659187,Germany,,7.0,2021,Thursday
91,92,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19",Recruiting,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,2104.0,"June 16, 2020",2020-12-19,"December 8, 2020","Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site 1, Long Beach, California, United States|Regeneron Study Site 2, Long Beach, California, United States|Regeneron Study Site 3, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Ridgewood, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Bucuresti, Romania",https://ClinicalTrials.gov/show/NCT04425629,Georgia,REGN10933+REGN10987 combination therapy|Placebo,12.0,2020,Saturday
92,93,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,Other: hyperimmune plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,49.0,"March 17, 2020",2020-05-07,"May 28, 2020","Catherine Klersy, Pavia, PV, Italy|Ospedale Asst Carlo Poma Mantova, Mantova, Italy",https://ClinicalTrials.gov/show/NCT04321421,Italy,,5.0,2020,Thursday
93,94,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",Drug: Aprotinin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"June 11, 2020",2020-08-31,"August 26, 2020","Regional State Budgetary Healthcare Institution ""Clinical Hospital №1"", Smolensk, Russian Federation",https://ClinicalTrials.gov/show/NCT04527133,Russian Federation,Aprotinin,8.0,2020,Monday
94,95,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease",Recruiting,Drug: Pamrevlumab|Drug: Placebo,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,130.0,"June 20, 2020",2021-01-01,"December 2, 2020","Research Center, Detroit, Michigan, United States|Research Center, Greensboro, North Carolina, United States|Research Center, Philadelphia, Pennsylvania, United States|Research Center, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04432298,United States,Pamrevlumab|Placebo,1.0,2021,Friday
95,96,Ivermectin for Severe COVID-19 Management,Completed,Drug: Ivermectin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60.0,"May 11, 2020",2020-09-02,"November 27, 2020","Afyonkarahisar Health Science University, Afyonkarahisar, Turkey|Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey|Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey|Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04646109,Turkey,Ivermectin,9.0,2020,Wednesday
96,97,COVID-19 Household Transmission Study,"Active, not recruiting",,All,"1 Year and older   (Child, Adult, Older Adult)",,315.0,"April 29, 2020",2021-06-01,"December 7, 2020","University of North Carolina Health Care, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04445233,United States,,6.0,2021,Tuesday
97,98,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,Terminated,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,148.0,"April 13, 2020",2020-07-20,"July 31, 2020","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04329611,Canada,Hydroxychloroquine,7.0,2020,Monday
98,99,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,Not yet recruiting,Dietary Supplement: Probiotics (2 strains 10x10^9 UFC)|Dietary Supplement: Placebo (potato starch and magnesium stearate),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84.0,"November 16, 2020",2021-03-01,"November 20, 2020","CIUSSS de L'Estrie-CHUS Hospital, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04621071,Canada,,3.0,2021,Monday
99,100,Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,Recruiting,Diagnostic Test: Detection of anti-COVID-19 antibody level,All,"18 Years to 90 Years   (Adult, Older Adult)",,6000.0,"May 4, 2020",2021-05-30,"May 15, 2020","Humanitas Rozzano/San Pio X, Rozzano, Lombardia, Italy",https://ClinicalTrials.gov/show/NCT04387929,Italy,,5.0,2021,Sunday
100,101,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Not yet recruiting,Drug: 1: Naproxen|Drug: 2: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,584.0,"April 13, 2020",2021-07-13,"April 14, 2020",,https://ClinicalTrials.gov/show/NCT04325633,Undefined,1: Naproxen|2: Standard of care,7.0,2021,Tuesday
101,102,Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients,Recruiting,Other: Individualized-Chinese herbal medicine,All,"Child, Adult, Older Adult",,150.0,"September 7, 2020",2021-12-31,"September 16, 2020","School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong, China",https://ClinicalTrials.gov/show/NCT04544605,China,,12.0,2021,Friday
102,103,Treatment of Patients With COVID-19 With Convalescent Plasma,Recruiting,Biological: convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 1, 2020",2022-05-22,"October 29, 2020","University of Sao Paulo - General Hospital, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04415086,Brazil,,5.0,2022,Sunday
103,104,TCM Differentiation and Treatment Protocol of COVID-19,Completed,Drug: TCM prescriptions,All,"18 Years to 80 Years   (Adult, Older Adult)",,340.0,"January 22, 2020",2020-05-30,"June 4, 2020","Huai'an fourth people's Hospital, Huaian, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04306497,China,TCM prescriptions,5.0,2020,Saturday
104,105,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,Drug: Baricitinib (janus kinase inhibitor),All,"18 Years and older   (Adult, Older Adult)",Phase 2,800.0,"April 17, 2020",2022-03-01,"July 24, 2020","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",https://ClinicalTrials.gov/show/NCT04321993,Canada,Baricitinib (janus kinase inhibitor),3.0,2022,Tuesday
105,106,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19",Not yet recruiting,Biological: COVI-VAC|Other: Placebo,All,18 Years to 30 Years   (Adult),Phase 1,48.0,December 2020,2022-05-01,"November 6, 2020","hVIVO, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04619628,United Kingdom,,5.0,2022,Sunday
106,107,Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Other: Blood donation from convalescent donor,All,"21 Years to 65 Years   (Adult, Older Adult)",,8.0,"April 14, 2020",2020-08-01,"July 7, 2020","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04351659,Singapore,,8.0,2020,Saturday
107,108,Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure,Not yet recruiting,Drug: Tranexamic acid|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,100.0,"December 1, 2020",2023-03-31,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04550338,Undefined,Tranexamic acid|Placebo,3.0,2023,Friday
108,109,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Active, not recruiting",Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,"May 12, 2020",2020-11-01,"October 30, 2020","Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital Universitario de Getafe, Getafe, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hosptial Quironsalud Madrid, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04382066,Spain,Plitidepsin 1.5 mg/day|Plitidepsin 2.0 mg/day|Plitidepsin 2.5 mg/day,11.0,2020,Sunday
109,110,Traditional Chinese Medicine for Severe COVID-19,Not yet recruiting,Drug: Traditional Chinese Medicine Prescription,All,"up to 85 Years   (Child, Adult, Older Adult)",Phase 3,50.0,March 2020,2020-04-01,"March 26, 2020","Hao Li, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04323332,China,Traditional Chinese Medicine Prescription,4.0,2020,Wednesday
110,111,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,Recruiting,Biological: multipeptide cocktail,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,"November 27, 2020",2021-12-20,"December 1, 2020","University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany",https://ClinicalTrials.gov/show/NCT04546841,Germany,,12.0,2021,Monday
111,112,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Recruiting,Other: blood samples|Other: feces samples (COVI-BIOME ancillary study)|Other: sweat samples (COVIDOG ancillary study),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"March 31, 2020",2022-03-31,"August 19, 2020","GH Pitié-Salpêtrière / Service d'Accueil des Urgences, Paris, Ile-de-France, France",https://ClinicalTrials.gov/show/NCT04352348,France,,3.0,2022,Thursday
112,113,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),"Active, not recruiting",Biological: SARS-CoV-2 convalescent plasma,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"April 10, 2020",2020-12-01,"May 15, 2020","Danderyd Hospital, Danderyd, Sweden",https://ClinicalTrials.gov/show/NCT04390178,Sweden,,12.0,2020,Tuesday
113,114,COVID-19 Ozanimod Intervention Study,Recruiting,Drug: Ozanimod|Other: Standard of care,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,48.0,"September 16, 2020",2024-01-01,"September 30, 2020","Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada",https://ClinicalTrials.gov/show/NCT04405102,Canada,Ozanimod,1.0,2024,Monday
114,115,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,Biological: Convalescent plasma,All,"Child, Adult, Older Adult",Phase 2,60.0,"August 18, 2020",2020-12-31,"August 27, 2020","D'Or Institute for Research and Education, Rio de Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04528368,Brazil,,12.0,2020,Thursday
115,116,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,Recruiting,Drug: Interferon beta-1b|Drug: Clofazimine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,81.0,"July 14, 2020",2021-09-30,"July 15, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong, China",https://ClinicalTrials.gov/show/NCT04465695,China,Interferon beta-1b|Clofazimine,9.0,2021,Thursday
116,117,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,Biological: UC-MSCs|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"February 1, 2020",2020-06-30,"April 9, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04339660,China,,6.0,2020,Tuesday
117,118,Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Other: demographic and clinical data obtained from hospital's electronic medical record.,All,"1 Year and older   (Child, Adult, Older Adult)",,187.0,"July 15, 2020",2020-11-30,"July 2, 2020",,https://ClinicalTrials.gov/show/NCT04454372,Undefined,,11.0,2020,Monday
118,119,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Recruiting,Drug: Lopinavir/ritonavir,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,300.0,"April 23, 2020",2021-03-01,"September 2, 2020","Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland",https://ClinicalTrials.gov/show/NCT04364022,Switzerland,Lopinavir/ritonavir,3.0,2021,Monday
119,120,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Biological: AG0302-COVID19,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"August 31, 2020",2021-09-30,"December 7, 2020","Osaka University Hospital, Osaka, Japan",https://ClinicalTrials.gov/show/NCT04527081,Japan,,9.0,2021,Thursday
120,121,Antibody Responses in Contacts of COVID-19 Patients,"Active, not recruiting",,All,"18 Years to 80 Years   (Adult, Older Adult)",,100.0,"June 15, 2020",2020-09-30,"June 23, 2020","AssiutU, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04444310,Egypt,,9.0,2020,Wednesday
121,122,Colchicine in COVID-19: a Pilot Study,Recruiting,Drug: Colchicine 1 MG Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,308.0,"April 18, 2020",2021-10-31,"November 5, 2020","Associazione Italiana Pneumologi Ospedalieri, Milan, Italy|Società Italiana di Reumatologia, Milan, Italy",https://ClinicalTrials.gov/show/NCT04375202,Italy,Colchicine 1 MG Oral Tablet,10.0,2021,Sunday
122,123,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"Active, not recruiting",Biological: AG0301-COVID19,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"June 29, 2020",2021-07-31,"November 16, 2020","Osaka City University Hospital, Osaka, Japan",https://ClinicalTrials.gov/show/NCT04463472,Japan,,7.0,2021,Saturday
123,124,Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy,Withdrawn,Drug: Tofacitinib|Other: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,0.0,"July 6, 2020",2020-10-18,"July 31, 2020","Hartford Hospital (HH), Hartford, Connecticut, United States|University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04412252,United States,Tofacitinib,10.0,2020,Sunday
124,125,Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2,Not yet recruiting,Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,24.0,September 2020,2020-10-01,"September 30, 2020",,https://ClinicalTrials.gov/show/NCT04375046,Undefined,Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2),10.0,2020,Thursday
125,126,Co-infection Management in COVID-19 Critically Ill,Completed,Diagnostic Test: FilmArray Pneumonia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,32.0,"March 23, 2020",2020-04-24,"May 11, 2020","Cliniques Universitaires Saint-Luc, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04382092,Belgium,,4.0,2020,Friday
126,127,Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection,Recruiting,Other: olfactory and gustatory tests,All,"18 Years and older   (Adult, Older Adult)",,454.0,"March 27, 2020",2020-11-01,"April 21, 2020","CHU de Nimes, Nîmes, France",https://ClinicalTrials.gov/show/NCT04354857,France,,11.0,2020,Sunday
127,128,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Withdrawn,Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,0.0,February 2020,2020-04-01,"March 17, 2020","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04287686,China,Recombinant human angiotensin-converting enzyme 2 (rhACE2),4.0,2020,Wednesday
128,129,COVID-19 and Vaccination Attitudes,Completed,Other: Survey,All,"Child, Adult, Older Adult",,1194.0,"April 14, 2020",2020-04-30,"November 13, 2020","Survey, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04352582,United Kingdom,,4.0,2020,Thursday
129,130,Favipiravir Therapy in Adults With Mild COVID-19,Recruiting,Drug: Favipiravir|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,576.0,"July 23, 2020",2021-06-01,"September 9, 2020","Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia|King Fahad Hospital - Madinah, Al Madīnah, Saudi Arabia|King Abdullah Medical City - Makkah, Mecca, Saudi Arabia|King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04464408,Saudi Arabia,Favipiravir|Placebo,6.0,2021,Tuesday
130,131,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,Other: home care monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,37.0,"April 21, 2020",2020-06-30,"September 14, 2020","Asl Alessandria, Casale Monferrato, Alessandria, Italy",https://ClinicalTrials.gov/show/NCT04361916,Italy,,6.0,2020,Tuesday
131,132,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Recruiting,Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170.0,"March 4, 2020",2021-12-31,"July 31, 2020","Purpan University Hospital, Toulouse, France",https://ClinicalTrials.gov/show/NCT04385108,France,,12.0,2021,Friday
132,133,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,Completed,,All,"18 Years and older   (Adult, Older Adult)",,693.0,"April 16, 2020",2020-05-29,"September 9, 2020","Hôpital de Warquignies, Boussu, Hainaut, Belgium|Hôpital de Jolimont, Haine-Saint-Paul, Hainaut, Belgium|Hôpital de Lobbes, Lobbes, Hainaut, Belgium|Hôpital de Mons, Mons, Hainaut, Belgium|Erasme Hospital CUB, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04344145,Belgium,,5.0,2020,Friday
133,134,Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA),Recruiting,,All,"Child, Adult, Older Adult",,4100.0,"October 25, 2020",2022-05-30,"November 12, 2020","Universidade Federal do Ceará, Fortaleza, CE, Brazil|Universidade de Brasília, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital Universitário Júlio Müller da Universidade Federal de Mato Grosso, Cuiabá, Mount, Brazil|Universidade Federal de Roraima - UFRR, Boa Vista, Roraima, Brazil|Centro de Pesquisas em Medicina Tropical de Rondônia (CEPEM), Porto Velho, RO, Brazil|Universidade Federal de Sergipe, Laranjeiras, SE, Brazil|Hospital Estadual de Serrana, Serrana, SP, Brazil|Faculdade Santa Marcelina, São Paulo, SP, Brazil|Faculdade de Medicina de São José do Rio Preto - FAMERP, São José Do Rio Preto, São Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04355338,Brazil,,5.0,2022,Monday
134,135,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,Recruiting,Biological: Prolastin|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"July 29, 2020",2021-04-01,"October 9, 2020","Hospital Germans Trias, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital Valle de Hebrón, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Príncipe de Asturias, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04495101,Spain,Standard Medical Treatment,4.0,2021,Thursday
135,136,VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection,Not yet recruiting,Other: Exposure,All,"18 Years and older   (Adult, Older Adult)",,500.0,June 2020,2021-03-01,"May 19, 2020","Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de São João, Oporto, Portugal",https://ClinicalTrials.gov/show/NCT04370808,Portugal,,3.0,2021,Monday
136,137,COVID-19 Plasma Collection,Recruiting,Other: Plasma Donation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"April 13, 2020",2021-04-12,"May 11, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04344015,United States,,4.0,2021,Monday
137,138,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Drug: SOC + IFX-1|Drug: SOC + Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,390.0,"March 31, 2020",2021-08-31,"December 7, 2020","University of Aachen, Aachen, Germany|University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands",https://ClinicalTrials.gov/show/NCT04333420,Germany,SOC + IFX-1|SOC + Placebo,8.0,2021,Tuesday
138,139,DAS181 for STOP COVID-19,Withdrawn,Drug: DAS181|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,0.0,"July 25, 2020",2020-11-30,"August 11, 2020","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy",https://ClinicalTrials.gov/show/NCT04354389,Italy,DAS181|Placebo,11.0,2020,Monday
139,140,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Not yet recruiting,Drug: Clazakizumab|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,May 2020,2020-08-01,"May 8, 2020","Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04381052,United States,Clazakizumab,8.0,2020,Saturday
140,141,Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis,Not yet recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,"August 1, 2020",2022-08-01,"July 22, 2020","Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia",https://ClinicalTrials.gov/show/NCT04480632,Colombia,,8.0,2022,Monday
141,142,A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),Recruiting,Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: Low-dose placebo (18-59 years) & Two dose regimen|Biological: Low-dose placebo (18-59 years) & Three dose regimen|Biological: High-dose placebo (18-59 years) & Two dose regimen|Biological: High-dose placebo (18-59 years) & Three dose regimen|Biological: Low-dose placebo (60-85 years) & Two dose regimen|Biological: Low-dose placebo (60-85 years) & Three dose regimen|Biological: High-dose placebo (60-85 years) & Two dose regimen|Biological: High-dose placebo (60-85 years) & Three dose regimen,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,960.0,"November 17, 2020",2021-11-18,"November 23, 2020","Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04640402,China,,11.0,2021,Thursday
142,143,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",Not yet recruiting,Other: Aerobic Exercise Training|Other: Education,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,90.0,"December 16, 2020",2023-12-31,"December 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04595773,United States,,12.0,2023,Sunday
143,144,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,Recruiting,"Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,90.0,"February 21, 2020",2022-08-31,"November 17, 2020","Chongqing Public Health Medical Center, Chongqing, China",https://ClinicalTrials.gov/show/NCT04324996,China,,8.0,2022,Wednesday
144,145,A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19,Not yet recruiting,Drug: Lianhua Qingwen|Drug: Placebo,All,"21 Years and older   (Adult, Older Adult)",Phase 3,300.0,July 2020,2021-02-01,"June 17, 2020",,https://ClinicalTrials.gov/show/NCT04433013,Undefined,Lianhua Qingwen|Placebo,2.0,2021,Monday
145,146,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),Recruiting,Biological: Group A (AG0302-COVID19)|Biological: Group A (Placebo)|Biological: Group B (AG0302-COVID19)|Biological: Group B (Placebo),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,500.0,"November 23, 2020",2022-03-31,"December 7, 2020","UHW Narita Hospital, Narita, Chiba, Japan|Medical Corporation Heishinkai OCROM Clinic, Suita, Osaka, Japan|Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic, Shibuya-ku, Tokyo, Japan|Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan|Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan|Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan|NISHI-UMEDA Clinic for Asian Medical Collaboration, Osaka, Japan|Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan",https://ClinicalTrials.gov/show/NCT04655625,Japan,,3.0,2022,Thursday
146,147,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,Device: MLS Laser|Other: Regular Inpatient Medical Care,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,10.0,"April 30, 2020",2020-07-16,"August 5, 2020","Lowell General Hospital, Lowell, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04391712,United States,,7.0,2020,Thursday
147,148,An Observational Study of Neurologic Function After COVID-19 Infection,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"October 28, 2020",2022-12-01,"November 19, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04564287,United States,,12.0,2022,Thursday
148,149,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",Recruiting,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,2970.0,"June 10, 2020",2021-01-25,"November 10, 2020","Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Chandler, Arizona, United States|Regeneron Study Site 1, Tucson, Arizona, United States|Regeneron Study Site 2, Tucson, Arizona, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Mission Hills, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pensacola, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Glenview, Illinois, United States|Regeneron Study Site, Urbana, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Grand Rapids, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Chesterfield, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Englewood, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Pennington, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site 1, Buffalo, New York, United States|Regeneron Study Site 2, Buffalo, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, West Islip, New York, United States|Regeneron Study Site, White Plains, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Concord, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site 1, Amarillo, Texas, United States|Regeneron Study Site 2, Amarillo, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Sugar Land, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site 1, Seattle, Washington, United States|Regeneron Study Site 2, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Salvador, Bahia, Brazil|Regeneron Study Site, Fortaleza, Ceara, Brazil|Regeneron Study Site, Passo Fundo, RS, Brazil|Regeneron Study Site, Chapeco, Santa Catarina, Brazil|Regeneron Study Site, Criciuma, Santa Catarina, Brazil|Regeneron Study Site, Botucatu, Sao Paolo, Brazil|Regeneron Study Site, Campinas, Sao Paolo, Brazil|Regeneron Study Site, Sao Paolo, Brazil|Regeneron Study Site, Sao Paolo, Brazil|Regeneron Study Site, Las Condes, Santiago De Chile, Chile|Regeneron Study Site, Santiago de Chile, Chile|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucuresti, Romania",https://ClinicalTrials.gov/show/NCT04426695,Brazil,REGN10933+REGN10987 combination therapy|Placebo,1.0,2021,Monday
149,150,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Other: plasma hyperimmune|Drug: standard therapy,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,400.0,"May 1, 2020",2021-05-15,"May 12, 2020","Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Italy|Azienda Ospedaliera Pugliese Ciaccio Catanzaro, Catanzaro, Italy|Azienda Ospedaliera Annunziata, Cosenza, Italy|Azienda Sanitaria Provinciale, Crotone, Italy|Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy|Azienda Sanitaria Provinciale, Vibo Valentia, Italy",https://ClinicalTrials.gov/show/NCT04385043,Italy,standard therapy,5.0,2021,Saturday
150,151,Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients,Not yet recruiting,Drug: Chloroquine phosphate,All,18 Years to 59 Years   (Adult),Phase 1,200.0,"July 27, 2020",2021-01-31,"July 14, 2020","Centro Médico Nacional ""20 de Noviembre"", Mexico City, Benito Juárez, Mexico",https://ClinicalTrials.gov/show/NCT04443270,Mexico,Chloroquine phosphate,1.0,2021,Sunday
151,152,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,Biological: SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,"May 7, 2020",2020-12-01,"May 27, 2020","Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04384497,Sweden,,12.0,2020,Tuesday
152,153,Screening for COVID-19,Not yet recruiting,Diagnostic Test: suspected of COVID-19 infection,All,"18 Years to 80 Years   (Adult, Older Adult)",,200.0,"November 15, 2020",2021-12-30,"November 4, 2020",,https://ClinicalTrials.gov/show/NCT04615208,Undefined,,12.0,2021,Thursday
153,154,COVID-19 : Study of INFLAmmasome and PLAtelets Functions,Recruiting,Biological: Blood samples,All,"18 Years and older   (Adult, Older Adult)",,110.0,"April 16, 2020",2022-04-01,"November 30, 2020","CHU Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04397822,France,,4.0,2022,Friday
154,155,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 2, 2020",2020-12-01,"October 12, 2020","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04432324,Spain,Standard Medical Treatment,12.0,2020,Tuesday
155,156,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Completed,Drug: Favipiravir|Drug: Standard of care,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,200.0,"May 21, 2020",2020-08-20,"November 5, 2020","State Clinical Hospital №50, Moscow, Russian Federation|Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation|City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation|Medical institute Ogarev Mordovia State university, Saransk, Russian Federation|Smolensk clinical hospital №1, Smolensk, Russian Federation",https://ClinicalTrials.gov/show/NCT04542694,Russian Federation,Favipiravir|Standard of care,8.0,2020,Thursday
156,157,Safety and Efficacy of Ruxolitinib for COVID-19,Not yet recruiting,Drug: Ruxolitinib,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,80.0,November 2020,2021-10-01,"August 25, 2020",,https://ClinicalTrials.gov/show/NCT04348071,Undefined,Ruxolitinib,10.0,2021,Friday
157,158,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Recruiting,Biological: Lenzilumab|Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200.0,"October 19, 2020",2021-07-01,"December 4, 2020","Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|Kern Medical Center, Bakersfield, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT04583969,Georgia,Remdesivir,7.0,2021,Thursday
158,159,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Biological: Liquid Alpha1-Proteinase Inhibitor (Human)|Drug: Placebo|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,November 2020,2021-09-01,"November 16, 2020","CHI Health Center, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04547140,United States,Placebo|Standard Medical Treatment,9.0,2021,Wednesday
159,160,Safety and Efficacy of Baricitinib for COVID-19,Not yet recruiting,Drug: Baricitinib,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,80.0,November 2020,2021-10-01,"August 25, 2020","University of Colorado, Denver, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT04340232,United States,Baricitinib,10.0,2021,Friday
160,161,Favipiravir in Hospitalized COVID-19 Patients,Not yet recruiting,Drug: Favipiravir|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 20, 2020",2020-05-05,"April 28, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04359615,"Iran, Islamic Republic of",Favipiravir|Hydroxychloroquine,5.0,2020,Tuesday
161,162,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),Recruiting,Biological: CoronaVac|Biological: Placebo,All,18 Years to 59 Years   (Adult),Phase 3,13000.0,"September 14, 2020",2021-04-15,"October 9, 2020","T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic, Ankara, Turkey Region, Turkey|T.R. Ministry of Health Ankara Provincial Health Directorate Ankara Training and Research Hospital, Infectious Diseases, Ankara, Turkey Region, Turkey|Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey Region, Turkey|Çukurova University Faculty of Medicine, Department of Infectious Diseases, Adana, Turkey|Hacettepe University Faculty of Medicine Department of Infections Diseases and Clinical Microbiology, Ankara, Turkey|T.C Ministry of Health Ankara Provincial Health Directorate Health Sciences University Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey|Bursa Uludağ University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa, Turkey|Dicle University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Diyarbakır, Turkey|Gaziantep University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Gaziantep, Turkey|Acıbadem Atakent Hospital, Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|Altınbaş University Medical Park Bahçelievler Infectious Diseases and Microbiology, Istanbul, Turkey|Cerrahpaşa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|Istanbul Medipol University Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey|Istanbul University Istanbul Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey|T.R. Ministry of Health Istanbul Provincial Health Directorate Marmara Univesity Istanbul Pendik Education and Research Hospital, Istanbul, Turkey|T.R. Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Taşçıoğlu City Hospital, Infectious Diseases Clinic, Istanbul, Turkey|T.R. Ministry of Health Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey|Ege University Faculty of Medicine Hospital, Department of Infectious Diseasesaculty of Medicine Hospital, Department of Infectious Diseases, İzmir, Turkey|Republic Of Turkey Ministry Of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, İzmir, Turkey|T.R. Ministry of Health İzmir Provincial Health Directorate İzmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases, İzmir, Turkey|T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department, Kayseri, Turkey|Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Kocaeli, Turkey|Malatya İnönü University Faculty of Medicine, Department of Infectious Diseases, Malatya, Turkey|Karadeniz Technical University Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology, Trabzon, Turkey",https://ClinicalTrials.gov/show/NCT04582344,Turkey,,4.0,2021,Thursday
162,163,Losmapimod Safety and Efficacy in COVID-19,Recruiting,Drug: Losmapimod oral tablet|Drug: Placebo oral tablet,All,"50 Years and older   (Adult, Older Adult)",Phase 3,410.0,"August 28, 2020",2020-11-01,"November 25, 2020","University of California Irvine - Irvine Medical Center, Irvine, California, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|United Medical Memorial Hospital, Houston, Texas, United States|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil|Irmandade de Santa Casa de Misericordia de Porto Alegre, Centro Histórico, Porto Alegre - RS, Brazil|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|JM Research Cuernavaca, Cuernavaca, Morelos, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada, S.C., Culiacán, Sinaloa, Mexico",https://ClinicalTrials.gov/show/NCT04511819,Brazil,Losmapimod oral tablet|Placebo oral tablet,11.0,2020,Sunday
163,164,Azithromycin in Hospitalized COVID-19 Patients,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 20, 2020",2020-05-05,"April 24, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04359316,"Iran, Islamic Republic of",Hydroxychloroquine|Azithromycin,5.0,2020,Tuesday
164,165,COVID-19 Treatment in South Africa,Recruiting,Other: Standard of care (Paracetamol)|Drug: Artesunate-amodiaquine|Drug: Pyronaridine-artesunate|Drug: Favipiravir plus Nitazoxanide|Drug: Sofosbuvir/daclatasvir,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,250.0,"September 3, 2020",2021-01-01,"October 8, 2020","Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg, South Africa",https://ClinicalTrials.gov/show/NCT04532931,South Africa,Artesunate-amodiaquine|Pyronaridine-artesunate|Favipiravir plus Nitazoxanide|Sofosbuvir/daclatasvir,1.0,2021,Friday
165,166,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),Recruiting,Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 29, 2020",2021-03-01,"November 16, 2020","Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Complejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital Clínico Universitario de Santiago -CHUS, Santiago, Spain|Hospital Universitari Joan XXIII, Tarragona, Spain",https://ClinicalTrials.gov/show/NCT04547127,Spain,Standard Medical Treatment,3.0,2021,Monday
166,167,Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients,Not yet recruiting,Drug: Thymalfasin,All,"60 Years and older   (Adult, Older Adult)",Phase 2,240.0,September 2020,2021-08-01,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04428008,Undefined,Thymalfasin,8.0,2021,Sunday
167,168,Vitamin D and COVID-19 Trial,Not yet recruiting,Dietary Supplement: vitamin D|Dietary Supplement: Placebo,All,"30 Years and older   (Adult, Older Adult)",Phase 3,2700.0,"December 1, 2020",2021-03-01,"November 20, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04536298,United States,,3.0,2021,Monday
168,169,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 9, 2020",2020-04-27,"May 5, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04343768,"Iran, Islamic Republic of",Hydroxychloroquine|Lopinavir / Ritonavir|Interferon Beta-1A|Interferon Beta-1B,4.0,2020,Monday
169,170,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,Not yet recruiting,Genetic: Whole Genome Analysis|Genetic: T-cell receptor (TCR) repertoire|Genetic: SARS-CoV-2 viral composition,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,January 2021,2022-08-01,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04364828,Undefined,,8.0,2022,Monday
170,171,Immunosupressive Treatment in COVID-19 Patients,Recruiting,Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins,All,"18 Years and older   (Adult, Older Adult)",,500.0,May 2020,2020-05-01,"May 12, 2020","Hospital Virgen Macarena, Sevilla, Spain",https://ClinicalTrials.gov/show/NCT04382781,Spain,NO-Immunosuppressive|Immunosuppressive|Immunoglubulins,5.0,2020,Friday
171,172,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,Terminated,Drug: Acalabrutinib,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,8.0,"September 21, 2020",2020-11-18,"December 2, 2020","Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04497948,Brazil,Acalabrutinib,11.0,2020,Wednesday
172,173,Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection,Available,Drug: Ruxolitinib,All,"12 Years and older   (Child, Adult, Older Adult)",,,,,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04355793,Undefined,Ruxolitinib,,n,
173,174,The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial,Withdrawn,Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures,All,18 Years to 59 Years   (Adult),Phase 3,0.0,December 2020,2021-05-01,"November 6, 2020","Philippine General Hospital - University of the Philippines Manila, Manila, Philippines",https://ClinicalTrials.gov/show/NCT04364815,Philippines,Hydroxychloroquine plus standard preventive measures|Placebo plus standard preventive measures,5.0,2021,Saturday
174,175,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,Behavioral: Positive COVID Test Result - Hypothetical Scenario|Behavioral: Negative COVID Test Result - Hypothetical Scenario|Behavioral: Unavailable COVID Test Result - Hypothetical Scenario,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,1400.0,"July 23, 2020",2020-07-29,"August 20, 2020","UCLA Health Department of Medicine, Quality Office, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04459520,United States,,7.0,2020,Wednesday
175,176,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"Active, not recruiting",Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,969.0,"August 4, 2020",2020-12-30,"December 9, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04492475,Georgia,Interferon beta-1a|Remdesivir,12.0,2020,Wednesday
176,177,Classification of COVID-19 Infection in Posteroanterior Chest X-rays,Completed,Device: CovX,All,"18 Years and older   (Adult, Older Adult)",,230.0,"April 1, 2020",2020-04-17,"April 24, 2020","Dascena, Oakland, California, United States",https://ClinicalTrials.gov/show/NCT04358536,United States,,4.0,2020,Friday
177,178,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,85.0,"March 30, 2020",2021-12-31,"September 2, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04329832,United States,Hydroxychloroquine|Azithromycin,12.0,2021,Friday
178,179,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),Recruiting,Drug: Rivaroxaban|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"September 2, 2020",2020-12-01,"December 9, 2020","Woodland Research Northwest LLC - ERG - PPDS, Rogers, Arkansas, United States|Science 37, Inc, Los Angeles, California, United States|Allergy and Asthma Medical Group and Research Center - CRN - PPDS, San Diego, California, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|LCC Medical Research - Miami - BTC - PPDS, Miami, Florida, United States|Adult Medicine of Lake County, Mount Dora, Florida, United States|Providea Health Partners LLC, Evergreen Park, Illinois, United States|Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States|Encompass Care, North Las Vegas, Nevada, United States|Riverside Medical Group - Circuit- PPDS, Secaucus, New Jersey, United States|NYC Health + Hospitals/Lincoln, Bronx, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Harlem Hospital Center, New York, New York, United States|Premier Family Physicians - Austin - Hunt - PPDS, Austin, Texas, United States|Village Health Partners - Plano - Hunt - PPDS, Plano, Texas, United States|South Texas Allergy and Asthma Medical Professionals, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04504032,Jersey,Rivaroxaban|Placebo,12.0,2020,Tuesday
179,180,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Drug: Omegaven®|Drug: Sodium chloride,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"June 23, 2020",2021-04-30,"December 1, 2020","Karolinska Universitetssjuhuset, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04647604,Sweden,Omegaven®|Sodium chloride,4.0,2021,Friday
180,181,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Recruiting,Biological: convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,410.0,"August 25, 2020",2020-12-31,"August 26, 2020","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Tlalpan, Mexico",https://ClinicalTrials.gov/show/NCT04388410,Mexico,,12.0,2020,Thursday
181,182,Keto-diet for Intubated Critical Care COVID-19,Withdrawn,Dietary Supplement: Ketogenic diet|Other: standard of care,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,0.0,"September 1, 2020",2021-12-31,"August 25, 2020",,https://ClinicalTrials.gov/show/NCT04358835,Undefined,,12.0,2021,Friday
182,183,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,Recruiting,Biological: High-titer Convalescent COVID-19 Plasma (CCP1)|Biological: Standard-titer Convalescent COVID-19 plasma (CCP2),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,56.0,"August 27, 2020",2021-05-01,"October 5, 2020","University of North Carolina Health Care, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04524507,United States,,5.0,2021,Saturday
183,184,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Recruiting,Biological: MSCs,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,"January 27, 2020",2021-12-01,"April 15, 2020","Beijing 302 Military Hospital of China, Beijing, China",https://ClinicalTrials.gov/show/NCT04252118,China,,12.0,2021,Wednesday
184,185,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,Recruiting,Drug: BDB-001 Injection|Other: Conventional treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,368.0,"July 23, 2020",2022-08-07,"July 27, 2020","Southwest Hospital Chongqing, Chongqing, Chongqing, China|RSUP Persahabatan(Persahabatan General Hospital), East Jakarta, Jakarta, Indonesia|RSUD Pasar Minggu(Pasar Minggu General Hospital), South Jakarta, Jakarta, Indonesia|RSUD Cengkareng(Cengkareng General Hospital), West Jakrata, Jakrata, Indonesia",https://ClinicalTrials.gov/show/NCT04449588,China,BDB-001 Injection,8.0,2022,Sunday
185,186,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1034.0,"May 8, 2020",2020-07-31,"December 2, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Hospital Clinico San Carlos - Enfermedades Infecciosas, Madrid, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, City Of London, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04401579,Denmark,Remdesivir|Baricitinib,7.0,2020,Friday
186,187,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1062.0,"February 21, 2020",2020-05-21,"December 9, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04280705,Denmark,Remdesivir,5.0,2020,Thursday
187,188,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,180.0,"April 27, 2020",2024-12-01,"November 30, 2020","Medstar Washington Medical Center, Washington, District of Columbia, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Medstar Montgomery Medical Center, Olney, Maryland, United States",https://ClinicalTrials.gov/show/NCT04362865,United States,,12.0,2024,Sunday
188,189,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,Recruiting,Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose|Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - High dose|Biological: One COVID-19 vaccine candidate (TMV-083) administration - High dose|Other: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,90.0,"August 10, 2020",2021-10-01,"September 28, 2020","SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium|CIC Cochin - Pasteur, Paris, France",https://ClinicalTrials.gov/show/NCT04497298,Belgium,,10.0,2021,Friday
189,190,Clinical and Biological Predictors of COVID-19 Disease in Older Patients,Recruiting,,All,65 Years and older   (Older Adult),,300.0,"April 3, 2020",2020-12-01,"September 22, 2020","IRCCS INRCA Hospital, Ancona, Italy|IRCCS INRCA Hospital, Casatenovo, Italy|IRCCS INRCA Hospital, Fermo, Italy",https://ClinicalTrials.gov/show/NCT04348396,Italy,,12.0,2020,Tuesday
190,191,Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire,Recruiting,Other: COVID-19,All,4 Years to 13 Years   (Child),,1500.0,"April 30, 2019",2021-03-01,"September 1, 2020","Unity Health Toronto, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04534595,Canada,,3.0,2021,Monday
191,192,Study of Niclosamide in Moderate Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,Drug: Niclosamide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,436.0,"October 7, 2020",2022-06-01,"November 4, 2020","Helen Keller Hospital, Sheffield, Alabama, United States|Baptist Health Research Institute, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04603924,United States,Niclosamide|Placebo,6.0,2022,Wednesday
192,193,Loneliness During Strict and Lifted Social Distancing Protocols Against the COVID-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,10084.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04444115,Undefined,,7.0,2020,Monday
193,194,A Longitudinal Study of COVID-19 Sequelae and Immunity,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,900.0,"June 17, 2020",2027-12-31,"November 12, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04411147,United States,,12.0,2027,Friday
194,195,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),Recruiting,Drug: Baricitinib|Drug: Dexamethasone|Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1500.0,"November 24, 2020",2021-06-30,"December 11, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|VA Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States",https://ClinicalTrials.gov/show/NCT04640168,Georgia,Baricitinib|Dexamethasone|Remdesivir,6.0,2021,Wednesday
195,196,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Biological: Mesenchymal Stromal Cells|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"May 1, 2020",2020-12-31,"October 14, 2020","Hospital Universitario Rio Hortega, Valladolid, Spain",https://ClinicalTrials.gov/show/NCT04361942,Spain,,12.0,2020,Thursday
196,197,COVID-19: Respiratory and Sleep Follow-up,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,400.0,"June 1, 2020",2026-03-05,"June 30, 2020","Hôpital Avicenne, Bobigny, France|Centre Hospitalier Henri Mondor, APHP, Créteil, France|CHU Grenoble Alpes, Grenoble, France|CHRU Nancy, Nancy, France",https://ClinicalTrials.gov/show/NCT04406324,France,,3.0,2026,Thursday
197,198,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Terminated,Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,"June 16, 2020",2020-12-01,"December 8, 2020","Mayo Clinic in Arizona, Phoenix, Arizona, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Atlantic Health System / Overlook Medical Center, Summit, New Jersey, United States|St. David's South Austin Medical Center, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|HCA Houston Healthcare Medical Center, Houston, Texas, United States|HCA Houston Healthcare Mainland, Texas City, Texas, United States",https://ClinicalTrials.gov/show/NCT04410354,Jersey,Merimepodib|Matching Placebo|Remdesivir,12.0,2020,Tuesday
198,199,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,Recruiting,Drug: Pyronaridine-Artesunate|Drug: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,76.0,"July 9, 2020",2021-02-01,"October 14, 2020","Korea University Ansan Hospital, Ansan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyungpook national university hospital, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Sahmyook Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04475107,"Korea, Republic of",Pyronaridine-Artesunate|Placebo,2.0,2021,Monday
199,200,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30000.0,"March 20, 2020",2021-06-30,"November 4, 2020","Universidad de Granada, Granada, Spain",https://ClinicalTrials.gov/show/NCT04449731,Spain,,6.0,2021,Wednesday
200,201,Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19),Completed,,All,"18 Years to 99 Years   (Adult, Older Adult)",,111.0,"February 1, 2020",2020-06-30,"November 24, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04641988,France,,6.0,2020,Tuesday
201,202,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Drug: Ciclesonide Metered Dose Inhaler [Alvesco],All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,94.0,"April 1, 2020",2020-12-31,"September 16, 2020","Korea University Guro Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04330586,"Korea, Republic of",Ciclesonide Metered Dose Inhaler [Alvesco],12.0,2020,Thursday
202,203,Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Recruiting,Device: Web application users,All,"18 Years and older   (Adult, Older Adult)",,12000000.0,"March 17, 2020",2020-11-15,"October 14, 2020","All French Emergency services, Le Mans, France",https://ClinicalTrials.gov/show/NCT04331171,France,,11.0,2020,Sunday
203,204,COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Placebo,All,"40 Years and older   (Adult, Older Adult)",Phase 3,336.0,"May 19, 2020",2021-04-30,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04397328,Undefined,Hydroxychloroquine|Placebo,4.0,2021,Friday
204,205,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Drug: Acalabrutinib,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,62.0,"June 13, 2020",2020-11-16,"December 2, 2020","Research Site, Anniston, Alabama, United States|Research Site, Escondido, California, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Newport Beach, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States",https://ClinicalTrials.gov/show/NCT04380688,India,Acalabrutinib,11.0,2020,Monday
205,206,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,Recruiting,Other: Placebo|Drug: Remdesivir|Biological: Risankizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200.0,"October 14, 2020",2021-07-01,"December 4, 2020","Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|Kern Medical Center, Bakersfield, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT04583956,Georgia,Remdesivir,7.0,2021,Thursday
206,207,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Drug: unfractionated Heparin|Drug: Unfractionated heparin nebulized|Drug: acetylsalicylic acid|Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310.0,"July 8, 2020",2021-04-30,"July 10, 2020","Vanderson Rocha, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04466670,Brazil,unfractionated Heparin|Unfractionated heparin nebulized|acetylsalicylic acid|Enoxaparin,4.0,2021,Friday
207,208,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"Active, not recruiting",Drug: Acalabrutinib,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,163.0,"June 12, 2020",2020-11-23,"October 19, 2020","Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Monte Grande, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Botucatu, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Curico, Chile|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Talca, Chile|Research Site, Bobigny, France|Research Site, Villejuif Cedex, France|Research Site, Köln, Germany|Research Site, Bangalore, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, D.F, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Chancay, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Cape Town, South Africa|Research Site, Madrid, Spain|Research Site, Mérida, Spain|Research Site, Pozuelo de Alarcón, Spain|Research Site, Ankara, Turkey|Research Site, Bakirkoy, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Umraniye, Turkey",https://ClinicalTrials.gov/show/NCT04346199,Argentina,Acalabrutinib,11.0,2020,Monday
208,209,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,Recruiting,Drug: 0.5% Povidone Iodine|Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse|Drug: 1% Hydrogen Peroxide|Drug: 0.9% Normal Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,60.0,"October 1, 2020",2020-11-01,"October 27, 2020","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04603794,United States,0.5% Povidone Iodine|0.12% Chlorhexidine Gluconate Mouth Rinse|1% Hydrogen Peroxide|0.9% Normal Saline,11.0,2020,Sunday
209,210,"Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings",Not yet recruiting,,All,"5 Years and older   (Child, Adult, Older Adult)",,1000.0,October 2020,2021-03-01,"September 29, 2020",,https://ClinicalTrials.gov/show/NCT04568499,Undefined,,3.0,2021,Monday
210,211,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan,All,"60 Years and older   (Adult, Older Adult)",Phase 3,1600.0,"April 25, 2020",2021-06-01,"July 27, 2020","CHU de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04359953,France,Hydroxychloroquine|Azithromycin|Telmisartan,6.0,2021,Tuesday
211,212,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Recruiting,Biological: SARS-CoV-2 antibody based IVIG therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,"June 19, 2020",2021-03-01,"November 27, 2020","Dow University of Health Sciences, Karachi, Sindh, Pakistan",https://ClinicalTrials.gov/show/NCT04521309,Pakistan,,3.0,2021,Monday
212,213,Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,Recruiting,Other: COVID-19,All,"18 Years and older   (Adult, Older Adult)",,500.0,"May 1, 2020",2023-06-01,"October 9, 2020","St. Claraspital AG - Department of Pulmonary Medicine, Basel, Switzerland|Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center, Bern, Switzerland|University and Hospital of Fribourg, Fribourg, Switzerland|Hôpitaux Universitaires de Genève - Service de Pneumologie, Genève, Switzerland|CHUV - Service de Pneumologie, Lausanne, Switzerland|Clinica Moncucco, Lugano, Switzerland|Hôpital du Valais - Service de Pneumologie, Sion, Switzerland|Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum, St. Gallen, Switzerland|Universitätsspital Zürich - Klinik für Pneumologie, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04581135,Switzerland,,6.0,2023,Thursday
213,214,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,Recruiting,Drug: Nafamostat Mesilate,All,"18 Years and older   (Adult, Older Adult)",Phase 3,186.0,"August 13, 2020",2021-08-12,"September 7, 2020","Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal",https://ClinicalTrials.gov/show/NCT04390594,Senegal,Nafamostat Mesilate,8.0,2021,Thursday
214,215,Cardiac Injury in COVID-19: a Pathology Study,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,60.0,"April 23, 2020",2021-03-01,"August 10, 2020","ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy",https://ClinicalTrials.gov/show/NCT04367792,Italy,,3.0,2021,Monday
215,216,"Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,700.0,"May 1, 2020",2020-07-01,"May 5, 2020",,https://ClinicalTrials.gov/show/NCT04374695,Undefined,,7.0,2020,Wednesday
216,217,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,Recruiting,Device: Vielight RX Plus,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,280.0,"September 2, 2020",2021-03-01,"September 14, 2020","Progressive Medical Research, Port Orange, Florida, United States|Dr. Michael Zahavi, Oshawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04418505,Canada,,3.0,2021,Monday
217,218,Telmisartan for Treatment of COVID-19 Patients,Recruiting,Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"May 19, 2020",2020-10-01,"August 6, 2020","Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital Español de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04355936,Argentina,Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.,10.0,2020,Thursday
218,219,COVID-19 - Cytokine Storm,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,300.0,"June 28, 2020",2020-12-01,"August 13, 2020","Hadassah Medical Center, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04474067,Israel,,12.0,2020,Tuesday
219,220,Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study,Not yet recruiting,Diagnostic Test: Brainstem Responses Assessment Sedation Score (BRASS)|Diagnostic Test: Electroencephalogram with EKG lead,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,September 2020,2021-06-01,"September 9, 2020","Hôpital Cochin, Paris, France|HEGP, Paris, France",https://ClinicalTrials.gov/show/NCT04527198,France,,6.0,2021,Tuesday
220,221,Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19,Not yet recruiting,Combination Product: Hydroxychloroquine plus Nitazoxanide|Other: Standard care,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,May 2020,2020-12-01,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04361318,Undefined,,12.0,2020,Tuesday
221,222,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Recruiting,Drug: Prazosin|Other: Standard of care,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,220.0,"May 13, 2020",2021-06-30,"December 10, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04365257,United States,Prazosin,6.0,2021,Wednesday
222,223,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1300.0,"May 12, 2020",2021-03-30,"November 27, 2020","Centro de Pesquisas Clínicas Dr. Marco Mota HCOR, Maceió, Alagoas, Brazil|Hospital e Clínica São Roque, Ipiaú, Bahia, Brazil|Clínica Otorhinus, Salvador, Bahia, Brazil|Hospital da Bahia, Salvador, Bahia, Brazil|Hospital Santa Izabel, Salvador, Bahia, Brazil|Instituto Cárdio Pulmonar da Bahia, Salvador, Bahia, Brazil|Hospital SAMUR, Vitória Da Conquista, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, Ceará, Brazil|Unimed Sul Capixaba, Cachoeiro De Itapemirim, Espírito Santo, Brazil|Hospital das Clínicas Universidade Federal de Goiás, Goiânia, Goiás, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Agerais, Brazil|Hospital Júlia Kubitschek, Belo Horizonte, Minas Gerais, Brazil|Instituto da Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Casa de Caridade de Carangola, Carangola, Minas Gerais, Brazil|Hospital Maternidade e Pronto Socorro Santa Lucia, Poços De Caldas, Minas Gerais, Brazil|Hospital da Unimed, São João Del Rei, Minas Gerais, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, Minas Gerais, Brazil|Hospital de Clínicas da Universidade Federal do Triangulo Mineiro, Uberaba, Minas Gerais, Brazil|Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil|Hospital do Rocio, Campo Largo, Paraná, Brazil|Clínica Clinilive, Maringá, Paraná, Brazil|Hospital Universitário Regional de Maringá, Maringá, Paraná, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco, Brazil|SECRETARIA MUNICIPAL DE SAÚDE DE SAIRÉ (Unidade Mista Olília Mendonça Souto Maior), Sairé, Pernambuco, Brazil|Complexo Hospitalar de Niterói, Niterói, Rio De Janeiro, Brazil|Hospital Unimed Volta Redonda, Volta Redonda, Rio De Janeiro, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Porto Alegre (ISCMPA), Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil|CEPEM Centro de Pesquisa de Medicina Tropical de Rondônia, Porto Velho, Rondônia, Brazil|Irmandade de Misericórdia Do Hospital Da Santa Casa de Monte Alto, Monte alto, Salto Alto, Brazil|Maestri e Kormann Consultoria Medico Cientifica, Blumenau, Santa Catarina, Brazil|Imigrantes Hospital e Maternidade, Brusque, Santa Catarina, Brazil|Hospital São José, Criciúma, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Santa Casa de Araras, Araras, São Paulo, Brazil|Hospital de Amor, Barretos, São Paulo, Brazil|Santa Casa de Misericórdia de Barretos, Barretos, São Paulo, Brazil|Alphacor Cardiologia Clinica E Diagnóstica LTDA, Barueri, São Paulo, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, São Paulo, Brazil|Hospital de Cordeirópolis, Cordeirópolis, São Paulo, Brazil|Centro de Combate ao Coronavírus de Itapevi, Itapevi, São Paulo, Brazil|Dux Medicina, Jundiaí, São Paulo, Brazil|Hospital Carlos Fenando Malzoni, Matão, São Paulo, Brazil|Centro de Atendimento Para O Enfrentamento A Covid-19 Da Prefeitura Municipal de Monte Altoprefeitura de Monte Alto, Monte alto, São Paulo, Brazil|Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Hospital Casa de Saúde de Santos, Santos, São Paulo, Brazil|Kaiser Clínica e Hospital Dia, São José Do Rio Preto, São Paulo, Brazil|Hospital Policlin, São José Dos Campos, São Paulo, Brazil|Hospital Regional de São José dos Campos, São José Dos Campos, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|ESF Dr. João Paccola Primo, Lençois Paulista, Brazil|Cardioclinica da Ilha do Governador, Rio De Janeiro, Brazil|International Research Center - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital do Coração, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital Leforte, São Paulo, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Samaritano, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Hospital São Camilo Pompéia, São Paulo, Brazil|Hospital São Paulo - UNIFESP, São Paulo, Brazil|Hospital Sírio-Libanês, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04466540,Angola,Hydroxychloroquine|Placebo,3.0,2021,Tuesday
223,224,"Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1315.0,"August 31, 2020",2021-01-31,"September 14, 2020","CHU Bordeaux, Bordeaux, France|Clinique Bordeaux Nord, Bordeaux, France|Clinique Saint Augustin, Bordeaux, France|CHU de Grenoble Alpes, Grenoble, France|Hôpital Arnaud-de-Villeneuve CHU de Montpellier, Montpellier, France|Hôpitaux de Brabois CHU de Nancy, Nancy, France|Hôpital de la Milétrie CHU de Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04481620,France,,1.0,2021,Sunday
224,225,Interferon Beta 1a in Hospitalized COVID-19 Patients,Enrolling by invitation,Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine,All,"50 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 15, 2020",2020-04-24,"April 20, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04350671,"Iran, Islamic Republic of",Interferon Beta-1A|Lopinavir / Ritonavir|Single Dose of Hydroxychloroquine,4.0,2020,Friday
225,226,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Drug: Tocilizumab Injection,All,"Child, Adult, Older Adult",Phase 2,400.0,"March 19, 2020",2022-12-19,"October 22, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",https://ClinicalTrials.gov/show/NCT04317092,Italy,Tocilizumab Injection,12.0,2022,Monday
226,227,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Completed,Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,45.0,"May 18, 2020",2020-09-29,"October 5, 2020","Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina|Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04381884,Argentina,IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,9.0,2020,Tuesday
227,228,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),Recruiting,Biological: Convalescent plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,1200.0,"May 14, 2020",2020-12-31,"November 5, 2020","Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Peter Lougheed Center, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Sturgeon Community Hospital, St. Albert, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Campbellton Regional Hospital, Campbellton, New Brunswick, Canada|Edmundston Regional Hospital, Edmundston, New Brunswick, Canada|Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada|Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Bluewater Health, Sarnia, Ontario, Canada|Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hôpital Charles-Le Moyne, Longueuil, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Québec, Quebec City, Quebec, Canada|Centre hospitalier régional de St-Jérôme, Saint-Jérôme, Quebec, Canada|Ciussse De L'Estrie CHUS, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",https://ClinicalTrials.gov/show/NCT04348656,Canada,,12.0,2020,Thursday
228,229,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",Recruiting,Biological: AZD1222|Biological: Placebo,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,40000.0,"August 28, 2020",2023-02-21,"December 2, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Berkeley, California, United States|Research Site, El Centro, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Francisco, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, Atlantis, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ankeny, Iowa, United States|Research Site, Fairway, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Bloomington, Minnesota, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Berlin, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lackland Air Force Base, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellingham, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudad Autónoma de Buenos Aire, Argentina|Research Site, Quillota, Chile|Research Site, Region Metropolitana, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Floridablanca, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Callao, Peru|Research Site, Cercado De Lima, Peru|Research Site, Cercardo De Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru",https://ClinicalTrials.gov/show/NCT04516746,Argentina,,2.0,2023,Tuesday
229,230,Emotional Support and Stress Management in Patients Diagnosed With COVID-19,Not yet recruiting,"Behavioral: Training video on anxiety, fear and loneliness in the COVID-19 environment.",All,"18 Years and older   (Adult, Older Adult)",,150.0,September 2020,2020-12-31,"July 22, 2020","Montserrat Montaña, Sabadell, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04482023,Montserrat,,12.0,2020,Thursday
230,231,Atovaquone for Treatment of COVID-19,Recruiting,Drug: Experimental Group|Drug: Placebo Group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"July 22, 2020",2021-03-01,"July 30, 2020","University of Texas Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04456153,United States,Experimental Group|Placebo Group,3.0,2021,Monday
231,232,Umifenovir in Hospitalized COVID-19 Patients,Enrolling by invitation,Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 15, 2020",2020-04-24,"April 20, 2020","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04350684,"Iran, Islamic Republic of",Umifenovir|Interferon-β 1a|Lopinavir / Ritonavir|Single Dose of Hydroxychloroquine|Standards of Care,4.0,2020,Friday
232,233,Niclosamide for Mild to Moderate COVID-19,Recruiting,Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"October 1, 2020",2021-02-12,"November 12, 2020","Tufts Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04399356,United States,Niclosamide|Placebo,2.0,2021,Friday
233,234,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Recruiting,Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy,All,"18 Years and older   (Adult, Older Adult)",,120.0,"April 20, 2020",2020-12-01,"June 9, 2020","Duke University Medial Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04350073,United States,,12.0,2020,Tuesday
234,235,Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults,Recruiting,Drug: Baricitinib or Anakinra,All,70 Years and older   (Older Adult),,576.0,"April 20, 2020",2020-07-31,"April 27, 2020","Complejo Hospitalario Universitario de Albacete, Albacete, Spain",https://ClinicalTrials.gov/show/NCT04362943,Spain,Baricitinib or Anakinra,7.0,2020,Friday
235,236,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),Completed,"Biological: Reporting of anosmia, ageusia and other clinical symptoms",All,"18 Years and older   (Adult, Older Adult)",,809.0,"March 1, 2020",2020-04-30,"June 1, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04407494,France,,4.0,2020,Thursday
236,237,Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,120.0,"December 16, 2020",2023-04-30,"December 11, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04394884,United States,,4.0,2023,Sunday
237,238,CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch,Recruiting,Device: Apple Watch Series 5,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 15, 2020",2020-07-01,"May 6, 2020","Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany",https://ClinicalTrials.gov/show/NCT04376853,Germany,,7.0,2020,Wednesday
238,239,Ruxolitinib to Combat COVID-19,Withdrawn,Drug: Ruxolitinib|Procedure: Peripheral blood draw,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"June 30, 2020",2021-12-31,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04354714,Undefined,Ruxolitinib,12.0,2021,Friday
239,240,Repurposing of Chlorpromazine in Covid-19 Treatment,Not yet recruiting,Drug: CHLORPROMAZINE (CPZ)|Combination Product: Standard of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,40.0,"April 29, 2020",2020-09-30,"April 29, 2020","Centre Hospitalier Sainte-Anne, Paris, France",https://ClinicalTrials.gov/show/NCT04366739,France,CHLORPROMAZINE (CPZ),9.0,2020,Wednesday
240,241,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Not yet recruiting,Drug: Rivaroxaban|Other: Standard Of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"August 1, 2020",2021-05-30,"July 16, 2020","Kardiologie und Angiologie I Universitätsherzzentrum Freiburg, Freiburg, Baden-Württemberg, Germany|Clinic for Gastroenterology, Infectology and Poisoning Universitäsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Cardiology and Pneumology Clinic Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Bayern, Germany|Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich, Munich, Bayern, Germany|Cardiology, Pneumology and Intensive Care Clinic, München Klinik Neuperlach, München, Bayern, Germany|Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken, Hennigsdorf, Brandenburg, Germany|Clinic for Cardiology, Angiology und Nephrology Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Hessen, Germany|Clinic and Polyclinic Internal Medicine Universitätsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|Cardiology and Pneumology Clinic Universitätsmedizin Göttingen, Göttingen, Niedersachsen, Germany|Clinic for Cardiology and Intensive Care - Klinikum Bielefeld, Bielefeld, Nordrhein-Westfalen, Germany|Medical Clinic I. Marien Hospital, Universitätsklinikum der Ruhr Universität Bochum, Herne, Herne, Nordrhein-Westfalen, Germany|Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universitätsklinikum Wupperthal, Wuppertal, Nordrhein-Westfalen, Germany|Center for Cardiology, University Medicine Mainz, Mainz, Rheinland-Pfalz, Germany|Clinic for Vascular Medicine, Städtisches Krankenhaus Dresden, Dresden, Sachsen, Germany|Medical Clinic I. Universitätsklinikum Carl Gustav Carus, Dresden, Dresden, Sachsen, Germany|Cardiology, Pneumology and Intensive Care Clinic Helios Klinikum Pirna, Dresden, Pirna, Sachsen, Germany|Medical Clinic II, University Clinic Schleswig-Holstein - Campus Lübeck, Lübeck, Schleswig-Holstein, Germany|Department of Pneumology and Infectology Charité University Medicine Berlin, Campus Mitte, Berlin, Germany|Internal Medicine II, Cardiology, Sana Klinikum, Lichtenberg. Berlin, Berlin, Germany|Medical Clinic II. St. Joseph Hospital Berlin, Berlin, Germany|Department of Cardiology Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany|Internal Medicine, Hospital Bethel Berlin in Lichterfelde, Berlin, Germany|Internal Medicine/Cardiology department Unfallkrankenhaus Berlin, Berlin, Germany|Department of Cardiology Charité University Medicine Berlin, Campus Virchow, Berlin, Germany|Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin, Berlin, Germany|Intensive Care and Cardiology, Hospital Havelhöhe, Berlin, Germany|Internal Medicine Deparment Hospital Waldfriede, Berlin, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04416048,Germany,Rivaroxaban,5.0,2021,Sunday
241,242,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Recruiting,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#",All,"18 Years and older   (Adult, Older Adult)",Phase 1,216.0,"October 30, 2020",2022-01-07,"December 1, 2020","Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04636333,China,,1.0,2022,Friday
242,243,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,Recruiting,Drug: Maraviroc 300 mg|Other: Standard care therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"June 26, 2020",2020-12-20,"July 9, 2020","Hospital Clínic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04441385,Spain,Maraviroc 300 mg,12.0,2020,Sunday
243,244,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1200.0,"April 14, 2020",2020-11-30,"June 23, 2020","CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04328285,France,Hydroxychloroquine|Placebo of Hydroxychloroquine|Lopinavir and ritonavir|Placebo of LPV/r Tablets,11.0,2020,Monday
244,245,Crizanlizumab for Treating COVID-19 Vasculopathy,Recruiting,Drug: Crizanlizumab|Other: 0.9% saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"July 9, 2020",2021-01-31,"October 19, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04435184,United States,Crizanlizumab,1.0,2021,Sunday
245,246,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion,Not yet recruiting,Drug: Hydroxychloroquine Sulfate 200 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1500.0,September 2020,2025-08-01,"July 13, 2020",,https://ClinicalTrials.gov/show/NCT04389359,Undefined,Hydroxychloroquine Sulfate 200 MG,8.0,2025,Friday
246,247,Endothelial Function and COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,100.0,"June 3, 2020",2020-09-30,"August 25, 2020","Mayo Clinic, Rochester, Minnesota, United States|Hospital Clínico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04525443,Spain,,9.0,2020,Wednesday
247,248,"Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults",Not yet recruiting,Other: this study is non- interventional,All,"Child, Adult, Older Adult",,160.0,April 2020,2020-10-01,"April 14, 2020","University Hospital Cologne, Cologne, NRW, Germany",https://ClinicalTrials.gov/show/NCT04341168,Germany,,10.0,2020,Thursday
248,249,Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19,Recruiting,,All,"18 Years to 75 Years   (Adult, Older Adult)",,60.0,"May 5, 2020",2021-04-01,"August 18, 2020","Hôpital Pitie Salpétrère, Paris, France",https://ClinicalTrials.gov/show/NCT04379466,France,,4.0,2021,Thursday
249,250,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,Completed,Drug: Sarilumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1912.0,"March 18, 2020",2020-09-02,"October 1, 2020","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States",https://ClinicalTrials.gov/show/NCT04315298,Georgia,Sarilumab|Placebo,9.0,2020,Wednesday
250,251,PROLIFIC ChemoprophylaxisTrial (COVID-19),Recruiting,Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1000.0,"May 11, 2020",2021-04-01,"May 13, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",https://ClinicalTrials.gov/show/NCT04352933,United Kingdom,Hydroxychloroquine - Daily dosing|Hydroxychloroquine - Weekly Dosing,4.0,2021,Thursday
251,252,Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults,Not yet recruiting,Drug: Maraviroc + Currently used therapy|Procedure: Curently used therapy for COVID-19 non-critical patients|Drug: Favipiravir + Currently used therapy|Drug: Maraviroc+Favipiravir+CT,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,100.0,November 2020,2021-01-01,"November 4, 2020","Hospital General de México ""Dr. Eduardo Liceaga"", Mexico City, Cdmx, Mexico",https://ClinicalTrials.gov/show/NCT04475991,Mexico,Maraviroc + Currently used therapy|Favipiravir + Currently used therapy|Maraviroc+Favipiravir+CT,1.0,2021,Friday
252,253,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,Recruiting,Drug: Brequinar|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,"June 25, 2020",2021-04-01,"October 28, 2020","Hartford Hospital, Hartford, Connecticut, United States|Baptist Medical Center, Jacksonville, Florida, United States|University of South Florida/Tampa General, Tampa, Florida, United States|University of New Mexico, Albuquerque, New Mexico, United States|Temple University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04425252,Mexico,Brequinar,4.0,2021,Thursday
253,254,Validation of COVID-19 Tests,"Active, not recruiting",Diagnostic Test: Covid-19 Rapid Test Kit (RAPG-COV-019)|Diagnostic Test: Quantitative IgG Test,All,"18 Years to 70 Years   (Adult, Older Adult)",,500.0,"March 16, 2020",2020-08-01,"May 27, 2020","Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04404062,United Kingdom,,8.0,2020,Saturday
254,255,Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19),Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,July 2020,2021-04-01,"July 21, 2020","Stony Brook University Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04452942,United States,,4.0,2021,Thursday
255,256,The COVID-19 Mobile Health Study (CMHS),Recruiting,"Other: nCapp, a cell phone-based auto-diagnosis system",All,"18 Years to 90 Years   (Adult, Older Adult)",,450.0,"February 14, 2020",2020-05-31,"February 19, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04275947,China,,5.0,2020,Sunday
256,257,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Not yet recruiting,Dietary Supplement: Vitamin D3 (cholecalciferol)|Dietary Supplement: Zinc (zinc gluconate)|Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,700.0,"December 7, 2020",2021-12-31,"November 23, 2020","Saifee Hospital, Mumbai, Maharashtra, India|King Edward Memorial (KEM) Hospital, Pune, Maharashtra, India",https://ClinicalTrials.gov/show/NCT04641195,India,,12.0,2021,Friday
257,258,COVID-19 Pandemic and Worldwide Organ Procurement,Recruiting,,All,"Child, Adult, Older Adult",,230000.0,"February 1, 2020",2022-02-01,"June 4, 2020","Paris Transplant Group, Paris, France",https://ClinicalTrials.gov/show/NCT04416256,France,,2.0,2022,Tuesday
258,259,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Recruiting,Drug: Placebo|Drug: Ruxolitinib,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,500.0,"May 24, 2020",2021-04-30,"October 20, 2020","Honor Health Research Institute, Scottsdale, Arizona, United States|Sharp Memorial Hospital, San Diego, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Teradan Clinical Trials, Brandon, Florida, United States|University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Northshore University Health System, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mercy Research, Springfield, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Njms Clinical Research Unit, Newark, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Kettering Cancer Care, Dayton, Ohio, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Allegheny Health Network, Wexford, Pennsylvania, United States|St David'S Medical Center, Austin, Texas, United States|University of Texas Health Science Center At Houston - McGovern Medical School, Houston, Texas, United States|University of Texas Health Science Cente, San Antonio, Texas, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States|Sbih City Hospital 15, Saint Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04377620,India,Placebo|Ruxolitinib,4.0,2021,Friday
259,260,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Drug: Favipiravir|Drug: Standard of care (SOC)|Drug: standard concomitant therapy,All,18 Years to 60 Years   (Adult),Phase 3,168.0,"May 20, 2020",2020-08-01,"August 6, 2020","Medical center LLC ""Neuroprofi"", Korolev, Russian Federation|Federal budgetary institution of science ""Central Research Institute of Epidemiology"" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare, Moscow, Russian Federation|Medical centers JSC ""Medsi Group of Companies"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""City Clinical Hospital №57 of the Moscow City Healthcare Department"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""Infectious Diseases Clinical Hospital №1 of the Moscow City Healthcare Department"", Moscow, Russian Federation|Medical center LLC ""Medical Center Eco-safety"", Saint Petersburg, Russian Federation|St. Petersburg State Budgetary Healthcare Institution ""City Hospital No. 40 of the Kurortny District"", Saint Petersburg, Russian Federation|Budgetary healthcare institution of the Voronezh region ""Voronezh Regional Clinical Hospital No. 1"", Voronezh, Russian Federation|State Budgetary Healthcare Institution of the Moscow Region ""Zhukovskaya City Clinical Hospital""., Zhukovskiy, Russian Federation",https://ClinicalTrials.gov/show/NCT04501783,Russian Federation,Favipiravir|Standard of care (SOC)|standard concomitant therapy,8.0,2020,Saturday
260,261,Vitamin D and COVID-19 Management,Not yet recruiting,"Dietary Supplement: Ddrops® products, 50,000 IU, Oral|Dietary Supplement: Vitamin D3",All,"17 Years and older   (Child, Adult, Older Adult)",Phase 3,64.0,June 2020,2020-12-01,"June 5, 2020",,https://ClinicalTrials.gov/show/NCT04385940,Undefined,,12.0,2020,Tuesday
261,262,Hydroxychloroquine in COVID-19 Patients,Recruiting,Drug: Hydroxychloroquine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,200.0,"March 21, 2020",2020-08-01,"May 19, 2020","SNH, Mecca, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04394442,Saudi Arabia,Hydroxychloroquine,8.0,2020,Saturday
262,263,Methodist Health System COVID-19 Patient Registry,Recruiting,Other: Treatment for COVID-19,All,"18 Years and older   (Adult, Older Adult)",,500.0,"June 20, 2020",2026-12-01,"September 24, 2020","Clinical Research Institute Methodist Health System, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04477889,United States,,12.0,2026,Tuesday
263,264,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Not yet recruiting,Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,"September 4, 2020",2021-09-03,"September 3, 2020","Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt",https://ClinicalTrials.gov/show/NCT04535869,Egypt,Sofosbuvir 400 MG plus Daclatasvir 200mg,9.0,2021,Friday
264,265,COVID-19 With Convalescent Plasma,Completed,Biological: convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",,78.0,"January 1, 2020",2020-11-01,"November 5, 2020","Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04616976,China,,11.0,2020,Sunday
265,266,COVID-19 Active Research Experience (CARE),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100000.0,"April 2, 2020",2022-06-01,"November 17, 2020","IQVIA, Cambridge, Massachusetts, United States|IQVIA, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04368065,United Kingdom,,6.0,2022,Wednesday
266,267,Dynamic Evaluation of COVID-19 Diagnostic Tests,Recruiting,Diagnostic Test: COVID-19 diagnostic test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,165.0,"July 13, 2020",2020-12-01,"September 25, 2020","CH Tourcoing, Tourcoing, France",https://ClinicalTrials.gov/show/NCT04337996,France,,12.0,2020,Tuesday
267,268,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,342.0,"April 3, 2020",2021-03-01,"December 9, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium",https://ClinicalTrials.gov/show/NCT04330638,Belgium,Anakinra|Siltuximab|Tocilizumab,3.0,2021,Monday
268,269,Rapid Experimental Medicine for COVID-19,Recruiting,Drug: Nafamostat Mesilate|Drug: TD139|Other: Standard care,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,60.0,"July 3, 2020",2021-12-03,"August 21, 2020","NHS Lothian, Edinburgh, United Kingdom",https://ClinicalTrials.gov/show/NCT04473053,United Kingdom,Nafamostat Mesilate|TD139,12.0,2021,Friday
269,270,A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19),Recruiting,Other: blood sample,All,"Child, Adult, Older Adult",,500.0,"February 1, 2020",2022-12-30,"July 8, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04347850,France,,12.0,2022,Friday
270,271,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,Completed,Other: Survey Group,,"Child, Adult, Older Adult",,1819.0,"March 24, 2020",2020-04-17,"April 29, 2020","Fondazione Policlinico Universitario ""Agostino Gemelli"", Rome, Italy",https://ClinicalTrials.gov/show/NCT04367896,Italy,,4.0,2020,Friday
271,272,Lanadelumab for Treatment of COVID-19 Disease,Recruiting,Biological: lanadelumab|Other: regular care,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,80.0,"October 3, 2020",2021-08-03,"September 14, 2020","Jereoen Bosch hospital, 's-Hertogenbosch, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Tergooi ziekenhuizen, Blaricum, Netherlands|Amphia hospital, Breda, Netherlands|Haga hospital, Den Haag, Netherlands|Radboudumc, Nijmegen, Netherlands|Elisabeth-Tweesteden ziekenhuis, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala klinieken, Zwolle, Netherlands",https://ClinicalTrials.gov/show/NCT04422509,Netherlands,,8.0,2021,Tuesday
272,273,COVID-19 Patient Positioning Pragmatic Trial,Enrolling by invitation,Other: Prone|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"April 27, 2020",2021-06-01,"December 8, 2020","NorthShore University HealthSystem, Highland Park, Illinois, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|UT Houston, Houston, Texas, United States|University of Texas San Antonio, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04359797,United States,,6.0,2021,Tuesday
273,274,A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,Recruiting,Drug: MRx-4DP0004|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,June 2020,2020-09-01,"July 1, 2020","University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom",https://ClinicalTrials.gov/show/NCT04363372,United Kingdom,MRx-4DP0004|Placebo,9.0,2020,Tuesday
274,275,Allocetra-OTS in COVID-19,"Active, not recruiting",Biological: Allocetra-OTS,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,5.0,"August 1, 2020",2021-02-01,"October 19, 2020","Hadassah Medical Center, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04513470,Israel,,2.0,2021,Monday
275,276,Famotidine Outpatient COVID-19 Treatment Study,Completed,Drug: Famotidine,All,"18 Years and older   (Adult, Older Adult)",,10.0,"May 12, 2020",2020-05-25,"June 4, 2020","Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States",https://ClinicalTrials.gov/show/NCT04389567,United States,Famotidine,5.0,2020,Monday
276,277,Leflunomide in Mild COVID-19 Patients,Recruiting,Drug: Leflunomide,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"May 5, 2020",2021-02-01,"October 29, 2020","University of Chicago, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04361214,United States,Leflunomide,2.0,2021,Monday
277,278,"Novel COVID-19, A National Analysis",Completed,Other: Prevalence of COVID-19,All,"Child, Adult, Older Adult",,61.0,"May 20, 2020",2020-07-28,"August 4, 2020","Assiut University Hospitals, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04413045,Egypt,,7.0,2020,Tuesday
278,279,Beat COVID-19 - Observational Trial,Recruiting,,All,"18 Years to 110 Years   (Adult, Older Adult)",,100000.0,"April 6, 2020",2021-07-01,"April 9, 2020","Beat COIVD, LLC, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04337762,United States,,7.0,2021,Thursday
279,280,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Recruiting,Drug: BI 764198|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,90.0,"November 3, 2020",2021-05-05,"December 1, 2020","Rapides Regional Medical Center, Alexandria, Louisiana, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Mercy Health St. Vincent Medical Center, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT04604184,United States,BI 764198|Placebo,5.0,2021,Wednesday
280,281,Treating COVID-19 With Hydroxychloroquine (TEACH),Suspended,Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,626.0,"April 15, 2020",2021-06-01,"July 2, 2020","State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04369742,United States,Hydroxychloroquine (HCQ),6.0,2021,Tuesday
281,282,Duke COVID-19 Shared Data and Specimen Repository,Recruiting,,All,"Child, Adult, Older Adult",,100000.0,"April 18, 2020",2025-04-30,"July 23, 2020","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04368234,United States,,4.0,2025,Wednesday
282,283,Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica,Not yet recruiting,Genetic: 1. Characterize the immune response after infection with SARS-CoV-2,All,"6 Months to 100 Years   (Child, Adult, Older Adult)",,2000.0,"September 14, 2020",2022-09-14,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04537338,Undefined,,9.0,2022,Wednesday
283,284,"A COVID-19 Symptom, Exposure and Immune Response Registry","Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"May 29, 2020",2021-05-01,"October 9, 2020","ObvioHealth, Orlando, Florida, United States",https://ClinicalTrials.gov/show/NCT04348942,United States,,5.0,2021,Saturday
284,285,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,Biological: Convalescent plasma,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1200.0,"June 24, 2020",2021-12-01,"July 7, 2020","Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lower Manhattan Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04418518,United States,,12.0,2021,Wednesday
285,286,COPING With COVID-19( CWC-19),Withdrawn,Behavioral: Crisis management coaching,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,"March 27, 2020",2020-05-01,"September 23, 2020","Duke University, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04343690,United States,,5.0,2020,Friday
286,287,COVID-19 Pandemic and Academic Performance of Veterinary Students,Completed,Other: survey,All,18 Years to 60 Years   (Adult),,1426.0,"April 13, 2020",2020-08-10,"September 9, 2020","South Valley University, Qinā, Egypt",https://ClinicalTrials.gov/show/NCT04387214,Egypt,,8.0,2020,Monday
287,288,Complementary Intervention for COVID-19,Recruiting,Dietary Supplement: Licorice extract,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,70.0,"January 1, 2020",2021-01-01,"July 28, 2020","Faculty of Medicine, Assiut University, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04487964,Egypt,,1.0,2021,Friday
288,289,Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,Recruiting,Drug: Methylprednisolone|Drug: Heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,268.0,"July 20, 2020",2020-12-31,"July 24, 2020","D'Or Institute for Research and Education, Rio de Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04485429,Brazil,Methylprednisolone|Heparin,12.0,2020,Thursday
289,290,Hypertonic Saline for COVID-19 Symptoms,Recruiting,Other: Wearing surgical face mask sprayed with hypertonic saline,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"July 1, 2020",2021-05-01,"July 10, 2020","King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04465604,Saudi Arabia,,5.0,2021,Saturday
290,291,COVID-19: A POC Test Under Research & Evaluation,Recruiting,Diagnostic Test: Sample Collection/Performance Evaluation (A)|Diagnostic Test: Sample Collection/Performance Evaluation (B),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"April 30, 2020",2022-04-30,"June 4, 2020","Barts Health NHS Trust, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04408066,United Kingdom,,4.0,2022,Saturday
291,292,Low Dose Whole Lung Radiotherapy for Older Patients With COVID-19 Pneumonitis,Not yet recruiting,Radiation: Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis,All,65 Years and older   (Older Adult),Phase 1|Phase 2,500.0,November 2020,2021-12-01,"July 30, 2020",,https://ClinicalTrials.gov/show/NCT04493294,Undefined,,12.0,2021,Wednesday
292,293,Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).,Not yet recruiting,Drug: Olokizumab 64 mg|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,376.0,"June 30, 2020",2021-01-29,"June 30, 2020","George Washington University Medical Center, Washington, District of Columbia, United States|Center For Haptitis C/ Atlanta Medical Center, Atlanta, Georgia, United States|PMG Research of DuPage Medical Group, Downers Grove, Illinois, United States|Northwest Indiana Center for Clinical Research, Portage, Indiana, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|PMG Research, Inc., Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04452474,Georgia,Olokizumab 64 mg|Placebo,1.0,2021,Friday
293,294,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,Recruiting,Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 3,7000.0,"September 7, 2020",2021-09-01,"November 5, 2020","University of Florida at Gainesville, Gainesville, Florida, United States|University of Floridia at Jacksonville, Jacksonville, Florida, United States|Bond Community Health Center, Tallahassee, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Intermountain Healthcare, Murray, Utah, United States",https://ClinicalTrials.gov/show/NCT04498273,United States,Apixaban 2.5 MG|Apixaban 5MG|Aspirin|Placebo,9.0,2021,Wednesday
294,295,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Completed,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372.0,"April 23, 2020",2020-07-24,"September 29, 2020","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04380519,Russian Federation,Olokizumab 64 mg|Placebo,7.0,2020,Friday
295,296,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"Active, not recruiting",Drug: Sargramostim|Other: Control,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,80.0,"March 24, 2020",2021-03-31,"December 9, 2020","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium",https://ClinicalTrials.gov/show/NCT04326920,Belgium,Sargramostim,3.0,2021,Wednesday
296,297,Anxiety And Depression During COVID-19 IN INDIA,Recruiting,Behavioral: Registery Data Collection,All,"18 Years to 90 Years   (Adult, Older Adult)",,1000.0,"April 24, 2020",2021-02-24,"July 15, 2020","Max Super Speciality hospital, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04369300,India,,2.0,2021,Wednesday
297,298,MSCT Chest in Suspected COVID-19 Patients,Not yet recruiting,Device: MSCT,All,"18 Years and older   (Adult, Older Adult)",,150.0,"July 30, 2020",2020-10-30,"July 30, 2020","Assiut university, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04492865,Egypt,,10.0,2020,Friday
298,299,Hyperbaric Oxygen for COVID-19 Patients,Terminated,Device: hyperbaric oxygen therapy (HBOT),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 6, 2020",2020-05-29,"June 4, 2020","NYU Winthrop Hospital, Mineola, New York, United States",https://ClinicalTrials.gov/show/NCT04332081,United States,,5.0,2020,Friday
299,300,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Recruiting,Radiation: Single fraction whole lung radiotherapy,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"May 10, 2020",2022-08-30,"July 22, 2020","Radiation Oncology Department, ASST SpedaliCivili, Brescia, Brescia, Italy",https://ClinicalTrials.gov/show/NCT04377477,Italy,,8.0,2022,Tuesday
300,301,Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19,Recruiting,Drug: Plant Polyphenol|Dietary Supplement: Vitamin D3,All,"45 Years and older   (Adult, Older Adult)",Phase 2,200.0,"September 12, 2020",2021-01-01,"September 24, 2020","Mt Carmel HealthSystems, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04400890,United States,Plant Polyphenol,1.0,2021,Friday
301,302,A Pilot Study of Sildenafil in COVID-19,Recruiting,Drug: Sildenafil citrate tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10.0,"February 9, 2020",2020-11-09,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04304313,China,Sildenafil citrate tablets,11.0,2020,Monday
302,303,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",Recruiting,Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 5, 2020",2020-06-01,"May 13, 2020","Hôpital Cochin, Paris, France",https://ClinicalTrials.gov/show/NCT04365725,France,Remdesivir,6.0,2020,Monday
303,304,Cardiovascular Effects of COVID-19,Recruiting,Drug: AT-001,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 8, 2020",2020-12-31,"April 28, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04365699,United States,AT-001,12.0,2020,Thursday
304,305,Abatacept for Patients With COVID-19 and Respiratory Distress,Withdrawn,Drug: Abatacept,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,0.0,August 2020,2020-12-01,"July 20, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04477642,Israel,Abatacept,12.0,2020,Tuesday
305,306,COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study,Not yet recruiting,,All,"18 Years to 75 Years   (Adult, Older Adult)",,314.0,"June 7, 2020",2020-08-30,"June 9, 2020","Max Super Speciality Hospital, Saket (A Unit Of Devki Devi Foundation), New Delhi, Dlelhi, India",https://ClinicalTrials.gov/show/NCT04422379,India,,8.0,2020,Sunday
306,307,Tele-monitoring of COVID-19 Survivors for Long-Term Impacts,Not yet recruiting,Combination Product: cardiovascular and respiratory systems monitoring,All,"18 Years to 90 Years   (Adult, Older Adult)",,20.0,"December 1, 2020",2021-11-01,"November 25, 2020",,https://ClinicalTrials.gov/show/NCT04644341,Undefined,,11.0,2021,Monday
307,308,Convalescent Plasma in COVID-19 Elderly Patients,Completed,Biological: Convalescent plasma,All,65 Years and older   (Older Adult),Phase 2,21.0,"May 15, 2020",2020-09-03,"October 5, 2020","Transfusion Service, Mantova, Italy",https://ClinicalTrials.gov/show/NCT04569188,Italy,,9.0,2020,Thursday
308,309,Arrhythmias in Patients With COVID-19,Completed,Device: C3+ Holter Monitor,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 16, 2020",2020-09-01,"September 9, 2020","Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmark",https://ClinicalTrials.gov/show/NCT04395664,Denmark,,9.0,2020,Tuesday
309,310,Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,Recruiting,Drug: Zilucoplan®|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,81.0,"May 22, 2020",2021-09-01,"July 9, 2020","OLVZ Aalst, Aalst, Belgium|AZ Sint Jan Brugge, Brugge, Belgium|Erasmus University Hospital, Brussels, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jan Yperman Ziekenhuis Ieper, Ieper, Belgium|University Hospital Liège, Liège, Belgium|AZ Delta, Roeselare, Belgium|AZ Vesalius, Tongeren, Belgium",https://ClinicalTrials.gov/show/NCT04382755,Belgium,Zilucoplan®|Placebo,9.0,2021,Wednesday
310,311,Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program,Available,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",,,,,"April 29, 2020",,https://ClinicalTrials.gov/show/NCT04363034,Undefined,,,n,
311,312,Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak),Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 15, 2020",2022-04-15,"April 17, 2020","St. Georges Hospital Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04351646,United Kingdom,,4.0,2022,Friday
312,313,SCB-2019 as COVID-19 Vaccine,Recruiting,Biological: SCB-2019|Biological: SCB-2019 with AS03 adjuvant|Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,150.0,"June 19, 2020",2021-03-30,"June 23, 2020","Linear Clinical Research Ltd, Nedlands, Western Australia, Australia",https://ClinicalTrials.gov/show/NCT04405908,Australia,,3.0,2021,Tuesday
313,314,Immune Biomarkers of Outcome From COVID-19,Recruiting,Diagnostic Test: Peripheral blood sampling,All,"18 Years and older   (Adult, Older Adult)",,200.0,"April 29, 2020",2021-02-19,"December 3, 2020","University Hospitals Plymouth NHS Trust, Plymouth, Devon, United Kingdom",https://ClinicalTrials.gov/show/NCT04436484,United Kingdom,,2.0,2021,Friday
314,315,To Observe Whether Isoflurane Can Treat COVID-19 Patients,Completed,,All,"18 Years and older   (Adult, Older Adult)",,35.0,"April 20, 2020",2020-06-30,"September 2, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04492943,United States,,6.0,2020,Tuesday
315,316,Awake Prone Position for Early Hypoxemia in COVID-19,Enrolling by invitation,Other: Self-prone position recommendation|Other: Usual care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,560.0,"April 23, 2020",2020-12-01,"December 3, 2020","Long Beach Medical Center - MemorialCare, Long Beach, California, United States|Alvarado Hospital, San Diego, California, United States|St. Joseph's Hospital National Jewish Health, Denver, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Piedmont Atlanta, Atlanta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Creighton University, Omaha, Nebraska, United States|Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas, United States|VCU Medical Center, Richmond, Virginia, United States|Hospital Universitario La Paz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04344587,Georgia,,12.0,2020,Tuesday
316,317,Safety in Convalescent Plasma Transfusion to COVID-19,Recruiting,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"May 8, 2020",2021-04-30,"July 28, 2020","Hospital San José, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04333355,Mexico,,4.0,2021,Friday
317,318,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Enrolling by invitation,Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20.0,"July 17, 2020",2020-10-01,"July 22, 2020","Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04441996,Georgia,,10.0,2020,Thursday
318,319,Camostat Mesylate in COVID-19 Outpatients,Recruiting,Drug: Camostat Mesilate|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,114.0,"June 19, 2020",2021-05-31,"November 24, 2020","Yale University, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04353284,United States,Camostat Mesilate,5.0,2021,Monday
319,320,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,Other: Surgical facial mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6000.0,"April 2, 2020",2020-06-02,"August 3, 2020","Rigshospitalet, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04337541,Denmark,,6.0,2020,Tuesday
320,321,Convalescent Plasma for the Treatment of COVID-19,Recruiting,Drug: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"April 15, 2020",2021-04-14,"June 25, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04389710,United States,Convalescent Plasma,4.0,2021,Wednesday
321,322,Clinical Course and Treatment of COVID-19 Inpatients in Hospital,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"August 1, 2020",2021-08-31,"August 26, 2020","Institut für Pneumologie an der Universität zu Köln / Wissenschaftliches Institut Bethanien für Pneumologie e.V., Solingen, Nordrhein-Westfalen, Germany",https://ClinicalTrials.gov/show/NCT04527497,Germany,,8.0,2021,Tuesday
322,323,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"Active, not recruiting",Drug: Gimsilumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,227.0,"April 12, 2020",2021-03-01,"December 3, 2020","Banner University Medical Center, Phoenix, Arizona, United States|HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States|HonorHealth, Scottsdale, Arizona, United States|HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States|Banner University Medical Center, Tucson, Arizona, United States|UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Miami Cancer institute, Miami, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott & White All Saints Medical Center, Fort Worth, Texas, United States|Memorial Hermann Hospital Affiliated with University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|Baylor Scott & White Medical Center, Irving, Texas, United States|Baylor Scott & White Medical Center, Plano, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States",https://ClinicalTrials.gov/show/NCT04351243,Georgia,Gimsilumab|Placebo,3.0,2021,Monday
323,324,CAP-1002 in Severe COVID-19 Disease,No longer available,Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells,All,"18 Years and older   (Adult, Older Adult)",,,,,"December 1, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04338347,United States,,,n,
324,325,Vocal Feature Analysis Algorithm for COVID-19 Detection,Recruiting,Device: Device used to record voice for screening,All,"18 Years and older   (Adult, Older Adult)",,400.0,"June 1, 2020",2020-12-01,"October 30, 2020","Soniphi, Sebastopol, California, United States",https://ClinicalTrials.gov/show/NCT04418544,United States,,12.0,2020,Tuesday
325,326,GRAd-COV2 Vaccine Against COVID-19,Recruiting,Biological: GRAd-COV2,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,90.0,"August 10, 2020",2021-07-31,"August 31, 2020","INMI Spallanzani, Rome, Italy|Centro Ricerche Cliniche, Verona, Italy",https://ClinicalTrials.gov/show/NCT04528641,Italy,,7.0,2021,Saturday
326,327,Attitude and Perception Towards COVID-19 Pandemic,Enrolling by invitation,Other: questionnaire,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",,5000.0,"May 19, 2020",2020-10-01,"August 4, 2020","Zagazig University, Zagazig, Sharkia, Egypt",https://ClinicalTrials.gov/show/NCT04400812,Egypt,,10.0,2020,Thursday
327,328,Geriatric Population COVID-19 Observational Study (GEROCOVIDobs),Recruiting,,All,"60 Years and older   (Adult, Older Adult)",,1500.0,"April 25, 2020",2020-11-30,"May 7, 2020","RSA La Quiete, Castiglione Cosentino, Calabria, Italy|ASP Catanzaro, Catanzaro Lido, Calabria, Italy|AOU Ferrara, Ferrara, Emilia Romagna, Italy|Policlinico Campus Bio-Medico, Rome, Roma, Italy|AOU Careggi, Firenze, Toscana, Italy|AOU Pisana Geriatria, Pisa, Toscana, Italy|Ospedale di Comunita' ULSS 6 Euganea- COVID Center, Camposampiero, Veneto, Italy",https://ClinicalTrials.gov/show/NCT04379440,Italy,,11.0,2020,Monday
328,329,Atorvastatin as Adjunctive Therapy in COVID-19,Not yet recruiting,Drug: Atorvastatin,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,300.0,"May 20, 2020",2022-05-08,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04380402,Undefined,Atorvastatin,5.0,2022,Sunday
329,330,The Role of Ultrasound in COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 31, 2020",2021-03-01,"November 16, 2020","Cardiovascular Non-Invasive Imaging Research Laboratory, department of Cardiology, Herlev & Gentofte Hospital, Hellerup, Denmark",https://ClinicalTrials.gov/show/NCT04377035,Denmark,,3.0,2021,Monday
330,331,Dietary Intake and Eating Habits During the COVID-19 Pandemic,Recruiting,Other: Diet tracking and survey,All,"18 Years and older   (Adult, Older Adult)",,1920.0,"May 25, 2020",2022-08-31,"September 18, 2020","McGill University - School of Human Nutrition, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04407533,Canada,,8.0,2022,Wednesday
331,332,Evaluating the Immune Response for COVID-19,Recruiting,Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"May 1, 2020",2020-12-31,"November 3, 2020","Assaf-Harofeh Medical Center, Ramla, Israel",https://ClinicalTrials.gov/show/NCT04348422,Israel,,12.0,2020,Thursday
332,333,SCIL-1Ra in COVID-19 Feasibility & PK/PD,Suspended,Drug: Anakinra 100Mg/0.67Ml Inj Syringe,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5.0,"May 28, 2020",2020-12-31,"October 23, 2020","Manchester Univesity NHS Foundation Trust, Manchester, United Kingdom|Salford Royal NHS Foundation Tust, Salford, United Kingdom",https://ClinicalTrials.gov/show/NCT04462757,United Kingdom,Anakinra 100Mg/0.67Ml Inj Syringe,12.0,2020,Thursday
333,334,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,77.0,"April 21, 2020",2020-09-20,"October 8, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04359277,United States,Enoxaparin Higher Dose|Lower-dose prophylactic anticoagulation,9.0,2020,Sunday
334,335,Administration of Chlorpromazine as a Treatment for COVID-19,Not yet recruiting,Drug: Chlorpromazine,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"August 1, 2020",2020-11-01,"July 8, 2020","Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04354805,Egypt,Chlorpromazine,11.0,2020,Sunday
335,336,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,Drug: Amiodarone|Drug: Verapamil,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2|Phase 3,804.0,"April 27, 2020",2021-04-10,"April 17, 2020","Nicolaus Copernicus University, Bydgoszcz, Poland",https://ClinicalTrials.gov/show/NCT04351763,Poland,Amiodarone|Verapamil,4.0,2021,Saturday
336,337,Detection of COVID-19 Subjects Using DiaNose Exhalation Test,Not yet recruiting,Device: DiaNose,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"August 1, 2020",2021-06-30,"July 20, 2020",,https://ClinicalTrials.gov/show/NCT04476927,Undefined,,6.0,2021,Wednesday
337,338,Antiviral Agents Against COVID-19 Infection,Not yet recruiting,Drug: Atazanavir|Drug: Daclatasvir 60 mg|Drug: Sofusbuvir + Daclastavir 60 mg|Drug: Placebo Atazanavir|Drug: Placebo Daclatasvir 60 mg|Drug: Placebo Sofusbuvir + Daclatasvir 60 mg,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,1005.0,"December 1, 2020",2021-04-30,"November 16, 2020","Hospital do Coracao, Sao Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04468087,Brazil,Atazanavir|Daclatasvir 60 mg|Sofusbuvir + Daclastavir 60 mg|Placebo Atazanavir|Placebo Daclatasvir 60 mg|Placebo Sofusbuvir + Daclatasvir 60 mg,4.0,2021,Friday
338,339,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,17.0,"April 22, 2020",2020-10-12,"November 2, 2020","Institute for Tropical Medicine, Tübingen, Germany",https://ClinicalTrials.gov/show/NCT04340544,Germany,Hydroxychloroquine|Placebo,10.0,2020,Monday
339,340,Tofacitinib for Treatment of Moderate COVID-19,"Active, not recruiting",Drug: Tofacitinib 10 mg|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,60.0,"July 29, 2020",2021-03-31,"December 9, 2020","Yale New Haven Health System, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04415151,United States,Tofacitinib 10 mg|Placebo,3.0,2021,Wednesday
340,341,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,Procedure: Prone position ventilation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"May 11, 2020",2020-12-01,"May 14, 2020","Nordsjællands Hospital, Hillerød, Region Hovedstanden, Denmark",https://ClinicalTrials.gov/show/NCT04384900,Denmark,,12.0,2020,Tuesday
341,342,Etoposide in Patients With COVID-19 Infection,Recruiting,Drug: Etoposide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64.0,"May 8, 2020",2021-12-01,"September 4, 2020","Boston Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04356690,United States,Etoposide,12.0,2021,Wednesday
342,343,ACT-20 in Patients With Severe COVID-19 Pneumonia,Not yet recruiting,Biological: ACT-20-MSC|Biological: ACT-20-CM|Biological: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,70.0,May 2020,2020-10-01,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04398303,Undefined,,10.0,2020,Thursday
343,344,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,Recruiting,Drug: OP-101|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"July 1, 2020",2021-01-31,"November 19, 2020","Research Site, Loma Linda, California, United States|Research site, Fort Lauderdale, Florida, United States|Research Site, Atlanta, Georgia, United States|Research site, Baltimore, Maryland, United States|Research Site, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04458298,Georgia,OP-101|Placebo,1.0,2021,Sunday
344,345,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Recruiting,Diagnostic Test: Outpatient MRI,All,"18 Years and older   (Adult, Older Adult)",,507.0,"April 21, 2020",2023-05-31,"April 30, 2020","Mayo Clinic Healthcare, London, United Kingdom|Gemini, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04369807,United Kingdom,,5.0,2023,Wednesday
345,346,Treatment of Angiotensin Peptide (1-7) for COVID-19,Recruiting,Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 25, 2020",2020-09-30,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04375124,Turkey,,9.0,2020,Wednesday
346,347,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Recruiting,Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo,Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,100.0,"October 26, 2020",2022-09-01,"December 8, 2020","University of Florida Clinincal Research Vehicle, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT04509999,United States,Bicalutamide 150 Mg Oral Tablet|Placebo,9.0,2022,Thursday
347,348,Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction,Recruiting,,All,"18 Years to 90 Years   (Adult, Older Adult)",,50.0,"April 16, 2020",2021-07-31,"May 27, 2020","Klinik für Anästhesiologie, Düsseldorf, Germany",https://ClinicalTrials.gov/show/NCT04381351,Germany,,7.0,2021,Saturday
348,349,Cyclosporine in Patients With Moderate COVID-19,Recruiting,Drug: Cyclosporine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"June 30, 2020",2021-12-01,"October 23, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04412785,United States,Cyclosporine,12.0,2021,Wednesday
349,350,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Recruiting,Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"March 20, 2020",2020-08-31,"May 15, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04377789,Turkey,,8.0,2020,Monday
350,351,Respiratory Physiotherapy in Severe COVID-19 Patients,Recruiting,Other: Respiratory physiotherapy,All,"18 Years to 80 Years   (Adult, Older Adult)",,80.0,"March 1, 2020",2020-09-30,"August 11, 2020","Department of Pathophysiology and Transplantation, University of Milan Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",https://ClinicalTrials.gov/show/NCT04459819,Italy,,9.0,2020,Wednesday
351,352,Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19,Not yet recruiting,"Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir|Drug: Standard of care treatment",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,July 2020,2020-12-01,"June 25, 2020",,https://ClinicalTrials.gov/show/NCT04443725,Undefined,"Hydroxychloroquine , Sofosbuvir, daclatasvir|Standard of care treatment",12.0,2020,Tuesday
352,353,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Recruiting,Drug: PF-06650833|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,68.0,"November 30, 2020",2021-03-31,"December 3, 2020","Yale New Haven Hospital, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04575610,United States,PF-06650833|Placebo,3.0,2021,Wednesday
353,354,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Recruiting,Drug: Nitric Oxide,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"September 2, 2020",2020-12-01,"September 11, 2020","University Health Network, Toronto General Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04383002,Canada,Nitric Oxide,12.0,2020,Tuesday
354,355,Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,Completed,,All,"up to 100 Years   (Child, Adult, Older Adult)",,200.0,"April 6, 2020",2020-08-30,"November 3, 2020","Cliniques Universitaires Saint Luc, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04376398,Belgium,,8.0,2020,Sunday
355,356,Hexoskin Feasibility Study With COVID-19 Patients,Not yet recruiting,Device: Monitoring physiological data with the Hexoskin smart shirt,All,"55 Years and older   (Adult, Older Adult)",,16.0,"July 15, 2020",2020-12-15,"July 1, 2020",,https://ClinicalTrials.gov/show/NCT04453891,Undefined,,12.0,2020,Tuesday
356,357,PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,Not yet recruiting,Dietary Supplement: Placebo|Dietary Supplement: Vitamin D,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 3,2414.0,"November 30, 2020",2021-06-30,"November 23, 2020","CHUM, Montreal, Quebec, Canada|CHU Sainte-Justine (CHUSJ), Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04483635,Canada,,6.0,2021,Wednesday
357,358,Ozone Auto-hemotherapy for COVID-19 Pneumonia,Not yet recruiting,Biological: Ozone auto-hemotherapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,208.0,"May 25, 2020",2020-12-25,"June 9, 2020","Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Nuestra Señora del Rosario, Ibiza, Spain|Hospital Quirón Rey Juan Carlos I, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain|Fundació Althaia de Manresa, Manresa, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Clinica Claro, Vigo, Spain",https://ClinicalTrials.gov/show/NCT04370223,Spain,,12.0,2020,Friday
358,359,The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,375.0,"March 14, 2020",2020-05-15,"March 31, 2020","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark",https://ClinicalTrials.gov/show/NCT04327674,Denmark,,5.0,2020,Friday
359,360,Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic,Recruiting,,All,"Child, Adult, Older Adult",,1000.0,"July 2, 2020",2020-12-31,"August 20, 2020","Institut für Pneumologie an der Universität zu Köln / Wissenschaftliches Institut Bethanien für Pneumologie e.V., Solingen, Nordrhein-Westfalen, Germany",https://ClinicalTrials.gov/show/NCT04521088,Germany,,12.0,2020,Thursday
360,361,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Not yet recruiting,"Dietary Supplement: D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|Dietary Supplement: Placebo",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12.0,"October 1, 2020",2022-01-01,"October 12, 2020",,https://ClinicalTrials.gov/show/NCT04573764,Undefined,,1.0,2022,Saturday
361,362,Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study,Not yet recruiting,Other: Deep Venous Disease Diagnostic,All,"Child, Adult, Older Adult",,50.0,April 2020,2020-12-31,"April 27, 2020","Red de Investigacion Vascular (SEACV), Madrid, Spain",https://ClinicalTrials.gov/show/NCT04361981,Spain,,12.0,2020,Thursday
362,363,A Study of LAM-002A for the Prevention of Progression of COVID-19,Recruiting,Drug: Apilimod Dimesylate Capsule|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,142.0,"July 15, 2020",2021-04-30,"November 4, 2020","Yale University, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04446377,United States,Apilimod Dimesylate Capsule,4.0,2021,Friday
363,364,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs",Not yet recruiting,Other: Rehabilitation-focused program,All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,506.0,"November 1, 2021",2024-10-31,"November 13, 2020","VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04628039,United States,,10.0,2024,Thursday
364,365,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,Other: Prone Positioning|Other: Supine Positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"July 13, 2020",2020-12-01,"July 16, 2020","UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|UCHealth Medical Center of the Rockies, Loveland, Colorado, United States",https://ClinicalTrials.gov/show/NCT04424797,United States,,12.0,2020,Tuesday
365,366,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,Device: miniprobe Alveoflex,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,15.0,"August 1, 2020",2021-09-01,"July 24, 2020","Federal Research Clinical Center FMBA Russia, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04451889,Russian Federation,,9.0,2021,Wednesday
366,367,Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19),Recruiting,Other: Observational,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 30, 2020",2021-05-01,"September 23, 2020","Methodist Dallas Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04561193,United States,,5.0,2021,Saturday
367,368,A Clinical Trial for Hospitalized Patients With COVID-19 in Ceará: ResCOVID Study,Recruiting,Other: Clinical Observation,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"April 2, 2020",2021-12-30,"December 2, 2020","Hospital Leonardo Da Vinci, Fortaleza, Ceara, Brazil",https://ClinicalTrials.gov/show/NCT04649827,Brazil,,12.0,2021,Thursday
368,369,Ramipril for the Treatment of COVID-19,Enrolling by invitation,Drug: Ramipril 2.5 MG Oral Capsule|Drug: Placebo oral capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,560.0,"May 11, 2020",2021-05-01,"July 8, 2020","University of California, San Diego, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT04366050,United States,Ramipril 2.5 MG Oral Capsule|Placebo oral capsule,5.0,2021,Saturday
369,370,Remote-by-Default Care in the COVID-19 Pandemic,"Active, not recruiting",,All,"Child, Adult, Older Adult",,1.0,"June 1, 2020",2021-11-30,"June 17, 2020","University of Oxford, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04435041,United Kingdom,,11.0,2021,Tuesday
370,371,"Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19",Recruiting,Other: Data collection from lumbar puncture|Other: Data collection from blood draw|Other: CNS magnetic resonance imaging (MRI) imaging|Other: Microscopy of defined brain regions on autopsy specimens,All,"18 Years and older   (Adult, Older Adult)",,40.0,"August 12, 2020",2022-12-01,"October 19, 2020","Neurosurgery, University Hospital Basel, Basel, Switzerland|Kantonsspital Baselland Liestal, Liestal, Switzerland",https://ClinicalTrials.gov/show/NCT04472013,Switzerland,,12.0,2022,Thursday
371,372,Comparison of Two Different Doses of Bemiparin in COVID-19,Recruiting,Drug: Bemiparin sodium,All,"18 Years and older   (Adult, Older Adult)",Phase 3,164.0,"October 26, 2020",2021-07-31,"October 27, 2020","Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Clinic, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Universitario Bellvitge, L'Hospitalet De Llobregat, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital Universitario Río Hortega, Valladolid, Spain",https://ClinicalTrials.gov/show/NCT04604327,Spain,Bemiparin sodium,7.0,2021,Saturday
372,373,Mesenchymal Stem Cell Infusion for COVID-19 Infection,Recruiting,Drug: Mesenchymal stem cells|Other: Placebo,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 2,20.0,"May 1, 2020",2020-09-30,"June 30, 2020","NIBMT, Rawalpindi, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04444271,Pakistan,Mesenchymal stem cells,9.0,2020,Wednesday
373,374,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Drug: Sirolimus|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 24, 2020",2020-09-01,"May 20, 2020","Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04341675,United States,Sirolimus|Placebo,9.0,2020,Tuesday
374,375,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Drug: Prednisone,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,184.0,"June 23, 2020",2020-12-30,"October 20, 2020","Hospital Santiago Oriente, Santiago, Peñalolen, Chile",https://ClinicalTrials.gov/show/NCT04451174,Chile,Prednisone,12.0,2020,Wednesday
375,376,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Drug: Imatinib|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,204.0,"June 2, 2020",2023-06-01,"June 4, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04394416,United States,Imatinib|Placebo oral tablet,6.0,2023,Thursday
376,377,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,173.0,"April 9, 2020",2020-11-13,"December 10, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04329923,United States,Hydroxychloroquine Sulfate 400 mg twice a day|Hydroxychloroquine Sulfate 600 mg twice a day|Hydroxychloroquine Sulfate 600 mg once a day|Placebo oral tablet,11.0,2020,Friday
377,378,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,Recruiting,Biological: COVID-19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,"May 13, 2020",2021-06-30,"December 4, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04397757,United States,,6.0,2021,Wednesday
378,379,Convalescent Plasma for the Treatment of Patients With COVID-19,No longer available,Biological: COVID-19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",,,,,"August 28, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States",https://ClinicalTrials.gov/show/NCT04372368,United States,,,n,
379,380,Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial,Not yet recruiting,"Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo",All,"60 Years and older   (Adult, Older Adult)",Phase 4,120.0,"October 27, 2020",2021-12-31,"July 31, 2020","Hospital Universitario de Getafe, Getafe, Spain",https://ClinicalTrials.gov/show/NCT04361643,Spain,"Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Placebo",12.0,2021,Friday
380,381,Inflammatory Regulation Effect of NAC on COVID-19 Treatment,Not yet recruiting,Drug: N-Acetyl cysteine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1180.0,"August 1, 2020",2021-08-30,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04455243,Undefined,N-Acetyl cysteine|Placebo,8.0,2021,Monday
381,382,Desidustat in the Management of COVID-19 Patients,Recruiting,Drug: Desidustat|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"July 25, 2020",2021-01-30,"August 13, 2020","Avant Sante Site 1, Monterrey, Mexico",https://ClinicalTrials.gov/show/NCT04463602,Mexico,Desidustat,1.0,2021,Saturday
382,383,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",Completed,,All,"Child, Adult, Older Adult",,3400.0,"March 23, 2020",2020-06-30,"September 16, 2020","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",https://ClinicalTrials.gov/show/NCT04318418,Italy,,6.0,2020,Tuesday
383,384,The Evaluation of Hemostasis in Hospitalized COVID-19 Patients,Recruiting,Diagnostic Test: Phlebotomy,All,"3 Years and older   (Child, Adult, Older Adult)",,100.0,"June 30, 2020",2021-06-01,"October 22, 2020","Sinai Center for Thrombosis Research, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04493307,United States,,6.0,2021,Tuesday
384,385,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Completed,,All,"18 Years and older   (Adult, Older Adult)",,8.0,"February 14, 2020",2020-02-25,"March 10, 2020","Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04285801,Hong Kong,,2.0,2020,Tuesday
385,386,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,Terminated,Drug: chloroquine|Other: standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,5.0,"June 1, 2020",2020-09-01,"October 14, 2020","Haemek Medical Center, Afula, Israel",https://ClinicalTrials.gov/show/NCT04333628,Israel,chloroquine,9.0,2020,Tuesday
386,387,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,Recruiting,Drug: Tocilizumab|Drug: Placebo,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,300.0,"June 12, 2020",2021-12-31,"November 17, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",https://ClinicalTrials.gov/show/NCT04412772,United States,Tocilizumab|Placebo,12.0,2021,Friday
387,388,Longitudinal Population-based Observational Study of COVID-19 in the UK Population,Recruiting,,All,"16 Years and older   (Child, Adult, Older Adult)",,12000.0,"May 1, 2020",2025-04-01,"October 30, 2020","Queen Mary University of London, London, County (optional), United Kingdom",https://ClinicalTrials.gov/show/NCT04330599,United Kingdom,,4.0,2025,Tuesday
388,389,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Completed,Other: Rehabilitation,All,28 Years to 45 Years   (Adult),Not Applicable,270.0,"March 11, 2020",2020-04-26,"April 28, 2020","Istanbul Bilgi University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04365738,Turkey,,4.0,2020,Sunday
389,390,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Recruiting,Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"June 1, 2020",2021-05-01,"September 9, 2020","University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04372628,Israel,Lopinavir/Ritonavir 400 mg/100 mg,5.0,2021,Saturday
390,391,Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia,Not yet recruiting,Biological: Umbilical cord derived mesenchymal stem cells|Biological: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,30.0,July 2020,2020-11-01,"June 12, 2020",,https://ClinicalTrials.gov/show/NCT04429763,Undefined,,11.0,2020,Sunday
391,392,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Drug: aerosolized DNase|Drug: NaCl,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 4, 2020",2020-12-01,"September 9, 2020","Lund ED, Lund, Sweden",https://ClinicalTrials.gov/show/NCT04541979,Sweden,aerosolized DNase|NaCl,12.0,2020,Tuesday
392,393,Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19,Not yet recruiting,Drug: prophylactic lactoferrin daily,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,July 2020,2020-11-01,"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04427865,Undefined,prophylactic lactoferrin daily,11.0,2020,Sunday
393,394,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,Device: Auricular percutaneous neurostimulation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"July 13, 2020",2021-07-31,"August 19, 2020","Olive View-UCLA Medical Center, Sylmar, California, United States",https://ClinicalTrials.gov/show/NCT04514627,United States,,7.0,2021,Saturday
394,395,A Study of Baricitinib (LY3009104) in Participants With COVID-19,Recruiting,Drug: Baricitinib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1400.0,"September 7, 2019",2021-06-20,"December 4, 2020","Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Valleywise Health, Phoenix, Arizona, United States|St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Westchester General Hospital, Miami, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|White Oak Medical Center, Adventist Healthcare, Silver Spring, Maryland, United States|South Shore Hospital, Weymouth, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Renown Regional Med. Center, Reno, Nevada, United States|SUNY Downstate, Brooklyn, New York, United States|East Carolina University, Greenville, North Carolina, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States|Swedish Medical Center, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Sanatorio Sagrado Corazón, Ciudad de Buenos Aires, AR, Argentina|ClÃ-nica Zabala, Ciudad de Buenos Aires, AR, Argentina|Hospital Z.G.A.D ""Evita Pueblo"", Berazategui, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Caba, Buenos Aires, Argentina|Fundacion Sanatorio Guemes, Caba, Buenos Aires, Argentina|Casa Hospital San Juan de Dios, Ramos Mejía, Buenos Aires, Argentina|Hospital Interzonal General de Agudos ""Eva Peron"", San Martin, Buenos Aires, Argentina|Clinica Adventista Belgrano, Caba, Ciudad Autónoma De Buenos Aire, Argentina|Centros de Investigaciones Cli-nicas. Clinica Viedma, Viedma, Rio Negro, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Hospital San Roque, Cordoba, Argentina|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro Hospitalar de Reabilitacao Ana Carolina Moura Xavier, Curitiba, Parana, Brazil|CEPETI Centro de Ensino e Pesquisa em Terapia Intensiva, Curitiba, Paraná, Brazil|CPCLIN, Natal, Rio Grande Do Norte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Carlos Fernando Malzoni Matao, Matao, Sao Paulo, Brazil|Pesquisare, Santo Andre, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo André, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP, Botucatu, São Paulo, Brazil|IPECC - Instituto de Pesquisa Clinica de Campinas, Campinas, São Paulo, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|CECIP - Centro de Estudos do Interior Paulista, Jaú, São Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos EPP Ltda, São Bernardo do Campo, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiencia, São Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Casa de Saude Santa Marcelina - Centro de Pesquisa Clinica, São Paulo, Brazil|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Unity Hospital, Surat, Gujarat, India|Medanta-The Medicity, Gurgaon, Haryana, India|Government Medical College (GMC) Aurangabad, Aurangabad, Maharashtra, India|Government Medical College, Nagpur, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|Aakash Healthcare Super Speciality Hospital, New Delhi, India|Ospedale SS Annunziata, Chieti Scalo, Chieti, Italy|INMI Lazzaro Spallanzani, Roma, Rome, Italy|Ospedale Luigi Sacco, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|Nuovo Ospedale di Prato S. Stefano, Prato, Italy|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Edogawa Medicare Hospital, Edogawa-ku, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|Hospital General Agustín O'Horán, Yucatan, Merida, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran- Medicina Critica, Federal District, Mexico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|GCM Medical Group, PSC- Hato Rey, San Juan, Puerto Rico|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Saint-Petersburg City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|The Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Barnet Hospital, Barnet, Herts, United Kingdom|St. George's University Hospitals NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04421027,Argentina,Baricitinib|Placebo,6.0,2021,Sunday
395,396,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),Recruiting,Biological: GAMUNEX-C|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"September 17, 2020",2021-05-01,"November 24, 2020","University of Louisville, Louisville, Kentucky, United States|McLaren Flint, Flint, Michigan, United States|McLaren Health Care-Macomb, Mount Clemens, Michigan, United States|McLaren Health Care Oakland, Pontiac, Michigan, United States|CHI Health, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|CHRISTUS Health, Tyler, Texas, United States|MultiCare Deaconness Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States",https://ClinicalTrials.gov/show/NCT04480424,United States,Standard Medical Treatment,5.0,2021,Saturday
396,397,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"April 13, 2020",2025-06-30,"May 8, 2020","Manuel Monreal, Badalona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04380792,Spain,,6.0,2025,Monday
397,398,Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19),Recruiting,Other: Data monitoring for 48h within the first 12 hours of admission for COVID-19,All,"18 Years and older   (Adult, Older Adult)",,384.0,"May 16, 2020",2020-11-01,"May 27, 2020","Louis Mourier hospital (AP-HP), Colombes, France|Brabois Hospital (CHRU de Nancy), Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04376879,France,,11.0,2020,Sunday
398,399,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Drug: Treatment and prophylaxis|Other: Standard Public Health measures,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2300.0,"March 18, 2020",2020-06-15,"June 30, 2020","Departament de Salut, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04304053,Spain,Treatment and prophylaxis,6.0,2020,Monday
399,400,Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,Not yet recruiting,Drug: HCQ & AZ vs HCQ+SIR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,58.0,"May 1, 2020",2020-09-01,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04374903,Jordan,HCQ & AZ vs HCQ+SIR,9.0,2020,Tuesday
400,401,Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter,Recruiting,Device: Seraph 100,All,"18 Years to 99 Years   (Adult, Older Adult)",,100.0,"April 15, 2020",2021-10-01,"April 24, 2020","Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany|Hannover Medical School, Hannover, Germany",https://ClinicalTrials.gov/show/NCT04361500,Germany,,10.0,2021,Friday
401,402,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),Recruiting,Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"May 1, 2020",2021-04-25,"May 21, 2020","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States",https://ClinicalTrials.gov/show/NCT04355143,United States,Colchicine Tablets,4.0,2021,Sunday
402,403,Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection,"Active, not recruiting",Diagnostic Test: Prognostic score,All,"18 Years to 100 Years   (Adult, Older Adult)",,250.0,"April 1, 2020",2021-06-01,"July 23, 2020","Glasgow Royal Infirmary, Glasgow, United Kingdom",https://ClinicalTrials.gov/show/NCT04484545,United Kingdom,,6.0,2021,Tuesday
403,404,Study to Assess the Effect of Meplazumab on COVID-19,Not yet recruiting,Drug: Meplazumab for Injection|Drug: Sterile normal saline (0.9%),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,456.0,"December 30, 2020",2021-09-30,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04586153,Undefined,Meplazumab for Injection|Sterile normal saline (0.9%),9.0,2021,Thursday
404,405,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Drug: Therapeutic Anticoagulation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,462.0,"May 11, 2020",2020-12-01,"September 4, 2020","St. Michael's Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04362085,Canada,Therapeutic Anticoagulation,12.0,2020,Tuesday
405,406,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,Diagnostic Test: diagnostic tests for COVID-19 infection,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,100.0,"May 8, 2020",2021-06-01,"August 11, 2020","Texas Cardiac Arrhythmia Institute, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04372004,United States,,6.0,2021,Tuesday
406,407,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,April 2020,2020-06-01,"April 17, 2020","University of Chicago, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04351620,United States,Hydroxychloroquine,6.0,2020,Monday
407,408,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"April 21, 2020",2030-04-14,"September 14, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04360278,United States,,4.0,2030,Sunday
408,409,Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak,Recruiting,Other: survey,All,"25 Years to 65 Years   (Adult, Older Adult)",,400.0,"March 11, 2020",2020-04-16,"April 7, 2020","Assiut University Hospitals, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04319315,Egypt,,4.0,2020,Thursday
409,410,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),Recruiting,Drug: Camostat Mesilate|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"November 9, 2020",2021-01-01,"December 10, 2020","Cullman Clinical Trials, Cullman, Alabama, United States|Synergy Healthcare, LLC, Bradenton, Florida, United States|Clinical Research of Brandon, LLC, Brandon, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|A+ Research, Miami, Florida, United States|NextPhase Research Alliance (at CANO HEALTH), Miami, Florida, United States|Ezy Medical Research, Miami, Florida, United States|Eminat LLC, Miramar, Florida, United States|Invictus Clinical Research Group, LLC, Pompano Beach, Florida, United States|Visionaries Clinical Research, LLC, Atlanta, Georgia, United States|Family Care Research, Boise, Idaho, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Oakland Medical Research Center, Troy, Michigan, United States|Cary Research Group, Cary, North Carolina, United States|Onsite Solutions, Charlotte, North Carolina, United States|STAT Research, Springboro, Ohio, United States|Toledo Institute of Clinical Research, Inc., Toledo, Ohio, United States|Pharma Corp Clin Trials, Charleston, South Carolina, United States|Advanced Medical Trials, Georgetown, Texas, United States|Next Innovative Clinical Research, Houston, Texas, United States|Rio Grand Valley Clinical Research Institute, Pharr, Texas, United States",https://ClinicalTrials.gov/show/NCT04583592,Georgia,Camostat Mesilate|Placebo,1.0,2021,Friday
410,411,"BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19",Not yet recruiting,"Diagnostic Test: N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I",All,"Child, Adult, Older Adult",,90.0,August 2020,2021-09-01,"August 21, 2020",,https://ClinicalTrials.gov/show/NCT04433026,Undefined,,9.0,2021,Wednesday
411,412,Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment,Not yet recruiting,Drug: Ascorbic Acid,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66.0,May 2020,2021-05-01,"May 5, 2020",,https://ClinicalTrials.gov/show/NCT04363216,Undefined,Ascorbic Acid,5.0,2021,Saturday
412,413,"Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",Recruiting,,All,30 Years to 55 Years   (Adult),,200.0,"June 1, 2020",2022-05-31,"December 8, 2020","NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04403386,United States,,5.0,2022,Tuesday
413,414,Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,Not yet recruiting,Drug: HCQ & AZ,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 1, 2020",2020-10-15,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04354597,Jordan,HCQ & AZ,10.0,2020,Thursday
414,415,Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients,Recruiting,Diagnostic Test: CT-Scan,All,"18 Years and older   (Adult, Older Adult)",,40.0,"March 15, 2020",2020-07-15,"June 11, 2020","Tepecik Training and Research Hospital, Izmir, Izmir, Konak, Turkey",https://ClinicalTrials.gov/show/NCT04424849,Turkey,,7.0,2020,Wednesday
415,416,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,Recruiting,Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,"July 6, 2020",2021-04-01,"October 8, 2020","Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System, Inc. / Chilton Medical Center, Pompton Plains, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Instituto Dor de Pesquisa E Ensino, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04382586,Brazil,Zanubrutinib|Supportive Care|Placebo,4.0,2021,Thursday
416,417,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Recruiting,Drug: Cholecalciferol,All,"Child, Adult, Older Adult",Phase 4,80.0,"April 4, 2020",2020-12-30,"September 17, 2020","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain",https://ClinicalTrials.gov/show/NCT04552951,Spain,Cholecalciferol,12.0,2020,Wednesday
417,418,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"45 Years and older   (Adult, Older Adult)",Phase 3,1550.0,"April 2, 2020",2021-12-31,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04334382,United States,Hydroxychloroquine|Azithromycin,12.0,2021,Friday
418,419,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,Biological: CCP,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"August 12, 2020",2021-08-12,"August 21, 2020","Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States",https://ClinicalTrials.gov/show/NCT04438057,United States,,8.0,2021,Thursday
419,420,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,Procedure: blood sampling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,99.0,"April 9, 2020",2020-05-14,"June 9, 2020","Rouen University Hospital, Rouen, France",https://ClinicalTrials.gov/show/NCT04367662,France,,5.0,2020,Thursday
420,421,Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients,Recruiting,Other: Survey,All,"18 Years and older   (Adult, Older Adult)",,25000.0,"July 11, 2020",2021-06-01,"July 16, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04473118,Qatar,,6.0,2021,Tuesday
421,422,Tobacco and Nicotine Consumption and the Risk of Acquisition of Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Behavioral: questionnaire,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"October 12, 2020",2020-12-01,"October 12, 2020",,https://ClinicalTrials.gov/show/NCT04583761,Undefined,,12.0,2020,Tuesday
422,423,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Recruiting,Drug: PHR160 Spray|Drug: Placebo|Drug: Standard treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,224.0,"August 15, 2020",2020-12-15,"November 4, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04463420,"Iran, Islamic Republic of",PHR160 Spray|Placebo|Standard treatment,12.0,2020,Tuesday
423,424,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,Not yet recruiting,"Other: chlorine dioxide|Dietary Supplement: zinc acetate|Drug: Famotidine|Other: placebo|Dietary Supplement: lactoferrin, green tea extract",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,120.0,"November 9, 2020",2021-01-31,"November 10, 2020",,https://ClinicalTrials.gov/show/NCT04621149,Undefined,Famotidine,1.0,2021,Sunday
424,425,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Completed,Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"June 22, 2020",2020-07-06,"July 21, 2020","Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04410159,Malaysia,Povidone-Iodine|Essential oils,7.0,2020,Monday
425,426,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,Recruiting,Device: Viruxal Oral and Nasal Spray|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,128.0,"September 4, 2020",2021-03-01,"September 17, 2020","National Hospital of Iceland (Landspítali), Reykjavík, Iceland",https://ClinicalTrials.gov/show/NCT04357990,Iceland,,3.0,2021,Monday
426,427,Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients,Not yet recruiting,Drug: Ulinastatin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,160.0,December 2020,2021-06-01,"November 27, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04393311,United States,Ulinastatin|Placebo,6.0,2021,Tuesday
427,428,"Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial",Not yet recruiting,Procedure: Extended sampling and procedures,All,"15 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,400.0,"April 28, 2020",2026-04-14,"April 29, 2020","Incectious Diseases Clinic, Umeå, Västerbotten, Sweden",https://ClinicalTrials.gov/show/NCT04368013,Sweden,,4.0,2026,Tuesday
428,429,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Completed,Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"May 1, 2020",2020-09-23,"September 25, 2020","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04392414,Russian Federation,,9.0,2020,Wednesday
429,430,Convalescent Plasma as a Possible Treatment for COVID-19,Recruiting,Biological: Convalescent plasma|Biological: Placebo,All,"40 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 5, 2020",2021-05-05,"June 22, 2020","University of Illinois at Chicago, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04442191,United States,,5.0,2021,Wednesday
430,431,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,Recruiting,Drug: EC-18|Drug: Placebo EC-18,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 28, 2020",2022-05-01,"August 6, 2020","Chungbuk National University Hospital, Cheongju-si, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04500132,"Korea, Republic of",EC-18|Placebo EC-18,5.0,2022,Sunday
431,432,Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19,Not yet recruiting,Biological: Mesenchymal Stromal Cells infusion,All,"Child, Adult, Older Adult",Phase 1,10.0,"July 25, 2020",2020-12-30,"July 10, 2020",,https://ClinicalTrials.gov/show/NCT04467047,Undefined,,12.0,2020,Wednesday
432,433,Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19,Available,Biological: Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",,,,,"April 24, 2020","Tulane Medical Center, New Orleans, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04358211,United States,,,n,
433,434,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"Active, not recruiting",Drug: HB-adMSC|Drug: Placebo,All,"Child, Adult, Older Adult",Phase 2,100.0,"June 30, 2020",2020-10-31,"October 23, 2020","River Oaks Hospital and Clinics, Houston, Texas, United States|United Memorial Medical Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04362189,United States,HB-adMSC|Placebo,10.0,2020,Saturday
434,435,INB03 for the Treatment of Pulmonary Complications From COVID-19,Recruiting,Drug: INB03|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,366.0,"October 21, 2020",2021-02-01,"October 26, 2020","NEA Baptist, Jonesboro, Arkansas, United States|Jewish Hospital, Louisville, Kentucky, United States|Mississippi Baptist, Kosciusko, Mississippi, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04370236,United States,INB03|Placebo,2.0,2021,Monday
435,436,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recruiting,Drug: RhACE2 APN01|Drug: Physiological saline solution,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,200.0,"April 30, 2020",2020-12-01,"October 6, 2020","Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany|Regional State Budgetary Educational Institution ""Clinical Hospital № 5, Barnaul"", Barnaul, Russian Federation|State Healthcare Institution ""State Clinical Hspital № 15 named after O.M. Filatov"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital №52 of Health Department of Moscow"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow"", Moscow, Russian Federation|Saint Petersburg SBHI City Hospital 38 named after N A Semashko, Pushkin, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Ryazan State Medical University named after I.P. Pavlov"" HD RF, Ryazan, Russian Federation|Alexandrovskaya Hospital, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint-Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "" Saratov State Medical University named after V.I. Razumovsky"" HD RF, Saratov, Russian Federation|Regional State Budgetary Healthcare Institution ""Clinical Hospital №1"", Smolensk, Russian Federation|State budgetary institution of Healthcare of Tver region ""Regional clinical hospital"", Tver, Russian Federation|Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems ""Healthy Ageing"", Yaroslavl, Russian Federation|Cambridge University Hospitals NHS Trust/University of Cambridge, Cambridge, United Kingdom",https://ClinicalTrials.gov/show/NCT04335136,Austria,RhACE2 APN01|Physiological saline solution,12.0,2020,Tuesday
436,437,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Completed,Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,108.0,"May 4, 2020",2020-11-06,"November 9, 2020","Jose Manuel Arreola Guerra, Aguascalientes, Mexico",https://ClinicalTrials.gov/show/NCT04391127,Mexico,Hydroxychloroquine|Ivermectin|Placebo,11.0,2020,Friday
437,438,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Completed,Diagnostic Test: IP-10 in CDS protocol,All,"18 Years and older   (Adult, Older Adult)",,52.0,"April 7, 2020",2020-05-12,"May 15, 2020","Rabin Medical Center, Petach Tikva, Israel",https://ClinicalTrials.gov/show/NCT04389645,Israel,,5.0,2020,Tuesday
438,439,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,Device: GO2 PEEP MOUTHPIECE,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2.0,"April 8, 2020",2020-08-31,"October 19, 2020","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04331366,Georgia,,8.0,2020,Monday
439,440,Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,Not yet recruiting,Drug: Enoxaparin,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1370.0,July 2020,2021-07-01,"July 30, 2020",,https://ClinicalTrials.gov/show/NCT04492254,Undefined,Enoxaparin,7.0,2021,Thursday
440,441,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Biological: SARS-CoV-2 Specific T Cells,All,"1 Year to 90 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,18.0,"July 1, 2020",2022-12-01,"July 7, 2020","Changi General Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Sengkang General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04457726,Singapore,,12.0,2022,Thursday
441,442,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Active, not recruiting",Drug: Favipiravir + Standard of Care|Drug: Standard of Care,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,50.0,"April 17, 2020",2020-11-01,"November 6, 2020","HonorHealth, Scottsdale, Arizona, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Boston Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Memorial Health Care, Worcester, Massachusetts, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04358549,Jersey,Favipiravir + Standard of Care|Standard of Care,11.0,2020,Sunday
442,443,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Drug: Clazakizumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"July 13, 2020",2021-07-31,"July 31, 2020","Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04494724,United States,Clazakizumab|Placebo,7.0,2021,Saturday
443,444,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Recruiting,Drug: Interferon beta-1a|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900.0,"March 18, 2020",2022-05-18,"November 30, 2020","Peter Lougheed Centre, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Misericordia Community Hospital, Edmonton, Alberta, Canada|University of Alberta Hopsital, Edmonton, Alberta, Canada|Grey Nuns Community Hospital, Edmonton, Alberta, Canada|Lions Gate Hospital, North Vancouver, British Columbia, Canada|Richmond Hospital, Richmond, British Columbia, Canada|Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada|Island Health - Victoria General Hospital, Victoria, British Columbia, Canada|Island Health - Nanaimo Regional General Hospital, Victoria, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Saint John's, Newfoundland and Labrador, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|William Osler Health System - Brampton Civic Hospital, Brampton, Ontario, Canada|William Osler Health System - Etobicoke General Hospital, Etobicoke, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St.Joseph's Health Care, London, Ontario, Canada|University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada|Trillium Health Partners-Credit Valley Hospital, Mississauga, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Hôpital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Niagara Health, Saint Catharines, Ontario, Canada|Scarborough Health Network - Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - Birchmount Hospital, Scarborough, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Michael Garron Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health Toronto - St. Joseph's Health Centre, Toronto, Ontario, Canada|CISSS de la Montérégie Centre, Greenfield Park, Quebec, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",https://ClinicalTrials.gov/show/NCT04330690,Canada,Interferon beta-1a|Remdesivir,5.0,2022,Wednesday
444,445,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Recruiting,Behavioral: Exercise training,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"September 25, 2020",2021-05-01,"November 30, 2020","Rigshospitalet, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04549337,Denmark,,5.0,2021,Saturday
445,446,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,"Active, not recruiting",Biological: Ampion|Other: Standard of Care,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 1,10.0,"July 27, 2020",2020-11-13,"September 30, 2020","Research Site, Colorado Springs, Colorado, United States",https://ClinicalTrials.gov/show/NCT04456452,United States,,11.0,2020,Friday
446,447,Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia,Not yet recruiting,Drug: Prednisone|Drug: Hydrocortisone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,210.0,June 2020,2020-12-01,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04359511,Undefined,Prednisone|Hydrocortisone,12.0,2020,Tuesday
447,448,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),Recruiting,Drug: AT-527|Other: Placebo,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,190.0,"May 26, 2020",2021-01-01,"October 27, 2020","Atea Study Site, Scottsdale, Arizona, United States|Atea Study Site, Los Angeles, California, United States|Atea Study Site, Sacramento, California, United States|Atea Study Site, Washington, District of Columbia, United States|Atea Study Site, Orlando, Florida, United States|Atea Study Site, Atlanta, Georgia, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Chicago, Illinois, United States|Atea Study Site, Boston, Massachusetts, United States|Atea Study Site, Butte, Montana, United States|Atea Study Site, Albuquerque, New Mexico, United States|Atea Study Site, Bronx, New York, United States|Atea Study Site, New York, New York, United States|Atea Study Site, Charlotte, North Carolina, United States|Atea Study Site, Cincinnati, Ohio, United States|Atea Study Site, Columbus, Ohio, United States|Atea Study Site, Charleston, South Carolina, United States|Atea Study Site, Columbia, South Carolina, United States|Atea Study Site, Tacoma, Washington, United States|Atea Study Site, Brussels, Belgium|Atea Study Site, Mechelen, Belgium|Atea Study Site, Belo Horizonte, Brazil|Atea Study Site, Brasília, Brazil|Atea Study Site, Campo Largo, Brazil|Atea Study Site, Porto Alegre, Brazil|Atea Study Site, São Paulo, Brazil|Atea Study Site, Chisinau, Moldova, Republic of|Atea Study Site, Bucharest, Romania|Atea Study Site, Bloemfontein, South Africa|Atea Study Site, Cape Town, South Africa|Atea Study Site, George, South Africa|Atea Study Site, Worcester, South Africa|Atea Study Site, Brovary, Ukraine|Atea Study Site, Kyiv, Ukraine",https://ClinicalTrials.gov/show/NCT04396106,Belgium,AT-527,1.0,2021,Friday
448,449,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,32.0,"April 4, 2020",2020-06-05,"August 3, 2020","University of Chicago Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04331795,United States,Tocilizumab,6.0,2020,Friday
449,450,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,"Active, not recruiting",Drug: Hydroxychloroquine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,228.0,"April 3, 2020",2020-07-30,"May 5, 2020","Baylor University Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04333225,United States,Hydroxychloroquine,7.0,2020,Thursday
450,451,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",Not yet recruiting,Dietary Supplement: 5-ALA-Phosphate + SFC (5-ALA + SFC),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40.0,November 2020,2020-12-01,"October 8, 2020","Bahrain Defense Force Royal Medical Services, Military Hospital, Manama, Bahrain",https://ClinicalTrials.gov/show/NCT04542850,Bahrain,,12.0,2020,Tuesday
451,452,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),Recruiting,Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2|Phase 3,500.0,"April 16, 2020",2020-12-31,"April 24, 2020","Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04351724,Austria,Chloroquine or Hydroxychloroquine|Lopinavir/Ritonavir|Rivaroxaban|Thromboprophylaxis|Candesartan|non-RAS blocking antihypertensives|Clazakizumab|placebo for clazakizumab,12.0,2020,Thursday
452,453,Immune Profiling of COVID19-patients Admitted to ICU,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 27, 2020",2022-06-01,"July 16, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04473131,Qatar,,6.0,2022,Wednesday
453,454,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,40.0,"March 19, 2020",2020-07-01,"September 1, 2020","Institut Mutualiste Montsouris, Paris, France",https://ClinicalTrials.gov/show/NCT04452617,France,,7.0,2020,Wednesday
454,455,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,600.0,"April 13, 2020",2021-12-10,"August 24, 2020","University Medical Center New Orleans, New Orleans, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04344444,United States,Hydroxychloroquine|Azithromycin,12.0,2021,Friday
455,456,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,700.0,"May 7, 2020",2020-12-07,"June 16, 2020","Wellstar Kennestone Hospital, Marietta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04429867,Georgia,Hydroxychloroquine|Placebo,12.0,2020,Monday
456,457,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans,Recruiting,"Drug: Nitric Oxide lozenges, 30 mg|Drug: Placebo",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,100.0,"November 1, 2020",2021-07-31,"December 9, 2020","American Institute of Therapeutics, Lake Bluff, Illinois, United States",https://ClinicalTrials.gov/show/NCT04601077,United States,"Nitric Oxide lozenges, 30 mg|Placebo",7.0,2021,Saturday
457,458,COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses,Recruiting,Diagnostic Test: blood draw|Diagnostic Test: fingertip tests for POC assays|Diagnostic Test: saliva collection|Diagnostic Test: collection of swabs,All,"18 Years and older   (Adult, Older Adult)",,550.0,"April 10, 2020",2022-05-30,"July 23, 2020","Department of Health, Economics and Health Directorate Canton Basel-Land, Liestal, Switzerland",https://ClinicalTrials.gov/show/NCT04483908,Switzerland,,5.0,2022,Monday
458,459,A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）,Not yet recruiting,Drug: FNC+Standard of Care|Drug: FNC dummy tablet+Standard of Care,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,342.0,"June 12, 2020",2020-08-12,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04425772,Undefined,FNC+Standard of Care|FNC dummy tablet+Standard of Care,8.0,2020,Wednesday
459,460,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,"Active, not recruiting",Other: Cash transfer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,392.0,"April 20, 2020",2020-12-30,"July 7, 2020","Municipality of Assiginack Family Health Team, Assiginack, Ontario, Canada|St Michael's Hospital Academic Family Health Team, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04359264,Canada,,12.0,2020,Wednesday
460,461,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,"Active, not recruiting",Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,9.0,"May 1, 2020",2022-05-01,"November 27, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04377659,United States,Tocilizumab,5.0,2022,Sunday
461,462,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Recruiting,Device: CytoSorb-Therapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,24.0,"April 1, 2020",2021-02-01,"April 14, 2020","University Medical Center Hamburg-Eppendorf, Hamburg, Germany",https://ClinicalTrials.gov/show/NCT04344080,Germany,,2.0,2021,Monday
462,463,Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients,Not yet recruiting,Drug: Methotrexate,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,"May 1, 2020",2020-11-30,"April 29, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04352465,Brazil,Methotrexate,11.0,2020,Monday
463,464,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"April 13, 2020",2025-06-13,"May 8, 2020","Manuel Monreal, Badalona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04380779,Spain,,6.0,2025,Friday
464,465,Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age,Recruiting,Drug: Favipiravir,All,"15 Years and older   (Child, Adult, Older Adult)",,1000.0,"June 11, 2020",2020-09-30,"July 20, 2020","Hacettepe University, School of Medicine, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04474457,Turkey,Favipiravir,9.0,2020,Wednesday
465,466,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,Recruiting,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,All,"12 Years to 120 Years   (Child, Adult, Older Adult)",Phase 3,800.0,"August 13, 2020",2020-12-30,"October 29, 2020","Invesclinic US LLC, Fort Lauderdale, Florida, United States|RH Medical Urgent Care, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04486313,United States,Nitazoxanide|Placebo,12.0,2020,Wednesday
466,467,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Drug: GNS561,All,"18 Years and older   (Adult, Older Adult)",Phase 2,178.0,"November 18, 2020",2021-10-30,"November 20, 2020","Genoscience Pharma, Marseille, France",https://ClinicalTrials.gov/show/NCT04637828,France,GNS561,10.0,2021,Saturday
467,468,"Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia",Not yet recruiting,Drug: Canakinumab 150 MG/ML [Ilaris],All,"18 Years to 100 Years   (Adult, Older Adult)",,100.0,April 2020,2020-09-01,"April 16, 2020",,https://ClinicalTrials.gov/show/NCT04348448,Undefined,Canakinumab 150 MG/ML [Ilaris],9.0,2020,Tuesday
468,469,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,Biological: WJ-MSCs,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,"March 16, 2020",2020-09-30,"March 18, 2020","Stem Cells Arabia, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04313322,Jordan,,9.0,2020,Wednesday
469,470,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Drug: LY3819253|Drug: LY3832479|Drug: Placebo,All,18 Years to 64 Years   (Adult),Phase 2,500.0,"October 29, 2020",2021-03-15,"December 10, 2020","The Institute for Liver Health, Mesa, Arizona, United States|Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Surprise, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Valley Research, Fresno, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Inland Empire CT, LLC, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Cleveland Clinic of Weston Florida, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|QPS Missouri, Springfield, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Prime Global Research, LLC, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, LLC, Dayton, Ohio, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase R and D, Knoxville, Tennessee, United States|Central Texas Clinical Rch, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|1960 Family Practice, PA, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC- Hato Rey, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04634409,Georgia,LY3819253|LY3832479|Placebo,3.0,2021,Monday
470,471,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Recruiting,Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,45.0,"August 15, 2020",2021-01-01,"October 23, 2020","Stanford Health Care, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04347954,United States,Povidone-Iodine 2%|Povidone-Iodine 0.5%|Isotonic saline 0.9%,1.0,2021,Friday
471,472,Natural Language Processing (NLP) Analysis of Free Text Notes to Investigate Coronavirus (COVID-19),Not yet recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,200.0,July 2020,2021-07-01,"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04432961,Undefined,,7.0,2021,Thursday
472,473,Registry of CytoSorb Therapy in COVID-19 ICU Patients,Recruiting,Device: CytoSorb 300 mL device,All,"18 Years and older   (Adult, Older Adult)",,500.0,"August 28, 2020",2021-10-01,"October 5, 2020","Medical Center of Aurora, Aurora, Colorado, United States|University of Chicago Medicine, Chicago, Illinois, United States|Baptist Memorial Hospital, Southaven, Mississippi, United States|New York University Medical Center, New York, New York, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04391920,United States,,10.0,2021,Friday
473,474,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Recruiting,Radiation: Radiation therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"July 23, 2020",2021-12-31,"September 25, 2020","Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04427566,United States,,12.0,2021,Friday
474,475,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Active, not recruiting",Drug: Ivermectin Oral Product|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,476.0,"July 14, 2020",2020-12-21,"December 3, 2020","Centro de Estudios en Infectología Pediátrica, Cali, Valle, Colombia",https://ClinicalTrials.gov/show/NCT04405843,Colombia,Ivermectin Oral Product|Placebo,12.0,2020,Monday
475,476,A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients,Not yet recruiting,Drug: BAT2020,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,174.0,"October 20, 2020",2021-08-18,"September 29, 2020","Snake River Research, Idaho Falls, Idaho, United States",https://ClinicalTrials.gov/show/NCT04432766,United States,BAT2020,8.0,2021,Wednesday
476,477,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.,Completed,,All,"Child, Adult, Older Adult",,306.0,"February 2, 2020",2020-04-01,"April 28, 2020","Tongji Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04365634,China,,4.0,2020,Wednesday
477,478,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,Recruiting,Drug: Ivermectin Oral Product,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 12, 2020",2020-10-31,"June 16, 2020","Sheba Medical Center, Ramat-Gan, Israel",https://ClinicalTrials.gov/show/NCT04429711,Israel,Ivermectin Oral Product,10.0,2020,Saturday
478,479,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate,All,"16 Years to 99 Years   (Child, Adult, Older Adult)",Phase 2,65.0,"March 11, 2020",2020-04-30,"May 27, 2020","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04307693,"Korea, Republic of",Lopinavir/ritonavir|Hydroxychloroquine sulfate,4.0,2020,Thursday
479,480,Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19,Not yet recruiting,Drug: Isoquercetin (IQC-950AN),All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,November 2020,2021-05-01,"October 26, 2020",,https://ClinicalTrials.gov/show/NCT04536090,Undefined,Isoquercetin (IQC-950AN),5.0,2021,Saturday
480,481,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Recruiting,Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,48.0,"April 9, 2020",2020-05-09,"April 14, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04344236,United States,Saline oral/nasal rinse|0.5% Povidone/Iodine oral/nasal rinse|0.12% Chlorhexidine oral/nasal rinse,5.0,2020,Saturday
481,482,Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19,Not yet recruiting,Biological: N-803|Other: Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,"June 1, 2020",2020-07-11,"June 1, 2020",,https://ClinicalTrials.gov/show/NCT04385849,Undefined,,7.0,2020,Saturday
482,483,Non-contact ECG Sensor System for COVID19,Recruiting,Device: Non-contact ECG,All,"18 Years and older   (Adult, Older Adult)",,100.0,"September 8, 2020",2021-12-15,"September 9, 2020","Northwestern Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04341506,United States,,12.0,2021,Wednesday
483,484,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation,Recruiting,Other: Data collection and clinical testing of subjects,All,"18 Years to 80 Years   (Adult, Older Adult)",,50.0,"May 15, 2020",2020-11-15,"May 22, 2020","Medical ICU. Hospital Universitario Ramón y Cajal, Madrid, Spain|Surgical ICU. Hospital Universitario Ramón y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04400461,Spain,,11.0,2020,Sunday
484,485,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,Recruiting,Biological: Bactek-R,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,100.0,"June 10, 2020",2021-07-31,"June 30, 2020","Hospital Metropolitano Santiago, Santiago De Los Caballeros, Dominican Republic",https://ClinicalTrials.gov/show/NCT04363814,Dominica,,7.0,2021,Saturday
485,486,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,Terminated,Drug: Hydroxychloroquine,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,17.0,"March 26, 2020",2020-08-31,"November 17, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",https://ClinicalTrials.gov/show/NCT04345692,United States,Hydroxychloroquine,8.0,2020,Monday
486,487,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,Completed,Drug: Levilimab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,206.0,"April 29, 2020",2020-08-03,"November 18, 2020","State Budgetary Healthcare Institution Kaluga region ""Kaluga Regional Clinical Hospital"", Kaluga, Russian Federation|State Budget Institution of the Republic of Dagestan ""Republican Clinical Hospital"", Machačkala, Russian Federation|A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation|City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow, Russian Federation|City Clinical Hospital No.52, Moscow, Russian Federation|City Clinical Hospital № 15 named. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with Clinic"", Office of the President of the Russian Federation, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Railway clinical hospital named after N.A. Semashko, Moscow, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation|North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Bashkir State Medical University"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""North Ossetian State Medical Academy"" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation",https://ClinicalTrials.gov/show/NCT04397562,Russian Federation,Levilimab|Placebo,8.0,2020,Monday
487,488,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),Recruiting,Drug: RBT-9 (90 mg)|Drug: 0.9% sodium chloride (normal saline),All,"18 Years and older   (Adult, Older Adult)",Phase 2,252.0,"August 5, 2020",2021-12-31,"September 28, 2020","New Smyrna Beach, FL, New Smyrna Beach, Florida, United States|Fort Worth, TX, Fort Worth, Texas, United States|Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04364763,United States,RBT-9 (90 mg)|0.9% sodium chloride (normal saline),12.0,2021,Friday
488,489,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,Recruiting,Drug: Convalesscent Plasma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,106.0,"August 30, 2020",2021-02-01,"November 20, 2020","University Hospital Ulm, Ulm, Baden-Württmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany|University Hospital Berlin, Charite, Berlin, Germany|Universitiy Hospital Dresden, Dresden, Germany|University Düsseldorf, Düsseldorf, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital Gießen, Gießen, Germany|University Hopsital Greifswald, Greifswald, Germany|Städtisches Klinikum Karslruhe, Karlsruhe, Germany|Universtity Hospital Schleswig-Holstein, Kiel, Germany|Universtity Hospital Schleswig-Holstein, Lübeck, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Marburg, Marburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|University Hospital Tübingen, Tübingen, Germany",https://ClinicalTrials.gov/show/NCT04433910,Germany,Convalesscent Plasma,2.0,2021,Monday
489,490,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,"Active, not recruiting",Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"June 9, 2020",2021-04-30,"October 22, 2020","San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04421404,United States,,4.0,2021,Friday
490,491,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,Recruiting,Drug: Degarelix|Other: Saline,Male,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,198.0,"July 6, 2020",2021-07-06,"December 4, 2020","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, Los Angeles, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Philadelphia MultiService Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04397718,United States,Degarelix,7.0,2021,Tuesday
491,492,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,Completed,Drug: LY3819253|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,24.0,"May 28, 2020",2020-08-26,"October 30, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States|Veterans Affairs Medical Center San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Alexandria Center for Life - NYC/ NYCEDC, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Unified Research Enterprise Brody School of Medicine at ECU, Greenville, North Carolina, United States|Temple Univ School of Med, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04411628,Georgia,LY3819253|Placebo,8.0,2020,Wednesday
492,493,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,Drug: Chloroquine Sulfate|Drug: Hydroxychloroquine|Other: Standard supportive care,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 4,25.0,"April 14, 2020",2020-06-08,"June 19, 2020","UMCU, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04362332,Netherlands,Chloroquine Sulfate|Hydroxychloroquine,6.0,2020,Monday
493,494,Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults,Not yet recruiting,Biological: AV-COVID-19,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,175.0,February 2021,2022-02-01,"December 8, 2020",,https://ClinicalTrials.gov/show/NCT04386252,Undefined,,2.0,2022,Tuesday
494,495,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"Active, not recruiting",Drug: Peginterferon Lambda-1a|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120.0,"April 24, 2020",2021-05-01,"September 28, 2020","Stanford University School of Medicine, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04331899,United States,Peginterferon Lambda-1a,5.0,2021,Saturday
495,496,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death,Withdrawn,Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,0.0,"April 30, 2020",2020-04-30,"June 30, 2020",,https://ClinicalTrials.gov/show/NCT04323631,Undefined,Hydroxychloroquine,4.0,2020,Thursday
496,497,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Recruiting,Drug: Nafamostat Mesilate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"September 25, 2020",2021-03-01,"November 10, 2020","A108_02CVD2014 Site# 9, Barnaul, Russian Federation|A108_02CVD2014 Site# 26, Krasnoyarsk, Russian Federation|A108_02CVD2014 Site# 5, Moscow, Russian Federation|A108_02CVD2014 Site# 8, Moscow, Russian Federation|A108_02CVD2014 Site# 31, Ryazan, Russian Federation|A108_02CVD2014 Site# 25, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 30, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation|A108_02CVD2014 Site# 4, St. Petersburg, Russian Federation|A108_02CVD2014 site#1, Ufa, Russian Federation",https://ClinicalTrials.gov/show/NCT04623021,Russian Federation,Nafamostat Mesilate,3.0,2021,Monday
497,498,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Drug: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 28, 2020",2025-04-28,"June 16, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT04434131,Mexico,Convalescent Plasma,4.0,2025,Monday
498,499,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Drug: LY3819253|Drug: LY3832479|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,1200.0,"June 17, 2020",2021-03-11,"December 4, 2020","Arizona Clin Trials-Mesa, Mesa, Arizona, United States|Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Perseverance Research Center, Scottsdale, Arizona, United States|CRI of Arizona, LLC, Surprise, Arizona, United States|Fiel Family Medicine, Tempe, Arizona, United States|Orange Grove Banner Clinic, Tucson, Arizona, United States|Arizona Clin Trials-Tucson, Tucson, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States|Smart Cures Clin Research, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|VCT-Covina, Covina, California, United States|AMCR Institute, Escondido, California, United States|Valley Research, Fresno, California, United States|Chemidox Clinical Trials, Lancaster, California, United States|Ark Clinical Research, Long Beach, California, United States|Long Beach Clinical Trials LLC, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Central Valley Research, LLC, Modesto, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|University of CA, Irvine, Orange, California, United States|Inland Empire CT, LLC, Rialto, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Zion Medical Center, San Diego, California, United States|Kaiser Permanente - SD Med Ctr, San Diego, California, United States|Wolverine Clinical Trials, LLC, Santa Ana, California, United States|St. Joe Heritage HC-Santa Rosa, Santa Rosa, California, United States|Stanford University Hospital, Stanford, California, United States|Mazur, Statner, Dutta, Nathan, Thousand Oaks, California, United States|Infect Disease Doctors Med Grp, Walnut Creek, California, United States|Allianz Research Institute, Westminster, California, United States|Georgetown Univ Sch of Med, Washington, District of Columbia, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|I R & Health Center, Inc., Hialeah, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Elixia CRC, Hollywood, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|GCPR, Saint Petersburg, Florida, United States|Testing Matters Lab, Sunrise, Florida, United States|Advent Health Tampa, Tampa, Florida, United States|Triple O Research Inst, West Palm Beach, Florida, United States|Cleveland Clinic of Weston Florida, Weston, Florida, United States|Clinical Site Partners, LLC DBA CSP Orlando, Winter Park, Florida, United States|Gwinnett Research Inst, Buford, Georgia, United States|Paramount Rch Sol - College Pk, College Park, Georgia, United States|IACT Health - VHC, Columbus, Georgia, United States|Central Georgia Infectious Disease, Macon, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Northwestern University, Chicago, Illinois, United States|J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Franciscan Health Hammond, Dyer, Indiana, United States|Qualmedica Research Evansville, Evansville, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|St.Vincent - Indy, Indianapolis, Indiana, United States|Qualmedica Research, LLC, Owensboro, Kentucky, United States|Tandem Clinical Research,LLC, Marrero, Louisiana, United States|Imperial Health Urgent Care Center - Moss Bluff, Moss Bluff, Louisiana, United States|Nola Research Works, LLC, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|U of MA Mem Med Ctr, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Revive Research Institute, Farmington Hills, Michigan, United States|Revival Research Institute, Sterling Heights, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States|QPS Missouri, Springfield, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Care Access Research - Bronx, Bronx, New York, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Monroe Biomed Research, Monroe, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Hometown UC and Rch- Cincy, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|OH State Univ College of Med, Columbus, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Remington-Davis, Inc, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|META Medical Research Institute, LLC, Dayton, Ohio, United States|Ascension St. John Tulsa OK, Tulsa, Oklahoma, United States|Jefferson Hosp for Neurosci, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|VITALINK - Anderson, Anderson, South Carolina, United States|VITALINK - Gaffney, Gaffney, South Carolina, United States|VITALINK - Greenville, Greenville, South Carolina, United States|VITALINK - Spartanburg, Spartanburg, South Carolina, United States|VITALINK - Union, Union, South Carolina, United States|Univ Diab & Endo Consult, Chattanooga, Tennessee, United States|New Phase R and D, Knoxville, Tennessee, United States|Central Texas Clinical Rch, Austin, Texas, United States|Gadolin Research, LLC, Beaumont, Texas, United States|Crossroads Clinical Research, Corpus Christi, Texas, United States|B S & W Med Center, Dallas, Texas, United States|Baylor - Fort Worth, Fort Worth, Texas, United States|Houston Methodist Research Ins, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Centex-Houston, Houston, Texas, United States|BioPharma Clinc Site, Houston, Texas, United States|Centex-Wesfield, Houston, Texas, United States|B S & W Med Center, Irving, Texas, United States|BioPharma Family Practice Center McAllen, McAllen, Texas, United States|BRCR Medical Center, Inc, McAllen, Texas, United States|North Hills Medical Research, North Richland Hills, Texas, United States|Bay Area Infectious Diseases Associates, Pasadena, Texas, United States|Baylor - Round Rock, Round Rock, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|APD Clinical Research, Splendora, Texas, United States|Crossroads Clin Rch-Victoria, Victoria, Texas, United States|CLS Research Ctr, PLLC, Webster, Texas, United States|CARE ID, Annandale, Virginia, United States|Evergreen Health Research, Kirkland, Washington, United States|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Dorado Medical Complex Inc, Dorado, Puerto Rico|GCM Medical Group, PSC- Hato Rey, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04427501,Georgia,LY3819253|LY3832479|Placebo,3.0,2021,Thursday
499,500,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,Suspended,Drug: Hydroxychloroquine|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440.0,"April 3, 2020",2020-10-30,"July 15, 2020","ISGlobal, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04331834,Spain,Hydroxychloroquine|Placebos,10.0,2020,Friday
500,501,Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers,Recruiting,Biological: hAd5-S-Fusion+N-ETSD vaccine,All,18 Years to 55 Years   (Adult),Phase 1,35.0,"October 19, 2020",2021-11-19,"November 20, 2020","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",https://ClinicalTrials.gov/show/NCT04591717,United States,,11.0,2021,Friday
501,502,Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program,Not yet recruiting,,All,"18 Years to 120 Years   (Adult, Older Adult)",,9.0,"July 1, 2020",2020-08-31,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04443803,Undefined,,8.0,2020,Monday
502,503,Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk,Withdrawn,Drug: Hydroxychloroquine Sulfate,All,"18 Months to 85 Years   (Child, Adult, Older Adult)",Not Applicable,0.0,June 2020,2021-07-01,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04371926,Undefined,Hydroxychloroquine Sulfate,7.0,2021,Thursday
503,504,"Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)",Recruiting,Other: Non Intervention,Female,"18 Years and older   (Adult, Older Adult)",,3000.0,"May 1, 2020",2022-12-31,"July 21, 2020","Peking University First Hospital, Beijing, Beijing, China|Kwong Wah Hospital, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Hospital Universitario de Torrejón, Torrejón De Ardoz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04465474,China,,12.0,2022,Saturday
504,505,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,Drug: PUL-042 Inhalation Solution|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"June 9, 2020",2021-03-01,"October 19, 2020","University of California Irvine, Orange, California, United States|Premier Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04313023,Georgia,PUL-042 Inhalation Solution|Placebo,3.0,2021,Monday
505,506,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"April 6, 2020",2021-03-31,"April 7, 2020","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04336254,China,,3.0,2021,Wednesday
506,507,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,Recruiting,Drug: RDV|Drug: Placebo to Match RDV,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1264.0,"September 18, 2020",2021-01-01,"December 10, 2020","Arizona Liver Health, Chandler, Arizona, United States|Arizona Clinical Trials, Tucson, Arizona, United States|St Joseph Hospital Eureka, Eureka, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|Mills Clinical Research, Los Angeles, California, United States|UC Davis Health, Sacramento, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Centura Health Porter Place, Denver, Colorado, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|CTMD Research, Inc, Palm Springs, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|St. Josephs Comprehensive Research Institute, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast, Vero Beach, Florida, United States|Triple O Research Institute PA, West Palm Beach, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States|Be Well Medical Center, Berkley, Michigan, United States|Memorial Hospital of Gulfport, Gulfport, Mississippi, United States|Quality Clinical Research Inc., Omaha, Nebraska, United States|AB Clinical Trials, Las Vegas, Nevada, United States|New York Presbyterian Hospital, Flushing, New York, United States|Nuvance Health, Lagrangeville, New York, United States|Northwell Health, New Hyde Park, New York, United States|Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Rosedale Infectious Diseases, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Cherokee Nation WW Hastings Hospital, Tahlequah, Oklahoma, United States|Central Texas Clinical Research, Austin, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Care United Research, LLC, Forney, Texas, United States|University of Texas, Houston, Texas, United States|The Crofoot Research Center, Inc, Houston, Texas, United States|Laguna Clinical Research Associates, Laredo, Texas, United States|Diagnostic Clinic of Longview - Center for Clinical Research, Longview, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Hvidovre Hospital, Hvidovre, Denmark",https://ClinicalTrials.gov/show/NCT04501952,Denmark,RDV|Placebo to Match RDV,1.0,2021,Friday
507,508,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",Recruiting,Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276.0,"April 2, 2020",2020-10-01,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04332094,Spain,Tocilizumab|Hydroxychloroquine|Azithromycin,10.0,2020,Thursday
508,509,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Drug: Remdesivir|Drug: Standard of Care,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,4891.0,"March 6, 2020",2020-06-30,"July 27, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT04292899,China,Remdesivir|Standard of Care,6.0,2020,Tuesday
509,510,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",Recruiting,Drug: Hydroxychloroquine|Drug: Mucodentol|Device: Personal protective equipment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"July 15, 2020",2020-12-15,"July 10, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04466280,"Iran, Islamic Republic of",Hydroxychloroquine|Mucodentol,12.0,2020,Tuesday
510,511,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,Recruiting,Biological: Adsorbed COVID-19 (inactivated) Vaccine|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,13060.0,"July 21, 2020",2021-10-01,"December 11, 2020","Universidade de Brasília, Brasilia, DF, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Hospital Universitário Júlio Müller, Cuiabá, Mount, Brazil|Hospital Universitário Maria Aparecida Pedrossian, Campo Grande, MS, Brazil|Hospital das Clínicas da Universidade Federal do Paraná, Curitiba, PR, Brazil|Hospital Escola da Universidade Federal de Pelotas, Pelotas, RS, Brazil|Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, RS, Brazil|Hospital de Amor - Fundação Pio XII, Barretos, SP, Brazil|Hospital das Clínicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirao Preto, SP, Brazil|Instituto de Infectologia Emílio Ribas, Sao Paulo, SP, Brazil|Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil|Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, SP, Brazil|Universidade Municipal de São Caetano do Sul, São Caetano do Sul, SP, Brazil|Faculdade de Medicina de São José do Rio Preto - FAMERP, São José Do Rio Preto, São Paulo, Brazil|Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04456595,Brazil,,10.0,2021,Friday
511,512,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Recruiting,Diagnostic Test: COVID 19 serology|Other: COVID 19 Self-Questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"September 9, 2020",2021-09-01,"November 12, 2020","Limoges university Hospital, Limoges, France|Montpellier University Hospital, Montpellier, France|Pitié Salpêtrière Hospital - Hépatologie, Paris, France|Pitié Salpêtrière Hospital - Médecine interne, Paris, France|Haut-Lévêque Hospital - Gastro-entérologie, Pessac, France|Haut-Lévêque Hospital - Médecine interne, Pessac, France|Joseph Ducuing Hospital - Médecine interne, Toulouse, France|Toulouse university Hospital - Larrey Dermatologie, Toulouse, France|Toulouse University Hospital - Rhumatologie, Toulouse, France|Toulouse University Hospital, Toulouse, France|University Hospital of Toulouse - Rangueil Médecine interne, Toulouse, France|University hospital Toulouse - Purpan Médecine interne, Toulouse, France",https://ClinicalTrials.gov/show/NCT04481633,France,,9.0,2021,Wednesday
512,513,#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Mannitol,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,800.0,"May 12, 2020",2020-10-01,"May 12, 2020","Unisanté, Lausanne, Vaud, Switzerland",https://ClinicalTrials.gov/show/NCT04385264,Switzerland,Hydroxychloroquine|Mannitol,10.0,2020,Thursday
513,514,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,Completed,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline,All,"30 Years and older   (Adult, Older Adult)",Phase 4,18.0,"April 28, 2020",2020-09-30,"December 9, 2020","St Francis Hospital, Roslyn, New York, United States",https://ClinicalTrials.gov/show/NCT04370782,United States,Hydroxychloroquine|Azithromycin|Zinc Sulfate|Doxycycline,9.0,2020,Wednesday
514,515,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,Drug: PUL-042 Inhalation Solution|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 16, 2020",2021-03-01,"October 19, 2020","University of California Irvine, Orange, California, United States|Premeir Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|DBC Research Corp., Tamarac, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04312997,United States,PUL-042 Inhalation Solution|Placebo,3.0,2021,Monday
515,516,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Recruiting,Drug: Remdesivir (RDV)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,282.0,"September 14, 2020",2021-04-01,"December 9, 2020","The Institute for Liver Health, Mesa, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Saint Josephs Clinical Research, Anaheim, California, United States|Franco Felizarta, MD, Bakersfield, California, United States|Aurora FDRC Inc., Costa Mesa, California, United States|Elevated Health, Huntington Beach, California, United States|Western Clinical Research, Placentia, California, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Westchester Research Center at Westchester General Hospital, Miami, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Triple O Research Institute, PA, West Palm Beach, Florida, United States|Family Care Research, Boise, Idaho, United States|CTU Covid Research Center, New Orleans, Louisiana, United States|STAT Research, Vandalia, Ohio, United States|Baylor Research Institute, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04539262,United States,Remdesivir (RDV)|Placebo,4.0,2021,Thursday
516,517,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",Recruiting,Biological: bacTRL-Spike,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,October 2020,2022-02-28,"October 27, 2020","Nucleus Network Pty Ltd (Trading as Centre for Clinical Studies), Melbourne, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04334980,Australia,,2.0,2022,Monday
517,518,Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19,Recruiting,Drug: UNI911 INHALATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,44.0,"June 29, 2020",2020-12-31,"October 6, 2020","DanTrials, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04576312,Denmark,UNI911 INHALATION,12.0,2020,Thursday
518,519,Tetrandrine Tablets Used in the Treatment of COVID-19,Enrolling by invitation,Drug: Tetrandrine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60.0,"March 5, 2020",2021-05-01,"March 16, 2020","Tetrandrine Tablets, Jinhua, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04308317,China,Tetrandrine,5.0,2021,Saturday
519,520,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Recruiting,Drug: Ciclesonide|Drug: Placebo,All,"12 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,400.0,"June 8, 2020",2020-12-01,"June 11, 2020","University of Buffalo, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT04377711,United States,Ciclesonide|Placebo,12.0,2020,Tuesday
520,521,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,Recruiting,Drug: Nitazoxanide Tablets|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"May 25, 2020",2020-07-31,"June 9, 2020","Hospital Vera Cruz, Campinas, São Paulo, Brazil|Centro de Genomas, São Paulo, Brazil|Hospital Emílio Ribas, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04348409,Brazil,Nitazoxanide Tablets|Placebo,7.0,2020,Friday
521,522,Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 8, 2020",2022-03-01,"October 8, 2020","HEGP, Paris, France",https://ClinicalTrials.gov/show/NCT04418375,France,,3.0,2022,Tuesday
522,523,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,Not yet recruiting,Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,4000.0,"April 30, 2020",2021-05-30,"April 22, 2020",,https://ClinicalTrials.gov/show/NCT04353518,Undefined,Suspension of heat killed (autoclaved) Mycobacterium w,5.0,2021,Sunday
523,524,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019),Enrolling by invitation,,All,"Child, Adult, Older Adult",,100000.0,"January 1, 2020",2021-10-30,"September 30, 2020","Hospital Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitario La Princesa, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04569851,Spain,,10.0,2021,Saturday
524,525,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1500.0,"July 31, 2020",2022-11-01,"September 29, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States",https://ClinicalTrials.gov/show/NCT04488081,United States,Remdesivir|Cenicriviroc|Icatibant|Razuprotafib|Apremilast,11.0,2022,Tuesday
525,526,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,Recruiting,Drug: Telmisartan 40mg|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"July 1, 2020",2021-06-30,"August 3, 2020","University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States",https://ClinicalTrials.gov/show/NCT04360551,United States,Telmisartan 40mg|Placebo,6.0,2021,Wednesday
526,527,ImmuneSense™ COVID-19 Study,Recruiting,Other: T-Detect™ SARS-CoV-2 Assay,All,"18 Years to 89 Years   (Adult, Older Adult)",,125.0,"October 9, 2020",2021-01-09,"December 3, 2020","Adaptive Biotechnologies Clinical Investigational Site, Secaucus, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04583982,Jersey,,1.0,2021,Saturday
527,528,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"March 31, 2020",2020-07-01,"May 6, 2020","New York University School of Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04343989,United States,Clazakizumab 25 mg|Clazakizumab 12.5 mg,7.0,2020,Wednesday
528,529,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Drug: Bivalirudin Injection|Drug: Standard treatment,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,100.0,"June 28, 2020",2021-03-28,"June 24, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04445935,Qatar,Bivalirudin Injection|Standard treatment,3.0,2021,Sunday
529,530,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,Recruiting,"Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,300.0,"July 29, 2020",2021-04-23,"November 25, 2020","Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom|Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, United Kingdom|Royal Preston Hospital, Preston, United Kingdom",https://ClinicalTrials.gov/show/NCT04460183,United Kingdom,"RESP301, a Nitric Oxide generating solution",4.0,2021,Friday
530,531,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",Enrolling by invitation,Drug: HB-adMSCs|Drug: Placebos,All,"Child, Adult, Older Adult",Phase 2,100.0,"May 14, 2020",2021-04-30,"July 14, 2020","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",https://ClinicalTrials.gov/show/NCT04348435,United States,HB-adMSCs|Placebos,4.0,2021,Friday
531,532,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,Suspended,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,400.0,"April 23, 2020",2020-06-30,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04329572,Brazil,Hydroxychloroquine Sulfate|Azithromycin Tablets,6.0,2020,Tuesday
532,533,Cytokine Storm Among Bangladeshi Patients With COVID-19,Not yet recruiting,,All,"18 Years to 90 Years   (Adult, Older Adult)",,75.0,October 2020,2021-06-01,"October 27, 2020","Icddr,B, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04598334,Bangladesh,,6.0,2021,Tuesday
533,534,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,Device: Flow controlled ventilation (Evone-ventilator),All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,20.0,"May 28, 2020",2020-08-01,"June 25, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04399317,Qatar,,8.0,2020,Saturday
534,535,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Drug: Remdesivir|Drug: Standard of Care,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1113.0,"March 15, 2020",2020-06-26,"July 27, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT04292730,China,Remdesivir|Standard of Care,6.0,2020,Friday
535,536,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: Remdesivir,All,"up to 18 Years   (Child, Adult)",Phase 2|Phase 3,52.0,"July 21, 2020",2021-02-01,"December 10, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|Ronald Reagan University of California, Los Angeles Medical Center, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Tampa General Hospital (Inpatient Visits), Tampa, Florida, United States|Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Spectrum Health/Helen De Vos Children's Hospital, Grand Rapids, Michigan, United States|Children's Minnesota, Minneapolis, Minnesota, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|NYC Health + Hospitals/Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Northwell Health-Cohen Children's Medical Center, New Hyde Park, New York, United States|Carolinas Medical Center-Levine Children's Hospital, Charlotte, North Carolina, United States|Lehigh Valley Hospital/Lehigh Valley Health Network (LVH/LVHN), Allentown, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Azienda Ospedaliero Universitaria Meyer, Florence, Italy|University Hospital of Parma, Parma, Italy|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04431453,Italy,Remdesivir,2.0,2021,Monday
536,537,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,Recruiting,Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12000.0,"June 15, 2020",2022-06-15,"August 7, 2020","Institut de Cancerologie de l'Ouest, Angers, France",https://ClinicalTrials.gov/show/NCT04421625,France,,6.0,2022,Wednesday
537,538,Predictors of COVID-19 Infection and Disease Progression,Recruiting,Diagnostic Test: Rt PCR,All,"Child, Adult, Older Adult",,100.0,"March 15, 2020",2020-09-15,"July 23, 2020","Prof. Refat Sadeq, Port Said, Egypt",https://ClinicalTrials.gov/show/NCT04484597,Egypt,,9.0,2020,Tuesday
538,539,Testing for COVID-19 Infection in Asymptomatic Persons,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 20, 2020",2020-12-31,"April 14, 2020",,https://ClinicalTrials.gov/show/NCT04345510,Undefined,,12.0,2020,Thursday
539,540,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,Recruiting,Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP),All,"18 Years and older   (Adult, Older Adult)",Phase 2,180.0,"June 15, 2020",2021-12-15,"October 19, 2020","AO Città della salute e della scienza di Torino, Torino, Italy",https://ClinicalTrials.gov/show/NCT04428021,Italy,Standard Therapy Protocol (STP),12.0,2021,Wednesday
540,541,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,Recruiting,Other: Blood and derivatives.|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,278.0,"April 3, 2020",2020-07-01,"April 15, 2020","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04345523,Spain,Standard of Care,7.0,2020,Wednesday
541,542,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),Recruiting,Drug: Nitazoxanide|Drug: Placebo,All,18 Years to 59 Years   (Adult),Phase 2|Phase 3,135.0,"June 26, 2020",2020-12-26,"October 8, 2020","Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina",https://ClinicalTrials.gov/show/NCT04463264,Argentina,Nitazoxanide|Placebo,12.0,2020,Saturday
542,543,Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients,Enrolling by invitation,Diagnostic Test: Humoral and cellular immunity,All,"18 Years and older   (Adult, Older Adult)",,60.0,"October 1, 2020",2021-12-31,"December 2, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",https://ClinicalTrials.gov/show/NCT04649840,Belarus,,12.0,2021,Friday
543,544,Trial to Promote Recovery From COVID-19 With Endocrine Therapy,Not yet recruiting,Drug: Bicalutamide 150 Mg Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"January 4, 2021",2021-12-01,"December 9, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04374279,United States,Bicalutamide 150 Mg Oral Tablet,12.0,2021,Wednesday
544,545,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Recruiting,Biological: Biological,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,150.0,"June 23, 2020",2020-09-30,"September 10, 2020","Hospital Central Militar, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04542967,Mexico,,9.0,2020,Wednesday
545,546,Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Drug: Surfactant,All,"18 Years to 75 Years   (Adult, Older Adult)",,120.0,"July 3, 2020",2021-12-01,"September 29, 2020","FSAEI of Higher Education I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04568018,Russian Federation,Surfactant,12.0,2021,Wednesday
546,547,Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T),Not yet recruiting,Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral,All,"18 Years and older   (Adult, Older Adult)",Phase 2,562.0,May 2020,2020-12-01,"May 7, 2020","Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04379479,Mexico,Dialyzable Leukocyte Extract|Placebo oral,12.0,2020,Tuesday
547,548,Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence,Recruiting,,All,"up to 99 Years   (Child, Adult, Older Adult)",,500.0,"December 16, 2020",2025-08-31,"December 11, 2020","Niaid/Lcim, Rockville, Maryland, United States",https://ClinicalTrials.gov/show/NCT04582903,United States,,8.0,2025,Sunday
548,549,Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study,"Active, not recruiting",Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins (Cardiovascular Agents),All,"18 Years and older   (Adult, Older Adult)",,22784.0,"March 1, 2020",2022-12-31,"June 11, 2020","Södersjukhuset, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04426084,Sweden,Antihypertensive Agents|Statins (Cardiovascular Agents),12.0,2022,Saturday
549,550,Home Usability Study of the SARS-CoV-2 (COVID-19) Test,Completed,Diagnostic Test: SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,30.0,"May 18, 2020",2020-06-16,"August 11, 2020","Exact Sciences, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04395391,United States,,6.0,2020,Tuesday
550,551,Health After Covid-19 in Tyrol,Recruiting,Other: online survey,All,"16 Years and older   (Child, Adult, Older Adult)",,1000.0,"September 30, 2020",2021-12-31,"December 10, 2020","Medizinische Universität Innsbruck, Innsbruck, Tyrol, Austria",https://ClinicalTrials.gov/show/NCT04661462,Austria,,12.0,2021,Friday
551,552,Early Versus Delayed Intubation of Patients With COVID-19,Not yet recruiting,Other: Endotracheal intubation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"November 18, 2020",2021-05-01,"November 17, 2020","Evangelismos Hospital, Athens, Attiki, Greece",https://ClinicalTrials.gov/show/NCT04632043,Greece,,5.0,2021,Saturday
552,553,Study of Hemostasis in Case of Severe COVID-19,Not yet recruiting,Other: Extra blood sample,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 17, 2020",2021-05-01,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04359992,Undefined,,5.0,2021,Saturday
553,554,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Completed,Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,146.0,"April 4, 2020",2020-07-14,"July 16, 2020","Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04473170,United Arab Emirates,COVID-19 standard care,7.0,2020,Tuesday
554,555,Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.,Withdrawn,Biological: vaccine BCG|Other: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0.0,August 2020,2021-11-01,"November 27, 2020","Program for Research and Control in Tropical Diseases - PECET, Medellín, Antioquia, Colombia",https://ClinicalTrials.gov/show/NCT04362124,Colombia,,11.0,2021,Monday
555,556,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",Completed,Drug: Povidone-Iodine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"September 1, 2020",2020-10-23,"October 26, 2020","University Hospital of Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04371965,France,Povidone-Iodine,10.0,2020,Friday
556,557,Control of COVID-19 Outbreaks in Long Term Care,Recruiting,Drug: Favipiravir|Drug: Favipiravir Placebo,All,65 Years and older   (Older Adult),Phase 2,760.0,"October 16, 2020",2021-03-01,"October 23, 2020","Mount Sinai Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04448119,Canada,Favipiravir|Favipiravir Placebo,3.0,2021,Monday
557,558,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Recruiting,Drug: Azithromycin Capsule,All,"19 Years and older   (Adult, Older Adult)",Phase 3,800.0,"May 29, 2020",2020-10-13,"June 9, 2020","Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom",https://ClinicalTrials.gov/show/NCT04381962,United Kingdom,Azithromycin Capsule,10.0,2020,Tuesday
558,559,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,Recruiting,Drug: Zavegepant (BHV-3500)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"April 25, 2020",2021-04-01,"September 25, 2020","Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Roper Hospital, Charleston, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04346615,United States,Zavegepant (BHV-3500)|Placebo,4.0,2021,Thursday
559,560,RAPA-501-Allo Off-the-Shelf Therapy of COVID-19,Not yet recruiting,Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,88.0,"December 30, 2020",2022-06-01,"November 25, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04482699,Jersey,,6.0,2022,Wednesday
560,561,Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19),Withdrawn,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,August 2020,2021-09-01,"October 29, 2020","Oregon Health and Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04363866,United States,Hydroxychloroquine|Placebo,9.0,2021,Wednesday
561,562,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Drug: Pegylated interferon lambda,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"June 22, 2020",2021-09-30,"December 11, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04343976,United States,Pegylated interferon lambda,9.0,2021,Thursday
562,563,Myocardial Damage in COVID-19,Enrolling by invitation,Other: non,All,"18 Years and older   (Adult, Older Adult)",,500.0,"January 1, 2020",2020-03-18,"March 18, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04312464,China,,3.0,2020,Wednesday
563,564,Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce,Recruiting,Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",,20000.0,"May 18, 2020",2021-04-30,"July 29, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04491292,United States,,4.0,2021,Friday
564,565,Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120.0,October 2020,2022-06-01,"September 2, 2020","Kootenai Health, Coeur d'Alene, Idaho, United States",https://ClinicalTrials.gov/show/NCT04382625,United States,Hydroxychloroquine,6.0,2022,Wednesday
565,566,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Recruiting,Other: Media Intervention|Procedure: Meditation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Yoga,All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1,50.0,"June 17, 2020",2021-07-01,"September 23, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04482647,United States,,7.0,2021,Thursday
566,567,"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19",Completed,Other: Questionaire,All,"Child, Adult, Older Adult",,202.0,"April 20, 2020",2020-05-05,"September 3, 2020","Fayoum University, Fayoum, Egypt",https://ClinicalTrials.gov/show/NCT04537117,Egypt,,5.0,2020,Tuesday
567,568,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,Completed,,,"Child, Adult, Older Adult",,18.0,"March 20, 2020",2020-05-26,"November 25, 2020","Policlinic Ibiza Hospital, Ibiza, Spain",https://ClinicalTrials.gov/show/NCT04444531,Spain,,5.0,2020,Tuesday
568,569,COVID SAFE: COVID-19 Screening Assessment for Exposure,Enrolling by invitation,Behavioral: Saliva-based testing,All,"18 Years and older   (Adult, Older Adult)",,600.0,"September 9, 2020",2021-03-01,"September 11, 2020","Penn Medicine, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04508777,United States,,3.0,2021,Monday
569,570,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,Recruiting,Radiation: Low Dose Radiotherapy,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,30.0,"July 24, 2020",2021-04-05,"September 1, 2020","Social Secure Mexican Institute, Leon, Guanajuato, Mexico",https://ClinicalTrials.gov/show/NCT04534790,Mexico,,4.0,2021,Monday
570,571,CovidDB: The Covid-19 Inpatient Database,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"March 30, 2020",2023-06-30,"April 21, 2020","RoMed - Klinikum Bad Aibling, Bad Aibling, Germany|DONAUISAR Klinikum Deggendorf, Deggendorf, Germany|DONAUISAR Klinikum Dingolfing, Dingolfing, Germany|RoMed - Klinikum Prien am Chiemsee, Prien, Germany|RoMed - Klinikum Rosenheim, Rosenheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany|Klinikum Altmühlfranken, Weißenburg, Germany|Timiş County Emergency Clinical Hospital, Timisoara, Romania",https://ClinicalTrials.gov/show/NCT04344171,Germany,,6.0,2023,Friday
571,572,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Recruiting,Drug: Angiotensin Receptor Blockers,All,"18 Years and older   (Adult, Older Adult)",Phase 4,605.0,"June 19, 2020",2021-04-30,"July 16, 2020","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal prince Alfred Virtual Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04394117,Australia,Angiotensin Receptor Blockers,4.0,2021,Friday
572,573,Stopping ACE-inhibitors in COVID-19,Recruiting,"Drug: ACE inhibitor, angiotensin receptor blocker",All,"18 Years and older   (Adult, Older Adult)",Phase 4,208.0,"April 15, 2020",2022-05-15,"June 11, 2020","Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum München, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|München Klinik Bogenhausen und Schwabing, Munich, Germany|Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik für Innere Medizin Weilheim, Weilheim, Germany",https://ClinicalTrials.gov/show/NCT04353596,Austria,"ACE inhibitor, angiotensin receptor blocker",5.0,2022,Sunday
573,574,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,Recruiting,Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,300.0,"May 22, 2020",2020-10-30,"June 17, 2020","Policlinico S. Orsola Malpighi Dipartimento Malattie Infettive, Bologna, Emilia Romagna, Italy|Azienda Ospedaliero-Universitaria di Parma Anestesia e Rianimazione Dipartimento di Medicina e Chirurgia, Parma, Emilia Romagna, Italy|I.R.C.C.S. ""Casa Sollievo della Sofferenza"", San Giovanni Rotondo (FG) UOVD Emostasi e trombosi- Poliambulatorio Giovanni Paolo II Viale Padre Pio n.7 San Giovanni Rotondo (FG), San Giovanni Rotondo, Foggia, Italy|Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy|Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy|Azienda Ospedaliero-Universitaria ""Policlinico - V. Emanuele"", Catania Anestesia e Rianimazione UO Malattie Infettive, Catania, Italy|ASST Cremona Unità Operativa di Chirurgia Vascolare Dipartimento di Medicina di Laboratorio e di Radiologia- Centro Emostasi e Trombosi, Cremona, Italy|Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy|Ospedale Carlo Poma di Mantova MALATTIE INFETTIVE Padiglione 37 Str. Lago Paiolo, 10, 46100 Mantova, Mantova, Italy|AZIENDA OSPEDALIERA Regionale S CARLO POTENZA Struttura Complessa Interaziendale ""Malattie Infettive"", Matera, Italy|Ospedale San Raffaele Unità Funzionale dell'Unità Operativa di Malattie Infettive Osp. San Raffaele, Milano, Italy|Ospedale Amedeo di Savoia Torino Università di Torino Malattie Infettive, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona UOC Malattie Infettive e Tropicali, Verona, Italy",https://ClinicalTrials.gov/show/NCT04427098,Italy,Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin,10.0,2020,Friday
574,575,Immune Modulators for Treating COVID-19,Recruiting,Drug: Infliximab|Drug: Abatacept|Drug: Remdesivir|Drug: cenicriviroc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2160.0,"October 15, 2020",2021-09-01,"November 16, 2020","University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|University of Kansas, Kansas City, Kansas, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers New Jersey Medical School, New Brunswick, New Jersey, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|Gundersen Health System, La Crosse, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04593940,Jersey,Infliximab|Abatacept|Remdesivir|cenicriviroc,9.0,2021,Wednesday
575,576,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Recruiting,Procedure: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 23, 2020",2021-09-15,"November 4, 2020","""Evangelismos"" General Hospital, Athens, Attiki, Greece|""Agios Savas"" Oncology Hospital, Athens, Attiki, Greece|""Alexandra"" General Hospital, Athens, Attiki, Greece|""Sotiria"" General Hospital, Athens, Attiki, Greece|Attikon"" University General Hospital, Athens, Chaidari, Greece|University General Hospital of Patras, Patra, Rio, Greece",https://ClinicalTrials.gov/show/NCT04408209,Greece,,9.0,2021,Wednesday
576,577,A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease,Recruiting,Other: other,All,"18 Years to 80 Years   (Adult, Older Adult)",,1000.0,"January 17, 2020",2020-12-31,"July 14, 2020","Xinqiao Hospital of Chongqing, Chongqing, China",https://ClinicalTrials.gov/show/NCT04347369,China,,12.0,2020,Thursday
577,578,The COvid-19 Symptom MOntelukast Trial,Not yet recruiting,Drug: Montelukast 10mg,All,"40 Years and older   (Adult, Older Adult)",Phase 3,600.0,"October 1, 2020",2021-12-01,"September 1, 2020",,https://ClinicalTrials.gov/show/NCT04389411,Undefined,Montelukast 10mg,12.0,2021,Wednesday
578,579,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic,Completed,Other: COVID-19 pandemic,All,"Child, Adult, Older Adult",,700.0,"January 1, 2020",2020-04-30,"August 20, 2020","Department of Rehabilitation and Physiotherapy Rehabilitation,, Poznań, Poland",https://ClinicalTrials.gov/show/NCT04521010,Poland,,4.0,2020,Thursday
579,580,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Completed,Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,196.0,"May 6, 2020",2020-11-26,"November 30, 2020","Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico",https://ClinicalTrials.gov/show/NCT04381858,Mexico,Plasma from COVID-19 convalescent patient|Human immunoglobulin,11.0,2020,Thursday
580,581,Fatigue and Sleep in Patients With COVID-19,Not yet recruiting,Other: survey,All,18 Years to 45 Years   (Adult),,720.0,"December 5, 2020",2021-06-30,"December 8, 2020",,https://ClinicalTrials.gov/show/NCT04657419,Undefined,,6.0,2021,Wednesday
581,582,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Recruiting,Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Drug: Antibiotics|Drug: Hormones|Drug: Anticoagulant Therapy|Device: Оxygen therapy,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"May 2, 2020",2021-12-01,"July 8, 2020","Institute of Cell Therapy, Kyiv, Ukraine",https://ClinicalTrials.gov/show/NCT04461925,Ukraine,Antibiotics|Hormones|Anticoagulant Therapy,12.0,2021,Wednesday
582,583,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"March 31, 2020",2020-06-06,"June 22, 2020","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy",https://ClinicalTrials.gov/show/NCT04346355,Italy,Tocilizumab,6.0,2020,Saturday
583,584,Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients,Not yet recruiting,Drug: SnPP Protoporphyrin plus Sunlight exposure|Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Other: placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,56.0,August 2020,2020-11-01,"June 24, 2020","Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt",https://ClinicalTrials.gov/show/NCT04371822,Egypt,SnPP Protoporphyrin plus Sunlight exposure|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.,11.0,2020,Sunday
584,585,Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers,Not yet recruiting,Diagnostic Test: COVID-19 antibodies testing,All,"Child, Adult, Older Adult",,250.0,"July 1, 2020",2021-09-01,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04445415,Undefined,,9.0,2021,Wednesday
585,586,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Recruiting,Drug: Bevacizumab,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,140.0,"March 17, 2020",2020-07-31,"March 26, 2020","Qilu Hospital of Shandong University, Jinan, Shandong, China",https://ClinicalTrials.gov/show/NCT04305106,China,Bevacizumab,7.0,2020,Friday
586,587,NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Not yet recruiting,Biological: NestaCell®|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,June 2020,2020-08-01,"June 9, 2020","Hospital Vera Cruz, Campinas, São Paulo, Brazil|Hospital de Barueri, São Paulo, Brazil|IncCOR, São Paulo, Brazil|UNIFESP, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04315987,Brazil,,8.0,2020,Saturday
587,588,Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia,Withdrawn,Drug: Lanadelumab|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,0.0,"October 31, 2020",2021-01-27,"October 12, 2020",,https://ClinicalTrials.gov/show/NCT04460105,Undefined,Lanadelumab,1.0,2021,Wednesday
588,589,The Noninvasive Ventilation to COVID-19 Patients,Completed,Device: noninvasive ventilation,All,"20 Years to 80 Years   (Adult, Older Adult)",,23.0,"February 1, 2020",2020-07-01,"September 29, 2020","The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04568655,China,,7.0,2020,Wednesday
589,590,"To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)",Not yet recruiting,Drug: DWRX2003|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,"October 6, 2020",2021-01-29,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04541485,Undefined,DWRX2003|Placebo,1.0,2021,Friday
590,591,Implementation of Physiotherapy on COVID-19 Patients in ICU,Recruiting,Other: Phsyiotherapy,All,"18 Years and older   (Adult, Older Adult)",,150.0,"April 1, 2017",2022-12-01,"April 16, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04347070,France,,12.0,2022,Thursday
591,592,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Active, not recruiting",Biological: BCG vaccine|Biological: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2014.0,"April 16, 2020",2021-05-01,"June 4, 2020","Radboud University, Nijmegen, Gelderland, Netherlands|UMC Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04417335,Netherlands,,5.0,2021,Saturday
592,593,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Drug: methylprednisolone therapy|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80.0,"January 26, 2020",2020-04-13,"June 16, 2020","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04244591,China,methylprednisolone therapy,4.0,2020,Monday
593,594,"Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures (COVISTRESS Screening)",Recruiting,,All,"16 Years and older   (Child, Adult, Older Adult)",,1000.0,"May 1, 2020",2025-12-01,"September 4, 2020","Univeristy Hospital, Clermont-Ferrand, Clermont-Ferrand, France",https://ClinicalTrials.gov/show/NCT04538586,France,,12.0,2025,Monday
594,595,PEP Flute-selfcare in COVID-19,Recruiting,Device: PEP flute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"October 6, 2020",2021-04-30,"October 8, 2020","Research Unit for Dietary Studies at the Parker Institute, Bispebjerg and Frederiksberg Hospitals, Frederiksberg, Denmark",https://ClinicalTrials.gov/show/NCT04530435,Denmark,,4.0,2021,Friday
595,596,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Drug: Tocilizumab (TCZ)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450.0,"April 3, 2020",2020-07-28,"September 25, 2020","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",https://ClinicalTrials.gov/show/NCT04320615,Canada,Tocilizumab (TCZ)|Placebo,7.0,2020,Tuesday
596,597,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,Enrolling by invitation,Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,72.0,"June 16, 2020",2020-11-01,"December 1, 2020","Icddr,B, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04407130,Bangladesh,Ivermectin + Doxycycline + Placebo|Ivermectin + Placebo|Placebo,11.0,2020,Sunday
597,598,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"Active, not recruiting",Drug: Placebo|Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,379.0,"May 14, 2020",2021-12-01,"November 4, 2020","Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|El Centro Regional Medical Center, El Centro, California, United States|Harper University Hospital, Fountain Valley, California, United States|eStudySite, La Mesa, California, United States|Highland Hospital Oakland, Oakland, California, United States|St. Joseph'S Hospital, Orange, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Miami Veterans Administration Healthcare System - NAVREF, Miami, Florida, United States|University of Miami Pulmonary, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St. Lukes Boise Medical Center, Boise, Idaho, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Optum Health Care, Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|NYC Health and Hospitals Queens, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Novant Health Presbyterian Medical Center (Presbyterian Hospital), Charlotte, North Carolina, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Novant Health Rowan Medical Center, Salisbury, North Carolina, United States|Novant Health Foryth Medical Center, Winston-Salem, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|McAllen Medical Center, McAllen, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Sentara Medical Group, Virginia Beach, Virginia, United States|Hospital Unversitario Walter Cantidio, Fortaleza, CE, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Centro Multidisciplinar de Estudos Clínicos CEMEC FMABC, Sao Bernardo Do Campo, SP, Brazil|BR Trials - Pesquisa Clínica, Sao Paulo, SP, Brazil|Escola Paulista de Medicina Da Universidade Federal de São Paulo - EPMUNIFESP, Sao Paulo, SP, Brazil|Aga Khan University Hospital, Nairobi, Kenya|Organismo Publico Descentralizado Hospital Juarez de Mexico, Ciudad De México, Mexico|Hospital General de Culiacan, Culiacan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Hospital Militar Central, Jesus Maria, Peru|Hospital Nacional Sergio E. Bernales, Lima, Peru|Hospital Nacional Arzobispo Loayza; Oncology, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Nacional Hipolito; Unanue, Lima, Peru|Hospital Maria Auxiliadora, Lima, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|University of the Free State, Bloemfontein, South Africa|George Provincial Hospital, George, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Milpark Hospital, Parktown West, South Africa|University of Stellenbosch; Respiratory Research, Parow, South Africa",https://ClinicalTrials.gov/show/NCT04372186,Brazil,Placebo|Tocilizumab,12.0,2021,Wednesday
598,599,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,Recruiting,Biological: Abatacept|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,129.0,"August 24, 2020",2021-01-14,"November 17, 2020","Norton Infectious Disease Institute, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Atlantic Health System, Morristown, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|Local Institution, Dallas, Texas, United States|Local Institution, Guaynabo, Puerto Rico|Local Institution, Monterrey Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04472494,Jersey,,1.0,2021,Thursday
599,600,Covid-19 Pediatric Observatory,Recruiting,Other: hospitalized children with Covid19,All,"up to 18 Years   (Child, Adult)",,250.0,"April 7, 2020",2021-06-30,"July 17, 2020","Chu Felix Guyon, Saint Denis, La Réunion, France|Ch St Esprit, Agen, France|Ch General Aix En Provence -, Aix-en-Provence, France|CHU Angers, Angers, France|CH d'ANGOULEME, Angoulème, France|Pringy - Ch D'Annecy, Annecy, France|CH Argenteuil, Argenteuil, France|Ch Armentieres, Armentières, France|CH Arpajon, Arpajon, France|Ch Auxerre, Auxerre, France|CH GENERAL Henri Duffaut, Avignon, France|CHU de BESANCON, Besançon, France|Hopital Femme Enfant, Caen, France|Ch de Pontoise, Cergy-Pontoise, France|Ch W. Morey, Chalon-sur-Saône, France|CH de CHAMBERY, Chambéry, France|Ch Hotel Dieu, Chartres, France|CHU Estaing, Clermont-Ferrand, France|Hopital Louis Pasteur, Colmar, France|Hopital Louis Mourrier, Colombes, France|CH Sud Francilien, Corbeil-Essonnes, France|Centre Hospitalier intercommunal de Creteil, Creteil, France|Ch de Dax, Dax, France|Hopital D'Enfants Chu Dijon, Dijon, France|CH Louviers Val de Reuil, Elbeuf, France|CH Gonesse, Gonesse, France|CH d'HYERES, Hyères, France|Ch de Marne La Vallee, Jossigny, France|Chru de Grenoble, La Tronche, France|CHGénéral du HAVRE, Le Havre, France|Hopital Jeanne de Flandre, Lille, France|Hopital Roger Salengro - Lille, Lille, France|Hopital Saint Vincent de Paul, Lille, France|Ch de Longjumeau, Longjumeau, France|Lorient - Ch de Bretagne Sud, Lorient, France|Hopital Femme Mere Enfant-Bron, Lyon, France|Hopital de Mantes, Mantes-la-Jolie, France|Hopital Nord Enfants, Marseille, France|Hopital de Meaux, Meaux, France|Ch de Melun, Meulin, France|CH de Montargis, Montargis, France|CH de MONTBRISON, Montbrison, France|Hopital Arnaud de Villeneuve, Montpellier, France|CHRU de Nancy, Nancy, France|Nantes - Hopital Mere Enfant, Nantes, France|Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France|Hopital Lenval, Nice, France|CHU Nimes Caremeau, Nîmes, France|Chr Orleans, Orléans, France|Assistance Publique Hôpitaux de Paris, Paris, France|Hopital St Jean Roussillon, Perpignan, France|POISSY - CH de POISSY, Poissy, France|QUIMPER - CH de Cornouaille, Quimper, France|RANG du FLIERS - C.H.A.M., RANG du FLIERS, France|Hopital Américain CHU REIMS, Reims, France|CH RODEZ, Rodez, France|CH de ROMANS, Romans-sur-Isère, France|Chu Rouen, Rouen, France|Hopital Charles-Nicolle, Rouen, France|Chu St Etienne, Saint Etienne, France|Ch de Saint Denis, Saint-Denis, France|Ch de Saint Malo, Saint-Malo, France|Ch Du Pays Du Mont Blanc, Sallanches, France|Chg Salon de Provence, Salon de Provence, France|CH Hautepierre, Strasbourg, France|CH Tarbes, Tarbes, France|CH Bel Air, Thionville, France|Hopital Sainte Musse, Toulon, France|CHU Toulouse-hôpital des Enfants, Toulouse, France|Hôpital Gatien De Clocheville, Tours, France|CH de TROYES, Troyes, France|Hôpital Nord Franche-Comté, Trévenans, France|Ch Bretagne Atlantique, Vannes, France|Ch Le Chesnay, Versailles, France|Hopital de Villeneuve Saint Georges, Villeneuve-Saint-Georges, France|CH Jean Monnet, Épinal, France",https://ClinicalTrials.gov/show/NCT04336956,France,,6.0,2021,Wednesday
600,601,COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells,Not yet recruiting,"Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"June 1, 2020",2021-03-01,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04402892,Undefined,,3.0,2021,Monday
601,602,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,Recruiting,Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,390.0,"June 2, 2020",2021-03-03,"November 17, 2020","University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|eStudySite, La Mesa, California, United States|Alta Bates Summit Medical Center, Oakland, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Bay Pines VA Medical Center - NAVREF, Bay Pines, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|Northside Hospital; Peachtree Dunwoody Medical Center, Atlanta, Georgia, United States|WellStar Research Institute, Marietta, Georgia, United States|University Of Iowa Hospitals And Clinics, Coralville, Iowa, United States|DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS, Alexandria, Louisiana, United States|MedPharmics, Metairie, Louisiana, United States|Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Lincoln Medical Mental Health Center, Bronx, New York, United States|Jacobi Medical Center; Lewis M. Fraad Department of Pediatrics, Bronx, New York, United States|Staten Island University Hospital; Department of Pharmacy, Staten Island, New York, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center; Investigational Drug Services/Regional Research, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple Uni Medical Center; Pulmonary & Critical Care Medicine, Philadelphia, Pennsylvania, United States|Parkland Health & Hospital System, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility, Tacoma, Washington, United States|Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ, Rio de Janeiro, RJ, Brazil|Centro De Estudos Pesquisas em Molestias Infecciosas - CPCLIN, Natal, RN, Brazil|Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil|Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases, Mexico, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain|Hospital Clinico Universitario Valladolid, Valladolid, Spain",https://ClinicalTrials.gov/show/NCT04386616,Brazil,MSTT1041A|MSTT1041A-matched Placebo|UTTR1147A|UTTR1147A-matched Placebo,3.0,2021,Wednesday
602,603,Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients,Not yet recruiting,Other: Cardiorespiratory Exercise|Other: Modified Bai He Gu Jin Tang,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,172.0,"October 1, 2020",2023-06-30,"October 1, 2020","Linda Zhong, Kowloon Tong, Kowloon, Hong Kong",https://ClinicalTrials.gov/show/NCT04572360,Hong Kong,,6.0,2023,Friday
603,604,Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19,Not yet recruiting,Drug: Prednisone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120.0,"September 7, 2020",2021-12-15,"September 1, 2020",,https://ClinicalTrials.gov/show/NCT04534478,Undefined,Prednisone,12.0,2021,Wednesday
604,605,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Completed,Drug: Tociliuzumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"May 5, 2020",2020-08-12,"September 11, 2020","Mayo Clinic - Arizona, Phoenix, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",https://ClinicalTrials.gov/show/NCT04363736,Jamaica,Tociliuzumab,8.0,2020,Wednesday
605,606,Effect of COVID-19 Pandemic on Pediatric Cancer Care,Recruiting,,All,"Child, Adult, Older Adult",,20.0,"May 15, 2020",2021-09-01,"August 12, 2020","South Egypt Cancer Institute, Assiut University, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04374838,Egypt,,9.0,2021,Wednesday
606,607,COVID-19 Recovered Volunteer Research Participant Pool Registry,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"April 8, 2020",2042-04-20,"May 4, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04359602,United States,,4.0,2042,Sunday
607,608,Anti COVID-19 Convalescent Plasma Therapy,Not yet recruiting,Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,20.0,"April 14, 2020",2021-04-01,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04345679,Undefined,,4.0,2021,Thursday
608,609,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,Recruiting,Drug: LAU-7b|Drug: Placebo oral capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,240.0,"June 29, 2020",2021-05-30,"November 30, 2020","St Lukes Hospital, Boise, Idaho, United States|Anne Arundel Medical Center, 2001 Medical Parkway, Belcher Pavillion, Annapolis, Maryland, United States|Wayne State University, Harper University Hospital, Detroit, Michigan, United States|St-Paul's Hospital, Vancouver, British Columbia, Canada|Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi, Chicoutimi, Quebec, Canada|CIUSSSS de l'Est-de-l'Ile-de-Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CISSS Ds Laurentides, Saint-Jérôme, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04417257,Canada,LAU-7b|Placebo oral capsule,5.0,2021,Sunday
609,610,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Drug: Siltuximab|Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 15, 2020",2020-05-20,"April 17, 2020","Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain",https://ClinicalTrials.gov/show/NCT04329650,Spain,Siltuximab|Methylprednisolone,5.0,2020,Wednesday
610,611,Convalescent Plasma for COVID-19 Close Contacts,Recruiting,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%),All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,May 2020,2021-04-01,"May 15, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04390503,United States,,4.0,2021,Thursday
611,612,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,Recruiting,Drug: Camostat,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,389.0,"September 25, 2020",2021-08-31,"December 7, 2020","The University of Edinburgh, Edinburgh, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Clarence Medical Centre, Rhyl, United Kingdom|Velindre Cancer Centre, Wales, United Kingdom",https://ClinicalTrials.gov/show/NCT04455815,United Kingdom,Camostat,8.0,2021,Tuesday
612,613,PET/CT Imaging in COVID-19 Patients,Enrolling by invitation,Drug: 18F-αvβ6-BP,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,"May 1, 2020",2022-05-01,"July 7, 2020","University of California Davis, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT04376593,United States,18F-αvβ6-BP,5.0,2022,Sunday
613,614,COVID-19 - Quality of Life After Infection,Not yet recruiting,"Other: SF12, EQ-5D-5L and work status standardized quantitative assessments",All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 5, 2020",2022-04-30,"May 6, 2020",,https://ClinicalTrials.gov/show/NCT04377464,Undefined,,4.0,2022,Saturday
614,615,Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic,Recruiting,,All,"up to 18 Years   (Child, Adult)",,100.0,"January 1, 2020",2021-06-01,"May 27, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04404244,Egypt,,6.0,2021,Tuesday
615,616,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine,All,"15 Years to 100 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,30.0,"April 4, 2020",2020-05-20,"April 13, 2020","Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04331470,"Iran, Islamic Republic of",Levamisole Pill + Budesonide+Formoterol inhaler|Lopinavir/Ritonavir + hydoxychloroquine,5.0,2020,Wednesday
616,617,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,Not yet recruiting,Drug: thalidomide|Drug: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"February 20, 2020",2020-06-30,"February 21, 2020",,https://ClinicalTrials.gov/show/NCT04273529,Undefined,thalidomide|placebo,6.0,2020,Tuesday
617,618,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,Not yet recruiting,Drug: placebo|Drug: Thalidomide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"February 18, 2020",2020-05-30,"February 21, 2020",,https://ClinicalTrials.gov/show/NCT04273581,Undefined,placebo|Thalidomide,5.0,2020,Saturday
618,619,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Recruiting,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,500.0,"June 16, 2020",2020-12-01,"November 20, 2020","Valleywise Health Medical Center, Phoenix, Arizona, United States|eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|El Centro Regional Medical Center, El Centro, California, United States|Hoag Hospital Irvine, Irvine, California, United States|Providence St. John's Health Center, Santa Monica, California, United States|Stanford University, Stanford, California, United States|Yale University School of Medicine; HIV Clinical Trials Program, New Haven, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States|Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States|St Luke's Health System; Rheumatology Research, Boise, Idaho, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Medical Center, Novi, Michigan, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|Wyckoff Heights Medical Center, Staten Island, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|Cone Health Medical Group, Greensboro, North Carolina, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Providence Saint Vincent's Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health-Midlands, Columbia, South Carolina, United States|The Liver Institute at Methodist Dallas, Arlington, Texas, United States|Baylor Scott and White Medical Center - College Station, College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Medical Center - Irving, Irving, Texas, United States|Baylor Scott & White Hospital - Plano, Plano, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|The Providence Regional Medical Center Everett, Everett, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, AM, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil|Instituto de Pesquisa Clinica Evandro Chagas - IPEC FIOCRUZ, Rio de Janeiro, RJ, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, Sao Bernardo Do Campo, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Instituto de Infectologia Emilio Ribas, Sao Paulo, SP, Brazil|Instituto do Coração - HCFMUSP, Sao Paulo, SP, Brazil|CHRU de Tours, Chambray-lès-tours, France|APHP Raymond Poincare, Garches, France|Hotel Dieu - Nantes, Nantes, France|CHU de Nice, Nice, France|Hopital Cochin, Paris, France|Hôpital Nord Franche-Comté, Saint-Priest-en-Jarez, France|Medsi Clinic, Moscow, Adygeja, Russian Federation|Clinical Infectious Diseases Hospital #1; Chair of Infectious Disease and Epidemiology, Moskva, Moskovskaja Oblast, Russian Federation|City Clinical Hospital #15, Moscow, Russian Federation|City Clinical Hospital # 52, Moscow, Russian Federation|Pokrovsky City Hosptial, St Petersburg, Russian Federation|Medical Military Academy n.a S.M.Kirov, St.Petersburg, Russian Federation|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Principe de Asturias; Medicina Interna - Servicio de Enfermedades Infecciosas, Alcala de Henares, Madrid, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General Universitario de Guadalajara, Guadalajara, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain",https://ClinicalTrials.gov/show/NCT04409262,Brazil,Remdesivir|Tocilizumab|Placebo,12.0,2020,Tuesday
619,620,Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors,Not yet recruiting,"Diagnostic Test: Standard 12-lead ECG, NT-proBNP, echocardiography",All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 20, 2020",2020-05-01,"April 24, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04355884,Hong Kong,,5.0,2020,Friday
620,621,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,Drug: Sarilumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 22, 2020",2020-12-30,"December 10, 2020","Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04661527,Spain,Sarilumab,12.0,2020,Wednesday
621,622,COVID-19 Among Healthcare Workers in Belgian Hospitals,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,850.0,"April 22, 2020",2021-04-30,"November 3, 2020","Sciensano, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04373889,Belgium,,4.0,2021,Friday
622,623,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"Active, not recruiting",Drug: metenkefalin + tridecactide|Drug: The standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"May 1, 2020",2020-12-31,"October 5, 2020","Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Hospital Travnik, Travnik, Bosnia and Herzegovina|Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina",https://ClinicalTrials.gov/show/NCT04374032,Bosnia and Herzegovina,metenkefalin + tridecactide|The standard of care,12.0,2020,Thursday
623,624,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,Diagnostic Test: Lung ultrasound use in patients hospitalized with COVID,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,90.0,"July 1, 2020",2021-12-01,"September 28, 2020","University of Colorado, Denver, Colorado, United States",https://ClinicalTrials.gov/show/NCT04542421,United States,,12.0,2021,Wednesday
624,625,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",Not yet recruiting,Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,480.0,"April 30, 2020",2021-04-30,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04358809,Undefined,Suspension of heat killed (autoclaved) Mycobacterium w,4.0,2021,Friday
625,626,SARS-CoV-2/COVID-19 PREVALENCE STUDY,Not yet recruiting,,All,"2 Months and older   (Child, Adult, Older Adult)",,3920.0,"December 15, 2020",2021-03-30,"December 8, 2020","Children's Hospital Colorado CRS, Aurora, Colorado, United States|U of Miami, IDRU at Jackson Memorial Hospital CRS, Miami, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|UIC Project Wish CRS, Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|John's Hopkins CRS, Baltimore, Maryland, United States|New Jersey Medical School CRS, Newark, New Jersey, United States|Harlem Prevention, New York, New York, United States|Bronx Prevention Center, New York, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati CRS, Cincinnati, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|St. Louis University VTEU-CAIMED-PHSU, Ponce, Puerto Rico",https://ClinicalTrials.gov/show/NCT04658121,Georgia,,3.0,2021,Tuesday
626,627,Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19,Recruiting,Device: Aerosol-reducing Mask|Device: Standard Mask,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 18, 2020",2020-12-01,"September 18, 2020","London Health Science Centre, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04344925,Canada,,12.0,2020,Tuesday
627,628,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Drug: BCG Vaccine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"March 25, 2020",2021-04-30,"August 19, 2020","Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04328441,Netherlands,BCG Vaccine|Placebo,4.0,2021,Friday
628,629,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,500.0,"April 14, 2020",2020-08-15,"July 27, 2020","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico",https://ClinicalTrials.gov/show/NCT04315896,Mexico,Hydroxychloroquine|Placebo oral tablet,8.0,2020,Saturday
629,630,Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19,Available,Drug: T89 capsule,All,"Child, Adult, Older Adult",,,,,"November 27, 2020","MultiCare Health System, Tacoma, Washington, United States",https://ClinicalTrials.gov/show/NCT04646031,United States,T89 capsule,,n,
630,631,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Active, not recruiting",Biological: Inactivated SARS-CoV-2 vaccine (Vero cell)|Biological: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,3000.0,"September 16, 2020",2021-12-01,"November 27, 2020","Fundación Huésped, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Vacunar Liniers, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Vacunar Cañitas, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Vacunar Coghlan, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04560881,Argentina,,12.0,2021,Wednesday
631,632,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,Recruiting,Biological: MVC-COV1901,All,20 Years to 50 Years   (Adult),Phase 1,45.0,"October 7, 2020",2021-06-30,"October 27, 2020","National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04487210,Undefined,,6.0,2021,Wednesday
632,633,Expressive Writing for COVID-19 Resilience for Parents,Completed,Behavioral: Expressive writing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11.0,"May 27, 2020",2020-08-02,"October 19, 2020","Duke Integrative Medicine, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04589117,United States,,8.0,2020,Sunday
633,634,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,Recruiting,Drug: Chloroquine Phosphate Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"March 10, 2020",2020-08-30,"June 16, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04428268,Mexico,Chloroquine Phosphate Tablets,8.0,2020,Sunday
634,635,"A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19",Not yet recruiting,Drug: Favipiravir|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,256.0,June 2020,2020-09-01,"June 11, 2020","The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Shangcheng District, China|Peking University First Hospital, Beijing, Xicheng District, China|Department of Internal Medicine Pneumology and infectious diseases Neukölln Clinic, Berlin, Germany|Medical clinic and polyclinic IV Hospital of the University of Munich, München, Germany|Infectious Diseases Hospital Cluj-Napoca, Cluj-Napoca, Cluj, Romania|National Institute of Infectious Diseases ""Prof.Dr.Matei Bals"", Bucharest, Ilfov, Romania|""Dr.Victor Babes"" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timisoara, Timis, Romania|""Dr.Victor Babes"" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania|Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania|Emergency County Hospital ""Pius Brinzeu""Timisoara, Timişoara, Timis, Romania",https://ClinicalTrials.gov/show/NCT04425460,China,Favipiravir,9.0,2020,Tuesday
635,636,Study of Sargramostim in Patients With COVID-19,Recruiting,Drug: Sargramostim|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"August 18, 2020",2021-03-01,"December 10, 2020","St. Jude Medical Center, Fullerton, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|TidalHealth Peninsula Regional, Inc, Salisbury, Maryland, United States|Great Plains Health, North Platte, Nebraska, United States|Richmond University Medical Center, Staten Island, New York, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04411680,United States,Sargramostim|Standard of care,3.0,2021,Monday
636,637,QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 17, 2020",2020-06-05,"June 9, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04371744,France,,6.0,2020,Friday
637,638,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Suspended,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,"April 3, 2020",2020-10-30,"September 2, 2020","ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain",https://ClinicalTrials.gov/show/NCT04325061,Spain,Dexamethasone,10.0,2020,Friday
638,639,Neonatal Complications of Coronavirus Disease (COVID-19),Recruiting,Other: No intervention - exposure is to COVID-19,All,up to 29 Days   (Child),,500.0,"April 1, 2020",2021-09-30,"May 13, 2020","Imperial College, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04386109,United Kingdom,,9.0,2021,Thursday
639,640,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,Behavioral: Intermittent prone positioning instructions|Behavioral: Usual care positioning with no instructions,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"April 29, 2020",2020-08-06,"December 3, 2020","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04368000,United States,,8.0,2020,Thursday
640,641,Hydroxychloroquine for COVID-19,Recruiting,Drug: Hydroxychloroquine Sulfate|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,220.0,"March 29, 2020",2022-02-01,"November 6, 2020","Zollernalb Klinikum Balingen, Balingen, Germany|Klinikum Darmstadt, Darmstadt, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum am Steinenberg, Reutlingen, Germany|RoMed Klinikum Rosenheim, Rosenheim, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Institute for Tropical Medicine, Tübingen, Germany",https://ClinicalTrials.gov/show/NCT04342221,Germany,Hydroxychloroquine Sulfate|Placebo,2.0,2022,Tuesday
641,642,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,Recruiting,Drug: Anti-SARS-CoV-2 convalescent plasma,All,"19 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,136.0,"September 21, 2020",2021-06-30,"September 29, 2020","UP Philippine General Hospital, Manila, Philippines",https://ClinicalTrials.gov/show/NCT04567173,Philippines,Anti-SARS-CoV-2 convalescent plasma,6.0,2021,Wednesday
642,643,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,Not yet recruiting,Drug: STI-5656|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,December 2020,2021-05-01,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04528667,Undefined,STI-5656|Placebo,5.0,2021,Saturday
643,644,Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients,Recruiting,Drug: Interferon-ß-1a|Combination Product: Standard of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"November 2, 2020",2021-06-01,"November 10, 2020","IRCCS Ospedale San Raffaele, Milano, Italy",https://ClinicalTrials.gov/show/NCT04449380,Italy,Interferon-ß-1a,6.0,2021,Tuesday
644,645,"Rapid, Onsite COVID-19 Detection",Enrolling by invitation,Device: Rapid Onsite COVID-19 Detection,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,10000.0,"July 13, 2020",2021-07-01,"September 28, 2020","University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04460690,United States,,7.0,2021,Thursday
645,646,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Recruiting,Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,90.0,"September 11, 2020",2022-10-30,"November 25, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04643691,France,Losartan 50 mg and Spironolactone 25 mg pillules oral use,10.0,2022,Sunday
646,647,COVID-19 PrEP HCW HCQ Study,Completed,Drug: Hydroxychloroquine (HCQ),All,"18 Years and older   (Adult, Older Adult)",Phase 2,130.0,"April 3, 2020",2020-10-01,"October 5, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04354870,United States,Hydroxychloroquine (HCQ),10.0,2020,Thursday
647,648,Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients,Recruiting,,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",,30.0,"June 12, 2020",2021-02-15,"July 23, 2020","Sohag University Hospital, Sohag, Egypt",https://ClinicalTrials.gov/show/NCT04483622,Egypt,,2.0,2021,Monday
648,649,COVID-19: Salvage TOcilizumab as a Rescue Measure,Recruiting,Drug: iv Tocillizumab (TCZ),All,"18 Years and older   (Adult, Older Adult)",Phase 3,90.0,"August 14, 2020",2021-12-31,"October 8, 2020","Turku University Hospital, Turku, Finland",https://ClinicalTrials.gov/show/NCT04577534,Finland,iv Tocillizumab (TCZ),12.0,2021,Friday
649,650,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Recruiting,Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample,All,up to 17 Years   (Child),Not Applicable,1920.0,"July 29, 2020",2022-12-01,"August 21, 2020","Hôpital necker Enfants-Malades, ¨Paris, France",https://ClinicalTrials.gov/show/NCT04355533,France,,12.0,2022,Thursday
650,651,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19",Not yet recruiting,Biological: COVI-AMG|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,December 2020,2021-04-01,"November 5, 2020",,https://ClinicalTrials.gov/show/NCT04584697,Undefined,Placebo,4.0,2021,Thursday
651,652,Convalescent Plasma Treatment in COVID-19,Recruiting,Biological: Convalescent Plasma (CP)|Other: Drugs and supportive care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"April 26, 2020",2020-09-01,"July 22, 2020","Aga Khan University Hospital, Karachi, Sind, Pakistan",https://ClinicalTrials.gov/show/NCT04476888,Pakistan,,9.0,2020,Tuesday
652,653,Slovenian National COVID-19 Prevalence Study,Recruiting,Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing,All,"Child, Adult, Older Adult",,3000.0,"April 20, 2020",2020-12-01,"May 7, 2020","University of Ljubljana, Ljubljana, Slovenia",https://ClinicalTrials.gov/show/NCT04376996,Slovenia,,12.0,2020,Tuesday
653,654,Expressive Writing for COVID-19 Resilience,Completed,Behavioral: Expressive writing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,63.0,"May 26, 2020",2020-08-17,"October 19, 2020","Duke Integrative Medicine, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04589104,United States,,8.0,2020,Monday
654,655,Ruxolitinib in the Treatment of Covid-19,Not yet recruiting,Drug: INC424 / Ruxolitinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 1, 2020",2020-09-15,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04414098,Undefined,INC424 / Ruxolitinib,9.0,2020,Tuesday
655,656,Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection,Recruiting,Other: biological sample,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"June 8, 2020",2020-12-01,"November 12, 2020","Hôpital Cochin, Paris, France|Hôpital Européen Georges Pompidou, Paris, France",https://ClinicalTrials.gov/show/NCT04624997,France,,12.0,2020,Tuesday
656,657,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Recruiting,Other: Neuromuscular Electrical Stimulation|Other: Physical Therapy Exercise,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"April 17, 2020",2020-07-01,"May 11, 2020","San Luigi Gonzaga Hospital, Orbassano, TO, Italy",https://ClinicalTrials.gov/show/NCT04382729,Italy,,7.0,2020,Wednesday
657,658,"Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)",Not yet recruiting,"Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody (ADA)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,"December 31, 2020",2021-09-30,"November 25, 2020","Saint Louis University Hospital, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04498325,United States,NT-I7|Placebo,9.0,2021,Thursday
658,659,Estrogen Therapy in Non-severe COVID-19 Patients,Not yet recruiting,Drug: Estrogen Therapy,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60.0,"October 1, 2020",2021-03-30,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04539626,Undefined,Estrogen Therapy,3.0,2021,Tuesday
659,660,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,"April 28, 2020",2021-02-28,"August 21, 2020","University of South Alabama, Mobile, Alabama, United States",https://ClinicalTrials.gov/show/NCT04445285,United States,Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|0.9%sodium chloride,2.0,2021,Sunday
660,661,Defibrotide in COVID-19 Pneumonia,Not yet recruiting,Drug: Defibrotide Injection,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"April 6, 2020",2020-12-31,"April 6, 2020",,https://ClinicalTrials.gov/show/NCT04335201,Undefined,Defibrotide Injection,12.0,2020,Thursday
661,662,WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5200.0,"June 11, 2020",2021-12-30,"September 7, 2020","Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Hospital de Clinicas of the University, Buenos Aires, Argentina|Sanatorio Güemes Hospital, Buenos Aires, Argentina|University Clinical Center Republic of Srpska, Srpska, Bosnia and Herzegovina|Komfo Anokye Teaching Hospital, Kumasi, Ghana|Kumasi South Regional Hospital, Kumasi, Ghana|Dayanand medical college hospital, Ludhiyana, Punjab, India|Amin Hospital, Isfahan, Iran, Islamic Republic of|Amin Hospital, Isfahan, Iran, Islamic Republic of|Khorshid Hospital, Isfahan, Iran, Islamic Republic of|Fedail Hospital, Khartoum, Sudan",https://ClinicalTrials.gov/show/NCT04475471,Argentina,,12.0,2021,Thursday
662,663,COVID-19 Remote Monitoring,Withdrawn,Diagnostic Test: VitalConnect Vital Sign Patch,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,"April 17, 2020",2020-05-01,"August 20, 2020",,https://ClinicalTrials.gov/show/NCT04350476,Undefined,,5.0,2020,Friday
663,664,Neuroradiolological Analysis of COVID-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 3, 2020",2021-04-01,"April 29, 2020","Service d'Imagerie 2 - Neuroradiologie, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04368390,France,,4.0,2021,Thursday
664,665,Selective Estrogen Modulation and Melatonin in Early COVID-19,Not yet recruiting,Drug: Toremifene|Drug: Melatonin|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,390.0,December 2020,2021-09-01,"October 29, 2020",,https://ClinicalTrials.gov/show/NCT04531748,Undefined,Toremifene|Melatonin,9.0,2021,Wednesday
665,666,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",Recruiting,Biological: BNT162b1|Biological: BNT162b2|Other: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,43998.0,"April 29, 2020",2023-01-29,"November 23, 2020","North Alabama Research Center, LLC, Athens, Alabama, United States|Birmingham Clinical Research Unit, Birmingham, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Optimal Research, LLC, Huntsville, Alabama, United States|Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States|Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States|Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States|The Pain Center of Arizona, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States|Whiteriver Indian Hospital, Whiteriver, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, United States|Long Beach Clinical Trials Services Inc., Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|Paradigm Clinical Research Center, Redding, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|Kaiser Permanente Santa Clara, Santa Clara, California, United States|Bayview Research Group, Valley Village, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Clinical Research Consulting, LLC, Milford, Connecticut, United States|Yale Center for Clinical Investigations (CSRU), New Haven, Connecticut, United States|Alliance for Multispecialty Research, LLC-Coral Gable, Coral Gables, Florida, United States|DeLand Clinical Research Unit, DeLand, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Acevedo Clinical Research Associates, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|IACT Health, Columbus, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Optimal Research, LLC, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Alliance for Multispecialty Research, LLC, Newton, Kansas, United States|Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|LSUHSC-Shreveport Clinical Trials Office, Shreveport, Louisiana, United States|LSUHSC-Shreveport, Shreveport, Louisiana, United States|Pharmaron CPC, Inc., Baltimore, Maryland, United States|University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Michigan Center for Medical Research, Farmington Hills, Michigan, United States|MedPharmics, LLC, Gulfport, Mississippi, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research, Bozeman, Montana, United States|Methodist Physicians Clinic / CCT Research, Fremont, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Wake Research-Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Amici Clinical Research, Raritan, New Jersey, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Johns Hopkins Center for American Indian Health, Gallup, New Mexico, United States|Johns Hopkins Center for American Indian Health, Shiprock, New Mexico, United States|Meridian Clinical Research, LLC, Binghamton, New York, United States|Meridian Clinical Research LLC, Endwell, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|PMG Research of Charlotte LLC, Charlotte, North Carolina, United States|Duke University Medicine Circle- Duke Early Phase Clinical Research Unit, Durham, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|M3 Wake Research, Inc., Raleigh, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|PriMED Clinical Research, Dayton, Ohio, United States|Senders Pediatrics, South Euclid, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Kaiser Permanente Northwest-Center for Health Research, Portland, Oregon, United States|Lehigh Valley Health Network/Network Office of Research and Innovation, Allentown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Main Street Physician's Care, Little River, South Carolina, United States|Main Street Physician's Care, Loris, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Trinity Clinical Research, Tullahoma, Tennessee, United States|Benchmark Research, Austin, Texas, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Ventavia Research Group, LLC, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Ventavia Research Group, LLC, Keller, Texas, United States|SMS Clinical Research, LLC, Mesquite, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|Benchmark Research., San Angelo, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States|Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia, United States|Virginia Research Center LLC, Midlothian, Virginia, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Wenatchee Valley Hospital, Wenatchee, Washington, United States|Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Caba, Argentina|Hospital Santo Antonio/ Associacao Obras Sociais Irma Dulce, Salvador, BA, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca), Sao Paulo, Brazil|CRS Clinical Research Services Berlin GmbH, Berlin, Germany|Medizentrum Essen Borbeck, Essen, Germany|IKF Pneumologie GmbH & Co KG, Frankfurt am Main, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany|Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Stuhr, Germany|Newtown Clinical Research Centre, Johannesburg, Gauteng, South Africa|Jongaie Research, Pretoria, Gauteng, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital, Cape Town, Western CAPE, South Africa|Ankara Universitesi Tip Fakultesi, Ibni Sina Hastanesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Medipol Mega Universite Hastanesi, Istanbul, Turkey|Acibadem Atakent Hastanesi, Istanbul, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi, Sakarya, Turkey",https://ClinicalTrials.gov/show/NCT04368728,Argentina,,1.0,2023,Sunday
666,667,How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department,Completed,,All,"18 Years and older   (Adult, Older Adult)",,257.0,"February 1, 2020",2020-05-15,"May 26, 2020","Centre Hospitalier Princesse Grace, Monaco, MON, Monaco",https://ClinicalTrials.gov/show/NCT04401241,Monaco,,5.0,2020,Friday
667,668,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19",Recruiting,Drug: Silmitasertib|Drug: SOC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"December 3, 2020",2021-02-11,"December 11, 2020","Center for Advanced Research and Education, Gainesville, Georgia, United States",https://ClinicalTrials.gov/show/NCT04663737,Georgia,Silmitasertib|SOC,2.0,2021,Thursday
668,669,Max COVID19- Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"April 2, 2020",2020-06-30,"April 9, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04339608,India,,6.0,2020,Tuesday
669,670,COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation,Enrolling by invitation,Drug: Placebo|Drug: Fisetin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,"August 3, 2020",2021-07-01,"August 13, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04476953,United States,Placebo|Fisetin,7.0,2021,Thursday
670,671,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Not yet recruiting,Biological: Convalescent Plasma Infusion,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30.0,"December 1, 2020",2021-12-01,"November 25, 2020","University of the West Indies, Kingston, Jamaica",https://ClinicalTrials.gov/show/NCT04644198,Jamaica,,12.0,2021,Wednesday
671,672,Colchicine in Moderate Symptomatic COVID-19 Patients,Recruiting,Drug: Colchicine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"July 14, 2020",2020-12-01,"August 28, 2020","Dhaka Medical College Hospital, Dhaka-1000, Bangladesh",https://ClinicalTrials.gov/show/NCT04527562,Bangladesh,Colchicine|Placebo,12.0,2020,Tuesday
672,673,Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection,Not yet recruiting,Drug: NIVOLUMAB|Other: Routine standard of care,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,120.0,"June 15, 2020",2021-09-15,"June 4, 2020","Hôpital Lyon Sud Service Endocrinologie, Diabète et Nutrition, Pierre-Bénite, France",https://ClinicalTrials.gov/show/NCT04413838,France,NIVOLUMAB,9.0,2021,Wednesday
673,674,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,Behavioral: Cognitive and behavioral intervention.|Behavioral: Problem-solving and relationship improvement intervention.,All,30 Years to 60 Years   (Adult),Not Applicable,300.0,"February 1, 2020",2022-01-31,"July 9, 2020","Beijing Normal University, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04463433,China,,1.0,2022,Monday
674,675,Antioxidant Therapy for COVID-19 Study,Not yet recruiting,Dietary Supplement: Antioxidation Therapy|Other: Standard of Care,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90.0,"November 1, 2020",2021-04-30,"September 2, 2020","Abia State Isolation Centre, Amachara, Umuahia, Abia State, Nigeria|Benue State University Teaching Hospital, Makurdi, Benue State, Nigeria|Brigadier Abba Kyari Memorial Hospital, Borno, Borno State, Nigeria|University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria|University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria|Federal Medical Centre Idi-Aba, Abeokuta, Ogun State, Nigeria|Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria|Infectious Disease Hospital, Amanawa, Sokoto State, Nigeria|Murtala Muhammad Speciaist Hospital, Sokoto, Sokoto State, Nigeria|Occupational Therapy Center, Sokoto, Sokoto State, Nigeria|Usmanu Danfodiyo University Teaching Hospital, Sokoto, Sokoto State, Nigeria",https://ClinicalTrials.gov/show/NCT04466657,Niger,,4.0,2021,Friday
675,676,COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,Enrolling by invitation,"Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2",All,"Child, Adult, Older Adult",,300.0,"March 23, 2020",2020-12-31,"April 24, 2020","Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04356560,Denmark,,12.0,2020,Thursday
676,677,COVID-19 Antibodies Among Healthcare Workers,Completed,"Diagnostic Test: COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)",All,"18 Years to 99 Years   (Adult, Older Adult)",,156.0,"May 5, 2020",2020-06-01,"June 12, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04425889,Mexico,,6.0,2020,Monday
677,678,Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19,Recruiting,,All,"1 Year to 80 Years   (Child, Adult, Older Adult)",,500.0,"April 14, 2020",2020-12-01,"April 20, 2020","Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04346056,Egypt,,12.0,2020,Tuesday
678,679,Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,42.0,"July 1, 2020",2022-12-01,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04422626,Undefined,,12.0,2022,Thursday
679,680,Host Response Mediators in Coronavirus (COVID-19) Infection,Recruiting,Other: ARBs and/or ACE inhibitors|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 17, 2020",2022-06-30,"August 12, 2020","University of Calgary - Foothills, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Pauls Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|William Osler Health System, Brampton, Ontario, Canada|Queens University, Kingston, Ontario, Canada|Humber River Hospital, North York, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Center, Montréal, Quebec, Canada|Université de Sherbrooke, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04510623,Canada,,6.0,2022,Thursday
680,681,Efficacy and Safety of Sirolimus in COVID-19 Infection,Recruiting,Drug: Sirolimus,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"August 15, 2020",2020-11-30,"September 9, 2020","Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT04461340,Egypt,Sirolimus,11.0,2020,Monday
681,682,Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"July 1, 2020",2021-06-30,"December 1, 2020","Neurorehabilitation Clinic, University Hospital Ospedali Riuniti di Ancona, Ancona, Italy",https://ClinicalTrials.gov/show/NCT04456036,Italy,,6.0,2021,Wednesday
682,683,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2712.0,"May 14, 2020",2020-11-01,"May 15, 2020","Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy",https://ClinicalTrials.gov/show/NCT04366960,Italy,Enoxaparin,11.0,2020,Sunday
683,684,Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg),Recruiting,Other: No intervention - quality of life measure,All,"18 Years and older   (Adult, Older Adult)",,100.0,"October 7, 2020",2025-10-01,"November 19, 2020","Medialis, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04586413,United Kingdom,,10.0,2025,Wednesday
684,685,Impact of Adipose Tissue in COVID-19,Not yet recruiting,Other: Adipose tissue,All,"18 Years and older   (Adult, Older Adult)",,60.0,"November 23, 2020",2021-11-23,"November 20, 2020","Hôpital de la Pitié Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04639440,France,,11.0,2021,Tuesday
685,686,NO-mediated Vascular Function in Covid-19 Patient,Recruiting,Diagnostic Test: Single passive leg movement,All,"30 Years to 80 Years   (Adult, Older Adult)",,30.0,"May 30, 2020",2020-12-01,"November 12, 2020","ICS Maugeri IRCCS, U.O. Emergenza Coronavirus di Lumezzane, Lumezzane, Brescia, Italy",https://ClinicalTrials.gov/show/NCT04625036,Italy,,12.0,2020,Tuesday
686,687,Direct and Indirect Impact of COVID-19 In Older Populations,Recruiting,,All,70 Years and older   (Older Adult),,1000.0,"April 9, 2020",2021-10-09,"May 8, 2020","Chu Grenoble Alpes, Grenoble Cedex 9, Grenoble, France",https://ClinicalTrials.gov/show/NCT04381312,France,,10.0,2021,Saturday
687,688,Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial,Not yet recruiting,Biological: SARS-CoV-2 convalescent plasma|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,920.0,"December 3, 2020",2022-02-01,"December 2, 2020","Department of Infectious Disease, Falu Hospital, Falun, Dalarn, Sweden|Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden|Danderyd Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04649879,Sweden,,2.0,2022,Tuesday
688,689,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,Recruiting,Device: ADAM Sensor,All,"18 Years to 95 Years   (Adult, Older Adult)",,100.0,"April 20, 2020",2022-12-31,"May 21, 2020","Shirley Ryan AbilityLab, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04393558,United States,,12.0,2022,Saturday
689,690,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),Recruiting,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,All,"55 Years to 120 Years   (Adult, Older Adult)",Phase 3,800.0,"May 12, 2020",2020-12-31,"September 18, 2020","The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04343248,Georgia,Nitazoxanide|Placebo,12.0,2020,Thursday
690,691,Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations,Enrolling by invitation,Diagnostic Test: Pilot a rapid SARS-CoV-2 testing strategy|Other: Community-driven messages to promote COVID-19 testing,All,"Child, Adult, Older Adult",,1000.0,"June 3, 2020",2021-12-01,"September 22, 2020","Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04558307,United States,,12.0,2021,Wednesday
691,692,D-dimer Levels in Pregnant With COVID-19,Completed,Other: Blood D-dimer assay,Female,18 Years to 45 Years   (Adult),,300.0,"May 14, 2020",2020-05-29,"June 1, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkey",https://ClinicalTrials.gov/show/NCT04389554,Turkey,,5.0,2020,Friday
692,693,The Protective Potential of Exercise Training on the Cardiopulmonary Morbidity After COVID-19,Not yet recruiting,Behavioral: High intensity interval training|Behavioral: Standard care,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"January 1, 2021",2021-12-31,"December 1, 2020","Rigshospitalet, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04647734,Denmark,,12.0,2021,Friday
693,694,Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked,Recruiting,,All,"up to 20 Years   (Child, Adult)",,80.0,"June 15, 2020",2022-06-01,"July 2, 2020","Hôpital Necker, Paris, France",https://ClinicalTrials.gov/show/NCT04455347,France,,6.0,2022,Wednesday
694,695,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Not yet recruiting,Drug: Angiotensin 1-7,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,November 2020,2024-04-01,"November 5, 2020","Rambam Medical Center, Haifa, Israel",https://ClinicalTrials.gov/show/NCT04605887,Israel,Angiotensin 1-7,4.0,2024,Monday
695,696,Role of Inflammasomes in COVID-19 Disease,Recruiting,Other: COVID-19 patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 11, 2020",2021-06-12,"May 12, 2020","Ch Cannes, Réanimation, Cannes, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France",https://ClinicalTrials.gov/show/NCT04385017,France,,6.0,2021,Saturday
696,697,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Not yet recruiting,Radiation: Low dose Radiotherapy,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,13.0,October 2020,2021-04-01,"October 30, 2020","Lancashire Teaching Hospitals NHS, Preston, United Kingdom",https://ClinicalTrials.gov/show/NCT04572412,United Kingdom,,4.0,2021,Thursday
697,698,Catalysing the Containment of COVID-19,Recruiting,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2|Phase 3,960.0,"August 27, 2020",2021-08-01,"September 1, 2020","University of Cape Town, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04523090,South Africa,Nitazoxanide|Placebo,8.0,2021,Sunday
698,699,COVID-19 Infection in Patients With Hepatocellular Carcinoma,Recruiting,Diagnostic Test: nasopharyngeal Covid 19 RT-PCR,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 27, 2020",2020-10-01,"April 29, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04367805,France,,10.0,2020,Thursday
699,700,NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes,Not yet recruiting,Drug: NBT-NM108|Other: Usual Care Only,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,100.0,"October 1, 2020",2021-03-01,"September 16, 2020","University of South Florida Morsani College of Medicine, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT04540406,United States,NBT-NM108,3.0,2021,Monday
700,701,Fingolimod in COVID-19,Withdrawn,Drug: Fingolimod 0.5 mg,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,0.0,"February 22, 2020",2020-07-01,"November 13, 2020","Wan-Jin Chen, Fuzhou, China",https://ClinicalTrials.gov/show/NCT04280588,China,Fingolimod 0.5 mg,7.0,2020,Wednesday
701,702,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,Recruiting,Drug: MAS825|Drug: Matching placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 7, 2020",2021-04-09,"December 7, 2020","Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Bend, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States",https://ClinicalTrials.gov/show/NCT04382651,United States,MAS825|Matching placebo,4.0,2021,Friday
702,703,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,Device: Continuous vital sign monitoring - Isansys Patient Status Engine|Other: Machine Learning/AI Algorithm,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,60.0,"July 11, 2020",2021-02-01,"October 9, 2020","The Christie NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04581031,United Kingdom,,2.0,2021,Monday
703,704,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,Recruiting,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,4000.0,"May 13, 2020",2021-04-30,"October 29, 2020","HealthStar Research LLC, Hot Springs, Arkansas, United States|So Cal Clinical Research, Huntington Beach, California, United States|Long Beach Clinical Trials, LLC, Long Beach, California, United States|Meris Clinical Research, Brandon, Florida, United States|Invesclinica US LLC, Fort Lauderdale, Florida, United States|The Chappel Group Research, Kissimmee, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|DMI Research, Pinellas Park, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States|Chicago Medical Research Institute, Inc., Chicago, Illinois, United States|Quad Clinical Research, Chicago, Illinois, United States|Chicago Medical Research, LLC, Hazel Crest, Illinois, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Beacom Family Health Connection, Fremont, Nebraska, United States|North Jersey Community Research Initiative, Newark, New Jersey, United States|RH Medical Urgent Care Professional PLLC, Bronx, New York, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|The New York Center for Travel and Tropical Medicine, New York, New York, United States|Centex Studies, Inc., Houston, Texas, United States|SMS Clinical Research LLC, Mesquite, Texas, United States|LinQ Research LLC, Pearland, Texas, United States|Rio Grande Valley Clinical Research Institute, Pharr, Texas, United States|BFHC Research, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04359680,Jersey,Nitazoxanide|Placebo,4.0,2021,Friday
704,705,Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children,Recruiting,Other: no intervention. observational cohort study,All,"up to 18 Years   (Child, Adult)",,800.0,"April 9, 2020",2021-12-31,"July 29, 2020","Necker Hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04490811,France,,12.0,2021,Friday
705,706,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,Not yet recruiting,Biological: Low Dose of KBP-COVID-19|Biological: High Dose of KBP-COVID-19|Biological: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,180.0,"December 28, 2020",2022-03-23,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04473690,Undefined,,3.0,2022,Wednesday
706,707,MAVIPAN: My Life and the COVID-19 Pandemic,Recruiting,"Other: No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..",All,"14 Years and older   (Child, Adult, Older Adult)",,5000.0,"April 29, 2020",2025-04-29,"October 5, 2020","VITAM-Research Center in Sustainable Health, Québec, Canada",https://ClinicalTrials.gov/show/NCT04575571,Canada,,4.0,2025,Tuesday
707,708,COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 30, 2020",2021-06-29,"April 1, 2020","Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China",https://ClinicalTrials.gov/show/NCT04329559,China,,6.0,2021,Tuesday
708,709,Outpatient Use of Ivermectin in COVID-19,Not yet recruiting,Drug: Ivermectin Pill|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"October 1, 2020",2021-12-31,"August 28, 2020","Temple University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04530474,United States,Ivermectin Pill|Placebo,12.0,2021,Friday
709,710,Hypertension in Patients Hospitalized With COVID-19,Completed,,All,"18 Years to 100 Years   (Adult, Older Adult)",,275.0,"March 21, 2020",2020-03-30,"April 29, 2020","Hankou Hospital, Hankou, Hubei, China",https://ClinicalTrials.gov/show/NCT04318301,China,,3.0,2020,Monday
710,711,Role of Microparticles in Covid-19 Infection,Not yet recruiting,Other: Blood sample,All,"18 Years and older   (Adult, Older Adult)",,175.0,June 2020,2021-11-01,"June 26, 2020",,https://ClinicalTrials.gov/show/NCT04448743,Undefined,,11.0,2021,Monday
711,712,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,Recruiting,Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,July 2020,2021-03-01,"July 24, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04486482,United States,,3.0,2021,Monday
712,713,Health Professional Exposure Assessment to Covid-19,Recruiting,Diagnostic Test: Diagnostic test Covid-19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6000.0,"July 6, 2020",2020-12-01,"July 20, 2020","CH Roubaix, Roubaix, France|CH Tourcoing, Tourcoing, France|CH Wasquehal, Wasquehal, France|CH Wattrelos, Wattrelos, France",https://ClinicalTrials.gov/show/NCT04429724,France,,12.0,2020,Tuesday
713,714,Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,June 2020,2022-06-01,"April 27, 2020",,https://ClinicalTrials.gov/show/NCT04359459,Undefined,,6.0,2022,Wednesday
714,715,Implications of Covid-19 on the Lifestyle Changes,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1826.0,"May 4, 2020",2020-06-15,"July 20, 2020","Elisa Mazzini, Reggio Emilia, Italy",https://ClinicalTrials.gov/show/NCT04423978,Italy,,6.0,2020,Monday
715,716,SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem,Not yet recruiting,Diagnostic Test: Breath sample,All,"7 Years and older   (Child, Adult, Older Adult)",,1000.0,"August 4, 2020",2020-08-15,"August 4, 2020","Instituto Costarricense de Investigaciones Clínicas, San José, Costa Rica",https://ClinicalTrials.gov/show/NCT04497610,Costa Rica,,8.0,2020,Saturday
716,717,COVID-19: Human Epidemiology and Response to SARS-CoV-2,"Active, not recruiting",Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys,All,"Child, Adult, Older Adult",,5605.0,"May 1, 2020",2020-12-01,"August 7, 2020","Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD) and Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC) Site, Chicago, Illinois, United States|Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium (ICAC) Site, Boston, Massachusetts, United States|Henry Ford Health System: Childhood Allergy Study (CAS) Site, Detroit, Michigan, United States|Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04375761,United States,,12.0,2020,Tuesday
717,718,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Biological: Gam-COVID-Vac,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,38.0,"June 17, 2020",2020-08-10,"August 12, 2020","Main military clinical hospital named after academician N. N. Burdenko, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04436471,Russian Federation,,8.0,2020,Monday
718,719,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,Recruiting,Other: General Public cohort,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 23, 2020",2020-12-23,"May 6, 2020","University College London Hospital, London, United Kingdom|GP Practices, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04377815,United Kingdom,,12.0,2020,Wednesday
719,720,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Recruiting,Other: Moxibustion plus Cupping,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60.0,"May 10, 2020",2021-12-01,"June 5, 2020","Hubei Province Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04374084,China,,12.0,2021,Wednesday
720,721,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Drug: ABBV-47D11|Drug: Placebo for ABBV-47D11,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,"November 27, 2020",2021-05-01,"November 25, 2020","Glendale Adventist Medical Center /ID# 225188, Glendale, California, United States|University of Miami /ID# 225038, Miami, Florida, United States|University of Illinois Hospital and Health Sciences System /ID# 224323, Chicago, Illinois, United States|Loyola University Medical Ctr /ID# 224881, Maywood, Illinois, United States|Pikeville Medical Center /ID# 224539, Pikeville, Kentucky, United States|Henry Ford Health System /ID# 224320, Detroit, Michigan, United States|Michigan State University /ID# 224907, East Lansing, Michigan, United States|CHI Nebraska d/b/a CHI Health /ID# 224822, Omaha, Nebraska, United States|The Christ Hospital /ID# 224541, Cincinnati, Ohio, United States|Prisma Health Upstate /ID# 224556, Greenville, South Carolina, United States|EvergreenHealth /ID# 225169, Kirkland, Washington, United States",https://ClinicalTrials.gov/show/NCT04644120,United States,ABBV-47D11|Placebo for ABBV-47D11,5.0,2021,Saturday
721,722,Core Warming of COVID-19 Patients,Withdrawn,Device: ensoETM device,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,October 2020,2020-12-01,"October 19, 2020","Barnes-Jewish Hospital, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04426344,United States,,12.0,2020,Tuesday
722,723,COVID-19 Virtual Care at Home,Recruiting,Other: Virtual Care at Home,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"August 17, 2020",2021-12-31,"December 8, 2020","St. Mary's General Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Heart Research Institute, Ottawa, Ontario, Canada|Niagara Health, St. Catharines, Ontario, Canada|St. Joseph's Health Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04420182,Canada,,12.0,2021,Friday
723,724,Enzalutamide Treatment in COVID-19,Recruiting,Drug: Enzalutamide Pill,All,"50 Years and older   (Adult, Older Adult)",Phase 2,500.0,"July 15, 2020",2022-05-08,"July 17, 2020","Anders Bjartell, Malmö, Skåne, Sweden|Ryhovs Hospital, Jönköping, Småland, Sweden",https://ClinicalTrials.gov/show/NCT04475601,Sweden,Enzalutamide Pill,5.0,2022,Sunday
724,725,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",Recruiting,Drug: Placebo Administration|Biological: Vaccine Therapy,All,18 Years to 55 Years   (Adult),Phase 1,129.0,"December 23, 2020",2022-11-10,"December 11, 2020","City of Hope Medical Center, Duarte, California, United States",https://ClinicalTrials.gov/show/NCT04639466,United States,Placebo Administration,11.0,2022,Thursday
725,726,"Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19",Recruiting,"Diagnostic Test: Lung Function tests|Diagnostic Test: Exercise capacity|Diagnostic Test: Exercise physiology|Diagnostic Test: Health-related quality of life|Diagnostic Test: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening",All,"Child, Adult, Older Adult",,134.0,"May 15, 2020",2022-08-02,"June 1, 2020","Universidade de Passo Fundo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Univesidade de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04410107,Brazil,,8.0,2022,Tuesday
726,727,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,Not yet recruiting,Biological: UC-MSCs|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,48.0,"April 20, 2020",2022-02-15,"April 14, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04273646,China,Placebo,2.0,2022,Tuesday
727,728,Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,Not yet recruiting,Dietary Supplement: Rhea Health Tone®,All,18 Years to 50 Years   (Adult),Phase 2,69.0,"December 1, 2020",2021-02-15,"November 24, 2020",,https://ClinicalTrials.gov/show/NCT04627519,Undefined,,2.0,2021,Monday
728,729,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Drug: Nitazoxanide and atazanavir/ritonavir|Other: Standard of Care,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,98.0,"October 9, 2020",2021-03-21,"October 14, 2020","Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria|Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria|State Specialist Hospital Asubiaro, Osogbo, Osun State, Nigeria|Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria",https://ClinicalTrials.gov/show/NCT04459286,Niger,Nitazoxanide and atazanavir/ritonavir,3.0,2021,Sunday
729,730,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Completed,Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB),All,"18 Years and older   (Adult, Older Adult)",,314.0,"May 10, 2020",2020-08-01,"August 4, 2020","King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04357535,Saudi Arabia,Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB),8.0,2020,Saturday
730,731,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,Completed,Drug: Clarithromycin 500mg|Drug: Azithromycin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"April 1, 2020",2020-07-30,"November 10, 2020","south-Vally University faculty of medicine, Qena, Egypt",https://ClinicalTrials.gov/show/NCT04622891,Egypt,Clarithromycin 500mg|Azithromycin|Placebo,7.0,2020,Thursday
731,732,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,Recruiting,Biological: AdimrSC-2f,All,20 Years to 60 Years   (Adult),Phase 1,70.0,"August 24, 2020",2021-03-20,"September 24, 2020","National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04522089,Undefined,,3.0,2021,Saturday
732,733,"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,20000.0,"May 9, 2020",2040-04-27,"September 28, 2020","Villanova University, Villanova, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04370821,United States,,4.0,2040,Friday
733,734,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,Recruiting,"Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28",All,3 Years to 17 Years   (Child),Phase 1|Phase 2,552.0,"October 31, 2020",2021-09-01,"November 9, 2020","Zanhuang county Center for Disease Control and Prevention, Shijiazhuang, Hebei, China",https://ClinicalTrials.gov/show/NCT04551547,China,,9.0,2021,Wednesday
734,735,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Biological: Convalescent Plasma,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,100.0,"August 14, 2020",2021-12-31,"October 19, 2020","Norton Hospital, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audubon Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04513158,United States,,12.0,2021,Friday
735,736,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",Not yet recruiting,Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,34020.0,December 2020,2022-03-01,"December 9, 2020","CEMEC Pesquisa Clinica, São Bernardo do Campo, São Paulo, Brazil|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia",https://ClinicalTrials.gov/show/NCT04659239,Brazil,,3.0,2022,Tuesday
736,737,Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain,Completed,,All,"Child, Adult, Older Adult",,4035.0,"March 18, 2020",2020-04-17,"May 11, 2020","Comp. Hosp. Univ. A Coruña, A Coruña, Spain|H. Quiron A Coruña, A Coruña, Spain|H. de Alcaniz, Alcañiz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral (CAIDM), Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, Breña Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de Dénia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan Ramón Jiménez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de Jaén, Jaén, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, Leganés, Spain|H. San Pedro, Logroño, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion Jiménez Díaz, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de Alcorcón, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de Móstoles, Madrid, Spain|H. Univ. Gregorio Marañon, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. Ramón y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, Mataró, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, Mondragón, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, Málaga, Spain|H. Virgen de la Victoria, Málaga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, Palamós, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San Sebastián De Los Reyes, Spain|H. de Donostia, San Sebastián, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, Ávila, Spain",https://ClinicalTrials.gov/show/NCT04355871,China,,4.0,2020,Friday
737,738,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,Recruiting,Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"July 2, 2020",2020-12-01,"August 14, 2020","Healthstar Research, Hot Springs, Arkansas, United States|Axon Clinical Research, Riverside, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Vista Health Research, Miami, Florida, United States|Bio-Medical Research, Miami, Florida, United States|Mount Vernon Clinical Research, Atlanta, Georgia, United States|Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Carolina Institute For Clinical Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|TruCare Internal Medicine and Infectious Diseases, DuBois, Pennsylvania, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Global Medical Research, DeSoto, Texas, United States|Centex Studies, Houston, Texas, United States|Infectious Diseases Associates of Central Virginia, Lynchburg, Virginia, United States",https://ClinicalTrials.gov/show/NCT04414124,Georgia,,12.0,2020,Tuesday
738,739,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Recruiting,Drug: Azithromycin|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2271.0,"May 22, 2020",2021-12-30,"December 8, 2020","University of California San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04332107,United States,Azithromycin|Placebos,12.0,2021,Thursday
739,740,Convalescent Plasma Trial in COVID -19 Patients,Completed,Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"April 19, 2020",2020-07-09,"July 28, 2020","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",https://ClinicalTrials.gov/show/NCT04356534,Bahrain,,7.0,2020,Thursday
740,741,Hyperimmune Plasma for Patients With COVID-19,Recruiting,Other: treated with hyperimmune plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"July 2, 2020",2022-07-02,"November 3, 2020","Anna Falanga, Bergamo, Italy",https://ClinicalTrials.gov/show/NCT04614012,Italy,,7.0,2022,Saturday
741,742,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Placebo on a 0- and 28-day schedule|Biological: Placebo on a 0- and 14-day schedule,All,18 Years to 59 Years   (Adult),Phase 1|Phase 2,942.0,"May 15, 2020",2021-09-01,"June 4, 2020","West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China",https://ClinicalTrials.gov/show/NCT04412538,China,,9.0,2021,Wednesday
742,743,Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness,Available,Drug: Ruxolitinib,All,"6 Years to 90 Years   (Child, Adult, Older Adult)",,,,,"July 9, 2020","Novartis Investigative Site, Curug, Indonesia|Novartis Investigative Site, Caserta, CE, Italy|Novartis Investigative Site, La Spezia, SP, Italy|Novartis Investigative Site, Cirie, Torino, Italy|Novartis Investigative Site, Torino, Italy",https://ClinicalTrials.gov/show/NCT04337359,Indonesia,Ruxolitinib,,n,
743,744,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection: a Randomized Clinical Trial,Not yet recruiting,Drug: Tocilizumab|Drug: Heparin - Therapeutic dosage|Drug: Heparin - Prophylactic dosage,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308.0,"October 20, 2020",2021-12-31,"October 23, 2020",,https://ClinicalTrials.gov/show/NCT04600141,Undefined,Tocilizumab|Heparin - Therapeutic dosage|Heparin - Prophylactic dosage,12.0,2021,Friday
744,745,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,Recruiting,Drug: Chloroquine phosphate|Other: Telemedicine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"April 16, 2020",2020-12-31,"May 22, 2020","Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland",https://ClinicalTrials.gov/show/NCT04331600,Poland,Chloroquine phosphate,12.0,2020,Thursday
745,746,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,Other: Best Practice|Biological: Mesenchymal Stem Cell,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,"July 29, 2020",2021-04-30,"October 23, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04565665,United States,,4.0,2021,Friday
746,747,Intravenous Infusion of CAP-1002 in Patients With COVID-19,Recruiting,Biological: CAP-1002|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"November 15, 2020",2021-06-30,"November 24, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|PharmaTex Research, LLC, Amarillo, Texas, United States",https://ClinicalTrials.gov/show/NCT04623671,United States,,6.0,2021,Wednesday
747,748,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Recruiting,Drug: Transfusion of COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"April 15, 2020",2020-06-01,"May 20, 2020","SMIT, Saint Antoine hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04345991,France,Transfusion of COVID-19 convalescent plasma,6.0,2020,Monday
748,749,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Terminated,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1.0,"April 14, 2020",2020-07-15,"November 16, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT04435808,Mexico,Hydroxychloroquine,7.0,2020,Wednesday
749,750,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,Diagnostic Test: Conjunctival swab and nasopharyngeal swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 17, 2020",2021-03-31,"June 23, 2020","Medical University Innsbruck, Innsbruck, Tirol, Austria",https://ClinicalTrials.gov/show/NCT04444596,Austria,,3.0,2021,Wednesday
750,751,Rehabilitation Needs After COVID-19 Hospital Treatment,Recruiting,"Other: none, this study is observational",All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 30, 2020",2020-12-31,"July 13, 2020","Azienda USL-IRCCS S.Maria Nuova Hospital, Reggio Emilia, Italy",https://ClinicalTrials.gov/show/NCT04438239,Italy,,12.0,2020,Thursday
751,752,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years,Enrolling by invitation,Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Placebo on a 0- and 28-day schedule,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,471.0,"July 10, 2020",2021-11-01,"July 14, 2020","West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China",https://ClinicalTrials.gov/show/NCT04470609,China,,11.0,2021,Monday
752,753,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28",All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,422.0,"May 22, 2020",2021-05-30,"September 10, 2020","Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China",https://ClinicalTrials.gov/show/NCT04383574,China,,5.0,2021,Sunday
753,754,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule,All,18 Years to 59 Years   (Adult),Phase 1|Phase 2,744.0,"April 16, 2020",2020-12-13,"August 4, 2020","Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04352608,China,,12.0,2020,Sunday
754,755,TXA and Corona Virus 2019 (COVID19) in Outpatients,Recruiting,Drug: Tranexamic acid tablets|Drug: Placebo oral tablet,All,"19 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 1, 2020",2020-12-31,"June 12, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04338074,United States,Tranexamic acid tablets|Placebo oral tablet,12.0,2020,Thursday
755,756,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans",Not yet recruiting,Biological: TY027|Other: 0.9% saline,All,"21 Years to 100 Years   (Adult, Older Adult)",Phase 3,1305.0,"December 4, 2020",2021-12-30,"December 2, 2020","Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04649515,Singapore,,12.0,2021,Thursday
756,757,Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,Drug: Cenicriviroc (CVC)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,183.0,"August 25, 2020",2021-09-30,"August 26, 2020","Medical Department of Hepatology and Gastroenterology, Charité University Medicine, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany",https://ClinicalTrials.gov/show/NCT04500418,Germany,Cenicriviroc (CVC)|Placebo,9.0,2021,Thursday
757,758,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Recruiting,Device: Volatile Organic Compounds analysis,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 14, 2020",2020-11-16,"July 14, 2020","Hôpital Foch, Suresnes, France",https://ClinicalTrials.gov/show/NCT04379154,France,,11.0,2020,Monday
758,759,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: Razuprotafib Subcutaneous Solution|Drug: Placebo Subcutaneous Solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,180.0,"October 21, 2020",2021-02-01,"November 17, 2020","University of Southern California, Los Angeles, California, United States|University of California- Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Snake River Research, Idaho Falls, Idaho, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04511650,United States,Razuprotafib Subcutaneous Solution|Placebo Subcutaneous Solution,2.0,2021,Monday
759,760,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Recruiting,Other: Probiorinse|Other: Saline solution,All,18 Years to 59 Years   (Adult),Not Applicable,40.0,"July 16, 2020",2020-12-31,"October 8, 2020","Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04458519,Canada,,12.0,2020,Thursday
760,761,The VOICE-COVID-19,Recruiting,Device: Alexa Amazon,All,"18 Years and older   (Adult, Older Adult)",,200.0,"July 1, 2020",2020-11-01,"September 28, 2020","Muhc-Rimuhc, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04508972,Canada,,11.0,2020,Sunday
761,762,Hematology and Clinical Picture in Pediatric COVID-19 Infection,Completed,,All,"up to 18 Years   (Child, Adult)",,29.0,"August 12, 2020",2020-08-23,"September 9, 2020","Benha Faculty of Medicine, Banhā, Qalubia, Egypt",https://ClinicalTrials.gov/show/NCT04487119,Egypt,,8.0,2020,Sunday
762,763,The Heart Hive COVID-19 Study,Recruiting,Other: COVID-19 experience surveys,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"July 26, 2020",2022-07-01,"September 2, 2020","Imperial College London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04468256,United Kingdom,,7.0,2022,Friday
763,764,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Recruiting,Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80.0,"April 16, 2020",2020-09-30,"July 1, 2020","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04344457,United States,Hydroxychloroquine|Indomethacin|Zithromax Oral Product,9.0,2020,Wednesday
764,765,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Recruiting,Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage,All,"Child, Adult, Older Adult",Not Applicable,200.0,"March 20, 2020",2020-12-01,"April 15, 2020","CHU Brugmann, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04346017,Belgium,,12.0,2020,Tuesday
765,766,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Recruiting,Drug: Iloprost|Drug: Isotonic saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"June 15, 2020",2021-05-31,"July 13, 2020","Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark|Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre, Denmark",https://ClinicalTrials.gov/show/NCT04420741,Denmark,Iloprost|Isotonic saline,5.0,2021,Monday
766,767,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients,Completed,Drug: Retrospective case-control analysis,All,"18 Years and older   (Adult, Older Adult)",,338.0,"May 14, 2020",2020-06-15,"July 9, 2020","ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|Ospedale dell'Angelo, Venezia-Mestre, Mestre, Italy|Humanitas Hospital, Milan, Italy|University of Pavia, Pavia, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy",https://ClinicalTrials.gov/show/NCT04382794,Italy,Retrospective case-control analysis,6.0,2020,Monday
767,768,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,Completed,Diagnostic Test: PET-CT of 18F-FDG,All,"18 Years and older   (Adult, Older Adult)",,22.0,"March 15, 2020",2020-07-30,"August 13, 2020","CHRU of Nancy, Vandœuvre-lès-Nancy, Grand Est, France",https://ClinicalTrials.gov/show/NCT04512118,France,,7.0,2020,Thursday
768,769,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Recruiting,Drug: Ruxolitinib Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"April 15, 2020",2020-06-01,"April 17, 2020","Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico",https://ClinicalTrials.gov/show/NCT04334044,Mali,Ruxolitinib Oral Tablet,6.0,2020,Monday
769,770,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,Recruiting,Drug: chlorine dioxide 3000 ppm,All,"Child, Adult, Older Adult",,20.0,"April 1, 2020",2020-06-01,"May 27, 2020","Hospital Fhsj, Bogota, Cundinamarca, Colombia|San Carlos Hospital, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04343742,Colombia,chlorine dioxide 3000 ppm,6.0,2020,Monday
770,771,Predictive Factors COVID-19 Patients,Recruiting,Other: Predictive factors for clinical response in patients with COVID-19.,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 30, 2020",2021-04-30,"November 9, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",https://ClinicalTrials.gov/show/NCT04427345,Italy,,4.0,2021,Friday
771,772,Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"December 15, 2020",2021-06-30,"November 16, 2020","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04437706,United States,,6.0,2021,Wednesday
772,773,Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Recruiting,,All,"Child, Adult, Older Adult",,400.0,"March 15, 2020",2021-05-01,"April 14, 2020","Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04345536,Norway,,5.0,2021,Saturday
773,774,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,426.0,"April 8, 2020",2021-07-31,"November 16, 2020","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands",https://ClinicalTrials.gov/show/NCT04342182,Netherlands,,7.0,2021,Saturday
774,775,Impact of COVID-19 on Personal Protection Among Dentist in Egypt,Completed,Other: Survey,All,"18 Years to 75 Years   (Adult, Older Adult)",,323.0,"May 20, 2020",2020-07-15,"July 22, 2020","Faculty of Dentistry, Fayoum, Egypt",https://ClinicalTrials.gov/show/NCT04403828,Egypt,,7.0,2020,Wednesday
775,776,COVID - AirPollution,Recruiting,,All,"50 Years and older   (Adult, Older Adult)",,250.0,"June 4, 2020",2020-09-04,"July 22, 2020","Unité de neurologie-gériatrie, Hôpital Erasme, Cliniques Universitaires de Bruxelles, Bruxelles, Belgium|Service de Gériatrie, Hôpital Larrey, Hôpitaux Universitaires d'Angers, Angers, France|Unité de soins palliatifs gériatriques, Centre Hospitalier Départemental de Bischwiller, Bischwiller, France|Unité post urgence gériatriques, Hôpital Pellegrin, Hôpitaux Universitaires de Bordeaux, Bordeaux, France|Service de Gériatrie, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France|Service de gériatrie-gérontologie, Hôpitaux Universitaires de Lille, Lille, France|Service de médecine aigüe gériatrique, Hôpital Nord Laennec, Hôpitaux Universitaires de Nantes, Nantes, France|Service de Gériatrie, Hôpitaux Bichat et Bretonnaux, Assistance Publique des Hôpitaux de Paris, Paris, France|Service de Médecine Interne et Gériatrie, Hôpitaux Universitaires de Reims, Reims, France|Service de Gériatrie, Hôpital de la Robertsau, Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Service de médecine gériatrique, Hôpitaux Universitaires de Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04463862,Belgium,,9.0,2020,Friday
776,777,Corticosteroids in Severe COVID-19(ASAP-C Study),Not yet recruiting,Other: questionnaire,All,"up to 100 Years   (Child, Adult, Older Adult)",,2000.0,"January 1, 2021",2021-04-01,"December 1, 2020","University Hospital Brno, Brno, Czechia",https://ClinicalTrials.gov/show/NCT04648410,Undefined,,4.0,2021,Thursday
777,778,Ivermectin Nasal Spray for COVID19 Patients,Not yet recruiting,Drug: Ivermectin nasal|Drug: Ivermectin oral|Other: standard care,All,18 Years to 60 Years   (Adult),Phase 2,60.0,September 2020,2020-12-01,"August 12, 2020",,https://ClinicalTrials.gov/show/NCT04510233,Undefined,Ivermectin nasal|Ivermectin oral,12.0,2020,Tuesday
778,779,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Recruiting,Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"April 30, 2020",2021-07-30,"December 3, 2020","All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India|All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India|Sir Sundar Lal Hospital Institute of Medical Sciences Banaras Hindu University, Varanasi, Uttar Pradesh, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All lndia Institute of Medical Science, Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04347174,India,Suspension of heat killed (autoclaved) Mycobacterium w|Standard therapy of COVID-19,7.0,2021,Friday
779,780,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Drug: Chloroquine phosphate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,250.0,"April 7, 2020",2022-04-01,"May 29, 2020","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",https://ClinicalTrials.gov/show/NCT04328493,Undefined,Chloroquine phosphate,4.0,2022,Friday
780,781,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra],All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,300.0,"April 16, 2020",2021-01-01,"November 12, 2020","Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04354428,United States,Ascorbic Acid|Hydroxychloroquine Sulfate|Azithromycin|Folic Acid|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra],1.0,2021,Friday
781,782,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,Drug: Melatonin|Drug: The usual treatment,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,55.0,"May 12, 2020",2020-09-25,"June 1, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04409522,"Iran, Islamic Republic of",Melatonin|The usual treatment,9.0,2020,Friday
782,783,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Drug: Colchicine Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"March 20, 2020",2020-09-30,"July 28, 2020","SBMU, Tehran, Iran, Islamic Republic of|Nooshin Dalili, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04360980,"Iran, Islamic Republic of",Colchicine Tablets,9.0,2020,Wednesday
783,784,Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness,Not yet recruiting,Biological: COVID-19 convalescent plasma treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"December 1, 2020",2022-05-01,"November 24, 2020","Wroclaw Medical University, Wroclaw, Dolnośląskie, Poland",https://ClinicalTrials.gov/show/NCT04642014,Poland,,5.0,2022,Sunday
784,785,Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,"Active, not recruiting",Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"August 7, 2020",2022-06-30,"September 10, 2020","VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04545047,Jamaica,,6.0,2022,Thursday
785,786,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,Biological: BCG vaccine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1000.0,"October 1, 2020",2022-10-01,"December 9, 2020","Universidade Federal do Rio de Janeiro, Rio De Janeiro, RJ, Brazil",https://ClinicalTrials.gov/show/NCT04659941,Brazil,,10.0,2022,Saturday
786,787,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"Active, not recruiting",Drug: Progesterone 100 MG,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"April 27, 2020",2021-04-17,"September 16, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04365127,United States,Progesterone 100 MG,4.0,2021,Saturday
787,788,CAPTION AI to Minimize Risk of COVID Exposure,Withdrawn,Device: Caption AI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,July 2020,2020-11-09,"August 10, 2020","Duke Health, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04336774,United States,,11.0,2020,Monday
788,789,Fase I Clinical Trial on NK Cells for COVID-19,Not yet recruiting,Biological: Natural Killer Cells infusion,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,"January 2, 2021",2021-03-30,"November 18, 2020","Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil",https://ClinicalTrials.gov/show/NCT04634370,Brazil,,3.0,2021,Tuesday
789,790,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Drug: EDP1815|Drug: Dapagliflozin|Drug: Ambrisentan|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1407.0,"July 3, 2020",2021-06-15,"July 8, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04393246,United Kingdom,EDP1815|Dapagliflozin|Ambrisentan,6.0,2021,Tuesday
790,791,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),Recruiting,Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret],All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,180.0,"May 8, 2020",2021-03-01,"June 23, 2020","Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Cataluña, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT04443881,Spain,Anakinra 149 MG/ML Prefilled Syringe [Kineret],3.0,2021,Monday
791,792,Effect of COVID-19 on Platelet Aggregation,Recruiting,Other: venipuncture in peripheral vein,All,"18 Years and older   (Adult, Older Adult)",,200.0,"April 29, 2020",2021-07-30,"November 5, 2020","Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04447131,Brazil,,7.0,2021,Friday
792,793,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Not yet recruiting,Drug: bamlanivimab,All,65 Years and older   (Older Adult),Phase 4,7500.0,December 2020,2021-05-01,"December 7, 2020",,https://ClinicalTrials.gov/show/NCT04656691,Undefined,bamlanivimab,5.0,2021,Saturday
793,794,Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants,Not yet recruiting,Drug: CNM-ZnAg|Drug: Placebo,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 2,238.0,December 2020,2021-08-01,"November 2, 2020",,https://ClinicalTrials.gov/show/NCT04610138,Undefined,CNM-ZnAg|Placebo,8.0,2021,Sunday
794,795,Genetics of COVID-19 Susceptibility and Manifestations,Recruiting,,All,"3 Years and older   (Child, Adult, Older Adult)",,2500.0,"December 16, 2020",2025-06-01,"December 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04371432,United States,,6.0,2025,Sunday
795,796,NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30,Completed,Other: Interview,All,"18 Years and older   (Adult, Older Adult)",,403.0,"April 30, 2020",2020-07-10,"July 28, 2020","Marie-France VAILLANT, Grenoble, France",https://ClinicalTrials.gov/show/NCT04365816,France,,7.0,2020,Friday
796,797,Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,Not yet recruiting,Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,104.0,"April 30, 2020",2020-07-30,"April 29, 2020","Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04363060,France,amoxicillin/clavulanate,7.0,2020,Thursday
797,798,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,Recruiting,Drug: Hydroxychloroquine + Metabolic cofactor supplementation|Drug: Hydroxychloroquine + Sorbitol,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400.0,"September 21, 2020",2021-03-31,"October 6, 2020","University of Health Sciences Istanbul Ümraniye Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04573153,Turkey,Hydroxychloroquine + Metabolic cofactor supplementation|Hydroxychloroquine + Sorbitol,3.0,2021,Wednesday
798,799,Povidone-Iodine Rinses in the Management of COVID-19,Not yet recruiting,Drug: Povidone-iodine|Drug: Placebo,All,"19 Years and older   (Adult, Older Adult)",Early Phase 1,81.0,"July 1, 2020",2020-12-01,"June 29, 2020",,https://ClinicalTrials.gov/show/NCT04449965,Undefined,Povidone-iodine|Placebo,12.0,2020,Tuesday
799,800,Iota-carrageenan Nasal Spray COVID-19 Prophylaxis for Healthcare Professionals,Not yet recruiting,Device: Carrageenan nasal and throat spray|Device: Saline nasal and throat spray,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,480.0,"December 20, 2020",2021-12-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04590365,Undefined,,12.0,2021,Wednesday
800,801,Proctologic Practice and Covid-19,Completed,,All,"Child, Adult, Older Adult",,1050.0,"April 15, 2020",2020-04-26,"May 18, 2020","Gallo Gallo, Catanzaro, Italy",https://ClinicalTrials.gov/show/NCT04392245,Italy,,4.0,2020,Sunday
801,802,Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients,Recruiting,Drug: Famotidine 20 MG,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Phase 3,200.0,"August 1, 2020",2020-10-30,"August 11, 2020","Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinājpur, Bangladesh",https://ClinicalTrials.gov/show/NCT04504240,Bangladesh,Famotidine 20 MG,10.0,2020,Friday
802,803,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Active, not recruiting",Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1.0,"May 14, 2020",2021-06-04,"June 9, 2020","Sanford Health, Sioux Falls, South Dakota, United States",https://ClinicalTrials.gov/show/NCT04372017,United States,Hydroxychloroquine,6.0,2021,Friday
803,804,Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA,Recruiting,Device: Seraph®-100 Microbind® Affinity Blood Filter,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 1, 2020",2021-12-31,"September 1, 2020","AdventHealth Orlando, Orlando, Florida, United States",https://ClinicalTrials.gov/show/NCT04413955,United States,,12.0,2021,Friday
804,805,Assessment of SARS-CoV-2 Seroprevalence in Detention,Not yet recruiting,Biological: Blood draw,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,2500.0,"September 1, 2020",2021-01-01,"August 18, 2020",,https://ClinicalTrials.gov/show/NCT04516512,Undefined,,1.0,2021,Friday
805,806,Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,1000.0,"April 22, 2020",2021-07-30,"July 22, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04368884,India,,7.0,2021,Friday
806,807,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",Recruiting,Biological: SAB-185|Other: Normal Saline,All,18 Years to 60 Years   (Adult),Phase 1,21.0,"August 20, 2020",2020-12-01,"September 9, 2020","Quantum Clinical Trials, Miami Beach, Florida, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Sanford Health, Sioux Falls, South Dakota, United States",https://ClinicalTrials.gov/show/NCT04469179,United States,,12.0,2020,Tuesday
807,808,CSL324 in COVID-19,Withdrawn,Biological: CSL324|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,September 2020,2021-05-01,"October 14, 2020",,https://ClinicalTrials.gov/show/NCT04519424,Undefined,Placebo,5.0,2021,Saturday
808,809,VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),Suspended,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet,All,"216 Months and older   (Adult, Older Adult)",Phase 3,300.0,"April 30, 2020",2021-08-01,"June 22, 2020","San Francisco VA, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04363203,United States,Hydroxychloroquine|Azithromycin|Placebo oral tablet,8.0,2021,Sunday
809,810,Immunophenotyping Assessment in a COVID-19 Cohort,Enrolling by invitation,Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care Assessments,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"May 1, 2020",2021-12-01,"October 19, 2020","University of Arizona (UA) College of Medicine - Tucson: UA Health Sciences Asthma and Airway Disease Research Center, Tucson, Arizona, United States|University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|University of South Florida Health Tampa, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Oklahoma ,Oklahoma Health Sciences Center: Pulmonary/Critical Care, Department of Medicine, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Texas at Austin: UT Health Austin, Austin, Texas, United States|Baylor College of Medicine: Department of Medicine, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04378777,Georgia,,12.0,2021,Wednesday
810,811,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,Completed,Other: observation,All,70 Years and older   (Older Adult),,353.0,"March 22, 2020",2020-04-05,"June 16, 2020","Angers University Hospital, Angers, France",https://ClinicalTrials.gov/show/NCT04343781,France,,4.0,2020,Sunday
811,812,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)",Recruiting,Dietary Supplement: Investigational Product - ViraCide|Other: Placebo - Starch Powder Soft gels,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,124.0,"September 16, 2020",2021-01-30,"October 29, 2020","Department of General medicine/ clinical research. Government medical college and Government general hospital, Srikakulam, Andhra Pradesh, India|Gunjkar Multispeciality Hospital, Pune, Maharashtra, India",https://ClinicalTrials.gov/show/NCT04596085,India,,1.0,2021,Saturday
812,813,Survey of the Anxiety Associated With the COVID-19 Pandemic,Recruiting,Diagnostic Test: Online Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,7500.0,"March 27, 2020",2021-04-01,"July 13, 2020","Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04331106,Germany,,4.0,2021,Thursday
813,814,A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,Suspended,Drug: Remdesivir|Drug: Remdesivir placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308.0,"February 12, 2020",2020-04-27,"April 15, 2020","Jin Yin-tan hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04252664,China,Remdesivir|Remdesivir placebo,4.0,2020,Monday
814,815,The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers),Not yet recruiting,Device: Wearable Medical Device (Empatica E4)|Diagnostic Test: COVID-19 PCR Swab|Diagnostic Test: Pulse Oximeter,All,"18 Years and older   (Adult, Older Adult)",,60.0,"August 1, 2020",2020-09-30,"August 4, 2020",,https://ClinicalTrials.gov/show/NCT04363489,Undefined,,9.0,2020,Wednesday
815,816,"Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19",Not yet recruiting,"Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|Device: Capillary and salivary sampling",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1210.0,"May 25, 2020",2021-03-25,"May 28, 2020",,https://ClinicalTrials.gov/show/NCT04405492,Undefined,,3.0,2021,Thursday
816,817,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Recruiting,Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,94.0,"July 7, 2020",2021-04-30,"July 20, 2020","University of Wisconsin-Madison, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04478019,United States,10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse,4.0,2021,Friday
817,818,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Recruiting,Biological: MSC|Drug: Control,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20.0,"August 1, 2020",2020-12-30,"November 12, 2020","Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico",https://ClinicalTrials.gov/show/NCT04611256,Mexico,Control,12.0,2020,Wednesday
818,819,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,Recruiting,Biological: VIR-7831|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1360.0,"August 27, 2020",2021-07-01,"December 10, 2020","Investigative Site, Anniston, Alabama, United States|Investigative Site, Cullman, Alabama, United States|Investigative Site, Mesa, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Northridge, California, United States|Investigative Site, Oxnard, California, United States|Investigative Site, Sacramento, California, United States|Investigative Site, Doral, Florida, United States|Investigative Site, Gainesville, Florida, United States|Investigative Site, Hialeah, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miramar, Florida, United States|Investigative Site, North Miami, Florida, United States|Investigative Site, Palmetto Bay, Florida, United States|Investigative Site, Pembroke Pines, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Decatur, Georgia, United States|Investigative Site, Idaho Falls, Idaho, United States|Investigative Site, Lake Charles, Louisiana, United States|Investigative Site, Marrero, Louisiana, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Caro, Michigan, United States|Investigative Site, Hazelwood, Missouri, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Santa Fe, New Mexico, United States|Investigative Site, Bronx, New York, United States|Investigative Site, Asheboro, North Carolina, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Smithfield, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Austin, Texas, United States|Investigative Site, Baytown, Texas, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, Forney, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Humble, Texas, United States|Investigative Site, Laredo, Texas, United States|Investigative Site, McAllen, Texas, United States|Investigative Site, Mesquite, Texas, United States|Investigative Site, Sugar Land, Texas, United States|Investigative Site, Kirkland, Washington, United States|Investigative Site, Seattle, Washington, United States|Investigative Site, Vienna, Austria|Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Investigative Site, Maringá, Parana, Brazil|Investigative Site, Natal, Rio Grande Do Norte, Brazil|Investigative Site, Passo Fundo, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Chapecó, Santa Catarina, Brazil|Investigative Site, Santo André, Sao Paulo, Brazil|Investigative Site, Vila Assuncao, Sao Paulo, Brazil|Investigative Site, Campinas, São Paulo, Brazil|Investigative Site, Sarnia, Ontario, Canada|Investigative Site, Toronto, Ontario, Canada|Investigative Site, Santiago, Region Metropolitana, Chile|Investigative Site, Argenteuil, France|Investigative Site, Limoges, France|Investigative Site, Melun, France|Investigative Site, Valenciennes, France|Investigative Site, Bellavista, Callao, Peru|Investigative Site, El Agustino, Lima, Peru|Investigative Site, Huaral, Lima, Peru|Investigative Site, San Isidro, Lima, Peru|Investigative Site, Bella Vista, Peru|Investigative Site, Lima, Peru|Investigative Site, Terrassa, Barcelona, Spain|Investigative Site, Albacete, Spain|Investigative Site, Centelles, Spain|Investigative Site, Girona, Spain|Investigative Site, Granada, Spain|Investigative Site, Vigo, Spain|Investigative Site, Belfast, United Kingdom",https://ClinicalTrials.gov/show/NCT04545060,Austria,Placebo,7.0,2021,Thursday
819,820,Asunercept in Patients With Severe COVID-19,Recruiting,Biological: Asunercept,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"October 9, 2020",2021-05-01,"November 18, 2020","Federal State Budgetary Educational Institution of Higher Education ""Kuban State Medical University"" of the Ministry of Health of the Russian Federation, Krasnodar, Russian Federation|State Budgetary Healthcare Institution ""Scientific Research Institute - Regional clinical hospital No. 1 n.a. professor S.V. Ochapovsky"" of the Ministry of Healthcare of Krasnodar Krai, Krasnodar, Russian Federation|State Budgetary Institution of Health of the Nizhny Novgorod Region ""Infectious Clinical Hospital No. 2 of Nizhny Novgorod"", Nizhny Novgorod, Russian Federation|Saint Petersburg state budgetary healthcare institution ""Botkin clinical infectious diseases hospital"", Saint Petersburg, Russian Federation|Saint Petersburg state budgetary healthcare institution ""City hospital of Saint George the great Martyr"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Healthcare Institution ""Mariinskaya City hospital"", Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Bashkir State Medical University"" of the Ministry of Health of the Russian Federation, Ufa, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Bashkir State Medical University"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital Universitario Infanta Sofia, San Sebastián De Los Reyes, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT04535674,Russian Federation,,5.0,2021,Saturday
820,821,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Recruiting,Other: Home-use Test and Follow-up Questionnaire,All,"21 Years to 70 Years   (Adult, Older Adult)",,5000.0,"July 23, 2020",2021-03-31,"July 30, 2020","Clinical Nutrition Research Centre, Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04492904,Singapore,,3.0,2021,Wednesday
821,822,Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo,Not yet recruiting,Drug: DWJ1248|Drug: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,90.0,August 2020,2020-12-01,"August 20, 2020",,https://ClinicalTrials.gov/show/NCT04521296,Undefined,DWJ1248|Placebo,12.0,2020,Tuesday
822,823,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,Drug: favipiravir|Drug: Standard of care therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,100.0,"April 18, 2020",2020-06-20,"June 25, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04349241,Egypt,favipiravir|Standard of care therapy,6.0,2020,Saturday
823,824,Evaluating Clinical Parameters of COVID-19 in Pregnancy,Recruiting,,All,18 Years to 60 Years   (Adult),,116.0,"October 9, 2020",2021-12-02,"October 12, 2020","Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04470583,United Kingdom,,12.0,2021,Thursday
824,825,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,Other: blood sample,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,115.0,"April 22, 2020",2021-02-22,"May 1, 2020","CHU de nice, Nice, Alpes-Maritimes, France",https://ClinicalTrials.gov/show/NCT04371510,France,,2.0,2021,Monday
825,826,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Drug: GC4419|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"September 9, 2020",2021-12-01,"December 10, 2020","University of Iowa, Iowa City, Iowa, United States|Mercy Research, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04555096,United States,GC4419|Placebo,12.0,2021,Wednesday
826,827,"A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",Recruiting,Drug: Galidesivir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,132.0,"April 9, 2020",2021-05-31,"July 23, 2020","Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil|Hospital Sao Vicente de Paulo-PPDS, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Foundation Regional Faculty of Medicine of São José do Rio Preto, São José Do Rio Preto, SP, Brazil|Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT03891420,Brazil,Galidesivir|Placebo,5.0,2021,Monday
827,828,Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support,Completed,Behavioral: Prone position,All,"18 Years to 80 Years   (Adult, Older Adult)",,93.0,"March 1, 2020",2020-11-30,"December 2, 2020","Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy",https://ClinicalTrials.gov/show/NCT04649658,Italy,,11.0,2020,Monday
828,829,"Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"June 5, 2020",2021-07-31,"June 11, 2020","University of Pécs 1st Department of Internal Medicine Intensive Care Unit, Pécs, Hungary|University of Pécs First Department of Internal Medicine, Pécs, Hungary|University of Pécs Infection Department of the Coronavirus Center, Pécs, Hungary|University of Pécs Institute of Laboratory Medicine, Pécs, Hungary|University of Pécs Szentágotahi Research Centre, Pécs, Hungary|University of Pécs Szentágothai Research Centre Genomics and Bioinformatics Core Facility, Pécs, Hungary|University of Szeged Szentágothai Research Centre Virology Research Group, Pécs, Hungary|University of Szeged Department of Anaesthesiology And Inthensive Therapy, Szeged, Hungary|University of Szeged Department of Dermatology and Allergology, Szeged, Hungary|University of Szeged Department of Medical Biology, Szeged, Hungary|University of Szeged Department of Paediatrics, Szeged, Hungary|University of Szeged First Department of Medicine, Szeged, Hungary|University of Szeged Institute of Clinical Microbiology, Szeged, Hungary|University of Szeged Institute of Medical Microbiology and Immunobiology, Szeged, Hungary",https://ClinicalTrials.gov/show/NCT04426253,Hungary,,7.0,2021,Saturday
829,830,"Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic",Not yet recruiting,Other: Questionnaire,All,23 Years to 55 Years   (Adult),,384.0,May 2020,2020-06-01,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04403581,Undefined,,6.0,2020,Monday
830,831,Tableted COVID-19 Therapeutic Vaccine,"Active, not recruiting",Biological: V-SARS,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"May 15, 2020",2021-06-15,"May 27, 2020","Immunitor Inc, Vancouver, BC - British Columbia, Canada|Aldar Bourinbayar, Ulaanbaatar, BZD, 3-khoroo, Mongolia",https://ClinicalTrials.gov/show/NCT04380532,Canada,,6.0,2021,Tuesday
831,832,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,Recruiting,Biological: BNT162b3,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,120.0,"September 9, 2020",2021-12-01,"September 16, 2020","Contract Research Organization, Berlin, Germany|Contract Research Organization, Mannheim, Germany",https://ClinicalTrials.gov/show/NCT04537949,Germany,,12.0,2021,Wednesday
832,833,Endoscopic Interventions in Patients With COVID-19,Completed,Procedure: Endoscopic intervention,All,"Child, Adult, Older Adult",,10.0,"March 1, 2020",2020-05-15,"June 9, 2020","University Hospital of Tuebingen, Tuebingen, Germany",https://ClinicalTrials.gov/show/NCT04423003,Germany,,5.0,2020,Friday
833,834,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Not yet recruiting,Biological: PSC-04,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,20.0,"December 15, 2020",2021-01-15,"November 6, 2020","Fresno Community Hospital, Fresno, California, United States",https://ClinicalTrials.gov/show/NCT04486001,United States,,1.0,2021,Friday
834,835,COVID-19 Follow up Intensive Care Studies,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"July 1, 2020",2022-02-01,"July 28, 2020","University Medical Center Groningen, Groningen, Netherlands",https://ClinicalTrials.gov/show/NCT04460170,Netherlands,,2.0,2022,Tuesday
835,836,Saliva as Source of Detection for SARS-CoV-2,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"July 13, 2020",2021-06-01,"September 17, 2020","Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04424446,United States,,6.0,2021,Tuesday
836,837,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,Recruiting,Drug: Low Molecular Weight Heparin,All,"18 Years and older   (Adult, Older Adult)",,877.0,"June 1, 2020",2020-12-01,"September 17, 2020","Giuseppe Camporese, Padova, Italy",https://ClinicalTrials.gov/show/NCT04393805,Italy,Low Molecular Weight Heparin,12.0,2020,Tuesday
837,838,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,Drug: oral co-trimoxazole,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,94.0,"July 12, 2020",2021-01-30,"July 16, 2020","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04470531,Bangladesh,oral co-trimoxazole,1.0,2021,Saturday
838,839,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Active, not recruiting",Biological: Administration of Equine immunoglobulin anti SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",Phase 2,26.0,"September 6, 2020",2020-12-06,"November 16, 2020","Centro Especializado de Atención COVID19 (CEACO), San José, Costa Rica|Hospital Dr. Rafael Ángel Calderón Guardia, San José, Costa Rica|Hospital México, San José, Costa Rica|Hospital San Juan de Dios, San José, Costa Rica",https://ClinicalTrials.gov/show/NCT04610502,Costa Rica,,12.0,2020,Sunday
839,840,"COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)",Recruiting,Other: BioMedomics COVID-19 IgM-IgG Rapid Test,All,"18 Years and older   (Adult, Older Adult)",,600.0,"March 30, 2020",2020-09-01,"April 30, 2020","AO San Paolo, Milan, IT, Italy",https://ClinicalTrials.gov/show/NCT04367402,Italy,,9.0,2020,Tuesday
840,841,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Enrolling by invitation,Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"July 12, 2020",2021-07-01,"October 5, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04346628,United States,Favipiravir|Placebo,7.0,2021,Thursday
841,842,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,508.0,"April 12, 2020",2021-01-31,"May 18, 2020","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04341389,China,,1.0,2021,Sunday
842,843,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,"Active, not recruiting",Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30.0,"June 12, 2020",2020-12-21,"November 19, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|aTyr Investigative Site, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|aTyr Investigative Site, Vineland, New Jersey, United States|aTyr Investigative Site, Toledo, Ohio, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Alliance Medical Service, Cardio Pulmonary Research, Guaynabo, Puerto Rico|Manati Medical Center, Manatí, Puerto Rico",https://ClinicalTrials.gov/show/NCT04412668,Jersey,ATYR1923 1 mg/kg|ATYR1923 3 mg/kg|Placebo,12.0,2020,Monday
843,844,A Survey Study to Assess the Impact of the COVID-19 Pandemic on Participants With Pre-Existing Mental Health Diagnosis,Not yet recruiting,Other: survey,All,"18 Years to 80 Years   (Adult, Older Adult)",,1000.0,"October 31, 2020",2021-12-31,"October 14, 2020",,https://ClinicalTrials.gov/show/NCT04568135,Undefined,,12.0,2021,Friday
844,845,Community Pharmacists Behaviour During Covid-19,Recruiting,,All,"Child, Adult, Older Adult",,50.0,"May 2, 2020",2021-04-01,"May 19, 2020","Damanhour university, Beheira, Damanhour, Egypt|Damanhour universty, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT04374513,Egypt,,4.0,2021,Thursday
845,846,Silymarin in COVID-19 Pneumonia,Recruiting,Drug: Silymarin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,"August 16, 2020",2021-02-28,"August 18, 2020","Cairo University, Giza, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04394208,Egypt,Silymarin|Placebo,2.0,2021,Sunday
846,847,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution",Not yet recruiting,"Procedure: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection",All,"18 Years and older   (Adult, Older Adult)",,120.0,"December 7, 2020",2022-07-30,"December 11, 2020","C.H.U.de Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04664023,France,,7.0,2022,Saturday
847,848,Piclidenoson for Treatment of COVID-19,Not yet recruiting,Drug: Piclidenoson|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"January 6, 2021",2021-07-06,"December 3, 2020","Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah tikva, Israel",https://ClinicalTrials.gov/show/NCT04333472,Israel,Piclidenoson|Placebo,7.0,2021,Tuesday
848,849,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Completed,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"May 1, 2020",2020-07-07,"August 3, 2020","Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04358068,United States,Hydroxychloroquine (HCQ)|Azithromycin (Azithro)|Placebo for Hydroxychloroquine|Placebo for Azithromycin,7.0,2020,Tuesday
849,850,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,Recruiting,Device: Electric pad for human external pain therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,274.0,"August 27, 2020",2022-06-01,"November 5, 2020","Hospital Dr. Ángel Leaño, Guadalajara, Jalisco, Mexico|Hospital Regional de Alta Especialidad ""Dr. Juan Graham Casasus"", Villahermosa, Tabasco, Mexico|Unidad Temporal Movil COVID-19 Autódromo Hermanos Rodríguez IMSS, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04363541,Mexico,,6.0,2022,Wednesday
850,851,Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers,Not yet recruiting,Drug: Previfenon®|Drug: Placebo,All,"25 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,524.0,"September 30, 2020",2021-10-30,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04446065,Undefined,Previfenon®|Placebo,10.0,2021,Saturday
851,852,Surveillance of Individuals Following SARS-CoV-2 Exposure,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1050.0,"July 7, 2020",2023-08-01,"August 4, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04383444,United States,,8.0,2023,Tuesday
852,853,Genetic Basis of COVID-19 Infection,Recruiting,Diagnostic Test: Whole Exome Sequencing,All,"up to 50 Years   (Child, Adult)",,50.0,"May 10, 2020",2021-05-01,"May 12, 2020","Mansoura University, Mansoura, Dakahlyia, Egypt",https://ClinicalTrials.gov/show/NCT04384250,Egypt,,5.0,2021,Saturday
853,854,COVID-19 And Geko Evaluation: The CAGE Study,Not yet recruiting,Device: geko T3,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,December 2020,2021-04-01,"December 3, 2020","London Health Sciences Centre, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04651374,Canada,,4.0,2021,Thursday
854,855,Long-term Characterization of Patients With Severe/Critical Infection by COVID-19 Virus,Not yet recruiting,Radiation: chest radiography|Radiation: thoracic computed tomography scan|Diagnostic Test: spirometry|Diagnostic Test: Diffusing capacity of carbon monoxide|Diagnostic Test: 6 minute walk test|Diagnostic Test: saint george respiratory questionnaire,All,"18 Years to 100 Years   (Adult, Older Adult)",,112.0,"November 21, 2020",2021-10-01,"November 19, 2020",,https://ClinicalTrials.gov/show/NCT04559100,Undefined,,10.0,2021,Friday
855,856,Canakinumab MAP in COVID-19 Pneumonia With CRS,Available,Drug: canakinumab,All,"18 Years to 100 Years   (Adult, Older Adult)",,,,,"July 20, 2020",,https://ClinicalTrials.gov/show/NCT04476706,Undefined,canakinumab,,n,
856,857,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,"April 30, 2020",2021-04-01,"July 14, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States",https://ClinicalTrials.gov/show/NCT04471051,United States,,4.0,2021,Thursday
857,858,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Recruiting,Procedure: Awake prone positioning|Procedure: Standard oxygen therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 3, 2020",2020-12-30,"August 4, 2020","Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital General de Occidente, Guadalajara, Jalisco, Mexico",https://ClinicalTrials.gov/show/NCT04477655,Mexico,,12.0,2020,Wednesday
858,859,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Drug: Povidone-Iodine Nasal Spray and Gargle,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,300.0,"April 29, 2020",2021-05-01,"November 24, 2020","University of Kentucky, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04364802,United States,Povidone-Iodine Nasal Spray and Gargle,5.0,2021,Saturday
859,860,Prevalence Of COVID-19 Among Health-workers in a French General Hospital,Recruiting,"Diagnostic Test: Serelogy testing, RT PCR",All,"18 Years and older   (Adult, Older Adult)",,1300.0,"August 3, 2020",2021-06-30,"September 16, 2020","Centre Hospitalier Sud Essonne, Etampes, France",https://ClinicalTrials.gov/show/NCT04548908,France,,6.0,2021,Wednesday
860,861,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,Recruiting,Biological: Lenzilumab|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,"April 30, 2020",2020-09-01,"August 5, 2020","Mayo Clinic, Phoenix, Arizona, United States|University of Southern California (USC) Medical Center, Los Angeles, California, United States|USC - Los Angeles County Medical Center, Los Angeles, California, United States|Baptist Medical Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Atrium Health, Charlotte, North Carolina, United States|St. David's Healthcare, Austin, Texas, United States|St. David's North Austin Medical Center, Austin, Texas, United States|Texas Health, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04351152,Georgia,Standard of Care,9.0,2020,Tuesday
861,862,A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,Recruiting,Drug: LY3819253|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2400.0,"August 2, 2020",2021-06-29,"November 10, 2020","Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States|Care Access Research, Phoenix, Arizona, United States|Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States|Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Belmont Village Lincoln Park, Lincoln Park, Illinois, United States|Family Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Care Access Rch Lake Charles, Lake Charles, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States|Care Access, Boston, Massachusetts, United States|St. Paul IDA-CARe, Saint Paul, Minnesota, United States|Care Access, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Hospital & Medical Center, Omaha, Nebraska, United States|Care Access Research - Bronx, Bronx, New York, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Donahoe Manor, Bedford, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04497987,Georgia,LY3819253|Placebo,6.0,2021,Tuesday
862,863,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Biological: Gam-COVID-Vac Lyo,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,38.0,"June 17, 2020",2020-08-10,"August 12, 2020","Sechenov First Moscow State Medical University, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04437875,Russian Federation,,8.0,2020,Monday
863,864,Preventing COVID-19 in Healthcare Workers With HCQ: A RCT,Withdrawn,Drug: Hydroxychloroquine|Other: Vitamin C,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"April 20, 2020",2020-12-30,"November 2, 2020",,https://ClinicalTrials.gov/show/NCT04347889,Undefined,Hydroxychloroquine,12.0,2020,Wednesday
864,865,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,50.0,"April 8, 2020",2022-05-01,"August 24, 2020","Stanford University School of Medicine, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04330521,United States,,5.0,2022,Sunday
865,866,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Biological: mRNA-1273,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,120.0,"March 16, 2020",2021-11-22,"December 4, 2020","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04283461,Georgia,,11.0,2021,Monday
866,867,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Recruiting,Dietary Supplement: Probiotic|Dietary Supplement: Control,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,314.0,"April 24, 2020",2020-10-01,"April 30, 2020","Raquel Rodriguez Blanque, Granada, Spain",https://ClinicalTrials.gov/show/NCT04366180,Spain,,10.0,2020,Thursday
867,868,"COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)",Recruiting,Other: Saliva based assay: crude RNA extraction|Other: Validation of the NGS method|Other: Validation of the LAMP assays|Other: Validation of the POCT Antigen tests,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"October 24, 2020",2021-03-01,"November 13, 2020","Cantonal Office of Public Health, Economics and Health Directorate, Canton Basel-Landschaft, Liestal, Switzerland",https://ClinicalTrials.gov/show/NCT04625257,Switzerland,,3.0,2021,Monday
868,869,Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 (COVID-19) Epidemic,Recruiting,Behavioral: Semi-directive interview|Behavioral: Questionnaire : Preparedness for Caregiving Scale,All,"18 Years and older   (Adult, Older Adult)",,75.0,"September 17, 2020",2021-01-01,"November 12, 2020","URC/CIC Paris Centre, Paris, France",https://ClinicalTrials.gov/show/NCT04625296,France,,1.0,2021,Friday
869,870,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Completed,Other: convalescent plasma application to SARS-CoV-2 infected patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15.0,"March 31, 2020",2020-06-30,"August 4, 2020","Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT04389944,Switzerland,,6.0,2020,Tuesday
870,871,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,Drug: Sofosbuvir plus Ledipasvir,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,250.0,"April 15, 2020",2020-07-23,"August 28, 2020","Almaza Military Fever Hospital, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04530422,Egypt,Sofosbuvir plus Ledipasvir,7.0,2020,Thursday
871,872,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,Enrolling by invitation,Other: Certified cloth face mask plus preventive information|Behavioral: Preventive information,All,"10 Years and older   (Child, Adult, Older Adult)",Not Applicable,66000.0,"July 20, 2020",2021-08-01,"November 24, 2020","Bandim Health Project, Bissau, Bissau Codex, Guinea-Bissau",https://ClinicalTrials.gov/show/NCT04471766,Guinea,,8.0,2021,Sunday
872,873,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,Recruiting,Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1000.0,"May 8, 2020",2020-07-30,"June 2, 2020","Hacettepe University, School of Medicine, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04411433,Turkey,Favipiravir (3200 mg + 1200 mg)|Favipiravir (3600 mg + 1600 mg)|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Hydroxychloroquine|Hydroxychloroquine combined with Azithromycin,7.0,2020,Thursday
873,874,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,Recruiting,Drug: Bemiparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 4, 2020",2021-03-31,"June 11, 2020","Hospital Universitario HM Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04420299,Spain,Bemiparin,3.0,2021,Wednesday
874,875,Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19,Not yet recruiting,Drug: Metformin|Drug: Naltrexone,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,80.0,November 2020,2021-05-01,"October 28, 2020","AgelessRx, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04604678,United States,Metformin|Naltrexone,5.0,2021,Saturday
875,876,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,Diagnostic Test: Nasal Swab|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Throat swab|Diagnostic Test: Fingerstick|Diagnostic Test: Saliva specimen,All,"Child, Adult, Older Adult",Not Applicable,400.0,"June 26, 2020",2020-12-31,"October 22, 2020","Children's Pediatric Associates of Altamonte Springs, Altamonte Springs, Florida, United States|Chappel Group, Kissimmee, Florida, United States|Good Samaritan Minute Clinic, Georgia Tech, Atlanta, Georgia, United States|Gvozden Pediatrics, Millersville, Maryland, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Physicians Quality Care of Jackson, Jackson, Tennessee, United States|Village Health Partners, Plano, Texas, United States",https://ClinicalTrials.gov/show/NCT04557046,Georgia,,12.0,2020,Thursday
876,877,Acceptance of Telemedicine During the COVID-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 1, 2020",2020-10-31,"May 28, 2020",,https://ClinicalTrials.gov/show/NCT04400448,Undefined,,10.0,2020,Saturday
877,878,Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),"Active, not recruiting",Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19,All,"18 Years and older   (Adult, Older Adult)",,3500.0,"June 22, 2020",2020-09-30,"July 29, 2020","Parc Tauli University Hospital, Sabadell, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04490837,Spain,,9.0,2020,Wednesday
878,879,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Drug: Brazilian Green Propolis Extract (EPP-AF)|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"June 2, 2020",2020-08-30,"September 30, 2020","Hospital Sao Rafael, Salvador, BA, Brazil",https://ClinicalTrials.gov/show/NCT04480593,Brazil,Brazilian Green Propolis Extract (EPP-AF),8.0,2020,Sunday
879,880,WGS Analysis of COVID-19 Positive Patients,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"August 3, 2020",2020-12-01,"November 27, 2020","Vanda Pharmaceuticals, Inc., Washington, District of Columbia, United States",https://ClinicalTrials.gov/show/NCT04353401,United States,,12.0,2020,Tuesday
880,881,Smell and Taste Disorders in COVID-19 Patients,Recruiting,Other: Investigation of smell and taste disorders,All,"18 Years and older   (Adult, Older Adult)",,500.0,"June 11, 2020",2020-12-31,"November 9, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",https://ClinicalTrials.gov/show/NCT04427332,Italy,,12.0,2020,Thursday
881,882,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Recruiting,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160.0,"April 1, 2020",2021-04-30,"May 8, 2020","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04336332,Jersey,Hydroxychloroquine Sulfate,4.0,2021,Friday
882,883,Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial,Withdrawn,Drug: Dexamethasone injection|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"September 1, 2020",2021-01-30,"October 28, 2020",,https://ClinicalTrials.gov/show/NCT04360876,Undefined,Dexamethasone injection|Placebos,1.0,2021,Saturday
883,884,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Recruiting,Drug: Molgramostim nebuliser solution|Other: Placebo nebuliser solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,238.0,"September 24, 2020",2022-12-25,"October 5, 2020","Prof. Dr. Susanne Herold, PhD, Gießen, Germany",https://ClinicalTrials.gov/show/NCT04569877,Germany,Molgramostim nebuliser solution,12.0,2022,Sunday
884,885,COVID-19 in Home Healthcare,Completed,,All,"Child, Adult, Older Adult",,155.0,"May 2, 2020",2020-10-10,"November 24, 2020","Dept of anesthesia, Linköping, Sweden",https://ClinicalTrials.gov/show/NCT04642196,Sweden,,10.0,2020,Saturday
885,886,Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,40.0,January 2021,2021-05-01,"November 12, 2020",,https://ClinicalTrials.gov/show/NCT04625218,Undefined,,5.0,2021,Saturday
886,887,COVID-19 Detection Tests in Different Body Fluids,Not yet recruiting,,Male,"18 Years and older   (Adult, Older Adult)",,80.0,September 2020,2021-11-01,"August 13, 2020",,https://ClinicalTrials.gov/show/NCT04473352,Undefined,,11.0,2021,Monday
887,888,Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19,Not yet recruiting,Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"May 20, 2020",2020-12-01,"May 5, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04360122,Egypt,Levamisole|Isoprinosine|Levamisole and Isoprinosine,12.0,2020,Tuesday
888,889,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Drug: Povidone-Iodine 0.4% NI|Drug: Povidone-Iodine 0.5% NI|Drug: Povidone-Iodine 0.6% NI|Drug: Povidone-Iodine 0.5% NS|Drug: Povidone-Iodine 0.6% NS|Other: Placebo comparator: DW-NI|Other: Placebo comparator: DW-NS,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Phase 2,200.0,"July 1, 2020",2020-10-30,"September 16, 2020","Dhaka Medical College, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04549376,Bangladesh,Povidone-Iodine 0.4% NI|Povidone-Iodine 0.5% NI|Povidone-Iodine 0.6% NI|Povidone-Iodine 0.5% NS|Povidone-Iodine 0.6% NS,10.0,2020,Friday
889,890,Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"June 1, 2020",2021-06-01,"May 13, 2020","Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04386044,United Kingdom,,6.0,2021,Tuesday
890,891,Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection),Recruiting,Genetic: GENETIC,All,"18 Years to 70 Years   (Adult, Older Adult)",,40.0,"December 1, 2020",2021-12-01,"November 25, 2020","University Hospital LYON (Hospices Civils de LYON), Lyon, France",https://ClinicalTrials.gov/show/NCT04644146,France,,12.0,2021,Wednesday
891,892,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: TJ003234|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,384.0,"April 11, 2020",2021-12-01,"November 23, 2020","Georgetown University Hospital, Washington, District of Columbia, United States|The GW Medical Faculty Associates, Washington, District of Columbia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|UNM Hospitals, Albuquerque, New Mexico, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univeristy Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04341116,India,TJ003234|Placebo,12.0,2021,Wednesday
892,893,A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection,Not yet recruiting,Biological: AT-100,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,January 2021,2021-07-01,"December 9, 2020",,https://ClinicalTrials.gov/show/NCT04659122,Undefined,,7.0,2021,Thursday
893,894,Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS,Recruiting,"Device: Masimo, LidCO",All,"18 Years and older   (Adult, Older Adult)",,20.0,"May 1, 2020",2021-05-01,"May 18, 2020","Hvidovre Hospital, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04392089,Denmark,,5.0,2021,Saturday
894,895,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,Recruiting,Drug: Antroquinonol|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,174.0,"October 8, 2020",2021-03-31,"December 8, 2020","Franciscan Health Michigan City, Michigan City, Indiana, United States|Ascension.Via Christi Research, Wichita, Kansas, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04523181,India,Antroquinonol|Placebo,3.0,2021,Wednesday
895,896,Sildenafil in COVID-19,Recruiting,Drug: Sildenafil|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"August 19, 2020",2021-03-01,"November 3, 2020","Hospital Naval Almirante Nef, Viña Del Mar, Valparaiso, Chile",https://ClinicalTrials.gov/show/NCT04489446,Chile,Sildenafil|Placebo,3.0,2021,Monday
896,897,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Recruiting,Drug: 1: ILT101|Drug: 2: Placebo Comparator,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"October 23, 2020",2021-02-23,"November 20, 2020","Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04357444,France,1: ILT101|2: Placebo Comparator,2.0,2021,Tuesday
897,898,Spanish Survey on Third Wave of COVID-19,Not yet recruiting,Other: Online survey,All,"Child, Adult, Older Adult",,1000.0,"December 9, 2020",2020-12-20,"December 9, 2020","Universidad de Salamanca, Salamanca, Spain",https://ClinicalTrials.gov/show/NCT04659473,Spain,,12.0,2020,Sunday
898,899,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Completed,Drug: Ivermectin and Doxycyline|Drug: Standard of care,All,"16 Years to 86 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,140.0,"July 1, 2020",2020-10-14,"October 19, 2020","Akarkh Healt hdirectorate, Baghdad, Iraq",https://ClinicalTrials.gov/show/NCT04591600,Iraq,Ivermectin and Doxycyline|Standard of care,10.0,2020,Wednesday
899,900,Almitrine and COVID-19 Related Hypoxemia,Completed,,All,"18 Years and older   (Adult, Older Adult)",,17.0,"March 20, 2020",2020-04-25,"July 30, 2020","Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France",https://ClinicalTrials.gov/show/NCT04380727,France,,4.0,2020,Saturday
900,901,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Not yet recruiting,Drug: Duvelisib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,August 2020,2022-02-01,"July 28, 2020","Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04487886,Georgia,Duvelisib|Placebo,2.0,2022,Tuesday
901,902,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,Recruiting,Drug: AVIGAN|Drug: Placebo Comparator,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 3,780.0,"August 20, 2020",2021-01-31,"September 18, 2020","Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait|Mishref Field Hospital (Mishref), Kuwait City, Kuwait",https://ClinicalTrials.gov/show/NCT04529499,Kuwait,AVIGAN|Placebo Comparator,1.0,2021,Sunday
902,903,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Recruiting,Procedure: Biospecimen Collection|Other: Questionnaire Administration,All,"Child, Adult, Older Adult",Not Applicable,1500.0,"April 9, 2020",2021-04-30,"August 17, 2020","Lyndon Baines Johnson General Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04513990,United States,,4.0,2021,Friday
903,904,TD-0903 for ALI Associated With COVID-19,Recruiting,Drug: TD-0903|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,222.0,"June 24, 2020",2021-02-01,"October 19, 2020","Theravance Biopharma Investigational Site, Chisinau, Moldova, Republic of|Theravance Biopharma Investigational Site, Bucharest, Romania|Theravance Biopharma Investigational Site, Brovary, Ukraine|Theravance Biopharma Investigational Site, Kyiv, Ukraine|Theravance Biopharma Investigational Site, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04402866,"Moldova, Republic of",TD-0903|Placebo,2.0,2021,Monday
904,905,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Completed,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20.0,"May 1, 2020",2020-07-27,"October 1, 2020","Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04358081,United States,HCQ|HCQ+AZT|Placebo,7.0,2020,Monday
905,906,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,Procedure: Stellate Ganglion Block,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5.0,"April 24, 2020",2021-12-01,"November 3, 2020","West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States",https://ClinicalTrials.gov/show/NCT04402840,United States,,12.0,2021,Wednesday
906,907,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,Not yet recruiting,Biological: intradermal injection of BCG Vaccine|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900.0,"April 20, 2020",2020-12-01,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04350931,Egypt,,12.0,2020,Tuesday
907,908,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","Active, not recruiting",Biological: BNT162b2|Other: Placebo,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,160.0,"October 21, 2020",2021-11-30,"November 19, 2020","SOUSEIKAI Sumida Hospital, Sumida-ku, Tokyo, Japan|SOUSEIKAI PS Clinic, Fukuoka, Japan",https://ClinicalTrials.gov/show/NCT04588480,Japan,,11.0,2021,Tuesday
908,909,Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients,Completed,,All,"Child, Adult, Older Adult",,10.0,"March 11, 2020",2020-07-23,"November 16, 2020","CHRU of Nancy, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04629222,France,,7.0,2020,Thursday
909,910,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,Not yet recruiting,Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients,All,"18 Years and older   (Adult, Older Adult)",Phase 3,36.0,"June 19, 2020",2020-09-30,"June 17, 2020",,https://ClinicalTrials.gov/show/NCT04432103,Undefined,,9.0,2020,Wednesday
910,911,The Salivary Raman COVID-19 Fingerprint,Recruiting,"Other: Raman analysis of saliva, characterization of the Raman database and building of the classification model",All,"18 Years to 90 Years   (Adult, Older Adult)",,120.0,"June 1, 2020",2021-06-01,"October 12, 2020",", IRCCS Fondazione Don Carlo Gnocchi, Centro Spalenza, Rovato, BS, Italy|IRCCS Fondazione Don Carlo Gnocchi, Santa Maria Nascente Hospital (Milano), Milano, MI, Italy",https://ClinicalTrials.gov/show/NCT04583306,Italy,,6.0,2021,Tuesday
911,912,Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients,Completed,,All,"Child, Adult, Older Adult",,221.0,"March 28, 2020",2020-05-05,"June 16, 2020","Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State Of Mexico, Mexico",https://ClinicalTrials.gov/show/NCT04434157,Mexico,,5.0,2020,Tuesday
912,913,Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19,Not yet recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,"July 6, 2020",2021-04-01,"July 7, 2020","Hospital Universitario ""Dr. Gonzalo Valdés Valdés"", Saltillo, Coahuila, Mexico",https://ClinicalTrials.gov/show/NCT04452812,Mexico,,4.0,2021,Thursday
913,914,To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database,Not yet recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,100.0,"April 20, 2020",2020-12-01,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04346043,Egypt,,12.0,2020,Tuesday
914,915,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",Other: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"July 28, 2020",2021-06-27,"September 29, 2020","Paradigm Laboratories, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT04567953,United States,,6.0,2021,Sunday
915,916,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,Drug: IV Dexamethasone|Drug: Nasal Dexamethasone,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"July 14, 2020",2021-07-31,"November 12, 2020","Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Cdmx, Mexico|Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Cdmx, Mexico|El Instituto Nacional de Neurologia Y Neurocirugia Manuel Velasco Suarez, Mexico City, Cdmx, Mexico",https://ClinicalTrials.gov/show/NCT04513184,Mexico,IV Dexamethasone|Nasal Dexamethasone,7.0,2021,Saturday
916,917,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),Recruiting,Drug: Molnupiravir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1300.0,"October 19, 2020",2021-12-02,"December 10, 2020","UC Davis Medical Center ( Site 1809), Sacramento, California, United States|University Of Florida ( Site 1810), Gainesville, Florida, United States|Wellstar Kennestone Hospital ( Site 1801), Marietta, Georgia, United States|Loretto Hospital ( Site 1838), Chicago, Illinois, United States|LSU-HSC Shreveport ( Site 1824), Shreveport, Louisiana, United States|Henry Ford Health System ( Site 1821), Detroit, Michigan, United States|University of Mississippi Medical Center ( Site 1846), Jackson, Mississippi, United States|University of Nebraska Medical Center ( Site 1835), Omaha, Nebraska, United States|Carolinas Medical Center ( Site 1850), Charlotte, North Carolina, United States|Sanford Health ( Site 1851), Fargo, North Dakota, United States|Swedish Medical Center ( Site 1812), Edmonds, Washington, United States|Valley Medical Center ( Site 1815), Renton, Washington, United States|Swedish Medical Center ( Site 1861), Seattle, Washington, United States|Chronos Pesquisa Clínica ( Site 0105), Brasilia, Distrito Federal, Brazil|Santa Casa de Misericordia de Belo Horizonte ( Site 0100), Belo Horizonte, Minas Gerais, Brazil|Hospital Tacchini ( Site 0107), Bento Goncalves, Rio Grande Do Sul, Brazil|FUNFARME Hospital de Base Centro Integrado de Pesquisa ( Site 0101), Sao Jose do Rio Preto, Sao Paulo, Brazil|Hospital Sotero del Rio [Santiago, Chile] ( Site 0304), Santiago, Region M. De Santiago, Chile|Complejo Hospitalario San Jose ( Site 0306), Santiago, Region M. De Santiago, Chile|Servicio de Salud Sur Hospital Lucio Cordova ( Site 0305), Santiago, Region M. De Santiago, Chile|Clinica de la Costa Ltda. ( Site 0402), Barranquilla, Atlantico, Colombia|Fundacion Cardiovascular de Colombia ( Site 0403), Bucaramanca, Santander, Colombia|Groupe Hospitalier Pellegrin ( Site 0511), Bordeaux, Gironde, France|C.H.U. de Toulouse, Hopital de Purpan ( Site 0501), Toulouse, Midi-Pyrenees, France|Centre Hospitalier de Tourcoing ( Site 0502), Tourcoing, Nord, France|Hopital Bichat - Claude Bernard ( Site 0503), Paris, France|Chaim Sheba Medical Center ( Site 2100), Ramat Gan, Tel Abib, Israel|Rambam Medical Center ( Site 2102), Haifa, Israel|Hadassah Medical Center. Ein Kerem ( Site 2103), Jerusalem, Israel|Inha University Hospital ( Site 2204), Incheon, Korea, Republic of|Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 1001), Lodz-Baluty, Lodzkie, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1004), Lublin, Lubelskie, Poland|Centrum Medyczne w Lancucie Sp.zo.o. ( Site 1000), Lancut, Podkarpackie, Poland|Krasnogorsk City Hospital Number 1 ( Site 1119), Krasnogorsk, Moskovskaya Oblast, Russian Federation|City Clinical Hospital #40 ( Site 1109), Moscow, Moskva, Russian Federation|FSBI Central Hospital with Policlinics ( Site 1105), Moscow, Moskva, Russian Federation|Moscow Clinical Hospital #52 ( Site 1103), Moscow, Moskva, Russian Federation|City Hospital #40 ( Site 1113), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Pokrovskaya hospital ( Site 1116), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Hospital #1 ( Site 1112), Smolensk, Smolenskaya Oblast, Russian Federation|Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1100), Kazan, Tatarstan, Respublika, Russian Federation|IATROS International ( Site 1202), Bloemfontein, Free State, South Africa|Hospital Universitari Vall d Hebron ( Site 1305), Barcelona, Spain|Hospital Clinic ( Site 1304), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ( Site 1303), Barcelona, Spain|Hospital Universitario Gregorio Maranon ( Site 1302), Madrid, Spain|Hospital Universitario Ramon y Cajal ( Site 1301), Madrid, Spain|Hospital Universitario La Paz ( Site 1300), Madrid, Spain|CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Сommunal non-com. Institution Oleksandrivska clinical hospital Kyiv ( Site 1600), Kyiv, Kyivska Oblast, Ukraine|Odesa City Clinical Infectious Hospital ( Site 1611), Odesa, Odeska Oblast, Ukraine|Communal Non-Commercial Enterprise Central City Hospital ( Site 1615), Rivne, Rivnenska Oblast, Ukraine|Royal Free London NHS Foundation Trust ( Site 1700), London, London, City Of, United Kingdom|King's College Hospital ( Site 1705), London, London, City Of, United Kingdom|North Manchester General Hospital ( Site 1701), Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04575584,Brazil,Molnupiravir|Placebo,12.0,2021,Thursday
917,918,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Recruiting,Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 2,144.0,"May 1, 2020",2022-05-01,"June 2, 2020","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04373044,United States,Baricitinib|Hydroxychloroquine|Placebo Administration,5.0,2022,Sunday
918,919,Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,Recruiting,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA],All,"18 Years and older   (Adult, Older Adult)",,30.0,"June 16, 2020",2021-05-15,"November 12, 2020","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",https://ClinicalTrials.gov/show/NCT04359667,Croatia,Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA],5.0,2021,Saturday
919,920,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),Recruiting,Drug: Molnupiravir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1450.0,"October 19, 2020",2021-11-30,"December 10, 2020","Phoenix Medical Group ( Site 1822), Peoria, Arizona, United States|Ruane Clinical Research Group, Inc. ( Site 2406), Los Angeles, California, United States|Men's Health Foundation ( Site 1820), Los Angeles, California, United States|UC Davis Medical Center ( Site 1833), Sacramento, California, United States|Emerson Clinical Research Institute ( Site 1828), Washington, District of Columbia, United States|Midway Immunology and Research Center ( Site 1837), Fort Pierce, Florida, United States|Indago Research & Health Center, Inc ( Site 1809), Hialeah, Florida, United States|Advanced Research For Health Improvement LLC ( Site 1816), Immokalee, Florida, United States|Advanced Research For Health Improvement LLC ( Site 1813), Naples, Florida, United States|Bliss Healthcare Services ( Site 1847), Orlando, Florida, United States|Javara Inc. ( Site 1869), Albany, Georgia, United States|IACT Health ( Site 1818), Columbus, Georgia, United States|Javara Inc. ( Site 1868), Fayetteville, Georgia, United States|Loretto Hospital ( Site 1886), Chicago, Illinois, United States|University of Nebraska Medical Center ( Site 2414), Omaha, Nebraska, United States|Saint Hope Foundation, Inc. ( Site 1830), Bellaire, Texas, United States|The Crofoot Research Center, Inc. ( Site 1812), Houston, Texas, United States|Javara Inc. ( Site 1866), Sugar Land, Texas, United States|Swedish Medical Center First Hill ( Site 1807), Seattle, Washington, United States|Multicare Health System ( Site 1811), Spokane, Washington, United States|Multicare Health System ( Site 1814), University Place, Washington, United States|Chronos Pesquisa Clínica ( Site 0155), Brasilia, Distrito Federal, Brazil|Santa Casa de Misericordia de Belo Horizonte ( Site 0150), Belo Horizonte, Minas Gerais, Brazil|Hospital Tacchini ( Site 0157), Bento Goncalves, Rio Grande Do Sul, Brazil|Instituto de Infectologia Emilio Ribas ( Site 0153), Sao Paulo, Brazil|Fundacion Arturo Lopez Perez ( Site 0305), Santiago, Region M. De Santiago, Chile|Espacio EME ( Site 0304), Santiago, Region M. De Santiago, Chile|Clinica Bicentenario Spa ( Site 0306), Santiago, Region M. De Santiago, Chile|Oncomedica S.A. ( Site 0407), Monteria, Cordoba, Colombia|Caja de Compensación Familiar CAFAM. Sede Centro de Atención en Salud CAFAM Floresta ( Site 0406), Bogota, Cundinamarca, Colombia|Fundacion Valle del Lili ( Site 0401), Cali, Valle Del Cauca, Colombia|Groupe Hospitalier Pellegrin ( Site 0511), Bordeaux, Gironde, France|C.H.U. de Toulouse Hopital Purpan ( Site 0501), Toulouse, Midi-Pyrenees, France|Centre Hospitalier de Tourcoing ( Site 0502), Tourcoing, Nord, France|Hopital Bichat Claude Bernard ( Site 0503), Paris, France|Hadassah Medical Center. Ein Kerem ( Site 2100), Jerusalem, Israel|Central Clinical Hospital with Polyclinic ( Site 1105), Moscow, Moskva, Russian Federation|Medical Research Institute LLC ( Site 1116), Saint Petersburg, Sankt-Peterburg, Russian Federation|St.Petersburg Outpatient Clinic #109 ( Site 1119), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Limited liability company ""Scientific research center Eco-safety"" ( Site 1117), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Smolensk State Medical University ( Site 1110), Smolensk, Smolenskaya Oblast, Russian Federation|Strategic Medical System LLC ( Site 1114), Saint-Petersburg, Russian Federation|IATROS International ( Site 1212), Bloemfontein, Free State, South Africa|Be Part Yoluntu Centre ( Site 1218), Paarl, Western Cape, Western Cape, South Africa|Hospital General Universitario Gregorio Maranon ( Site 1302), Madrid, Madrid, Comunidad De, Spain|Hospital Clinic ( Site 1304), Barcelona, Spain|Hospital Universitari Germans Trias i Pujol ( Site 1303), Barcelona, Spain|Hospital Universitario Ramon y Cajal ( Site 1301), Madrid, Spain|CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Non profit municipal enterprise City hospital student of Kharkiv city council ( Site 1621), Kharkiv, Kharkivska Oblast, Ukraine|LLC ""Adonis plus"" ( Site 1619), Kyiv, Kyivska Oblast, Ukraine|Kyiv railway clinical hospital 2 of Branch Health center ( Site 1602), Kyiv, Kyivska Oblast, Ukraine|ARTEM. State Holding Company ( Site 1618), Kyiv, Kyivska Oblast, Ukraine|Layton Medical Centre ( Site 1705), Blackpool, Lancashire (England), United Kingdom|Royal Free London NHS Foundation Trust ( Site 1700), London, London, City Of, United Kingdom|King's College Hospital ( Site 1707), London, London, City Of, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust ( Site 1704), Newcastle upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT04575597,Brazil,Molnupiravir|Placebo,11.0,2021,Tuesday
920,921,European Pathology Laboratories and COVID-19,Completed,Other: Activity,All,"Child, Adult, Older Adult",,71.0,"March 15, 2020",2020-05-31,"July 20, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04476823,France,,5.0,2020,Sunday
921,922,"Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19",Enrolling by invitation,,All,"18 Months and older   (Child, Adult, Older Adult)",,1000.0,"August 1, 2020",2021-08-01,"August 10, 2020","Fundacion Jimenez Diaz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04505709,Spain,,8.0,2021,Sunday
922,923,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Completed,Drug: HCQ|Other: Standard therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,325.0,"March 1, 2020",2020-07-31,"August 4, 2020","Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India",https://ClinicalTrials.gov/show/NCT04408456,India,HCQ,7.0,2020,Friday
923,924,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Active, not recruiting","Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|Other: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,100.0,"July 27, 2020",2020-10-04,"September 22, 2020","Federal State Budgetary Institution of Healthcare ""Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency"" (FGBUZ MSCH-163, FMBA of Russia), Koltsovo, Novosibirsk Region, Russian Federation",https://ClinicalTrials.gov/show/NCT04527575,Russian Federation,,10.0,2020,Sunday
924,925,BCG Vaccination to Prevent COVID-19,Recruiting,Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Drug: Preservative-free saline,All,18 Years to 64 Years   (Adult),Phase 3,550.0,"December 7, 2020",2023-04-01,"December 9, 2020","Uniformed Services University, Bethesda, Maryland, United States|Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04632537,United States,Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Preservative-free saline,4.0,2023,Saturday
925,926,The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection,Not yet recruiting,Dietary Supplement: NRICM101,All,"Child, Adult, Older Adult",,51000.0,"December 20, 2020",2022-12-31,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04664049,Undefined,,12.0,2022,Saturday
926,927,DISulfiram for COvid-19 (DISCO) Trial,Not yet recruiting,Drug: Disulfiram|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"December 1, 2020",2022-06-01,"November 27, 2020","University of California San Francisco, Fresno, Fresno, California, United States|San Francisco General Hospital, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04485130,United States,Disulfiram|Placebo,6.0,2022,Wednesday
927,928,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,Completed,Other: Personal protective equipment from biological hazard,All,18 Years to 45 Years   (Adult),,6.0,"June 3, 2020",2020-06-27,"July 28, 2020","Federal State Budgetary Scientific Institution Izmerov Research Institute of Occupational Health, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04427267,Russian Federation,,6.0,2020,Saturday
928,929,Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection,Not yet recruiting,Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs|Diagnostic Test: Computed Tomography (CT)|Diagnostic Test: Pulmonary Function Tests (PFT)|Diagnostic Test: Six Minute Walk Test (6MWT)|Diagnostic Test: Sputum analysis|Diagnostic Test: Blood analysis|Other: Questionnaires,All,"18 Years to 80 Years   (Adult, Older Adult)",,200.0,"December 1, 2020",2024-12-01,"November 13, 2020","Department of Medicine (Respirology), McMaster University, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04584671,Canada,,12.0,2024,Sunday
929,930,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,Recruiting,Drug: AZD1656|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"August 12, 2020",2021-03-01,"November 9, 2020","Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, United Kingdom|Medway NHS Foundation Trust, Gillingham, United Kingdom|Hull & East Yorkshire NHS Trust, Hull, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|Penine Acute Hospitals NHS Trust, Salford, United Kingdom|Sheffield Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Somerset NHS Foundation Trust, Taunton, United Kingdom|Walsall Healthcare NHS Trust, Walsall, United Kingdom",https://ClinicalTrials.gov/show/NCT04516759,United Kingdom,AZD1656,3.0,2021,Monday
930,931,Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?,Recruiting,Diagnostic Test: Tuberculin test,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",,100.0,"April 11, 2020",2020-06-30,"April 15, 2020","AssiutU, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04347876,Egypt,,6.0,2020,Tuesday
931,932,A Study of LY3127804 in Participants With COVID-19,Terminated,Drug: LY3127804|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,95.0,"April 20, 2020",2020-10-12,"October 29, 2020","Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States|Banner Univ Med Ctr Tucson, Tucson, Arizona, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Nuvance Danbury Hospital, Danbury, Connecticut, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Henry Ford Hospital Detroit, Detroit, Michigan, United States|Allina Hospital Network, Minneapolis, Minnesota, United States|State University of New York Hospital, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04342897,India,LY3127804|Placebo,10.0,2020,Monday
932,933,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","Active, not recruiting",Biological: V591|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,260.0,"August 27, 2020",2022-04-26,"December 7, 2020","Research Centers of America, LLC ( Site 0014), Hollywood, Florida, United States|Alliance for Multispecialty Research, LLC ( Site 0013), Wichita, Kansas, United States|Central Kentucky Research Associates, Inc. ( Site 0011), Lexington, Kentucky, United States|The Center for Pharmaceutical Research PC ( Site 0012), Kansas City, Missouri, United States|SCRI-CCCIT GesmbH ( Site 0006), Salzburg, Austria|Medizinische Universitaet Wien ( Site 0007), Wien, Austria|Universitair Ziekenhuis Gent ( Site 0003), Gent, Oost-Vlaanderen, Belgium|SGS Life Science Services ( Site 0001), Antwerpen, Belgium|ATC - Clinical Pharmacology Unit ( Site 0002), Liege, Belgium",https://ClinicalTrials.gov/show/NCT04498247,Austria,,4.0,2022,Tuesday
933,934,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Recruiting,Drug: Fuzheng Huayu Tablet|Drug: Vitamin C tablets|Other: Placebo|Other: respiratory function rehabilitation training,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,160.0,"April 23, 2020",2021-12-01,"September 23, 2020","Shuguang Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04279197,China,Fuzheng Huayu Tablet|Vitamin C tablets,12.0,2021,Wednesday
934,935,Laparoscopy and COVID-19 Contamination,Not yet recruiting,Other: Additional and minimal collection of products of the human body carried out during a sample for standard of care,All,"18 Years and older   (Adult, Older Adult)",,20.0,"November 1, 2020",2022-01-01,"October 29, 2020","AP-HP, Bicêtre Hospital, Le Kremlin Bicêtre, France",https://ClinicalTrials.gov/show/NCT04608383,France,,1.0,2022,Saturday
935,936,Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19,Not yet recruiting,Drug: Enzalutamide,Male,"50 Years and older   (Adult, Older Adult)",Phase 2,90.0,July 2020,2021-12-01,"July 2, 2020","Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland",https://ClinicalTrials.gov/show/NCT04456049,Switzerland,Enzalutamide,12.0,2021,Wednesday
936,937,Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,Not yet recruiting,Other: - Synthetic anti-malarial drugs,All,"18 Years and older   (Adult, Older Adult)",,6000000.0,April 2020,2020-06-01,"April 22, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",https://ClinicalTrials.gov/show/NCT04356417,France,,6.0,2020,Monday
937,938,Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"April 22, 2020",2020-12-01,"June 2, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04348214,Egypt,,12.0,2020,Tuesday
938,939,FOLLOW-UP OF PATIENTS WITH COVID-19.,Recruiting,Other: Follow-up of patients with COVID-19,All,"18 Years and older   (Adult, Older Adult)",,200.0,"October 27, 2020",2023-04-27,"October 30, 2020","Hopitaux Universitaires de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04609839,France,,4.0,2023,Thursday
939,940,Computed Tomography for COVID-19 Diagnosis,Not yet recruiting,Diagnostic Test: Chest computed tomography (CT)|Diagnostic Test: Reverse-transcription polymerase chain reaction (RT-PCR),All,"18 Years and older   (Adult, Older Adult)",,10000.0,April 2020,2020-07-01,"April 22, 2020","Cochin Hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04355507,France,,7.0,2020,Wednesday
940,941,Frailty in Elderly Patients With COVID-19,Recruiting,Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 16, 2020",2021-03-01,"November 9, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",https://ClinicalTrials.gov/show/NCT04412265,Italy,,3.0,2021,Monday
941,942,Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,Recruiting,Procedure: Biospecimen Collection|Other: Diagnostic Laboratory Biomarker Analysis|Other: Electronic Health Record Review|Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",,800.0,"July 13, 2020",2022-08-21,"September 21, 2020","City of Hope Medical Center, Duarte, California, United States",https://ClinicalTrials.gov/show/NCT04497779,United States,,8.0,2022,Sunday
942,943,The COVID-RASi Trial (COVID-19),Not yet recruiting,Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin II Receptor Blockers,All,65 Years and older   (Older Adult),Phase 3,1155.0,"October 30, 2020",2022-08-01,"October 19, 2020","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04591210,Canada,Angiotensin converting enzyme inhibitor|Angiotensin II Receptor Blockers,8.0,2022,Monday
943,944,COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach,Not yet recruiting,,All,"15 Years to 75 Years   (Child, Adult, Older Adult)",,800.0,"September 1, 2020",2021-09-01,"June 16, 2020","Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the",https://ClinicalTrials.gov/show/NCT04424940,Congo,,9.0,2021,Wednesday
944,945,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,Recruiting,Drug: MR or M-M-R II ® vaccine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,"September 4, 2020",2021-08-01,"November 23, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States|Unity Health Toronto, Toronto, Ontario, Canada|University of Ghana Medical Centre, Accra, Greater Accra Region, Ghana|St James's Hospital, Dublin, Leinster, Ireland|Radboud University Medical Center, Nijmegen, Netherlands|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Infectious Diseases Institute Kampala, Uganda, Kampala, Uganda|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia|University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe",https://ClinicalTrials.gov/show/NCT04333732,Canada,MR or M-M-R II ® vaccine|Placebo,8.0,2021,Sunday
945,946,"Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19",Recruiting,Drug: Oral,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,320.0,"August 19, 2020",2021-12-31,"September 1, 2020","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",https://ClinicalTrials.gov/show/NCT04303299,Thailand,Oral,12.0,2021,Friday
946,947,Case Fatalities in Hospitalised COVID-19 Patients in the UK,Completed,Other: Patient Characteristics|Other: COVID-19 treatments|Other: Differences in triage|Other: Surge capacity,All,"Child, Adult, Older Adult",,70000.0,"February 24, 2020",2020-08-02,"August 26, 2020","University of Edinburgh, Edinburgh, United Kingdom",https://ClinicalTrials.gov/show/NCT04527458,United Kingdom,,8.0,2020,Sunday
947,948,Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19,Not yet recruiting,Combination Product: Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|Other: Standard treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,160.0,November 2020,2020-12-01,"October 26, 2020",,https://ClinicalTrials.gov/show/NCT04568096,Undefined,,12.0,2020,Tuesday
948,949,Non-invasive Ventilatory Support of Patients Affected by COVID-19,"Active, not recruiting",Device: Non-invasive ventilatory support,All,"18 Years and older   (Adult, Older Adult)",,900.0,"March 26, 2020",2020-12-30,"November 9, 2020","Policlinico San Marco - Ospedale Zingonia, Zingonia, BG, Italy|ASST Papa Giovanni XXIII - Bergamo, Bergamo, Italy|Azienda Ospedaliera - Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|ASST Spedali Civili - Brescia, Brescia, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|ASST Lariana - Ospedale Sant'Anna, Como, Italy|ASST Crema - Ospedale Maggiore di Crema, Crema, Italy|ASST Cremona - Ospedale di Cremona, Cremona, Italy|Istituto Clinico Humanitas Gavazzeni, Cremona, Italy|ASST Garda - Presidio di Desenzano del Garda, Desenzano Del Garda, Italy|ASST Monza - Desio, Desio, Italy|ASST Spedali Civili -Ospedale di Gardone Val Trompia, Gardone Val Trompia, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, Italy|ASST Ovest milanese - Ospedale di Legnano, Legnano, Italy|ASST Lodi - Ospedale Maggiore di Lodi, Lodi, Italy|ASST OVEST Milanese - Ospedale di Magenta, Magenta, Italy|ASST Garda - Ospedale di Manerbio, Manerbio, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|ASST Melegnano e della Martesana - Presidio di Melzo-Gorgonzola, Melzo, Italy|ASST Fatebenefratelli - Presidi Fatebenefratelli & M. Melloni, Milano, Italy|ASST Fatebenefratelli - Sacco, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|ASST Spedali Civili -Presidio Ospedaliero di Montichiari, Montichiari, Italy|ASST Monza - Ospedale San Gerardo, Monza, Italy|Fondazione IRCCS Policlinico San Matteo - Pavia, Pavia, Italy|Policlinico San Pietro, Ponte San Pietro, Italy|Istituto Clinico Humanitas Rozzano, Rozzano, Italy|ASST Valle Olona - Ospedale di Saronno, Saronno, Italy|ASST Bergamo OVEST - Ospedale ""Treviglio-Caravaggio"" di Treviglio, Treviglio, Italy|Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|ASST Vimercate - Ospedale di Vimercate, Vimercate, Italy|ASST Melegnano e della Martesana - Ospedale di Vizzolo Predabissi, Vizzolo Predabissi, Italy",https://ClinicalTrials.gov/show/NCT04382235,Italy,,12.0,2020,Wednesday
949,950,Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias,Recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",,300.0,"November 23, 2020",2020-12-31,"December 2, 2020","Medical University of Innsbruck, Innsbruck, Tyrol, Austria",https://ClinicalTrials.gov/show/NCT04649320,Austria,,12.0,2020,Thursday
950,951,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,Diagnostic Test: ENT exam|Diagnostic Test: Olfactometry|Diagnostic Test: Brain MRI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"September 3, 2020",2021-09-03,"October 5, 2020","Hopital Foch, Suresnes, Ile-de-France, France|Hopital Raymond Poincare, Garches, France",https://ClinicalTrials.gov/show/NCT04526054,France,,9.0,2021,Friday
951,952,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),Recruiting,Drug: FOY-305|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,110.0,"November 9, 2020",2021-05-31,"December 8, 2020","Chiba Clinical Site 1, Narita, Chiba, Japan|Fukuoka Clinical Site 1, Okawa, Fukuoka, Japan|Ishikawa Clinical Site 1, Kanazawa, Ishikawa, Japan|Kanagawa Clinical Site 1, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site 2, Yokosuka, Kanagawa, Japan|Mie Clinical Site 1, Yokkaichi, Mie, Japan|Saitama Clinical Site 1, Kuki, Saitama, Japan|Saitama Clinical Site 2, Kumagaya, Saitama, Japan|Tokyo Clinical Site 5, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site 9, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site1, Hachioji, Tokyo, Japan|Tokyo Clinical Site 7, Itabashi-ku, Tokyo, Japan|Tokyo Clinical Site 3, Meguro-ku, Tokyo, Japan|Tokyo Clinical Site 4, Shinagawa-ku, Tokyo, Japan|Tokyo Clinical Site 8, Sibuya-ku, Tokyo, Japan|Tokyo Clinical Site2, Sibuya-ku, Tokyo, Japan|Tokyo Clinical Site 6, Tachikawa, Tokyo, Japan|Osaka Clinical Site 1, Osaka, Japan",https://ClinicalTrials.gov/show/NCT04657497,Japan,FOY-305|Placebo,5.0,2021,Monday
952,953,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Biological: COVID-19 Convalescent Plasma,All,65 Years and older   (Older Adult),Phase 2|Phase 3,182.0,"May 27, 2020",2021-06-30,"October 6, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy|Ospedale SS Annunziata, Chieti, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy",https://ClinicalTrials.gov/show/NCT04374526,Italy,,6.0,2021,Wednesday
953,954,COVID-19 and Chilblains,Completed,Diagnostic Test: Biological sample collection,All,"Child, Adult, Older Adult",Not Applicable,269.0,"July 21, 2020",2020-10-19,"November 4, 2020","CHU Angers, Angers, France|CHRU Brest, Brest, France|CHU Nantes, Nantes, France|CHU Rennes, Rennes, France|CHRU Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04455308,France,,10.0,2020,Monday
954,955,Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,Withdrawn,Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"April 1, 2020",2021-04-01,"November 20, 2020",,https://ClinicalTrials.gov/show/NCT04365231,Undefined,Hydroxychloroquine and azithromycin treatment,4.0,2021,Thursday
955,956,Austrian COVID-19 Registry,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 1, 2020",2021-12-01,"November 30, 2020","LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie), Feldkirch, Austria|Kepler Universitätsklinikum Linz, Med. Campus III., Klinik für Lungenheilkunde / Pneumologie, Linz, Austria|IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria|KH Zams: Innere Medizin Internistische Onkologie und Hämatologie, Zams, Austria",https://ClinicalTrials.gov/show/NCT04351529,Austria,,12.0,2021,Wednesday
956,957,The McGill RAAS-COVID-19 Trial,Not yet recruiting,Other: Temporarily holding the RAAS inhibitor [intervention]|Other: RAAS inhibitor [continued standard of care],All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"September 1, 2020",2021-09-01,"August 19, 2020",,https://ClinicalTrials.gov/show/NCT04508985,Undefined,,9.0,2021,Wednesday
957,958,Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS),Recruiting,Diagnostic Test: Breath test,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 25, 2020",2021-03-25,"September 14, 2020","NHS Lothian, Edinburgh, United Kingdom",https://ClinicalTrials.gov/show/NCT04329507,United Kingdom,,3.0,2021,Thursday
958,959,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,Recruiting,Drug: Favipiravir|Drug: Oseltamivir 75mg,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100.0,"April 16, 2020",2020-10-30,"September 22, 2020","Cipto Mangunkusumo National Referral Hospital, Jakarta, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04558463,Indonesia,Favipiravir|Oseltamivir 75mg,10.0,2020,Friday
959,960,COVID-19 Infection in Cancer Pantients,Recruiting,Other: No intervention on patients,All,"Child, Adult, Older Adult",,150.0,"January 1, 2020",2021-08-01,"September 29, 2020","Oncology Unit, Hospital Andrea Tortora, Pagani, Salerno, Italy",https://ClinicalTrials.gov/show/NCT04569292,Italy,,8.0,2021,Sunday
960,961,The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes,Not yet recruiting,Other: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19),All,"20 Years and older   (Adult, Older Adult)",,2500.0,"June 15, 2020",2023-07-31,"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04389476,Undefined,,7.0,2023,Monday
961,962,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,Recruiting,Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet|Other: Supportive tratment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,165.0,"April 13, 2020",2021-05-01,"November 9, 2020","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04346147,Spain,Imatinib tablets|Baricitinib Oral Tablet,5.0,2021,Saturday
962,963,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,Recruiting,Drug: Trimodulin|Other: Placebo (human albumin 1%),All,"18 Years and older   (Adult, Older Adult)",Phase 2,164.0,"October 6, 2020",2021-03-01,"November 3, 2020","Investigational Site # 3401, Barcelona, Spain|Investigational Site # 3402, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04576728,Spain,Trimodulin,3.0,2021,Monday
963,964,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,Other: Remote controlled exercise|Other: Home exercise,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,122.0,"September 1, 2020",2022-08-01,"November 5, 2020","Koc University School of Medicine, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04482634,Turkey,,8.0,2022,Monday
964,965,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,45000.0,"July 16, 2020",2021-09-16,"October 30, 2020","Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S, Sanabis, Bahrain|Katameya Medical Center, Cairo, Egypt|Vacsera health Care facilities , MoH, Cairo, Egypt|Prince Hamza Hospital, Amman, Jordan|Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates|Al Qarain Primary Health Care Centre-MOHAP, Sharjah, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04510207,Bahrain,,9.0,2021,Thursday
965,966,COVID-19 (VA CURES-1),Recruiting,Drug: Convalescent Plasma|Other: Masked Saline Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,702.0,"November 16, 2020",2022-07-18,"November 24, 2020","Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Orlando VA Medical Center, Orlando, FL, Orlando, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States|VA Southern Nevada Healthcare System, North Las Vegas, NV, Las Vegas, Nevada, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04539275,Georgia,Convalescent Plasma,7.0,2022,Monday
966,967,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,Device: Performing of lung ultrasound,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"June 15, 2020",2021-06-15,"June 16, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04432805,France,,6.0,2021,Tuesday
967,968,Convalescent Plasma for COVID-19 Research Donor Study,Recruiting,,All,"17 Years to 65 Years   (Child, Adult, Older Adult)",,1000.0,"June 30, 2020",2022-03-31,"September 18, 2020","The Hospital for Sick Children, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04555109,Canada,,3.0,2022,Thursday
968,969,COVID-19 and Deep Venous Thrombosis,Completed,,All,"18 Years and older   (Adult, Older Adult)",,12.0,"April 17, 2020",2020-05-15,"May 19, 2020","Jessa hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04338932,Belgium,,5.0,2020,Friday
969,970,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Completed,Diagnostic Test: RT-qPCR test|Diagnostic Test: COVID-VIRO® test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"October 13, 2020",2020-10-17,"December 7, 2020","Centre Hospitalier Régional d'Orléans, France, Orléans, France",https://ClinicalTrials.gov/show/NCT04609969,France,,10.0,2020,Saturday
970,971,Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study),Completed,Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19,All,"Child, Adult, Older Adult",,1707.0,"April 1, 2020",2020-06-30,"August 19, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain",https://ClinicalTrials.gov/show/NCT04518735,Spain,,6.0,2020,Tuesday
971,972,LYT-100 in Post-acute COVID-19 Respiratory Disease,Not yet recruiting,Drug: LYT-100|Other: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,168.0,December 2020,2021-12-01,"December 7, 2020","Southeastern Research Center, Winston-Salem, North Carolina, United States|National Institute for Infectious Diseases ""Prof. Dr. Matei Balş"" (Arnsia Eploratory Medicine), Bucharest, Romania",https://ClinicalTrials.gov/show/NCT04652518,Oman,LYT-100,12.0,2021,Wednesday
972,973,Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19,Not yet recruiting,Diagnostic Test: ELISPOT|Diagnostic Test: QUANTIFERON,All,"18 Years and older   (Adult, Older Adult)",,100.0,"December 1, 2020",2022-12-01,"December 1, 2020","CHU Saint-Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04648709,France,,12.0,2022,Thursday
973,974,COVID-19 and Cancer Consortium Registry,Recruiting,Other: Web-based REDCap survey,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"March 17, 2020",2022-12-01,"November 19, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04354701,United States,,12.0,2022,Thursday
974,975,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Recruiting,Other: Prone decubitus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,404.0,"April 27, 2020",2021-11-24,"November 13, 2020","Intensive Care Unit, University Hospital, Aix, Aix-en-Provence, France|Medical Intensive Care Unit, University Hospital, Amiens, Amiens, France|Intensive Care Unit, Hospital, Argenteuil, Argenteuil, France|Intensive Care Unit, Hospital,, Blois, France|Medical Intensive Care Unit, University Hospital, Bordeaux, Bordeaux, France|Medical Intensive Care Unit, University Hospital, Brest, Brest, France|Medical Intensive Care Unit, Hospital, Béthune, Béthune, France|Medical Intensive Care Unit, University Hospital, Caen, Caen, France|Intensive Care Unit, Louis Mourier-APHP, Colombes, France|Intensive Care Unit, Hospital, Dax, Dax, France|Medical Intensive Care Unit, University Hospital, Dijon, Dijon, France|Medical Intensive Care Unit, University Hospital, Grenoble, Grenoble, France|Intensive Care Unit, Hospital, La Roche-sur-Yon, La Roche-sur-Yon, France|Intensive Care Unit, Hospital, Le Mans, Le Mans, France|Intensive Care Unit, University Hospital, Lille, Lille, France|Intensive Care Unit, Hospital, Lorient, Lorient, France|Medical Intensive Care Unit, Hospital, Mont-de-Marsan, Mont-de-Marsan, France|Medical Intensive Care Unit, University Hospital, Montpellier, Montpellier, France|Medical Intensive Care Unit, University Hospital, Nantes, Nantes, France|Medical Intensive Care Unit, University Hospital, Nice, NIce, France|Medical Intensive Care Unit, Hospital, Orléans, Orléans, France|Medical Intensive Care Unit, Tenon-APHP, Paris, France|Medical Intensive Care Unit, University Hospital, Poitiers, Poitiers, France|Medical Intensive Care Unit, University Hospital, Tours, Tours, France|Surgical Intensive Care Unit, University Hospital, Tours, Tours, France|Intensive Care Unit, Hospital, Valence, Valence, France|Medical Intensive Care Unit, University Hospital, Nancy, Vandœuvre-lès-Nancy, France|Intensive Care Unit, Hospital, Vannes, Vannes, France",https://ClinicalTrials.gov/show/NCT04358939,France,,11.0,2021,Wednesday
975,976,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Drug: Methylprednisolone|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,72.0,"May 15, 2020",2021-02-01,"June 22, 2020","Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain",https://ClinicalTrials.gov/show/NCT04438980,Spain,Methylprednisolone,2.0,2021,Monday
976,977,Physical Activity Program Implementation in Hospitalized Positive Covid-19 Older Adults,Recruiting,Other: physical activity program,All,75 Years and older   (Older Adult),,30.0,"November 1, 2020",2021-12-31,"December 2, 2020","University Hospital Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04647682,France,,12.0,2021,Friday
977,978,Effect of Using Barrier Devices for Intubation in COVID-19 Patients,Completed,Device: aerosol box|Device: transparent sheet,All,"Child, Adult, Older Adult",,13.0,"June 10, 2020",2020-06-30,"December 4, 2020","Kocaeli Derince Training and Research Hospital, Kocaeli, Izmit, Turkey",https://ClinicalTrials.gov/show/NCT04412226,Turkey,,6.0,2020,Tuesday
978,979,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Drug: Chloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,3217.0,"March 28, 2020",2021-02-14,"November 13, 2020","Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia",https://ClinicalTrials.gov/show/NCT04627467,Colombia,Chloroquine,2.0,2021,Sunday
979,980,Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients,Withdrawn,Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,0.0,April 2020,2020-09-01,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04371406,Undefined,Hydroxychloroquine and Azithromycin,9.0,2020,Tuesday
980,981,Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS,Not yet recruiting,Drug: AVM0703|Drug: Placebo|Drug: hydrocortisone,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,8.0,November 2020,2023-06-01,"September 18, 2020",,https://ClinicalTrials.gov/show/NCT04366115,Undefined,AVM0703|Placebo|hydrocortisone,6.0,2023,Thursday
981,982,COVID-19 and Mental Health,"Active, not recruiting",Other: Exposure to the SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"June 1, 2020",2021-06-01,"September 11, 2020","Northeastern University, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04407195,United States,,6.0,2021,Tuesday
982,983,Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients,Available,Biological: COVID-19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",,,,,"June 9, 2020","Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04420988,Jersey,,,n,
983,984,COVID-19 in Patients With Chronic Liver Diseases,Enrolling by invitation,Other: Prospective Chart Review,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 6, 2020",2021-06-01,"July 27, 2020","University of Arizona,, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|UCSF Fresno, Fresno, California, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Georgetown University, Washington, District of Columbia, United States|VA Medical Center, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Oschner Medical Center, Baton Rouge, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Hennepin County Medical Center (HCMC), Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04439084,Israel,,6.0,2021,Tuesday
984,985,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,Drug: TD-0903|Drug: Placebo,All,18 Years to 50 Years   (Adult),Phase 1,54.0,"April 23, 2020",2020-06-24,"September 2, 2020","Theravance Biopharma Investigational Site, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04350736,United Kingdom,TD-0903|Placebo,6.0,2020,Wednesday
985,986,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Not yet recruiting,Drug: rhDNase I,All,"18 Years and older   (Adult, Older Adult)",Phase 1,25.0,November 2020,2021-08-01,"October 28, 2020",,https://ClinicalTrials.gov/show/NCT04409925,Undefined,rhDNase I,8.0,2021,Sunday
986,987,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"Active, not recruiting",Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine,All,"Child, Adult, Older Adult",Phase 1,89.0,"September 26, 2020",2021-09-27,"September 29, 2020","A rehabilitation centre in Wuhan, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04568811,China,,9.0,2021,Monday
987,988,Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19,Not yet recruiting,Biological: SARS-CoV-2 convalescent plasma treatment|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,236.0,July 2020,2021-02-01,"June 11, 2020","Fundación Santa Fe de Bogotá, Bogotá, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04425837,Colombia,,2.0,2021,Monday
988,989,COVID-19 Saliva Test Research Study,Recruiting,Diagnostic Test: Saliva and NPS test,All,"18 Years to 117 Years   (Adult, Older Adult)",,400.0,"June 29, 2020",2020-09-29,"August 28, 2020","Gloucestershire Royal Hospital, Gloucester, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom",https://ClinicalTrials.gov/show/NCT04531501,United Kingdom,,9.0,2020,Tuesday
989,990,Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Biological: BM-MSCs|Biological: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,April 2020,2020-12-01,"April 15, 2020","Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04346368,China,,12.0,2020,Tuesday
990,991,"Australasian COVID-19 Trial (ASCOT): An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)",Recruiting,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2400.0,"July 28, 2020",2022-12-31,"November 23, 2020","Calvary Public Bruce Hospital, Bruce, Australian Capital Territory, Australia|The Canberra Hospital, Canberra, Australian Capital Territory, Australia|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|The Sutherland Hospital, Caringbah, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Griffith Base Hospital, Griffith, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Lismore Base Hospital, Lismore, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Cairns Hospital, Cairns, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mackay Base Hospital, Mackay, Queensland, Australia|Logan Hospital, Meadowbrook, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Mater, South Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Townsville University Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Ballarat Health Services, Ballarat Central, Victoria, Australia|St John of God Ballarat Hospital, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital - Penninsula Health, Frankston, Victoria, Australia|Peninsula Private Hospital, Frankston, Victoria, Australia|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Latrobe Regional Hospital, Traralgon, Victoria, Australia|Northeast Health Wangaratta, Wangaratta, Victoria, Australia|West Gippsland Hospital, Warragul, Victoria, Australia|Albury Wodonga Health, Wodonga, Victoria, Australia|Rockingham General Hospital, Cooloongup, Western Australia, Australia|Joondalup Health Campus, Joondalup, Western Australia, Australia|St John of God Midland Public and Private Hospitals, Midland, Western Australia, Australia|Armadale Health Service, Mount Nasura, Western Australia, Australia|Fiona Stanley Hospita, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Knox Private Hospital, Wantirna, Australia",https://ClinicalTrials.gov/show/NCT04483960,Australia,Hydroxychloroquine|Lopinavir / Ritonavir,12.0,2022,Saturday
991,992,Niclosamide in COVID-19,Not yet recruiting,Drug: Niclosamide Oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,148.0,"November 1, 2020",2021-05-01,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04542434,Undefined,Niclosamide Oral Tablet|Placebo,5.0,2021,Saturday
992,993,Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19),Not yet recruiting,Drug: Fluoxetine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,40.0,September 2020,2021-10-01,"September 30, 2020","Milton S. Hershey Medical Center Clinical Research Center, Hershey, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04570449,United States,Fluoxetine|Placebo,10.0,2021,Friday
993,994,COVID-19 and the Developement of Phobic Fears of Disease,Recruiting,Other: Questionnaires for specific phobia,All,"18 Years to 90 Years   (Adult, Older Adult)",,600.0,"April 15, 2020",2024-04-15,"May 6, 2020","Medical University of Graz, Graz, Styria, Austria",https://ClinicalTrials.gov/show/NCT04359121,Austria,,4.0,2024,Monday
994,995,"Pharmacokinetics, Safety, and Tolerability of CSL760, an Anti- COVID-19 Hyperimmune Intravenous Immunoglobulin, in Healthy Adult Subjects",Not yet recruiting,Biological: CSL760,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24.0,December 2020,2021-04-01,"November 20, 2020",,https://ClinicalTrials.gov/show/NCT04638634,Undefined,,4.0,2021,Thursday
995,996,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,Recruiting,Biological: Bacille Calmette-Guérin (BCG)|Other: Placebo Comparator,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"May 4, 2020",2021-04-28,"May 7, 2020","TASK Foundation, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04379336,South Africa,,4.0,2021,Wednesday
996,997,Efficacy and Safety of COVID-19 Convalescent Plasma,Recruiting,Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 30, 2020",2021-04-29,"May 22, 2020","Institute for Transfusion Medicine of RNM, Skopje, North Macedonia",https://ClinicalTrials.gov/show/NCT04397523,Undefined,,4.0,2021,Thursday
997,998,N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia,Recruiting,"Other: Pro BNP , Vitamin D",All,"18 Years and older   (Adult, Older Adult)",,100.0,"July 1, 2020",2021-01-01,"July 27, 2020","Kasr Alainy Cairo University, Cairo, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04487951,Egypt,,1.0,2021,Friday
998,999,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,120.0,"December 16, 2020",2022-09-01,"December 11, 2020","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04565067,United States,,9.0,2022,Thursday
999,1000,Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population,"Active, not recruiting",,All,"10 Years to 50 Years   (Child, Adult)",,250.0,"April 1, 2020",2021-01-01,"December 7, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04653857,France,,1.0,2021,Friday
1000,1001,Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.,Not yet recruiting,Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,75.0,September 2020,2021-06-01,"July 10, 2020","LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia",https://ClinicalTrials.gov/show/NCT04395170,Colombia,Standard (specific) therapy for COVID-19,6.0,2021,Tuesday
1001,1002,COVID-19 IgG Antibodies in the Serum of Recovered Patients,Not yet recruiting,Diagnostic Test: IgG antibodies immunoassay,All,"20 Years and older   (Adult, Older Adult)",,100.0,"August 1, 2020",2021-09-01,"July 16, 2020","Faculty of medicine- Assiut university, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04470414,Egypt,,9.0,2021,Wednesday
1002,1003,Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,90.0,"April 16, 2020",2021-07-01,"December 10, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04348240,United States,,7.0,2021,Thursday
1003,1004,"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",No longer available,Drug: Remestemcel-L,All,"18 Years and older   (Adult, Older Adult)",,,,,"April 29, 2020","Mount Sinai Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04366830,United States,Remestemcel-L,,n,
1004,1005,COVID-19 Project ECHO in Nursing Homes,Not yet recruiting,Other: Project ECHO,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"December 12, 2020",2022-07-01,"November 20, 2020",,https://ClinicalTrials.gov/show/NCT04499391,Undefined,,7.0,2022,Friday
1005,1006,Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia,Enrolling by invitation,"Diagnostic Test: spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire",All,"18 Years to 80 Years   (Adult, Older Adult)",,37.0,"October 15, 2020",2021-03-01,"October 23, 2020","Koç University Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04599998,Turkey,,3.0,2021,Monday
1006,1007,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,Completed,,All,70 Years and older   (Older Adult),,100.0,"May 7, 2020",2020-09-07,"November 25, 2020","Service SSR Gériatrique, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04427358,France,,9.0,2020,Monday
1007,1008,Oral 25-hydroxyvitamin D3 and COVID-19,Recruiting,Drug: Oral 25-Hydroxyvitamin D3,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,1500.0,"April 14, 2020",2021-03-15,"June 12, 2020","Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04386850,"Iran, Islamic Republic of",Oral 25-Hydroxyvitamin D3,3.0,2021,Monday
1008,1009,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Not yet recruiting,"Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,January 2021,2023-01-01,"October 5, 2020","Fondation A de Rothschild, Paris, France",https://ClinicalTrials.gov/show/NCT04427254,France,"Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies",1.0,2023,Sunday
1009,1010,TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study),Not yet recruiting,Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1378.0,"July 31, 2020",2020-11-15,"July 28, 2020","Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina",https://ClinicalTrials.gov/show/NCT04405271,Argentina,Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Placebo,11.0,2020,Sunday
1010,1011,Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"April 1, 2020",2021-03-31,"April 13, 2020","Ospedale San Salvatore, L'Aquila, Italy",https://ClinicalTrials.gov/show/NCT04332913,Italy,,3.0,2021,Wednesday
1011,1012,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),"Active, not recruiting",Drug: Sarilumab|Other: Standar of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 13, 2020",2020-12-01,"November 10, 2020","Hospital Universitario de la Princesa, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04357808,Spain,Sarilumab,12.0,2020,Tuesday
1012,1013,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,Dietary Supplement: Oxaloacetate Medical Food/Dietary Supplement,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40.0,"October 15, 2020",2021-06-15,"October 19, 2020","Energy Medicine research Institute, Boulder, Colorado, United States",https://ClinicalTrials.gov/show/NCT04592354,United States,,6.0,2021,Tuesday
1013,1014,Seroconversion in COVID-19 Recovered Population,"Active, not recruiting",Diagnostic Test: IgG SARS CoV2,All,"Child, Adult, Older Adult",,275.0,"July 1, 2020",2020-10-30,"September 23, 2020","Lahore General Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04558385,Pakistan,,10.0,2020,Friday
1014,1015,CLBS119 for Repair of COVID-19 Induced Pulmonary Damage,Recruiting,Biological: CLBS119,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,"October 5, 2020",2021-05-01,"October 9, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04522817,United States,,5.0,2021,Saturday
1015,1016,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,Other: Discontinuation of ACEi/ARB|Other: Continuation of ACEi/ARB,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,215.0,"May 18, 2020",2020-12-01,"June 5, 2020","Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Capital Region Of Denmark, Denmark|Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Capital Region Of Denmark, Denmark",https://ClinicalTrials.gov/show/NCT04351581,Denmark,,12.0,2020,Tuesday
1016,1017,CICERO- A Care Home Study of COVID-19,Not yet recruiting,Diagnostic Test: Q16 testing|Diagnostic Test: Nasopharyngeal swab and main laboratory,All,"18 Years to 130 Years   (Adult, Older Adult)",Not Applicable,50.0,"July 2, 2020",2020-09-28,"July 1, 2020","Queen Mary University London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04453553,United Kingdom,,9.0,2020,Monday
1017,1018,The Clinical Study of Carrimycin on Treatment Patients With COVID-19,Not yet recruiting,Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,520.0,"February 23, 2020",2021-02-28,"February 27, 2020",,https://ClinicalTrials.gov/show/NCT04286503,Undefined,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,2.0,2021,Sunday
1018,1019,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Other: Placebo Tablet|Other: Placebo capsules,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,456.0,"April 14, 2020",2020-08-30,"July 30, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04349592,Qatar,Hydroxychloroquine|Azithromycin,8.0,2020,Sunday
1019,1020,"Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.",Recruiting,Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 27, 2020",2022-03-01,"April 15, 2020","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy",https://ClinicalTrials.gov/show/NCT04345315,Italy,,3.0,2022,Tuesday
1020,1021,Vitamin D on Prevention and Treatment of COVID-19,Not yet recruiting,Dietary Supplement: Vitamin D,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200.0,"April 10, 2020",2020-06-30,"April 7, 2020","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain",https://ClinicalTrials.gov/show/NCT04334005,Spain,,6.0,2020,Tuesday
1021,1022,COVID-19 PCR Test Results in Asymptomatic Pregnants,Completed,Diagnostic Test: Reverse transcription polymerase chain reaction,Female,"Child, Adult, Older Adult",,179.0,"April 10, 2020",2020-05-21,"June 1, 2020","Istanbul Medipol University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04410939,Turkey,,5.0,2020,Thursday
1022,1023,Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,Completed,Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux,All,"18 Years and older   (Adult, Older Adult)",,90.0,"May 1, 2020",2020-07-31,"September 17, 2020","Giuseppe Camporese, Padova, Italy",https://ClinicalTrials.gov/show/NCT04359212,Italy,thromboprophylaxis with low-molecular-weight heparin or fondaparinux,7.0,2020,Friday
1023,1024,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,100.0,"March 5, 2020",2020-07-09,"August 19, 2020","General Hospital of Central Theater Command, Wuhan, Hubei, China|Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04288102,China,,7.0,2020,Thursday
1024,1025,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine,Completed,Drug: Corticosteroid with or without colchicine,All,"18 Years and older   (Adult, Older Adult)",,301.0,"March 20, 2020",2020-08-20,"December 4, 2020","Clínica Medellín - Grupo Quirónsalud, Medellín, Antioquia, Colombia",https://ClinicalTrials.gov/show/NCT04654416,Colombia,Corticosteroid with or without colchicine,8.0,2020,Thursday
1025,1026,Detection of COVID-19 Decompensation,Enrolling by invitation,"Device: Use of the pinpointIQ solution (physIQ, Inc.)",All,"18 Years and older   (Adult, Older Adult)",,400.0,"October 5, 2020",2021-01-22,"October 5, 2020","University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04575532,United States,,1.0,2021,Friday
1026,1027,"COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7",Not yet recruiting,"Combination Product: Tomeka®|Drug: ""Vernonia amygdalina""",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,2000.0,November 2020,2022-12-01,"September 3, 2020","Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the",https://ClinicalTrials.gov/show/NCT04537585,Congo,"""Vernonia amygdalina""",12.0,2022,Thursday
1027,1028,Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).,Recruiting,Diagnostic Test: COVID-19 test|Diagnostic Test: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",,140.0,"October 26, 2020",2021-12-01,"November 17, 2020","Sherbrooke University, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04632732,Canada,,12.0,2021,Wednesday
1028,1029,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3.0,"May 13, 2020",2020-11-04,"November 6, 2020","František Duška, Praha, Česká Republika, Czechia",https://ClinicalTrials.gov/show/NCT04339816,Undefined,Azithromycin|Hydroxychloroquine|Placebo,11.0,2020,Wednesday
1029,1030,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,Recruiting,Drug: Brequinar|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"November 19, 2020",2021-02-28,"December 9, 2020","Central Alabama Research, Homewood, Alabama, United States|Ark Clinical Research, Long Beach, California, United States|Doral Medical Research, Doral, Florida, United States|IACT Health, Columbus, Georgia, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Wilmington Health, Wilmington, North Carolina, United States|Remington-Davis, Inc., Columbus, Ohio, United States|VitaLink - Gaffney, Gaffney, South Carolina, United States|Self Regional Healthcare Research Center - Self Medical Group, Greenwood, South Carolina, United States|VitaLink Research, Spartanburg, South Carolina, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Centex Studies, Inc. - McAllen, McAllen, Texas, United States|Synexus Clinical Research US, Inc. - Olympus Family Medicine, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04575038,Georgia,Brequinar|Placebo,2.0,2021,Sunday
1030,1031,COVID-19 and Hereditary Metabolic Diseases,Not yet recruiting,,All,"Child, Adult, Older Adult",,77.0,January 2021,2023-01-01,"November 27, 2020",,https://ClinicalTrials.gov/show/NCT04645498,Undefined,,1.0,2023,Sunday
1031,1032,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Recruiting,Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,122.0,April 2020,2020-08-01,"April 17, 2020","Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France",https://ClinicalTrials.gov/show/NCT04347980,France,Dexamethasone and Hydroxychloroquine|Hydroxychloroquine,8.0,2020,Saturday
1032,1033,Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,Biological: Tigerase® and best available care|Other: Best available care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"June 1, 2020",2020-07-20,"October 14, 2020","City Clinical Hospital #15, Moscow, Russian Federation|I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation|City Clinical Hospital #51, Moscow, Russian Federation|City Clinical Hospital #52, Moscow, Russian Federation|N.V. Sklifosovsky Scientific Research Institute of First Aid, Moscow, Russian Federation|Siberian State Medical University (SibMed), Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04459325,Russian Federation,,7.0,2020,Monday
1033,1034,COVID 19 Serology in Pulmonologists,Completed,,All,"18 Years and older   (Adult, Older Adult)",,97.0,"May 1, 2020",2020-05-30,"June 9, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04422574,France,,5.0,2020,Saturday
1034,1035,Home Pulse Oximeter Use in Patients With COVID-19,Completed,Device: Home Pulse Oximetry Monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,209.0,"March 20, 2020",2020-04-22,"May 6, 2020","Swedish Hospital, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04373161,United States,,4.0,2020,Wednesday
1035,1036,A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease,Not yet recruiting,Drug: Tafenoquine Oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,275.0,October 2020,2021-02-01,"August 31, 2020",,https://ClinicalTrials.gov/show/NCT04533347,Undefined,Tafenoquine Oral Tablet|Placebo,2.0,2021,Monday
1036,1037,COVID-19 Watch + COVID-19 Pulse,Not yet recruiting,Device: pulse oximeter|Other: COVID Watch,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,850.0,"December 5, 2020",2021-10-31,"November 19, 2020",,https://ClinicalTrials.gov/show/NCT04581863,Undefined,,10.0,2021,Sunday
1037,1038,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,Recruiting,Drug: Standard of Care (SOC) + ANG-3777|Drug: Standard Of Care (SOC) + Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"July 31, 2020",2020-10-01,"August 4, 2020","UPCLIN - Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP), Ribeirão Preto, Brazil|Hospital Guilherme Alvaro, Santos, Brazil|Escola Paulista de Medicina (Universidade Federal de São Paulo), São Paulo, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, Brazil|Hospital Heliópolis-SP, São Paulo, Brazil|Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04459676,Brazil,Standard of Care (SOC) + ANG-3777|Standard Of Care (SOC) + Placebo,10.0,2020,Thursday
1038,1039,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,Drug: Rivaroxaban|Other: Placebo|Other: Standard of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,4000.0,"August 13, 2020",2021-04-06,"November 16, 2020","University of Arizona, Tucson, Arizona, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Florida Hospital Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northshore Universite Healthsystem, Evanston, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Lenox Hill Hospital -Northwell Health, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04508023,Georgia,Rivaroxaban,4.0,2021,Tuesday
1039,1040,Longitudinal COVID-19 Cohort Study,Recruiting,Other: COVID-19+ observational,All,"18 Years and older   (Adult, Older Adult)",,225.0,"April 16, 2020",2023-05-31,"December 8, 2020","University of Vermont College of Medicine, Burlington, Vermont, United States",https://ClinicalTrials.gov/show/NCT04393155,United States,,5.0,2023,Wednesday
1040,1041,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,"Active, not recruiting",Drug: Sodium Bicarbonate,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"August 1, 2020",2020-11-01,"October 6, 2020","Gomhoria Street, Mansoura, Outside U.S./Canada, Egypt",https://ClinicalTrials.gov/show/NCT04374591,Canada,Sodium Bicarbonate,11.0,2020,Sunday
1041,1042,Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,"Active, not recruiting",,All,"18 Years to 99 Years   (Adult, Older Adult)",,200.0,"April 1, 2019",2020-10-20,"April 27, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04355715,France,,10.0,2020,Tuesday
1042,1043,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,Other: Nasal lavage,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"September 24, 2020",2020-12-31,"September 22, 2020","Augusta University, Augusta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04559035,Georgia,,12.0,2020,Thursday
1043,1044,ACTIV-3: Therapeutics for Inpatients With COVID-19,"Active, not recruiting",Drug: LY3819253|Drug: Placebo|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10000.0,"August 4, 2020",2021-07-01,"November 9, 2020","Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States|Community Regional Medical Center (Site 203-005), 2823 Fresno Street, Fresno, California, United States|Keck Hospital of USC (Site 301-020), 1500 San Pablo Street, Los Angeles, California, United States|Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd., Los Angeles, California, United States|Mount Zion Hospital, UCSF Medical Center (Site 203-007), 1600 Divisadero St., San Francisco, California, United States|San Francisco VA Healthcare System (Site 074-002), 4150 Clement St., San Francisco, California, United States|Moffitt-Long Hospital, UCSF Medical Center (Site 203-001), 505 Parnassus Ave., San Francisco, California, United States|Stanford University Hospital & Cinics (Site 203-003), 300 Pasteur Dr., Stanford, California, United States|University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue, Aurora, Colorado, United States|Denver Public Health (Site 017-004), 605 Bannock St., MC2600 (Infectious Disease Clinic), Denver, Colorado, United States|National Jewish Health (Site 204-003), 1400 Jackson Street, Denver, Colorado, United States|MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW, Washington, District of Columbia, United States|Bay Pines VA Healthcare System (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104, Bay Pines, Florida, United States|Miami VA Healthcare System (Site 074-003), 1201 NW 16 Street, Miami, Florida, United States|The Emory Clinic (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE, Atlanta, Georgia, United States|Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States|University of Kentucky Hospital (Site 210-004), 1000 South Limestone St., Lexington, Kentucky, United States|Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway, New Orleans, Louisiana, United States|University of Maryland (Site 301-019), 22 South Greene Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 202-002), 55 Fruit Street, Boston, Massachusetts, United States|Baystate Medical Center (Site 201-001), 759 Chestnut Street, Springfield, Massachusetts, United States|University of Michigan (Site 205-001), 1500 East Medical Center Drive, Ann Arbor, Michigan, United States|Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd., Detroit, Michigan, United States|Hennepin Healthcare (Site 027-001), 701 Park Avenue, Minneapolis, Minnesota, United States|University of Mississippi Medical Center (Site 202-005), 2500 North State Street, Jackson, Mississippi, United States|Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive, Lebanon, New Hampshire, United States|Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road, Bronx, New York, United States|Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street, Bronx, New York, United States|Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation (Site 207-001), 9410 Carnegie Avenue, L15, Cleveland, Ohio, United States|Cleveland Clinic Foundation (Site 207-005), 9500 Euclid Avenue, Cleveland, Ohio, United States|Cleveland Clinic Foundation (Site 207-006), 9500 Euclid Avenue, Cleveland, Ohio, United States|Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd., Portland, Oregon, United States|Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive, Nashville, Tennessee, United States|UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor, Dallas, Texas, United States|Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave., Dallas, Texas, United States|Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd., Houston, Texas, United States|Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street, Murray, Utah, United States|University of Utah Health (Site 211-002), 419 Wakara Way, Suite 207, Salt Lake City, Utah, United States|University of Virginia (Site 301-021), 1215 Lee Street, Charlottesville, Virginia, United States|Virginia Commonwealth University Health System (Site 210-005), 1250 East Marshall Street, Richmond, Virginia, United States|Harborview Medical Center (Site 208-001), 325 9th Avenue, Seattle, Washington, United States|University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street, Seattle, Washington, United States|WVU Medicine (Site 301-023), One Medical Center Drive, Morgantown, West Virginia, United States|Aalborg University Hospital (Site 625-005), Hobrovej 18, Aalborg, Denmark|Department of Infectious Diseases (Site 625-002), Aarhus University Hospital, Skejby, Palle Juul-Hensens Boulevard 99, Aarhus N, Denmark|Righospitalet (Site 625-006), Blegdamsvej 9,, Copenhagen Ø, Denmark|Herlev Hospital (Site 625-012), Medicinsk Afdeling, Herlev Ringvej 75, Herlev, Denmark|Nordsjællands Hospital (Site 625-009), Dyrehavevej 29, Hillerød, Denmark|Hvidovre Hospital (Site 625-001), Department of Infectious Diseases, Kettegård allé 30, Hvidovre, Denmark|Medicinsk Afdeling (Site 625-011), Kolding Sygehus, Sygehusvej 24, Kolding, Denmark|Odense Universitetshospital (Site 625-004), Infektionsmedicinsk Forskningsenhed,J.B. Winsløwsgade 4, Odense, Denmark|Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng, Singapore, Singapore|Germans Trias i Pujol Hospital (Site 626-003), Unidad de enfermedades infecciosas, Carretera de Canyet s/n, Badalona, Barcelona, Spain|Hospital Del Mar (Site 626-025), Paseo Maritimo 25-29, Barcelona, Spain|Hospital Clínic de Barcelona (Site 626-004), Carrer de Villaroel 170, Barcelona, Spain|Hospital General Universitario Gregorio Marañón (Site 626-001), Dr. Esquerdo, 46, Madrid, Spain|Hospital Clinico San Carlos (Site 626-017), Enfermedades infecciosas, C/Martin Lagos CN, Madrid, Spain|UCICEC (Clinical Trial Unit) Hospital Universitario La Paz (Site 626-012), Paseo de la Castellana 261, 2° planta Hospital Maternal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04501978,Denmark,LY3819253|Placebo|Remdesivir,7.0,2021,Thursday
1044,1045,COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1336.0,"June 15, 2020",2020-08-31,"December 4, 2020","Medical University Innsbruck, Innsbruck, Tyrol, Austria",https://ClinicalTrials.gov/show/NCT04649333,Austria,,8.0,2020,Monday
1045,1046,Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"June 1, 2020",2020-11-09,"September 2, 2020","Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",https://ClinicalTrials.gov/show/NCT04323878,Italy,,11.0,2020,Monday
1046,1047,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",Recruiting,Other: COVID-19 exposure,Female,"Child, Adult, Older Adult",,50.0,"November 17, 2020",2022-06-30,"December 9, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04659759,United States,,6.0,2022,Thursday
1047,1048,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment,Completed,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 8, 2020",2020-09-30,"October 8, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04343339,France,,9.0,2020,Wednesday
1048,1049,The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia,Not yet recruiting,Drug: Imatinib Mesylate|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30.0,June 2020,2020-10-01,"June 9, 2020",,https://ClinicalTrials.gov/show/NCT04422678,Undefined,Imatinib Mesylate|Standard of Care,10.0,2020,Thursday
1049,1050,Treat COVID-19 Patients With Regadenoson,Not yet recruiting,Drug: Regadenoson|Other: Placebo Control,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"November 1, 2020",2022-01-31,"October 28, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04606069,United States,Regadenoson,1.0,2022,Monday
1050,1051,Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece,Completed,Other: Online Survey about Dietary and Lifestyle Habits,All,"24 Months to 18 Years   (Child, Adult)",,397.0,"April 30, 2020",2020-05-24,"June 18, 2020","Department of Nutrition-Dietetics, Tríkala, Thessaly, Greece",https://ClinicalTrials.gov/show/NCT04437121,Greece,,5.0,2020,Sunday
1051,1052,Elmo Respiratory Support Project - COVID-19,Recruiting,Other: ELMO PROJECT AT COVID-19: STUDY IN HUMANS|Device: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"August 2, 2020",2020-12-01,"November 27, 2020","Hospital Leonardo Da Vinci, Fortaleza, Brazil",https://ClinicalTrials.gov/show/NCT04470258,Brazil,,12.0,2020,Tuesday
1052,1053,COVID 19-Caregivers IGg Seroconversion,Not yet recruiting,Other: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",,130.0,"May 25, 2020",2020-12-25,"May 11, 2020","CHU de Limoges, Limoges, France",https://ClinicalTrials.gov/show/NCT04353323,France,,12.0,2020,Friday
1053,1054,"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)",Available,Biological: Remestemcel-L|Drug: Hydrocortisone|Drug: Diphenhydramine,All,2 Months to 17 Years   (Child),,,,,"October 23, 2020",,https://ClinicalTrials.gov/show/NCT04456439,Undefined,Hydrocortisone|Diphenhydramine,,n,
1054,1055,COVID-19 Risk From Attending Outpatient Appointments,"Active, not recruiting",Other: Observational,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",,34000.0,"January 1, 2020",2021-01-01,"September 14, 2020","Nottingham University Hospitals, NHS Trust, Nottingham, Nottinghamshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04544176,United Kingdom,,1.0,2021,Friday
1055,1056,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),Recruiting,Diagnostic Test: Rapid Diagnostic Test vs PCR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1250.0,"September 25, 2020",2020-12-31,"November 12, 2020","Unisanté, Lausanne, Vaud, Switzerland",https://ClinicalTrials.gov/show/NCT04613310,Switzerland,,12.0,2020,Thursday
1056,1057,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,Recruiting,Device: Telerehabilitation,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 11, 2020",2021-03-01,"May 21, 2020","Clinical exercise Physiology and rehabilitation research laboratory, Lamia, Greece",https://ClinicalTrials.gov/show/NCT04368845,Greece,,3.0,2021,Monday
1057,1058,EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA,Withdrawn,Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"June 2, 2020",2020-06-02,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04347512,Undefined,Hydroxychloroquine and azithromycin treatment arm.|Hydroxychloroquine|Control arm,6.0,2020,Tuesday
1058,1059,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,Not yet recruiting,Biological: Decidual Stromal Cells (DSC),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20.0,"August 24, 2020",2021-02-24,"August 11, 2020","Toronto General Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04451291,Canada,,2.0,2021,Wednesday
1059,1060,"COVID-19 Vaccine Messaging, Part 1",Completed,Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery message,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4000.0,"July 3, 2020",2020-07-08,"July 21, 2020","Yale University, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04460703,United States,,7.0,2020,Wednesday
1060,1061,Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized),Not yet recruiting,Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1000.0,October 2020,2020-12-01,"October 26, 2020","Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04353180,Egypt,Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Standard treatment,12.0,2020,Tuesday
1061,1062,WHO COVID-19 Solidarity Trial for COVID-19 Treatments,Not yet recruiting,Drug: Remdesivir|Drug: Acalabrutinib|Drug: Interferon beta-1a|Other: Standard of Care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,100.0,"December 1, 2020",2021-12-31,"December 1, 2020","Univeristy of the West Indies, Kingston, Jamaica",https://ClinicalTrials.gov/show/NCT04647669,Jamaica,Remdesivir|Acalabrutinib|Interferon beta-1a,12.0,2021,Friday
1062,1063,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Recruiting,Device: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35.0,"June 1, 2020",2021-07-01,"July 20, 2020","Zan Mitrev Clinic, Skopje, North Macedonia",https://ClinicalTrials.gov/show/NCT04478539,Undefined,,7.0,2021,Thursday
1063,1064,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Completed,Device: Active PBMT/sMF|Device: Placebo PBMT/sMF,All,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,30.0,"May 18, 2020",2020-09-17,"October 29, 2020","Hospital Tacchini, Bento Gonçalves, RS, Brazil",https://ClinicalTrials.gov/show/NCT04386694,Brazil,,9.0,2020,Thursday
1064,1065,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500.0,"April 8, 2020",2021-05-08,"May 6, 2020","Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel",https://ClinicalTrials.gov/show/NCT04377750,Israel,Tocilizumab,5.0,2021,Saturday
1065,1066,The Corona and COVID-19 Study in Telemark and Agder,Recruiting,,All,"18 Years to 85 Years   (Adult, Older Adult)",,5000.0,"July 1, 2020",2035-12-31,"August 18, 2020","Telemark Hospital, Skien, Vestfold And Telemark, Norway",https://ClinicalTrials.gov/show/NCT04514003,Norway,,12.0,2035,Monday
1066,1067,Impact of the COVID-19 Pandemic on Vaccination,Recruiting,Other: Vaccine coverage assessment,All,"18 Years and older   (Adult, Older Adult)",,500.0,"November 1, 2020",2021-05-30,"December 10, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04657263,France,,5.0,2021,Sunday
1067,1068,Swallowing Impairment After COVID-19 Infection,Not yet recruiting,Diagnostic Test: Videofluoroscopic Swallowing Study (VFSS),All,"18 Years and older   (Adult, Older Adult)",,75.0,"November 15, 2020",2021-12-31,"November 3, 2020","University of Florida, Gainesville, Florida, United States|McMaster University, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04537650,Canada,,12.0,2021,Friday
1068,1069,Sex-Informed Data in the COVID-19 Pandemic.,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,88.0,"September 1, 2020",2022-06-01,"November 18, 2020","Sapienza University of Rome - Policlinico Umberto I Roma, Rome, Italy",https://ClinicalTrials.gov/show/NCT04497402,Italy,,6.0,2022,Wednesday
1069,1070,Predictors of Severe COVID-19 Outcomes,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"May 28, 2020",2021-03-01,"November 19, 2020","University of Illinois at Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Inova Health Care Services, Falls Church, Virginia, United States",https://ClinicalTrials.gov/show/NCT04388813,United States,,3.0,2021,Monday
1070,1071,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,Recruiting,Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,60.0,"June 27, 2020",2021-05-01,"July 15, 2020","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04353206,United States,,5.0,2021,Saturday
1071,1072,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,Completed,Other: COVID-19 and Intensive Care,All,"18 Years and older   (Adult, Older Adult)",,9905.0,"May 27, 2020",2020-06-04,"August 25, 2020","Björn Ahlström, Falun, Sweden",https://ClinicalTrials.gov/show/NCT04390074,Sweden,,6.0,2020,Thursday
1072,1073,COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis,Not yet recruiting,Drug: Apixaban 2.5 MG|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,5320.0,December 2020,2021-09-01,"December 2, 2020",,https://ClinicalTrials.gov/show/NCT04650087,Undefined,Apixaban 2.5 MG|Placebo,9.0,2021,Wednesday
1073,1074,Nebulized PL for Post-COVID-19 Syndrome,Recruiting,Biological: Nebulized Platelet Lysate|Other: Nebulized Sterile Saline,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40.0,"December 8, 2020",2021-12-30,"December 4, 2020","Centeno-Schultz Clinic, Broomfield, Colorado, United States",https://ClinicalTrials.gov/show/NCT04487691,United States,,12.0,2021,Thursday
1074,1075,National Covid-19 Surveillance Physicians,Recruiting,Diagnostic Test: Antibody test (SARS-CoV2),All,"18 Years to 99 Years   (Adult, Older Adult)",,600.0,"June 1, 2020",2020-09-30,"July 8, 2020","University Hospital Duesseldorf, Dept. of Anesthesiology, Duesseldorf, Germany",https://ClinicalTrials.gov/show/NCT04459312,Germany,,9.0,2020,Wednesday
1075,1076,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Completed,Device: Spartan COVID-19 System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,27.0,"June 28, 2020",2020-08-30,"November 13, 2020","Humber River Hospital, North York, Ontario, Canada|The Univeristy of Ottawa Heart Institute, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04473248,Canada,,8.0,2020,Sunday
1076,1077,Dysphagia Management During COVID-19 Pandemic,Not yet recruiting,Other: Survey,All,25 Years to 60 Years   (Adult),,50.0,"August 20, 2020",2020-11-30,"August 12, 2020","Hacetttepe University, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04509752,Turkey,,11.0,2020,Monday
1077,1078,FREEDOM COVID-19 Anticoagulation Strategy,Recruiting,Drug: Enoxaparin|Drug: Apixaban,All,"18 Years and older   (Adult, Older Adult)",Phase 4,3600.0,"September 8, 2020",2021-06-01,"October 14, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04512079,United States,Enoxaparin|Apixaban,6.0,2021,Tuesday
1078,1079,TREM-1 Pathway Activation in COVID-19,Not yet recruiting,Other: blood sampling,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"October 1, 2020",2023-04-01,"September 10, 2020","CHRU Limoges, Limoges, France|Central hospital, Nancy, France",https://ClinicalTrials.gov/show/NCT04544891,France,,4.0,2023,Saturday
1079,1080,Forecast Number of Covid-19 Cases Worldwide,Completed,Other: Model Building|Other: Model validation,All,"Child, Adult, Older Adult",,7882471.0,"December 31, 2019",2020-06-20,"July 8, 2020","Republic of Turkey, Health Sciences University, Izmir Bozyaka Education and Training Hospital, İzmir, Turkey",https://ClinicalTrials.gov/show/NCT04460274,Turkey,,6.0,2020,Saturday
1080,1081,Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva,Recruiting,Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Saliva sample|Other: Data collection,All,"Child, Adult, Older Adult",,2750.0,October 2020,2021-06-01,"October 30, 2020","SARS-CoV-2 screening device of Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France",https://ClinicalTrials.gov/show/NCT04578509,France,,6.0,2021,Tuesday
1081,1082,Convalescent Plasma in Outpatients With COVID-19,Enrolling by invitation,Biological: Convalescent Plasma|Biological: Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,"August 11, 2020",2022-12-01,"December 4, 2020","Chandler Regional Medical Center, Chandler, Arizona, United States|Valleywise Health Medical Center, Phoenix, Arizona, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Cooper University Hospital, Camden, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Utah Healthcare, Salt Lake City, Utah, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04355767,Georgia,,12.0,2022,Thursday
1082,1083,Study for Quantitative Analysis of the Recovered COVID-19 Patients by <Sup>18<Sup>F-FDG-PET/CT,"Active, not recruiting",,All,"18 Years to 85 Years   (Adult, Older Adult)",,60.0,"July 1, 2020",2023-07-31,"August 19, 2020","Hongjun Jin, Zhuhai, Guangzhou, China",https://ClinicalTrials.gov/show/NCT04519255,China,,7.0,2023,Monday
1083,1084,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Recruiting,Dietary Supplement: L-citrulline|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"November 2, 2020",2021-09-15,"November 6, 2020","Brest University Hospital, Brest, Britanny, France|Rennes University Hospital, Rennes, Britanny, France|Saint-Malo Hospital, Saint-Malo, Britanny, France|Vannes Hospital, Vannes, Britanny, France|Angers University Hospital, Angers, France",https://ClinicalTrials.gov/show/NCT04404426,France,,9.0,2021,Wednesday
1084,1085,Healthy Volunteer COVID-19 Antibody Testing Study,Not yet recruiting,Diagnostic Test: COVID-19 antibody point of care test kit,All,"18 Years and older   (Adult, Older Adult)",,200.0,"September 1, 2020",2021-04-30,"September 14, 2020",,https://ClinicalTrials.gov/show/NCT04529460,Undefined,,4.0,2021,Friday
1085,1086,Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients,"Active, not recruiting",Other: retrospective metagenomics on clinical samples collected during hospitalization,All,"18 Years and older   (Adult, Older Adult)",,180.0,"March 9, 2020",2020-12-31,"August 18, 2020","CHU Henri Mondor, Créteil, France",https://ClinicalTrials.gov/show/NCT04516486,France,,12.0,2020,Thursday
1086,1087,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,Recruiting,Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"September 9, 2020",2021-12-31,"September 11, 2020","National Institute of Integrative Medicine, Melbourne, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04395768,Australia,Hydroxychloroquine|Azithromycin,12.0,2021,Friday
1087,1088,Using Smart Watches to Detect and Monitor COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100000.0,"April 2, 2020",2022-02-01,"November 10, 2020","Duke University, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04623047,United States,,2.0,2022,Tuesday
1088,1089,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,Recruiting,Drug: Melphalan|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 30, 2020",2020-10-30,"May 12, 2020","Kirill Zykov, Moscow, Russian Federation|Clinical hospital, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04380376,Russian Federation,Melphalan,10.0,2020,Friday
1089,1090,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device),All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"April 14, 2020",2022-04-01,"October 27, 2020","Hôpital d'Instruction des Armées Laveran, Marseille, France|Centre Hospitalier Intercommunal de Toulon - La Seyne-sur-Mer, Toulon, France|Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France",https://ClinicalTrials.gov/show/NCT04344431,France,,4.0,2022,Friday
1090,1091,Convalescent Plasma for COVID-19 Patients,Enrolling by invitation,Biological: Convalescent COVID 19 Plasma,All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,10.0,"August 1, 2020",2020-12-30,"August 20, 2020","Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam",https://ClinicalTrials.gov/show/NCT04516954,Undefined,,12.0,2020,Wednesday
1091,1092,The Prevent Severe COVID-19 (PRESECO) Study,Not yet recruiting,Drug: Favipiravir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,826.0,November 2020,2021-10-01,"October 23, 2020",,https://ClinicalTrials.gov/show/NCT04600895,Undefined,Favipiravir|Placebo,10.0,2021,Friday
1092,1093,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 11, 2020",2021-02-01,"June 26, 2020","Karolinska University Hospital, Huddinge, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04412291,Sweden,Anakinra Prefilled Syringe|Tocilizumab Prefilled Syringe|Standard-of-care treatment,2.0,2021,Monday
1093,1094,"ARB, ACEi, DRi in COVID-19",Recruiting,Drug: Angiotensin converting enzyme inhibitor,All,"18 Years to 90 Years   (Adult, Older Adult)",,10.0,"April 1, 2020",2021-08-01,"April 28, 2020","Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukraine",https://ClinicalTrials.gov/show/NCT04364984,Ukraine,Angiotensin converting enzyme inhibitor,8.0,2021,Sunday
1094,1095,Antibiotic Misuse During COVID-19 Pandemic,Completed,Other: online questionnaires,All,"20 Years and older   (Adult, Older Adult)",,413.0,"July 20, 2020",2020-09-15,"December 10, 2020","BeniSuefU, Cairo, BeniSuef, Egypt",https://ClinicalTrials.gov/show/NCT04553055,Egypt,,9.0,2020,Tuesday
1095,1096,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Drug: Low dose Low molecular weight heparin or Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,172.0,"November 12, 2020",2021-09-30,"November 18, 2020","Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Marienkrankenhaus, Hamburg, Germany|Universitärsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hanover, Germany|Krankenhaus Köln-Merheim, Köln, Germany|TU München Klinikum rechts der Isar, München, Germany|Universitätsklinikum Münster, Münster, Germany",https://ClinicalTrials.gov/show/NCT04542408,Germany,Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Low dose Low molecular weight heparin or Placebo,9.0,2021,Thursday
1096,1097,Covid-19: Possible Role of Neutrophil Extracellular Traps,Recruiting,Diagnostic Test: NETosis markers,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 1, 2020",2021-12-31,"July 8, 2020","Univeristy of Verona, Verona, Italy",https://ClinicalTrials.gov/show/NCT04412382,Italy,,12.0,2021,Friday
1097,1098,Urine Alkalinisation to Prevent AKI in COVID-19,Not yet recruiting,Drug: Sodium Bicarbonate 150Meq/L/D5W Inj,All,"18 Years and older   (Adult, Older Adult)",Phase 3,80.0,"February 1, 2021",2022-03-30,"December 7, 2020",,https://ClinicalTrials.gov/show/NCT04655716,Undefined,Sodium Bicarbonate 150Meq/L/D5W Inj,3.0,2022,Wednesday
1098,1099,Convalescent Plasma for Severe COVID-19 Patients,Recruiting,Biological: Convalescent Plasma|Other: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160.0,"July 16, 2020",2021-10-01,"September 14, 2020","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04547660,Brazil,,10.0,2021,Friday
1099,1100,Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19),Recruiting,,All,"Child, Adult, Older Adult",,186.0,"July 20, 2020",2021-06-30,"August 11, 2020","Mekelle University College of Health Sciences, Mekelle, Ethiopia",https://ClinicalTrials.gov/show/NCT04473365,Ethiopia,,6.0,2021,Wednesday
1100,1101,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,Not yet recruiting,Drug: Acebilustat|Drug: Camostat,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,240.0,January 2021,2022-01-01,"December 11, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04662086,United States,Acebilustat|Camostat,1.0,2022,Saturday
1101,1102,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Drug: Interferon beta-1b|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"November 20, 2020",2021-09-30,"December 10, 2020","Queen Mary Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04647695,Hong Kong,Interferon beta-1b|Remdesivir,9.0,2021,Thursday
1102,1103,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Recruiting,Biological: Mesenchymal stromal cells|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"September 15, 2020",2022-01-01,"November 6, 2020","Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04615429,Spain,,1.0,2022,Saturday
1103,1104,Modulation of Hyperinflammation in COVID-19,Recruiting,Device: Control group|Device: SLEDD with a L-MOD,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"April 28, 2020",2021-01-01,"September 18, 2020","University Hospital, London, Ontario, Canada|Victoria Hospital - Critical Care Trauma Centre, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04353674,Canada,,1.0,2021,Friday
1104,1105,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,Recruiting,Other: Smartphone-based voice and self-reported symptom collection,All,"12 Years and older   (Child, Adult, Older Adult)",,300.0,"September 10, 2020",2020-12-31,"October 9, 2020","UC San Diego Medical Center, San Diego, California, United States|Brigham & Woman's Hospital, Boston, Massachusetts, United States|Montefiore Medical Center, New York, New York, United States|Deenanath Mangeshkar Hospital & Research Centre, Pune, India",https://ClinicalTrials.gov/show/NCT04582331,India,,12.0,2020,Thursday
1105,1106,A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients,Not yet recruiting,Drug: Gargle/Mouthwash,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50.0,"August 1, 2020",2021-03-31,"June 26, 2020",,https://ClinicalTrials.gov/show/NCT04341688,Undefined,Gargle/Mouthwash,3.0,2021,Wednesday
1106,1107,Low Dose Radiotherapy for COVID-19 Pneumonitis,Recruiting,Radiation: Radiotherapy,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,41.0,"May 1, 2020",2020-09-08,"June 9, 2020","Servicio de Oncología Radioterápica. Hospital Clínico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04420390,Spain,,9.0,2020,Tuesday
1107,1108,Kidney Injury Severity and COVID-19,"Active, not recruiting",Diagnostic Test: mRNA in urine test,All,"18 Years and older   (Adult, Older Adult)",,120.0,"May 15, 2020",2020-11-15,"July 28, 2020","Sechenov University., Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04386564,Russian Federation,,11.0,2020,Sunday
1108,1109,Serological Profile of Children and Young Adolescents With at Least One COVID-19 Diagnosed Family Member,Not yet recruiting,Diagnostic Test: Serological test and phone interview,All,"4 Years to 99 Years   (Child, Adult, Older Adult)",,40.0,"December 5, 2020",2021-12-31,"December 4, 2020","UOC Maxillofacial Surgery and Odontology, University of Milan, Milan, Lombardy, Italy",https://ClinicalTrials.gov/show/NCT04649944,Italy,,12.0,2021,Friday
1109,1110,Chest Radiography in COVID-19 Patients,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"August 1, 2020",2021-03-01,"July 24, 2020",,https://ClinicalTrials.gov/show/NCT04485338,Undefined,,3.0,2021,Monday
1110,1111,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,Not yet recruiting,Drug: Camostat|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,January 2021,2022-01-01,"December 10, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04662073,United States,Camostat|Placebo,1.0,2022,Saturday
1111,1112,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Recruiting,Other: Respiratory rehabilitation program (RR).|Other: Respiratory tele-rehabilitation program (TRR).,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,118.0,December 2020,2022-12-01,"December 11, 2020","Hôpital Renée Sabran, Hyères, Var, France|HIA Sainte Anne, Toulon, Var, France",https://ClinicalTrials.gov/show/NCT04634318,France,,12.0,2022,Thursday
1112,1113,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,Device: Saliva test kit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3015.0,"November 20, 2020",2021-04-01,"December 11, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04568122,United States,,4.0,2021,Thursday
1113,1114,ImmuneRACE - Immune Response Action to COVID-19 Events,Recruiting,,All,"18 Years to 89 Years   (Adult, Older Adult)",,1000.0,"April 24, 2020",2021-01-31,"July 31, 2020","Adaptive Biotechnologies, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04494893,United States,,1.0,2021,Sunday
1114,1115,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,Not yet recruiting,Drug: Acebilustat|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,January 2021,2022-01-01,"December 10, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04662060,United States,Acebilustat|Placebo,1.0,2022,Saturday
1115,1116,Suloexide in the Treatment of Early Stages of COVID-19,Completed,Drug: Sulodexide|Drug: Placebo,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,243.0,"June 5, 2020",2020-09-07,"September 9, 2020","Clinedem, San Luis Rio Colorado, Sonora, Mexico",https://ClinicalTrials.gov/show/NCT04483830,Mexico,Sulodexide|Placebo,9.0,2020,Monday
1116,1117,Helmet Non-Invasive Ventilation for COVID-19 Patients,Not yet recruiting,Device: Helmet non-invasive ventilation,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,320.0,October 2020,2022-01-01,"September 16, 2020","Intensive Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04477668,Saudi Arabia,,1.0,2022,Saturday
1117,1118,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Drug: Unfractionated heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,656.0,"June 1, 2020",2021-06-01,"November 19, 2020","San Camilo Clinic, Buenos Aires, Argentina|15th May hospital, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04635241,Argentina,Unfractionated heparin,6.0,2021,Tuesday
1118,1119,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department,Recruiting,Other: integrated clinical evaluation,All,"18 Years and older   (Adult, Older Adult)",,400.0,"November 1, 2020",2021-07-31,"November 16, 2020","Ospedale U. Parini, Medicina e Chirurgia d'accettazione e Urgenza (MeCAU), Aosta, Italy|A.O. S. Croce e Carle, Medicina e Chirurgia d'Urgenza, Cuneo, Italy|A.O.U. Careggi, Medicina e Chirurgia d'Urgenza e Accettazione, Firenze, Italy|A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, S.C. Medicina d'Urgenza U (MECAU), Torino, Italy|Ospedale San Giovanni Bosco, Medicina e Chirurgia d'accettazione e urgenza (MeCAU), Torino, Italy",https://ClinicalTrials.gov/show/NCT04629183,Italy,,7.0,2021,Saturday
1119,1120,Western Kenya Integrated COVID-19 Response,Recruiting,"Other: Training of youth, community health assistants and community health workers.|Other: Training clinicians in basic critical care and the management of severe COVID-19 cases",All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,200000.0,"May 18, 2020",2020-12-19,"October 20, 2020","Surgical Systems Research Group/Tropical Institute of Community Health, Kisumu, Kenya",https://ClinicalTrials.gov/show/NCT04501458,Kenya,,12.0,2020,Saturday
1120,1121,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,"Active, not recruiting",Other: COVID-19 PCR and serology testing,All,"18 Years and older   (Adult, Older Adult)",,500.0,"June 9, 2020",2021-06-30,"November 17, 2020","Duke CTSI Translational Population Health Office, Kannapolis, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04424004,United States,,6.0,2021,Wednesday
1121,1122,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Recruiting,Biological: GC5131|Other: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 20, 2020",2021-08-01,"September 18, 2020","Samsung Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04555148,"Korea, Republic of",,8.0,2021,Sunday
1122,1123,"The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice",Recruiting,,All,"Child, Adult, Older Adult",,450.0,"September 22, 2020",2020-10-30,"September 24, 2020","Asalam, Maadi, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04558203,Egypt,,10.0,2020,Friday
1123,1124,Late Clinical Events Associated With COVID-19 Infection,Not yet recruiting,Other: Questionnaire|Other: Biocollection|Other: Follow-up visit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,October 2020,2022-08-01,"October 19, 2020","Ch Ajaccio, Ajaccio, France|CHU Amiens Picardie, Amiens, France|Chu Angers, Angers, France|Ch Auxerre, Auxerre, France|CHU Caen, Caen, France|CHRU Lille, Lille, France|CH Melun Marc Jacquet, Melun, France|CHU Nice, Nice, France|AP-HP Hôpital Bichat, Paris, France|AP-HP Hôpital Hôtel-Dieu, Paris, France|CH Roubaix, Roubaix, France|CHU de Saint-Etienne, Saint-Priest-en-Jarez, France|CH Tourcoing, Tourcoing, France|CHRU Tours, Tours, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Centre Hospitalier Bretagne Atlantique, Vannes, France|CH André Rosemon de Cayenne, Cayenne, French Guiana",https://ClinicalTrials.gov/show/NCT04591613,France,,8.0,2022,Monday
1124,1125,LLLT Treatment of Lung Inflammation in COVID-19,Not yet recruiting,Device: Non-invasive red LLLT treatment to chest of patient.|Device: Sham Device Treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64.0,"March 31, 2021",2022-03-31,"December 4, 2020","Wellness Junction, Millsboro, Delaware, United States",https://ClinicalTrials.gov/show/NCT04524715,United States,,3.0,2022,Thursday
1125,1126,Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,Recruiting,Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",,120.0,"May 18, 2020",2020-07-24,"May 28, 2020","Institute of Epidemiology, Disease Control and Research (IEDCR), Mohakhali, Dhaka (For sample collection & sample storage), Institute for Developing Science & Health Initiatives (ideSHi); Mohakhali, Dhaka (For sample analysis, data collection, data analys, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04403672,Bangladesh,,7.0,2020,Friday
1126,1127,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak,Completed,,All,"Child, Adult, Older Adult",,60.0,"November 1, 2020",2020-11-10,"December 3, 2020","Yarmouk University, Irbid, Jordan",https://ClinicalTrials.gov/show/NCT04650035,Jordan,,11.0,2020,Tuesday
1127,1128,Clinical Study Spartan COVID-19 V2 System,Recruiting,Diagnostic Test: Spartan COVID-19 Test,All,"18 Years and older   (Adult, Older Adult)",,100.0,"October 30, 2020",2020-11-01,"November 13, 2020","Wake Research Mt. Vernon, Sandy Springs, Georgia, United States|Clinical Chemistry Research Lab, University of Maryand-Baltimore, Baltimore, Maryland, United States|Wake Research ClinSearch, Chattanooga, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04575168,Georgia,,11.0,2020,Sunday
1128,1129,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With Salivette® Cortisol for Viral RNA Sampling for RT-qPCR,Recruiting,Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"October 26, 2020",2020-11-26,"December 1, 2020","Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico",https://ClinicalTrials.gov/show/NCT04599959,Mexico,,11.0,2020,Thursday
1129,1130,Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen,Withdrawn,Drug: Opaganib,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,0.0,August 2020,2021-06-01,"August 11, 2020","Shaare Zedek Medical Center, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04502069,Israel,Opaganib,6.0,2021,Tuesday
1130,1131,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Drug: Ivermectin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,500.0,"August 19, 2020",2021-01-31,"September 16, 2020","Ministry of Public Health of the Province of Corrientes, Corrientes, Argentina",https://ClinicalTrials.gov/show/NCT04529525,Argentina,Ivermectin|Placebo,1.0,2021,Sunday
1131,1132,COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,June 2020,2020-09-01,"June 16, 2020","CHU Poitiers, Poitiers, France|CHU Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04433325,France,,9.0,2020,Tuesday
1132,1133,Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics,"Active, not recruiting",Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection,All,"22 Years to 72 Years   (Adult, Older Adult)",Early Phase 1,20.0,"July 18, 2020",2021-01-28,"November 12, 2020","Medicine Invention Design Incorporation (MIDI) - IORG0007849, North Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT03305341,United States,,1.0,2021,Thursday
1133,1134,Use of the Nasal Cannula During COVID-19,Enrolling by invitation,,All,"Child, Adult, Older Adult",,100.0,"April 30, 2020",2020-11-30,"October 6, 2020","Carolina Frederico, Buenos Aires, Caba, Argentina",https://ClinicalTrials.gov/show/NCT04376580,Argentina,,11.0,2020,Monday
1134,1135,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"April 14, 2020",2021-04-30,"April 21, 2020","San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04355247,Puerto Rico,MethylPREDNISolone 80 Mg/mL Injectable Suspension,4.0,2021,Friday
1135,1136,Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study,Not yet recruiting,Other: Observational,All,"18 Years and older   (Adult, Older Adult)",,200.0,"November 20, 2020",2022-02-01,"November 18, 2020","Uniformed Services University, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04606498,United States,,2.0,2022,Tuesday
1136,1137,Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients,Recruiting,Diagnostic Test: Lab workup (on admission and regularly during follow up).,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 27, 2020",2020-12-30,"October 14, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04584606,Egypt,,12.0,2020,Wednesday
1137,1138,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,Recruiting,Device: Core Warming|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"August 19, 2020",2020-12-01,"September 25, 2020","Sharp Memorial Hospital, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04494867,United States,,12.0,2020,Tuesday
1138,1139,Hyperpolarized 129Xe MRI of Survivors of COVID-19,Not yet recruiting,Drug: Hyperpolarized Xe129,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"January 1, 2021",2021-12-31,"December 9, 2020",,https://ClinicalTrials.gov/show/NCT04659707,Undefined,Hyperpolarized Xe129,12.0,2021,Friday
1139,1140,Physical Activity and the Risk of COVID-19 Infection and Mortality,Completed,,All,"18 Years and older   (Adult, Older Adult)",,132069.0,"January 1, 2014",2020-07-31,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04631861,Undefined,,7.0,2020,Friday
1140,1141,Favipiravir vs Hydroxychloroquine in COVID -19,Recruiting,Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients,All,"21 Years and older   (Adult, Older Adult)",Phase 2,150.0,"August 11, 2020",2021-05-14,"August 18, 2020","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain",https://ClinicalTrials.gov/show/NCT04387760,Bahrain,Hydroxychloroquine|Favipiravir,5.0,2021,Friday
1141,1142,Compassionate Use of Hyperbaric Oxygen Therapy,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 15, 2020",2022-05-11,"October 23, 2020","White River Wound Healing Center, Batesville, Arkansas, United States|Community Hospital, Monterey, California, United States|Innovative Healing Systems, Tampa, Florida, United States|Decatur Memorial Hospital, Decatur, Indiana, United States|Providence Medical Wound Care Center, Kansas City, Kansas, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|The Wound Treatment Center, Opelousas, Louisiana, United States|Christus Shreveport Bossier Hyperbaric & Wound Care Center, Shreveport, Louisiana, United States|Ascension Providence Rochester Hospital Wound Care Center, Rochester, Michigan, United States|CHI, Chattanooga, Tennessee, United States|Klinika Baromedical, Poznan, Wielkopolskie, Poland",https://ClinicalTrials.gov/show/NCT04386265,India,,5.0,2022,Wednesday
1142,1143,Lung Recruitment Device for COVID-19,Not yet recruiting,Procedure: Chest physiotherapy using a non-invasive oscillating device,All,"Child, Adult, Older Adult",Not Applicable,50.0,"May 1, 2020",2020-12-31,"April 28, 2020",,https://ClinicalTrials.gov/show/NCT04361435,Undefined,,12.0,2020,Thursday
1143,1144,COVID-19 Study of Safety and Tolerability of Alvelestat,Recruiting,Drug: Alvelestat|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,"November 1, 2020",2021-09-30,"October 19, 2020","UAB Lung Health Center, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04539795,United States,Alvelestat|Placebo,9.0,2021,Thursday
1144,1145,Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study,Not yet recruiting,,All,18 Years to 40 Years   (Adult),,50.0,"September 15, 2020",2020-12-15,"July 27, 2020",,https://ClinicalTrials.gov/show/NCT04487665,Undefined,,12.0,2020,Tuesday
1145,1146,Maternal Morbidity and Mortality During the COVID-19 Pandemic,Recruiting,,Female,"Child, Adult, Older Adult",,26400.0,"June 23, 2020",2021-12-31,"August 21, 2020","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University-St. Luke's Hospital, New York, New York, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Brown Univeristy, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04519502,United States,,12.0,2021,Friday
1146,1147,Patients Reactions Towards Their Diagnosis as Having COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"October 10, 2020",2020-12-15,"November 10, 2020","Asalam, Maadi, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04581928,Egypt,,12.0,2020,Tuesday
1147,1148,Cri Analog PG1 Effectiveness and Safety in Covid-19,Not yet recruiting,"Drug: Analogs, Prostaglandin E1|Drug: Standard therapeutic protocol",All,"18 Years and older   (Adult, Older Adult)",Phase 2,284.0,"October 1, 2020",2021-03-01,"September 2, 2020",,https://ClinicalTrials.gov/show/NCT04536363,Undefined,"Analogs, Prostaglandin E1|Standard therapeutic protocol",3.0,2021,Monday
1148,1149,Efficacy and Safety of Ovotransferrin in COVID-19 Patients,Not yet recruiting,Dietary Supplement: Ovotransferrin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"December 1, 2020",2021-03-30,"November 24, 2020","Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy",https://ClinicalTrials.gov/show/NCT04643054,Italy,,3.0,2021,Tuesday
1149,1150,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,Enrolling by invitation,Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,90.0,"October 1, 2020",2021-12-30,"October 26, 2020","Medical Centre Dinasty, Samara, Russian Federation",https://ClinicalTrials.gov/show/NCT04602442,Russian Federation,EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation,12.0,2021,Thursday
1150,1151,Convalescent Plasma for COVID-19 Patients (CPCP),Not yet recruiting,Biological: Convalescent Plasma as Therapy for Covid-19 patients,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,44.0,"December 1, 2020",2021-10-30,"September 1, 2020","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",https://ClinicalTrials.gov/show/NCT04521036,Undefined,,10.0,2021,Saturday
1151,1152,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Completed,Drug: Ivermectin and Doxycycline|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"June 1, 2020",2020-09-10,"October 9, 2020","Dhaka Medical College, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04523831,Bangladesh,Ivermectin and Doxycycline|Standard of care,9.0,2020,Thursday
1152,1153,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,Device: Hyperbaric oxygen therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"April 30, 2020",2020-11-01,"November 3, 2020","Amir Hadanny, Zerifin, Israel",https://ClinicalTrials.gov/show/NCT04358926,Israel,,11.0,2020,Sunday
1153,1154,IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19),Not yet recruiting,Biological: IC14|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,July 2020,2021-09-01,"June 24, 2020","University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04391309,United States,,9.0,2021,Wednesday
1154,1155,Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age,Recruiting,Other: Data collection from medical files,All,90 Years and older   (Older Adult),,50.0,"June 9, 2020",2020-12-01,"August 7, 2020","CHU Brugmann, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04499300,Belgium,,12.0,2020,Tuesday
1155,1156,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Recruiting,Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,550.0,"April 10, 2020",2020-12-31,"April 14, 2020","Hopital Bichat - Aphp, Paris, France",https://ClinicalTrials.gov/show/NCT04344730,France,Dexamethasone injection|placebo,12.0,2020,Thursday
1156,1157,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Drug: Dociparastat sodium|Drug: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,524.0,"June 3, 2020",2021-03-01,"October 5, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States|Our Lady of the Lake, Baton Rouge, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Texas Health Harris Methodist Hospital Fort Worth, Dallas, Texas, United States|Sentara Clinical Trials, Norfolk, Virginia, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04389840,United States,Dociparastat sodium|Placebo,3.0,2021,Monday
1157,1158,"Allocetra-OTS in COVID-19, Phase II",Recruiting,Biological: Allocetra-OTS,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24.0,"October 20, 2020",2021-03-01,"October 22, 2020","Barzilai Medical Center, Ashkelon, Israel|Hadassah Medical Center, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",https://ClinicalTrials.gov/show/NCT04590053,Israel,,3.0,2021,Monday
1158,1159,Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19,"Active, not recruiting",Diagnostic Test: SARS-CoV-2 antibody immunoassays,All,"Child, Adult, Older Adult",,70.0,"July 27, 2020",2020-11-30,"August 3, 2020","Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04496141,Hong Kong,,11.0,2020,Monday
1159,1160,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 27, 2020",2020-12-31,"September 16, 2020","410 Lakeville Road, Suite 107, New Hyde Park, New York, United States",https://ClinicalTrials.gov/show/NCT04476602,United States,,12.0,2020,Thursday
1160,1161,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,Recruiting,Biological: COVID-19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,"April 30, 2020",2021-06-30,"December 4, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04388527,United States,,6.0,2021,Wednesday
1161,1162,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19",Not yet recruiting,Drug: rNAPc2|Drug: Heparin,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"December 4, 2020",2021-05-31,"December 8, 2020",,https://ClinicalTrials.gov/show/NCT04655586,Undefined,rNAPc2|Heparin,5.0,2021,Monday
1162,1163,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),Not yet recruiting,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Biological: Two doses of placebo at the schedule of day 0, 28（high-dose group）|Biological: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）",All,"18 Years and older   (Adult, Older Adult)",Phase 1,168.0,"August 28, 2020",2021-08-28,"September 1, 2020","Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04530656,China,,8.0,2021,Saturday
1163,1164,Checkpoint Blockade in COVID-19 Pandemic,Recruiting,Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24.0,"April 9, 2020",2021-06-30,"November 27, 2020","Hospital Quirónsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04335305,Spain,Tocilizumab,6.0,2021,Wednesday
1164,1165,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Not yet recruiting,Drug: Sarilumab Prefilled Syringe,All,"18 Years to 84 Years   (Adult, Older Adult)",Early Phase 1,40.0,May 2020,2020-12-01,"May 13, 2020",,https://ClinicalTrials.gov/show/NCT04386239,Undefined,Sarilumab Prefilled Syringe,12.0,2020,Tuesday
1165,1166,Assesment of the Metabolomic Signature in COVID-19 Patients,Recruiting,Other: COVID-19 patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"August 7, 2020",2021-10-07,"November 10, 2020","CHU de nice, Nice, Alpes-Maritimes, France",https://ClinicalTrials.gov/show/NCT04497272,France,,10.0,2021,Thursday
1166,1167,Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic,Not yet recruiting,Other: State-trait anxiety inventory scale|Other: Edinburgh Postnatal Depression Scale (EDPS),Female,"Child, Adult, Older Adult",,150.0,October 2020,2021-06-01,"September 22, 2020",,https://ClinicalTrials.gov/show/NCT04558749,Undefined,,6.0,2021,Tuesday
1167,1168,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Recruiting,Drug: Thymalfasin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"September 10, 2020",2021-06-01,"September 14, 2020","The Miriam Hospital, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04487444,United States,Thymalfasin,6.0,2021,Tuesday
1168,1169,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Recruiting,Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,260.0,"April 18, 2020",2022-04-01,"May 20, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04338828,United States,Nitric Oxide Gas,4.0,2022,Friday
1169,1170,Clinical Study Spartan COVID-19 V2 System (Canada Alternate),Recruiting,Diagnostic Test: Spartan COVID-19 v2 System,All,"18 Years and older   (Adult, Older Adult)",,60.0,"November 17, 2020",2021-01-01,"December 2, 2020","The Ottawa hospital, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04628208,Canada,,1.0,2021,Friday
1170,1171,Bucillamine in Treatment of Patients With COVID-19,Enrolling by invitation,Drug: Bucillamine|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1000.0,"November 27, 2020",2021-05-01,"December 8, 2020","C & R Research Services USA, Coral Gables, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Verus Clinical Research, Miami, Florida, United States|Amavita Clinical Research, North Miami Beach, Florida, United States|Machuca Family Medicine, Las Vegas, Nevada, United States|Encore Imaging and Medical Research, Houston, Texas, United States|Family Practice Center, McAllen, Texas, United States",https://ClinicalTrials.gov/show/NCT04504734,United States,Bucillamine|Placebo,5.0,2021,Saturday
1171,1172,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"Active, not recruiting",Combination Product: AZD7442|Other: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,60.0,"August 18, 2020",2021-10-25,"November 16, 2020","Research Site, Harrow, United Kingdom",https://ClinicalTrials.gov/show/NCT04507256,United Kingdom,,10.0,2021,Monday
1172,1173,Rehabilitation After Admission in Intensive Care Unit for COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,40.0,"April 1, 2020",2021-05-01,"August 25, 2020","Etablissement de santé Filieris, Freyming-Merlebach, Moselle, France|Hopital Legouest, Metz, Moselle, France|CHR Metz Thionville, Metz, Moselle, France",https://ClinicalTrials.gov/show/NCT04523051,France,,5.0,2021,Saturday
1173,1174,DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19),Not yet recruiting,Drug: Doxycycline|Drug: Placebo,All,"46 Years and older   (Adult, Older Adult)",Phase 3,330.0,"June 1, 2020",2020-12-01,"May 18, 2020","CHU Avicenne - APHP, Bobigny, France|CHU Bordeaux, Bordeaux, France|CHU Caen, Caen, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Nantes, Nantes, France",https://ClinicalTrials.gov/show/NCT04371952,France,Doxycycline|Placebo,12.0,2020,Tuesday
1174,1175,Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),Recruiting,Drug: Heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,3000.0,"May 20, 2020",2021-01-01,"June 4, 2020","University of Chicago, Chicago, Illinois, United States|Ochsner Clinic, Jefferson, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States|Deborah Heart and Lung Center, Browns Mills, New Jersey, United States|Albany Medical College, Albany, New York, United States|Mount Sinai Health System, New York, New York, United States|Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of São Paulo, São Paulo, Brazil|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Center Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier de l'université de Montréal (CHUM), Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Quebec-University Laval, Québec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04372589,Brazil,Heparin,1.0,2021,Friday
1175,1176,The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19,Recruiting,Other: Observation,All,"18 Years and older   (Adult, Older Adult)",,150.0,"September 1, 2020",2023-12-31,"October 6, 2020","Sørlandet Hospital Trust, Arendal, Norway|Haukeland University Hospital, Bergen, Norway|Nordlandssykehuset, Bodo, Norway|Vestre Viken Hospital Trust Drammen, Drammen, Norway|Østfold Hospital Trust Kalnes, Grålum, Norway|Sørlandet Hospital Trust, Kristiansand, Kristiansand, Norway|Innlandet Hospital Trust, Lillehammer, Norway|Akershus University Hospital, Lørenskog, Norway|Møre og Romsdal Hospital Trust, Molde, Norway|Oslo University Hospital, Oslo, Norway|Ostfold Hospital Trust, Sarpsborg, Norway|Skien Hospital, Skien, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, Tromsø, Norway|St. Olav Hospital, Trondheim, Norway",https://ClinicalTrials.gov/show/NCT04576351,Norway,,12.0,2023,Sunday
1176,1177,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Recruiting,Drug: TM5614|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80.0,"November 16, 2020",2022-06-30,"November 20, 2020","Northwestern University, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04634799,United States,TM5614,6.0,2022,Thursday
1177,1178,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Recruiting,Device: Contrast-enhanced CMR|Diagnostic Test: Exercise test ECG|Biological: Blood sample|Diagnostic Test: Resting 12 lead ECG|Diagnostic Test: 24 hour Holter ECG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240.0,"June 13, 2020",2021-04-13,"November 19, 2020","Bordeaux University Hospital, Pessac, France",https://ClinicalTrials.gov/show/NCT04636320,France,,4.0,2021,Tuesday
1178,1179,TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19,Not yet recruiting,Biological: Anti-SARS-CoV-2 immunoglobulin,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,41.0,"December 1, 2020",2021-03-31,"October 5, 2020",,https://ClinicalTrials.gov/show/NCT04573855,Undefined,,3.0,2021,Wednesday
1179,1180,Response of Korean Medicine Hospital to COVID-19,Completed,Other: Survey,All,"Child, Adult, Older Adult",,485.0,"June 10, 2020",2020-08-10,"August 27, 2020","Jaseng Hospital of Korean Medicine, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04529447,"Korea, Republic of",,8.0,2020,Monday
1180,1181,Using Travelan to Boost Immune Response in Vitro to COVID-19,"Active, not recruiting",Other: Travelan OTC,Male,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5.0,"November 1, 2020",2020-12-31,"November 27, 2020","Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04643561,Israel,,12.0,2020,Thursday
1181,1182,Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale,Recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,100.0,"September 2, 2020",2021-12-02,"October 14, 2020","Hacettepe University, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04584450,Turkey,,12.0,2021,Thursday
1182,1183,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,Recruiting,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,40000.0,"September 15, 2020",2022-01-30,"December 4, 2020","Fundación Socolinsky Centro de Vacunación Proteger - Recoleta, Caba, Buenos Aires, Argentina|Hospital Pirovano, Caba, Buenos Aires, Argentina|Htal de Alta Complejidad Cuenca Alta Néstor Kirchner, Cañuelas, Buenos Aires, Argentina|Hospital Interzonal de Agudos ""San Juan de Dios"" de La Plata, La Plata, Buenos Aires, Argentina|Hospital Rossi, La Plata, Buenos Aires, Argentina|Inst. Médico Platense, La Plata, Buenos Aires, Argentina|Instituto de Investigaciones Clínicas, Mar Del Plata, Buenos Aires, Argentina|Htal Mariano y Luciano de la Vega, Moreno, Buenos Aires, Argentina|Hospital Houssay, Vicente López, Buenos Aires, Argentina|Hospital Zonal General de Agudos ""Cetrangolo"", Vicente López, Buenos Aires, Argentina|Instituto Cer, Vicente López, Quilmes, Argentina|Previvax Centro de Vacunación, Córdoba, Argentina|Hospital Dr. Hernan Henriquez Aravena Temuco, Temuco, IX Region, Chile|CIMER Centro de Investigaciones Medicas Respiratorias Santiago, Providencia, Region Metropolitana, Chile|Hospital San Borja Arriarán Santiago, Santiago, Region Metropolitana, Chile|Clínica Andes Salud Concepción, Concepción, VII Región, Chile|Hospital de Puerto Montt Dr. Eduardo Schütz Schoroeder Puerto Montt, Puerto Montt, X Región De Los Lagos, Chile|Hospital Base de Osorno, Osorno, XIV Región, Chile|Clinica Alemana de Valdivia Valdivia, Valdivia, XIV Región, Chile|Centro de investigación Médica Aguascalientes (CIMA), Aguascalientes, Ags, Mexico|Hospital Juárez de México (HJM), Ciudad de México, Cdmx, Mexico|Instuto de Ciencias Médicas y de la Nutrición Salvador Subirán (INCMNSZ), Tlalpan, Cdmx, Mexico|Centro de Investigacion Integral MEDIVEST SC, Chihuahua, Chhihuahia, Mexico|Centro de Investigacion Clinica Chapultepec SA de CV (Hidra), Coyoacán, Ciudad De Mexico, Mexico|Clinical Research Institute Saltillo SA de CV, Saltillo, Cuahuila, Mexico|Centro de Investigación Clínica del Pacifico S.A. de C.V. (CICPA), Acapulco, Guerrero, Mexico|Asociación Mexicana para la investigación clínica (AMIC), Pachuca de Soto, Hidalgo, Mexico|Instituto Jaliscience de Metabolismo, S. C., Guadalajara, Jalisco, Mexico|Asociación de investigación pediátrica y adultos (AINPAD), Morelia, Mochoacán De Ocampo, Mexico|JM Research, Cuernavaca, Morelos, Mexico|Hospital Metropolitano ""Dr. Bernardo Sepúlveda"", San Nicolás De Los Garza, Nuevo León, Mexico|Oaxaca site management organization (OSMO), Oaxaca, Oax, Mexico|Centro de Investigación y Avances Médicos Especializados (CIAME), Cancún, Quintana Roo, Mexico|FAICIC, Veracruz, Veracrua, Mexico|Kohler & Milstein Research, Mérida, Yucatan, Mexico|MIRO (Medical Invetigation Research Organisation SC), Chihuahua, Mexico|Instituto Nacional de Pediatría (INP), Ciudad de México, Mexico|Instituto de Investigaciones aplicada a las Neurociencias (IIAN), Durango, Mexico|Administración de Especialistas de Puebla S.C. (UDEP), Puebla, Mexico|Shifa International Hospital, Islamabad, Islamabad Capital Territory, Pakistan|Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punajb, Pakistan|University of Health Scinces, Lahore, Lahore, Punjab, Pakistan|Aga Khan University Hospital, Karachi, Sindh, Pakistan|The Indus Hospital, Karachi, Sindh, Pakistan|Ryazan State Medical University, Ryazan', Ryazan,, Russian Federation|OOO ""Kurator"", St. Petersburg, Saint Petersburg, Russian Federation|Research Center Eco-safety, Saint Petersburg, Saint-Petersburg, Russian Federation|OOO ""Baltijskaya Meditsina"", Saint Petersburg, Saint-Petersburg, Russian Federation|Research Center Eco-safety, Saint Petersburg, Saint-Petersburg, Russian Federation|Federal State Budgetary Institution ""Scientific Research Institute of Influenza named after A. A. Smorodintsev"" of the Ministry of Healthcare of the Russian Federation named after A. A. Smorodintsev"" of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, Saint-Petersburg, Russian Federation|Saint Petersburg State Budgetary Healthcare Institution ""City Polyclinic #106"", Saint Petersburg, Saint-Petersburg, Russian Federation|State Budgetary Healthcare Institution of Sverdlovsk Region ""Aramil City Hospital"", Aramil, Sverdlovsk, Russian Federation|Non-state Institution of Healthcare ""Road Clinical Hospital at Chelyabinsk station of open corporate society ""Russian Railways"", Chelyabinsk, Russian Federation|Municipal Budgetary Institution ""Central City Clinical Hospital # 6"", Ekaterinburg, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Polyclinic #2 of the Moscow City Healthcare Department"", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of Ministry of Healthcare of the Russian Federation (Sechenovsky University), Moscow, Russian Federation|Private Healthcare Institution ""Clinical Hospital ""RZHD-Meditsina"" of Nizhniy Novgorod"", Nizhniy Novgorod, Russian Federation|""Life Benefits Service, Ltd', Novosibirsk, Russian Federation|OOO ""Clinical and Diagnostic Center ""Ul'tramed"", Omsk, Russian Federation|Budgetary Institution of Heathcare of Omsk region ""City Clinical Hospital #1 n.a. Kabanova A.N."", Omsk, Russian Federation|OOO Zvyezdnaya Klinika, Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""Children Scientific and Clinical Centre of Infectional Diseases of Federal Medical and Biological Agency "", Saint Petersburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Saratov State Medical University named after V.I. Razumovsky"" the Ministry of Health of the Russian Federation - Clinical hospital n.a. S.R.Mirotvortseva, Saratov, Russian Federation|OOO ""Uromed"", Smolensk, Russian Federation|OOO ""Medical Scientific and Practical Center"", Tomsk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Siberia State Medical University"" of the Ministry of Healthcare of the Russian Federation, Tomsk, Russian Federation|State Autonomous Healthcare Institution of Yaroslavl region ""Clinical Emergency Hospital named after N.V. Solovyev"", Yaroslavl, Russian Federation|Federal State Budgetary Institution ""Scientific Research Institute of Influenza named after A. A. Smorodintsev"" of the Ministry of Healthcare of the Russian Federation, Yaroslavl, Russian Federation|State Budgetary Healthcare Institution of Yaroslavl Region "" Clinical Hospital #2"", Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04526990,Argentina,,1.0,2022,Sunday
1183,1184,Mild Hypothermia for COVID-19 ARDS,Recruiting,Other: Hypothermia Via Cooling Machine- Arctic Sun 5000,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,20.0,"May 18, 2020",2020-12-31,"September 30, 2020","North Shore University Hospital, Manhasset, New York, United States",https://ClinicalTrials.gov/show/NCT04570462,United States,,12.0,2020,Thursday
1184,1185,Outcomes in Emergency Laparotomies During COVID-19 Pandemic,Completed,Procedure: Emergency Laparotomy,All,"18 Years and older   (Adult, Older Adult)",,94.0,"March 23, 2020",2020-06-16,"July 23, 2020","Queen's Hospital, Romford, United Kingdom",https://ClinicalTrials.gov/show/NCT04419571,United Kingdom,,6.0,2020,Tuesday
1185,1186,COVID Screening Strategies in Homeless Shelters,Recruiting,Diagnostic Test: COVID-19 Swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"April 10, 2020",2020-06-01,"June 18, 2020","Various Homeless Shelters, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04438070,Canada,,6.0,2020,Monday
1186,1187,Efficacy and Safety of Corticosteroids in COVID-19,Completed,Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,86.0,"February 14, 2020",2020-04-15,"May 11, 2020","Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China",https://ClinicalTrials.gov/show/NCT04273321,China,Methylprednisolone,4.0,2020,Wednesday
1187,1188,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,Recruiting,Drug: ISIS 721744|Drug: Normal Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,110.0,"October 21, 2020",2021-12-01,"October 27, 2020","Hospital Naval Marcílio Dias, Rio De Janeiro, Brazil|BP-A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil|Hospital São Paulo - UNIFESP, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04549922,Brazil,ISIS 721744|Normal Saline,12.0,2021,Wednesday
1188,1189,How Brazilian Chiropractors Are Facing the COVID-19 Pandemic,Not yet recruiting,Other: Electronic survey,All,"Child, Adult, Older Adult",,948.0,"August 26, 2020",2020-09-18,"September 1, 2020",,https://ClinicalTrials.gov/show/NCT04534621,Undefined,,9.0,2020,Friday
1189,1190,Study to Evaluate the Effect of a Probiotic in COVID-19,Recruiting,Dietary Supplement: Probiotic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 4, 2020",2021-05-01,"May 15, 2020","Hospital Universitario del Vinalopó, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja, Alicante, Spain",https://ClinicalTrials.gov/show/NCT04390477,Spain,,5.0,2021,Saturday
1190,1191,Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger,Withdrawn,Drug: Lopinavir-Ritonavir Drug Combination|Combination Product: Standard Care,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,0.0,"June 1, 2020",2021-12-31,"June 29, 2020",,https://ClinicalTrials.gov/show/NCT04409483,Undefined,Lopinavir-Ritonavir Drug Combination,12.0,2021,Friday
1191,1192,Changes in Cellular Immune Profile During COVID-19 Infection,Recruiting,Other: Leukapheresis,All,18 Years to 60 Years   (Adult),Not Applicable,25.0,"April 15, 2020",2020-12-31,"July 20, 2020","Seraph Research Institute, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04470999,United States,,12.0,2020,Thursday
1192,1193,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Not yet recruiting,Drug: Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,234.0,October 2020,2022-08-01,"September 16, 2020","The Ottawa Hospital, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04500626,Canada,Oxygen,8.0,2022,Monday
1193,1194,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic,Completed,Diagnostic Test: COVID-19 diagnostic PCR,All,18 Years to 50 Years   (Adult),,100000.0,"March 10, 2020",2020-07-14,"July 21, 2020","Seda Yilmaz Semerci, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04480060,Turkey,,7.0,2020,Tuesday
1194,1195,Protecting Health Care Workers During the COVID-19 Outbreak,Completed,Dietary Supplement: Ayurvedic Kadha,All,18 Years to 60 Years   (Adult),,52.0,"March 1, 2020",2020-04-02,"May 14, 2020","Samta Ayurveda Prakoshtha, Jaipur, Rajasthan, India",https://ClinicalTrials.gov/show/NCT04387643,India,,4.0,2020,Thursday
1195,1196,Decision Support System Algorithm for COVID-19 Diagnosis,Not yet recruiting,Diagnostic Test: Thorax CT,All,"18 Years and older   (Adult, Older Adult)",,10000.0,August 2020,2021-08-01,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04479319,Undefined,,8.0,2021,Sunday
1196,1197,Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,"May 8, 2020",2021-12-31,"July 28, 2020","Amsterdam University Center - location VUmc, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus MC, Rotterdam, Netherlands",https://ClinicalTrials.gov/show/NCT04488562,Netherlands,,12.0,2021,Friday
1197,1198,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,Diagnostic Test: Passive Microwave Radiometry,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,195.0,"July 1, 2020",2020-08-01,"September 29, 2020","Educational - clinical - scientific medical center of KSMA, Bishkek, Chui, Kyrgyzstan",https://ClinicalTrials.gov/show/NCT04568525,Kyrgyzstan,,8.0,2020,Saturday
1198,1199,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"May 1, 2020",2022-06-01,"November 18, 2020","Vanderblt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04347538,United States,,6.0,2022,Wednesday
1199,1200,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Recruiting,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo,All,"6 Years and older   (Child, Adult, Older Adult)",Phase 2,481.0,"September 24, 2020",2022-10-20,"November 27, 2020","Taixing City center for Disease Control and Prevention, Taizhou, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04566770,China,,10.0,2022,Thursday
1200,1201,Randomised Study of Plasma Exchange in Severe COVID-19,Recruiting,Drug: OCTAPLAS,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,20.0,"October 16, 2020",2021-11-01,"November 10, 2020","University College London Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04623255,United Kingdom,OCTAPLAS,11.0,2021,Monday
1201,1202,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,Procedure: Ophthalmologic exam,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 7, 2020",2021-05-01,"September 14, 2020","Fondation A de Rothschild, Paris, France",https://ClinicalTrials.gov/show/NCT04387292,France,,5.0,2021,Saturday
1202,1203,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,Recruiting,Drug: NOX66,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"September 30, 2020",2021-06-01,"October 14, 2020","Institute of Emergency Medicine, Chisinau, Moldova, Republic of",https://ClinicalTrials.gov/show/NCT04555213,"Moldova, Republic of",NOX66,6.0,2021,Tuesday
1203,1204,A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19,Not yet recruiting,Drug: Defibrotide,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,42.0,"January 1, 2021",2023-11-01,"December 3, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04652115,United States,Defibrotide,11.0,2023,Wednesday
1204,1205,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,Recruiting,Diagnostic Test: Capillary Collection & Testing|Diagnostic Test: Venous Draw & Testing,All,"2 Years and older   (Child, Adult, Older Adult)",Not Applicable,200.0,"August 20, 2020",2022-12-31,"October 22, 2020","Eclipse Clinical Research, Tucson, Arizona, United States|Centura Health Physician Group, Northglenn Office, Northglenn, Colorado, United States|Professional Research Network of Kansas, Wichita, Kansas, United States|Physicians Quality Care of Jackson, Jackson, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04597047,United States,,12.0,2022,Saturday
1205,1206,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet,All,"19 Years and older   (Adult, Older Adult)",Phase 4,90.0,"April 10, 2020",2020-07-31,"April 21, 2020","SB Celje, Celje, Slovenia",https://ClinicalTrials.gov/show/NCT04355026,Slovenia,Bromhexine Oral Tablet and/or hydroxychloroquine tablet,7.0,2020,Friday
1206,1207,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,126.0,"November 19, 2020",2021-06-30,"October 20, 2020","CHU Bichat Claude Bernard, Paris, France",https://ClinicalTrials.gov/show/NCT04594356,France,,6.0,2021,Wednesday
1207,1208,Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection,Not yet recruiting,Drug: MPT0B640,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,December 2020,2021-12-01,"August 26, 2020",,https://ClinicalTrials.gov/show/NCT04526717,Undefined,MPT0B640,12.0,2021,Wednesday
1208,1209,Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19,Approved for marketing,Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",,,,,"September 2, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04338360,United States,,,n,
1209,1210,Minnesota COVID-19 Testing Project,Not yet recruiting,Behavioral: A $10 Survey Incentive|Behavioral: A $20 Survey Incentive|Behavioral: Emphasis of Government Involvement|Behavioral: Emphasis of Academic Researchers Involvement|Behavioral: Cost-Benefit Frame|Behavioral: Duty Frame|Behavioral: Racial/Ethnic Frame|Behavioral: No Messaging,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"September 28, 2020",2021-06-30,"September 29, 2020",,https://ClinicalTrials.gov/show/NCT04568889,Undefined,,6.0,2021,Wednesday
1210,1211,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Recruiting,Biological: Octagam 10%|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,208.0,"June 1, 2020",2020-12-30,"November 20, 2020","Octapharma Research Site, Sheffield, Alabama, United States|Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Loma Linda, California, United States|Octapharma Research Site, Newport Beach, California, United States|Octapharma Research Site, Orange, California, United States|Octapharma Research Site, San Diego, California, United States|Octapharma Research Site, Washington, District of Columbia, United States|Octapharma Research Site, Honolulu, Hawaii, United States|Octapharma Research Site, Iowa City, Iowa, United States|Octapharma Research Site, Covington, Louisiana, United States|Octapharma Research Site, Midland, Michigan, United States|Octapharma Research Site, Las Vegas, Nevada, United States|Octapharma Research Site, Minot, North Dakota, United States|Octapharma Research Site, Charleston, South Carolina, United States|Octapharma Research Site, Tyler, Texas, United States",https://ClinicalTrials.gov/show/NCT04400058,United States,,12.0,2020,Wednesday
1211,1212,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Completed,Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C,Male,21 Years to 60 Years   (Adult),Phase 3,4257.0,"May 13, 2020",2020-08-31,"October 19, 2020","Tuas South Dormitory, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04446104,Singapore,Hydroxychloroquine Sulfate Tablets|Ivermectin 3mg Tab|Zinc|Povidone-Iodine,8.0,2020,Monday
1212,1213,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Respiratory Distress,Not yet recruiting,Device: Hyperbaric Oxygen Therapy (HBOT),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600.0,"November 16, 2020",2021-12-15,"November 10, 2020","Greenwich Hospital - Yale New Haven Health, Greenwich, Connecticut, United States|NYU Winthrop Hospital, Mineola, New York, United States",https://ClinicalTrials.gov/show/NCT04619719,United States,,12.0,2021,Wednesday
1213,1214,Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic,Completed,Procedure: Emergency surgery,All,"18 Years and older   (Adult, Older Adult)",,15.0,"April 1, 2020",2020-05-31,"July 7, 2020","Khoo Teck Puat Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04450277,Singapore,,5.0,2020,Sunday
1214,1215,Study to Investigate the Benefits of Colchicine in Patients With COVID-19,Withdrawn,Drug: Colchicine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"December 15, 2020",2021-06-14,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04603690,Undefined,Colchicine,6.0,2021,Monday
1215,1216,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Drug: Tofacitinib 10 mg|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,260.0,"September 16, 2020",2021-01-31,"November 16, 2020","Centro de Pesquisa Clínica do Coração, Aracaju, Brazil|Hospital Universitário São Francisco de Assis Na Providência de Deu, Bragança Paulista, Brazil|Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista, Bragança Paulista, Brazil|Hospital do Coração do Brasil, Brasilia, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, Brazil|Unimed Fortaleza Sociedade Corporativa Médica LTD, Fortaleza, Brazil|Hospital Regional Jorge Rossmann, Itanhaem, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Brazil|Hospital Bruno Born, Lajeado, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Irmandade da Santa Casa de Misericórdia, Porto Alegre, Brazil|Hospital São Rafael, Salvador, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José Do Rio Preto, Brazil|Hospital Regional de Registro, São José Dos Campos, Brazil|Hospital Regional de São José dos Campos, São José Dos Campos, Brazil|Beneficência Portuguesa, São Paulo, Brazil|BP Mirante, São Paulo, Brazil|Instituto do Coração, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04469114,Brazil,Tofacitinib 10 mg|Placebo,1.0,2021,Sunday
1216,1217,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Recruiting,Drug: N-acetylcysteine|Other: Peripheral Blood,All,"18 Years and older   (Adult, Older Adult)",Phase 2,84.0,"May 1, 2020",2022-05-01,"November 27, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04374461,United States,N-acetylcysteine,5.0,2022,Sunday
1217,1218,Safe Return to Regular Clinical Operation After COVID-19 Pandemic,Not yet recruiting,Diagnostic Test: molecular testing for virus RNA using RT-PCR,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,400.0,"May 17, 2020",2020-12-30,"May 6, 2020","king Fahad specialist hospital, Dammam, Eastern Province, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04377802,Saudi Arabia,,12.0,2020,Wednesday
1218,1219,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Recruiting,Drug: Chloroquine or Hydroxychloroquine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,200.0,"March 23, 2020",2030-12-23,"December 3, 2020","Tanta University, Assiut University, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04353336,Egypt,Chloroquine or Hydroxychloroquine,12.0,2030,Monday
1219,1220,Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool,Recruiting,Diagnostic Test: Face mask sampling,All,"16 Years and older   (Child, Adult, Older Adult)",,630.0,"June 12, 2020",2025-06-01,"July 22, 2020","University Hospitals of Leicester NHS Trust, Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04481646,United Kingdom,,6.0,2025,Sunday
1220,1221,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC,Not yet recruiting,Drug: Atorvastatin|Drug: Placebo Atrovastatin,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,80.0,"November 10, 2020",2021-05-01,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04631536,Undefined,Atorvastatin|Placebo Atrovastatin,5.0,2021,Saturday
1221,1222,IMU-838 and Oseltamivir in the Treatment of COVID-19,Recruiting,Drug: IMU-838|Drug: Oseltamivir,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,120.0,"June 15, 2020",2021-07-01,"August 21, 2020","University Hospital Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom",https://ClinicalTrials.gov/show/NCT04516915,United Kingdom,IMU-838|Oseltamivir,7.0,2021,Thursday
1222,1223,COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH,Enrolling by invitation,Diagnostic Test: Serology Test,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"July 19, 2020",2021-06-15,"July 29, 2020","Johns Hopkins Aramco Healthcare, Dhahran, Eastern, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04469647,Saudi Arabia,,6.0,2021,Tuesday
1223,1224,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),Recruiting,Drug: theraputic heparin|Drug: prophylactic heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000.0,"September 4, 2020",2021-12-01,"October 1, 2020","NYU Langone, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04505774,United States,theraputic heparin|prophylactic heparin,12.0,2021,Wednesday
1224,1225,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Completed,Drug: Ivermectin (IVM),All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,"April 18, 2020",2020-06-01,"November 4, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",https://ClinicalTrials.gov/show/NCT04343092,Iraq,Ivermectin (IVM),6.0,2020,Monday
1225,1226,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,Other: patients COVID 19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"June 1, 2020",2021-06-01,"November 9, 2020","CH Antibes, Antibes, Alpes Maritimes, France|Ch Cannes, Pneumologie, Cannes, Alpes Maritimes, France|Ch Grasse, Grasse, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France",https://ClinicalTrials.gov/show/NCT04418206,France,,6.0,2021,Tuesday
1226,1227,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,Recruiting,Drug: RTB101|Drug: Placebo,All,65 Years and older   (Older Adult),Phase 2,60.0,"October 13, 2020",2021-02-01,"October 26, 2020","University of Connecticut, UConn Center on Aging, Farmington, Connecticut, United States|Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04584710,United States,RTB101|Placebo,2.0,2021,Monday
1227,1228,Dornase Alfa Administered to Patients With COVID-19 (DACOVID),Completed,Drug: Dornase Alfa,All,"18 Years to 85 Years   (Adult, Older Adult)",,5.0,"March 31, 2020",2020-09-04,"November 13, 2020","Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States",https://ClinicalTrials.gov/show/NCT04387786,United States,Dornase Alfa,9.0,2020,Friday
1228,1229,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,Recruiting,Genetic: Whole exome sequencing,All,"18 Years and older   (Adult, Older Adult)",,60.0,"August 20, 2020",2021-09-01,"August 27, 2020","Texas Cardiac Arrhythmia Institute, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04506229,United States,,9.0,2021,Wednesday
1229,1230,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),All,18 Years to 60 Years   (Adult),Phase 1,108.0,"March 16, 2020",2022-12-20,"May 19, 2020","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04313127,China,,12.0,2022,Tuesday
1230,1231,Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19),Not yet recruiting,Diagnostic Test: Quidel Sofia SARS Antigen FIA,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"November 1, 2020",2021-01-31,"October 30, 2020",,https://ClinicalTrials.gov/show/NCT04610489,Undefined,,1.0,2021,Sunday
1231,1232,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"Active, not recruiting",Drug: CD24Fc|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,243.0,"April 8, 2020",2020-12-30,"November 24, 2020","Baptist Health Research Institute, Jacksonville, Florida, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Texas at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04317040,Jersey,CD24Fc|Placebo,12.0,2020,Wednesday
1232,1233,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,Recruiting,Drug: Disulfiram|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,200.0,"November 20, 2020",2021-04-01,"November 30, 2020","ETICA, Salvador, Bahia, Brazil",https://ClinicalTrials.gov/show/NCT04594343,Brazil,Disulfiram|Placebo,4.0,2021,Thursday
1233,1234,Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia,Recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"April 17, 2020",2020-12-20,"May 19, 2020","Jessa hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04334252,Belgium,,12.0,2020,Sunday
1234,1235,A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19,Not yet recruiting,Combination Product: MW33 injection|Combination Product: MW33 injection placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,150.0,November 2020,2021-09-01,"November 16, 2020",,https://ClinicalTrials.gov/show/NCT04627584,Undefined,,9.0,2021,Wednesday
1235,1236,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,Biological: ConvP|Biological: FFP,All,"50 Years and older   (Adult, Older Adult)",Phase 3,690.0,"October 12, 2020",2023-11-01,"October 19, 2020","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|University Medical Center Groningen (UMCG), Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Bernhoven Hospital, Uden, Netherlands",https://ClinicalTrials.gov/show/NCT04589949,Netherlands,,11.0,2023,Wednesday
1236,1237,Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients,Not yet recruiting,Drug: Angiotensin-(1-7)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,160.0,January 2021,2021-06-01,"November 27, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04570501,United States,Angiotensin-(1-7)|Placebo,6.0,2021,Tuesday
1237,1238,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive,Completed,Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days,All,18 Years to 60 Years   (Adult),,201.0,"July 1, 2020",2020-08-30,"October 28, 2020","Dr.Deb Sanjay Nag, Jamshedpur, Jharkhand, India",https://ClinicalTrials.gov/show/NCT04605952,India,,8.0,2020,Sunday
1238,1239,Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19),Recruiting,Drug: Pegylated Interferon-α2b|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"August 11, 2020",2021-01-30,"August 13, 2020","Avant Sante Site 1, Monterrey, Mexico",https://ClinicalTrials.gov/show/NCT04480138,Mexico,Pegylated Interferon-α2b,1.0,2021,Saturday
1239,1240,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,Other: Baseline and during hospitalization blood samples|Other: Baseline blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"October 19, 2020",2021-10-01,"November 3, 2020","Foch hospital, Suresnes, France",https://ClinicalTrials.gov/show/NCT04613297,France,,10.0,2021,Friday
1240,1241,PCR Cycle Threshold Values and COVID-19 Outcomes,Recruiting,Diagnostic Test: PCR Value,All,"Child, Adult, Older Adult",,800.0,"November 24, 2020",2021-03-31,"December 4, 2020","University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04651413,United Kingdom,,3.0,2021,Wednesday
1241,1242,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Completed,Drug: Guduchi Ghan Vati,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46.0,"May 1, 2020",2020-08-18,"September 9, 2020","Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India",https://ClinicalTrials.gov/show/NCT04542876,India,Guduchi Ghan Vati,8.0,2020,Tuesday
1242,1243,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,Recruiting,Drug: Atovaquone/Azithromycin,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2,25.0,"April 20, 2020",2021-12-01,"December 2, 2020","HonorHealth, Scottsdale, Arizona, United States",https://ClinicalTrials.gov/show/NCT04339426,United States,Atovaquone/Azithromycin,12.0,2021,Wednesday
1243,1244,IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients,Recruiting,Diagnostic Test: interleuken 6 level measurment|Diagnostic Test: Interleukin-6 Gene-174C detection,All,"Child, Adult, Older Adult",,120.0,"September 15, 2020",2021-01-01,"September 17, 2020","Bsant Safwat Kasem, Tanta, El Gharbyia, Egypt",https://ClinicalTrials.gov/show/NCT04544033,Egypt,,1.0,2021,Friday
1244,1245,Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients,Not yet recruiting,Drug: Hydroxychloroquine,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,500.0,"August 31, 2020",2021-12-31,"August 11, 2020",,https://ClinicalTrials.gov/show/NCT04437693,Undefined,Hydroxychloroquine,12.0,2021,Friday
1245,1246,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Not yet recruiting,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets,All,18 Years to 50 Years   (Adult),Phase 3,75.0,"March 28, 2020",2020-06-28,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",https://ClinicalTrials.gov/show/NCT04328272,Pakistan,Hydroxychloroquine 200 Mg Oral Tablet|Azithromycin 500Mg Oral Tablet,6.0,2020,Sunday
1246,1247,AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience,Not yet recruiting,,All,"Child, Adult, Older Adult",,500.0,"April 1, 2020",2021-03-01,"April 10, 2020",,https://ClinicalTrials.gov/show/NCT04341103,Undefined,,3.0,2021,Monday
1247,1248,CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis,"Active, not recruiting",Diagnostic Test: Imaging by thoracic scanner,All,"Child, Adult, Older Adult",,1000.0,"March 1, 2020",2020-07-01,"June 5, 2020","CHU la Timone, Marseille, France|CHU Montpellier, Montpellier, France|CHU de Nimes, Nîmes, France|CHU Poitiers, Poitiers, France|CHU Strasbourg, Strasbourg, France|CHU Martinique, Fort-de-France, Martinique",https://ClinicalTrials.gov/show/NCT04418245,France,,7.0,2020,Wednesday
1248,1249,Trial to Study the Benefit of Colchicine in Patients With COVID-19,Recruiting,Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,102.0,"April 30, 2020",2020-11-20,"May 5, 2020","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",https://ClinicalTrials.gov/show/NCT04350320,Spain,Colchicine Tablets|Standard therapy for COVID-19 according to the stablished hospital protocols.,11.0,2020,Friday
1249,1250,Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID),Not yet recruiting,Procedure: ECMO Implantation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 1, 2020",2022-05-01,"June 23, 2020","University Hospital Tuebingen, Tuebingen, Germany",https://ClinicalTrials.gov/show/NCT04341285,Germany,,5.0,2022,Sunday
1250,1251,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Recruiting,Biological: Biological sampling,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 4, 2020",2021-12-31,"May 8, 2020","Luxembourg Institute of Health, Luxembourg, Luxembourg",https://ClinicalTrials.gov/show/NCT04380987,Luxembourg,,12.0,2021,Friday
1251,1252,Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,20.0,"April 6, 2020",2021-04-06,"April 21, 2020","Dept. of Intensive Care 542, University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04354584,Denmark,,4.0,2021,Tuesday
1252,1253,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,576.0,"May 4, 2020",2021-05-01,"September 4, 2020","CHU Angers, Angers, France|CHU de Brest, Brest, France|CHU de Dijon, Dijon, France|CHU Grenoble, Grenoble, France|CHU Lille, Lille, France|CHU Lyon, Lyon, France|CHU Marseille, Marseille, France|CHU Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Paris - Avicenne, Paris, France|CHU Paris - Bichat, Paris, France|CHU Paris - HEGP, Paris, France|CHU Paris - Mondor, Paris, France|CHU Paris - Tenon, Paris, France|Hôpital Lariboisière/ St Louis, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Pitié-Salpêtrière, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France|CHU Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04368221,France,,5.0,2021,Saturday
1253,1254,Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital,Recruiting,Diagnostic Test: Diagnostic Test: serology test for COVID-19,All,"18 Years and older   (Adult, Older Adult)",,258.0,"August 26, 2020",2022-10-01,"September 14, 2020","BENNANI, Marseille, France",https://ClinicalTrials.gov/show/NCT04525911,France,,10.0,2022,Saturday
1254,1255,Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection,Not yet recruiting,Other: no intervention,All,"1 Year to 100 Years   (Child, Adult, Older Adult)",,27000.0,"September 1, 2020",2020-12-31,"August 19, 2020","GSTT NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04519034,United Kingdom,,12.0,2020,Thursday
1255,1256,Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,Device: BIOVITALS,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 1, 2020",2022-01-31,"April 15, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04343794,Hong Kong,,1.0,2022,Monday
1256,1257,COVID-19 SAFE Enrollment,"Active, not recruiting",Behavioral: Opt-out Recruitment Email|Behavioral: Opt-in Recruitment Email,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1200.0,"September 9, 2020",2020-11-01,"November 6, 2020","Penn Medicine, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04506268,United States,,11.0,2020,Sunday
1257,1258,Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?,Recruiting,Other: Questionnaire|Diagnostic Test: IgG,All,"8 Years to 80 Years   (Child, Adult, Older Adult)",,100.0,April 2020,2020-05-01,"April 7, 2020","AssiutU, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04336657,Egypt,,5.0,2020,Friday
1258,1259,"Study Evaluating Safety, Tolerability and Efficacy of Allocetra-OTS in Patients With COVID-19",Not yet recruiting,Drug: Allocetra-OTS|Other: Ringer's lactate,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,50.0,March 2021,2022-03-01,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04659304,Undefined,Allocetra-OTS,3.0,2022,Tuesday
1259,1260,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Recruiting,"Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo",All,"18 Years and older   (Adult, Older Adult)",Phase 2,124.0,"July 1, 2020",2020-12-01,"September 30, 2020","Nova Clinical Research, LLC, Bradenton, Florida, United States|Theia Clinical Research, LLC, Saint Petersburg, Florida, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Inspira Health Center Vineland, Vineland, New Jersey, United States|Sisters of Charity Hospital/ St. Joseph's Campus, Buffalo, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Monument Health Clinical Research, Rapid City, South Dakota, United States|PharmaTex Research, Amarillo, Texas, United States|UT Health Science Center, McGovern Medical School, Houston, Texas, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States",https://ClinicalTrials.gov/show/NCT04409509,Jersey,Placebo,12.0,2020,Tuesday
1260,1261,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,Recruiting,Biological: Ad26.COV2.S|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,"November 15, 2020",2023-05-11,"November 25, 2020","Achieve Clinical Research, LLC, Vestavia Hills, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Synexus Clinical Research US, Inc, Cerritos, California, United States|eStudySite, Chula Vista, California, United States|Catalina Research Institute, Montclair, California, United States|Benchmark Research, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Paradigm Clinical Research Centers, Inc., Wheat Ridge, Colorado, United States|JEM Research, LLC, Atlantis, Florida, United States|Prestige Clinical Research Center, Inc., Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Health Awareness inc., Jupiter, Florida, United States|Altus Research, Inc, Lake Worth, Florida, United States|Compass Research, Melbourne, Melbourne, Florida, United States|Behavioral Clinical Research , Inc, North Miami, Florida, United States|Clinical NeuroScience Solutions, Inc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Accel Research Sites, Eatonton, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centennial Medical Group, Elkridge, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Hassman Research Institute, LLC., Berlin, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Medpharmics, LLC, Albuquerque, New Mexico, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Allergy Asthma Immunology of Rochester, PC (AAIR) - Research Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|American Health Network, LLC, Charlotte, North Carolina, United States|Wilmington Health Associates, Wilmington, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinical NeuroScience Solutions, Inc, Memphis, Tennessee, United States|Centennial Medical Center, Nashville, Tennessee, United States|Tekton Research Inc., Austin, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc., McAllen, Texas, United States|Endeavor Clinical Trials, LLC, San Antonio, Texas, United States|JBR Clinical Research, Salt Lake City, Utah, United States|Alliance for Multispeciality Research, Norfolk, Virginia, United States|Anima, Alken, Belgium|Institute of Tropical Medicine Antwerp, Antwerpen, Belgium|Hopital Erasme, Brussel, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|Az Sint-Maarten, Mechelen, Belgium|Private Practice RESPISOM Namur, Namur, Belgium|IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S., Barranquilla, Colombia|Caja de Compensacion Familiar Cafam, Bogota, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|Hospital General de Medellin Luz Castro de Gutierrez E.S.E, Medellin, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Yopal - Casanare, Colombia|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Grenoble - Hôpital Albert Michallon, La Tronche, France|CHU de Montpellier, Hopital Saint-Eloi, Montpellier, France|Hopital Saint-Antoine, Paris Cedex 12, France|Hopital Cochin, Paris, France|Groupe Hospitalier Sud Hôpital Haut-Leveque Service d'hematologie, Pessac, France|CHU Saint-Etienne - Hôpital Nord, Saint-Etienne Cedex 2, France|Hopital Purpan, Toulouse Cedex 09, France|Centre Hospitalier Universitaire de Tours, Tours Cedex, France|Hôpital de Brabois Adultes, Vandoeuvre les Nancy, France|Uniklinik Köln, Köln, Germany|Klinikum rechts der Isar der TU Munchen, München, Germany|Riverside Medical Center, Bacolod, Philippines|West Visayas State University Medical Center, Iloilo City, Philippines|Tropical Disease Foundation, Makati, Philippines|Makati Medical Center, Manila, Philippines|Medical Center Manila, Manila, Philippines|TREAD Research Tygerberg Hospital, Cape Town, South Africa|Centre of Tuberculosis Research Innovation, Cape Town, South Africa|Worthwhile Clinical trials, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Dr AA Mahomed Medical Centre, Moloto, South Africa|VX Pharma, Pretoria, South Africa|Dr J.M. Engelbrecht Trial Site, Somerset West, South Africa|Be Part Yoluntu Centre, Western Cape, South Africa|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Univ. de La Paz, Madrid, Spain|Hosp. Quiron Madrid Pozuelo, Madrid, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Powys Teaching Local Health Board - Bronllys Hospital, Brecon, United Kingdom|Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Bristol NHS Trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Royal Free Hospital, Hampstead, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Guy's and St Thomas' Hospital, London,, United Kingdom|Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|University of Oxford, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT04614948,Belgium,,5.0,2023,Thursday
1261,1262,Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,Not yet recruiting,Drug: Ruxolitinib,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,64.0,"April 20, 2020",2021-01-31,"April 13, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04331665,Canada,Ruxolitinib,1.0,2021,Sunday
1262,1263,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,Not yet recruiting,Drug: Camostat Mesilate|Drug: Placebo|Other: Standard of Care Treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,November 2020,2021-04-01,"November 17, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04524663,United States,Camostat Mesilate|Placebo,4.0,2021,Thursday
1263,1264,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,Completed,Other: Shanshamani Vati Plus,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,26.0,"October 8, 2020",2020-11-03,"November 19, 2020","Aarogyam (UK) CIC, Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04621903,United Kingdom,,11.0,2020,Tuesday
1264,1265,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,Recruiting,Biological: Ampion|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"October 28, 2020",2021-03-31,"December 2, 2020","Research Site, Colorado Springs, Colorado, United States",https://ClinicalTrials.gov/show/NCT04606784,United States,,3.0,2021,Wednesday
1265,1266,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,Drug: Camostat|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,150.0,"November 4, 2020",2023-01-01,"November 12, 2020","Ghent University Hospital, Algemene Inwendige Ziekten, Gent, Belgium",https://ClinicalTrials.gov/show/NCT04625114,Belgium,Camostat|Placebo,1.0,2023,Sunday
1266,1267,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,Device: Control swab|Device: Prototype swab,All,"up to 99 Years   (Child, Adult, Older Adult)",Not Applicable,40.0,"April 24, 2020",2020-07-31,"April 29, 2020","University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT04368260,United States,,7.0,2020,Friday
1267,1268,"Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19",Recruiting,,All,70 Years and older   (Older Adult),,255.0,"March 15, 2020",2021-01-31,"December 2, 2020","Angers University Hospital, Angers, France",https://ClinicalTrials.gov/show/NCT04560608,France,,1.0,2021,Sunday
1268,1269,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home,Recruiting,Device: Connected devices measurements,All,"18 Years and older   (Adult, Older Adult)",,400.0,"September 14, 2020",2021-09-14,"September 23, 2020","CHU Grenoble-Alpes, Grenoble, Auvergne-Rhône-Alpes, France|CHU d'Amiens, Amiens, Hauts-de-France, France|Hôpital d'Instruction des Armées Bégin, Saint-Mandé, Ile De France, France|Hôpital d'Instruction des Armées Percy, Clamart, Ile-de-France, France",https://ClinicalTrials.gov/show/NCT04560855,France,,9.0,2021,Tuesday
1269,1270,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",Completed,Behavioral: turkish physicians,All,25 Years to 55 Years   (Adult),,200.0,"March 26, 2020",2020-05-28,"June 5, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",https://ClinicalTrials.gov/show/NCT04327531,Turkey,,5.0,2020,Thursday
1270,1271,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Not yet recruiting,Drug: Naltrexone|Dietary Supplement: NAD+,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60.0,November 2020,2021-06-01,"October 28, 2020","AgelessRx, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04604704,United States,Naltrexone,6.0,2021,Tuesday
1271,1272,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Not yet recruiting,Device: current IPAC-UHN PPE|Device: modified IPAC-UHN PPE,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,42.0,"June 1, 2020",2020-08-31,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04373096,Undefined,,8.0,2020,Monday
1272,1273,Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients,Recruiting,Other: No interventions planned,All,"Child, Adult, Older Adult",,40.0,"April 1, 2020",2020-12-01,"May 1, 2020","Jessa Hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04371679,Belgium,,12.0,2020,Tuesday
1273,1274,Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Completed,,All,"Child, Adult, Older Adult",,517.0,"May 15, 2020",2020-06-06,"August 7, 2020","Carme Hernández, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04503434,Spain,,6.0,2020,Saturday
1274,1275,Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment,Enrolling by invitation,Biological: Antibody testing,All,"18 Years and older   (Adult, Older Adult)",,70812.0,"January 1, 2021",2022-12-31,"September 10, 2020","Feinstein Institutes for Medical Research, Northwell Health, Great Neck, New York, United States",https://ClinicalTrials.gov/show/NCT04542200,United States,,12.0,2022,Saturday
1275,1276,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,Not yet recruiting,Drug: Brexanolone|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,November 2020,2021-10-01,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04537806,Undefined,Brexanolone|Placebo,10.0,2021,Friday
1276,1277,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Terminated,Behavioral: Nudge,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,45.0,"July 27, 2020",2020-09-30,"October 5, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04379375,United States,,9.0,2020,Wednesday
1277,1278,An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease,Completed,Other: No intervention,All,"18 Years to 75 Years   (Adult, Older Adult)",,347.0,"April 24, 2020",2020-05-31,"June 17, 2020","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04352491,India,,5.0,2020,Sunday
1278,1279,The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19,Not yet recruiting,Drug: SCTA01|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,795.0,"February 10, 2021",2021-10-10,"November 25, 2020",,https://ClinicalTrials.gov/show/NCT04644185,Undefined,SCTA01,10.0,2021,Sunday
1279,1280,Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia,Not yet recruiting,Drug: AstroStem-V,All,"19 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"December 1, 2020",2022-04-01,"September 11, 2020",,https://ClinicalTrials.gov/show/NCT04527224,Undefined,AstroStem-V,4.0,2022,Friday
1280,1281,The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19,Not yet recruiting,Drug: Lucinactant,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,October 2020,2021-04-01,"October 8, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04389671,United States,Lucinactant,4.0,2021,Thursday
1281,1282,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",Device: Virtual reality therapy first|Device: Conventional therapy first,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 18, 2020",2020-12-01,"September 3, 2020","Comitê de Ética da Universidade Federal, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04537858,Brazil,,12.0,2020,Tuesday
1282,1283,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600.0,"March 29, 2020",2022-03-01,"April 27, 2020","Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04318444,United States,Hydroxychloroquine|Placebo oral tablet,3.0,2022,Tuesday
1283,1284,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,Completed,Other: Admission to ICU for COVID-19,All,"18 Years and older   (Adult, Older Adult)",,1563.0,"March 6, 2020",2020-05-06,"July 9, 2020","Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Östergötland, Linköping, Östergötland, Sweden",https://ClinicalTrials.gov/show/NCT04462393,Sweden,,5.0,2020,Wednesday
1284,1285,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,Drug: Favipiravir|Drug: Only Standard Treatment,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,50.0,May 2020,2020-07-01,"May 26, 2020","Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4), Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04402203,Bangladesh,Favipiravir|Only Standard Treatment,7.0,2020,Wednesday
1285,1286,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),Recruiting,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses),All,"18 Years and older   (Adult, Older Adult)",Phase 2,78.0,"May 4, 2020",2020-08-04,"June 17, 2020","Hospital Universitario Ramón y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04435717,Spain,Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses),8.0,2020,Tuesday
1286,1287,Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19,Recruiting,Biological: COVI-GUARD|Other: Standard of Care|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,"September 17, 2020",2021-02-01,"November 20, 2020","Temple University Lung Center, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04454398,United States,Placebo,2.0,2021,Monday
1287,1288,Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19,Enrolling by invitation,Other: Telehealth,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 14, 2020",2021-04-01,"April 22, 2020","Duke Cancer Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04357574,United States,,4.0,2021,Thursday
1288,1289,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,Recruiting,Biological: Ad26.COV2.S|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60000.0,"September 7, 2020",2023-03-10,"December 3, 2020","Synexus Clinical Research US, Inc, Birmingham, Alabama, United States|University of Alabama Birmingham, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States|Optimal Research, Huntsville, Alabama, United States|Coastal Clinical Research, Inc, Mobile, Alabama, United States|Synexus Clinical Research US, Inc, Glendale, Arizona, United States|VA Medical Center, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|East Bay AIDS Center (EBAC) CRS, Oakland, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSD Antiviral Research Center AVRC, San Diego, California, United States|Wr-McCr, Llc, San Diego, California, United States|VA Medical Center, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Denver, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale Medical Group, New Haven, Connecticut, United States|Alliance for Multispeciality Research, Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|North Florida South Georgia Veteran Health System, Gainesville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Research Centers of America, LLC, Hollywood, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|University of Miami- Jackson Memorial Hospital, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|James A Haley VA Hospital GNS, Tampa, Florida, United States|Synexus Clinical Research US, Inc, The Villages, Florida, United States|Emory University of Medicine, Atlanta, Georgia, United States|The Hope Clinic at Emory University, Decatur, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Jesse Brown VAMC Department of Surgery, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The Core Center, Chicago, Illinois, United States|University of IL Chicago, Chicago, Illinois, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Optimal Research, Peoria, Illinois, United States|Synexus Clinical Research US, Inc, Evansville, Indiana, United States|Indiana University Adult Cystic Fibrosis Center, Indianapolis, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Benchmark Research, Metairie, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Investigative Clinical Research, L.L.C., Annapolis, Maryland, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States|Fenway Health, Boston, Massachusetts, United States|University of Michigan Neuorsurgery A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|MediSync Clinical Research, Petal, Mississippi, United States|The Center For Pharmaceutical Research, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Meridian Clinical Research - Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Bronx Veterans Affairs Medical Center, Bronx, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Bronx Prevention Research Center CRS, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|New York Blood Center, New York, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Tryon Medical Group, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Durham VAMC, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc, Akron, Ohio, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Synexus Clinical Research US, Inc, Columbus, Ohio, United States|Corvallis Clinic PC, Corvallis, Oregon, United States|Clinical Research Institute of Southern Oregon, P.C., Medford, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|VA Medical Center, Columbia, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Avera Health, Harrisburg, South Dakota, United States|PMG Research of Bristol, Bristol, Tennessee, United States|AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Clinical Research Associates Inc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Optimal Research, LLC, Austin, Texas, United States|AIDS Arms Incorporated Trinity Health and Wellness Center, Dallas, Texas, United States|Synexus Clinical Research US, Inc, Dallas, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University Of Texas Medical School At Houston, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Gordon Crofoot, MD, Houston, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Health Research of Hampton Roads, Inc, Newport News, Virginia, United States|Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States|CIPREC, Buenos Aires, Argentina|Helios Salud Sa, Buenos Aires, Argentina|CEMEDIC, Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma Buenos Aires, Argentina|Clinical Trials Division-Stamboulian Servicios de Salud, Ciudad Autonoma Buenos Aires, Argentina|Clínica y Maternidad Suizo Argentina, Ciudad Autonoma de Buenos Aires, Argentina|Fundacion Huesped, Ciudad Autonoma De Buenos Aire, Argentina|CEMIC Saavedra, Ciudad de Buenos Aires, Argentina|Hospital J. M. Ramos Mejía, Ciudad de Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Faculdade de Medicina Barretos FACISB, Barretos, Brazil|Hospital Das Clinicas Da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil|L2IP - Instituto de Pesquisas Clínicas, Brasília, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|Fundação Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil|Hospital São José, Criciúma, Brazil|Oncovida - Centro de Onco-Hematologia de Mato Grosso, Cuiabá, Brazil|Hospital Nossa Senhora Das Gracas, Curitiba, Brazil|Centro de Estudos e Pesquisas em Moléstias Infecciosas, Natal, Brazil|IEC - Instituto Evandro Chagas, Para, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirão Preto, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Brasil de Pesquisa Clinica, Rio de Janeiro, Brazil|FIO CRUZ- Fundação Oswaldo Cruz - Inst de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, Brazil|Hospital Geral De Nova Igaucu Brazil, Rio de Janeiro, Brazil|Fundação Bahiana De Infectologia, Salvador, Brazil|Obras Sociais Irma Dulce, Salvador, Brazil|Hospital da Universidade Federal de Santa Maria CEP/UFSM, Santa Maria, Brazil|Universidade Municipal de Sao Caetano do Sul, Sao Caetano do Sul, Brazil|Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Brazil|Centro de Referência E Treinamento Dst/Aids, Sao Paulo, Brazil|CPQuali Pesquisa Clinica LTDA ME, São Paulo, Brazil|Instituto de infectologia Emilio Ribas, São Paulo, Brazil|Hospital Sirio Libanes, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil|Cepic - Centro Paulista De Investigacao Clinica, São Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil|Bioclinica Santiago Bulnes, Santiago, Chile|Facultad de Medicina Universidad de Chile, Santiago, Chile|Hospital Padre Hurtado, Santiago, Chile|Clinica del Maule, Talca, Chile|Hospital Dr Hernan Henriquez Aravena, Temuco, Chile|Centro de Estudios Clínicos V Región Ltda, Viña del Mar, Chile|Clinica de la Costa, Barranquilla, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Colombia|Hospital Universidad del Norte, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Asistencia Cientifica de Alta Complejidad S.A.S, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Medplus Medicina Prepagada S.A., Bogota, Colombia|Centro de Investigaciones Clinicas S.A.S., Cali, Colombia|Fundación Valle del Lili, Cali, Colombia|Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca, Floridablanca, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Programa de Estudio y Control de Enfermedades Tropicales, Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Colombia|Hospital Pablo Tobon Uribe, Medellín, Colombia|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de Mexico, Mexico|Instituto Nacional de Salud Publica, Cuernavaca, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico|Unidad de Atención Medica e Investigacion en Salud (UNAMIS), Merida, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital General Dr. Manuel Gea González, Mexico City, Mexico|Centro Medico Nacional Siglo XXI IMSS, Mexico, Mexico|CAIMED Investigacion en salud S.A de C.V., Mexico, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico|Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez', Monterrey, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Infectolab, Tijuana, Mexico|Centro de Invetigaciones Medicas, Callao, Peru|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Centro de Investigaciones Tecnologicas, Biomedica y medio ambientales (CITBM), Callao, Peru|Asociacion Civil Selva Amazonica (ACSA), Iquitos, Peru|Asociacion Civil Impacta Salud y Educacion - Barranco, Lima - Barranco, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil Via Libre, Lima, Peru|Instituto de Investigacion Nutricional, Lima, Peru|Asociacion Civil Impacta Salud y Educacion- San Miguel CRS, Lima, Peru|Josha Research, Bloemfontein, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|Family Clinical Research Unit FAM-CRU, Cape Town, South Africa|TASK Central, Cape Town, South Africa|Desmond Tutu HIV Foundation, Cape Town, South Africa|University of Cape Town IDM/CIDRI Research Site, Cape Town, South Africa|Desmond Tutu Hiv Foundation - University of Cape Town, Cape Town, South Africa|Masiphumelele Research Centre, Cape Town, South Africa|Ndlovu Elandsdoorn Site, Dennilton, South Africa|SA Medical Research Council, Durban, South Africa|SA Medical Research Council, Durban, South Africa|South African Medical Research Council Isipingo Clinical Research Site, Isipingo Rail, South Africa|CRISMO Bertha Gxowa Research Centre, Johannesburg, South Africa|Shandukani Research Centre, Johannesburg, South Africa|The Aurum Institute Klerksdorp Clinical Research Centre, Klerksdorp, South Africa|Qhakaza Mbokodo Research Centre, KwaZulu-Natal, South Africa|South African Medical Research Council Chatsworth Clinical Research Site, KwaZulu-Natal, South Africa|Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal, South Africa|Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa|Mzansi Ethical Research Centre, Middelburg, South Africa|Nelson Mandela Academic Clinical Research Unit 'NeMACRU', Mthatha, South Africa|PHOENIX PHARMA (Pty) Ltd, Port Elizabeth, South Africa|MeCRU Clinical Research Unit, Pretoria, South Africa|Synexus Watermeyer, Pretoria, South Africa|The Aurum Institute Rustenburg Clinical Research Site, Rustenburg, South Africa|Setshaba Research Centre, Soshanguve, South Africa|Perinatal HIV Research Unit (PHRU), Kliptown, Soweto, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa|The Aurum Institute: Tembisa - Clinic 4, Tembisa, South Africa|CAPRISA Vulindlela Clinic, Vulindlela, South Africa|University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng, South Africa|SATVI, Brewelskloof Hospital, Worcester, South Africa",https://ClinicalTrials.gov/show/NCT04505722,Argentina,,3.0,2023,Friday
1289,1290,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Recruiting,Drug: Opaganib|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,270.0,"August 21, 2020",2021-02-01,"December 1, 2020","ABC-201 Site 401, Sao Paulo, Brazil|ABC-201 Site 702, Ashdod, Israel|ABC-201 Site 704, Holon, Israel|ABC-201 Site 701, Jerusalem, Israel|ABC-201 Site 705, Nahariya, Israel|ABC-201 Site 703, Safed, Israel|ABC-201 Site 501, Mexico City, Mexico|ABC-201 Site 503, Sinaloa, Mexico|ABC-201 Site 110, Barnaul, Russian Federation|ABC-201 Site 122, Kirovsk, Russian Federation|ABC-201 Site 101, Moscow, Russian Federation|ABC-201 Site 132, Moscow, Russian Federation|ABC-201 Site 120, Murmansk, Russian Federation|ABC-201 Site 103, Ryazan, Russian Federation|ABC-201 Site 114, Ryazan, Russian Federation|ABC-201 Site 129, Saint Petersburg, Russian Federation|ABC-201 Site 108, Saratov, Russian Federation|ABC-201 Site 102, Smolensk, Russian Federation|ABC-201 Site 109, St Petersburg, Russian Federation|ABC-201 Site 111, St Petersburg, Russian Federation|ABC-201 Site 104, Tver, Russian Federation|ABC-201 Site 118, Volgograd, Russian Federation|ABC-201 Site 112, Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04467840,Brazil,Opaganib|Placebo,2.0,2021,Monday
1290,1291,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Recruiting,Drug: Remdesivir|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"September 4, 2020",2021-01-31,"October 28, 2020","Combined Military Hospital, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04596839,Bangladesh,Remdesivir,1.0,2021,Sunday
1291,1292,Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?,Not yet recruiting,Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|Drug: The standard therapy,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,1000.0,November 2020,2021-12-01,"November 10, 2020",,https://ClinicalTrials.gov/show/NCT04623385,Undefined,The standard therapy,12.0,2021,Wednesday
1292,1293,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,Other: convalescent plasma,All,18 Years to 55 Years   (Adult),Not Applicable,2000.0,"May 1, 2020",2021-04-01,"September 29, 2020","National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistan",https://ClinicalTrials.gov/show/NCT04352751,Pakistan,,4.0,2021,Thursday
1293,1294,"Study of the Spread of COVID-19 in Saint Petersburg, Russia","Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,1038.0,"May 27, 2020",2020-10-28,"August 25, 2020","Clinic ""Scandinavia"", Saint Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04406038,Russian Federation,,10.0,2020,Wednesday
1294,1295,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Recruiting,Device: Innova Lateral Flow Device,All,up to 17 Years   (Child),Not Applicable,400.0,"November 5, 2020",2020-11-19,"November 16, 2020","Alder Hey in the Park, Liverpool, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04629157,United Kingdom,,11.0,2020,Thursday
1295,1296,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,Recruiting,Biological: F-652|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,38.0,"October 9, 2020",2021-06-30,"September 16, 2020","Tulane University School of Medicine, New Orleans, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04498377,United States,,6.0,2021,Wednesday
1296,1297,Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"February 22, 2020",2020-08-31,"May 14, 2020","Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico, Milan, Italy",https://ClinicalTrials.gov/show/NCT04388670,Italy,,8.0,2020,Monday
1297,1298,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Drug: Clazakizumab|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,30.0,"May 7, 2020",2020-12-01,"October 28, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04363502,United States,Clazakizumab|Placebo,12.0,2020,Tuesday
1298,1299,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19,Not yet recruiting,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,June 2020,2020-08-01,"June 17, 2020",,https://ClinicalTrials.gov/show/NCT04435314,Undefined,Nitazoxanide|Placebo,8.0,2020,Saturday
1299,1300,Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Drug: poractant alfa,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,20.0,"May 29, 2020",2021-01-30,"July 28, 2020","CH Francois Quesnay, Mantes la Jolie, France",https://ClinicalTrials.gov/show/NCT04384731,France,poractant alfa,1.0,2021,Saturday
1300,1301,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),Not yet recruiting,Drug: Enoxaparin|Drug: Rivaroxaban,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,150.0,"December 1, 2020",2021-07-31,"November 23, 2020",,https://ClinicalTrials.gov/show/NCT04640181,Undefined,Enoxaparin|Rivaroxaban,7.0,2021,Saturday
1301,1302,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"Active, not recruiting",Drug: Convalescent Plasma|Other: Standard Care Therapy,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,100.0,"May 9, 2020",2021-08-09,"July 22, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04374487,India,Convalescent Plasma,8.0,2021,Monday
1302,1303,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Recruiting,Biological: Convalescent plasma transfusion,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"June 6, 2020",2021-12-31,"August 6, 2020","Inova Fairfax Medical Campus, Falls Church, Virginia, United States",https://ClinicalTrials.gov/show/NCT04502472,United States,,12.0,2021,Friday
1303,1304,Patterns of Arrhythmias and Conduction Block in COVID-19 Patients and Its Relation to Myocardial Injury Detected by Cardiac Magnetic Resonance,Not yet recruiting,Diagnostic Test: Cardiac Magnetic resonance imaging,All,"18 Years to 80 Years   (Adult, Older Adult)",,50.0,"November 1, 2020",2024-01-01,"October 14, 2020",,https://ClinicalTrials.gov/show/NCT04584411,Undefined,,1.0,2024,Monday
1304,1305,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Not yet recruiting,Behavioral: Hospital: DD-CA|Behavioral: Hospital: Usual Care (UC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,172.0,"December 1, 2020",2021-08-31,"November 13, 2020",,https://ClinicalTrials.gov/show/NCT04591015,Undefined,,8.0,2021,Tuesday
1305,1306,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Recruiting,Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Drug: Telmisartan 40Mg Oral Tablet|Drug: Atorvastatin 20 Mg Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,294.0,"November 27, 2020",2021-03-26,"December 1, 2020","Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire",https://ClinicalTrials.gov/show/NCT04466241,Côte d'Ivoire,Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Telmisartan 40Mg Oral Tablet|Atorvastatin 20 Mg Oral Tablet,3.0,2021,Friday
1306,1307,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,Recruiting,Drug: COVID-19 Convalscent Plasma,All,"15 Years to 85 Years   (Child, Adult, Older Adult)",Phase 1,300.0,"May 21, 2020",2020-12-30,"July 21, 2020","Ministry Of Health, Kuwait, Kuwait",https://ClinicalTrials.gov/show/NCT04474340,Kuwait,COVID-19 Convalscent Plasma,12.0,2020,Wednesday
1307,1308,Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs,Completed,Other: Cardiopulmonary resuscitation|Other: Modified Rankin score,All,"18 Years and older   (Adult, Older Adult)",,186.0,"May 2, 2020",2020-06-30,"November 10, 2020","CHU Felix Guyon, Saint-Denis, La Reunion, France|CHU Amiens Picardie, Amiens, France|CH Angoulème, Angoulême, France|CH Argenteuil, Argenteuil, France|CH Bethune, Beuvry, France|CHU Ambroise Paré AP-HP, Boulogne-Billancourt, France|CH Brive, Brive-la-Gaillarde, France|CHU Caen, Caen, France|Hôpital Privé St Martin, Caen, France|CH Cahors, Cahors, France|CHU Antoine Béclère AP-HP, Clamart, France|CH Louis Mourier AP-HP, Colombes, France|CHU Henri Mondor AP-HP, Créteil, France|CHU Dijon, Dijon, France|CH de la Dracénie, Draguignan, France|CHI Frejus St Raphael, Fréjus, France|Grand Hôpital de l'Est Francilien, Jossigny, France|CH Versailles, Le Chesnay, France|CHU Kremlin Bicêtre, Le Kremlin-Bicêtre, France|CH Lens, Lens, France|CHRU Roger Salengro, Lille, France|CHU Meaux, Meaux, France|Groupe Hospitalier Sud Ile de France, Melun, France|CHU Montpellier, Montpellier, France|CHR Orléans, Orléans, France|CHU Lariboisière AP-HP, Paris, France|CHU Saint Louis AP-HP, Paris, France|CHU St Antoine, Paris, France|Groupe Hospitalier Saint Joseph, Paris, France|CHU Necker Enfants Malades, Paris, France|CHU Pitié Salpétrière, Paris, France|CHU Rouen, Rouen, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Hôpital Nord Franche Comté, Trévenans, France|CH Etampes, Étampes, France|CHU Martinique - Fort de France, Fort-de-France, Martinique",https://ClinicalTrials.gov/show/NCT04373759,France,,6.0,2020,Tuesday
1308,1309,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Completed,Other: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|Other: placebo rinse,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,23.0,"June 18, 2020",2020-10-23,"November 20, 2020","Escuela odontologia. Facultad de Salud Hospital del Valle, Cali, Colombia",https://ClinicalTrials.gov/show/NCT04563689,Colombia,,10.0,2020,Friday
1309,1310,Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia,Not yet recruiting,Drug: Nafamostat Mesylate,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,84.0,"June 10, 2020",2021-04-30,"June 9, 2020",,https://ClinicalTrials.gov/show/NCT04418128,Undefined,Nafamostat Mesylate,4.0,2021,Friday
1310,1311,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Recruiting,Drug: Icosapent ethyl,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,100.0,"June 4, 2020",2020-12-01,"September 11, 2020","North York Diagnostic and Cardiology Clinic, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04412018,Canada,Icosapent ethyl,12.0,2020,Tuesday
1311,1312,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Recruiting,Device: Volatile Organic Compounds analysis|Other: Canine odor detection of Volatile Organic Compounds,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"October 21, 2020",2021-10-01,"November 4, 2020","Foch hospital, Suresnes, France",https://ClinicalTrials.gov/show/NCT04614883,France,,10.0,2021,Friday
1312,1313,Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers,Recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,385.0,"April 15, 2020",2020-12-01,"April 30, 2020","Centre François Baclesse, Caen, France",https://ClinicalTrials.gov/show/NCT04366154,France,,12.0,2020,Tuesday
1313,1314,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,"Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,20.0,"April 19, 2020",2020-09-21,"May 4, 2020","Imam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04370288,"Iran, Islamic Republic of","MCN (Methylene blue, vitamin C, N-acetyl cysteine)",9.0,2020,Monday
1314,1315,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,Drug: Quercetin|Dietary Supplement: bromelain|Drug: Zinc|Drug: Vitamin C,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60.0,"June 20, 2020",2020-07-30,"July 13, 2020","Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04468139,Saudi Arabia,Quercetin|Zinc|Vitamin C,7.0,2020,Thursday
1315,1316,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,Other: Moderate Intensity Aerobic Exercises,All,24 Years to 45 Years   (Adult),Not Applicable,30.0,"January 1, 2020",2020-10-01,"October 9, 2020","Motaz Alawna, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04581291,Turkey,,10.0,2020,Thursday
1316,1317,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"April 14, 2020",2021-03-31,"April 17, 2020","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico",https://ClinicalTrials.gov/show/NCT04318015,Mexico,Hydroxychloroquine|Placebo oral tablet,3.0,2021,Wednesday
1317,1318,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,1124.0,"April 6, 2020",2022-05-01,"August 21, 2020","National Research Center for Preventive Medicine of the Ministry of Health, Moscow, Russian Federation|National Medical and Surgical Center named after N.I.Pirogov of the Ministry of Health of Russian Federation, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04522076,Russian Federation,,5.0,2022,Sunday
1318,1319,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,Recruiting,Drug: Niclosamide suspension|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"October 8, 2020",2021-02-14,"October 12, 2020","Akdeniz Üniversitesi Tıp Fakültesi Hastanesi, Antalya, Turkey|Antalya Eğitim ve Araştırma Hastanesi, Antalya, Turkey|Gaziantep Üniversitesi Tıp Fakültesi Hastanesi, Gaziantep, Turkey|Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi, Istanbul, Turkey|Dokuz Eylül Üniversitesi Hastanesi, İzmir, Turkey|İzmir SBÜ Tepecik Eğitim ve Araştırma Hastanesi, İzmir, Turkey|SBÜ Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi, İzmir, Turkey|İzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi, İzmir, Turkey",https://ClinicalTrials.gov/show/NCT04558021,Turkey,Niclosamide suspension,2.0,2021,Sunday
1319,1320,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Drug: Tacrolimus|Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,84.0,"April 1, 2020",2020-07-01,"April 10, 2020","Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04341038,Spain,Tacrolimus|Methylprednisolone,7.0,2020,Wednesday
1320,1321,Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Recruiting,Diagnostic Test: Point-of-care test for SARS-CoV-2,All,"18 Years to 100 Years   (Adult, Older Adult)",,1000.0,"June 19, 2020",2021-05-31,"July 7, 2020","Manchester University NHS Foundation Trust, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04408170,United Kingdom,,5.0,2021,Monday
1321,1322,Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome,Not yet recruiting,Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"November 6, 2020",2022-08-06,"November 12, 2020",,https://ClinicalTrials.gov/show/NCT04625738,Undefined,,8.0,2022,Saturday
1322,1323,COVID 19 Biomarkers,Recruiting,Diagnostic Test: serum inflammatory biomarkers,All,"Child, Adult, Older Adult",,150.0,"March 30, 2020",2021-09-30,"May 8, 2020","Vancouver General Hospital, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04363008,Canada,,9.0,2021,Thursday
1323,1324,Impact of COVID-19 on Pediatric Dental Practice In Egypt.,Not yet recruiting,,All,"18 Years to 75 Years   (Adult, Older Adult)",,290.0,February 2021,2022-01-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04592510,Undefined,,1.0,2022,Saturday
1324,1325,"RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU",Not yet recruiting,Dietary Supplement: zinc gluconate and ascorbic acid,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50.0,"October 1, 2020",2021-09-01,"September 22, 2020","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04558424,Bangladesh,,9.0,2021,Wednesday
1325,1326,Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers.,Not yet recruiting,,All,"18 Years to 70 Years   (Adult, Older Adult)",,600.0,"January 15, 2021",2021-02-15,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04477213,Undefined,,2.0,2021,Monday
1326,1327,Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment,Not yet recruiting,Drug: Aerosolized 13 cis retinoic acid|Drug: Aerosolized All trans retinoic acid|Other: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,360.0,October 2020,2020-12-01,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04396067,Undefined,Aerosolized 13 cis retinoic acid|Aerosolized All trans retinoic acid,12.0,2020,Tuesday
1327,1328,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,Recruiting,Device: CytoSorb,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,24.0,"May 3, 2020",2020-12-01,"August 19, 2020","CHU Brugmann, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04518969,Belgium,,12.0,2020,Tuesday
1328,1329,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,Recruiting,Drug: Abivertinib|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"October 9, 2020",2021-03-01,"December 11, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04440007,United States,Abivertinib,3.0,2021,Monday
1329,1330,Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,Not yet recruiting,Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,November 2020,2021-04-01,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04551768,Undefined,50 mg/mL Virazole|100 mg/mL Virazole,4.0,2021,Thursday
1330,1331,"Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection",Recruiting,Drug: Antithrombin III,All,"Child, Adult, Older Adult",,300.0,"October 19, 2020",2021-01-01,"December 3, 2020","Octapharma Research Site, Innsbruck, Austria|Octapharma Research Site, Wien, Austria|Octapharma Research Site, Strasbourg, France|Octapharma Research Site, Aachen, Germany|Octapharma Research Site, Essen, Germany",https://ClinicalTrials.gov/show/NCT04651400,Austria,Antithrombin III,1.0,2021,Friday
1331,1332,"Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)",Recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"May 29, 2020",2020-12-01,"August 4, 2020","CHU Brugmann, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04497246,Belgium,,12.0,2020,Tuesday
1332,1333,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,Drug: liposomal lactoferrin,All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"April 15, 2020",2020-07-02,"July 17, 2020","University of Rome Tor Vergata, Rome, Italy",https://ClinicalTrials.gov/show/NCT04475120,Italy,liposomal lactoferrin,7.0,2020,Thursday
1333,1334,Prediction of Clinical Course in COVID19 Patients,Recruiting,Other: CT-Scan,All,"18 Years and older   (Adult, Older Adult)",,800.0,"March 1, 2020",2020-09-30,"May 18, 2020","Chu Saint-Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04377685,France,,9.0,2020,Wednesday
1334,1335,A Novel Nomogram to Predict Severity of COVID-19,Recruiting,Other: other,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"January 17, 2020",2021-12-31,"July 14, 2020","Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China",https://ClinicalTrials.gov/show/NCT04366024,China,,12.0,2021,Friday
1335,1336,Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients,Not yet recruiting,Drug: Nitazoxanide|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,300.0,July 2020,2020-09-01,"June 22, 2020",,https://ClinicalTrials.gov/show/NCT04441398,Undefined,Nitazoxanide|Placebo,9.0,2020,Tuesday
1336,1337,SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,Not yet recruiting,Diagnostic Test: Presence of specific anti-SARS-CoV-2 antibodies,All,"18 Years and older   (Adult, Older Adult)",,5400.0,July 2020,2020-10-01,"July 22, 2020",,https://ClinicalTrials.gov/show/NCT04482361,Undefined,,10.0,2020,Thursday
1337,1338,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,"July 30, 2020",2020-12-06,"November 20, 2020","Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04486508,"Iran, Islamic Republic of",intermediate dose Enoxaparin/ unfractionated heparin|standard prophylactic dose Enoxaparin/ unfractionated heparin|Atorvastatin 20mg|Matched placebo,12.0,2020,Sunday
1338,1339,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Recruiting,Biological: Infusion IV of Mesenchymal Stem cells,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10.0,"May 1, 2020",2021-05-01,"June 4, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04416139,Mexico,,5.0,2021,Saturday
1339,1340,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Recruiting,Device: RD-X19,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"November 18, 2020",2021-04-30,"December 10, 2020","Site 2, Miami, Florida, United States|Site 1, College Station, Texas, United States",https://ClinicalTrials.gov/show/NCT04662671,United States,,4.0,2021,Friday
1340,1341,Virtual Assistant for COVID-19 PPE,Not yet recruiting,"Other: Virtual Assistant first, then Human Coach|Other: Human Coach first, then Virtual Assistant",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 30, 2020",2021-05-01,"June 17, 2020",,https://ClinicalTrials.gov/show/NCT04435275,Undefined,,5.0,2021,Saturday
1341,1342,Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,Not yet recruiting,Drug: 50 mg/mL Virazole|Drug: 100 mg/mL Virazole,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,November 2020,2021-04-01,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04356677,Undefined,50 mg/mL Virazole|100 mg/mL Virazole,4.0,2021,Thursday
1342,1343,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Drug: Interleukin-7|Drug: Placebo,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"June 8, 2020",2020-12-30,"June 22, 2020","University Hospital of Limoges, Limoges, France|Hôpital Edouard Herriot, Lyon, France",https://ClinicalTrials.gov/show/NCT04407689,France,Interleukin-7|Placebo,12.0,2020,Wednesday
1343,1344,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,Recruiting,Drug: Interleukin-7|Drug: Placebos,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"May 14, 2020",2020-12-30,"May 15, 2020","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04379076,United Kingdom,Interleukin-7|Placebos,12.0,2020,Wednesday
1344,1345,Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19,Not yet recruiting,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,380.0,December 2020,2021-05-01,"November 27, 2020",,https://ClinicalTrials.gov/show/NCT04423861,Undefined,Nitazoxanide|Placebo,5.0,2021,Saturday
1345,1346,Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?,Not yet recruiting,,All,"Child, Adult, Older Adult",,60.0,"July 1, 2020",2020-11-01,"June 26, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04445610,Egypt,,11.0,2020,Sunday
1346,1347,Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19,Not yet recruiting,Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid),All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2,45.0,"October 20, 2020",2020-11-20,"October 6, 2020","Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt",https://ClinicalTrials.gov/show/NCT04577378,Egypt,Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid),11.0,2020,Friday
1347,1348,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Recruiting,"Dietary Supplement: Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Combination Product: Standard Therapy",All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"October 23, 2020",2021-11-01,"October 28, 2020","Anestesia e Rianimazione Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy",https://ClinicalTrials.gov/show/NCT04568876,Italy,,11.0,2021,Monday
1348,1349,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Drug: BGB-DXP593|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,180.0,"October 30, 2020",2021-02-28,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04551898,Undefined,BGB-DXP593|Placebo,2.0,2021,Sunday
1349,1350,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 1|Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 2|Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 1|Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 2|Biological: SARS-CoV-2 vaccine formulation 2 without adjuvant|Biological: Placebo (0.9% normal saline),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,440.0,"September 3, 2020",2021-10-01,"November 19, 2020","Investigational Site Number 8400004, Birmingham, Alabama, United States|Investigational Site Number 8400012, Rolling Hills Estates, California, United States|Investigational Site Number 8400011, Hollywood, Florida, United States|Investigational Site Number 8400019, Melbourne, Florida, United States|Investigational Site Number 8400016, Boston, Massachusetts, United States|Investigational Site Number 8400002, Omaha, Nebraska, United States|Investigational Site Number 8400001, Rochester, New York, United States|Investigational Site Number 8400007, Rochester, New York, United States|Investigational Site Number 8400008, Cleveland, Ohio, United States|Investigational Site Number 8400003, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400014, Mount Pleasant, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04537208,United States,,10.0,2021,Friday
1350,1351,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Completed,Drug: 20 Mg Prednisone for 14 days|Drug: control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450.0,"April 1, 2020",2020-07-30,"September 16, 2020","south-Vally University faculty of medicine, Qena, Kena, Egypt",https://ClinicalTrials.gov/show/NCT04551781,Egypt,20 Mg Prednisone for 14 days|control,7.0,2020,Thursday
1351,1352,A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing,Not yet recruiting,Diagnostic Test: comparison of sample collection methods,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,300.0,September 2020,2022-09-01,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04537572,Undefined,,9.0,2022,Thursday
1352,1353,ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Recruiting,Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test,All,"Child, Adult, Older Adult",,5000.0,"March 27, 2020",2021-01-31,"April 27, 2020","St. David's Medical Center, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04352764,United States,,1.0,2021,Sunday
1353,1354,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,Recruiting,Biological: SBI-101,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,22.0,"November 19, 2020",2021-07-01,"November 23, 2020","University of New Mexico School of Medicine, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT04445220,Mexico,,7.0,2021,Thursday
1354,1355,Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19,Not yet recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"May 15, 2020",2022-01-01,"May 7, 2020",,https://ClinicalTrials.gov/show/NCT04377997,Undefined,Enoxaparin,1.0,2022,Saturday
1355,1356,Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic,Recruiting,Other: stress and anxiety questionnaire,All,"18 Years and older   (Adult, Older Adult)",,200.0,"April 18, 2020",2020-08-18,"May 12, 2020","SAMU Hospices Civils de Lyon, Lyon, France|Service d'accueil des urgences, Hôpital Edouard Herriot, Hospices Civlis de Lyon, Lyon, France|Service d'accueil des urgences, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service d'accueil des urgences, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France|Hôpital de Villefranche-sur-Saône, Villefranche-sur-Saône, France",https://ClinicalTrials.gov/show/NCT04383886,France,,8.0,2020,Tuesday
1356,1357,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,Diagnostic Test: Lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 16, 2020",2020-12-30,"August 17, 2020","Ziekenhuis Oost Limburg, Genk, Limburg, Belgium",https://ClinicalTrials.gov/show/NCT04338568,Belgium,,12.0,2020,Wednesday
1357,1358,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,Recruiting,Device: COVID-19 barrier box,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"May 1, 2020",2021-01-01,"May 28, 2020","Providence Health Care, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04366141,Canada,,1.0,2021,Friday
1358,1359,Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers,Not yet recruiting,Diagnostic Test: Serologic SARS-CoV-2 screening,All,"18 Years and older   (Adult, Older Adult)",,50.0,"June 1, 2020",2020-08-31,"May 28, 2020",,https://ClinicalTrials.gov/show/NCT04387890,Undefined,,8.0,2020,Monday
1359,1360,EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID ),Not yet recruiting,Device: MindRhythm Harmony,All,"18 Years and older   (Adult, Older Adult)",,250.0,"October 1, 2020",2021-06-01,"September 2, 2020",,https://ClinicalTrials.gov/show/NCT04445493,Undefined,,6.0,2021,Tuesday
1360,1361,Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique,Not yet recruiting,,All,"Child, Adult, Older Adult",,15393.0,"July 15, 2020",2021-07-14,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04442165,Undefined,,7.0,2021,Wednesday
1361,1362,"Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation",Not yet recruiting,Drug: nangibotide|Drug: placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,August 2020,2021-03-01,"July 28, 2020","Réanimation Médicale, Hôpital Central, Nancy, France",https://ClinicalTrials.gov/show/NCT04429334,France,nangibotide|placebo,3.0,2021,Monday
1362,1363,The COVID-19 PUI Reality Check (CPRC) Study,Recruiting,Diagnostic Test: SARS-CoV-2 antibody testing,All,"18 Years and older   (Adult, Older Adult)",,400.0,"July 16, 2020",2021-07-01,"August 20, 2020","Bassett Medical Center, Cooperstown, New York, United States",https://ClinicalTrials.gov/show/NCT04474288,United States,,7.0,2021,Thursday
1363,1364,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Terminated,Other: Let It Out (LIO)-C|Other: Neutral writing control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"May 26, 2020",2020-08-31,"October 8, 2020","University College London, London, Kent, United Kingdom",https://ClinicalTrials.gov/show/NCT04386668,United Kingdom,,8.0,2020,Monday
1364,1365,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,Suspended,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,200.0,"April 20, 2020",2020-07-31,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04348474,Brazil,Hydroxychloroquine Sulfate|Azithromycin Tablets,7.0,2020,Friday
1365,1366,Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,700.0,"May 1, 2020",2020-08-01,"July 29, 2020","UH Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04380714,France,,8.0,2020,Saturday
1366,1367,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions,Completed,Other: questionnaire,All,"Child, Adult, Older Adult",,230.0,"June 15, 2020",2020-09-01,"October 14, 2020","Centre Hospitalier Universitaire de Rennes, Rennes, France",https://ClinicalTrials.gov/show/NCT04579289,France,,9.0,2020,Tuesday
1367,1368,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,Drug: Colchicine|Drug: Prednisone tablet|Drug: standard of care,All,65 Years and older   (Older Adult),Phase 2|Phase 3,144.0,"October 22, 2020",2021-10-01,"November 9, 2020","Centre Blauclínic Dolors Aleu, Barcelona, Spain|Hospital Clinic, Department of Internal Medicine, Barcelona, Spain|Clinica Sant Antoni, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04492358,Spain,Colchicine|Prednisone tablet|standard of care,10.0,2021,Friday
1368,1369,Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);,Recruiting,Other: Physical exercise|Behavioral: Education sessions,All,"18 Years and older   (Adult, Older Adult)",,60.0,"March 15, 2020",2021-08-31,"May 12, 2020","Kantonsspital Winterthur, Winterthur, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04375709,Switzerland,,8.0,2021,Tuesday
1369,1370,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,Drug: Nebulised unfractionated heparin (UFH),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,202.0,"November 1, 2020",2022-06-01,"November 17, 2020","Frederick Health Hospital, Frederick, Maryland, United States",https://ClinicalTrials.gov/show/NCT04545541,United States,Nebulised unfractionated heparin (UFH),6.0,2022,Wednesday
1370,1371,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19",Not yet recruiting,Biological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IV,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,865.0,September 2020,2021-04-01,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04401475,Undefined,,4.0,2021,Thursday
1371,1372,Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,Withdrawn,Biological: UC-MSCs|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,0.0,"February 24, 2020",2020-02-25,"March 18, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04293692,China,,2.0,2020,Tuesday
1372,1373,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Recruiting,,All,"Child, Adult, Older Adult",,10000.0,"April 9, 2020",2021-12-01,"May 13, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04358029,United States,,12.0,2021,Wednesday
1373,1374,Physical Activity Following the Containment Period Imposed by the COVID-19 Pandemic in Patients,Recruiting,"Other: Questionnaire, phone call",All,"18 Years and older   (Adult, Older Adult)",,600.0,"June 12, 2020",2021-08-01,"October 27, 2020","CHU Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04451317,France,,8.0,2021,Sunday
1374,1375,Northern Colorado COVID-19 Biobank,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"July 8, 2020",2022-07-30,"October 27, 2020","Colorado State University, Fort Collins, Colorado, United States|Poudre Valley Hospital, UCHealth, Fort Collins, Colorado, United States|Greeley Hospital, UCHealth, Greeley, Colorado, United States|Medical Center of the Rockies, UCHealth, Loveland, Colorado, United States",https://ClinicalTrials.gov/show/NCT04603677,United States,,7.0,2022,Saturday
1375,1376,Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19,Not yet recruiting,Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO,All,"18 Years to 80 Years   (Adult, Older Adult)",,100.0,"September 1, 2020",2021-02-01,"September 1, 2020","Sir Ganga Ram Hospital, New delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04534712,India,,2.0,2021,Monday
1376,1377,TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia,Not yet recruiting,Drug: Tofacitinib|Drug: Hydroxychloroquine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,116.0,June 2020,2020-10-01,"May 15, 2020",,https://ClinicalTrials.gov/show/NCT04390061,Undefined,Tofacitinib|Hydroxychloroquine,10.0,2020,Thursday
1377,1378,Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1080.0,September 2020,2022-12-01,"September 4, 2020","Les Hôpitaux Universitaires de Strasbourg, Strasbourg, Bas-Rhin, France",https://ClinicalTrials.gov/show/NCT04528901,France,,12.0,2022,Thursday
1378,1379,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,Biological: COVID19 convalescent plasma infusion,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"April 18, 2020",2021-02-25,"September 2, 2020","Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04535063,Argentina,,2.0,2021,Thursday
1379,1380,Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection,Enrolling by invitation,Diagnostic Test: Lung Function Test,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 23, 2020",2021-12-31,"September 24, 2020","Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo-HCFMUSP, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04563156,Brazil,,12.0,2021,Friday
1380,1381,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,Drug: Ruxolitinib|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,432.0,"May 2, 2020",2020-10-17,"November 12, 2020","Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sorocaba, SP, Brazil|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Colombes Cedex, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04362137,Argentina,Ruxolitinib|Placebo,10.0,2020,Saturday
1381,1382,Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19,Recruiting,Other: Sample collection,All,"18 Years and older   (Adult, Older Adult)",,727.0,"May 13, 2020",2021-08-01,"December 7, 2020","Alabama Vaccine CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Bridge HIV CRS, San Francisco, California, United States|George Washington University CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|Adolescent & Young Adult Research at The CORE Center (AYAR at CORE), Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health Clinical Research Site CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Bronx Prevention Research Center CRS, Bronx, New York, United States|Harlem Prevention Center CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Vanderbilt Vaccine CRS, Nashville, Tennessee, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|Malawi CRS, Lilongwe, Malawi|Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo, Mozambique|CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista, Callao, Peru|San Miguel CRS, San Miguel, Lima, Peru|Asociacion Civil Selva Amazonica (ACSA) CRS, Iquitos, Maynas, Peru|Via Libra CRS, Lima, Peru|Barranco CRS, Lima, Peru|Josha Research CRS, Bloemfontein, South Africa|Emavundleni CRS, Cape Town, South Africa|Groote Schuur HIV CRS, Cape Town, South Africa|Khayelitsha CRS / (CIDRI UCT), Cape Town, South Africa|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa|Chatsworth CRS, Chatsworth, South Africa|Botha's Hill CRS, Durban, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Vulindlela CRS, Durban, South Africa|Isipingo CRS, Isipingo, South Africa|Kliptown Soweto CRS, Johannesburg, South Africa|Soweto HVTN CRS, Johannesburg, South Africa|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa|Synexus Stanza Clinical Research Centre CRS, Pretoria, South Africa|Rustenburg CRS, Rustenburg, South Africa|Setshaba Research Centre CRS, Soshanguve, South Africa|Tembisa Clinic 4 CRS, Tembisa, South Africa|The Aurum Institute Tembisa Clinical Research Centre CRS, Tembisa, South Africa|Tongaat CRS, Tongaat, South Africa|Verulam CRS, Verulam, South Africa|National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya, Tanzania|Matero Reference Clinic CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Lusaka CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Ndola CRS, Ndola, Zambia|St Mary's CRS, Chitungwiza, Zimbabwe|Zengeza CRS, Chitungwiza, Zimbabwe|Seke South CRS, Harare, Zimbabwe",https://ClinicalTrials.gov/show/NCT04403880,Georgia,,8.0,2021,Sunday
1382,1383,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: ATI-450|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36.0,"July 20, 2020",2022-07-01,"August 21, 2020","The University of Kansas Medical Center, Kansas City, Kansas, United States",https://ClinicalTrials.gov/show/NCT04481685,United States,ATI-450|Placebo,7.0,2022,Friday
1383,1384,Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,582.0,July 2020,2022-06-01,"July 23, 2020","Rambam Health Care Campus, Haifa, Israel",https://ClinicalTrials.gov/show/NCT04438837,Israel,Hydroxychloroquine,6.0,2022,Wednesday
1384,1385,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,Recruiting,Biological: immune plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 15, 2020",2020-12-31,"November 10, 2020","Ospedale delle Apuane, Massa, Toscana, Italy",https://ClinicalTrials.gov/show/NCT04622826,Italy,,12.0,2020,Thursday
1385,1386,Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients,Enrolling by invitation,,All,"Child, Adult, Older Adult",,50.0,"March 20, 2020",2020-05-31,"May 13, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04361565,France,,5.0,2020,Sunday
1386,1387,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Drug: Danoprevir+Ritonavir,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,10.0,"March 18, 2020",2020-04-15,"June 2, 2020","Huoshenshan Hostipal, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04345276,China,Danoprevir+Ritonavir,4.0,2020,Wednesday
1387,1388,Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia,Not yet recruiting,Drug: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Other: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,950.0,"August 30, 2020",2021-04-01,"August 19, 2020",,https://ClinicalTrials.gov/show/NCT04519125,Undefined,Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE),4.0,2021,Thursday
1388,1389,Eosinophil and Anticoagulation in COVID-19 Patients,Completed,Drug: LMWH,All,"18 Years and older   (Adult, Older Adult)",,80.0,"May 15, 2020",2020-07-15,"August 18, 2020","Bursa Yüksek İhtisas Hastanesi, Yıldırım, Turkey",https://ClinicalTrials.gov/show/NCT04507282,Turkey,LMWH,7.0,2020,Wednesday
1389,1390,Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Drug: Ganovo+ritonavir+/-Interferon nebulization,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,11.0,"February 17, 2020",2020-03-19,"April 13, 2020","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China",https://ClinicalTrials.gov/show/NCT04291729,China,Ganovo+ritonavir+/-Interferon nebulization,3.0,2020,Thursday
1390,1391,Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP),"Active, not recruiting",Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection,All,"22 Years to 72 Years   (Adult, Older Adult)",Early Phase 1,20.0,"July 20, 2020",2020-11-28,"September 28, 2020","Medicine Invention Design, Inc. (MIDI) - c/o - MIDINC Clinical Investigator Working Site, North Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT03348670,United States,,11.0,2020,Saturday
1391,1392,A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers,Recruiting,Procedure: Blood sampling|Procedure: Throat swab,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 22, 2020",2021-01-31,"July 7, 2020","Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, NRW, Germany",https://ClinicalTrials.gov/show/NCT04405466,Germany,,1.0,2021,Sunday
1392,1393,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,Not yet recruiting,Drug: EC-18|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"November 16, 2020",2021-11-01,"October 29, 2020",,https://ClinicalTrials.gov/show/NCT04569227,Undefined,EC-18|Placebo,11.0,2021,Monday
1393,1394,Polyvalent Immunoglobulin in COVID-19 Related ARds,Recruiting,Drug: Human immunoglobulin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,138.0,"April 11, 2020",2021-06-01,"September 22, 2020","CHU Sud Amiens, Amiens, France|CHU Angers, Angers, France|Service de réanimation polyvalente, rond point de Girac, Angoulême, France|CH Aulnay, Aulnay-sous-Bois, France|Centre hospitalier de Béthune, Beuvry, France|Hopital Avicenne, Bobigny, France|CH Chalons en champagne, Chalons en champagne, France|CH-Nord-Ardennes, Charleville-Mézières, France|Hopital d'instruction des armées Percy, Clamart, France|Centre Hospitalier de Dieppe, Dieppe, France|Hôpital Raymond Poincaré, Garches, France|CHU de Grenoble, Grenoble, France|Grand hopital de l'est Francilien - site de Jossigny, Jossigny, France|Hopital Robert Boulin, Libourne, France|Pôle de Médecine intensive/réanimation Hôpital Salengro, CHRU de Lille, Lille, France|Groupement Hospitalier Edouar Herriot, Lyon, France|Hôpital de la Croix Rousse Novembre 2019, Lyon, France|Hopital Jacques Cartier, Massy, France|Hopital Jacques Monod, Montivilliers, France|Service de Médecine Intensive-Réanimation, CHU, Nantes, France|CHR Orléans, Orléans, France|Centre Hospitalier Sainte-Anne, Paris, France|CHU Lariboisiere, Paris, France|CHU Pitié Salpétriere Service de réanimation chirurgicale, Paris, France|CHU Saint Antoine, Paris, France|Fondation ophtalmologique Rotschild, Paris, France|Hôpital Paris Saint-Joseph, Paris, France|Hôpital Pitié Salpêtrière, Paris, France|Institut Mutualiste Montsouris, Paris, France|CHU Robert Débré, Reims, France|CH Poissy, Saint-Germain-en-Laye, France|Groupe hospitalier Saint Vincent, Strasbourg, France|Hôpital de Hautepierre, Strasbourg, France|Hopital de Tarbes, Tarbes, France|Hôpital Nord Franche-Comté, Trévenans, France|CH Valenciennes, Valenciennes, France|Chu Nancy - Brabois, Vandœuvre-lès-Nancy, France|Hopital de Vannes, Vannes, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, Étampes, France",https://ClinicalTrials.gov/show/NCT04350580,France,Human immunoglobulin|Placebo,6.0,2021,Tuesday
1394,1395,Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors,Recruiting,Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Survey Administration,All,"Child, Adult, Older Adult",,1242.0,"May 12, 2020",2021-07-21,"June 25, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04447222,United States,,7.0,2021,Wednesday
1395,1396,COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"May 18, 2020",2020-12-31,"August 12, 2020","Paris Saint Louis, Paris, France",https://ClinicalTrials.gov/show/NCT04416438,France,,12.0,2020,Thursday
1396,1397,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Recruiting,Diagnostic Test: EUROIMMUN assay,All,"18 Years and older   (Adult, Older Adult)",,56000.0,"April 10, 2020",2021-06-01,"August 25, 2020","Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States",https://ClinicalTrials.gov/show/NCT04349202,United States,,6.0,2021,Tuesday
1397,1398,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Drug: CYT107|Drug: Placebo,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"September 15, 2020",2021-03-31,"October 12, 2020","University of Florida College of Medicine, Gainesville, Florida, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Rutgers Health, New Brunswick, New Jersey, United States|Stony Brook Medicine, Stony Brook, New York, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04442178,Jersey,CYT107|Placebo,3.0,2021,Wednesday
1398,1399,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ),Not yet recruiting,Drug: CYT107|Drug: Placebo,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"December 20, 2020",2021-12-31,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04426201,Undefined,CYT107|Placebo,12.0,2021,Friday
1399,1400,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,Recruiting,Drug: Isoflurane Inhalant Product|Drug: Sevoflurane inhalant product,All,"18 Years and older   (Adult, Older Adult)",Phase 3,752.0,"June 15, 2020",2023-06-15,"September 2, 2020","University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Universite de Sherbrooke, Sherbrooke, Quebec, Canada|University Health Network - Toronto Western Hopsital, Toronto, Canada",https://ClinicalTrials.gov/show/NCT04415060,Canada,Isoflurane Inhalant Product|Sevoflurane inhalant product,6.0,2023,Thursday
1400,1401,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Active, not recruiting",Biological: Gam-COVID-Vac|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 3,100.0,"September 28, 2020",2021-04-10,"December 2, 2020","Health Institution ""14th Central Regional Polyclinic of the Partisan district of Minsk"", Minsk, Belarus|Health Institution ""19th Central Regional Polyclinic of the Pervomaysk district of Minsk"", Minsk, Belarus|Health Institution ""1st Central Regional Clinical Polyclinic of the Central district of Minsk"", Minsk, Belarus|Health Institution ""28th Regional Polyclinic of Minsk"", Minsk, Belarus|Health Institution ""4th City Polyclinic of Minsk"", Minsk, Belarus|Health Institution ""5th City Clinical Polyclinic of Minsk"", Minsk, Belarus|Health Institution ""Minsk Order of the Red Banner of Labor Regional Clinical Hospital, Minsk, Belarus|Health Institution ""Vitebsk Regional Clinical Hospital"", Vitebsk, Belarus",https://ClinicalTrials.gov/show/NCT04564716,Belarus,,4.0,2021,Saturday
1401,1402,Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers,Recruiting,Drug: Nicotine patch|Drug: Placebo patch,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1633.0,"October 22, 2020",2021-10-01,"November 13, 2020","Centre Hospitalier Gonesse, Gonesse, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Hôpital Pitié Salpêtrière - Service de Médecine Interne, Paris, France|Hôpital Sainte-Anne, Paris, France",https://ClinicalTrials.gov/show/NCT04583410,France,Nicotine patch|Placebo patch,10.0,2021,Friday
1402,1403,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting","Biological: SARS-CoV-2 rS - Phase 1|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Other: Normal saline solution (NSS), Placebo - Phase 1|Other: Normal saline solution (NSS), Placebo - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2|Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2|Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2",All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 1|Phase 2,1419.0,"May 25, 2020",2021-11-18,"October 9, 2020","Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2, Savannah, Georgia, United States|Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2, Meridian, Idaho, United States|Alliance for Multispecialty Research, LLC - Phase 2, Newton, Kansas, United States|Alliance for Multispecialty Research, LLC - Phase 2, Wichita, Kansas, United States|Central Kentucky Research Associates Inc - Phase 2, Lexington, Kentucky, United States|Meridian Clinical Research-(Rockville Maryland) - Platinum - PPDS - Phase 2, Rockville, Maryland, United States|Synexus Clinical Research US, Inc. - Cincinnati - Phase 2, Cincinnati, Ohio, United States|Rapid Medical Research Inc - ERN-PPDS - Phase 2, Cleveland, Ohio, United States|Paratus Clinical Research - Canberra - Phase 2, Bruce, Australian Capital Territory, Australia|Paratus Clinical Research - Western Sydney - Phase 2, Blacktown, New South Wales, Australia|Paratus Clinical Research - Central Coast - Phase 2, Kanwal, New South Wales, Australia|Australian Clinical Research Network - Phase 2, Maroubra, New South Wales, Australia|Scientia Clinical Research Limited - Phase 2, Randwick, New South Wales, Australia|Q Pharm Pty Limited - Phase 1, Herston, Queensland, Australia|University of the Sunshine Coast, Health Hub Morayfield - Phase 2, Morayfield, Queensland, Australia|University of the Sunshine Coast - Phase 2, Sippy Downs, Queensland, Australia|Barwon Health - Phase 2, Geelong, Victoria, Australia|Center for Clinical Studies - Phase 1 and Phase 2, Melbourne, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04368988,Australia,,11.0,2021,Thursday
1403,1404,Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic,Recruiting,Other: Survey Administration,All,"Child, Adult, Older Adult",,1152.0,"June 11, 2020",2021-07-01,"July 16, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04474301,United States,,7.0,2021,Thursday
1404,1405,New Treatment for COVID-19 Using Ethanol Vapor Inhalation .,Not yet recruiting,Drug: Ethanol with Asprin,All,20 Years to 60 Years   (Adult),Phase 3,80.0,"December 1, 2020",2022-06-01,"October 28, 2020",,https://ClinicalTrials.gov/show/NCT04554433,Undefined,Ethanol with Asprin,6.0,2022,Wednesday
1405,1406,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,Recruiting,Drug: Iota-Carrageenan,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"July 24, 2020",2020-11-30,"August 21, 2020","centro de educación médica e investigaciones clinicas (CEMIC), Buenos Aires, Capital Federal, Argentina",https://ClinicalTrials.gov/show/NCT04521322,Argentina,Iota-Carrageenan,11.0,2020,Monday
1406,1407,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Completed,Diagnostic Test: rapid salivary test,All,"Child, Adult, Older Adult",Not Applicable,122.0,"April 16, 2020",2020-07-31,"November 4, 2020","ASST dei Sette Laghi, Varese, VA, Italy",https://ClinicalTrials.gov/show/NCT04357327,Italy,,7.0,2020,Friday
1407,1408,"COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"May 5, 2020",2022-05-08,"August 24, 2020","Dr Luke Hodgson, Worthing, United Kingdom",https://ClinicalTrials.gov/show/NCT04524520,United Kingdom,,5.0,2022,Sunday
1408,1409,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Recruiting,Biological: Sample,Male,18 Years to 50 Years   (Adult),Not Applicable,50.0,"October 2, 2020",2022-02-01,"November 3, 2020","University Hospital Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04584593,France,,2.0,2022,Tuesday
1409,1410,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",Drug: inhalable hydroxychloroquine (HCQ)|Drug: supportive and symptomatic treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"July 15, 2020",2020-08-15,"July 20, 2020","Mansoura University Hospital, Mansoura, Outside U.S./Canada, Egypt",https://ClinicalTrials.gov/show/NCT04477083,Canada,inhalable hydroxychloroquine (HCQ)|supportive and symptomatic treatment,8.0,2020,Saturday
1410,1411,SuPAR in Adult Patients With Covid-19,Recruiting,Diagnostic Test: Soluble Urokinase Plasminogen Activator Receptor,All,"18 Years to 120 Years   (Adult, Older Adult)",,500.0,"October 11, 2020",2020-12-10,"December 7, 2020","University Hospital of Larisa, Department of Anesthesiology, Larissa, Thessaly, Greece",https://ClinicalTrials.gov/show/NCT04590794,Greece,,12.0,2020,Thursday
1411,1412,Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19,Not yet recruiting,Device: Observational measurement of biometric data. No change to health care provided.,All,"Child, Adult, Older Adult",,30.0,September 2020,2021-02-26,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04548895,Undefined,,2.0,2021,Friday
1412,1413,The Critical Care Response to the COVID-19 Pandemic in Madrid,Recruiting,,All,"Child, Adult, Older Adult",,2500.0,"April 24, 2020",2020-06-30,"May 28, 2020","Hospital Clinico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04393324,Spain,,6.0,2020,Tuesday
1413,1414,Low Dose Radiation Therapy for Covid-19 Pneumonia,"Active, not recruiting",Radiation: Low dose radiation therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"June 13, 2020",2020-09-01,"September 1, 2020","All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04394793,India,,9.0,2020,Tuesday
1414,1415,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,Other: Convalescent SARS COVID-19 plasma|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,333.0,"May 15, 2020",2020-09-27,"September 30, 2020","Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04383535,Argentina,,9.0,2020,Sunday
1415,1416,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,Recruiting,Drug: Camostat Mesylate|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,596.0,"December 3, 2020",2022-03-01,"December 7, 2020","Centre Hospitalier Victor Dupouy, Argenteuil, France|AP-HP Hôpital Henri Mondor, Créteil, France|AP-HP Hôpital Bichat, Paris, France|APHP - Saint Louis, Paris, France|Centre de Santé Richerand, Paris, France",https://ClinicalTrials.gov/show/NCT04608266,France,Camostat Mesylate|Placebo,3.0,2022,Tuesday
1416,1417,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Completed,Other: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|Other: Standard of Care,All,18 Years to 45 Years   (Adult),Not Applicable,10.0,"September 15, 2020",2020-10-16,"October 19, 2020","Mazumdar Shaw Medical Centre, Bangalore, Karnataka, India",https://ClinicalTrials.gov/show/NCT04512027,India,,10.0,2020,Friday
1417,1418,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV),Terminated,Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2.0,"August 19, 2020",2020-10-02,"November 12, 2020","AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France|Hôpital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France",https://ClinicalTrials.gov/show/NCT04366232,France,Anakinra alone (stages 2b/3)|Anakinra and Ruxolitinib (overcome stage 3),10.0,2020,Friday
1418,1419,Over-the-counter Medications & COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,14000.0,"July 23, 2020",2023-03-31,"August 7, 2020","University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04500639,Canada,,3.0,2023,Friday
1419,1420,Emergency Ventilator Splitting Between Two or More Patients (COVID-19),Not yet recruiting,Device: Emergency Ventilator Splitter,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4.0,December 2020,2021-01-01,"October 8, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04381013,United States,,1.0,2021,Friday
1420,1421,S-Nitrosylation Therapy of COVID-19,Not yet recruiting,Drug: SNO|Drug: Nitrogen gas,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 1,21.0,"October 31, 2020",2021-04-30,"August 27, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04528771,United States,SNO|Nitrogen gas,4.0,2021,Friday
1421,1422,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard,Recruiting,Biological: Mesenchymal Stromal Cells,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,"May 15, 2020",2021-06-01,"September 14, 2020","The Ottawa Hospital, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04400032,Canada,,6.0,2021,Tuesday
1422,1423,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Recruiting,Biological: Mesenchymal cells|Drug: Standard of care,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,106.0,"May 7, 2020",2021-05-31,"May 11, 2020","Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Complejo Universitario La Paz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04366271,Spain,Standard of care,5.0,2021,Monday
1423,1424,Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19,No longer available,Drug: Bamlanivimab,All,"12 Years and older   (Child, Adult, Older Adult)",,,,,"November 23, 2020",,https://ClinicalTrials.gov/show/NCT04603651,Undefined,Bamlanivimab,,n,
1424,1425,Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19,Not yet recruiting,Drug: Ramelteon 8mg,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,100.0,September 2020,2021-03-01,"July 24, 2020",,https://ClinicalTrials.gov/show/NCT04470297,Undefined,Ramelteon 8mg,3.0,2021,Monday
1425,1426,Diagnosis of Endocrine Dysfunctions in Covid-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 1, 2020",2020-05-30,"October 14, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04587375,France,,5.0,2020,Saturday
1426,1427,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",Recruiting,Biological: UB-612,All,20 Years to 55 Years   (Adult),Phase 1,60.0,"September 25, 2020",2021-08-31,"September 29, 2020","China Medical University Hospital, Taichung, Taiwan",https://ClinicalTrials.gov/show/NCT04545749,China,,8.0,2021,Tuesday
1427,1428,Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia,Not yet recruiting,Drug: Cyclosporin A,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,200.0,September 2020,2020-09-30,"September 7, 2020","Jose Luis Jl Galvez-Romero, Puebla, Mexico",https://ClinicalTrials.gov/show/NCT04540926,Mexico,Cyclosporin A,9.0,2020,Wednesday
1428,1429,Covid-19 Rapid Diagnostic Tests on Blood Drop,Completed,,All,"Child, Adult, Older Adult",,113.0,"July 15, 2020",2020-08-15,"November 10, 2020","CMC Ambroise Paré, Neuilly-sur-Seine, France",https://ClinicalTrials.gov/show/NCT04467008,France,,8.0,2020,Saturday
1429,1430,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Active, not recruiting",Drug: Fluvoxamine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,152.0,"April 10, 2020",2020-10-01,"September 1, 2020","BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04342663,United States,Fluvoxamine|Placebo,10.0,2020,Thursday
1430,1431,Sirolimus in COVID-19 Phase 1,Withdrawn,Drug: Sirolimus 1 MG/ML|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0.0,"July 6, 2020",2021-08-01,"December 7, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04371640,United States,Sirolimus 1 MG/ML|Placebo,8.0,2021,Sunday
1431,1432,Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial,Not yet recruiting,Biological: intravenous immunoglobulin therapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,60.0,"September 15, 2020",2020-11-15,"September 14, 2020","University of Health Sciences, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04548557,Pakistan,,11.0,2020,Sunday
1432,1433,Musculoskeletal Pain in Patients With Covid-19 Who Have Hospital Care,Not yet recruiting,Other: Interview,All,"18 Years and older   (Adult, Older Adult)",,100.0,"December 1, 2020",2021-07-31,"November 19, 2020","Jorge Hugo Villafañe, Milan, Italy",https://ClinicalTrials.gov/show/NCT04632355,Italy,,7.0,2021,Saturday
1433,1434,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Recruiting,Drug: Omega 3/Nigella Sativa Oil|Drug: Omega 3/Nigella Sativa Oil/Indian Costus|Drug: Omega 3/Nigella Sativa Oil/Quinine pills|Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule|Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Drug: Active Comparator,All,25 Years to 40 Years   (Adult),Phase 2|Phase 3,200.0,"September 20, 2020",2020-12-04,"September 18, 2020","Maternity and Children hospital, Mecca, Makkah, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04553705,Saudi Arabia,Omega 3/Nigella Sativa Oil|Omega 3/Nigella Sativa Oil/Indian Costus|Omega 3/Nigella Sativa Oil/Quinine pills|Omega 3/Nigella Sativa Oil/Anise seed capsule|Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Active Comparator,12.0,2020,Friday
1434,1435,Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients,Recruiting,Drug: NuSepin® 0.1 mg|Drug: NuSepin® 0.2 mg|Drug: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,60.0,"September 25, 2020",2020-11-30,"September 30, 2020","""Leon Daniello"" Clinical Hospital of Pneumophtisiology Cluj-Napoca Pneumology Clinic, Cluj-Napoca, Romania|Clinical Hospital for Infectious Diseases and Pneumophtisiology ""Victor Babes"", Craiova Infectious Diseases Clinic for Adults, Craiova, Romania|""Sf. Parascheva"" Infectious Diseases Clinical Hospital Iasi Infectious Diseases Department, Iaşi, Romania|""Sf. Ioan cel Nou"" Suceava County Emergency Hospital Infectious Diseases Department, Suceava, Romania",https://ClinicalTrials.gov/show/NCT04565379,Oman,NuSepin® 0.1 mg|NuSepin® 0.2 mg|Placebo,11.0,2020,Monday
1435,1436,Risks of COVID19 in the Pregnant Population,Recruiting,Other: Biospecimen collection,Female,18 Years to 45 Years   (Adult),,100.0,"May 8, 2020",2021-07-31,"July 13, 2020","Mayo Clinic Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04379284,United States,,7.0,2021,Saturday
1436,1437,COVID-19 Breastfeeding Guideline for African-Americans,Not yet recruiting,Behavioral: COVID-19 Breastfeeding Support,Female,18 Years to 45 Years   (Adult),Not Applicable,200.0,September 2020,2022-06-01,"July 20, 2020","Meharry Medical College, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04476940,United States,,6.0,2022,Wednesday
1437,1438,Photodynamic Therapy for the Treatment of COVID-19,Not yet recruiting,Procedure: photobiomodulation and photodynamic therapy,All,"Child, Adult, Older Adult",Not Applicable,60.0,August 2020,2021-02-01,"June 5, 2020",,https://ClinicalTrials.gov/show/NCT04416113,Undefined,,2.0,2021,Monday
1438,1439,COVID-19 Prophylaxis South Africa (COVER HCW),Not yet recruiting,Drug: Nitazoxanide|Drug: Sofosbuvir/Daclatasvir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,1950.0,December 2020,2021-07-01,"September 28, 2020","Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa|Sunnyside Office Park, Johannesburg, Gauteng, South Africa",https://ClinicalTrials.gov/show/NCT04561063,South Africa,Nitazoxanide|Sofosbuvir/Daclatasvir,7.0,2021,Thursday
1439,1440,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Biological: Human Amniotic Fluid,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"October 28, 2020",2021-09-15,"November 6, 2020","University of Utah Health, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04497389,United States,,9.0,2021,Wednesday
1440,1441,Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry,Recruiting,Drug: Patients with the treatment agains COVID19,All,"1 Year to 100 Years   (Child, Adult, Older Adult)",,1000.0,"April 22, 2020",2021-01-01,"June 2, 2020","Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain",https://ClinicalTrials.gov/show/NCT04347278,Spain,Patients with the treatment agains COVID19,1.0,2021,Friday
1441,1442,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting,"Active, not recruiting",Diagnostic Test: Testing for SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,4099.0,"April 1, 2020",2021-03-31,"August 27, 2020","University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT04519372,Switzerland,,3.0,2021,Wednesday
1442,1443,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Not yet recruiting,"Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"April 27, 2020",2021-11-27,"April 27, 2020",,https://ClinicalTrials.gov/show/NCT04363749,Undefined,,11.0,2021,Saturday
1443,1444,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,Recruiting,Drug: DFV890|Drug: Standard of Care (SoC),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,140.0,"May 27, 2020",2020-12-25,"December 10, 2020","Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Heidelberg, Baden-Württemberg, Germany|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Surat, Gujrat, India|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, San Martin de Porres, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04382053,Argentina,DFV890|Standard of Care (SoC),12.0,2020,Friday
1444,1445,Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,235.0,"April 23, 2020",2020-05-31,"April 30, 2020","SC Pronto Soccorso e Medicina d'Urgenza, Latisana, Udine, Italy",https://ClinicalTrials.gov/show/NCT04370275,Italy,,5.0,2020,Sunday
1445,1446,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,Recruiting,Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant|Other: Placebo,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 2,4400.0,"August 17, 2020",2021-11-01,"November 2, 2020","ZA018, Bloemfontein, Free State Of South Africa, South Africa|ZA003, Hillbrow, Gauteng, South Africa|Site ZA001, Johannesburg, Gauteng, South Africa|ZA012, Johannesburg, Gauteng, South Africa|Site ZA015, Pretoria, Gauteng, South Africa|ZA023, Pretoria, Gauteng, South Africa|ZA019, Durban, KwaZulu-Natal, South Africa|ZA020, Durban, KwaZulu-Natal, South Africa|ZA021, Durban, KwaZulu-Natal, South Africa|ZA024, Durban, KwaZulu-Natal, South Africa|ZA007, Thabazimbi, Limpopo, South Africa|ZA022, Madibeng, North-West, South Africa|ZA013, Cape Town, Western Cape, South Africa|ZA014, Worcester, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04533399,South Africa,,11.0,2021,Monday
1446,1447,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,700.0,"April 9, 2020",2020-12-01,"July 2, 2020","Idor, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04364893,Brazil,,12.0,2020,Tuesday
1447,1448,"Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",Not yet recruiting,Drug: Tinzaparin or unfractionated heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,808.0,"April 20, 2020",2020-09-30,"April 15, 2020","Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France|réanimation hôpital Cochin, Paris, France|Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France",https://ClinicalTrials.gov/show/NCT04344756,France,Tinzaparin or unfractionated heparin,9.0,2020,Wednesday
1448,1449,COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE),"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,1800.0,"April 10, 2020",2021-12-31,"May 7, 2020","Luxembourg Institute of Health, Strassen, Luxembourg",https://ClinicalTrials.gov/show/NCT04379297,Luxembourg,,12.0,2021,Friday
1449,1450,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Recruiting,Other: Obvio-19 app,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 29, 2020",2021-12-31,"August 14, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04437719,France,,12.0,2021,Friday
1450,1451,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,Recruiting,Drug: Nasal Spray,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,200.0,"August 8, 2020",2021-08-08,"November 10, 2020","Larkin Community Hospital Palm Springs Campus, Miami, Florida, United States|Larkin Community Hospital, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04610801,United States,Nasal Spray,8.0,2021,Sunday
1451,1452,Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +,Not yet recruiting,Other: Pulmonary ultrasound,All,"18 Years and older   (Adult, Older Adult)",,300.0,April 2020,2020-05-01,"April 6, 2020",,https://ClinicalTrials.gov/show/NCT04335019,Undefined,,5.0,2020,Friday
1452,1453,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Drug: mometasone furoate nasal spray,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"August 8, 2020",2020-11-03,"November 13, 2020","Benha University Hospital, Faculty of Medicine, Banhā, Qalubia, Egypt",https://ClinicalTrials.gov/show/NCT04484493,Egypt,mometasone furoate nasal spray,11.0,2020,Tuesday
1453,1454,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom",Recruiting,Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant|Other: Placebo|Biological: Licensed seasonal influenza vaccine,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,15000.0,"September 28, 2020",2022-01-14,"November 17, 2020","Belfast Health and Social Care Trust (BHSCT) (Site UK011), Belfast, Antrim, United Kingdom|Synexus Midlands Clinical Research Centre (Site UK024), Edgbaston, Birmingham, United Kingdom|The Royal Cornwall Hospitals NHS Trust (Site UK036), Truro, Cornwall, United Kingdom|Royal Devon and Exeter Hospital (Site UK013), Exeter, Devon, United Kingdom|""Maidstone Hospital - Central Research and Development Office Above Breast Care Centre - 1st Floor"" (Site UK028), Maidstone, Kent, United Kingdom|Queen Elizabeth University Hospital (Site UK008), Glasgow, Lanarkshire, United Kingdom|Blackpool Teaching Hospitals (Site UK010), Blackpool, Lancashire, United Kingdom|Salford Hospital (Site UK030), Oldham, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre (Site UK026), Waterloo, Liverpool, United Kingdom|Royal Free (Site UK012), Hampstead, London, United Kingdom|St. George's University Hospitals NHS Foundation Trust Clinical Research Facility (Site UK001), Tooting, London, United Kingdom|North Wales Clinical Research Centre (NWCRC) (Site UK027), Wrexham, North Wales, United Kingdom|Lakeside Healthcare, Lakeside Surgery (Site UK005), Corby, Northants, United Kingdom|Warneford Hospital (Site UK016), Oxford, Oxfordshire, United Kingdom|Aberdeen Royal Infirmary (Site UK007), Foresterhill, Aberdeen, United Kingdom|Bradford Teaching Hospitals NHS Trust (Site UK018), Bradford, United Kingdom|Synexus Wales Clinical Research Centre (Site UK025), Cardiff, United Kingdom|Synexus Lancashire Clinical Research Centre (Site UK022), Chorley, United Kingdom|Colchester Hospital (Site UK034), Colchester, United Kingdom|AES - Glasgow (Site UK033), Glasgow, United Kingdom|University Hartlepool Hospital (Site UK021), Hartlepool, United Kingdom|Synexus Hexham Clinical Research Centre (Site UK023), Hexham, United Kingdom|Royal Lancaster Infirmary (Site UK029), Lancaster, United Kingdom|Research & Innovation Centre, St. James's University Hospital (Site UK019), Leeds, United Kingdom|St. Thomas' Hospital (Site UK020), London, United Kingdom|Chelsea & Westminster NHS Foundation Trust (Site UK006), London, United Kingdom|AES - Synexus Manchester (Site UK032), Manchester, United Kingdom|Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk and Norwich University Hospital (Site UK015), Norwich, United Kingdom|Wansford and Kingscliffe Practice (Site UK035), Peterborough, United Kingdom|AES - Synexus Thames Valley (Site UK031), Reading, United Kingdom|University Hospital Southampton NHS Foundation Trust (UHS) (Site UK014), Southampton, United Kingdom|Midlands Partnership NHS Foundation Trust Headquarters (Site UK017), Stafford, United Kingdom|Stockport NHS Foundation Trust (Site UK009), Stockport, United Kingdom",https://ClinicalTrials.gov/show/NCT04583995,United Kingdom,,1.0,2022,Friday
1454,1455,Timing of Corticosteroids in COVID-19,Recruiting,Drug: Early-Dexamethasone|Drug: Late-Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,450.0,"August 26, 2020",2021-01-01,"November 10, 2020","Asalam, Maadi, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04530409,Egypt,Early-Dexamethasone|Late-Dexamethasone,1.0,2021,Friday
1455,1456,CoVID-19 Plasma in Treatment of COVID-19 Patients,Recruiting,Biological: Convalescent COVID 19 Plasma,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,100.0,"April 28, 2020",2020-08-01,"May 20, 2020","The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04355897,United States,,8.0,2020,Saturday
1456,1457,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Recruiting,Drug: Melatonin intravenous|Drug: Placebo intravenous,All,"18 Years and older   (Adult, Older Adult)",Phase 2,18.0,"June 20, 2020",2020-11-30,"September 29, 2020","Hospital Universitario La Paz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04568863,Spain,Melatonin intravenous|Placebo intravenous,11.0,2020,Monday
1457,1458,"Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients",Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,240.0,"June 19, 2020",2022-06-01,"July 15, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04456101,China,,6.0,2022,Wednesday
1458,1459,"Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",Not yet recruiting,Drug: Bevacizumab Injection,All,"18 Years and older   (Adult, Older Adult)",Phase 2,130.0,"April 15, 2020",2020-11-30,"April 17, 2020",,https://ClinicalTrials.gov/show/NCT04344782,Undefined,Bevacizumab Injection,11.0,2020,Monday
1459,1460,"Hydroxychloroquine, Azithromycin in the Treatment of Covid-19",Not yet recruiting,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,July 2020,2021-03-01,"June 19, 2020","University Hospital Farhat Hached, Sousse, Tunisia",https://ClinicalTrials.gov/show/NCT04405921,Tunisia,Hydroxychloroquine 200 Mg Oral Tablet|Azithromycin 250 MG,3.0,2021,Monday
1460,1461,Plasma Rich Antibodies From Recovered Patients From COVID19,Not yet recruiting,Other: Antibody-Rich Plasma from COVID-19 recovered patients,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,"April 20, 2020",2020-12-01,"April 20, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04348877,Egypt,,12.0,2020,Tuesday
1461,1462,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Recruiting,Drug: Pirfenidone|Other: Standard of care,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,"November 8, 2020",2021-12-01,"December 4, 2020","Soroka Medical Center, Be'er Sheva, Israel",https://ClinicalTrials.gov/show/NCT04653831,Israel,Pirfenidone,12.0,2021,Wednesday
1462,1463,Comparison of Two Corticosteroid Regimens for Post-COVID Diffuse Lung Disease,Recruiting,Drug: Medium dose prednisolone|Drug: Low dose prednisolone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"December 10, 2020",2021-12-09,"December 8, 2020","Postgraduate Institute of Medical Education and Research, Chandigarh, India",https://ClinicalTrials.gov/show/NCT04657484,India,Medium dose prednisolone|Low dose prednisolone,12.0,2021,Thursday
1463,1464,Nigella Sativa in COVID-19,Recruiting,Dietary Supplement: Nigella sativa,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,200.0,"May 21, 2020",2020-12-31,"May 26, 2020","King Abdulaziz University Hospital, Jeddah, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04401202,Saudi Arabia,,12.0,2020,Thursday
1464,1465,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Not yet recruiting,Behavioral: Brief informational infographic|Behavioral: Placebo control (non-behavioral infographic),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,October 2020,2021-02-01,"September 21, 2020",,https://ClinicalTrials.gov/show/NCT04557241,Undefined,,2.0,2021,Monday
1465,1466,"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic",Recruiting,Diagnostic Test: RT-PCR|Diagnostic Test: LAMP|Diagnostic Test: POOL RT-PCR|Diagnostic Test: POOL LAMP,All,21 Years to 64 Years   (Adult),,30.0,"October 8, 2020",2020-11-30,"October 12, 2020","Universidad Autónoma Juan Misael Saracho, Tarija, Bolivia",https://ClinicalTrials.gov/show/NCT04581083,Undefined,,11.0,2020,Monday
1466,1467,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Recruiting,Drug: Bardoxolone methyl|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,440.0,"September 8, 2020",2021-02-28,"November 3, 2020","HSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Coney Island Hospital, Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|NYU Bellevue Hospital Center, New York, New York, United States|NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04494646,United States,Bardoxolone methyl|Placebo,2.0,2021,Sunday
1467,1468,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",Other: Serology test follow-up,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450.0,"July 1, 2020",2021-12-31,"August 12, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04488484,France,,12.0,2021,Friday
1468,1469,Endovascular Thrombectomy in COVID-19 Infected Patients,Completed,Other: Mechanical Trombectomy,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 1, 2020",2020-06-30,"July 29, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04406090,France,,6.0,2020,Tuesday
1469,1470,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Active, not recruiting",Drug: Canakinumab|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,451.0,"April 30, 2020",2020-12-22,"December 9, 2020","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04362813,France,Canakinumab|Placebo,12.0,2020,Tuesday
1470,1471,The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry,Recruiting,Procedure: airway management during sedation or general anesthesia,All,"up to 18 Years   (Child, Adult)",,15000.0,"April 1, 2020",2025-12-01,"June 26, 2020","Boston Children's Hopsital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04449042,United States,,12.0,2025,Monday
1471,1472,One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia,Recruiting,"Diagnostic Test: Evaluation of clinical, instrumental and laboratory diagnostics tests",All,"18 Years and older   (Adult, Older Adult)",,380.0,"July 19, 2020",2021-12-31,"August 6, 2020","Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation",https://ClinicalTrials.gov/show/NCT04501822,Russian Federation,,12.0,2021,Friday
1472,1473,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"Active, not recruiting",Drug: HB-adMSCs,All,"Child, Adult, Older Adult",Phase 2,56.0,"April 22, 2020",2020-12-31,"October 23, 2020","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",https://ClinicalTrials.gov/show/NCT04349631,United States,HB-adMSCs,12.0,2020,Thursday
1473,1474,Immunological Profiling of Patients With COVID-19 in Respiratory Distress,Recruiting,Other: Immunological profiling,All,"18 Years and older   (Adult, Older Adult)",,130.0,"April 9, 2020",2022-04-01,"November 30, 2020","CHU de Nimes, Nîmes, France",https://ClinicalTrials.gov/show/NCT04351711,France,,4.0,2022,Friday
1474,1475,Exploring Brain Damages After COVID-19 Infection,Recruiting,Procedure: Auditory Evoked Potentials (AEP)|Procedure: Blink and Masseter Inhibitory Reflex,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,38.0,"May 19, 2020",2021-11-19,"November 30, 2020","CHU de Bordeaux, Bordeaux, France",https://ClinicalTrials.gov/show/NCT04405986,France,,11.0,2021,Friday
1475,1476,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",Completed,Device: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,5.0,"July 28, 2020",2020-09-20,"September 24, 2020","Fundacion Neumologica Colombiana, Bogotá, Bogota, Colombia|Universidad de la Sabana, Chia, Cundinamarca, Colombia|Clinica Universidad de la Sabana, Chía, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04497623,Colombia,,9.0,2020,Sunday
1476,1477,International Registry of Healthcare Workers Exposed to COVID-19 Patients,Recruiting,Other: Comparative Observational Cohort Study,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"August 13, 2020",2021-10-31,"November 12, 2020","Aga Khan University, Karachi, Pakistan",https://ClinicalTrials.gov/show/NCT04626076,Pakistan,,10.0,2021,Sunday
1477,1478,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,Completed,Biological: biological assays in particular on the lipid metabolism,All,"18 Years and older   (Adult, Older Adult)",,62.0,"April 7, 2020",2020-05-07,"June 23, 2020","Chu Dijon Bourgogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04435223,France,,5.0,2020,Thursday
1478,1479,French Cohort of COVID-19 Patients With Post-intensive Care Syndrome,Not yet recruiting,Behavioral: Post-intensive Care unit syndrome,All,"18 Months and older   (Child, Adult, Older Adult)",,50.0,"October 15, 2020",2021-09-15,"October 19, 2020","Department of Rehabilitation, Institute of Rheumatology Cochin, Paris, France",https://ClinicalTrials.gov/show/NCT04590170,France,,9.0,2021,Wednesday
1479,1480,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",Recruiting,Drug: IMU-838|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,230.0,"June 11, 2020",2020-10-01,"July 1, 2020","Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria|UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria|University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany|Clinic of the Hannover Medical School, Pneumology Clinic, Hannover, Germany",https://ClinicalTrials.gov/show/NCT04379271,Bulgaria,IMU-838,10.0,2020,Thursday
1480,1481,Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt,Recruiting,,All,"2 Years to 18 Years   (Child, Adult)",,150.0,"July 7, 2020",2020-08-01,"August 28, 2020","Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04531111,Egypt,,8.0,2020,Saturday
1481,1482,Inhaled Ciclesonide for Outpatients With COVID19,Recruiting,Drug: Normal Saline intranasal,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,454.0,"September 14, 2020",2021-03-25,"October 19, 2020","McGill University Health Center, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04435795,Canada,Normal Saline intranasal,3.0,2021,Thursday
1482,1483,COVID-19 Community Research Partnership,Recruiting,,All,"Child, Adult, Older Adult",,150000.0,"April 8, 2020",2021-12-01,"June 11, 2020","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04342884,United States,,12.0,2021,Wednesday
1483,1484,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Completed,Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops),All,"18 Years and older   (Adult, Older Adult)",,229.0,"June 1, 2020",2020-08-10,"October 19, 2020","Hospital Eurnekian, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04425850,Argentina,,8.0,2020,Monday
1484,1485,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,Recruiting,Behavioral: Self-management booklet (SWitCh: Stay well during COVID-19),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,548.0,"May 20, 2020",2021-12-22,"November 9, 2020","Online recruitment through Qualtrics, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04408157,United Kingdom,,12.0,2021,Wednesday
1485,1486,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,Recruiting,Drug: Cholecalciferol|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,"November 12, 2020",2021-02-28,"November 19, 2020","CHU Liège, Liège, Belgium",https://ClinicalTrials.gov/show/NCT04636086,Belgium,Cholecalciferol,2.0,2021,Sunday
1486,1487,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth,Recruiting,Other: Survey Administration,All,"18 Years and older   (Adult, Older Adult)",,250.0,"August 31, 2020",2023-12-31,"November 17, 2020","University of California, San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04630015,United States,,12.0,2023,Sunday
1487,1488,Hemostatic Profile in Patients Affected by COVID-19,Recruiting,Other: Observational study,All,"18 Years and older   (Adult, Older Adult)",,400.0,"March 25, 2020",2021-05-10,"October 20, 2020","Papa Giovanni XXIII Hospital - S.I.M.T., Bergamo, Italy",https://ClinicalTrials.gov/show/NCT04595110,Italy,,5.0,2021,Monday
1488,1489,COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 16, 2020",2020-07-05,"May 12, 2020","The Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT04385069,United Kingdom,,7.0,2020,Sunday
1489,1490,COVID-19 Anosmia Study,Recruiting,Drug: Omega-3 Fatty Acid Supplement|Drug: Placebo/Control,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"July 15, 2020",2021-06-01,"August 4, 2020","Mount Sinai Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04495816,United States,Omega-3 Fatty Acid Supplement|Placebo/Control,6.0,2021,Tuesday
1490,1491,Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm,"Active, not recruiting",Diagnostic Test: AI model,All,"18 Years to 120 Years   (Adult, Older Adult)",,4000.0,"March 1, 2020",2020-12-31,"September 24, 2020","University of Hong Kong, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04561024,Hong Kong,,12.0,2020,Thursday
1491,1492,Early CPAP in COVID-19 Confirmed or Suspected Patients,Recruiting,Device: Continuous Positive Airway Pressure,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"May 7, 2020",2021-05-01,"May 15, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04390191,United States,,5.0,2021,Saturday
1492,1493,Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease,Not yet recruiting,Dietary Supplement: Acetyl L-Carnitine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"December 15, 2020",2021-07-31,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04623619,Undefined,,7.0,2021,Saturday
1493,1494,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,Recruiting,Drug: Triazavirin (Riamilovir)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,420.0,"September 8, 2020",2021-12-31,"October 14, 2020","The Perinatal HIV Research Unit - Matlosana, Klerksdorp, North West Province, South Africa",https://ClinicalTrials.gov/show/NCT04581915,South Africa,Triazavirin (Riamilovir),12.0,2021,Friday
1494,1495,Ayurveda as Prophylaxis for Suspected COVID-19 Patients,Not yet recruiting,Other: Ayurveda,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"June 10, 2020",2020-10-01,"May 20, 2020","British Ayurvedic Medical Council, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04395976,United Kingdom,,10.0,2020,Thursday
1495,1496,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Suspended,Drug: inhaled type I interferon|Drug: WFI water nebulization,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 20, 2020",2021-04-01,"December 11, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04469491,France,inhaled type I interferon|WFI water nebulization,4.0,2021,Thursday
1496,1497,COVID-19 Seroprevalence Study in ITM Staff,Completed,,All,"Child, Adult, Older Adult",,330.0,"August 1, 2020",2020-09-09,"October 22, 2020","Institute of Tropical Medicine, Antwerp, Belgium",https://ClinicalTrials.gov/show/NCT04503447,Belgium,,9.0,2020,Wednesday
1497,1498,COVID-SErology in Rheumatoid Arthritis (COVID-19),"Active, not recruiting",Other: Serological analyses to be lead on a pre-existing biobank,All,"18 Years and older   (Adult, Older Adult)",,216.0,"May 1, 2020",2020-09-30,"June 1, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04407559,France,,9.0,2020,Wednesday
1498,1499,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Recruiting,Other: mHealth Assessments,All,"18 Years and older   (Adult, Older Adult)",,500.0,"July 22, 2020",2021-12-01,"October 19, 2020","Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT04397614,United States,,12.0,2021,Wednesday
1499,1500,Exploratory Study: COVID-19 and Pregnancy,Recruiting,Diagnostic Test: SARS-CoV-2 serology,Female,"17 Years to 50 Years   (Child, Adult)",,500.0,"September 21, 2020",2022-06-13,"December 2, 2020","Rossana P Fracisco, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04647994,Brazil,,6.0,2022,Monday
1500,1501,Gastrointestinal Manifestations Among Patients With COVID19,Completed,,All,"Child, Adult, Older Adult",,220.0,"June 1, 2020",2020-09-01,"September 10, 2020","Ahmed, Al Minyā, Alminya, Egypt",https://ClinicalTrials.gov/show/NCT04544150,Egypt,,9.0,2020,Tuesday
1501,1502,Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Completed,Drug: ACE Inhibitors and Calcium Channel Blockers,All,"18 Years to 99 Years   (Adult, Older Adult)",,54.0,"May 1, 2020",2020-05-08,"June 5, 2020","Vital Hospital, Bahcelievler, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04379310,Turkey,ACE Inhibitors and Calcium Channel Blockers,5.0,2020,Friday
1502,1503,Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs,"Active, not recruiting",Diagnostic Test: IgG SARS CoV 2 antibodies,All,20 Years to 60 Years   (Adult),,700.0,"July 1, 2020",2020-10-30,"September 30, 2020","Lahore General Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04563247,Pakistan,,10.0,2020,Friday
1503,1504,Impact of COVID-19 on Psoriasis Practice,Completed,,All,"25 Years and older   (Adult, Older Adult)",,197.0,"September 17, 2020",2020-10-23,"November 13, 2020","Department of Dermatology, Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04581044,Egypt,,10.0,2020,Friday
1504,1505,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Completed,Other: severity of lung involvement with COVID-19.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29.0,"June 5, 2020",2020-09-05,"October 6, 2020","Gaziosmanpasa Taksim Research and Education Hospital, Istanbul, Gazi̇osmanpaşa, Turkey",https://ClinicalTrials.gov/show/NCT04577235,Turkey,,9.0,2020,Saturday
1505,1506,"Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19",Recruiting,Other: Questionnaires|Other: Phone interviews,All,"18 Years and older   (Adult, Older Adult)",,57720.0,"October 27, 2020",2021-06-30,"November 2, 2020","Caisse Nationale d'Assurance Maladie, Paris, France|IPSOS, Paris, France",https://ClinicalTrials.gov/show/NCT04607941,France,,6.0,2021,Wednesday
1506,1507,Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World,Recruiting,"Diagnostic Test: SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)",All,"18 Years and older   (Adult, Older Adult)",,200.0,"October 26, 2020",2020-11-01,"October 27, 2020","La Rinconada, Puno, Peru",https://ClinicalTrials.gov/show/NCT04604249,Peru,,11.0,2020,Sunday
1507,1508,Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19),Recruiting,Diagnostic Test: Cardiac MRI|Diagnostic Test: Cardiac CT|Diagnostic Test: Electrocardiogram (ECG)|Diagnostic Test: Blood samples,All,"18 Years and older   (Adult, Older Adult)",,40.0,"June 10, 2020",2022-06-10,"November 12, 2020","University of Edinburgh, Edinburgh, Scotland, United Kingdom",https://ClinicalTrials.gov/show/NCT04625075,United Kingdom,,6.0,2022,Friday
1508,1509,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Recruiting,Diagnostic Test: Biological Sample Collection,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,30.0,"April 30, 2020",2021-06-01,"November 17, 2020","CHU de Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04387955,France,,6.0,2021,Tuesday
1509,1510,Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1580.0,"July 1, 2020",2020-09-01,"September 16, 2020","Landspitali National University Hospital, Reykjavík, Ísland, Iceland",https://ClinicalTrials.gov/show/NCT04546191,Iceland,,9.0,2020,Tuesday
1510,1511,COVID-19 Impact on Rheumatic Patients,Completed,Behavioral: self-administered structured questionnaire,All,"16 Years and older   (Child, Adult, Older Adult)",,360.0,"April 20, 2020",2020-05-20,"July 15, 2020","Kasr Alainy Hospital, Cairo, Non-US/Non-Canadian, Egypt",https://ClinicalTrials.gov/show/NCT04407299,Egypt,,5.0,2020,Wednesday
1511,1512,A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,660.0,"May 4, 2020",2020-07-31,"May 6, 2020","Military Hospital of Tunis, Tunis, Tunisia",https://ClinicalTrials.gov/show/NCT04377646,Tunisia,Hydroxychloroquine|Hydroxychloroquine (placebo)|Zinc|Zinc (Placebo),7.0,2020,Friday
1512,1513,The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"March 14, 2020",2022-07-14,"June 22, 2020","Swansea Univeristy, Swansea, United Kingdom",https://ClinicalTrials.gov/show/NCT04354519,United Kingdom,,7.0,2022,Thursday
1513,1514,Registry on NEN Patients and COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"June 15, 2020",2020-12-15,"July 7, 2020","European Institute of Oncology, IEO, IRCCS, Milan, MI, Italy",https://ClinicalTrials.gov/show/NCT04444401,Italy,,12.0,2020,Tuesday
1514,1515,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Recruiting,Drug: Colchicine|Other: Local standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2500.0,"April 17, 2020",2021-03-30,"November 23, 2020","Sanatorio Parque, Rosario, Santa Fe, Argentina",https://ClinicalTrials.gov/show/NCT04328480,Argentina,Colchicine,3.0,2021,Tuesday
1515,1516,Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19,Not yet recruiting,Diagnostic Test: SARS-CoV2 Autoantibody detection,All,"18 Years to 100 Years   (Adult, Older Adult)",,200.0,"September 15, 2020",2020-12-31,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04542980,Undefined,,12.0,2020,Thursday
1516,1517,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Recruiting,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"August 27, 2020",2022-02-17,"September 1, 2020","Dept. of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark., Aalborg, Denmark|Dept. of Intensive care, Aarhus University Hospital, Aarhus, Denmark|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Neuroanaesthesiology, Copenhagen, Denmark|Dept. of Thoracic Anaesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Gentofte Hospital, Hellerup, Denmark|Dept. of Anaesthesia and Intensive Care, Herlev Hospital, Herlev, Denmark|Dept. of Anaesthesia, Regional Hospital West Jutland, Herning, Herning, Denmark|Dept. of Intensive Care, Nordsjællands Hospital - Hillerød, Denmark., Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Dept. of Anaesthesia and Intensive Care, Lillebaelt Hospital, Kolding, Denmark|Dept. of Intensive Care, Køge University Hospital, Køge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Roskilde, Roskilde, Denmark|Dept. of Anaesthesia, Slagelse Hospital, Slagelse, Denmark|Dept. of Anaesthesia and Intensive Care, Viborg Hospital, Viborg, Denmark|Jawahar Lal Nehru Medical Collega, AMU, Aligarh, India|Apollo Hospital, Chennai, India|Amrita Institute of Medical Sciences, Kochi, India|Bombay Hospital & Medical Research Centre, Mumbai, India|K. J. Somaiya Super Specialty Hospital, Mumbai, India|P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India|S L Raheja Fortis Hospital, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Wockhardt hospitals, Mumbai, India|Indraprastha Apollo Hospital, New Delhi, India|Max Super Specialty Hospital, Saket, New Delhi, India|Symbiosis University Hospital and Research Centre, Pune, India|Vishwaraj Hospital, Pune, India|Rajendra Institute of Medical Sciences, Ranchi, India|Gotri General Hospital, Vadodara, India|Christian Medical College Vellore, Vellore, India|Dept. of Anaesthesia and Intensive Care, Sahlgranska Universitetssjukhuset, Göteborg, Sweden|Dept. of Infectious Diseases, Sahlgranska Universitetssjukhuset, Göteborg, Sweden|Dept. of Anaesthesia and Intensive Care, Universitetssjukhuset i Linköping, Linköping, Sweden|Dept. of Anaesthesia and Intensive Care, Skånes Universitetssjukhus (SUS) Malmö, Malmö, Sweden|Dept. of Infectious Diseases, Skånes Universitetssjukhus (SUS) Malmö, Malmö, Sweden|Dept. of Anaesthesia and Intensive Care, Vrinnevisjukhuset, Norrköping, Norrköping, Sweden|Dept. of Anaesthesia and Intensive Care, Capio St Görans Sjukhus, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Dept. of Anaesthesia and Intensive Care, Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Dept. of Cardiology, Södersjukhuset, Stockholm, Sweden|Dept. of Infectious Diseases, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Infectious Diseases, Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Dept. of Infectious Diseases, Södersjukhuset, Stockholm, Sweden|Dept. of Internal Medicine, Danderyds Sjukhuset, Stockholm, Sweden|Dept. of Internal Medicine, Södersjukhuset, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden|Dept. of Intensive Care Medicine, Bern University Hospital (Inselspital), Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04509973,Denmark,Dexamethasone,2.0,2022,Thursday
1517,1518,EMPOWER - BAME vs COVID,Not yet recruiting,,All,"6 Years and older   (Child, Adult, Older Adult)",,12800.0,"February 1, 2021",2024-02-01,"July 22, 2020","Future Genetics Limited, Birmingham, West Midlands, United Kingdom",https://ClinicalTrials.gov/show/NCT04399733,United Kingdom,,2.0,2024,Thursday
1518,1519,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19",Recruiting,Biological: Gam-COVID-Vac|Other: placebo,All,"18 Years to 111 Years   (Adult, Older Adult)",Phase 3,40000.0,"September 7, 2020",2021-05-01,"October 27, 2020","ARCHIMED V Clinic of new medical technologies limited liability company, Moscow, Russian Federation|Hadassah LTD, Moscow, Russian Federation|Medsi Group of companies joint-stock company"", Moscow, Russian Federation|Niarmedic Plus, Moscow, Russian Federation|State budgetary healthcare institution of the city of Moscow ""City clinical hospital No. 52 of the Moscow city health Department"", Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Consultation and Diagnosis Polyclinic No. 121, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, M. Konchalovsky Municipal Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, M. Zhadkevich Municipal Clinical Hospital, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 115, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 2, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 210, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 212, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 219, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Moscow, Municipal Polyclinic No. 220, Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution, Municipal Polyclinic No. 62, Moscow Healthcare Department, Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "" city polyclinic No. 109 Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "" city polyclinic No. 170 Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "" city polyclinic No. 36 Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "" city polyclinic No. 46 Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "" city polyclinic No. 6 Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow "" city polyclinic No. 68 Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""Diagnostic center No. 5 with polyclinic Department Of the Department of health of the city of Moscow"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""Diagnostic clinical center No. 1 Of the Department of health of the city of Moscow"", Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04530396,Russian Federation,,5.0,2021,Saturday
1519,1520,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Active, not recruiting",Drug: BLD-2660,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"May 4, 2020",2020-11-30,"October 30, 2020","Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Brandon, Florida, United States|Blade Research Site, Fort Pierce, Florida, United States|Blade Research Site, Panama City, Florida, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Idaho Falls, Idaho, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Ames, Iowa, United States|Blade Research Site, Lexington, Kentucky, United States|Blade Research Site, Louisville, Kentucky, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Farmington Hills, Michigan, United States|Blade Research Site, Omaha, Nebraska, United States|Blade Research Site, Ridgewood, New Jersey, United States|Blade Research Site, Charleston, North Carolina, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Blade Research Site, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Blade Research Site, Dallas, Texas, United States|Blade Research Site, Spokane, Washington, United States|Blade Research Site, Campinas, Sao Paulo, Brazil|Blade Research Site, Bahia, Brazil|Blade Research Site, Belo Horizonte, Brazil|Blade Research Site, Botucatu, Brazil|Blade Research Site, Porto Velho, Brazil|Blade Research Site, Ribeirão Preto, Brazil|Blade Research Site, São José Do Rio Preto, Brazil|Blade Research Site, Vitória, Brazil",https://ClinicalTrials.gov/show/NCT04334460,Brazil,BLD-2660,11.0,2020,Monday
1520,1521,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Drug: BIO101|Drug: Placebo,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,310.0,"June 16, 2020",2021-09-01,"December 10, 2020","University of California, Irvine, Irvine, California, United States|Barnum Medical Research, Inc. 1029 Keyser Ave Suite H, Natchitoches, Louisiana, United States|Beaumont Health, Royal Oak, Michigan, United States|CHU Saint-Pierre, Brussel, Belgium|AZ-Sint Maarten, Mechelen, Belgium|CHU CLU Namur (Saint-Elisabeth) Place Louise Godin, Namur, Belgium|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Municipal de Barueri Dr. Francisco Moran, Barueri, São Paulo, Brazil|Hospital e Maternidade Celso Pierro - PUCCAMP, Campinas, São Paulo, Brazil|Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São José Do Rio Preto, São Paulo, Brazil|Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar, São Paulo, Brazil|Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital, Paris, Paris Cedex 13, France|Centre Hospitalier Argenteuil, Argenteuil, France|Centre Hospitalier Universitaire Bordeaux, Bordeaux, France|Centre Hospitalier Rene Dubos, Cergy-Pontoise, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, Paris, France|FDI Clinical Research - San Juan City Hospital, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04472728,Belgium,BIO101|Placebo,9.0,2021,Wednesday
1521,1522,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Not yet recruiting,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,300.0,"January 1, 2021",2023-03-31,"December 11, 2020","University Hospital Brno, Brno, Czechia",https://ClinicalTrials.gov/show/NCT04663555,Undefined,Dexamethasone,3.0,2023,Friday
1522,1523,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Drug: Peginterferon Lambda-1A|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140.0,"May 13, 2020",2020-11-30,"May 18, 2020","Toronto General Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04354259,Canada,Peginterferon Lambda-1A,11.0,2020,Monday
1523,1524,Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia,Completed,Behavioral: Maslach Burnout Inventory (MBI),All,"18 Years to 70 Years   (Adult, Older Adult)",,800.0,"March 1, 2020",2020-07-01,"July 27, 2020","Ospedale Perrino Asl Brindisi, Brindisi, Italy|Piazza della Vittoria 14 Studio medico - Ginecologia e Ostetricia, Genoa, Italy",https://ClinicalTrials.gov/show/NCT04424771,Italy,,7.0,2020,Wednesday
1524,1525,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,Procedure: Surgery,All,"Child, Adult, Older Adult",,1000.0,"January 1, 2020",2020-09-30,"May 12, 2020","Hospital del Henares, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04323644,Spain,,9.0,2020,Wednesday
1525,1526,COVID-19 and HIV Patients,Recruiting,Other: Seroprevalence of SARS-CoV-2 infection in patients with HIV infection,All,"18 Years and older   (Adult, Older Adult)",,2200.0,"July 1, 2020",2022-06-30,"August 21, 2020","Valérie POURCHER, Paris, Ile De France, France",https://ClinicalTrials.gov/show/NCT04523012,France,,6.0,2022,Thursday
1526,1527,COVID-19 Survivorship Registry,Recruiting,Other: Questionnaires,All,"18 Years and older   (Adult, Older Adult)",,350.0,"July 17, 2020",2023-08-01,"November 17, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04527315,United States,,8.0,2023,Tuesday
1527,1528,A Phase II/III Study of Sargramostim,Not yet recruiting,Drug: Sargramostim|Drug: Placebo,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"November 24, 2020",2021-04-30,"November 24, 2020","IUHW Narita Hospital, Narita City, Chiba, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan|Japanese Red Cross Society Saitama Red Cross Hospital, Saitama City, Saitama, Japan|Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan",https://ClinicalTrials.gov/show/NCT04642950,Japan,Sargramostim|Placebo,4.0,2021,Friday
1528,1529,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",Other: Standard of Care (SoC)|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400.0,"June 29, 2020",2022-11-01,"October 5, 2020","Gesundheit Nord gGmbH, Bremen, Germany|Universitätsklinikum Gießen, Gießen, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Technische Universität München (TUM), München, Germany",https://ClinicalTrials.gov/show/NCT04575064,Germany,Remdesivir,11.0,2022,Tuesday
1529,1530,Echocardiographic Manifestation in Patient With COVID-19 （EARLY-MYO COVID-19）,Completed,Other: Echocardiography,All,"18 Years and older   (Adult, Older Adult)",,51.0,"January 21, 2020",2020-04-08,"May 19, 2020","Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04352842,China,,4.0,2020,Wednesday
1530,1531,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,600.0,"April 5, 2020",2020-08-29,"May 19, 2020","ProofPilot Online App (https://p.proofpilot.com), New York, New York, United States",https://ClinicalTrials.gov/show/NCT04393961,United States,,8.0,2020,Saturday
1531,1532,iNOPulse for COVID-19,Withdrawn,Drug: Inhaled nitric oxide (iNO)|Drug: Nitrogen gas|Drug: Oxygen gas,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"December 1, 2020",2021-07-15,"August 19, 2020","University of Miami Hospitals & Clinics, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04398290,United States,Inhaled nitric oxide (iNO)|Nitrogen gas|Oxygen gas,7.0,2021,Thursday
1532,1533,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Recruiting,Diagnostic Test: Optical Coherence Tomography (OCT),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"June 1, 2020",2020-12-31,"July 16, 2020","Incor - Heart Institute - University of Sao Paulo, São Paulo, Brazil|IRCCS San Raffaele, Milano, Italy",https://ClinicalTrials.gov/show/NCT04410549,Brazil,,12.0,2020,Thursday
1533,1534,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Recruiting,Procedure: Therapeutic Plasma Exchange (TPE),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"July 25, 2020",2020-12-29,"September 9, 2020","Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT04457349,Egypt,,12.0,2020,Tuesday
1534,1535,COVidIVERmectin: Ivermectin for Treatment of Covid-19,Recruiting,Drug: Ivermectin|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,102.0,"July 31, 2020",2020-12-01,"October 22, 2020","IRCCS Sacro Cuore Don Calabria hospital, Negrar, Verona, Italy|Policlinico S. Orsola, Bologna, Italy|Ospedale Luigi Sacco, Milan, Italy|Ospedale di Rovereto, Rovereto, Italy|Ospedale Amedeo di Savoia, Turin, Italy|Hospital Clinic/ISGlobal, Barcelona, Spain|Hospital La Paz-Carlos III, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04438850,Italy,Ivermectin,12.0,2020,Tuesday
1535,1536,CardioVascular Disease Progression and Prognosis in COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"September 20, 2020",2021-12-31,"October 28, 2020","Policlinico Sant'Orsola, Bologna, Italy",https://ClinicalTrials.gov/show/NCT04606732,Italy,,12.0,2021,Friday
1536,1537,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,Other: Prone Positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 1, 2020",2021-12-31,"October 12, 2020","Johns Hopkins Univeristy, Baltimore, Maryland, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|UPMC, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04517123,United States,,12.0,2021,Friday
1537,1538,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,Recruiting,Drug: Nuvastatic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,10.0,"September 1, 2020",2020-09-30,"September 10, 2020","Navin Hospital, Ghaziabad, Uttar Pradesh, India",https://ClinicalTrials.gov/show/NCT04542447,India,Nuvastatic,9.0,2020,Wednesday
1538,1539,COVID-19 Nasal Swab Trial,Not yet recruiting,Device: CanSwab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,December 2020,2021-02-28,"December 2, 2020","Health Sciences Centre, Winnipeg, Manitoba, Canada",https://ClinicalTrials.gov/show/NCT04649424,Canada,,2.0,2021,Sunday
1539,1540,IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study,"Active, not recruiting",,All,"18 Years to 80 Years   (Adult, Older Adult)",,100.0,"June 16, 2020",2020-07-30,"July 8, 2020","AssiutU, Assiut, Egypt|Assiut University Hospitals, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04462120,Egypt,,7.0,2020,Thursday
1540,1541,London's Exogenous Surfactant Study for COVID19,Not yet recruiting,Drug: Bovine Lipid Extract Surfactant,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"July 1, 2020",2021-07-01,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04375735,Undefined,Bovine Lipid Extract Surfactant,7.0,2021,Thursday
1541,1542,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,Drug: Fluoxetine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000.0,"May 1, 2020",2021-10-20,"May 6, 2020","University of Toledo, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT04377308,United States,Fluoxetine,10.0,2021,Wednesday
1542,1543,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,Recruiting,Other: observational,All,"up to 99 Years   (Child, Adult, Older Adult)",,1000.0,"March 1, 2020",2020-12-31,"April 27, 2020","Msp de Creil, Creil, France",https://ClinicalTrials.gov/show/NCT04363099,France,,12.0,2020,Thursday
1543,1544,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Biological: BBV152A - Phase I|Biological: BBV152B - Phase I|Biological: BBV152C - Phase I|Biological: Placebo - Phase I|Biological: BBV152A - Phase II|Biological: BBV152B - Phase II,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,755.0,"July 13, 2020",2021-06-30,"October 1, 2020","King George Hospital, Visakhapatnam, Andhra Pradesh, India|All India Institute of Medical Sciences, Patna, Bihar, India|Pt BD SHARMA,PGIMS/UHS, Rohtak, Haryana, India|Jeevan Rekha Hospital, Belgaum, Karnataka, India|Gillukar Multispeciality Hospital, Nagpur, Maharastra, India|All India Institute of Medical Sciences, Delhi, New Delhi, India|Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Orissa, India|SRM Hospital & Research center, Chennai, Tamilnadu, India|Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India|Rana Hospital and Trauma Center, Gorakhpur, Uttar Pradesh, India|Prakhar Hospital, Kanpur, Uttar Pradesh, India|Redkar Hospital and Research Centre, Goa, India",https://ClinicalTrials.gov/show/NCT04471519,India,,6.0,2021,Wednesday
1544,1545,Postpartum Sexual Function in Pregnant Women With COVID-19,Recruiting,,Female,18 Years to 45 Years   (Adult),,140.0,"May 14, 2020",2020-09-30,"September 2, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey",https://ClinicalTrials.gov/show/NCT04389489,Turkey,,9.0,2020,Wednesday
1545,1546,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,Recruiting,Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,132.0,"May 7, 2020",2021-05-01,"May 13, 2020","Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States",https://ClinicalTrials.gov/show/NCT04381988,Jersey,Hydroxychloroquine,5.0,2021,Saturday
1546,1547,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",Suspended,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27.0,"April 11, 2020",2020-08-01,"May 6, 2020","AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France",https://ClinicalTrials.gov/show/NCT04341870,France,Sarilumab|Azithromycin|Hydroxychloroquine,8.0,2020,Saturday
1547,1548,Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness,Recruiting,Diagnostic Test: echocardiogram 2D,All,18 Years to 45 Years   (Adult),,30.0,"September 1, 2020",2020-11-30,"August 4, 2020","Hospital Beneficencia Española de Puebla, Puebla, Mexico",https://ClinicalTrials.gov/show/NCT04498299,Mexico,,11.0,2020,Monday
1548,1549,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Recruiting,Combination Product: Hyperbaric Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"July 6, 2020",2020-12-30,"August 19, 2020","Hospital Central de San Isidro Dr. Angel Melchor Posse, San Isidro, Buenos Aires, Argentina|Hospital de Infecciosas F. J. Muñiz, Ciudad Autonoma de Buenos AIres, Caba, Argentina|Hospital General de Agudos D.F Santojanni, Ciudad Autonoma de Buenos AIres, Caba, Argentina",https://ClinicalTrials.gov/show/NCT04477954,Argentina,,12.0,2020,Wednesday
1549,1550,Coronavirus Response - Active Support for Hospitalised Covid-19 Patients,Withdrawn,Drug: Aspirin|Drug: Losartan|Drug: Simvastatin,All,"40 Years and older   (Adult, Older Adult)",Phase 3,0.0,October 2020,2021-08-01,"November 19, 2020","University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan",https://ClinicalTrials.gov/show/NCT04343001,Niger,Aspirin|Losartan|Simvastatin,8.0,2021,Sunday
1550,1551,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,Recruiting,Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 4,140.0,"July 31, 2020",2021-12-31,"August 4, 2020","Medical University of South Carolina, Charleston, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04482673,United States,Daily Vitamin D3|Daily placebo|Bolus vitamin D3|Bolus placebo,12.0,2021,Friday
1551,1552,Ketogenic Diet as Protective Factor During COVID-19,Recruiting,Dietary Supplement: Ketogenic diet with phytoextracts,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,28.0,"November 1, 2020",2021-08-30,"November 4, 2020","Ospedale San Bortolo, Vicenza, Italy",https://ClinicalTrials.gov/show/NCT04615975,Italy,,8.0,2021,Monday
1552,1553,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,"Active, not recruiting",Drug: RTB101|Drug: Placebo,All,65 Years and older   (Older Adult),Phase 2,36.0,"July 11, 2020",2021-01-01,"December 9, 2020","Nursing Home, Middletown, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04409327,United States,RTB101|Placebo,1.0,2021,Friday
1553,1554,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Recruiting,Procedure: Prone positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,56.0,"September 3, 2020",2021-06-30,"October 19, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04589936,United Kingdom,,6.0,2021,Wednesday
1554,1555,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Combination Product: Hydroxycloroquine and Azythromycine|Combination Product: Cospherunate/Azythromycine|Combination Product: Cospherunate/Phytomedicine/Azythromycien,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"June 1, 2020",2020-09-30,"August 7, 2020","Donka; Kenien; Gbessia, Conakry, Guinea",https://ClinicalTrials.gov/show/NCT04502342,Guinea,,9.0,2020,Wednesday
1555,1556,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,Drug: Prednisone|Other: Control group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,11.0,"April 21, 2020",2020-08-18,"October 26, 2020","Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital St Joseph Saint Luc, Lyon, France|Hôpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|CHU St Etienne, Saint-Étienne, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France|CHG Vienne, Vienne, France|Médipôle, Villeurbanne, France|Clinique des Portes du Sud, Vénissieux, France|CH Annecy-Genevois, Épagny, France",https://ClinicalTrials.gov/show/NCT04344288,France,Prednisone,8.0,2020,Tuesday
1556,1557,Testing the Accuracy of a Digital Test to Diagnose Covid-19,Recruiting,Diagnostic Test: Covid-19 swab PCR test,All,"18 Years and older   (Adult, Older Adult)",,1000000.0,"June 1, 2020",2021-05-10,"June 24, 2020","King's College London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04407585,United Kingdom,,5.0,2021,Monday
1557,1558,Donated Antibodies Working Against nCoV,Recruiting,Biological: Convalescent Plasma|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,483.0,"May 2, 2020",2021-11-02,"June 12, 2020","ZNA, Antwerpen, Belgium|Institut Bordet, Brussel, Belgium|UMC Sint-Pieter, Brussel, Belgium|CHU Brugmann, Brussel, Belgium|Erasmus Ziekenhuis, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St Luc, Brussel, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC Liège Mont Légia, Liège, Belgium|CHR Citadelle Liège, Liège, Belgium|CHU Liège Sart-Tilman, Liège, Belgium|CHR Jolimont Mons-Hainaut, Mons, Belgium|AZ Delta, Roeselare, Belgium",https://ClinicalTrials.gov/show/NCT04429854,Belgium,Standard of care,11.0,2021,Tuesday
1558,1559,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,"Active, not recruiting",Drug: Clazakizumab,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,17.0,"April 24, 2020",2021-03-31,"October 5, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04348500,United States,Clazakizumab,3.0,2021,Wednesday
1559,1560,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Recruiting,Drug: Heparin sodium|Drug: Enoxaparin,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,200.0,"June 1, 2020",2021-06-01,"August 31, 2020","Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04530578,Argentina,Heparin sodium|Enoxaparin,6.0,2021,Tuesday
1560,1561,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,Recruiting,Drug: EDP1815|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"August 26, 2020",2020-12-21,"November 13, 2020","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04488575,Jersey,EDP1815|Placebo,12.0,2020,Monday
1561,1562,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Drug: UNIKINON (Chloroquine phosphate) 200mg tablets,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,60.0,"April 6, 2020",2021-04-30,"June 2, 2020","Divine Providence Hospital ""Pammakaristos"", Athens, Greece|Athens General Hospital ""Hippokrateio"", Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 3rd University Pathology Clinic, Athens, Greece|Corfu General Hospital Agia Irini, Corfu, Greece|University General Hospital of Ioannina, Ioánnina, Greece|General Hospital of Athens ""Sismanoglio"", Maroúsi, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloníki, Greece",https://ClinicalTrials.gov/show/NCT04344951,Greece,UNIKINON (Chloroquine phosphate) 200mg tablets,4.0,2021,Friday
1562,1563,Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal,Recruiting,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",,200.0,"July 30, 2020",2020-12-30,"September 30, 2020","Narayani Hospital, Birgunj, Nepal|Seti Provincial Hospital, Dhangadi, Nepal|BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Nepal|Sukraraj Tropical Disease Hospital, Kathmandu, Nepal|TU Teaching Hospital, Kathmandu, Nepal|Bheri Provincial Hospital, Nepalgunj, Nepal",https://ClinicalTrials.gov/show/NCT04570982,Nepal,,12.0,2020,Wednesday
1563,1564,"Evaluating Auscul-X, a Touch Free Digital Stethoscope",Not yet recruiting,Device: Auscul-X,All,"18 Years to 100 Years   (Adult, Older Adult)",,40.0,September 2020,2021-01-01,"September 30, 2020","The University of Ottawa Heart Institute, Ottawa, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04570189,Canada,,1.0,2021,Friday
1564,1565,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Recruiting,Other: blood sampling|Other: additional blood tubes,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"May 5, 2020",2020-10-22,"June 12, 2020","Antibes Hospital, Antibes, France|Cannes Hospital, Cannes, France|Nice Hospital, Nice, France",https://ClinicalTrials.gov/show/NCT04355351,France,,10.0,2020,Thursday
1565,1566,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Recruiting,Drug: Favipiravir|Drug: Lopinavir/ Ritonavir|Other: Favipiravir Placebo|Other: Lopinavir/ Ritonavir Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,240.0,"September 24, 2020",2021-03-01,"October 30, 2020","Royal Free Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04499677,United Kingdom,Favipiravir|Lopinavir/ Ritonavir,3.0,2021,Monday
1566,1567,Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),Withdrawn,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"September 2, 2020",2020-09-02,"September 4, 2020","Institut de Cancérologie Strasbourg Europe, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04392128,France,Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Azithromycin 250 MG Oral Capsule|Placebo oral tablet|Placebo oral capsule,9.0,2020,Wednesday
1567,1568,Results of Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19,Not yet recruiting,"Other: Nursing care to reduce anxiety, fear and loneliness",All,"18 Years and older   (Adult, Older Adult)",,450.0,September 2020,2020-12-31,"July 22, 2020","CorporacionPT, Sabadell, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04481477,Spain,,12.0,2020,Thursday
1568,1569,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults",Recruiting,Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,216.0,"July 13, 2020",2021-09-01,"September 4, 2020","Nucleus Network Brisbane (Q-Pharm Pty Ltd), Herston, Queensland, Australia",https://ClinicalTrials.gov/show/NCT04495933,Australia,,9.0,2021,Wednesday
1569,1570,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"April 21, 2020",2021-04-21,"December 3, 2020","Hôpital Fondation A. de Rotschhild, Paris, France",https://ClinicalTrials.gov/show/NCT04355364,France,Dornase Alfa Inhalation Solution [Pulmozyme],4.0,2021,Wednesday
1570,1571,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,Not yet recruiting,Biological: Recombinant new coronavirus vaccine (CHO cell) group|Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group,All,"18 Years and older   (Adult, Older Adult)",Phase 3,29000.0,December 2020,2022-04-01,"November 30, 2020","Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China",https://ClinicalTrials.gov/show/NCT04646590,China,,4.0,2022,Friday
1571,1572,COVID19 Severity Prediction and Health Services Research Evaluation,Recruiting,Other: Predictors adverse evolution|Other: Predictors of health care provide,All,"Child, Adult, Older Adult",,20000.0,"June 1, 2020",2021-12-31,"July 15, 2020","Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain|Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain",https://ClinicalTrials.gov/show/NCT04463706,Spain,,12.0,2021,Friday
1572,1573,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10000.0,"March 24, 2020",2025-03-24,"July 7, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT04458948,Mexico,Hydroxychloroquine|Azithromycin,3.0,2025,Monday
1573,1574,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection,"Active, not recruiting",,All,"Child, Adult, Older Adult",,10.0,"April 1, 2020",2020-10-30,"July 29, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04361786,France,,10.0,2020,Friday
1574,1575,Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19,Not yet recruiting,Drug: semaglutide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"November 30, 2020",2022-03-31,"November 4, 2020","Instituto Prevent Senior, São Paulo, Brazil|State University of Campinas, São Paulo, Brazil|Trillium Health Partners, Mississauga, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network - Peter Munk Cardiac Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hospital de Infectologia, Mexico City, Mexico|Hospital General Regional, Mexico City, Mexico|Hospital Regional 2, Querétaro, Mexico|Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom",https://ClinicalTrials.gov/show/NCT04615871,Brazil,semaglutide,3.0,2022,Thursday
1575,1576,COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience,Completed,Drug: Hydroxychloroquine Pill,All,"18 Years and older   (Adult, Older Adult)",,199.0,"June 1, 2020",2020-07-15,"September 22, 2020","Faculty of Medicine Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04554979,Egypt,Hydroxychloroquine Pill,7.0,2020,Wednesday
1576,1577,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30.0,"February 6, 2020",2020-02-25,"April 13, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04261517,China,Hydroxychloroquine,2.0,2020,Tuesday
1577,1578,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,Recruiting,Dietary Supplement: Natural Honey|Other: Standard Care,All,"5 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,1000.0,"April 15, 2020",2021-01-15,"April 21, 2020","Mahmoud Tantawy, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04323345,Egypt,,1.0,2021,Friday
1578,1579,Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt,Completed,,All,"1 Year to 18 Years   (Child, Adult)",,36.0,"May 1, 2020",2020-08-31,"September 2, 2020","Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04536285,Egypt,,8.0,2020,Monday
1579,1580,Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia,Recruiting,Diagnostic Test: Butterfly,All,"Child, Adult, Older Adult",,34.0,"March 15, 2020",2020-06-10,"June 16, 2020","Azienda Ospedaliera Universitaria Senese, Siena, Si, Italy",https://ClinicalTrials.gov/show/NCT04433000,Italy,,6.0,2020,Wednesday
1580,1581,Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5500.0,April 2020,2020-09-10,"May 1, 2020","Istituto Auxologico Italiano, Milan, Italy",https://ClinicalTrials.gov/show/NCT04371289,Italy,,9.0,2020,Thursday
1581,1582,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,"Active, not recruiting",Drug: Octagam,All,"18 Years and older   (Adult, Older Adult)",Phase 4,34.0,"April 28, 2020",2020-11-30,"November 4, 2020","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hospital, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04411667,United States,Octagam,11.0,2020,Monday
1582,1583,Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2,Enrolling by invitation,,All,"18 Years to 75 Years   (Adult, Older Adult)",,250.0,"July 21, 2020",2022-12-01,"November 2, 2020","Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04611841,Russian Federation,,12.0,2022,Thursday
1583,1584,Convalescent Plasma in Pediatric COVID-19,Recruiting,Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies,All,"up to 22 Years   (Child, Adult)",Early Phase 1,50.0,July 2020,2022-06-01,"July 7, 2020","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04458363,Georgia,Standard COVID-19 therapies,6.0,2022,Wednesday
1584,1585,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Recruiting,Combination Product: Immunofree tablets and Reginmune capsule,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"August 7, 2020",2020-10-30,"October 20, 2020","Govt Medical College and Govt General Hospital (Old RIMSGGH), Srikakulam, Andhra Pradesh, India|Parul Institute of Ayurveda and Research Parul University, Vadodara, Gujrat, India|Lokmanya Hospital, Pune, Maharashtra, India",https://ClinicalTrials.gov/show/NCT04494204,India,,10.0,2020,Friday
1585,1586,"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela",Not yet recruiting,Biological: Gam-COVID-Vac|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2000.0,November 2020,2021-12-01,"November 24, 2020",,https://ClinicalTrials.gov/show/NCT04642339,Undefined,,12.0,2021,Wednesday
1586,1587,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,100.0,"May 2, 2020",2021-04-01,"May 19, 2020","Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04367831,United States,Enoxaparin Prophylactic Dose|Heparin Infusion|Heparin SC|Enoxaparin/Lovenox Intermediate Dose,4.0,2021,Thursday
1587,1588,Fear Among Dentists During COVID-19 Pandemic,Completed,,All,"20 Years and older   (Adult, Older Adult)",,216.0,"March 2, 2020",2020-05-05,"May 12, 2020","Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04383626,Egypt,,5.0,2020,Tuesday
1588,1589,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection,Not yet recruiting,Biological: Gam-COVID-Vac|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600.0,December 2020,2021-09-01,"November 23, 2020","Somaarth DDESS Palwal, Aurangabad, India|ESIC Medical College & Hospital, Faridabad, India|Maharaja Agrasen Superspecialty Hospital, Jaipur, India|GSVM Medical College, Kanpur, India|St. George's Hospital, Mumbai, India|Noble Hospital Private Limited, Pune, India",https://ClinicalTrials.gov/show/NCT04640233,India,,9.0,2021,Wednesday
1589,1590,Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,4.0,November 2020,2021-02-01,"November 20, 2020","Unité de Soins de Rééducation Post Réanimation, Service de Médecine Physique et de Réadaptation, Hôpital Raymond Poincaré, APHP, Garches, France",https://ClinicalTrials.gov/show/NCT04639427,France,,2.0,2021,Monday
1590,1591,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,Recruiting,Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"April 8, 2020",2021-01-15,"August 13, 2020","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain",https://ClinicalTrials.gov/show/NCT04348383,Spain,Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Placebo 250 cc 24 hours continuous infusion for 15 days,1.0,2021,Friday
1591,1592,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),Not yet recruiting,Drug: Nafamostat Mesilate|Drug: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,256.0,April 2020,2021-12-01,"April 20, 2020",,https://ClinicalTrials.gov/show/NCT04352400,Undefined,Nafamostat Mesilate|Placebo,12.0,2021,Wednesday
1592,1593,Tenecteplase in Patients With COVID-19,Recruiting,Drug: Tenecteplase|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"September 25, 2020",2021-04-01,"November 12, 2020","Mount Sinai Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04505592,United States,Tenecteplase|Placebo,4.0,2021,Thursday
1593,1594,"Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19",Recruiting,,Female,18 Years to 45 Years   (Adult),,75.0,"May 14, 2020",2020-09-30,"September 2, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey",https://ClinicalTrials.gov/show/NCT04389515,Turkey,,9.0,2020,Wednesday
1594,1595,Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes,Recruiting,,All,"Child, Adult, Older Adult",,700.0,"July 30, 2020",2020-12-31,"September 16, 2020","Endocrinology and metabolic diseases Unit, Parma, Italy",https://ClinicalTrials.gov/show/NCT04550403,Italy,,12.0,2020,Thursday
1595,1596,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Completed,Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,29.0,"April 20, 2020",2020-05-30,"June 12, 2020","Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04346446,India,Convalescent Plasma Transfusion|Random Donor Plasma,5.0,2020,Saturday
1596,1597,Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,"December 16, 2020",2021-12-31,"December 11, 2020","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04565080,United States,,12.0,2021,Friday
1597,1598,"International COVID19 Clinical Evaluation Registry,",Recruiting,Combination Product: Observational (registry),All,"Child, Adult, Older Adult",,6000.0,"March 23, 2020",2020-05-05,"April 28, 2020","Hospital Lclinico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04334291,Spain,,5.0,2020,Tuesday
1598,1599,Post COVID-19 Functional Status in Egypt,Recruiting,Other: Post COVID-19 Functional Satus Scale,All,"Child, Adult, Older Adult",,400.0,"July 1, 2020",2020-11-30,"September 9, 2020","Aliaa Hussein, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04479293,Egypt,,11.0,2020,Monday
1599,1600,Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,155.0,March 2021,2021-08-01,"October 26, 2020","Clinique de l'Estrée, Stains, France",https://ClinicalTrials.gov/show/NCT04414059,France,,8.0,2021,Sunday
1600,1601,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,Recruiting,Drug: mavrilimumab|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,573.0,"July 27, 2020",2021-04-01,"November 17, 2020","UCLA Medical Center, Los Angeles, California, United States|Sharp Health Care, San Diego, California, United States|Affinity Health, Oak Brook, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Allina Health System, Minneapolis, Minnesota, United States|Mercy Hospital, Springfield, Missouri, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Texas Health Sciences, Houston, Texas, United States|UPECLIN - Unidade de Pesquisa Clínica, Botucatu, Brazil|IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará, Fortaleza, Brazil|Hospital Bruno Born, Lajeado, Brazil|Centro de Pesquisas Clínicas, Natal, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil|Hospital Cardio Pulmonar, Salvador, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Clinica Las Condes, Santiago, Chile|Hospital Essalud Alberto Sabogal Sologuren, Bellavista, Peru|Essalud - Hospital de Emergencias Grau, Lima Cercado, Peru|Hospital Nacional Cayetano Heredia, San Martín De Porres, Peru|Clinica Providencia, San Miguel, Peru|IATROS International, Bloemfontein, South Africa|Tiervlei Trial Center, Cape Town, South Africa|TASK Eden, George, South Africa|Into Research - Little Company of Mary Medical Center, Pretoria, South Africa|Limpopo Clinical Research Initiative, Rustenburg, South Africa",https://ClinicalTrials.gov/show/NCT04447469,Brazil,mavrilimumab,4.0,2021,Thursday
1601,1602,Psychiatric Consultation for COVID-19 Patients,Not yet recruiting,Behavioral: Psychiatric counseling,All,"Child, Adult, Older Adult",,54.0,"May 28, 2020",2020-12-31,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04395872,Undefined,,12.0,2020,Thursday
1602,1603,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,Recruiting,Drug: Dexamethasone|Drug: Methylprednisolone,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,60.0,"August 2, 2020",2020-11-30,"August 18, 2020","Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh",https://ClinicalTrials.gov/show/NCT04499313,Bangladesh,Dexamethasone|Methylprednisolone,11.0,2020,Monday
1603,1604,Different PEEP Settings of COVID-19 Induced ARDS,Completed,Other: Gas exchanges at different PEEP|Other: lung mechanics at different PEEP|Other: Hemodynamics changes at different PEEP,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,"March 5, 2020",2020-03-25,"April 24, 2020","Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04359251,China,,3.0,2020,Wednesday
1604,1605,Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic,Completed,Procedure: Endoscopic procedure,All,"1 Year to 18 Years   (Child, Adult)",,77.0,"June 1, 2020",2020-08-31,"November 2, 2020","Tepecik Trh, İzmir, İ̇zmi̇r, Turkey",https://ClinicalTrials.gov/show/NCT04598256,Turkey,,8.0,2020,Monday
1605,1606,"EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY",Recruiting,Diagnostic Test: visual analogue scale,All,"Child, Adult, Older Adult",,100.0,"November 17, 2020",2021-06-01,"December 8, 2020","University General Hospital of Ioannina, Ioannina, Epirus, Greece",https://ClinicalTrials.gov/show/NCT04657445,Greece,,6.0,2021,Tuesday
1606,1607,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,Completed,,All,22 Weeks to 28 Weeks   (Child),,885.0,"August 21, 2020",2020-09-13,"October 8, 2020","Neonatalklinikken, Rigshospitalet, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04527601,Denmark,,9.0,2020,Sunday
1607,1608,Covid-19 Associated Coagulopathy,Recruiting,Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,170.0,"May 6, 2020",2021-04-16,"June 19, 2020","University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04360824,United States,Intermediate dose thromboprophylaxis|Standard of Care thromboprophylaxis,4.0,2021,Friday
1608,1609,HFNT vs. COT in COVID-19,Not yet recruiting,Device: High Flow Nasal Therapy|Device: Conventional Oxygen Therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,364.0,"January 10, 2021",2022-03-01,"December 7, 2020","Pulmonology and Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy, Arezzo, Italy|Respiratory Medicine Unit, ""Policlinico-Vittorio Emanuele San Marco"" University Hospital, Catania, Italy, Catania, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy G. Giglio Foundation, Cefalù, Italy, Cefalù, Italy|Department of Human Pathology of the Adult and Evolutive Age ""Gaetano Barresi"", Division of Anesthesia and Intensive Care, University of Messina, Policlinico ""G. Martino"", Messina, Italy, Messina, Italy|IRCCS MultiMedica, Value-Based Healthcare Unit, Sesto San Giovanni, Milan, Italy, Milan, Italy|University Hospital of Modena Policlinico, Respiratory Diseases Unit, Department of Medical and Surgical Sciences SMECHIMAI, University of Modena Reggio Emilia, Italy, Modena, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy, Palermo, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy, Palermo, Italy|Dipartimento Universitario di Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza ""G. D'Alessandro"" (PROMISE), Division of Respiratory Medicine, ""Paolo Giaccone"" University Hospital, University of Palermo, Italy, Palermo, Italy|Department of Medicina e Chirurgia Università Insubria Varese-Como, Italy, Pavia, Italy|Emergency Department, ""S. Maria della Misericordia"" Hospital, Perugia, Italy., Perugia, Italy|Department of Pneumology, A.O.U. Città della Salute e della Scienza of Turin, Italy., Turin, Italy",https://ClinicalTrials.gov/show/NCT04655638,Italy,,3.0,2022,Tuesday
1609,1610,Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19,Recruiting,Other: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests,All,"18 Years and older   (Adult, Older Adult)",,57.0,"June 29, 2020",2020-12-31,"July 13, 2020","hopital de la Croix Rousse, Lyon 4, Rhone Alpes, France",https://ClinicalTrials.gov/show/NCT04469153,France,,12.0,2020,Thursday
1610,1611,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,Completed,Drug: XC221|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,118.0,"July 25, 2020",2020-10-29,"November 13, 2020","Regional State Budgetary Institution of Healthcare ""City Hospital No. 5, Barnaul"", Barnaul, Altai Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow Region ""Zhukovskaya City Clinical Hospital"", Zhukovskiy, Moscow Region, Russian Federation|Municipal Budgetary Institution of Healthcare ""Central City Hospital of Novoshakhtinsk"", Novoshakhtinsk, Rostov Region, Russian Federation|State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 15 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University), Department of Faculty Therapy No. 2, Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 52 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 40 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Multidisciplinary Hospital"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Hospital No. 40 of Kurortny District"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Hospital No. 15"", Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Pokrovskaya Hospital"" (4th Cardiology Department), Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Pokrovskaya Hospital"", Saint Petersburg, Russian Federation|Regional State Budgetary Institution of Healthcare ""Medical-Sanitary Unit No. 2"", Tomsk, Russian Federation",https://ClinicalTrials.gov/show/NCT04487574,Russian Federation,XC221|Placebo,10.0,2020,Thursday
1611,1612,Clinical Features of Severe Patients With COVID-19,Recruiting,"Diagnostic Test: The demographic, clinical, laboratory, and instrumental data",All,"18 Years to 90 Years   (Adult, Older Adult)",,150.0,"April 6, 2020",2020-08-01,"June 29, 2020","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04450017,Russian Federation,,8.0,2020,Saturday
1612,1613,"NCI COVID-19 in Cancer Patients, NCCAPS Study",Recruiting,Procedure: Biospecimen Collection|Other: Data Collection|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,All,"Child, Adult, Older Adult",,2000.0,"May 21, 2020",2023-05-31,"December 4, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Veterans Administration Medical Center - Birmingham, Birmingham, Alabama, United States|USA Health Strada Patient Care Center, Mobile, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Banner Children's at Desert, Mesa, Arizona, United States|Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|PCR Oncology, Arroyo Grande, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Enloe Medical Center, Chico, California, United States|UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Veterans Affairs Loma Linda Healthcare System, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Kaiser Permanente Downtown Commons, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Salinas Valley Memorial, Salinas, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Cancer Center of Colorado at Sloan's Lake, Denver, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Florida Cancer Specialists - Bradenton, Bradenton, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States|Florida Cancer Specialists - Sarasota Downtown, Sarasota, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists - Venice Island, Venice, Florida, United States|Florida Cancer Specialists - Venice Healthpark, Venice, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|University Cancer and Blood Center LLC, Athens, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Northeast Georgia Medical Center Braselton, Braselton, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|IU Health North Hospital, Carmel, Indiana, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Blank Children's Hospital, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center - Covington, Covington, Louisiana, United States|Northshore Oncology Associates-Covington, Covington, Louisiana, United States|Ochsner Hematology Oncology North Shore - Covington (West Region), Covington, Louisiana, United States|Women's Cancer Care-Covington, Covington, Louisiana, United States|Mary Bird Perkins Cancer Center - Houma, Houma, Louisiana, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|LSU Healthcare Network / Metairie Multi-Specialty Clinic, Metairie, Louisiana, United States|Ochsner LSU Health Monroe Medical Center, Monroe, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|LSU Health Sciences Center at Shreveport, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States|Southern Maine Health Center/Biddeford Medical Center, Biddeford, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Maine Medical Partners - South Portland, South Portland, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|FMH James M Stockman Cancer Institute, Frederick, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|McLaren Cancer Institute-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Michigan State University Clinical Center, East Lansing, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Mid-Michigan Physicians-Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mid-Michigan Medical Center - Midland, Midland, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|McLaren-Port Huron, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Henry Ford Macomb Health Center - Shelby Township, Shelby, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Baptist Cancer Center-Grenada, Grenada, Mississippi, United States|Gulfport Memorial Hospital, Gulfport, Mississippi, United States|Mississippi Baptist Medical Center, Jackson, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi, United States|Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Cancer Care Specialists - Reno, Reno, Nevada, United States|Wentworth-Douglass Hospital, Dover, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus, Elizabeth, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Inspira Medical Center Mullica Hill, Mullica Hill, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Newton Medical Center, Newton, New Jersey, United States|Kennedy Health Systems-Cancer Center, Sewell, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|James J Peters VA Medical Center, Bronx, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Vidant Oncology-Kenansville, Kenansville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Vidant Oncology-Richlands, Richlands, North Carolina, United States|Nash General Hospital, Rocky Mount, North Carolina, United States|Marion L Shepard Cancer Center at Vidant Beaufort Hospital, Washington, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|University Pointe, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Saint Vincent Hospital, Erie, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Jefferson Hospital, Jefferson Hills, Pennsylvania, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Holy Redeemer Hospital and Medical Center, Meadowbrook, Pennsylvania, United States|Riddle Memorial Hospital, Media, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Abington Memorial Hospital-Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Baptist Hospital, Columbia, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center - West, Knoxville, Tennessee, United States|Thompson Oncology Group-Lenoir City, Lenoir City, Tennessee, United States|Thompson Oncology Group-Maryville, Maryville, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Baptist Memorial Hospital for Women, Memphis, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Thompson Oncology Group-Oak Ridge, Oak Ridge, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Baptist Hospitals of Southeast Texas Cancer Center, Beaumont, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Michael E DeBakey VA Medical Center, Houston, Texas, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Baptist Regional Cancer Network-Cancer Center of Southeast Texas, Port Arthur, Texas, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Audie L Murphy VA Hospital, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Farmington Health Center, Farmington, Utah, United States|University of Utah Sugarhouse Health Center, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Augusta Health Center for Cancer and Blood Disorders, Fishersville, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Cancer Institute at Reynolds Crossing, Richmond, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|VCU Massey Cancer Center at Stony Point, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Shenandoah Oncology PC, Winchester, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Overlake Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|Princeton Community Hospital, Princeton, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States|Ascension Saint Elizabeth Hospital, Appleton, Wisconsin, United States|Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Brookfield, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Ascension Calumet Hospital, Chilton, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Ascension Saint Francis - Reiman Cancer Center, Franklin, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|William S Middleton VA Medical Center, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Aspirus Medford Hospital, Medford, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital Ozaukee, Mequon, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital - Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Ascension Medical Group Southeast Wisconsin - Mayfair Road, Wauwatosa, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|CSSS Champlain-Charles Le Moyne, Greenfield Park, Quebec, Canada|Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04387656,Canada,,5.0,2023,Wednesday
1613,1614,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,58.0,"May 4, 2020",2020-08-17,"September 16, 2020","Hospital Clínico Universidad Católica, Santiago, Chile",https://ClinicalTrials.gov/show/NCT04375098,Chile,,8.0,2020,Monday
1614,1615,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,Drug: INO-4800|Device: CELLECTRA® 2000|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,6578.0,"November 30, 2020",2022-09-01,"December 8, 2020","Synexus Clinical Research US, Inc - Phoenix Southeast, Chandler, Arizona, United States|Central Phoenix Synexus Clinical Research, Phoenix, Arizona, United States|AMR Tempe, Tempe, Arizona, United States|Optimal Research, LLC, San Diego, California, United States|AMR South Florida, Coral Gables, Florida, United States|Clinical Research Trials of Florida, Inc, Tampa, Florida, United States|AMR Lexington, Lexington, Kentucky, United States|Walter Reed Army Institute of Research, Silver Spring, Maryland, United States|Ascension St. John Hospital, Detroit, Michigan, United States|AMR Kansas City, Kansas City, Missouri, United States|AMR, Clinical Research Consortium- Las Vegas, Las Vegas, Nevada, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tekton Research, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States",https://ClinicalTrials.gov/show/NCT04642638,Jordan,INO-4800|Placebo,9.0,2022,Thursday
1615,1616,Communication in ICU During COVID-19,Not yet recruiting,Behavioral: Communication,All,"18 Years to 100 Years   (Adult, Older Adult)",,200.0,"January 15, 2021",2021-02-15,"December 10, 2020","NMC Specialty Hospital, Dubai, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04602351,United Arab Emirates,,2.0,2021,Monday
1616,1617,Hydrogen Therapy in Patients With Moderate Covid-19,Not yet recruiting,"Drug: Mixture 3,6% H2 in N2 (96.4%)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,"December 1, 2020",2021-09-30,"November 18, 2020",,https://ClinicalTrials.gov/show/NCT04633980,Undefined,"Mixture 3,6% H2 in N2 (96.4%)",9.0,2021,Thursday
1617,1618,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Recruiting,Drug: Rivaroxaban 10 MG,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,320.0,"October 16, 2020",2021-06-30,"December 10, 2020","Science Valley Research Institute, Santo André, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04662684,Brazil,Rivaroxaban 10 MG,6.0,2021,Wednesday
1618,1619,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,"Active, not recruiting",Drug: Clarithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"May 6, 2020",2022-05-06,"October 14, 2020","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",https://ClinicalTrials.gov/show/NCT04398004,Greece,Clarithromycin,5.0,2022,Friday
1619,1620,Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France,Recruiting,,All,"Child, Adult, Older Adult",,9000.0,"May 6, 2020",2020-06-05,"June 9, 2020","CHU de Nîmes, Hôpital Universitaire Carémeau, Nimes, France",https://ClinicalTrials.gov/show/NCT04420286,France,,6.0,2020,Friday
1620,1621,Prevalence of COVID-19 Antibodies Kingman AZ,Enrolling by invitation,Diagnostic Test: VITROS Anti-SARS-CoV-2 IgG test,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"September 28, 2020",2020-12-28,"October 19, 2020","Kingman Regional Medical Center, Kingman, Arizona, United States",https://ClinicalTrials.gov/show/NCT04533360,United States,,12.0,2020,Monday
1621,1622,Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),Completed,Diagnostic Test: Quantitative analysis of anti-SARS-CoV-2-antibodies|Diagnostic Test: SARS-CoV-2 diagnostic rapid test,All,"8 Years and older   (Child, Adult, Older Adult)",,695.0,"May 18, 2020",2020-06-03,"July 1, 2020","Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia",https://ClinicalTrials.gov/show/NCT04453280,Czech Republic,,6.0,2020,Wednesday
1622,1623,COVID-19 and Venous Thromboembolism Risk,Enrolling by invitation,Other: Laboratory test positive for SARS-CoV-2 virus,All,"18 Years and older   (Adult, Older Adult)",,40000.0,"January 1, 2020",2022-06-21,"October 19, 2020","Kaiser Permanente Northern California, Oakland, California, United States|Kaiser Permanente Southern California, Pasadena, California, United States",https://ClinicalTrials.gov/show/NCT04569344,United States,,6.0,2022,Tuesday
1623,1624,Risk Factors Worsening COVID19 for Out-patient With Home Monitoring,Not yet recruiting,Other: Risk factors,All,"Child, Adult, Older Adult",,800.0,"June 30, 2020",2020-12-30,"June 22, 2020","Grenoble University Hospital, Grenoble, France",https://ClinicalTrials.gov/show/NCT04380662,France,,12.0,2020,Wednesday
1624,1625,Description of the Population With Genitourinary Tumors and COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,250.0,"November 24, 2020",2021-10-01,"December 2, 2020","Institut Català d'Oncologia L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Althaia, Manresa, Barcelona, Spain|Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Instituto Catalán de Oncología- Girona, Girona, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital Infanta Leonor,, Madrid, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Quironsalud, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Complejo Hospitalario Universitario Ourense, Orense, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Nuestra Señora del Prado, Talavera De La Reina, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Miguel Servet, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT04578132,China,,10.0,2021,Friday
1625,1626,Recovery of Patients From COVID-19 After Critical Illness,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"July 1, 2020",2022-04-01,"October 23, 2020","Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Ipswich Hospital, Ipswich, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Gold Coast Hospital, Southport, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital (Eastern Health), Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Australian New Zealand Intensive Care Research Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Alfred Hospital, Prahran, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04401254,Australia,,4.0,2022,Friday
1626,1627,Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 9, 2020",2020-05-17,"April 30, 2020","Service des Maladies Infectieuses et Tropicales, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04362345,France,,5.0,2020,Sunday
1627,1628,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,Recruiting,Dietary Supplement: Zinc Picolinate|Dietary Supplement: Resveratrol|Dietary Supplement: Zinc Picolinate Placebo|Dietary Supplement: Resveratrol Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"September 8, 2020",2022-06-01,"October 19, 2020","Swedish Medical Center, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04542993,United States,,6.0,2022,Wednesday
1628,1629,Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil),Recruiting,Other: Hospital admission|Other: Non-hospitalization procedures,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"July 27, 2020",2021-02-01,"September 3, 2020","Hospital Estadual Jayme dos Santos Neves, Serra, Espirito Santo, Brazil|Hospital Santa Rita de Cássia, Vitória, Espirito Santo, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Santa Casa de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Municipal Dr Moyses Deutsch M'Boi Mirim, São Paulo, Brazil|Hospital Municipal Vila Santa Catarina, São Paulo, Brazil|Hospital São Camilo - Ipiranga, São Paulo, Brazil|Hospital São Camilo - Pompéia, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04479488,Brazil,,2.0,2021,Monday
1629,1630,Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"March 1, 2020",2020-08-31,"July 23, 2020","Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04479150,Spain,,8.0,2020,Monday
1630,1631,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Recruiting,Device: Transcutaneous Auricular Vagus Nerve Stimulation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"June 27, 2020",2020-11-01,"July 7, 2020","Hospital Zonal Virgen del Carmen de Zárate, Zárate, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04379037,Argentina,,11.0,2020,Sunday
1631,1632,Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,Recruiting,Other: ECG-Holter,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 30, 2020",2021-04-01,"October 8, 2020","CHU Hopital nord, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04374045,France,,4.0,2021,Thursday
1632,1633,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Recruiting,"Drug: Patch, Nicotine|Drug: Patch, Placebo",All,"18 Years and older   (Adult, Older Adult)",Phase 3,220.0,November 2020,2021-11-01,"November 24, 2020","Hôpital Bicêtre - Service de Médecine Intensive Réanimation, Le Kremlin-Bicêtre, France|Groupement Hospitalier de la Région de Mulhouse Sud Alsace - Hop Emile MULLER, Mulhouse, France|Hôpital Pitié Salpêtrière - ICU, Paris, France|Hôpital Pitié Salpêtrière - ICU, Paris, France|Hôpital Pitié Salpêtrière - Intensive care unit, Paris, France",https://ClinicalTrials.gov/show/NCT04598594,France,"Patch, Nicotine|Patch, Placebo",11.0,2021,Monday
1633,1634,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,Completed,Other: Clinical assessment,Female,18 Years to 42 Years   (Adult),,108.0,"March 10, 2020",2020-08-10,"August 17, 2020","Ankara City Hospital, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04515108,Turkey,,8.0,2020,Monday
1634,1635,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Completed,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,392.0,"June 8, 2020",2020-09-05,"November 3, 2020","Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04552483,Brazil,Nitazoxanide|Placebo,9.0,2020,Saturday
1635,1636,Burden of COVID-19 Infection in Populations With High or Low Risk of Infection,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,3500.0,"December 15, 2020",2022-06-15,"November 23, 2020",,https://ClinicalTrials.gov/show/NCT04636203,Undefined,,6.0,2022,Wednesday
1636,1637,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|Biological: Standard of care (SOC) plus placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,"September 21, 2020",2022-07-31,"September 25, 2020","Universitas Hospital, Bloemfontein, Free State, South Africa|Mitchells Plain Hospital, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04516811,South Africa,,7.0,2022,Sunday
1637,1638,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,Recruiting,Drug: Dipyridamole,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"May 3, 2020",2021-05-30,"June 11, 2020","UConn Health, Farmington, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04424901,United States,Dipyridamole,5.0,2021,Sunday
1638,1639,Cardiovascular Consequences After COVID-19,Recruiting,Other: Infectious Disease and Cardiology Clinical Consultations,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 23, 2020",2021-11-30,"June 30, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04452630,France,,11.0,2021,Tuesday
1639,1640,Safety and Immunity of Covid-19 aAPC Vaccine,Recruiting,Biological: Pathogen-specific aAPC,All,"6 Months to 80 Years   (Child, Adult, Older Adult)",Phase 1,100.0,"February 15, 2020",2024-12-31,"March 9, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",https://ClinicalTrials.gov/show/NCT04299724,China,,12.0,2024,Tuesday
1640,1641,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,Drug: Dexamethasone 2 MG/ML|Drug: Methylprednisolone Injection,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100.0,"May 30, 2020",2020-07-01,"October 27, 2020","Fatima Memorial Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04603729,Pakistan,Dexamethasone 2 MG/ML|Methylprednisolone Injection,7.0,2020,Wednesday
1641,1642,Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia,"Active, not recruiting",Other: Blood samples,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 14, 2020",2020-11-30,"August 11, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, Ile De France, France",https://ClinicalTrials.gov/show/NCT04505605,France,,11.0,2020,Monday
1642,1643,Compensatory Reserve Index (CRI) for Management of COVID-19,Not yet recruiting,Device: CRI management,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100.0,December 2020,2021-09-01,"October 22, 2020",,https://ClinicalTrials.gov/show/NCT04457817,Undefined,,9.0,2021,Wednesday
1643,1644,Halodine Nasal Antiseptic in Patients With COVID-19,Not yet recruiting,Drug: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"October 15, 2020",2021-02-15,"September 4, 2020",,https://ClinicalTrials.gov/show/NCT04517188,Undefined,Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP,2.0,2021,Monday
1644,1645,Covid-19 Messaging to Underserved Communities - 2nd Experiment,"Active, not recruiting",Behavioral: Acknowledgement Racial Injustice AMA|Behavioral: African American Sender Acknowledgement|Behavioral: African American Sender in Informational Videos.|Behavioral: Racial Inequality Highlighted|Behavioral: AMA Acknowledgement Drug Pricing|Behavioral: White Sender in Acknowledgement|Behavioral: White Sender in Informational Videos|Behavioral: No Racial Inequality Highlighting|Behavioral: Placebo videos,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20000.0,"July 31, 2020",2021-09-01,"November 17, 2020","JPAL North America, Cambridge, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04502056,United States,,9.0,2021,Wednesday
1645,1646,Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study,Recruiting,"Other: Clinical, functional and radiological lung involvement evolution",All,"18 Years and older   (Adult, Older Adult)",,100.0,"July 30, 2020",2021-07-30,"October 28, 2020","Respiratory and Critical Care Unit - S.Orsola-Malpighi University Hospital, Bologna, Italy",https://ClinicalTrials.gov/show/NCT04605757,Italy,,7.0,2021,Friday
1646,1647,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,Other: Sampling of tissue,All,"Child, Adult, Older Adult",Not Applicable,90.0,"May 7, 2020",2022-12-31,"December 1, 2020","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",https://ClinicalTrials.gov/show/NCT04445597,Belgium,,12.0,2022,Saturday
1647,1648,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,Diagnostic Test: Direct Antigen Tests for COVID-19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 24, 2020",2020-09-24,"October 19, 2020","JFK Medical Center, Miami, Florida, United States|Kendall Regional, Miami, Florida, United States|Aventura Hospital and Medical Center, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04568356,United States,,9.0,2020,Thursday
1648,1649,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Drug: T3 solution for injection|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 29, 2020",2021-05-31,"June 2, 2020","Attikon University General Hospital, Haidari/Athens, Greece",https://ClinicalTrials.gov/show/NCT04348513,Greece,T3 solution for injection|Placebo,5.0,2021,Monday
1649,1650,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,Not yet recruiting,Drug: Interferon alfa|Drug: Selinexor|Drug: Lenzilumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2282.0,November 2020,2021-11-01,"October 30, 2020",,https://ClinicalTrials.gov/show/NCT04534725,Undefined,Interferon alfa|Selinexor|Lenzilumab,11.0,2021,Monday
1650,1651,Detection of COVID-19 Using Breath Analysis - Validation Study,Not yet recruiting,Diagnostic Test: Breath Biopsy Analysis,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,4000.0,"November 12, 2020",2021-02-28,"October 26, 2020","Shamir Medical Center, Be'er Ya'aqov, Israel",https://ClinicalTrials.gov/show/NCT04602949,Israel,,2.0,2021,Sunday
1651,1652,Test and Treat COVID 65plus+,"Active, not recruiting",Drug: Hydroxychloroquine|Other: Placebo,All,65 Years and older   (Older Adult),Phase 2|Phase 3,350.0,"April 21, 2020",2021-05-01,"November 5, 2020","Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany",https://ClinicalTrials.gov/show/NCT04351516,Germany,Hydroxychloroquine,5.0,2021,Saturday
1652,1653,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,Recruiting,Drug: dapansutrile capsules|Drug: placebo capsules,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"September 25, 2020",2021-02-01,"December 3, 2020","National Jewish Health, Denver, Colorado, United States|Atrium Health/Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States|PanAmerican Clinical Research LLC, Brownsville, Texas, United States|J & S Studies, Inc., College Station, Texas, United States|University Hospital Basel, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT04540120,Switzerland,dapansutrile capsules|placebo capsules,2.0,2021,Monday
1653,1654,Cytokine Status of Covid-19 Patients,Not yet recruiting,Diagnostic Test: Flow cytometric analysis,All,"18 Years to 80 Years   (Adult, Older Adult)",,50.0,"September 1, 2020",2020-10-15,"August 28, 2020","Istanbul Training and Reseach Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04531345,Turkey,,10.0,2020,Thursday
1654,1655,NeuroCovid - a Study of Intensive Care-requiring Covid-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"August 18, 2020",2022-11-01,"October 8, 2020","Karolinska Universitetssjukhuset Solna, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04578197,Sweden,,11.0,2022,Tuesday
1655,1656,COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"October 15, 2020",2024-04-30,"November 4, 2020","Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04559009,United States,,4.0,2024,Tuesday
1656,1657,Early Detection of COVID-19 Using Breath Analysis,Suspended,Diagnostic Test: Breath biopsy sampling using the ReCIVA Breath Sampler,All,18 Years to 55 Years   (Adult),Not Applicable,50.0,"September 22, 2020",2020-12-30,"October 26, 2020","IDF COVID 19 Isolation Facility, Ashkelon, Israel",https://ClinicalTrials.gov/show/NCT04602884,Israel,,12.0,2020,Wednesday
1657,1658,COVID-19 Mortality Prediction Model,Completed,Device: COViage,All,"18 Years and older   (Adult, Older Adult)",,114.0,"April 1, 2020",2020-04-17,"April 24, 2020","Dascena, Oakland, California, United States",https://ClinicalTrials.gov/show/NCT04358510,United States,,4.0,2020,Friday
1658,1659,The Açaí Berry COVID-19 Anti-Inflammation Trial,Recruiting,Dietary Supplement: Açaí palm berry extract - natural product|Other: Placebo,All,"40 Years and older   (Adult, Older Adult)",Phase 2,480.0,"August 4, 2020",2021-05-01,"August 7, 2020","Heart Health Institute Research Inc, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04404218,Canada,,5.0,2021,Saturday
1659,1660,Tannin Specific Natural Extract for COVID-19 Infection,Not yet recruiting,Dietary Supplement: ARBOX|Other: PLACEBO,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140.0,"June 1, 2020",2020-10-31,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04403646,Undefined,,10.0,2020,Saturday
1660,1661,COVID-19 Related Health and Infection Control Practices Among Dentists,"Active, not recruiting",Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 8, 2020",2021-06-08,"August 27, 2020","American Dental Association, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04423770,United States,,6.0,2021,Tuesday
1661,1662,"the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19",Not yet recruiting,Drug: High dose Interferon-beta 1a|Drug: Lopinavir/Ritonavir|Drug: Low dose Interferon-beta 1a,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,100.0,"August 20, 2020",2020-09-11,"August 20, 2020",,https://ClinicalTrials.gov/show/NCT04521400,Undefined,High dose Interferon-beta 1a|Lopinavir/Ritonavir|Low dose Interferon-beta 1a,9.0,2020,Friday
1662,1663,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Completed,Drug: HCQ,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,540.0,"April 10, 2020",2020-05-31,"August 21, 2020","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04491994,Pakistan,HCQ,5.0,2020,Sunday
1663,1664,Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children,Recruiting,Biological: Convalescent plasma (CP),All,"up to 18 Years   (Child, Adult)",Phase 2,100.0,"October 7, 2020",2022-05-01,"November 19, 2020","Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|McGill Univ Health Ctr - Montreal Children's Hospital, Montréal, Quebec, Canada|Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada",https://ClinicalTrials.gov/show/NCT04377568,Canada,,5.0,2022,Sunday
1664,1665,COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey,Not yet recruiting,Diagnostic Test: blood test for SARS-COV2 serology,All,"18 Years and older   (Adult, Older Adult)",,220.0,July 2020,2020-11-01,"July 21, 2020","Haltes pour femmes, Paris, France|LHSS Saint-Michel, Paris, France|LHSS Ridder-Plaisance, Paris, France",https://ClinicalTrials.gov/show/NCT04470648,France,,11.0,2020,Sunday
1665,1666,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma),All,"18 Years and older   (Adult, Older Adult)",Phase 2,219.0,"April 21, 2020",2021-04-01,"November 13, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States|Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil|Hospital Geral de Nova Iguaçu, Rio De Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04359810,Brazil,,4.0,2021,Thursday
1666,1667,Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"June 18, 2020",2020-08-18,"July 31, 2020","Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04446286,France,,8.0,2020,Tuesday
1667,1668,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Recruiting,Biological: blood samples,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"May 19, 2020",2021-01-19,"May 21, 2020","CH de Pau, Pau, France",https://ClinicalTrials.gov/show/NCT04361344,France,,1.0,2021,Tuesday
1668,1669,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Other: convalescent plasma from recovered COVID 19 donor,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,575.0,"April 18, 2020",2021-04-11,"August 11, 2020","John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Dammam Medical Complex, Dammam, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Madinah General Hospital, Medina, Saudi Arabia|Ohud Hospital, Medina, Saudi Arabia|Taibah University, Medina, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04347681,Saudi Arabia,,4.0,2021,Sunday
1669,1670,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,Procedure: AN69-Oxiris|Procedure: AN69-Standard,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,35.0,"October 2, 2020",2022-03-30,"October 22, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04597034,Mexico,,3.0,2022,Wednesday
1670,1671,Association of Comorbidities With COVID19,Recruiting,Diagnostic Test: realtime PCR,All,"Child, Adult, Older Adult",,100.0,"July 20, 2020",2020-11-20,"August 6, 2020","Faculty of Medicine, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04459390,Egypt,,11.0,2020,Friday
1671,1672,Home-Based Covid-19 Rehabilitation Program,Not yet recruiting,Behavioral: PT-Pal|Behavioral: Self-guided exercises,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"January 20, 2021",2022-03-01,"November 13, 2020",,https://ClinicalTrials.gov/show/NCT04406532,Undefined,,3.0,2022,Tuesday
1672,1673,Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial),Not yet recruiting,Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,2486.0,"April 1, 2020",2022-03-30,"April 1, 2020",,https://ClinicalTrials.gov/show/NCT04330144,Undefined,Hydroxychloroquine as post exposure prophylaxis,3.0,2022,Wednesday
1673,1674,NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure,Recruiting,Other: Monitoring for aggravation|Other: Evaluate HACOR score effectivity in this patients,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 1, 2020",2020-09-15,"July 29, 2020","Hospital General Universitario Morales Meseguer, Murcia, Spain",https://ClinicalTrials.gov/show/NCT04342104,Spain,,9.0,2020,Tuesday
1674,1675,Vienna Versus SARS-CoV-2 Virus Study,Recruiting,Diagnostic Test: Laboratory Analyses,All,"Child, Adult, Older Adult",,12000.0,"May 27, 2020",2021-06-27,"May 29, 2020","Medical University of Vienna, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04407429,Austria,,6.0,2021,Sunday
1675,1676,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,Drug: Eculizumab,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120.0,"April 16, 2020",2020-12-31,"April 27, 2020","Saint Louis, Paris, Ile De France, France|Réanimation médicale, Paris, France|saint Louis, Paris, France",https://ClinicalTrials.gov/show/NCT04346797,France,Eculizumab,12.0,2020,Thursday
1676,1677,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Recruiting,Diagnostic Test: Breath Biopsy,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,108.0,"July 3, 2020",2021-01-30,"October 26, 2020","Soroka Medical Center, Be'er Sheva, Israel|Meir Medical Center, Kfar Saba, Israel",https://ClinicalTrials.gov/show/NCT04602871,Israel,,1.0,2021,Saturday
1677,1678,Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients,Not yet recruiting,Diagnostic Test: conjunctival swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1280.0,December 2020,2021-12-01,"December 4, 2020",,https://ClinicalTrials.gov/show/NCT04654325,Undefined,,12.0,2021,Wednesday
1678,1679,"Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.",Not yet recruiting,Drug: Nivolumab Injection,All,"18 Years and older   (Adult, Older Adult)",Phase 2,92.0,"April 15, 2020",2020-09-30,"April 14, 2020","Pneumologie hôpital Tenon, Paris, France",https://ClinicalTrials.gov/show/NCT04343144,France,Nivolumab Injection,9.0,2020,Wednesday
1679,1680,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Not yet recruiting,Drug: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|Drug: Placebo of NICOTINE Transdermal patch,All,"18 Years and older   (Adult, Older Adult)",Phase 3,220.0,November 2020,2022-06-01,"November 6, 2020","Hospital Pitié-Salpêtrière - AP-HP, Paris, France",https://ClinicalTrials.gov/show/NCT04608201,France,Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|Placebo of NICOTINE Transdermal patch,6.0,2022,Wednesday
1680,1681,Nebulised Dornase Alfa for Treatment of COVID-19,Recruiting,Drug: Dornase Alfa Inhalation Solution [Pulmozyme],All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,50.0,"June 16, 2020",2021-11-01,"October 19, 2020","University College London Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04359654,United Kingdom,Dornase Alfa Inhalation Solution [Pulmozyme],11.0,2021,Monday
1681,1682,AiM Covid Self Monitoring,Completed,Other: Other,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 12, 2020",2020-05-28,"June 11, 2020","Mothers Touch Foundation, Mumbai, Maharashtra, India|NMP Medical Research Institite, Jaipur, Rajasthan, India",https://ClinicalTrials.gov/show/NCT04425044,India,,5.0,2020,Thursday
1682,1683,COVID-19 and Lung Ultrasound Utility,Recruiting,Device: Butterfly iQ,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,100.0,"September 15, 2020",2021-09-01,"October 19, 2020","Markham Stouffville Hospital, Markham, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04591158,Canada,,9.0,2021,Wednesday
1683,1684,Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,Withdrawn,Other: washed microbiota transplantation|Other: placebo,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,0.0,"February 5, 2020",2020-04-30,"March 17, 2020","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04251767,China,,4.0,2020,Thursday
1684,1685,Ivermectin in Adults With Severe COVID-19.,Recruiting,Drug: Ivermectin|Other: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,100.0,"December 7, 2020",2021-03-01,"December 10, 2020","Clinica CES, Medellín, Antioquia, Colombia",https://ClinicalTrials.gov/show/NCT04602507,Colombia,Ivermectin,3.0,2021,Monday
1685,1686,Face Masks to Reduce COVID-19 in Bangladesh,Recruiting,Device: Face mask|Behavioral: Face mask awareness,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450000.0,"November 15, 2020",2021-02-28,"November 16, 2020","Innovations for Poverty Action, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04630054,Bangladesh,,2.0,2021,Sunday
1686,1687,RT-PCR Database Analysis for COVID-19 Infections and Re-infection,"Active, not recruiting",,All,"Child, Adult, Older Adult",,7000000.0,"February 1, 2020",2021-03-30,"December 7, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04653844,France,,3.0,2021,Tuesday
1687,1688,Does COVID-19 Pandemic Reduce In-hospital Mortality?,Completed,Other: in-hospital mortality rate,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"March 11, 2020",2020-06-30,"July 21, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04480515,Turkey,,6.0,2020,Tuesday
1688,1689,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,Recruiting,Biological: CK0802|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,"September 29, 2020",2021-09-30,"November 16, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Baylor College of Medicine, St Luke's Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04468971,United States,Placebo,9.0,2021,Thursday
1689,1690,Borderline COVID-19 PCR Test Result,"Active, not recruiting",Diagnostic Test: SARS-CoV-2 PCR,All,"Child, Adult, Older Adult",,30000.0,"August 1, 2020",2020-12-30,"November 19, 2020","Clinical Laboratory Jessa Hospital, Hasselt, Limburg, Belgium",https://ClinicalTrials.gov/show/NCT04636294,Belgium,,12.0,2020,Wednesday
1690,1691,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",Device: Oxygen Therapy|Procedure: Physical Therapy,All,21 Years to 40 Years   (Adult),Not Applicable,60.0,"March 15, 2020",2020-06-23,"June 23, 2020","M. Sedky, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04368923,Egypt,,6.0,2020,Tuesday
1691,1692,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,15.0,"April 20, 2020",2020-11-06,"November 17, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04347928,France,,11.0,2020,Friday
1692,1693,Predicting Outcomes for Covid-19 Using Sonography,Enrolling by invitation,Diagnostic Test: Lung Ultrasound,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 21, 2020",2020-12-31,"September 2, 2020","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04384055,United States,,12.0,2020,Thursday
1693,1694,Predict Adverse Events by Covid-19 Nephritis,Recruiting,,All,"Child, Adult, Older Adult",,100.0,"April 27, 2020",2021-12-31,"June 4, 2020","University Medical Center Goettingen, Göttingen, Germany",https://ClinicalTrials.gov/show/NCT04347824,Germany,,12.0,2021,Friday
1694,1695,Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection,Not yet recruiting,Drug: Ruxolitinib Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",,13.0,"April 25, 2020",2020-05-31,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04361903,Undefined,Ruxolitinib Oral Tablet,5.0,2020,Sunday
1695,1696,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,Recruiting,Drug: SNG001|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,820.0,"March 16, 2020",2021-05-31,"August 27, 2020","Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital,, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom|Glenfield Hospital,, Leicester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|City Campus of Nottingham University, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT04385095,United Kingdom,SNG001|Placebo,5.0,2021,Monday
1696,1697,Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population,"Active, not recruiting",Diagnostic Test: Plasma IgG levels,All,"Child, Adult, Older Adult",,50.0,"July 1, 2020",2020-11-30,"October 5, 2020","Lahore General Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04568850,Pakistan,,11.0,2020,Monday
1697,1698,Semen Analysis Changes in Covid-19 Positivepatients,Completed,Diagnostic Test: semen analysis,Male,20 Years to 45 Years   (Adult),,100.0,"May 1, 2020",2020-10-15,"October 20, 2020","Mostafa Kamel, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04595240,Egypt,,10.0,2020,Thursday
1698,1699,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Drug: Remdesivir|Drug: Remdesivir placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,237.0,"February 6, 2020",2020-04-10,"April 15, 2020","Bin Cao, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04257656,China,Remdesivir|Remdesivir placebo,4.0,2020,Friday
1699,1700,AiM COVID for Covid 19 Tracking and Prediction,Completed,Other: No Intervention,All,"18 Years and older   (Adult, Older Adult)",,80.0,"March 28, 2020",2020-04-17,"April 21, 2020","Aarogyam (UK), Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04354753,United Kingdom,,4.0,2020,Friday
1700,1701,Immune Cell Subgroups in Covid 19 Patients,Recruiting,Diagnostic Test: Flow cytometric analysis,All,"18 Years to 80 Years   (Adult, Older Adult)",,60.0,"August 15, 2020",2020-09-15,"August 28, 2020","Istanbul Training and Reseach Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04531319,Turkey,,9.0,2020,Tuesday
1701,1702,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,Recruiting,Drug: Cyclosporine|Drug: Standard treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120.0,"April 16, 2020",2020-12-01,"August 28, 2020","Complejo Hospitalario Universitario La Coruña, La Coruña, Galicia, Spain|Hospital Quiron La Coruña, La Coruña, Galicia, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital General de Villalba, Villalba, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04392531,Spain,Cyclosporine|Standard treatment,12.0,2020,Tuesday
1702,1703,Pulmonary Embolism and COVID-19,Recruiting,Other: intensive care unit admission ratio,All,"18 Years to 80 Years   (Adult, Older Adult)",,600.0,"March 1, 2020",2020-12-01,"October 19, 2020","Uşak University, Usak, Turkey",https://ClinicalTrials.gov/show/NCT04590378,Turkey,,12.0,2020,Tuesday
1703,1704,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,Diagnostic Test: Blood group determination|Diagnostic Test: Antibody titration|Dietary Supplement: Probiotic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"April 14, 2020",2020-12-01,"July 8, 2020","CHU Brugmann, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04462627,Belgium,,12.0,2020,Tuesday
1704,1705,COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 30, 2020",2020-06-01,"June 2, 2020","Service Médecine Intensive et Réanimation, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04412473,France,,6.0,2020,Monday
1705,1706,Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,Recruiting,,All,"7 Years and older   (Child, Adult, Older Adult)",,250.0,"March 26, 2020",2021-03-01,"June 25, 2020","Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04448145,United States,,3.0,2021,Monday
1706,1707,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,Not yet recruiting,Diagnostic Test: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,September 2020,2021-03-01,"August 12, 2020",,https://ClinicalTrials.gov/show/NCT04510454,Undefined,,3.0,2021,Monday
1707,1708,Aggrenox To Treat Acute Covid-19,Recruiting,Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Other: Standard of care,All,"19 Years and older   (Adult, Older Adult)",Phase 3,132.0,"October 21, 2020",2021-12-15,"October 23, 2020","Rutgers New Jersey Medical School University Hospital, Newark, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04410328,Jersey,Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care,12.0,2021,Wednesday
1708,1709,Effect of Covid-19 on Outcomes of Pregnancy,"Active, not recruiting","Diagnostic Test: Covid-19 PCR , IGM",Female,18 Years to 40 Years   (Adult),,1000.0,"September 1, 2020",2021-12-01,"November 16, 2020","Medicine, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04629001,Egypt,,12.0,2021,Wednesday
1709,1710,Ivermectin In Treatment of COVID 19 Patients,Recruiting,Drug: Ivermectin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 9, 2020",2020-09-01,"June 11, 2020","isolation and referal hospitals for COVID 19 patients, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04425707,Egypt,Ivermectin,9.0,2020,Tuesday
1710,1711,Treatment of Covid-19 Using Infrared and/or Vitamin C,Not yet recruiting,Other: Infrared Energy and Dietary Supplement,All,"Child, Adult, Older Adult",Not Applicable,400.0,"October 30, 2020",2021-07-10,"October 26, 2020","GAAD Medical Research Institute Inc. O/A The Centre for Incurable Diseases, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04584437,Canada,,7.0,2021,Saturday
1711,1712,COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic,Not yet recruiting,,All,18 Years to 60 Years   (Adult),,28.0,"July 23, 2020",2020-12-01,"July 28, 2020",,https://ClinicalTrials.gov/show/NCT04487873,Undefined,,12.0,2020,Tuesday
1712,1713,Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"March 15, 2020",2021-12-01,"April 29, 2020","Godstrup Hospital, Herning, Denmark",https://ClinicalTrials.gov/show/NCT04367714,Denmark,,12.0,2021,Wednesday
1713,1714,Echocardiography in Critically-ill Patients With COVID-19 Pneumonia,Enrolling by invitation,,All,"Child, Adult, Older Adult",,1500.0,"May 12, 2020",2020-09-30,"June 4, 2020","University Hospital Ambroise Pare, Boulogne-Billancourt, Hauts De Seine, France",https://ClinicalTrials.gov/show/NCT04414410,France,,9.0,2020,Wednesday
1714,1715,Growth Hormone in Obese Cases With Covid-19,Withdrawn,Drug: Growth Hormone|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"October 26, 2020",2020-12-20,"September 16, 2020","Asalam, Maadi, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04532554,Egypt,Growth Hormone|Placebo,12.0,2020,Sunday
1715,1716,ACTIV-2: A Study for Outpatients With COVID-19,Recruiting,Drug: LY3819253|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,2000.0,"August 19, 2020",2021-02-01,"December 11, 2020","University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States|Jasper Summit Research, LLC. (Site 1056), 1280 Summit, Jasper, Alabama, United States|Atella Clinical Research (Site 1111), 5451 La Palma Avenue, La Palma, California, United States|University of Southern California (Site 1057), 1300 N Mission Rd., Rm 349, Los Angeles, California, United States|UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100, Los Angeles, California, United States|Central Valley Research, LLC (Site 1085), 400 E Orangeburg Ave., Ste. 5, Modesto, California, United States|Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210, Northridge, California, United States|Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive, Rancho Mirage, California, United States|University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd., Sacramento, California, United States|University of California San Diego (Site 1002), 220 Dickinson Street, San Diego, California, United States|Zion Medical Center (Site 1063), 4647 Zion Avenue, San Diego, California, United States|University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84, San Francisco, California, United States|Harbor UCLA (Site 1022), 1124 West Carson Street, Torrance, California, United States|University of Colorado (Site 1007), 12401 East 17th Avenue, Aurora, Colorado, United States|Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350, Bradenton, Florida, United States|Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave., Doral, Florida, United States|Holy Cross Health (Site 1072), 4725 North Federal Highway, Fort Lauderdale, Florida, United States|NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway, Gulf Breeze, Florida, United States|AGA Clinical Trials (Site 1026), 900 West 49th Street, Hialeah, Florida, United States|University of Florida Jacksonville (Site 1039), 655 West 8th Street, Jacksonville, Florida, United States|QC Trials (Site 1117), 300 W. 41st Street, Ste. 203, Miami Beach, Florida, United States|Lakes Research (Site 1037), 5801 NW 151 Street, Miami Lakes, Florida, United States|Miami Clinical Research (Site 1089), 2400 SW 69th Ave., Miami, Florida, United States|Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place, Vero Beach, Florida, United States|Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4, West Palm Beach, Florida, United States|The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast, Atlanta, Georgia, United States|Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive, Atlanta, Georgia, United States|IACT Health (Site 1035), 800 Talbotton Road, Columbus, Georgia, United States|Snake River Research, PLLC (Site 1120), 2900 Cortez Ave., Idaho Falls, Idaho, United States|Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201, Burr Ridge, Illinois, United States|Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd., Chicago, Illinois, United States|Northwestern University (Site 1025), 645 North Michigan Ave, Chicago, Illinois, United States|Rush University Medical Center (Site 1017), 600 Paulina St., Chicago, Illinois, United States|Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave., Chicago, Illinois, United States|University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard, Kansas City, Kansas, United States|MedPharmics (Site 1065), 3800 Houma Blvd., Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904, New Orleans, Louisiana, United States|Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States|Massachusetts General Hospital (Site 1016), 55 Fruit Street, Boston, Massachusetts, United States|Memorial Hospital at Gulfport (Site 1104), 4500 13th Street, Gulfport, Mississippi, United States|MedPharmics, LLC. (Site 1032), 15190 Community Rd., Gulfport, Mississippi, United States|Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200, Saint Louis, Missouri, United States|Mercury Street Medical Group (Site 1074), 300 W. Mercury St., Butte, Montana, United States|Quality Clinical Research (Site 1112), 10040 Regency Circle, Omaha, Nebraska, United States|Lincoln Hospital (Site 1092), 249 East 149th Street, Bronx, New York, United States|Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South, Bronx, New York, United States|Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd, Flushing, New York, United States|Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway, Jamaica, New York, United States|Columbia Partnership for Prevention and Control of HIV/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604, New York, New York, United States|Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street, New York, New York, United States|Canton-Potsdam Hospital (Site 1076), 50 Leroy Street, Potsdam, New York, United States|University of Rochester (Site 1010), 601 Elmwood Ave, Rochester, New York, United States|SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C, Stony Brook, New York, United States|University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor, Chapel Hill, North Carolina, United States|Duke University Medical Center (Site 1041), 40 Duke Medicine Circle, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Health (Site 1084), 801 Broadway N, Fargo, North Dakota, United States|Case Western Reserve University (Site 1033), 2061 Cornell Road, Cleveland, Ohio, United States|Ohio State University Medical Center (Site 1020), 480 Medical Center Drive, Columbus, Ohio, United States|Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way, Ohio City, Ohio, United States|Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street, Tulsa, Oklahoma, United States|Doylestown Hospital (Site 1122), 595 W State Street, Doylestown, Pennsylvania, United States|University of Pennsylvania (Site 1031), 3400 Spruce Street, Philadelphia, Pennsylvania, United States|The University of Pittsburgh (Site 1018), 3471 5th Ave., Pittsburgh, Pennsylvania, United States|Sanford USD Medical Center (Site 1078), 1305 W. 18th St., Sioux Falls, South Dakota, United States|Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183, Nashville, Tennessee, United States|Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560, Bellaire, Texas, United States|PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd., Brownsville, Texas, United States|Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive, Galveston, Texas, United States|Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street, Houston, Texas, United States|University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112, Houston, Texas, United States|SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave., Mesquite, Texas, United States|Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road, Falls Church, Virginia, United States|EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77, Kirkland, Washington, United States|University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave., Seattle, Washington, United States|Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road, Milwaukee, Wisconsin, United States|Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II, San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04518410,Georgia,LY3819253|Placebo,2.0,2021,Monday
1716,1717,Evaluation of Humoral Immunity Following COVID-19 in Pregnancy,Recruiting,Procedure: Blood sample,All,18 Years to 60 Years   (Adult),,96.0,"September 16, 2020",2023-07-03,"September 29, 2020","Chelsea and Westminster NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04568044,United Kingdom,,7.0,2023,Monday
1717,1718,Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1024.0,"March 1, 2020",2020-04-20,"June 25, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04420312,France,,4.0,2020,Monday
1718,1719,Covid-19 Risk Factors and Pattern Between Healthcare Workers,Not yet recruiting,,All,"18 Years to 70 Years   (Adult, Older Adult)",,165.0,December 2020,2022-01-01,"November 30, 2020",,https://ClinicalTrials.gov/show/NCT04646551,Undefined,,1.0,2022,Saturday
1719,1720,Collection of Anti-SARS-CoV-2 Immune Plasma,"Active, not recruiting",,All,"18 Years to 70 Years   (Adult, Older Adult)",,1500.0,"June 1, 2020",2025-04-01,"December 9, 2020","Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Infectious Diseases Research Unit, Miami, Florida, United States|Bloodworks Northwest, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04344977,United States,,4.0,2025,Tuesday
1720,1721,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,Recruiting,Drug: Bempegaldesleukin|Drug: Standard of Care|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,"November 13, 2020",2021-03-27,"November 27, 2020","Investigator Site, Hialeah, Florida, United States|Investigator site, Mesquite, Texas, United States",https://ClinicalTrials.gov/show/NCT04646044,United States,Bempegaldesleukin|Standard of Care,3.0,2021,Saturday
1721,1722,Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19,Not yet recruiting,Drug: Famotidine|Drug: N-Acetyl cysteine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,September 2020,2021-08-01,"September 10, 2020",,https://ClinicalTrials.gov/show/NCT04545008,Undefined,Famotidine|N-Acetyl cysteine,8.0,2021,Sunday
1722,1723,Sleep Quality in Healthcare Personnel During COVID-19,Completed,Other: Web Based Survey,All,"18 Years to 80 Years   (Adult, Older Adult)",,143.0,"March 30, 2020",2020-05-16,"June 23, 2020","AssiutU, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04395300,Egypt,,5.0,2020,Saturday
1723,1724,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,Drug: Mavrilimumab|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 2, 2020",2021-08-01,"September 10, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT04463004,United States,Mavrilimumab|Placebos,8.0,2021,Sunday
1724,1725,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,Not yet recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7911.0,October 2020,2021-10-01,"September 16, 2020","The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom",https://ClinicalTrials.gov/show/NCT04542031,United Kingdom,,10.0,2021,Friday
1725,1726,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Drug: Iodine Complex|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"July 14, 2020",2020-09-30,"July 16, 2020","Shaikh Zayed Hospital, Lahore, Pakistan",https://ClinicalTrials.gov/show/NCT04473261,Pakistan,Iodine Complex|Placebo,9.0,2020,Wednesday
1726,1727,Characteristics of Critically Ill COVID 19 Patients,Recruiting,Other: COVID19,All,"Child, Adult, Older Adult",,50.0,"July 8, 2020",2020-08-10,"July 9, 2020","Assiut university, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04465058,Egypt,,8.0,2020,Monday
1727,1728,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Recruiting,Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"July 16, 2020",2021-08-01,"August 21, 2020","William Beaumont Hospital, Royal Oak, Michigan, United States",https://ClinicalTrials.gov/show/NCT04432272,United States,,8.0,2021,Sunday
1728,1729,Covid-19 Breath Test,Recruiting,Diagnostic Test: Breath Test & Cheek Swab,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,250.0,"June 29, 2020",2021-06-14,"July 7, 2020","Ashford and St Peter's Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT04459962,United Kingdom,,6.0,2021,Monday
1729,1730,Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt,Completed,Other: Kaplan Meier analysis,All,36 Years to 63 Years   (Adult),,1064.0,"March 15, 2020",2020-07-01,"July 28, 2020","AssiutU, Assiut, Egypt|Aliae Mohamed-Hussein, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04488588,Egypt,,7.0,2020,Wednesday
1730,1731,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Completed,Drug: IVIG,All,"18 Years and older   (Adult, Older Adult)",Phase 3,76.0,"May 7, 2020",2020-09-15,"October 14, 2020","Site 08 - ""Central City Clinical Hospital of Ivano-Frankivsk City Council"", Ivano-Frankivs'k, Ivano-Frankivs'k Region, Ukraine|Site 02 - ""Bila Tserkva City Hospital №3"", Bila Tserkva, Kyiv Region, Ukraine|Site 03 - ""Lviv Regional Infectious Diseases Clinical Hospital"", Lviv, Lviv Region, Ukraine|Site 04 - ""City Clinical Infectious Diseases Hospital"", Odesa, Odesa, Odesa Region, Ukraine|Site 07 - ""Ternopil City Municipal Ambulance Hospital"", Ternopil', Ternopil' Region, Ukraine|Site 06 - ""Vinnytsia City Clinical Hospital №1"", Vinnitsia, Vinnitsia Region, Ukraine|Site 09 - ""Volyn Regional Clinical Hospital"", Luts'k, Volyn Region, Ukraine|Site 01 - ""Kyiv City Clinical Hospital №17"", Kyiv, Ukraine|Site 05 - ""Kyiv City Clinical Hospital №4"", Kyiv, Ukraine",https://ClinicalTrials.gov/show/NCT04500067,Ukraine,IVIG,9.0,2020,Tuesday
1731,1732,Covid-19 Pandemic: Patients' Experience in T1D,Enrolling by invitation,Other: Online survey,All,"1 Year and older   (Child, Adult, Older Adult)",,384.0,"April 29, 2020",2021-01-01,"May 12, 2020","Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04384471,Canada,,1.0,2021,Friday
1732,1733,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,Not yet recruiting,Drug: MRG-001|Drug: Placebo,All,18 Years to 39 Years   (Adult),Phase 1|Phase 2,12.0,"January 5, 2021",2021-06-05,"December 2, 2020",,https://ClinicalTrials.gov/show/NCT04646603,Undefined,MRG-001|Placebo,6.0,2021,Saturday
1733,1734,CoVid-19 - Infection and Antibody Formation in the Viennese Population,Enrolling by invitation,Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing,All,"6 Years to 85 Years   (Child, Adult, Older Adult)",,5500.0,"April 27, 2020",2020-09-30,"April 16, 2020","The LEAD Study Center, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04346264,Austria,,9.0,2020,Wednesday
1734,1735,Comorbidities And Complications Associated With Covid-19 Infection,Not yet recruiting,Other: complication,All,"18 Years to 100 Years   (Adult, Older Adult)",,200.0,"October 15, 2020",2023-02-25,"September 24, 2020",,https://ClinicalTrials.gov/show/NCT04563442,Undefined,,2.0,2023,Saturday
1735,1736,Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19,Recruiting,Diagnostic Test: ID NOW vs. Accula,All,"18 Years to 95 Years   (Adult, Older Adult)",,100.0,"May 10, 2020",2021-05-09,"July 9, 2020","Ascension St. John Hospital, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04403035,United States,,5.0,2021,Sunday
1736,1737,Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19),Completed,Other: [TIMP-2]*[IGFBP-7],All,"18 Years to 100 Years   (Adult, Older Adult)",,100.0,"March 1, 2020",2020-06-30,"July 29, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04393428,France,,6.0,2020,Tuesday
1737,1738,BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST),Not yet recruiting,Drug: BCG Vaccine|Other: Placebo,All,70 Years and older   (Older Adult),Phase 3,2100.0,September 2020,2021-11-30,"September 21, 2020",,https://ClinicalTrials.gov/show/NCT04534803,Undefined,BCG Vaccine,11.0,2021,Tuesday
1738,1739,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Terminated,Drug: Tocilizumab (TCZ)|Drug: Placebo,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,5.0,"April 26, 2020",2020-09-27,"October 14, 2020","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04335071,Switzerland,Tocilizumab (TCZ)|Placebo,9.0,2020,Sunday
1739,1740,Lactoferrin for Prevention of COVID-19 in Health Care Workers,Not yet recruiting,Dietary Supplement: Bovine Lactoferrin|Dietary Supplement: Maltodextrin,All,18 Years to 59 Years   (Adult),Phase 2,336.0,"September 1, 2020",2021-11-01,"September 2, 2020","Hospital Nacional Arzobispo Loayza, Lima, Lim, Peru|Hospital Cayetano Heredia, Lima, Peru",https://ClinicalTrials.gov/show/NCT04526821,Peru,,11.0,2021,Monday
1740,1741,Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,Completed,,All,"18 Years to 70 Years   (Adult, Older Adult)",,287.0,"May 4, 2020",2020-08-21,"September 7, 2020","Sciensano, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04356586,Belgium,,8.0,2020,Friday
1741,1742,Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"May 8, 2020",2022-03-01,"June 16, 2020","Mount Sinai Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04397939,United States,,3.0,2022,Tuesday
1742,1743,"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",Enrolling by invitation,Other: Complex diagnostic panel,All,"18 Years to 120 Years   (Adult, Older Adult)",,200.0,"June 8, 2020",2021-11-30,"September 30, 2020","Silesian Centre for Heart Disease, Zabrze, Silesia, Poland",https://ClinicalTrials.gov/show/NCT04453748,Poland,,11.0,2021,Tuesday
1743,1744,mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda,Not yet recruiting,Behavioral: Kukaa Salama: mHealth intervention|Device: Face Mask + Soap,All,"16 Years to 24 Years   (Child, Adult)",Not Applicable,404.0,"February 1, 2021",2021-09-20,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04631367,Undefined,,9.0,2021,Monday
1744,1745,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,Diagnostic Test: COVID-19 PCR and Serology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"May 13, 2020",2020-07-31,"May 18, 2020","North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States",https://ClinicalTrials.gov/show/NCT04392323,United States,,7.0,2020,Friday
1745,1746,IFN Beta-1b and Ribavirin for Covid-19,Recruiting,Drug: Interferon beta-1b|Drug: Ribavirin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,96.0,"July 29, 2020",2022-08-01,"July 31, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04494399,Hong Kong,Interferon beta-1b|Ribavirin,8.0,2022,Monday
1746,1747,Covid-19 Infection and New Onset Type 1 Diabetes,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,600.0,"November 1, 2020",2023-10-30,"November 10, 2020","Hospital of South West Jutland, Esbjerg, Denmark",https://ClinicalTrials.gov/show/NCT04623697,Denmark,,10.0,2023,Monday
1747,1748,Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19),Recruiting,Device: Ion Mobility Spectrometry (IMS),All,"18 Years and older   (Adult, Older Adult)",,392.0,"September 23, 2020",2021-03-01,"November 19, 2020","Technical University of Munich, Klinikum rechts der Isar, Munich, Germany",https://ClinicalTrials.gov/show/NCT04556318,Germany,,3.0,2021,Monday
1748,1749,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,Drug: Hydroxychloroquine (HCQ),All,"18 Years and older   (Adult, Older Adult)",Phase 3,7.0,"April 3, 2020",2020-05-28,"September 7, 2020","Groupement Hospitalier des Portes de Province, Montélimar, France|Centre Hospitalier de Roanne, Roanne, France|CHU Saint-Etienne, Saint-Étienne, France|Clinique Mutualiste, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04522466,France,Hydroxychloroquine (HCQ),5.0,2020,Thursday
1749,1750,CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19,Not yet recruiting,Drug: Edoxaban Tablets|Drug: Colchicine Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 3,420.0,"October 1, 2020",2021-12-31,"August 18, 2020","Bern University Hospital, Bern, Switzerland|Ospedale regionale Lugano, Lugano, Switzerland",https://ClinicalTrials.gov/show/NCT04516941,Switzerland,Edoxaban Tablets|Colchicine Tablets,12.0,2021,Friday
1750,1751,ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis,Recruiting,Other: MR-Pro-ADM,All,"18 Years and older   (Adult, Older Adult)",,183.0,"May 20, 2020",2020-10-07,"August 27, 2020","Hospital of Arras, Arras, France|Hospital of Boulogne/mer, Boulogne-sur-Mer, France|Hospital of DOUAI, Douai, France|Hospital of Dunkerque, Dunkerque, France|Hospital Dr Schaffner, Lens, France|Hospital of Roubaix, Roubaix, France|Hospital of Tourcoing, Tourcoing, France|Hospitalier of Valenciennes, Valenciennes, France",https://ClinicalTrials.gov/show/NCT04522310,France,,10.0,2020,Wednesday
1751,1752,Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19,Not yet recruiting,Diagnostic Test: serology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170.0,"September 8, 2020",2021-12-31,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04543006,Undefined,,12.0,2021,Friday
1752,1753,Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS,Completed,Other: Airway pressure release ventilation,All,"18 Years and older   (Adult, Older Adult)",,17.0,"April 15, 2020",2020-06-01,"September 14, 2020","Centre Hospitalier Régional Universitaire de Nancy, Nancy, France",https://ClinicalTrials.gov/show/NCT04386369,France,,6.0,2020,Monday
1753,1754,DIgital Online SuPport for COVID-19 StrEss,Recruiting,Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600.0,"April 8, 2020",2021-12-01,"April 14, 2020","Selfapy GmbH, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04324190,Germany,,12.0,2021,Wednesday
1754,1755,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,Completed,Other: questionnaire assesment,All,"18 Years and older   (Adult, Older Adult)",,312.0,"April 20, 2020",2020-04-27,"December 11, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04353011,France,,4.0,2020,Monday
1755,1756,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,Completed,Other: questionnaire assesment,All,"18 Years and older   (Adult, Older Adult)",,52.0,"April 23, 2020",2020-04-30,"December 11, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04351633,France,,4.0,2020,Thursday
1756,1757,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1372.0,"October 9, 2020",2021-06-30,"October 28, 2020","University of Nebraska, Omaha, Nebraska, United States|Brown University, Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States|St. Luc University Hospital, Brussels, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|University of Calgary - Foothills, Calgary, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queens University, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|Université de Sherbrooke, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire d'Angers, Angers, France|Chiba University, Chiba, Japan|Hospital Clínico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04606563,Belgium,Losartan,6.0,2021,Wednesday
1757,1758,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,134.0,"June 11, 2020",2022-06-11,"September 23, 2020","Centre Hospitalier du Mans, Le Mans, France",https://ClinicalTrials.gov/show/NCT04561154,France,,6.0,2022,Saturday
1758,1759,Baricitinib Therapy in COVID-19,Completed,Drug: Baricitinib 4 MG Oral Tablet,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,12.0,"March 16, 2020",2020-04-07,"April 24, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",https://ClinicalTrials.gov/show/NCT04358614,Italy,Baricitinib 4 MG Oral Tablet,4.0,2020,Tuesday
1759,1760,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,Recruiting,Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,194.0,"April 20, 2020",2020-08-01,"May 27, 2020","Intensive care department-Hospital Tenon, Paris, France",https://ClinicalTrials.gov/show/NCT04334850,France,,8.0,2020,Saturday
1760,1761,Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,Not yet recruiting,Drug: Oxytocin|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,145.0,"September 1, 2020",2020-12-31,"July 1, 2020","CNRS, Lyon, France|Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy|Ospedale San Francesco, Nuoro, Italy",https://ClinicalTrials.gov/show/NCT04386447,France,Oxytocin|Standard of Care,12.0,2020,Thursday
1761,1762,Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19,Not yet recruiting,Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,334.0,"June 1, 2020",2021-12-31,"April 8, 2020",,https://ClinicalTrials.gov/show/NCT04338906,Undefined,Camostat Mesilate|Placebo|Hydroxychloroquine,12.0,2021,Friday
1762,1763,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Drug: Ruxolitinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 22, 2020",2021-08-31,"September 10, 2020","Universitätsmedizin Göttingen - Klinik für Hämatologie und Onkologie, Göttingen, Germany|University Hospital Jena, Jena, Germany|Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany",https://ClinicalTrials.gov/show/NCT04338958,Germany,Ruxolitinib,8.0,2021,Tuesday
1763,1764,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","Active, not recruiting",Drug: INM005|Drug: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2|Phase 3,242.0,"July 27, 2020",2020-12-01,"October 28, 2020","Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Muñiz, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Pirovano, Ciudad Autonoma de Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04494984,Argentina,INM005|Placebo,12.0,2020,Tuesday
1764,1765,Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel,Withdrawn,Biological: BACMUNE (MV130)|Other: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0.0,October 2020,2021-12-01,"November 2, 2020","Instituto Nacional de Enfermedades Respiratorias (INER), Ciudad de México, Mexico|Hospital General de Pachuca, Pachuca de Soto, Mexico|Hospital de Ciudad Valles, San Luis Potosí, Mexico",https://ClinicalTrials.gov/show/NCT04452643,Mexico,,12.0,2021,Wednesday
1765,1766,COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression,Enrolling by invitation,Genetic: COVID-19 Androgen Sensitivity Test (CoVAST),Male,"18 Years to 90 Years   (Adult, Older Adult)",,200.0,"August 13, 2020",2023-06-24,"December 11, 2020","Applied Biology, Inc, Irvine, California, United States|University of California, Irvine - Dermatology Clinical Research, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04530500,United States,,6.0,2023,Saturday
1766,1767,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Recruiting,Drug: Sofosbuvir|Drug: Daclatasvir,All,"Child, Adult, Older Adult",Phase 2|Phase 3,100.0,"July 1, 2020",2021-04-10,"December 3, 2020","Cairo and Tanta Universitities, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04497649,Egypt,Sofosbuvir|Daclatasvir,4.0,2021,Saturday
1767,1768,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Recruiting,Other: Prone position|Other: Supine position,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18.0,"October 1, 2020",2021-05-01,"October 8, 2020","Hopital Saint Joseph, Marseille, France",https://ClinicalTrials.gov/show/NCT04543760,France,,5.0,2021,Saturday
1768,1769,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,Recruiting,Drug: Masitinib|Drug: Isoquercetin|Drug: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"June 1, 2020",2021-06-01,"November 10, 2020","Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France|Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France|CHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France|Hopital Nord, AP-HM, Marseille, France|CHR Orleans, Hopital de la Source, Orléans, France|Hopital Larrey, CHU du Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04622865,France,Masitinib|Isoquercetin|Best Supportive Care,6.0,2021,Tuesday
1769,1770,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,160.0,"March 3, 2020",2020-05-01,"May 4, 2020","Service de Radiologie B - NHC, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04373486,France,,5.0,2020,Friday
1770,1771,Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,Dietary Supplement: Manremyc|Dietary Supplement: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,315.0,"July 14, 2020",2021-12-01,"July 15, 2020","CAP Cornellà (La Gavarra), Cornellà De Llobregat, Barcelona, Spain|CAP Maresme, Mataró, Barcelona, Spain|Cap Sant Fèlix, Sabadell, Barcelona, Spain|EAP Riu Nord, Santa Coloma De Gramenet, BArcelona, Spain|Hospital Universitari Germans Trias i Pujol UBP Riscos Laborals, Badalona,, Badalona, Spain",https://ClinicalTrials.gov/show/NCT04452773,Spain,,12.0,2021,Wednesday
1771,1772,Optimising Resource Allocation Via Prediction of Outcomes for Covid-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"May 1, 2020",2021-01-31,"October 8, 2020","Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT04473105,United Kingdom,,1.0,2021,Sunday
1772,1773,Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to DEX in Patients With COVID-19 Pneumonia,Not yet recruiting,Drug: EG-HPCP-03a|Drug: EG-HPCP-03a Placebo|Drug: Standard of Care|Drug: Dexamethasone,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,96.0,December 2020,2021-12-01,"September 23, 2020",,https://ClinicalTrials.gov/show/NCT04561180,Undefined,EG-HPCP-03a|EG-HPCP-03a Placebo|Standard of Care|Dexamethasone,12.0,2021,Wednesday
1773,1774,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Biological: VXA-CoV2-1,All,18 Years to 54 Years   (Adult),Phase 1,35.0,"September 21, 2020",2021-10-01,"November 17, 2020","WCCT, Cypress, California, United States",https://ClinicalTrials.gov/show/NCT04563702,United States,,10.0,2021,Friday
1774,1775,OCTA Study: Retinal Vascular Changes in SARS-CoV-2 Patients,Completed,Diagnostic Test: Optical coherence tomography angiography,All,18 Years to 60 Years   (Adult),,40.0,"September 20, 2020",2020-10-22,"October 26, 2020","University of Naples ""Federico II"", Naples, Italy",https://ClinicalTrials.gov/show/NCT04601012,Italy,,10.0,2020,Thursday
1775,1776,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Recruiting,Drug: Enoxaparin,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300.0,"July 27, 2020",2021-07-31,"November 30, 2020","ASST Fatebenefratelli Sacco, Milan, Italy",https://ClinicalTrials.gov/show/NCT04646655,Italy,Enoxaparin,7.0,2021,Saturday
1776,1777,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,60.0,"November 1, 2020",2021-06-30,"October 14, 2020","Hôpital Corentin Celton, Issy-les-Moulineaux, France",https://ClinicalTrials.gov/show/NCT04513964,France,,6.0,2021,Wednesday
1777,1778,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,Recruiting,Drug: XCEL-UMC-BETA|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"May 13, 2020",2020-12-01,"May 15, 2020","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04390139,Spain,XCEL-UMC-BETA,12.0,2020,Tuesday
1778,1779,Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study,Not yet recruiting,Procedure: Vascular surgery,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 1, 2020",2020-11-01,"April 3, 2020","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04333693,Spain,,11.0,2020,Sunday
1779,1780,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,Biological: recovered covid 19 patients plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30.0,"May 29, 2020",2020-09-01,"August 28, 2020","South Valley University, Qinā, Egypt",https://ClinicalTrials.gov/show/NCT04530370,Egypt,,9.0,2020,Tuesday
1780,1781,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Recruiting,Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1344.0,"June 3, 2020",2023-01-31,"November 9, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|Mayo Clinic, Phoenix, Phoenix, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Netowrk, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Network, Norwalk Hospital, Norwalk, Connecticut, United States|University of Miami, Coral Gables, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|MedStar Washington Hospital Center, Hyattsville, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04373460,India,,1.0,2023,Tuesday
1781,1782,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"June 1, 2020",2021-12-31,"July 17, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04468035,France,,12.0,2021,Friday
1782,1783,Inspiratory Muscle Training in COVID-19 Patients,Not yet recruiting,Device: inspiratory muscle traiing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"November 1, 2020",2021-06-30,"October 20, 2020","Secretaria de Saúde do Distrito Federal, Brasilia, DF, Brazil",https://ClinicalTrials.gov/show/NCT04595097,Brazil,,6.0,2021,Wednesday
1783,1784,COVID-19 in Pediatric Oncology and Hematology Centers in France,Recruiting,"Other: No intervention, observational",All,"1 Month to 30 Years   (Child, Adult)",,300.0,"April 27, 2020",2023-04-27,"June 16, 2020","Jérémie Rouger-Gaudichon, Caen, France",https://ClinicalTrials.gov/show/NCT04433871,France,,4.0,2023,Thursday
1784,1785,Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients,Not yet recruiting,Drug: Tranexamic acid|Drug: Placebo oral tablet,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 30, 2021",2021-12-31,"November 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04338126,United States,Tranexamic acid|Placebo oral tablet,12.0,2021,Friday
1785,1786,Contrast Enhanced Ultrasound in COVID-19,Recruiting,Drug: Sulfur hexafluoride lipid-type A microspheres,All,up to 17 Years   (Child),Phase 3,30.0,December 2020,2022-12-01,"December 7, 2020","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04640038,United States,Sulfur hexafluoride lipid-type A microspheres,12.0,2022,Thursday
1786,1787,Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak,Recruiting,,All,"Child, Adult, Older Adult",,700.0,"May 2, 2020",2021-04-01,"May 26, 2020","Damanhour University, Damanhūr, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04401098,Egypt,,4.0,2021,Thursday
1787,1788,The Effect of Melatonin and Vitamin C on COVID-19,Not yet recruiting,Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"September 18, 2020",2021-12-01,"September 16, 2020","Lancaster General Health, Lancaster, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04530539,United States,,12.0,2021,Wednesday
1788,1789,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Recruiting,Other: Intervention group_rehabilitation program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"July 30, 2020",2021-11-30,"November 9, 2020","CHU Rennes, Rennes, France|Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France|Centre Hospitalier Bretagne Atlantique, Vannes, France",https://ClinicalTrials.gov/show/NCT04466800,France,,11.0,2021,Tuesday
1789,1790,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Recruiting,Drug: anti-SARS-CoV-2 IgY|Drug: Placebo,All,18 Years to 45 Years   (Adult),Phase 1,48.0,"September 18, 2020",2020-12-01,"September 30, 2020","Linear Clinical Research - Harry Perkins Research Institute, Nedlands, Western Australia, Australia",https://ClinicalTrials.gov/show/NCT04567810,Australia,anti-SARS-CoV-2 IgY|Placebo,12.0,2020,Tuesday
1790,1791,Neuropathology in Adults Intensive Care Unit Patients With COVID 19,Completed,Procedure: autopsy,All,"18 Years and older   (Adult, Older Adult)",,7.0,"March 10, 2020",2020-05-15,"July 1, 2020","Hôpital Raymond Poincaré, Garches, France",https://ClinicalTrials.gov/show/NCT04453670,France,,5.0,2020,Friday
1791,1792,The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients,Completed,Radiation: Non-enhanced CT scan of the chest,All,"18 Years and older   (Adult, Older Adult)",,76.0,"March 1, 2020",2020-09-01,"September 23, 2020","Security Forces Hospital, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04560530,Saudi Arabia,,9.0,2020,Tuesday
1792,1793,Microbial Infection and AMR in Hospitalized Patients With Covid 19,Recruiting,,All,"Child, Adult, Older Adult",,70.0,"September 24, 2020",2020-12-31,"September 22, 2020","Assiut hopital, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04479982,Egypt,,12.0,2020,Thursday
1793,1794,Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease,Not yet recruiting,Biological: Autologous Adipose MSC's,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,20.0,April 2020,2026-04-01,"April 21, 2020",,https://ClinicalTrials.gov/show/NCT04352803,Undefined,,4.0,2026,Wednesday
1794,1795,Attitude of Egyptian Population Toward COVID 19 in Ramadan,Recruiting,,All,"Child, Adult, Older Adult",,500.0,"April 24, 2020",2020-10-01,"May 26, 2020","Damanhour University, Damanhūr, Beheira, Egypt",https://ClinicalTrials.gov/show/NCT04401072,Egypt,,10.0,2020,Thursday
1795,1796,Hydrocortisone for COVID-19 and Severe Hypoxia,"Active, not recruiting",Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"April 17, 2020",2021-06-08,"September 7, 2020","Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Dept of Infectious diseases, Rigshospitalet, Copenhagen, Denmark|Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark|North Zealand Hospital, Hillerød, Denmark|Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark|Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark|Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Køge Hospital, Køge, Denmark|Dept of Intensive Care, Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Slagelse Hospital, Slagelse, Denmark|Viborg Hospital, Viborg, Denmark",https://ClinicalTrials.gov/show/NCT04348305,Denmark,Hydrocortisone|Sodium Chloride 9mg/mL,6.0,2021,Tuesday
1796,1797,Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context,Recruiting,Diagnostic Test: indirect calorimetry,All,"18 Years and older   (Adult, Older Adult)",,90.0,"July 3, 2020",2021-03-02,"July 24, 2020","Arras general hospital, Arras, France",https://ClinicalTrials.gov/show/NCT04391686,France,,3.0,2021,Tuesday
1797,1798,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,Diagnostic Test: Transpulmonary pressure measurements,All,up to 17 Years   (Child),Not Applicable,10.0,"May 21, 2020",2021-01-31,"August 19, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04519411,United States,,1.0,2021,Sunday
1798,1799,Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France,Recruiting,Other: Human Biological samples,All,"5 Years and older   (Child, Adult, Older Adult)",,2000.0,"March 13, 2020",2023-02-28,"September 16, 2020","CHU Amiens-Picardie, Amiens, France|EHPAD Villa Concorde, Asnieres sur seine, France|CHU François Mitterand, Dijon, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|CHU Limoges, Limoges, France|Hôpital de la Croix Rousse, Lyon, France|EHPAD Les Etangs, Mennecy, France|CHRU de Nancy, Nancy, France|Hôpitaux de Brabois, Nancy, France|CHR Orléans, Orléans, France|Institut Pasteur, Paris, France|EHPAD Villa Lecourbe, Paris, France|Hôpital la Pitié Salpetrière, Paris, France|CHU Poitiers, Poitiers, France|Hôpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-Étienne, France|CHRU de Strasbourg, Strasbourg, France|CH de Tourcoing, Tourcoing, France|Hôpital Bretonneau, Tours, France",https://ClinicalTrials.gov/show/NCT04325646,France,,2.0,2023,Tuesday
1799,1800,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),Not yet recruiting,Dietary Supplement: Bioarginina®,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,290.0,"November 18, 2020",2021-09-18,"November 23, 2020",,https://ClinicalTrials.gov/show/NCT04637906,Undefined,,9.0,2021,Saturday
1800,1801,Stellate Ganglion Blockade in COVID-19 Positive Patients,Not yet recruiting,Procedure: Stellate Ganglion Block,All,"19 Years to 85 Years   (Adult, Older Adult)",Not Applicable,10.0,July 2020,2021-07-01,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04445337,Undefined,,7.0,2021,Thursday
1801,1802,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Recruiting,Biological: Biological test,All,"Child, Adult, Older Adult",Not Applicable,500.0,"May 31, 2020",2021-05-31,"July 24, 2020","Centre hospitalier intercommunal de Créteil, Créteil, France",https://ClinicalTrials.gov/show/NCT04363385,France,,5.0,2021,Monday
1802,1803,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,960.0,"May 15, 2020",2023-12-31,"October 5, 2020","University of Kentucky, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04573634,United States,,12.0,2023,Sunday
1803,1804,Spread and Course of COVID-19 Infections,"Active, not recruiting",,All,18 Years to 64 Years   (Adult),,3000.0,"April 27, 2020",2021-06-30,"July 1, 2020","ETH, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04377724,Switzerland,,6.0,2021,Wednesday
1804,1805,The Effect of COVID-19 on Diabetes Mellitus,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,500.0,"March 20, 2020",2020-11-01,"October 19, 2020","Usak University Training and Research Hospital, Usak, Turkey",https://ClinicalTrials.gov/show/NCT04592055,Turkey,,11.0,2020,Sunday
1805,1806,Early Treatment of Cytokine Storm Syndrome in Covid-19,Recruiting,Drug: Anakinra|Drug: Normal saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,30.0,"July 29, 2020",2021-03-01,"September 11, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04362111,United States,Anakinra|Normal saline,3.0,2021,Monday
1806,1807,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1167.0,"May 8, 2020",2022-05-01,"May 18, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04390464,United Kingdom,Ravulizumab|Baricitinib,5.0,2022,Sunday
1807,1808,Back to School COVID-19 Simulation Study,"Active, not recruiting",Behavioral: Personal behaviours,All,"4 Years to 18 Years   (Child, Adult)",,240.0,"August 10, 2020",2020-12-01,"August 28, 2020","The Hospital for Sick Children, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04531254,Canada,,12.0,2020,Tuesday
1808,1809,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Recruiting,Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,All,"6 Months to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,100.0,"March 24, 2020",2024-12-31,"March 19, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",https://ClinicalTrials.gov/show/NCT04276896,China,,12.0,2024,Tuesday
1809,1810,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,Device: gammaCore® (Vagus nerve stimulation),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"April 20, 2020",2020-07-31,"April 29, 2020","Hospital Clínico Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04368156,Spain,,7.0,2020,Friday
1810,1811,Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19,Not yet recruiting,Drug: Ivermectin and Doxycycline|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,188.0,September 2020,2020-12-01,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04551755,Undefined,Ivermectin and Doxycycline,12.0,2020,Tuesday
1811,1812,OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,Suspended,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640.0,"May 7, 2020",2021-02-07,"September 29, 2020","Hôpital Privé d'Antony, Antony, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France",https://ClinicalTrials.gov/show/NCT04365582,France,Azithromycin|Hydroxychloroquine|Lopinavir 200Mg/Ritonavir 50Mg Tab,2.0,2021,Sunday
1812,1813,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,Biological: Convalescent Plasma|Drug: Standard of Care,All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,67.0,"June 1, 2020",2021-12-31,"September 29, 2020","Cairo University Hospital, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04438694,Egypt,Standard of Care,12.0,2021,Friday
1813,1814,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Recruiting,Drug: BGB DXP593|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,30.0,"September 8, 2020",2021-06-15,"November 25, 2020","Q Pharm Pty Limited, Herston, Queensland, Australia",https://ClinicalTrials.gov/show/NCT04532294,Australia,BGB DXP593|Placebo,6.0,2021,Tuesday
1814,1815,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,Drug: unfractionated Heparin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"June 29, 2020",2021-07-01,"July 27, 2020","University of São Paulo General Hospital, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04487990,Brazil,unfractionated Heparin,7.0,2021,Thursday
1815,1816,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Recruiting,Device: KELEA Excellerated Water|Device: Water Without an Elevated Level of KELEA,All,"Child, Adult, Older Adult",Not Applicable,100.0,"October 1, 2020",2020-11-30,"September 18, 2020","Institute of Progressive Medicine, South Pasadena, California, United States",https://ClinicalTrials.gov/show/NCT04490824,United States,,11.0,2020,Monday
1816,1817,Repeat Testing for SARS-CoV-2,Enrolling by invitation,Device: Saliva Assay,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,10000.0,"September 29, 2020",2021-09-01,"October 14, 2020","University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04579549,United States,,9.0,2021,Wednesday
1817,1818,Senior-COVID-Rea Multicentric Survey,Recruiting,Other: Group1,All,"60 Years and older   (Adult, Older Adult)",,185.0,"April 1, 2020",2020-08-15,"July 30, 2020","Resuscitation unit at Hospital Emile Roux, Le Puy-en-Velay, France|- Resuscitation unit of the Groupement Hospitalier Nord - Hospices Civils de Lyon, Lyon, France|- Resuscitation unit of the Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France|Resuscitation unit of the Groupement Hospitalier Centre - Hospices Civils de Lyon, Lyon, France|Resuscitation unit of the Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France|Service de Réanimation de l'Hôpital Nord Ouest, Villefranche-sur-Saône, France|Medipole Resuscitation unit, Villeurbanne, France",https://ClinicalTrials.gov/show/NCT04422340,France,,8.0,2020,Saturday
1818,1819,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Completed,Other: Physical Exercises,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20.0,"July 3, 2020",2020-10-03,"October 8, 2020","Bin Inam Rehabilitation Center., Faisalābad, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04445376,Pakistan,,10.0,2020,Saturday
1819,1820,Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia,Withdrawn,Other: severe covid-19 pneumonia with ET,All,"18 Years to 90 Years   (Adult, Older Adult)",,0.0,"August 7, 2020",2020-12-30,"July 20, 2020","Tongji Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04298814,China,,12.0,2020,Wednesday
1820,1821,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Recruiting,Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 2,200.0,"May 1, 2020",2020-09-25,"May 19, 2020","Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan",https://ClinicalTrials.gov/show/NCT04359537,Pakistan,Hydroxychloroquine Sulfate 200 MG,9.0,2020,Friday
1821,1822,Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19,Recruiting,Diagnostic Test: home spirometry,All,"18 Years to 85 Years   (Adult, Older Adult)",,90.0,"August 8, 2020",2021-09-01,"October 23, 2020","Sheba Medical Center, Ramat Gan, Israel",https://ClinicalTrials.gov/show/NCT04438863,Israel,,9.0,2021,Wednesday
1822,1823,Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement,Not yet recruiting,,All,"21 Years to 80 Years   (Adult, Older Adult)",,529.0,"September 1, 2020",2021-09-30,"August 20, 2020",,https://ClinicalTrials.gov/show/NCT04520191,Undefined,,9.0,2021,Thursday
1823,1824,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,Device: Biosensors,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,214.0,"April 22, 2020",2025-12-20,"May 13, 2020","Lillestrom legevakt, Lillestrom, Norway",https://ClinicalTrials.gov/show/NCT04335097,Norway,,12.0,2025,Saturday
1824,1825,Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study,Withdrawn,Diagnostic Test: Test PCR|Genetic: TDR|Other: Clinical Examination,All,"18 Years to 80 Years   (Adult, Older Adult)",,0.0,"May 15, 2020",2020-07-15,"August 27, 2020","Eshmoun Clinical Research Centre, Tunis, Tunisia",https://ClinicalTrials.gov/show/NCT04384614,Tunisia,,7.0,2020,Wednesday
1825,1826,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Completed,Diagnostic Test: Performance of the test antigenic and test RT-PCR,All,"up to 18 Years   (Child, Adult)",Not Applicable,500.0,"October 1, 2020",2020-11-25,"December 2, 2020","Centre hospitalier intercommunal de Créteil, Créteil, France|Cabinet de ville, Nogent sur Marne, France|Cabinet Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de ville 13 Villa Beauséjour, Vincennes, France",https://ClinicalTrials.gov/show/NCT04583189,France,,11.0,2020,Wednesday
1826,1827,Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19,Not yet recruiting,Drug: Tocilizumab 180 MG/ML|Drug: Methylprednisolone Sodium Succinate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,May 2020,2020-11-01,"May 6, 2020",,https://ClinicalTrials.gov/show/NCT04377503,Undefined,Tocilizumab 180 MG/ML|Methylprednisolone Sodium Succinate,11.0,2020,Sunday
1827,1828,Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS,Recruiting,Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20.0,"May 1, 2018",2020-12-31,"June 16, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT03376854,United States,Neuromuscular Blocking Agents,12.0,2020,Thursday
1828,1829,Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients,Not yet recruiting,Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin,All,"5 Years to 90 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,110.0,"June 1, 2020",2020-09-01,"May 12, 2020","Omdurman Teaching Hospital, Khartoum, Omdurman, Sudan|Jabra Hospital,, Khartoum, Sudan",https://ClinicalTrials.gov/show/NCT04381871,Sudan,,9.0,2020,Tuesday
1829,1830,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,Recruiting,Biological: Convalescent Plasma|Other: Saline solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"April 17, 2020",2023-04-30,"August 28, 2020","Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States|The University of Texas Health Science Center, Houston, Texas, United States|The University of Texas Health Science Center, Tyler, Texas, United States",https://ClinicalTrials.gov/show/NCT04364737,United States,,4.0,2023,Sunday
1830,1831,Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection,Not yet recruiting,Drug: Desferal 500 MG Injection,All,"Child, Adult, Older Adult",Phase 4,200.0,"June 1, 2020",2020-12-31,"May 15, 2020",,https://ClinicalTrials.gov/show/NCT04389801,Undefined,Desferal 500 MG Injection,12.0,2020,Thursday
1831,1832,Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"October 10, 2020",2022-02-28,"October 19, 2020","Jagiellonian University Medical College, Department of Neurology, Kraków, Poland",https://ClinicalTrials.gov/show/NCT04513210,Poland,,2.0,2022,Monday
1832,1833,Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome,Not yet recruiting,Device: Hyperbaric oxygen|Device: Sham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,"January 1, 2021",2023-01-01,"December 1, 2020","Assaf-Harofeh medical center, Zerifin, Israel",https://ClinicalTrials.gov/show/NCT04647656,Israel,,1.0,2023,Sunday
1833,1834,Silent Hypoxia and Awake Proning in COVID-19 Patients,Not yet recruiting,Other: Self measurement with pulse oximeter,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40.0,"November 30, 2020",2021-12-31,"December 3, 2020",,https://ClinicalTrials.gov/show/NCT04647747,Undefined,,12.0,2021,Friday
1834,1835,Characteristics of COVID-19 Patients in Kazakhstan in Early 2020,"Active, not recruiting",,All,"Child, Adult, Older Adult",,1000.0,"February 20, 2020",2020-12-01,"November 13, 2020","Semey Medical University, Semey, East Kazakhstan, Kazakhstan",https://ClinicalTrials.gov/show/NCT04627194,Kazakhstan,,12.0,2020,Tuesday
1835,1836,Predictive Factors for COVID-19 in Rheumatology,Not yet recruiting,Drug: Disease-modifying antirheumatic drugs (DMARDs),All,"18 Years to 100 Years   (Adult, Older Adult)",,150.0,October 2020,2021-10-31,"September 28, 2020",,https://ClinicalTrials.gov/show/NCT04567576,Undefined,Disease-modifying antirheumatic drugs (DMARDs),10.0,2021,Sunday
1836,1837,Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP,Not yet recruiting,Diagnostic Test: Serology test for COVID-19,All,"18 Years and older   (Adult, Older Adult)",,600.0,October 2020,2022-04-01,"October 5, 2020","BENNANI, Marseille, France",https://ClinicalTrials.gov/show/NCT04575545,France,,4.0,2022,Friday
1837,1838,Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins,Recruiting,Diagnostic Test: Sampling,All,"18 Years and older   (Adult, Older Adult)",,80.0,July 2020,2021-06-01,"July 27, 2020","TMC HealthCare, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT04465981,United States,,6.0,2021,Tuesday
1838,1839,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Combination Product: Hydroxychloroquine/Azithromycine|Combination Product: Quinquina-Stevia/Azythromycin|Combination Product: 4Plants/Azythromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,231.0,"June 1, 2020",2020-09-30,"August 7, 2020","Support Centers of Donka, Kenien and Gbessia, Conakry, Guinea",https://ClinicalTrials.gov/show/NCT04501965,Guinea,,9.0,2020,Wednesday
1839,1840,A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,950.0,November 2020,2021-05-01,"November 10, 2020",,https://ClinicalTrials.gov/show/NCT04623138,Undefined,,5.0,2021,Saturday
1840,1841,Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS),Not yet recruiting,Biological: MSC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,October 2020,2021-07-01,"June 29, 2020","University Hospital Tuebingen, Tuebingen, Germany",https://ClinicalTrials.gov/show/NCT04377334,Germany,,7.0,2021,Thursday
1841,1842,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Recruiting,Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,57.0,"April 27, 2020",2021-10-27,"November 24, 2020","CHRU de Nancy, Nancy, France|CHRU de Nancy, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04354610,France,,10.0,2021,Wednesday
1842,1843,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",Device: Test Group: experimental - UVC Therapy applied,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 26, 2020",2021-05-04,"November 24, 2020","Diyarbakır SBÜ Gazi Yaşargil Eğitim Ve Araştırma Hastanesi, Diyarbakır, Kayapınar, Turkey",https://ClinicalTrials.gov/show/NCT04642326,Turkey,,5.0,2021,Tuesday
1843,1844,Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 19, 2020",2022-01-31,"September 30, 2020","Guido Beldi, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04333862,Switzerland,,1.0,2022,Monday
1844,1845,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,Recruiting,Biological: BM-Allo.MSC|Biological: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,45.0,"August 3, 2020",2021-06-01,"August 7, 2020","St. Francis Medical Center, Lynwood, California, United States",https://ClinicalTrials.gov/show/NCT04397796,United States,,6.0,2021,Tuesday
1845,1846,"A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease",Not yet recruiting,Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,216.0,"September 1, 2020",2022-11-01,"June 23, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04424056,France,Anakinra +/- Ruxolitinib (stages 2b/3)|Anakinra and Ruxolitinib (Advanced stage 3)|Tocilizumab +/- ruxolitinib (stages 2b/3)|Tocilizumab and Ruxolitinib (Advanced stage 3),11.0,2022,Tuesday
1846,1847,Effect of Pioglitazone on T2DM Patients With COVID-19,Not yet recruiting,Drug: Pioglitazone 45 mg,All,"21 Years and older   (Adult, Older Adult)",Phase 4,1506.0,"November 15, 2020",2021-06-29,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04604223,Undefined,Pioglitazone 45 mg,6.0,2021,Tuesday
1847,1848,Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT),Not yet recruiting,Other: Questionnaires on psychological quality of life,All,"18 Years and older   (Adult, Older Adult)",,1800.0,"May 11, 2020",2020-08-01,"May 5, 2020","Gynaecology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France",https://ClinicalTrials.gov/show/NCT04375644,France,,8.0,2020,Saturday
1848,1849,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Not yet recruiting,Drug: Nebulized Furosemide|Drug: Nebulized Saline,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,640.0,"October 19, 2020",2021-10-01,"October 20, 2020","University of Alberta, Edmonton, Alberta, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Kingston Health Sciences Center, Kingston, Ontario, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04588792,Canada,Nebulized Furosemide|Nebulized Saline,10.0,2021,Friday
1849,1850,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Drug: Vitamin D|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1264.0,"August 11, 2020",2020-12-28,"November 10, 2020","Hospital de Alta Complejidad en Red El Cruce, Florencio Varela, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04411446,Argentina,Vitamin D|Placebo,12.0,2020,Monday
1850,1851,"Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)",Not yet recruiting,Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Drug: Drug: Standard treatment Standard treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,360.0,November 2020,2021-01-01,"October 26, 2020",,https://ClinicalTrials.gov/show/NCT04578236,Undefined,Drug: Standard treatment Standard treatment,1.0,2021,Friday
1851,1852,Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19,"Active, not recruiting",Other: No interventions,All,"18 Years and older   (Adult, Older Adult)",,264.0,"March 31, 2020",2022-06-01,"September 1, 2020","Dept Pulmonary Medicine, Lørenskog, Viken, Norway",https://ClinicalTrials.gov/show/NCT04535154,Norway,,6.0,2022,Wednesday
1852,1853,COVID-19 Survival - The COVIVA Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"March 19, 2020",2021-06-30,"May 4, 2020","University Hospital Basel, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT04366765,Switzerland,,6.0,2021,Wednesday
1853,1854,A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE),Not yet recruiting,Drug: AMY-101|Other: WFI 5% glucose,All,"18 Years and older   (Adult, Older Adult)",Phase 2,144.0,July 2020,2021-03-01,"May 20, 2020",,https://ClinicalTrials.gov/show/NCT04395456,Undefined,AMY-101,3.0,2021,Monday
1854,1855,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,Other: PSG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25.0,"April 28, 2020",2020-12-28,"June 12, 2020","Hopital Pellegrin, Bordeaux, France",https://ClinicalTrials.gov/show/NCT04371029,France,,12.0,2020,Monday
1855,1856,Covid-19 Pandemic Triage Score,Completed,Diagnostic Test: STC-19 score,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 1, 2020",2020-04-30,"June 25, 2020","Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France",https://ClinicalTrials.gov/show/NCT04371471,France,,4.0,2020,Thursday
1856,1857,Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19,"Active, not recruiting",Other: no intervention,All,"3 Months and older   (Child, Adult, Older Adult)",,40.0,"April 15, 2020",2021-01-15,"April 16, 2020","Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04349540,United Kingdom,,1.0,2021,Friday
1857,1858,The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19,Recruiting,"Other: hospitalisation, necessity of ICU, mortality rate, lung involvement",All,"18 Years to 80 Years   (Adult, Older Adult)",,2000.0,"March 20, 2020",2020-11-01,"October 19, 2020","Usak University Training and Research Hospital, Usak, Turkey",https://ClinicalTrials.gov/show/NCT04591704,Turkey,,11.0,2020,Sunday
1858,1859,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Recruiting,Other: Usual Care|Other: APPS,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"June 14, 2020",2020-09-30,"September 14, 2020","Carolinas Medical Center, Charlotte, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04547283,United States,,9.0,2020,Wednesday
1859,1860,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,1000.0,"February 20, 2020",2020-08-20,"August 25, 2020","2nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04525287,China,,8.0,2020,Thursday
1860,1861,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Biological: Convalescent plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,20.0,"May 20, 2020",2020-10-30,"May 27, 2020","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04403477,Bangladesh,,10.0,2020,Friday
1861,1862,Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19,Not yet recruiting,Other: blood sample,All,"18 Years and older   (Adult, Older Adult)",,80.0,November 2020,2021-11-01,"October 19, 2020","CHU Bicêtre, Le Kremlin-Bicêtre, France",https://ClinicalTrials.gov/show/NCT04590222,France,,11.0,2021,Monday
1862,1863,Baseline Vitamin D Deficiency and COVID-19 Disease Severity,Recruiting,Other: Vitamin D,All,"18 Years to 100 Years   (Adult, Older Adult)",,50.0,"October 27, 2020",2022-04-14,"November 16, 2020","Parkview Medical Center, Pueblo, Colorado, United States",https://ClinicalTrials.gov/show/NCT04628000,United States,,4.0,2022,Thursday
1863,1864,Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury,Not yet recruiting,Diagnostic Test: Non-invasive cardiac imaging,All,"18 Years to 99 Years   (Adult, Older Adult)",,20.0,June 2020,2021-06-01,"June 2, 2020","Cambridge Univeristy Hospitals NHS Foundation Trust, Cambridge, United Kingdom",https://ClinicalTrials.gov/show/NCT04412369,United Kingdom,,6.0,2021,Tuesday
1864,1865,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"September 19, 2020",2021-10-01,"October 30, 2020","Aalborg Hospital, Aalborg, Denmark",https://ClinicalTrials.gov/show/NCT04598620,Denmark,,10.0,2021,Friday
1865,1866,The Prone Position in Covid-19 Affected Patients,"Active, not recruiting",Procedure: Prone position,All,"18 Years to 75 Years   (Adult, Older Adult)",,56.0,"March 20, 2020",2020-12-31,"November 9, 2020","ASST Monza, Monza, MB, Italy",https://ClinicalTrials.gov/show/NCT04365959,Italy,,12.0,2020,Thursday
1866,1867,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Drug: Berberine|Drug: Montmorrillonite,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,76.0,"February 8, 2020",2020-04-23,"July 21, 2020","Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04479202,China,Berberine|Montmorrillonite,4.0,2020,Thursday
1867,1868,Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation,Recruiting,Other: Survey,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 1, 2020",2020-12-30,"May 6, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04376944,France,,12.0,2020,Wednesday
1868,1869,Neurocognitive Functions of Recovered COVID-19 Patients,Recruiting,Behavioral: Trier Social Stress Test,All,"18 Years to 65 Years   (Adult, Older Adult)",,160.0,"July 10, 2020",2020-12-10,"November 10, 2020","Wuhan Wuchang Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04622748,China,,12.0,2020,Thursday
1869,1870,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,Recruiting,Other: Health supplements,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"August 13, 2020",2022-04-30,"October 14, 2020","The Chinese University of Hong Kong, Sha Tin, Hong Kong",https://ClinicalTrials.gov/show/NCT04581018,Hong Kong,,4.0,2022,Saturday
1870,1871,Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19,Not yet recruiting,Dietary Supplement: Zinc gluconate|Dietary Supplement: 25-OH cholecalciferol,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,3140.0,April 2020,2020-07-01,"April 21, 2020",,https://ClinicalTrials.gov/show/NCT04351490,Undefined,,7.0,2020,Wednesday
1871,1872,COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,Not yet recruiting,Drug: Fisetin|Drug: Placebo,All,65 Years and older   (Older Adult),Phase 2,150.0,December 2020,2023-12-01,"September 3, 2020","Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04537299,United States,Fisetin|Placebo,12.0,2023,Friday
1872,1873,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,Recruiting,Drug: BTL-TML-COVID|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,40.0,"July 30, 2020",2021-02-01,"November 9, 2020","MedPharmics, Metairie, Louisiana, United States|Intermountain Clinical Reserach, Draper, Utah, United States",https://ClinicalTrials.gov/show/NCT04522830,United States,BTL-TML-COVID|Placebo,2.0,2021,Monday
1873,1874,Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic,Completed,,All,"Child, Adult, Older Adult",,267.0,"June 15, 2020",2020-06-25,"August 13, 2020","faculty of dentistry, Cairo university , Egypt, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04512300,Egypt,,6.0,2020,Thursday
1874,1875,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Other: Mesenchymal stromal cell-based therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"July 1, 2020",2020-10-31,"August 26, 2020","Hospital São Rafael, Salvador, Bahia, Brazil",https://ClinicalTrials.gov/show/NCT04525378,Brazil,,10.0,2020,Saturday
1875,1876,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Drug: Pulmozyme|Drug: Placebo,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 2,60.0,"July 5, 2020",2021-12-31,"October 26, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04402944,United States,Pulmozyme|Placebo,12.0,2021,Friday
1876,1877,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"April 25, 2020",2022-02-28,"October 23, 2020","Skåne University Hospital, Lund, Sweden",https://ClinicalTrials.gov/show/NCT04600440,Sweden,,2.0,2022,Monday
1877,1878,SQuISH-COVID: A Pilot Study,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 7, 2020",2020-05-29,"May 4, 2020","Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04372472,United States,,5.0,2020,Friday
1878,1879,Comparison Between Positive and Negative COVID-19 Pneumonia,Recruiting,"Other: Clinical, laboratory and imaging characteristics of pneumonia",All,"18 Years to 95 Years   (Adult, Older Adult)",,80.0,"March 15, 2020",2020-12-01,"November 4, 2020","Infectious diseases Unit of the ""Cervello-Villa Sofia"" Hospital, Palermo, PA, Italy|Internal Medicine Division of the ""Cervello-Villa Sofia"" Hospital, Palermo, PA, Italy|Pulmonology Unit Dedicated to COVID-19 Patients, Palermo, PA, Italy",https://ClinicalTrials.gov/show/NCT04507893,Italy,,12.0,2020,Tuesday
1879,1880,Predictive Models for Intensive Care Admission and Death of COVID-19,"Active, not recruiting","Other: predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?",All,"18 Years and older   (Adult, Older Adult)",,60.0,"March 1, 2020",2021-01-01,"May 26, 2020","Clinique Saint-Pierre, Ottignies, Brabant Wallon, Belgium",https://ClinicalTrials.gov/show/NCT04401228,Belgium,,1.0,2021,Friday
1880,1881,CORE Study COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"March 2, 2020",2021-09-30,"August 28, 2020","D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04531202,Brazil,,9.0,2021,Thursday
1881,1882,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Drug: Pyridostigmine Bromide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,436.0,"April 4, 2020",2021-04-30,"July 7, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",https://ClinicalTrials.gov/show/NCT04343963,Mexico,Pyridostigmine Bromide|Placebo,4.0,2021,Friday
1882,1883,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,800.0,"December 1, 2020",2021-12-31,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04616950,Undefined,,12.0,2021,Friday
1883,1884,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,Not yet recruiting,"Diagnostic Test: Assessing antibody responses, neutralizing capacity and memory B-cell function",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,150.0,"July 31, 2020",2021-07-01,"July 16, 2020","University Hospital Antwerp, Antwerpen, Belgium|Jessa Hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04469634,Belgium,,7.0,2021,Thursday
1884,1885,Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare,Recruiting,Diagnostic Test: Throat swab sample for measuring current infection with SARS-CoV-2|Diagnostic Test: Blood sample for serology to measure past infection with SARS-CoV-2,All,"18 Years to 99 Years   (Adult, Older Adult)",,40000.0,"April 23, 2020",2020-12-31,"June 2, 2020","Karolinska University Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04411576,Sweden,,12.0,2020,Thursday
1885,1886,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients,Completed,Drug: Dose of tinzaparin or dalteparin,All,"Child, Adult, Older Adult",,257.0,"March 1, 2020",2020-10-15,"October 20, 2020","Södersjukhuset, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04593654,Sweden,Dose of tinzaparin or dalteparin,10.0,2020,Thursday
1886,1887,COVID-19 Registry Rhineland-Palatinate (Germany),Recruiting,Other: Prospective oberservational registry,All,"Child, Adult, Older Adult",,4000.0,"April 6, 2020",2021-09-30,"April 8, 2020","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany",https://ClinicalTrials.gov/show/NCT04335188,Germany,,9.0,2021,Thursday
1887,1888,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,Not yet recruiting,Drug: Drug COVID19-0001-USR|Drug: normal saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"November 2, 2020",2021-01-29,"October 20, 2020","Cimedical, Barranquilla, Atlantico, Colombia",https://ClinicalTrials.gov/show/NCT04595136,Colombia,Drug COVID19-0001-USR|normal saline,1.0,2021,Friday
1888,1889,Mesenchymal Stem Cells for the Treatment of COVID-19,Completed,Biological: PrimePro|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"April 24, 2020",2020-09-01,"October 5, 2020","Southern California Hospital at Culver City / Southern California Hospital at Hollywood, Culver City, California, United States",https://ClinicalTrials.gov/show/NCT04573270,United States,,9.0,2020,Tuesday
1889,1890,Diabetes Outcomes in COVID-19 Pandemic,Completed,,All,"18 Years to 70 Years   (Adult, Older Adult)",,1282.0,"June 1, 2020",2020-07-30,"October 5, 2020","Services Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04573335,Pakistan,,7.0,2020,Thursday
1890,1891,Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury,Not yet recruiting,Drug: Colchicine|Other: Covid-19 Standard of Care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,75.0,"September 1, 2020",2022-01-01,"August 12, 2020",,https://ClinicalTrials.gov/show/NCT04510038,Undefined,Colchicine,1.0,2022,Saturday
1891,1892,IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation,Not yet recruiting,Drug: IVIG,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10.0,"November 1, 2020",2021-06-30,"November 4, 2020","Sharp Memorial Hospital, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04616001,United States,IVIG,6.0,2021,Wednesday
1892,1893,Can the Electronic Nose Smell COVID-19?,Completed,Device: Aeonose,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,219.0,"April 6, 2020",2020-07-01,"July 17, 2020","Maastricht University Medical Center, Maastricht, Netherlands",https://ClinicalTrials.gov/show/NCT04475562,Netherlands,,7.0,2020,Wednesday
1893,1894,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,Completed,Diagnostic Test: SARS-CoV-2 S1/S2 IgG,All,"18 Years and older   (Adult, Older Adult)",,63.0,"July 14, 2020",2020-11-03,"November 9, 2020","ASST Monza - Ospedale San Gerardo, Monza, MB, Italy",https://ClinicalTrials.gov/show/NCT04526405,Italy,,11.0,2020,Tuesday
1894,1895,One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting,"Active, not recruiting",Diagnostic Test: Lung ultrasound|Diagnostic Test: Muscle ultrasound,All,"18 Years to 100 Years   (Adult, Older Adult)",,60.0,"April 16, 2020",2021-07-13,"November 13, 2020","Centre Hospitalier de Béthune, Beuvry, Hauts-de-France, France|APHP - Hôpital Universitaire Pitié-Salpétrière, Paris, Ile De France, France|Hôpital Forcilles, Férolles-Attilly, Ile-de-France, France",https://ClinicalTrials.gov/show/NCT04373811,France,,7.0,2021,Tuesday
1895,1896,Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19,No longer available,Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System,All,"18 Years to 95 Years   (Adult, Older Adult)",,,,,"June 12, 2020",,https://ClinicalTrials.gov/show/NCT04358588,Undefined,iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System,,n,
1896,1897,A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure,Not yet recruiting,Drug: RLS-0071|Drug: Placebo,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,42.0,October 2020,2021-07-01,"October 5, 2020","Prestige Clinical Research Center, Coral Gables, Florida, United States",https://ClinicalTrials.gov/show/NCT04574869,United States,RLS-0071|Placebo,7.0,2021,Thursday
1897,1898,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",Recruiting,Biological: Kamada Anti-SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,"August 5, 2020",2021-02-01,"September 16, 2020","Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel|Kaplan Medical Center, Reẖovot, Israel",https://ClinicalTrials.gov/show/NCT04550325,Israel,,2.0,2021,Monday
1898,1899,"Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study",Completed,Other: newborns from covid 19 positive mothers,All,up to 15 Minutes   (Child),,40.0,"March 15, 2020",2020-05-30,"June 11, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",https://ClinicalTrials.gov/show/NCT04337320,Turkey,,5.0,2020,Saturday
1899,1900,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,Recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,500.0,"September 1, 2020",2020-12-01,"September 9, 2020","Centre d'Expertise Medicale du Personnel Navigant (CEMPN) de l'Hôpital d'Instruction des Armées Percy, Clamart, France|Centre d'Expertise Medicale du Personnel Navigant (CEMPN) de l'Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France",https://ClinicalTrials.gov/show/NCT04514874,France,,12.0,2020,Tuesday
1900,1901,Operation of the GHPSJ Clinical Ethical Reflection Assistance Group During the COVID-19 Period,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"November 9, 2020",2022-04-30,"October 14, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04586140,France,,4.0,2022,Saturday
1901,1902,Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,Completed,Other: thromboprofylaxis protocol|Other: standard protocol,All,"18 Years and older   (Adult, Older Adult)",,72.0,"May 4, 2020",2020-05-15,"May 19, 2020","Jessa hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04394000,Belgium,,5.0,2020,Friday
1902,1903,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,Diagnostic Test: chest x-ray,All,up to 7 Hours   (Child),Not Applicable,20.0,"May 30, 2020",2020-10-30,"July 14, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04470739,Turkey,,10.0,2020,Friday
1903,1904,Assessment of Lung Mechanics in COVID-19 Acute Respiratory Distress Syndrome,Not yet recruiting,Diagnostic Test: Assessment of lung mechanics and heart-lung interactions,All,"18 Years and older   (Adult, Older Adult)",,25.0,"October 20, 2020",2021-12-31,"October 22, 2020",,https://ClinicalTrials.gov/show/NCT04597853,Undefined,,12.0,2021,Friday
1904,1905,Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite,Withdrawn,Drug: Sodium Nitrite|Drug: Normal Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"July 22, 2020",2020-08-15,"September 16, 2020","Participating Research Facility, Tampa, Florida, United States|Participating Research Facility, Fort Worth, Texas, United States",https://ClinicalTrials.gov/show/NCT04401527,United States,Sodium Nitrite|Normal Saline,8.0,2020,Saturday
1905,1906,Low Dose Radiotherapy in COVID-19 Pneumonia,"Active, not recruiting",Radiation: Low Dose Radiotherapy,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5.0,"May 4, 2020",2020-12-01,"November 10, 2020","Imam Hossein Hospital, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04390412,"Iran, Islamic Republic of",,12.0,2020,Tuesday
1906,1907,Efficacy of Ivermectin in COVID-19,Recruiting,Drug: Ivermectin 6 MG Oral Tablet (2 tablets),All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,100.0,"April 15, 2020",2020-07-01,"May 19, 2020","Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04392713,Pakistan,Ivermectin 6 MG Oral Tablet (2 tablets),7.0,2020,Wednesday
1907,1908,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO,Completed,Device: vv-ECMO,All,"18 Years to 100 Years   (Adult, Older Adult)",,133.0,"May 19, 2020",2020-09-30,"November 4, 2020","University Clinic Freiburg, Freiburg, Germany",https://ClinicalTrials.gov/show/NCT04405973,Germany,,9.0,2020,Wednesday
1908,1909,Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients,Not yet recruiting,Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin,All,21 Years to 50 Years   (Adult),Not Applicable,100.0,"June 1, 2020",2021-01-01,"May 12, 2020",,https://ClinicalTrials.gov/show/NCT04383548,Undefined,,1.0,2021,Friday
1909,1910,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,Biological: Blood samples collection|Other: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75.0,"May 25, 2020",2020-11-25,"May 28, 2020","CHU Rennes, Rennes, France",https://ClinicalTrials.gov/show/NCT04373200,France,,11.0,2020,Wednesday
1910,1911,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,Completed,Diagnostic Test: Serological screening for IgG and IgM antibodies against COVID-19,All,"18 Years to 80 Years   (Adult, Older Adult)",,111.0,"April 20, 2020",2020-06-15,"July 28, 2020","Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador",https://ClinicalTrials.gov/show/NCT04374123,Ecuador,,6.0,2020,Monday
1911,1912,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,Completed,Diagnostic Test: COVID-19 PCR,All,"up to 50 Years   (Child, Adult)",,2000.0,"March 10, 2020",2020-07-14,"July 21, 2020","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey",https://ClinicalTrials.gov/show/NCT04479124,Turkey,,7.0,2020,Tuesday
1912,1913,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Recruiting,Biological: SCTA01|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,"July 24, 2020",2021-01-15,"August 5, 2020","Beijing SHIJITAN Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04483375,China,,1.0,2021,Friday
1913,1914,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Drug: Dexamethasone (high dose),All,"18 Years and older   (Adult, Older Adult)",Phase 3,284.0,"May 21, 2020",2021-01-31,"July 20, 2020","CEMIC (Centro de Educación Médica e Investigaciones Clínicas), Ciudad Autonoma de Buenos Aires, Argentina|Sanatorio Sagrado Corazon, Ciudad Autonoma de Buenos Aires, Argentina|Clínica Bazterrica, Ciudad Autónoma de Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04395105,Argentina,Dexamethasone (high dose),1.0,2021,Sunday
1914,1915,Inspiratory Muscle Training in Patients With COVID-19,Terminated,Device: power breathe,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55.0,"June 1, 2020",2020-10-23,"October 28, 2020","Municipal Hospital Vila Santa Catarina, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04603963,Brazil,,10.0,2020,Friday
1915,1916,Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),Not yet recruiting,Other: Cognitive Behavioural Group Therapy for Perinatal Anxiety,Female,18 Years to 45 Years   (Adult),Not Applicable,120.0,"August 10, 2020",2022-08-01,"August 3, 2020",,https://ClinicalTrials.gov/show/NCT04495803,Undefined,,8.0,2022,Monday
1916,1917,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,Enrolling by invitation,Drug: Clazakizumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,December 2020,2020-12-01,"December 9, 2020","Mayo Clinic in Arizona, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT04659772,United States,Clazakizumab|Placebo,12.0,2020,Tuesday
1917,1918,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia,Completed,Other: management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia,All,"18 Years to 99 Years   (Adult, Older Adult)",,40.0,"April 2, 2020",2020-06-30,"September 9, 2020","Geneva University Hospital, Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04542044,Switzerland,,6.0,2020,Tuesday
1918,1919,Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia,Withdrawn,Other: Brain MRI scan,All,"18 Years and older   (Adult, Older Adult)",,0.0,"May 20, 2020",2020-07-06,"August 5, 2020","CHU de Nimes, Nîmes, France",https://ClinicalTrials.gov/show/NCT04408391,France,,7.0,2020,Monday
1919,1920,COVID-19 Among Egyptian Health Care Providers,Completed,Other: self-administered questionnaire,All,"Child, Adult, Older Adult",,565.0,"April 22, 2020",2020-05-30,"July 7, 2020","Ahmed Abbas, Assiut, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04357431,Egypt,,5.0,2020,Saturday
1920,1921,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,Recruiting,Other: Standard Oxygen Delivery System|Other: Double-Trunk Mask|Other: Surgical Mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,27.0,"November 13, 2020",2021-11-13,"November 18, 2020","Cliniques universitaires Saint-Luc, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04629989,Belgium,,11.0,2021,Saturday
1921,1922,The Effects of Multi-modality Physiotherapy in Delaying or Preventing COVID-19 Patient From Admitting to ICU,Not yet recruiting,Device: Threshold IMT device|Other: Conventional physical therapy,All,21 Years to 60 Years   (Adult),Not Applicable,38.0,"November 1, 2020",2021-04-06,"November 5, 2020","Jaber Al-Ahmed Hospital, Kuwait city, Kuwait",https://ClinicalTrials.gov/show/NCT04617119,Kuwait,,4.0,2021,Tuesday
1922,1923,NOSOcomial COVID-19 in ICU (NOSOCOVID),Recruiting,Other: Patients admitted in Intensive Care Units,All,"18 Years and older   (Adult, Older Adult)",,600.0,"September 1, 2020",2021-03-01,"December 9, 2020","Nantes University Hospital, Nantes, France",https://ClinicalTrials.gov/show/NCT04659356,France,,3.0,2021,Monday
1923,1924,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",All,"Child, Adult, Older Adult",Phase 2|Phase 3,1800.0,"April 11, 2020",2020-09-14,"November 12, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04349410,United States,"Hydroxychloroquine, Azithromycin|Hydroxychloroquine, Doxycycline|Hydroxychloroquine, Clindamycin|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Remdesivir|Tocilizumab|Methylprednisolone|Interferon-Alpha2B|Losartan|Convalescent Serum",9.0,2020,Monday
1924,1925,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Not yet recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1800.0,October 2020,2021-12-01,"October 9, 2020","CHU Amiens Picardie, Amiens, France|CH Lens, Lens, France|CH Tourcoing, Tourcoing, France",https://ClinicalTrials.gov/show/NCT04581746,France,,12.0,2021,Wednesday
1925,1926,Ivermectin in Treatment of COVID-19,Recruiting,Drug: Ivermectin,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"May 31, 2020",2020-08-15,"June 24, 2020","Waheed Shouman, Zagazig, Sharkia, Egypt",https://ClinicalTrials.gov/show/NCT04445311,Egypt,Ivermectin,8.0,2020,Saturday
1926,1927,Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 23, 2020",2021-06-23,"November 10, 2020","University Medical Center Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04325412,Netherlands,,6.0,2021,Wednesday
1927,1928,Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects,Not yet recruiting,Drug: Povidine iodine nasal swabs,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,50.0,August 2020,2021-04-01,"August 12, 2020",,https://ClinicalTrials.gov/show/NCT04510402,Undefined,Povidine iodine nasal swabs,4.0,2021,Thursday
1928,1929,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,Recruiting,Other: pulmonary ultrasound,All,"18 Years and older   (Adult, Older Adult)",,400.0,"April 9, 2020",2020-12-01,"November 10, 2020","Chu de Nantes, Nantes, France",https://ClinicalTrials.gov/show/NCT04370249,France,,12.0,2020,Tuesday
1929,1930,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Recruiting,Drug: Hydroxychloroquine|Drug: Placebo,Female,"Child, Adult, Older Adult",Phase 3,714.0,"May 13, 2020",2021-08-01,"June 1, 2020","Hospital Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Clínic Maternity, Barcelona, Catalunya, Spain|University hospital of Torrejón, Madrid, Spain|HM Puerta del Sur, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04410562,Spain,Hydroxychloroquine|Placebo,8.0,2021,Sunday
1930,1931,Convalescent Plasma for Patients With COVID-19,Recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"May 4, 2020",2020-08-01,"May 12, 2020","Henry Ford Hospital, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04385199,United States,,8.0,2020,Saturday
1931,1932,Prognosis in Pregnant With COVID-19,Completed,"Diagnostic Test: imaging, blood tests",Female,18 Years to 45 Years   (Adult),,155.0,"March 15, 2020",2020-05-28,"July 2, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkey",https://ClinicalTrials.gov/show/NCT04409249,Turkey,,5.0,2020,Thursday
1932,1933,Can the Electronic Nose Smell COVID-19 Antibodies?,Completed,Device: Aeonose,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,222.0,"April 6, 2020",2020-07-01,"July 17, 2020","Maastricht University Medical Center, Maastricht, Netherlands",https://ClinicalTrials.gov/show/NCT04475575,Netherlands,,7.0,2020,Wednesday
1933,1934,Understanding Immunity to the COVID-19 Vaccines,Not yet recruiting,Other: No intervention,All,18 Years to 64 Years   (Adult),,1000.0,January 2021,2023-01-01,"December 11, 2020","Stanford University, Hospital, and Clinics, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04664309,United States,,1.0,2023,Sunday
1934,1935,COVID-19 in Patients With HIV,Recruiting,Other: No intervention,All,"Child, Adult, Older Adult",,500.0,"April 1, 2020",2020-10-01,"April 7, 2020","University of Missouri-Columbia, Columbia, Missouri, United States",https://ClinicalTrials.gov/show/NCT04333953,United States,,10.0,2020,Thursday
1935,1936,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Recruiting,Procedure: Auricular neuromodulation|Procedure: Control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 9, 2020",2021-03-01,"September 18, 2020","Fondation Adolphe de Rothschild, Paris, France",https://ClinicalTrials.gov/show/NCT04341415,France,,3.0,2021,Monday
1936,1937,Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,40.0,November 2020,2021-08-01,"November 18, 2020","Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov, Saint Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04633915,Russian Federation,,8.0,2021,Sunday
1937,1938,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,"Active, not recruiting",Dietary Supplement: Vitamin D,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,6200.0,"October 27, 2020",2021-06-30,"December 1, 2020","Queen Mary University of London, London, County (optional), United Kingdom",https://ClinicalTrials.gov/show/NCT04579640,United Kingdom,,6.0,2021,Wednesday
1938,1939,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"April 28, 2020",2021-03-31,"September 22, 2020","Geneva University Hospitals, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Locarno, Locarno, Switzerland|Hôpital du Valais, Sion, Switzerland",https://ClinicalTrials.gov/show/NCT04345848,Switzerland,Enoxaparin,3.0,2021,Wednesday
1939,1940,Niclosamide In Moderate COVID-19,Not yet recruiting,Drug: Niclosamide Oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,December 2020,2021-04-01,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04436458,Undefined,Niclosamide Oral Tablet|Placebo,4.0,2021,Thursday
1940,1941,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,Behavioral: Mental imagery,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250.0,"August 19, 2020",2020-12-01,"October 12, 2020","University of East London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04583449,United Kingdom,,12.0,2020,Tuesday
1941,1942,COVID-19 Child Health Investigation of Latent Disease in Hamburg,"Active, not recruiting",,All,"up to 18 Years   (Child, Adult)",,6000.0,"May 11, 2020",2021-03-31,"September 1, 2020","Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany",https://ClinicalTrials.gov/show/NCT04534608,Germany,,3.0,2021,Wednesday
1942,1943,Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.,"Active, not recruiting",,All,"Child, Adult, Older Adult",,149.0,"June 11, 2020",2020-10-30,"September 29, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04567979,Mexico,,10.0,2020,Friday
1943,1944,The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,Recruiting,Biological: CYP-001,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,"August 24, 2020",2021-03-31,"November 19, 2020","Nepean Hospital, Kingswood, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Footscray Hospital, Footscray, Victoria, Australia|Sunshine Hospital, Saint Albans, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04537351,Australia,,3.0,2021,Wednesday
1944,1945,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,Completed,,All,"18 Years and older   (Adult, Older Adult)",,220.0,"March 19, 2020",2020-05-08,"June 1, 2020","ASST - Papa Giovanni XXIII, Bergamo, Italy",https://ClinicalTrials.gov/show/NCT04322188,Italy,,5.0,2020,Friday
1945,1946,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,Completed,Other: Serologic testing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"May 6, 2020",2020-07-31,"September 1, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04383587,United States,,7.0,2020,Friday
1946,1947,Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,240.0,"March 30, 2020",2020-12-31,"June 22, 2020","IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy",https://ClinicalTrials.gov/show/NCT04441502,Italy,,12.0,2020,Thursday
1947,1948,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,Recruiting,Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,950.0,"September 21, 2020",2020-11-02,"September 28, 2020","Antenne Médicale des Ecoles Militaires de Santé de Lyon-Bron (EMSLB), Bron, France",https://ClinicalTrials.gov/show/NCT04516928,France,,11.0,2020,Monday
1948,1949,Lung Irradiation for COVID-19 Pneumonia,Recruiting,Radiation: Phase 1|Radiation: Phase 2,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,48.0,June 2020,2020-11-01,"June 25, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04393948,United States,,11.0,2020,Sunday
1949,1950,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,Completed,Diagnostic Test: PCR for COVID-19,All,18 Years to 50 Years   (Adult),,5000.0,"March 10, 2020",2020-07-14,"July 22, 2020","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04479137,Turkey,,7.0,2020,Tuesday
1950,1951,Myeloid Cells in Patients With Covid-19 Pneumonia,Not yet recruiting,Other: Blood sampling|Other: Nasal Brushing,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120.0,"November 1, 2020",2023-11-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04590261,Undefined,,11.0,2023,Wednesday
1951,1952,Post Covid-19 Cardiopulmonary and Immunological Changes,"Active, not recruiting",,All,"Child, Adult, Older Adult",,100.0,"May 11, 2020",2021-10-10,"May 19, 2020","Mansoura faculty of medicine, Mansoura, Dakahlia, Egypt",https://ClinicalTrials.gov/show/NCT04388436,Egypt,,10.0,2021,Sunday
1952,1953,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Not yet recruiting,Radiation: Lung Low Dose Radiation,All,65 Years and older   (Older Adult),Not Applicable,41.0,"October 1, 2020",2021-03-31,"July 31, 2020","Hospital Provincial de Castellon, Castellón De La Plana, Castellon, Spain",https://ClinicalTrials.gov/show/NCT04414293,Spain,,3.0,2021,Wednesday
1953,1954,Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19,Available,Biological: Convalescent Plasma,All,"12 Years and older   (Child, Adult, Older Adult)",,,,,"June 24, 2020","UMass Medical School, Worcester, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04445207,United States,,,n,
1954,1955,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,9.0,"April 16, 2020",2020-12-15,"August 4, 2020","Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico",https://ClinicalTrials.gov/show/NCT04456361,Mexico,,12.0,2020,Tuesday
1955,1956,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Recruiting,Drug: Icosapent ethyl (IPE)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2000.0,"August 14, 2020",2021-01-01,"November 23, 2020","Instituto de Investigaciones Clínicas - Rosario, Rosario, Santa Fe, Argentina",https://ClinicalTrials.gov/show/NCT04460651,Argentina,Icosapent ethyl (IPE)|Placebo,1.0,2021,Friday
1956,1957,PSYCHIATRIC Disorders and Covid-19,Recruiting,"Other: Brief Psychiatric Rating Scale|Other: Depression, Anxiety and Stress Scale|Other: Impact of Event Scale-Revised|Other: Connor-Davidson Resilience Scale 10 items (CD-RISC 10)",All,"15 Years and older   (Child, Adult, Older Adult)",,250.0,"April 24, 2020",2023-01-01,"July 21, 2020","Nantes University Hospital - IFAC, Nantes, France",https://ClinicalTrials.gov/show/NCT04358042,France,,1.0,2023,Sunday
1957,1958,Emotional Burden of Healthcare Professionals and Covid Infection 19,Not yet recruiting,Other: quetionnary,All,"Child, Adult, Older Adult",,200.0,"April 15, 2020",2021-06-15,"April 16, 2020","CH Esquirol, Limoges, France|CHU de Limoges, Limoges, France",https://ClinicalTrials.gov/show/NCT04350099,France,,6.0,2021,Tuesday
1958,1959,Prophylactic Ivermectin in COVID-19 Contacts,Completed,Drug: Ivermectin Tablets,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,340.0,"May 31, 2020",2020-07-27,"August 27, 2020","Zagazig University, Zagazig, Sharkia, Egypt",https://ClinicalTrials.gov/show/NCT04422561,Egypt,Ivermectin Tablets,7.0,2020,Monday
1959,1960,New Antiviral Drugs for Treatment of COVID-19,Not yet recruiting,"Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,100.0,October 2020,2022-05-01,"September 3, 2020","Mansoura University, Mansoura, Select A State Or Province, Egypt",https://ClinicalTrials.gov/show/NCT04392427,Egypt,"Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :",5.0,2022,Sunday
1960,1961,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Drug: Enoxaparin Prefilled Syringe [Lovenox],All,"up to 18 Years   (Child, Adult)",Phase 2,38.0,"June 2, 2020",2022-10-15,"July 27, 2020","Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States",https://ClinicalTrials.gov/show/NCT04354155,United States,Enoxaparin Prefilled Syringe [Lovenox],10.0,2022,Saturday
1961,1962,Ivermectin and Doxycycine in COVID-19 Treatment,Recruiting,Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,200.0,"June 1, 2020",2030-12-03,"August 4, 2020","Sherief Abd-Elsalam, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04403555,Egypt,Ivermectin|Doxycycline|Chloroquine,12.0,2030,Tuesday
1962,1963,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,Biological: blood test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"September 22, 2020",2021-03-01,"September 24, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04563676,France,,3.0,2021,Monday
1963,1964,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,"Active, not recruiting",Combination Product: INOpulse|Combination Product: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"July 12, 2020",2021-06-01,"December 1, 2020","Banner University Medical Center, Phoenix, Arizona, United States|Kaiser Permanente - Zion Medical Center, San Diego, California, United States|Kaiser Permanente - San Diego Medical Center, San Diego, California, United States|University of Miami Health System, Miami, Florida, United States|The Lung Research Center (St. Luke's), Chesterfield, Missouri, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Mercy Health St. Vincent Medical Center, Toledo, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist, Houston, Texas, United States|INOVA, Falls Church, Virginia, United States|St. Francis Medical Center, Richmond, Virginia, United States|Memorial Regional Medical Center, Richmond, Virginia, United States|Chippenham Medical Center, Richmond, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|St. Mary's Hospital, Richmond, Virginia, United States|Johnston-Willis Hospital, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT04421508,Mexico,,6.0,2021,Tuesday
1964,1965,Saved From COVID-19,Recruiting,Drug: Chloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,350.0,April 2020,2021-04-01,"April 21, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04349371,United States,Chloroquine|Placebo oral tablet,4.0,2021,Thursday
1965,1966,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,Device: Life2000® Ventilator,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"August 28, 2020",2020-10-01,"October 9, 2020","Park Nicolette, Bloomington, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04581161,United States,,10.0,2020,Thursday
1966,1967,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Drug: Remdesivir-HU,All,"12 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,2000.0,"October 12, 2020",2021-11-30,"November 27, 2020","Department of Pulmonology Semmelweis University, Budapest, Hungary|National Korányi Institute for Pulmonology, Budapest, Hungary|North - Central Buda Center New St. János Hospital, Budapest, Hungary|Institute of Infectology, University of Debrecen, Debrecen, Hungary|1st Department of Medicine, University of Pécs, Pécs, Hungary|Department of Internal Medicine University of Szeged, Szeged, Hungary|First Department of Internal Medicine, University of Szeged, Szeged, Hungary",https://ClinicalTrials.gov/show/NCT04610541,Hungary,Remdesivir-HU,11.0,2021,Tuesday
1967,1968,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER),Recruiting,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,"July 24, 2020",2025-07-01,"November 16, 2020","Miami VA Healthcare System, Miami, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04629105,United States,,7.0,2025,Tuesday
1968,1969,Evaluation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19,Recruiting,,Female,"18 Years to 90 Years   (Adult, Older Adult)",,225.0,"August 8, 2020",2022-01-23,"October 26, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04598347,Spain,,1.0,2022,Sunday
1969,1970,"Safety of TY027, a Treatment for COVID-19, in Humans","Active, not recruiting",Biological: TY027|Other: 0.9% Saline,All,21 Years to 50 Years   (Adult),Phase 1,32.0,"June 9, 2020",2021-02-01,"September 24, 2020","SingHealth Investigational Medicine Unit, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04429529,Singapore,,2.0,2021,Monday
1970,1971,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Drug: Favipiravir|Drug: Placebos,All,"Child, Adult, Older Adult",Phase 2|Phase 3,90.0,"April 20, 2020",2020-12-01,"September 29, 2020","Tanta University, Ainshams University, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04351295,Egypt,Favipiravir|Placebos,12.0,2020,Tuesday
1971,1972,COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1,Not yet recruiting,Drug: Nivolumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,15.0,"April 14, 2020",2021-08-31,"April 22, 2020",,https://ClinicalTrials.gov/show/NCT04356508,Undefined,Nivolumab,8.0,2021,Tuesday
1972,1973,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Not yet recruiting,Other: Closed face shield with Surgical face mask use|Other: Surgical face mask use only,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,233.0,December 2020,2021-03-01,"November 30, 2020",,https://ClinicalTrials.gov/show/NCT04647305,Undefined,,3.0,2021,Monday
1973,1974,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,Dietary Supplement: Vitamin C,All,"Child, Adult, Older Adult",Not Applicable,500.0,"March 13, 2020",2021-03-13,"March 26, 2020","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy",https://ClinicalTrials.gov/show/NCT04323514,Italy,,3.0,2021,Saturday
1974,1975,Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,Recruiting,,All,"Child, Adult, Older Adult",,143.0,"March 14, 2020",2020-07-31,"April 28, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France",https://ClinicalTrials.gov/show/NCT04366206,France,,7.0,2020,Friday
1975,1976,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Recruiting,Other: Biological sample and clinical data collection,All,"Child, Adult, Older Adult",,200.0,"May 6, 2020",2021-06-30,"May 12, 2020","NSW Health Pathology, Randwick, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|Blacktown Hospital, Blacktown, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|St Vincent's Hospital, Darlinghurst, Australia|Northern Beaches Hospital, Frenchs Forest, Australia|Royal North Shore Hospital, Saint Leonards, Australia|Westmead Hospital, Westmead, Australia",https://ClinicalTrials.gov/show/NCT04383652,Australia,,6.0,2021,Wednesday
1976,1977,COVID-19 Staff Testing of Antibody Responses Study (Co-Stars),Recruiting,Other: Blood test|Other: Standardised questionnaires,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 27, 2020",2026-07-27,"May 15, 2020","Great Ormond Street Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04380896,United Kingdom,,7.0,2026,Monday
1977,1978,Asymptomatic COVID-19 Trial,Withdrawn,Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo,All,"20 Years and older   (Adult, Older Adult)",Phase 2,0.0,"May 5, 2020",2021-04-01,"November 2, 2020","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04374552,Jersey,Hydroxychloroquine sulfate &Azithromycin|Placebo,4.0,2021,Thursday
1978,1979,Use of Remote Monitoring for COVID-19 Patient,Recruiting,Device: LifeSignals Biosensor 1AX*|Other: Standard of Care,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,300.0,"September 1, 2020",2021-06-01,"November 12, 2020","Montefiore Medical Center, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04425720,United States,,6.0,2021,Tuesday
1979,1980,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Recruiting,Drug: Linagliptin tablet|Drug: Insulin,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,28.0,"August 1, 2020",2020-09-30,"September 9, 2020","Hospital Regional de Alta Especialidad del Bajìo, Leòn, Guanajuato, Mexico",https://ClinicalTrials.gov/show/NCT04542213,Mexico,Linagliptin tablet|Insulin,9.0,2020,Wednesday
1980,1981,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308.0,"April 26, 2020",2021-04-26,"December 3, 2020","Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States",https://ClinicalTrials.gov/show/NCT04401293,Israel,Enoxaparin|Prophylactic/Intermediate Dose Enoxaparin,4.0,2021,Monday
1981,1982,Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.,Recruiting,Other: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",,120.0,"April 30, 2020",2021-09-30,"October 22, 2020","UniversityGrenobleHospital, Grenoble, France",https://ClinicalTrials.gov/show/NCT04596098,France,,9.0,2021,Thursday
1982,1983,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,Recruiting,Diagnostic Test: COVID-19 Antibody testing,All,"5 Years and older   (Child, Adult, Older Adult)",,8000.0,"June 16, 2020",2021-03-01,"July 21, 2020","Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04448717,Switzerland,,3.0,2021,Monday
1983,1984,Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19,Not yet recruiting,Drug: Artemisinin / Artesunate|Other: placebo,All,18 Years to 60 Years   (Adult),Phase 2,22.0,December 2020,2021-04-01,"September 17, 2020","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04387240,Saudi Arabia,Artemisinin / Artesunate,4.0,2021,Thursday
1984,1985,Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Not yet recruiting,Drug: Hydroxychloroquine|Dietary Supplement: Vitamins and Minerals|Drug: Azithromycin,All,"Child, Adult, Older Adult",Phase 1,5000.0,November 2020,2021-12-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04590274,Undefined,Hydroxychloroquine|Azithromycin,12.0,2021,Wednesday
1985,1986,"Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia",Withdrawn,Drug: HCQ|Drug: Azithromycin|Drug: Doxycycline|Dietary Supplement: Zinc,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,0.0,"May 15, 2020",2020-07-15,"August 27, 2020","Eshmoun Clinical Research Centre, Tunis, Tunisia",https://ClinicalTrials.gov/show/NCT04528927,Tunisia,HCQ|Azithromycin|Doxycycline,7.0,2020,Wednesday
1986,1987,Lung Ultrasound to Diagnose COVID-19,Recruiting,Diagnostic Test: COVID-19 RT-PCR|Procedure: lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 28, 2020",2021-09-28,"December 4, 2020","BAR, Amiens, France",https://ClinicalTrials.gov/show/NCT04368338,France,,9.0,2021,Tuesday
1987,1988,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,Other: Respiratory Training|Other: Aerobic training,All,35 Years to 45 Years   (Adult),Not Applicable,80.0,"July 2, 2020",2021-01-20,"November 3, 2020","Police hospital-Nasr city, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04613050,Egypt,,1.0,2021,Wednesday
1988,1989,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Active, not recruiting",Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2,20.0,"April 30, 2020",2020-12-01,"September 16, 2020","Prisma Health, Greenville, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04374149,United States,Ruxolitinib,12.0,2020,Tuesday
1989,1990,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine",Recruiting,"Biological: IIBR-100, low dose (prime)|Biological: IIBR-100 medium dose (prime)|Biological: IIBR-100 high-dose (prime)|Biological: IIBR-100 low-dose (prime-boost)|Other: Saline Placebo",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,1040.0,"October 28, 2020",2022-06-01,"November 3, 2020","Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel",https://ClinicalTrials.gov/show/NCT04608305,Israel,,6.0,2022,Wednesday
1990,1991,COVID-19 Biorepository,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 15, 2020",2021-12-31,"September 29, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",https://ClinicalTrials.gov/show/NCT04568148,United States,,12.0,2021,Friday
1991,1992,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,Drug: TriCor® 145mg tablets|Other: Usual Care|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,50.0,"December 13, 2020",2021-12-01,"December 10, 2020","Barzilai Medical Center, Ashkelon, Israel",https://ClinicalTrials.gov/show/NCT04661930,Israel,TriCor® 145mg tablets,12.0,2021,Wednesday
1992,1993,Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,20.0,"March 27, 2020",2020-08-31,"April 15, 2020","Department of nephrology, Klinikum rechts der Isar, München, Bavaria, Germany",https://ClinicalTrials.gov/show/NCT04347460,Germany,,8.0,2020,Monday
1993,1994,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,Recruiting,Drug: Ibrutinib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,46.0,"June 6, 2020",2021-04-16,"November 9, 2020","Desert Regional Medical Center /ID# 224276, Palm Springs, California, United States|Stanford Univ School Medicine /ID# 221954, Stanford, California, United States|Medstar Washington Hospital Center /ID# 221886, Washington, District of Columbia, United States|GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States|Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States|University of Miami /ID# 223227, Miami, Florida, United States|Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States|Brigham & Women's Hospital /ID# 221847, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 222994, Boston, Massachusetts, United States|Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04375397,Israel,Ibrutinib|Placebo,4.0,2021,Friday
1994,1995,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Recruiting,Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua|Drug: Artesunate,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240.0,"May 1, 2020",2021-05-01,"November 6, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04374019,United States,Ivermectin|Camostat Mesilate|Artesunate,5.0,2021,Saturday
1995,1996,Cardiac Imaging in SARS-CoV-2 (COVID-19),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,180.0,"May 22, 2020",2021-08-01,"August 6, 2020","Royal Alexandra Hospital, Paisley, Renfrewshire, United Kingdom|Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom",https://ClinicalTrials.gov/show/NCT04403607,United Kingdom,,8.0,2021,Sunday
1996,1997,Tocilizumab Treatment in Patients With COVID-19,"Active, not recruiting",Drug: Tocilizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,200.0,"June 1, 2020",2021-08-01,"November 30, 2020","National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",https://ClinicalTrials.gov/show/NCT04363853,Mexico,Tocilizumab,8.0,2021,Sunday
1997,1998,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,Drug: Ciclesonide Inhalation Aerosol,All,"18 Years and older   (Adult, Older Adult)",Phase 2,446.0,"May 29, 2020",2020-12-31,"August 24, 2020","Danderyd Hospital, Danderyd, Sweden|Capio S:t Görans Hospital, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Visby Hospital, Visby, Sweden|Västmanland County Hospital Västerås, Västerås, Sweden|Örebro University Hospital, Örebro, Sweden",https://ClinicalTrials.gov/show/NCT04381364,Sweden,Ciclesonide Inhalation Aerosol,12.0,2020,Thursday
1998,1999,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Completed,,All,"18 Years to 99 Years   (Adult, Older Adult)",,13.0,"March 27, 2020",2020-05-27,"June 22, 2020","Centre Hospitalier Princesse Grace, Monaco, Monaco",https://ClinicalTrials.gov/show/NCT04441489,Monaco,,5.0,2020,Wednesday
1999,2000,Rapid Detection of COVID-19 by Portable and Connected Biosensor,Not yet recruiting,Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: Biosensor,All,"Child, Adult, Older Adult",,200.0,September 2020,2020-12-01,"July 7, 2020",,https://ClinicalTrials.gov/show/NCT04367142,Undefined,,12.0,2020,Tuesday
2000,2001,EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19,Not yet recruiting,,All,"Child, Adult, Older Adult",,2000.0,"May 1, 2020",2022-04-30,"April 28, 2020",,https://ClinicalTrials.gov/show/NCT04364711,Undefined,,4.0,2022,Saturday
2001,2002,Sustained Immunity to SARS-CoV-2,Recruiting,Diagnostic Test: Serologic immunoassays to SARS-CoV-2 antibodies,All,"18 Years and older   (Adult, Older Adult)",,500.0,"June 23, 2020",2021-06-01,"September 24, 2020","Henry Ford Health System, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04562285,United States,,6.0,2021,Tuesday
2002,2003,Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,Not yet recruiting,Biological: Covax-19™,All,18 Years to 60 Years   (Adult),Phase 1,32.0,July 2020,2021-12-01,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04428073,Undefined,,12.0,2021,Wednesday
2003,2004,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Active, not recruiting",Other: blood sample,All,"Child, Adult, Older Adult",Not Applicable,1000.0,"March 16, 2020",2021-10-16,"December 1, 2020","Hopital Pitié Salpetrière, Paris, France",https://ClinicalTrials.gov/show/NCT04304690,France,,10.0,2021,Saturday
2004,2005,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Recruiting,Drug: Inhaled ILOPROST,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"May 23, 2020",2021-05-31,"June 24, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04445246,Qatar,Inhaled ILOPROST,5.0,2021,Monday
2005,2006,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Recruiting,Drug: Cholecalciferol,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,400.0,"July 15, 2020",2021-07-01,"September 2, 2020","Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico",https://ClinicalTrials.gov/show/NCT04535791,Mexico,Cholecalciferol,7.0,2021,Thursday
2006,2007,Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19),Not yet recruiting,,All,"11 Years and older   (Child, Adult, Older Adult)",,30.0,May 2020,2020-12-01,"April 27, 2020","Maison de Solenn, Cochin Hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04363671,France,,12.0,2020,Tuesday
2007,2008,Emergency Department (ED) Self-Monitoring Pilot COVID-19,Not yet recruiting,Other: Symptoms entered into the CovidX application,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,December 2020,2021-04-01,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04462783,Undefined,,4.0,2021,Thursday
2008,2009,Use of Convalescent Plasma for COVID-19,Recruiting,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,700.0,"July 14, 2020",2022-07-31,"July 28, 2020","Northside Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04408040,Georgia,,7.0,2022,Sunday
2009,2010,Sarilumab for Patients With Moderate COVID-19 Disease,Recruiting,Biological: SARILUMAB,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"April 10, 2020",2023-04-01,"September 11, 2020","VA Connecticut Healthcare System, West Haven, Connecticut, United States|VA Maine Healthcare System, Augusta, Maine, United States|VA Boston Healthcare System, Boston, Massachusetts, United States|Providence VA Medical Center, Providence, Rhode Island, United States|VA Medical Center - White River Junction, White River Junction, Vermont, United States",https://ClinicalTrials.gov/show/NCT04359901,United States,,4.0,2023,Saturday
2010,2011,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Drug: Favipiravir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,190.0,"August 1, 2020",2020-11-01,"August 19, 2020","Alfred Health, Melbourne, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04445467,Australia,Favipiravir,11.0,2020,Sunday
2011,2012,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy,Completed,Behavioral: COVID-surgRES questionaire,All,"18 Years and older   (Adult, Older Adult)",,800.0,"March 15, 2020",2020-05-01,"July 27, 2020","U.O.C. Chirurgia Generale Universitaria ""V. Bonomo"", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy",https://ClinicalTrials.gov/show/NCT04338945,Italy,,5.0,2020,Friday
2012,2013,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",Drug: Vit D,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"June 15, 2020",2020-09-10,"August 27, 2020","Deptt of Endocrinology, Chandigarh, India",https://ClinicalTrials.gov/show/NCT04459247,India,Vit D,9.0,2020,Thursday
2013,2014,COVID-19 Progression in End-Stage Kidney Disease,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,1000.0,"August 6, 2020",2021-03-01,"October 14, 2020","DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04495907,United States,,3.0,2021,Monday
2014,2015,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",Not yet recruiting,Drug: Ivermectin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66.0,June 2020,2020-10-01,"May 29, 2020",,https://ClinicalTrials.gov/show/NCT04407507,Undefined,Ivermectin|Placebo,10.0,2020,Thursday
2015,2016,Acquiring Convalescent Specimens for COVID-19 Antibodies,Recruiting,Procedure: Blood draw,All,"18 Years to 65 Years   (Adult, Older Adult)",,50.0,"March 25, 2020",2021-03-01,"July 9, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04342195,United States,,3.0,2021,Monday
2016,2017,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Recruiting,Biological: Convalescent Plasma|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"June 14, 2020",2021-05-30,"September 3, 2020","Maulana Azad Medical College, New Delhi, Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, Delhi, India|Rajiv Gandhi Super Speciality Hospital, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04425915,India,,5.0,2021,Sunday
2017,2018,SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling,Recruiting,Biological: Saliva collection|Other: Clinical assessment,All,"18 Years and older   (Adult, Older Adult)",,600.0,"July 23, 2020",2022-07-01,"August 17, 2020","Hôpital d'Instruction des Armées Laveran, Marseille, France",https://ClinicalTrials.gov/show/NCT04460638,France,,7.0,2022,Friday
2018,2019,Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers,Not yet recruiting,Biological: RUTI® vaccine|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,315.0,"July 30, 2020",2020-12-01,"July 29, 2020","Hospital Universitari Germans Trias i Pujol UBP Riscos Laborals, Badalona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04453488,Spain,,12.0,2020,Tuesday
2019,2020,The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Recruiting,Drug: Ivermectin|Drug: Nitazoxanide with ivermectin|Drug: Ivermectin wth chloroquine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,300.0,"June 16, 2020",2030-12-01,"August 4, 2020","Tanta University, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04351347,Egypt,Ivermectin|Nitazoxanide with ivermectin|Ivermectin wth chloroquine,12.0,2030,Sunday
2020,2021,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,Enrolling by invitation,Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2,All,"Child, Adult, Older Adult",,30000.0,"April 15, 2020",2021-08-01,"September 25, 2020","Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, København NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center København, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|Børne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hillerød, Denmark|Psykiatrisk Center Nordsjælland, Hillerød, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, Rønne, Denmark|Psykiatrisk Center Bornholm, Rønne, Denmark",https://ClinicalTrials.gov/show/NCT04346186,Denmark,,8.0,2021,Sunday
2021,2022,Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2 ),Not yet recruiting,Diagnostic Test: RT-PCR SARS-Cov2|Diagnostic Test: Sars-Cov2 serology,All,up to 15 Years   (Child),,630.0,"June 7, 2020",2020-11-15,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04416893,Undefined,,11.0,2020,Sunday
2022,2023,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Recruiting,Dietary Supplement: 300 mg of omega3-FA,All,"35 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"December 5, 2020",2021-03-30,"December 8, 2020","Mahmoud S Abu-Samak, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04658433,Jordan,,3.0,2021,Tuesday
2023,2024,Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?,Enrolling by invitation,Dietary Supplement: vitamin d,All,"Child, Adult, Older Adult",,100.0,"May 1, 2020",2020-06-30,"May 19, 2020","Bursa City Hospital, Bursa, Dogankoy, Turkey",https://ClinicalTrials.gov/show/NCT04394390,Turkey,,6.0,2020,Tuesday
2024,2025,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,164.0,"May 29, 2020",2021-12-01,"August 20, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04344600,United States,Peginterferon lambda alfa-1a subcutaneous injection,12.0,2021,Wednesday
2025,2026,Maternal-foetal Transmission of SARS-Cov-2,Recruiting,"Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta",Female,18 Years to 48 Years   (Adult),,50.0,"May 5, 2020",2021-05-01,"June 4, 2020","CHR Orléans, Orléans, France",https://ClinicalTrials.gov/show/NCT04395924,France,,5.0,2021,Saturday
2026,2027,A Study of Immune Responses to the Virus That Causes COVID-19,Recruiting,Other: Sample collection,All,"18 Years and older   (Adult, Older Adult)",,800.0,"July 20, 2020",2021-01-01,"December 7, 2020","Alabama CRS, Birmingham, Alabama, United States|Bridge HIV CRS, San Francisco, California, United States|University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS, Miami, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health (FH) CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|Fundacion Huesped CRS, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejía CRS, Buenos Aires, Argentina|Gaborone CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Kisumu Crs, Kisumu, Kenya|Malawi CRS, Lilongwe, Malawi|Merida CRS, Mérida, Mexico|Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS, Maputo, Mozambique|CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista, Peru|Asociacion Civil Selva Amazonica (ASCA) CRS, Iquitos, Peru|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|Via Libre CRS, Lima, Peru|Groote Schuur HIV CRS, Cape Town, South Africa|Khayelitsha CRS / (CIDRI UCT), Cape Town, South Africa|Masiphumelele Clinical Research Site (MASI) CRS, Cape Town, South Africa|Chatsworth CRS, Chatsworth, South Africa|Botha's Hill CRS, Durban, South Africa|CAPRISA eThekwini CRS, Durban, South Africa|Vulindlela CRS, Durban, South Africa|Ndlovu Research Centre CoVPN CRS, Elandsdoorn, South Africa|Isipingo CRS, Isipingo, South Africa|Kliptown Soweto CRS, Johannesburg, South Africa|Soweto HVTN CRS, Johannesburg, South Africa|Aurum Institute Klerksdorp CRS, Klerksdorp, South Africa|Qhakaza Mbokodo Research Clinic CRS, Ladysmith, South Africa|MeCRU CRS, Medunsa, South Africa|Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa|Rustenburg CRS, Rustenburg, South Africa|Setshaba Research Centre CRS, Soshanguve, South Africa|Tembisa Clinic 4 CoVPN CRS, Tembisa, South Africa|Tongaat CRS, Tongaat, South Africa|Verulam CRS, Verulam, South Africa|National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya, Tanzania|Matero Reference Clinic CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Lusaka CoVPN CRS, Lusaka, Zambia|Zambia Emory HIV Research Project - Ndola CoVPN CRS, Ndola, Zambia|St Mary's CRS, Chitungwiza, Zimbabwe|Milton Park CRS, Harare, Zimbabwe|Seke South CRS, Harare, Zimbabwe",https://ClinicalTrials.gov/show/NCT04431414,Argentina,,1.0,2021,Friday
2027,2028,Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 10, 2020",2021-06-01,"August 10, 2020","Groupe Hospitalier de Mulhouse et de la Région Sud-Alsace, Mulhouse, Alsace, France|Centre Hospitalier de la Côte Basque - Bayonne, Bayonne, France|Centre Hospitalier Métropole Savoie, Chambéry, France|Centre Hospitalier Colmar, Colmar, France|Centre Hospitalier Douai, Douai, France|Centre Hospitalier de Dunkerque, Dunkerque, France|Centre Hospitalier Départemental Vendée - La Roche sur Yon, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|Centre Hospitalier Robert Boulin - Libourne, Libourne, France|Centre Hospitalier Annecy Genevois, Metz-Tessy, France|Centre Hospitalier Régional Metz-Thioville, Metz, France|Centre Hospitalier Le Raincy Montfermeil, Montfermeil, France|Centre Hospitalier Régional Orléans, Orléans, France|Centre Hospitalier de Soissons, Soissons, France",https://ClinicalTrials.gov/show/NCT04505631,France,,6.0,2021,Tuesday
2028,2029,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Drug: Chloroquine|Drug: zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"June 23, 2020",2030-10-01,"December 3, 2020","Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04447534,Egypt,Chloroquine|zinc,10.0,2030,Tuesday
2029,2030,WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories,Recruiting,Other: Equipment with smartwatch throughout hospital stay on the general ward,All,"18 Years to 120 Years   (Adult, Older Adult)",,100.0,"May 1, 2020",2021-12-31,"November 5, 2020","Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04357834,Switzerland,,12.0,2021,Friday
2030,2031,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome,Recruiting,Device: Extracorporeal membrane oxygenation,All,"Child, Adult, Older Adult",,200.0,"March 1, 2020",2020-12-31,"May 21, 2020","Helsinki University Hospital, Helsinki, Finland|University Hospital Jean Minjoz, Besançon, France|Nancy University Hospital, Nancy, France|Henri Mondon Unoversity Hospital, Paris, France|Robert Debré University Hospital, Reims, France|Hamburg University Heart Center, Hamburg, Germany|Münster University Hospital, Münster, Germany|S. Orsola Hospital, Bologna, Italy|Lecco Hospital, Lecco, Italy|Karolinska University Hospital, Stockholm, Sweden|University Hospitals of Leicester, Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04383678,Finland,,12.0,2020,Thursday
2031,2032,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Recruiting,Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,30.0,"March 15, 2020",2020-06-10,"May 22, 2020","Outpatient treatment, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04399746,Mexico,Ivermectin|Azithromycin|Cholecalciferol,6.0,2020,Wednesday
2032,2033,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Active, not recruiting",Drug: Hydroxychloroquine Sulfate (HCQ),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,44.0,"April 14, 2020",2021-04-08,"June 9, 2020","Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04345653,Jersey,Hydroxychloroquine Sulfate (HCQ),4.0,2021,Thursday
2033,2034,Oscillation and Lung Expansion Therapy in Patients With COVID-19,Recruiting,Device: MetaNeb® System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"September 28, 2020",2021-01-01,"October 9, 2020","Emory University, Atlanta, Georgia, United States|Northwestern University, Evanston, Illinois, United States",https://ClinicalTrials.gov/show/NCT04582214,Georgia,,1.0,2021,Friday
2034,2035,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Recruiting,Drug: Pirfenidone|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,148.0,"August 1, 2020",2021-08-01,"November 5, 2020","University Hospital of Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital La Princes, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04607928,Spain,Pirfenidone|Placebo,8.0,2021,Sunday
2035,2036,IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.,Recruiting,Diagnostic Test: Clungene rapid test cassette,All,"18 Years and older   (Adult, Older Adult)",,90.0,"May 5, 2020",2020-12-01,"July 27, 2020","Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04402814,United States,,12.0,2020,Tuesday
2036,2037,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,"Active, not recruiting",Diagnostic Test: COVID 19 Diagnostic Test,All,"Child, Adult, Older Adult",,2500.0,"May 25, 2020",2020-08-31,"June 4, 2020","Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04416061,Hong Kong,,8.0,2020,Monday
2037,2038,Primary Prevention of Infection by COVID-19 in Health Providers,Not yet recruiting,Dietary Supplement: Group A: oropharygeal spray and immunostimulant|Dietary Supplement: Group B: Placebo oropharyngeal spray + Active principle immunostimulant|Dietary Supplement: Group C:Active principle oropharyngeal spray + Placebo taken PO|Dietary Supplement: Group D:Placebo oropharyngeal spray + Placebo taken PO,All,18 Years to 60 Years   (Adult),Not Applicable,300.0,July 2020,2020-09-01,"June 9, 2020",,https://ClinicalTrials.gov/show/NCT04420260,Undefined,,9.0,2020,Tuesday
2038,2039,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Completed,Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 4,240.0,"July 15, 2020",2020-10-30,"November 12, 2020","15th May Hospital, Helwan, Cairo, Egypt|Assiut University Hospital, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04498936,Egypt,Sofosbuvir and Ledipasvir|Nitazoxanide,10.0,2020,Friday
2039,2040,HYPONATREMIA IN COVID-19 PATIENTS,Completed,,All,"1 Month to 100 Years   (Child, Adult, Older Adult)",,250.0,"March 7, 2020",2020-07-21,"July 30, 2020","Hospital Posadas, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04493268,Argentina,,7.0,2020,Tuesday
2040,2041,Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS,Not yet recruiting,Drug: Rapamycin|Drug: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,January 2021,2023-01-01,"November 30, 2020","University Hospital System, San Antonio, Texas, United States|Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04482712,United States,Rapamycin|Placebo,1.0,2023,Sunday
2041,2042,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,Not yet recruiting,Behavioral: Tele-delivered psychological intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,June 2020,2022-02-01,"June 1, 2020",,https://ClinicalTrials.gov/show/NCT04409821,Undefined,,2.0,2022,Tuesday
2042,2043,Mother-infant Bonding During COVID-19,Recruiting,Behavioral: Family Nurture Intervention (FNI),All,up to 72 Hours   (Child),Not Applicable,280.0,"August 13, 2020",2021-12-01,"August 31, 2020","Morgan Stanley Children's Hopspital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04531618,United States,,12.0,2021,Wednesday
2043,2044,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,Procedure: Ophthalmologic exam,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23.0,"April 27, 2020",2020-07-29,"November 16, 2020","Fondation Adolphe de Rothschild, Paris, France",https://ClinicalTrials.gov/show/NCT04385810,France,,7.0,2020,Wednesday
2044,2045,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Not yet recruiting,Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,466.0,"August 1, 2020",2022-08-01,"July 31, 2020","Yale New Haven Hosptial System, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04472611,United States,Standard of Care (SOC) and Colchicine+Rosuvastatin,8.0,2022,Monday
2045,2046,Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,Drug: Hydroxychloroquine|Other: Placebo,All,"19 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,58.0,"April 17, 2020",2020-07-08,"August 20, 2020","University of South Alabama, Mobile, Alabama, United States",https://ClinicalTrials.gov/show/NCT04353271,United States,Hydroxychloroquine,7.0,2020,Wednesday
2046,2047,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,Completed,Diagnostic Test: SARS-CoV-2 Ab,All,"Child, Adult, Older Adult",,100.0,"March 30, 2020",2020-06-30,"July 21, 2020","AOU Cagliari, Cagliari, CA, Italy",https://ClinicalTrials.gov/show/NCT04480580,Italy,,6.0,2020,Tuesday
2047,2048,Efficacy of Tocilizumab on Patients With COVID-19,"Active, not recruiting",Drug: Tocilizumab|Drug: Placebos,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,243.0,"April 20, 2020",2020-10-01,"August 24, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04356937,United States,Tocilizumab|Placebos,10.0,2020,Thursday
2048,2049,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,Diagnostic Test: Peripheral venous ultrasound,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"August 4, 2020",2021-09-15,"November 5, 2020","Clinique Saint-Jean, Cagnes-sur-Mer, Alpes-Maritimes, France|Centre Azuréen de Cancérologie, Mougins, Alpes-Maritimes, France|CHU Nice, Nice, Alpes-Maritimes, France|Clinique Saint-Georges, Nice, Alpes-Maritimes, France|Centre Antoine Lacassagne, Nice, Alpes-Maritimes, France|CHPG, Monaco, Monaco",https://ClinicalTrials.gov/show/NCT04616846,France,,9.0,2021,Wednesday
2049,2050,Differential Leucocyte Count and Covid-19 Diagnosis,Not yet recruiting,Diagnostic Test: Differential Leucocyte Count (CLDC) device and algorithm,All,"18 Years and older   (Adult, Older Adult)",,1000.0,December 2020,2021-05-01,"November 30, 2020","IRCCS INM Neuromed, Department of Epidemiology and Prevention, Pozzilli, IS, Italy",https://ClinicalTrials.gov/show/NCT04643860,Italy,,5.0,2021,Saturday
2050,2051,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"September 1, 2020",2022-09-01,"September 18, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04554264,France,,9.0,2022,Thursday
2051,2052,"COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,May 2020,2020-05-01,"May 7, 2020","GastroMuñoz, Guayaquil, Guayas, Ecuador",https://ClinicalTrials.gov/show/NCT04362969,Ecuador,,5.0,2020,Friday
2052,2053,Acute Kidney Injury in Patients Hospitalized With COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,287.0,"February 26, 2020",2020-03-08,"March 30, 2020","Hankou Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04316299,China,,3.0,2020,Sunday
2053,2054,RGD PET/CT Imaging in COVID-19 Patients,Recruiting,Diagnostic Test: [68Ga]Ga-DOTA-(RGD)2 PET/CT,All,"18 Years and older   (Adult, Older Adult)",,10.0,"October 15, 2020",2021-01-30,"October 22, 2020","Radboudumc, Nijmegen, Netherlands",https://ClinicalTrials.gov/show/NCT04596943,Netherlands,,1.0,2021,Saturday
2054,2055,Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 17, 2020",2020-07-01,"June 1, 2020","Hospital Clínico San Carlos, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04403932,Spain,,7.0,2020,Wednesday
2055,2056,COVID-19 Pandemic and Parents of Disabled Children,Completed,Other: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,309.0,"July 5, 2020",2020-09-15,"November 3, 2020","Health Science University Gaziosmanpasa Training and Research Hospital, İstanbul, Gaziosmanpasa, Turkey",https://ClinicalTrials.gov/show/NCT04525742,Turkey,,9.0,2020,Tuesday
2056,2057,"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",Not yet recruiting,Drug: Tocilizumab Injection|Drug: Deferoxamine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,260.0,"September 4, 2020",2020-10-04,"August 27, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",https://ClinicalTrials.gov/show/NCT04361032,Tunisia,Tocilizumab Injection|Deferoxamine,10.0,2020,Sunday
2057,2058,COVID-19 Search in Conjunctival Cells,Completed,Diagnostic Test: conjunctival swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"March 26, 2020",2020-05-30,"July 23, 2020","Maria Cristina Savastano, Roma, Italy",https://ClinicalTrials.gov/show/NCT04364594,Italy,,5.0,2020,Saturday
2058,2059,The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease,Recruiting,Other: Interview,All,"18 Years and older   (Adult, Older Adult)",,800.0,"April 24, 2020",2021-03-30,"May 13, 2020","KeimyungUniversity, Daegu, Jung-gu, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04387279,"Korea, Republic of",,3.0,2021,Tuesday
2059,2060,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,Completed,Behavioral: Online support Group,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,32.0,"April 3, 2020",2020-08-31,"December 1, 2020","Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04379661,United States,,8.0,2020,Monday
2060,2061,Outcomes of Patients With COVID-19 in the Intensive Care Unit,Completed,,All,"18 Years and older   (Adult, Older Adult)",,150.0,"April 1, 2020",2020-06-04,"November 10, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico",https://ClinicalTrials.gov/show/NCT04336345,Mexico,,6.0,2020,Thursday
2061,2062,EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up,Recruiting,Device: EarSats Pulse Oximeter Probe,All,"18 Years and older   (Adult, Older Adult)",,60.0,"August 26, 2020",2020-08-26,"August 27, 2020","Imperial College Healthcare NHS Trust, London, Non-US/Non-Canadian, United Kingdom",https://ClinicalTrials.gov/show/NCT04529408,United Kingdom,,8.0,2020,Wednesday
2062,2063,Baricitinib Compared to Standard Therapy in Patients With COVID-19,Not yet recruiting,Drug: Baricitinib Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"May 20, 2020",2020-07-30,"May 20, 2020","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",https://ClinicalTrials.gov/show/NCT04393051,Italy,Baricitinib Oral Tablet,7.0,2020,Thursday
2063,2064,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,Recruiting,Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire,All,18 Years to 62 Years   (Adult),,900.0,"May 14, 2020",2020-07-31,"June 9, 2020","Hôpital d'Instuction des Armées Sainte-Anne, Toulon, France|Hôpital d'Instruction des Armées Robert Picqué, Villenave-d'Ornon, France",https://ClinicalTrials.gov/show/NCT04387838,France,,7.0,2020,Friday
2064,2065,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Recruiting,Biological: Convalescent Plasma from COVID-19 donors,All,"15 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,100.0,"April 7, 2020",2021-04-06,"May 12, 2020","Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile",https://ClinicalTrials.gov/show/NCT04384588,Chile,,4.0,2021,Tuesday
2065,2066,Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study,Recruiting,,All,"18 Years to 75 Years   (Adult, Older Adult)",,200.0,"April 28, 2020",2021-05-30,"June 9, 2020","Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, India",https://ClinicalTrials.gov/show/NCT04368871,India,,5.0,2021,Sunday
2066,2067,Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva Sample,Not yet recruiting,Diagnostic Test: TestNPass,All,"18 Years and older   (Adult, Older Adult)",,60.0,"December 15, 2020",2021-03-15,"December 8, 2020","Grenoble University Hospital, Grenoble cedex 9, France",https://ClinicalTrials.gov/show/NCT04654442,France,,3.0,2021,Monday
2067,2068,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Recruiting,Biological: BCG vaccine (Freeze-dried),All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 3,2175.0,"July 1, 2020",2021-05-01,"July 23, 2020","Tuberculosis Research Centre, Chennai, Tamilnadu, India",https://ClinicalTrials.gov/show/NCT04475302,India,,5.0,2021,Saturday
2068,2069,Convalescent Plasma vs. Standard Plasma for COVID-19,Enrolling by invitation,Biological: Convalescent Plasma|Biological: Standard Donor Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,500.0,"April 8, 2020",2021-08-31,"April 17, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04344535,United States,,8.0,2021,Tuesday
2069,2070,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",Recruiting,Biological: avdoralimab|Other: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,168.0,"April 27, 2020",2020-12-31,"October 23, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04371367,France,,12.0,2020,Thursday
2070,2071,Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff,Recruiting,Other: Clinical interview|Biological: Blood collection|Biological: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",,800.0,"June 4, 2020",2021-06-04,"June 9, 2020","Hôpital d'Instuction des Armées Percy, Clamart, France",https://ClinicalTrials.gov/show/NCT04408001,France,,6.0,2021,Friday
2071,2072,Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to COVID 19,Completed,Diagnostic Test: clinical features and laboratory values,All,"18 Years and older   (Adult, Older Adult)",,445.0,"March 22, 2020",2020-12-08,"December 9, 2020","Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey",https://ClinicalTrials.gov/show/NCT04659876,Turkey,,12.0,2020,Tuesday
2072,2073,Registry of Sustained Immunity to COVID-19 Among ESKD Patients,"Active, not recruiting",,All,"18 Years to 80 Years   (Adult, Older Adult)",,2504.0,"July 20, 2020",2021-03-01,"August 27, 2020","DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04495764,United States,,3.0,2021,Monday
2073,2074,Prediction of Acute Kidney Injury in Patients With COVID-19,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"May 25, 2020",2021-03-01,"May 28, 2020","University Hospital Münster, Münster, Germany",https://ClinicalTrials.gov/show/NCT04406688,Germany,,3.0,2021,Monday
2074,2075,Anakinra for COVID-19 Respiratory Symptoms,Suspended,Drug: Anakinra plus oSOC|Drug: oSOC,All,"18 Years and older   (Adult, Older Adult)",Phase 3,71.0,"April 27, 2020",2020-11-03,"October 27, 2020","CHRU de TOURS, Tours, France",https://ClinicalTrials.gov/show/NCT04364009,France,Anakinra plus oSOC|oSOC,11.0,2020,Tuesday
2075,2076,Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors,Not yet recruiting,"Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC|Drug: Placebo",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,422.0,December 2020,2021-09-01,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04615949,Undefined,"Cannabidiol, pharmaceutically produced with < 5 ppm THC|Placebo",9.0,2021,Wednesday
2076,2077,Lessening Organ Dysfunction With VITamin C - COVID-19,Recruiting,Drug: Vitamin C|Drug: Control,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,"August 14, 2020",2022-01-01,"August 18, 2020","Research Center of the CHUS, Sherbrooke, Quebec, Canada|Research Centre of the CHUS, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04401150,Canada,Vitamin C|Control,1.0,2022,Saturday
2077,2078,Femoral frACturEs and COVID-19.,Recruiting,Other: COVID-19,All,"45 Years and older   (Adult, Older Adult)",,140.0,"November 14, 2020",2020-12-31,"December 8, 2020","IRCCS Istituto Ortopedico Galeazzi, Milano, Italy",https://ClinicalTrials.gov/show/NCT04657510,Italy,,12.0,2020,Thursday
2078,2079,Evaluation of Antibody Tests for COVID-19,Completed,Diagnostic Test: Diagnostic test,All,"18 Years and older   (Adult, Older Adult)",,461.0,"April 23, 2020",2020-07-08,"August 20, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04360954,United States,,7.0,2020,Wednesday
2079,2080,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1000.0,"April 3, 2020",2022-04-01,"April 10, 2020","Gustave Roussy, Villejuif, Val De Marne, France",https://ClinicalTrials.gov/show/NCT04341207,France,Hydroxychloroquine|Azithromycin,4.0,2022,Friday
2080,2081,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110),Recruiting,Diagnostic Test: Anti-SARS-CoV2 Serology|Behavioral: Questionnaire|Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"May 26, 2020",2021-02-01,"June 9, 2020","24e antenne médicale de Creil, Creil, France",https://ClinicalTrials.gov/show/NCT04404270,France,,2.0,2021,Monday
2081,2082,"Efficacy, Safety, and Immunogenicity of an Inactivated Vaccine Against COVID-19 in High Infection Risk Adults",Recruiting,Biological: SARS-CoV-2 inactivated vaccine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2300.0,"November 27, 2020",2022-03-01,"December 3, 2020","Centro de Especialidades Médicas, Red de Salud UC Christus, Santiago, RM, Chile",https://ClinicalTrials.gov/show/NCT04651790,Chile,,3.0,2022,Tuesday
2082,2083,Surgical Telemedicine in the COVID-19 Pandemic Era,Completed,Other: Completion of pre-pandemic survey|Other: Completion of survey after peak of pandemic|Other: Completion of post telemedicine encounter survey,All,"31 Days to 18 Years   (Child, Adult)",,180.0,"July 1, 2020",2020-10-01,"October 28, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT04376710,United States,,10.0,2020,Thursday
2083,2084,Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS,Not yet recruiting,Biological: Human umbilical cord mesenchymal stem cells + best supportive care|Other: Placebo control + best supportive care,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,39.0,"February 1, 2021",2021-12-30,"November 27, 2020",,https://ClinicalTrials.gov/show/NCT04452097,Undefined,,12.0,2021,Thursday
2084,2085,Understanding COVID-19,Recruiting,Other: NA (no intervention),All,"Child, Adult, Older Adult",,250.0,"March 27, 2020",2022-03-31,"April 13, 2020","University Hospitals of Geneva, Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04329546,Switzerland,,3.0,2022,Thursday
2085,2086,LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia,Not yet recruiting,Drug: LB1148|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"October 31, 2020",2021-03-31,"September 2, 2020",,https://ClinicalTrials.gov/show/NCT04390217,Undefined,LB1148|Placebo,3.0,2021,Wednesday
2086,2087,Use of UC-MSCs for COVID-19 Patients,Completed,Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,"April 25, 2020",2020-10-31,"November 12, 2020","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04355728,United States,,10.0,2020,Saturday
2087,2088,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,Recruiting,Other: Lung CT scan analysis in COVID-19 patients,All,"18 Years and older   (Adult, Older Adult)",,500.0,"May 7, 2020",2021-06-15,"November 9, 2020","Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino",https://ClinicalTrials.gov/show/NCT04395482,Italy,,6.0,2021,Tuesday
2088,2089,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Active, not recruiting",Drug: Treamid|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"September 8, 2020",2020-11-01,"November 18, 2020","State Federal-Funded Educational Institution of Higher Professional Training ""Kazan State Medical University"" of the Ministry of Health Care and Social Development of the Russian Federation, Kazan, Russian Federation|Federal State-Funded Research Institution ""Research Institute of Complex Cardiovascular Diseases"", Kemerovo, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training ""Kemerovo State Medical University"" of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russian Federation|SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation|State Federal-Funded Institution of Health Care of the city of Moscow ""City Clinical Hospital named after M.E. Zhadkevich of the Moscow City Health Department"", Moscow, Russian Federation|Moscow State Medical-Dentist University n.a. A.I. Evdokimov on basis of SMHI ""City Hospital № 62"", branch 5, Moscow, Russian Federation|State Budgetary Institution of Healthcare ""Leningrad region Clinical Hospital"", Saint Petersburg, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training ""Saratov State Medical University named after V.I. Razumovsky"" of the Ministry of Healthcare of the Russian Federation, Saratov, Russian Federation|State Federal-Funded Institution of Health Care ""Republican Clinical Hospital named after G.G. Kuvatov"", Ufa, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training ""Bashkir State Medical University"" of the Ministry of Healthcare of the Russian Federation, Ufa, Russian Federation|State Federal-Funded Educational Institution of Higher Professional Training ""Volgograd State Medical University"" of the Ministry of Healthcare of the Russian Federation, Volgograd, Russian Federation|State autonomous healthcare institution of Yaroslavl Region ""Сlinical hospital for emergency medical care n. a. N.V. Solovyov"", Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04527354,Russian Federation,Treamid|Placebo,11.0,2020,Sunday
2089,2090,QuadraMune(TM) for Prevention of COVID-19,Recruiting,Dietary Supplement: QuadraMune(TM),All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,500.0,"June 8, 2020",2020-11-08,"June 9, 2020","Therapeutic Solutions International, Oceanside, California, United States",https://ClinicalTrials.gov/show/NCT04421391,United States,,11.0,2020,Sunday
2090,2091,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Not yet recruiting,Biological: Mesenchymal Stromal Cells|Other: Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30.0,December 2020,2022-09-01,"November 12, 2020","Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04345601,United States,,9.0,2022,Thursday
2091,2092,Semen Parameters and COVID-19 in Infertile Men,Completed,Other: Clinical assessment,Male,18 Years to 40 Years   (Adult),,21.0,"January 7, 2020",2020-10-10,"November 30, 2020","Ankara City Hospital, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04643522,Turkey,,10.0,2020,Saturday
2092,2093,Correlation Fear of COVID-19 & Dental Treatment Anxiety,Completed,Other: Cross Sectional study using scientifically validated psychometric Scales,All,"20 Years and older   (Adult, Older Adult)",,385.0,"June 16, 2020",2020-07-25,"August 4, 2020","Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04497818,Saudi Arabia,,7.0,2020,Saturday
2093,2094,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",Recruiting,Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody),All,"15 Years to 45 Years   (Child, Adult)",Phase 1,40.0,"June 5, 2020",2020-12-11,"June 22, 2020","Huashan Hospital affiliated to Fudan University, Shanghai, China",https://ClinicalTrials.gov/show/NCT04441918,China,,12.0,2020,Friday
2094,2095,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,Recruiting,Drug: Pacritinib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,364.0,"May 22, 2020",2021-10-31,"December 4, 2020","St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California, United States|Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|St. Vincent Medical Group, Inc, Indianapolis, Indiana, United States|St. Agnes Healthcare, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Ascension Providence Hospital - Novi Campus, Novi, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Overlook Medical Center, Morristown, New Jersey, United States|Chilton Medical Center, Pompton Plains, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States|Ascension All Saints, Racine, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04404361,Georgia,Pacritinib|Placebo,10.0,2021,Sunday
2095,2096,LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID),Recruiting,,All,"Child, Adult, Older Adult",,200.0,"April 21, 2020",2020-12-31,"October 22, 2020","Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|H. Clínica Benidorm, Benidorm, Alicante, Spain|Hospital de Elche, Elche, Alicante, Spain|Hospital General Universitario de Elda, Elda, Alicante, Spain|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Cetir Centre Mèdic, Esplugues De Llobregat, Barcelona, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain|Complejo Hospitalario de la Coruña, La Coruña, Coruña, Spain|H. Insular de Gran Canarias, Las Palmas De Gran Canaria, Gran Canarias, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario de Móstoles, Móstoles, Madrid, Spain|Hospital de Manacor, Manacor, Mallorca, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Instituto Onkologikoa, San Sebastián, País Vasco, Spain|Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|H. Universitario de Canarias, La Laguna, Tenerife, Spain|Hospital Universitario de La Ribera, Alzira, Valencia, Spain|Hospital de Manises, Manises, Valencia, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|H. Gen. Universitario Alicante, Alicante, Spain|H. Universitario Quirón Dexeus, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital La Mancha Centro, Ciudad Real, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Universitario de Puerto Real, Cádiz, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Guadalajara, Guadalajara, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital San Millan Y San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Santa María Naí, Ourense, Spain|Hospital Son Espases, Palma de Mallorca, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital universitario Nuestra Señora Candelaria, Tenerife, Spain|H. General U. de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Politècnic i Universitari La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|H. Miguel Servet, Zaragoza, Spain|Hospital Ntra. Sra. Sónsoles, Ávila, Spain|Hospital Universitario de Áraba, Vitoria, Áraba, Spain",https://ClinicalTrials.gov/show/NCT04344002,China,,12.0,2020,Thursday
2096,2097,Predicting Death and ICU Admission in COVID-19 Patients in ED,Completed,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"March 1, 2020",2020-04-15,"May 5, 2020","Marcello Covino, Roma, RM, Italy",https://ClinicalTrials.gov/show/NCT04371562,Italy,,4.0,2020,Wednesday
2097,2098,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,Diagnostic Test: Data collection and rhinopharyngeal swab,All,up to 15 Years   (Child),Not Applicable,605.0,"April 14, 2020",2020-06-01,"July 9, 2020","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|14 Av rené Samuel, Clamart, France|Cabinet du Dr Corrard, Combs-la-Ville, France|10 rue Delambre, Lagny-sur-Marne, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|4 allée des Norottes, Noisy-le-Grand, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|132 Boulevard du Montparnasse, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|15 Quai Louis Blériot, Paris, France|Cabinet du Dr Michot, Paris, France|24 rue Volta, Puteaux, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France",https://ClinicalTrials.gov/show/NCT04318431,France,,6.0,2020,Monday
2098,2099,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Not yet recruiting,Drug: Lidocaine 2%|Drug: Control,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"November 4, 2020",2024-02-04,"November 2, 2020",,https://ClinicalTrials.gov/show/NCT04609865,Undefined,Lidocaine 2%|Control,2.0,2024,Sunday
2099,2100,To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study),Recruiting,,All,"18 Years to 75 Years   (Adult, Older Adult)",,1000.0,"April 25, 2020",2020-12-25,"July 14, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04367064,India,,12.0,2020,Friday
2100,2101,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Drug: Heparin|Drug: 0.9% Sodium-chloride,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"June 1, 2020",2020-12-31,"December 9, 2020","Frederick Health Hospital, Frederick, Maryland, United States",https://ClinicalTrials.gov/show/NCT04397510,United States,Heparin|0.9% Sodium-chloride,12.0,2020,Thursday
2101,2102,Cardiovascular Risk Stratification in Covid-19,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,60000.0,"June 8, 2020",2021-12-01,"September 21, 2020","Oregon Health and Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04555187,United States,,12.0,2021,Wednesday
2102,2103,Oral Isotretinoin and Covid-19 Infection,Not yet recruiting,,All,"16 Years to 40 Years   (Child, Adult)",,300.0,"January 15, 2021",2021-05-31,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04663906,Undefined,,5.0,2021,Monday
2103,2104,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Completed,Device: COViage,All,"Child, Adult, Older Adult",Not Applicable,290.0,"March 10, 2020",2020-06-04,"June 9, 2020","Dascena, Oakland, California, United States",https://ClinicalTrials.gov/show/NCT04423991,United States,,6.0,2020,Thursday
2104,2105,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,"Active, not recruiting",Drug: NP-120 (Ifenprodil),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,682.0,"August 5, 2020",2022-02-01,"December 10, 2020","Westchester Research Center, Miami, Florida, United States|Affinity Health - Loretto Hospital, Chicago, Illinois, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Promedica Health: Toledo Hospital and BayPark Hospital, Toledo, Ohio, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Makati Medical Center, Manila, Philippines|Philippine General Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|National Institute of Infectious Diseases, Bucharest, Romania",https://ClinicalTrials.gov/show/NCT04382924,Australia,NP-120 (Ifenprodil),2.0,2022,Tuesday
2105,2106,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Recruiting,Drug: Renin-angiotensin system inhibitors,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,240.0,"July 25, 2020",2022-02-14,"July 31, 2020","Instituto do Coração - Incor HCFMUSP, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04493359,Brazil,Renin-angiotensin system inhibitors,2.0,2022,Monday
2106,2107,"Anakinra, COVID-19, Cytokine Storm",Not yet recruiting,Drug: Anakinra|Drug: 0.9% Saline,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2,100.0,November 2020,2022-02-01,"November 3, 2020","Weill Cornell Medcine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04603742,United States,Anakinra|0.9% Saline,2.0,2022,Tuesday
2107,2108,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Not yet recruiting,Drug: allogeneic mesenchymal stem cell|Other: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 1,9.0,"October 26, 2020",2021-01-31,"October 26, 2020","Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia",https://ClinicalTrials.gov/show/NCT04535856,Indonesia,allogeneic mesenchymal stem cell,1.0,2021,Sunday
2108,2109,Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,176.0,"May 23, 2020",2022-05-23,"May 28, 2020","Univsersity of Sao Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04406233,Brazil,,5.0,2022,Monday
2109,2110,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),Recruiting,Drug: PTC299|Other: SOC|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,380.0,"July 9, 2020",2021-01-30,"November 16, 2020","University of California, Irvine, Orange, California, United States|Augusta University, Augusta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Salisbury VA Medical Center, Salisbury, North Carolina, United States|University Hospitals Cleveland, Cleveland, Ohio, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Columbia VA Health Care System, Columbia, South Carolina, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|Hospital Vera Cruz, Belo Horizonte, MG, Brazil|Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, SP, Brazil|Hospital Guilherme Alvaro, Santos, SP, Brazil|Hospital Santa Casa de Misecórdia de Sorocoba, Sorocaba, SP, Brazil|Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brazil|Escola Paulista de Medicina (UNIFESP), São Paulo, SP, Brazil|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04439071,Australia,PTC299|Placebo,1.0,2021,Saturday
2110,2111,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,Procedure: alveolar recruitment,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,10.0,"May 6, 2020",2021-06-01,"May 21, 2020","University of Szeged, Szeged, Hungary",https://ClinicalTrials.gov/show/NCT04360837,Hungary,,6.0,2021,Tuesday
2111,2112,Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population,Recruiting,,All,18 Years to 60 Years   (Adult),,500.0,"May 30, 2020",2020-08-30,"July 16, 2020","Cairo university, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04391881,Egypt,,8.0,2020,Sunday
2112,2113,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,16000.0,"May 8, 2020",2021-05-01,"October 19, 2020","Hospital Universitario Príncipe Asturias, Alcalá De Henares, Spain|Hospital Universitario Torrecárdenas, Almería, Spain|Agència de Salut Pública Barcelona, Barcelona, Spain|Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut d'Investigación en Atenció Primària, IDIAP Jordi Gol, Barcelona, Spain|Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Parc Sanitari Sant Joan de Déu, Barcelona, Spain|Psmar-Imim, Barcelona, Spain|Sistema de Emergencias Médicas de Cataluña, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital El Bierzo, León, Spain|Gerencia de Atención Primaria de Madrid-FIIBAP, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Donostia, San Sebastián, Spain|Hospital Clínic Universitari, Valencia, Spain|Hospital Universitario Araba-Santiago, Vitoria, Spain",https://ClinicalTrials.gov/show/NCT04556565,Spain,,5.0,2021,Saturday
2113,2114,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),Recruiting,Device: TCC-COVID mHealth solution,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"May 20, 2020",2021-05-19,"May 22, 2020","The Sutherland Hospital, Caringbah, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia",https://ClinicalTrials.gov/show/NCT04399109,Australia,,5.0,2021,Wednesday
2114,2115,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"May 26, 2020",2020-06-30,"July 10, 2020","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital Municipal de Badalona, Badalona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04466462,Spain,,6.0,2020,Tuesday
2115,2116,Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT),Not yet recruiting,Drug: Methylprednisolone|Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,680.0,"November 25, 2020",2021-04-30,"November 19, 2020",,https://ClinicalTrials.gov/show/NCT04636671,Undefined,Methylprednisolone|Dexamethasone,4.0,2021,Friday
2116,2117,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,Not yet recruiting,Biological: Allogeneic NK transfer,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"April 13, 2020",2020-11-10,"April 14, 2020","Fundacion Salud De Los Andes, Bogotá, Bogotá Distrito Capital, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04344548,Colombia,,11.0,2020,Tuesday
2117,2118,Screening of Health-care Workers in an University Hospital for SARS-CoV-2,Recruiting,Other: Investigation of the prevalence of test positivity,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"June 1, 2020",2020-12-01,"November 9, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",https://ClinicalTrials.gov/show/NCT04567836,Italy,,12.0,2020,Tuesday
2118,2119,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Completed,Device: Hydrogen Oxygen Generator with Nebulizer|Other: Standard-of-care,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90.0,"January 21, 2020",2020-03-23,"May 15, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04378712,China,,3.0,2020,Monday
2119,2120,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,Recruiting,Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution,All,"18 Years and older   (Adult, Older Adult)",Phase 4,750.0,"August 5, 2020",2021-05-01,"August 18, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04409834,United States,Unfractionated Heparin IV|Enoxaparin 1 mg/kg|Clopidogrel|Unfractionated heparin SC|Enoxaparin 40 Mg/0.4 mL Injectable Solution,5.0,2021,Saturday
2120,2121,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Recruiting,Biological: IMM-101|Other: Observation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"June 25, 2020",2021-03-31,"November 10, 2020","Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04442048,Canada,,3.0,2021,Wednesday
2121,2122,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,"Active, not recruiting",Drug: Ivermectin|Drug: Placebo,All,18 Years to 59 Years   (Adult),Phase 2,24.0,"July 31, 2020",2020-12-30,"September 23, 2020","Clinica Universidad de Navarra, Pamplona, Navarra, Spain",https://ClinicalTrials.gov/show/NCT04390022,Spain,Ivermectin|Placebo,12.0,2020,Wednesday
2122,2123,Will Hydroxychloroquine Impede or Prevent COVID-19,Recruiting,Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,3000.0,"April 7, 2020",2021-12-31,"December 9, 2020","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04341441,United States,Hydroxychloroquine - Daily Dosing|Hydroxychloroquine - Weekly Dosing,12.0,2021,Friday
2123,2124,Camostat With Bicalutamide for COVID-19,Not yet recruiting,Drug: Camostat Mesilate|Drug: Bicalutamide 150 mg,All,"60 Years and older   (Adult, Older Adult)",Phase 1,60.0,January 2021,2023-01-01,"December 3, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04652765,United States,Camostat Mesilate|Bicalutamide 150 mg,1.0,2023,Sunday
2124,2125,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,Diagnostic Test: Serological testing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3500.0,"May 12, 2020",2021-05-12,"June 11, 2020","UZ Brussel, Jette, Brussel, Belgium",https://ClinicalTrials.gov/show/NCT04426292,Belgium,,5.0,2021,Wednesday
2125,2126,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),Recruiting,Biological: V590|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,252.0,"October 29, 2020",2021-12-13,"December 1, 2020","Celerion ( Site 0002), Tempe, Arizona, United States|Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States|QPS Miami Research Associates ( Site 0005), South Miami, Florida, United States|Bio-Kinetic Clinical Applications (QPS) ( Site 0006), Springfield, Missouri, United States|Celerion ( Site 0001), Lincoln, Nebraska, United States|Alliance for Multispecialty Reseach, LLC ( Site 0004), Knoxville, Tennessee, United States|Worldwide Clinical Trials ( Site 0007), San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04569786,United States,,12.0,2021,Monday
2126,2127,Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19,Recruiting,Other: Active COVID-19 disease,All,"16 Years and older   (Child, Adult, Older Adult)",,200.0,"April 15, 2020",2020-08-15,"August 13, 2020","UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI, IMSS., México, Ciudad De México, Mexico",https://ClinicalTrials.gov/show/NCT04423640,Mexico,,8.0,2020,Saturday
2127,2128,Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus,Completed,Other: Follow-up phone call,All,"15 Years and older   (Child, Adult, Older Adult)",,4734.0,"April 27, 2020",2020-07-17,"November 9, 2020","University Hospital of Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04615676,France,,7.0,2020,Friday
2128,2129,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",Recruiting,Drug: IgIV,All,75 Years and older   (Older Adult),Phase 2,35.0,"May 5, 2020",2021-05-05,"May 27, 2020","Centre Hospitalier de Versailles, Le Chesnay, France",https://ClinicalTrials.gov/show/NCT04403269,France,IgIV,5.0,2021,Wednesday
2129,2130,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,Other: Mindfulness based intervention,All,"Child, Adult, Older Adult",Not Applicable,1000.0,"March 10, 2020",2020-04-26,"September 18, 2020","La Paz University Hospital, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04555005,Spain,,4.0,2020,Sunday
2130,2131,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Drug: GX-19|Drug: Saline,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,210.0,"June 17, 2020",2022-06-17,"July 28, 2020","Severance hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04445389,"Korea, Republic of",GX-19|Saline,6.0,2022,Friday
2131,2132,C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19,Not yet recruiting,Device: C2Rx|Other: Standard of Care (SOC),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,"September 15, 2020",2021-01-15,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04537975,Undefined,,1.0,2021,Friday
2132,2133,Hydrogen-oxygen Gas Mixture Inhalation in Patients With Convalescent Coronavirus Disease 2019 (COVID-19),Not yet recruiting,"Device: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Device: OLO-1 Medical Molecular Sieve Oxygen Generator",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,198.0,"October 31, 2020",2021-12-31,"October 22, 2020","Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04594460,China,,12.0,2021,Friday
2133,2134,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198","Active, not recruiting",Drug: BRII-198|Drug: Placebo,All,18 Years to 49 Years   (Adult),Phase 1,17.0,"July 13, 2020",2021-03-01,"December 3, 2020","Investigative Site, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04479644,China,BRII-198|Placebo,3.0,2021,Monday
2134,2135,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196","Active, not recruiting",Drug: BRII-196|Drug: Placebo,All,18 Years to 49 Years   (Adult),Phase 1,16.0,"July 12, 2020",2021-03-01,"December 3, 2020","Investigative Site, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04479631,China,BRII-196|Placebo,3.0,2021,Monday
2135,2136,Recovery Profiles in Patients With SARS-CoV-2 Outcomes Undergoing Rehabilitation,Recruiting,Behavioral: Early rehabilitation|Behavioral: Subacute rehabilitation|Behavioral: Mindfulness training|Behavioral: Personalized ambulatory training,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 30, 2020",2021-06-03,"November 4, 2020","Department of Neuroscience and Rehabilitation, University Hospital of Ferrara, Ferrara, Emilia Romagna, Italy",https://ClinicalTrials.gov/show/NCT04615390,Italy,,6.0,2021,Thursday
2136,2137,COVID-19 and Obstetric Transmission,Recruiting,Diagnostic Test: RT-PCR and antibody testing,Female,18 Years to 50 Years   (Adult),,200.0,"April 28, 2020",2021-07-31,"June 9, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04418557,United States,,7.0,2021,Saturday
2137,2138,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Recruiting,Drug: Almitrine|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,212.0,"September 3, 2020",2020-12-01,"September 23, 2020","Hospital Pitié-Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04357457,France,Almitrine|Placebo,12.0,2020,Tuesday
2138,2139,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial,Recruiting,Behavioral: Telemedicine visit|Behavioral: In-person postoperative visit,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,70.0,"September 28, 2020",2021-06-30,"December 3, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04652674,United States,,6.0,2021,Wednesday
2139,2140,Extracellular Vesicle Infusion Therapy for Severe COVID-19,Not yet recruiting,Biological: DB-001,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,60.0,"September 1, 2020",2020-12-31,"July 30, 2020",,https://ClinicalTrials.gov/show/NCT04493242,Undefined,,12.0,2020,Thursday
2140,2141,Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),Withdrawn,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,0.0,"May 5, 2020",2020-07-15,"August 28, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",https://ClinicalTrials.gov/show/NCT04351919,Tunisia,Hydroxychloroquine|Azithromycin,7.0,2020,Wednesday
2141,2142,Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge,Not yet recruiting,Biological: IN01 vaccine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"December 1, 2020",2022-06-01,"September 24, 2020","Hospital El Pilar, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04537130,Spain,,6.0,2022,Wednesday
2142,2143,Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients,Not yet recruiting,Other: Systemic indirect endovenous ozone therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,July 2020,2020-12-01,"June 23, 2020","SEOT, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04359303,Spain,,12.0,2020,Tuesday
2143,2144,The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors,Recruiting,Other: Quality-of-Life Assessment|Other: Survey Administration,All,18 Years to 39 Years   (Adult),,600.0,"July 13, 2020",2021-12-31,"September 16, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04551378,United States,,12.0,2021,Friday
2144,2145,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Recruiting,Drug: EIDD-2801|Drug: Placebo (PBO),All,"18 Years and older   (Adult, Older Adult)",Phase 2,204.0,"June 16, 2020",2021-02-28,"December 9, 2020","Benchmark Research, Colton, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|FOMAT Medical Research, Oxnard, California, United States|Indago Research and Health Center, Inc., Hialeah, Florida, United States|NOLA Research, New Orleans, Louisiana, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Duke, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Care United Research, LLC, Forney, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Fred Hutch, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04405570,United States,EIDD-2801|Placebo (PBO),2.0,2021,Sunday
2145,2146,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Recruiting,Device: mouthrinse with bêta-cyclodextrin and citrox|Device: mouthrinse without bêta-cyclodextrin and citrox,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,206.0,"April 27, 2020",2020-12-20,"September 23, 2020","Clinic of the Protestant Infirmary in Lyon, Caluire-et-Cuire, France|CH Emile Roux, Le Puy en Velay, France|Intercommunal Hospital Center of Mont de Marsan, Mont de Marsan, France",https://ClinicalTrials.gov/show/NCT04352959,France,,12.0,2020,Sunday
2146,2147,SARS-CoV2 Antibodies in Pediatric Patients (COVID-19),Not yet recruiting,Diagnostic Test: Blood test for IgG antibodies against SARS-CoV-2,All,"up to 18 Years   (Child, Adult)",,2000.0,"October 5, 2020",2022-05-01,"October 9, 2020",,https://ClinicalTrials.gov/show/NCT04581148,Undefined,,5.0,2022,Sunday
2147,2148,Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2,Not yet recruiting,Combination Product: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid,All,18 Years to 60 Years   (Adult),Phase 1,24.0,July 2020,2020-12-01,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04382950,Undefined,,12.0,2020,Tuesday
2148,2149,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Recruiting,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72.0,"April 23, 2020",2021-12-01,"June 11, 2020","Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital U. Puerto Real, Puerto Real, Cádiz, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital U. Torrecárdenas, Almería, Spain|Hospital U. Puerta del Mar, Cádiz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital Regional U. de Málaga, Málaga, Spain|Hospital U. Virgen de la Victoria, Málaga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital U. Nuestra Señora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain",https://ClinicalTrials.gov/show/NCT04366245,Spain,Standard of care for SARS-CoV-2 infection,12.0,2021,Wednesday
2149,2150,Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).,Not yet recruiting,Diagnostic Test: Immune response study,All,"18 Years to 85 Years   (Adult, Older Adult)",,90.0,"September 1, 2020",2021-09-30,"August 26, 2020",,https://ClinicalTrials.gov/show/NCT04526977,Undefined,,9.0,2021,Thursday
2150,2151,Impact of Covid-19 in Congenital Heart Disease,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"March 1, 2020",2020-12-30,"April 14, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04336384,France,,12.0,2020,Wednesday
2151,2152,The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications,Not yet recruiting,"Drug: Camostat Mesylate|Drug: Microcrystalline Cellulose, NF",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,200.0,"February 1, 2021",2021-07-30,"October 28, 2020",,https://ClinicalTrials.gov/show/NCT04435015,Undefined,"Camostat Mesylate|Microcrystalline Cellulose, NF",7.0,2021,Friday
2152,2153,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,Recruiting,Drug: Favipiravir,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 3,150.0,"October 7, 2020",2021-06-01,"October 23, 2020","Department of Pulmonology Semmelweis University, Budapest, Hungary|National Korányi Institute for Pulmonology, Budapest, Hungary|Institute of Infectology, University of Debrecen, Debrecen, Hungary|1st Department of Medicine, University of Pécs, Pécs, Hungary|First Department of Internal Medicine, University of Szeged, Szeged, Hungary",https://ClinicalTrials.gov/show/NCT04600999,Hungary,Favipiravir,6.0,2021,Tuesday
2153,2154,Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19,Not yet recruiting,Biological: UCMSCs|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,"March 1, 2021",2024-06-01,"September 9, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04490486,United States,,6.0,2024,Saturday
2154,2155,Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,Recruiting,Other: Quality-of-Life Assessment|Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",,50000.0,"June 11, 2020",2021-07-01,"August 5, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04500600,United States,,7.0,2021,Thursday
2155,2156,SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19,Available,Biological: eculizumab,All,"18 Years and older   (Adult, Older Adult)",,,,,"August 18, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Boston Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Hôpital Henri Mondor, Creteil, France|Hôpital Garches Raymond Poincaré, Garches, France|Hôpital de Bicêtre, Le Kremlin Bicêtre, France|Hôpital Saint Louis, Paris, France|Hôpital Paul Brousse, Villejuif, France",https://ClinicalTrials.gov/show/NCT04355494,France,,,n,
2156,2157,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19",Recruiting,Biological: MVA-SARS-2-S vaccinations (days 0 & 28),All,18 Years to 55 Years   (Adult),Phase 1,30.0,"October 5, 2020",2021-05-01,"December 1, 2020","CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany",https://ClinicalTrials.gov/show/NCT04569383,Germany,,5.0,2021,Saturday
2157,2158,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 14, 2020",2020-10-31,"July 24, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04485364,France,,10.0,2020,Saturday
2158,2159,Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients,Not yet recruiting,Procedure: Follow-up at 14 days,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 6, 2020",2021-01-29,"April 8, 2020",,https://ClinicalTrials.gov/show/NCT04338100,Undefined,,1.0,2021,Friday
2159,2160,Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,Completed,"Diagnostic Test: PCR, lung ultrasound",Female,18 Years to 40 Years   (Adult),,131.0,"March 15, 2020",2020-07-10,"July 28, 2020","Zeynep Kamil Maternity and Childrens Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04443140,Turkey,,7.0,2020,Friday
2160,2161,COVID-19 in Patients With Anosmia in Egypt,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"July 1, 2020",2020-10-30,"July 17, 2020","Ain Shams University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04473157,Egypt,,10.0,2020,Friday
2161,2162,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,Recruiting,Drug: GLS-1200|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,225.0,"June 1, 2020",2021-03-01,"December 3, 2020","Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04408183,United States,GLS-1200|Placebo,3.0,2021,Monday
2162,2163,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 27, 2020",2020-12-27,"May 1, 2020","AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04369365,Austria,Azithromycin 500 milligram (mg) oral Tablet|Placebo,12.0,2020,Sunday
2163,2164,HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19,Withdrawn,Drug: Hydroxychloroquine and Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"June 30, 2020",2020-10-30,"October 5, 2020","Núcleo de Oncologia da Bahia - NOB, Salvador, BA, Brazil|Oncoclínicas BH, Belo Horizonte, MG, Brazil|Centro Oncológico do Triângulo - COT, Uberlândia, MG, Brazil|Multihemo, Recife, PE, Brazil|Oncoclinicas RJ, Rio De Janeiro, RJ, Brazil|Centro de Pesquisa em Oncologia PUCRS, Porto Alegre, RS, Brazil|Centro Paulista de Oncologia, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04575558,Brazil,Hydroxychloroquine and Azithromycin,10.0,2020,Friday
2164,2165,Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection,Withdrawn,Drug: Treatment with Dexmedetomidine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"April 20, 2020",2020-11-20,"September 2, 2020","University Hospital, Limoges, France",https://ClinicalTrials.gov/show/NCT04350086,France,Treatment with Dexmedetomidine,11.0,2020,Friday
2165,2166,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Drug: Mavrilimumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 20, 2020",2021-05-31,"July 30, 2020","University of Cincinnati, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04492514,United States,Mavrilimumab|Placebo,5.0,2021,Monday
2166,2167,COVID19 Clinical Predictors and Outcome,Recruiting,Other: SARS-CoV2 Infection,All,"18 Years and older   (Adult, Older Adult)",,800.0,"June 15, 2020",2022-04-30,"October 22, 2020","St. George's University Hospitals Foundation Trust., London, United Kingdom",https://ClinicalTrials.gov/show/NCT04416347,United Kingdom,,4.0,2022,Saturday
2167,2168,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,Not yet recruiting,Drug: Placebo|Drug: DuACT,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,40.0,December 2020,2021-03-01,"November 9, 2020","Sunnyside Office Park, Johannesburg, Gauteng, South Africa",https://ClinicalTrials.gov/show/NCT04563208,South Africa,Placebo|DuACT,3.0,2021,Monday
2168,2169,"Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study",Recruiting,Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",,700.0,"July 13, 2020",2021-03-31,"December 3, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04652505,United States,,3.0,2021,Wednesday
2169,2170,Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients,Not yet recruiting,Device: Hyperbaric Chamber,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"June 1, 2020",2021-03-30,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04409886,Undefined,,3.0,2021,Tuesday
2170,2171,Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,"April 17, 2020",2020-12-17,"April 24, 2020","Service de réanimation Hôpital Avicenne, Bobigny, France|Service de réanimation Hôpital Bichat, Paris, France|Service de réanimation Hôpital Tenon, Paris, France",https://ClinicalTrials.gov/show/NCT04355481,France,,12.0,2020,Thursday
2171,2172,LILLE COVID RESEARCH NETWORK (Covid-19),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"August 10, 2020",2022-08-01,"November 19, 2020","Hop Claude Huriez Chr Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04475211,France,,8.0,2022,Monday
2172,2173,Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19,Completed,Other: No special intervention,All,"18 Years to 105 Years   (Adult, Older Adult)",,106.0,"March 31, 2020",2020-06-30,"July 17, 2020","CHU Amiens, Amiens, France|CH de la Côte Basque, Bayonne, France|CHU Ambroise Paré, Boulogne-Billancourt, France|CHU Caen, Caen, France|CHG de Chambery, Chambéry, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|CHU Nîmes, Nîmes, France|CHR Orléans, Orléans, France|CHU Cochin, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen, Rouen, France|CH Saint-Quentin, Saint-Quentin, France|CHU Larrey - Toulouse, Toulouse, France|CHU de Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04341766,France,,6.0,2020,Tuesday
2173,2174,"The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines",Not yet recruiting,Diagnostic Test: nasal pharyngeal (NP) swab samples|Diagnostic Test: peripheral blood draw,All,"Child, Adult, Older Adult",,500.0,"June 1, 2020",2021-06-30,"May 18, 2020",,https://ClinicalTrials.gov/show/NCT04391400,Undefined,,6.0,2021,Wednesday
2174,2175,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Recruiting,Other: Ketogenic diet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 1, 2020",2021-05-30,"September 30, 2020","Samir Giuseppe Sukkar, Genova, Italy",https://ClinicalTrials.gov/show/NCT04492228,Italy,,5.0,2021,Sunday
2175,2176,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,Drug: Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 1,40.0,July 2020,2020-09-01,"July 7, 2020","Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia|Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia|Universitas Indonesia Hospital, Depok, West Java, Indonesia",https://ClinicalTrials.gov/show/NCT04457609,Indonesia,Oseltamivir|Azithromycin,9.0,2020,Tuesday
2176,2177,Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19,Recruiting,"Diagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care",All,"16 Years and older   (Child, Adult, Older Adult)",,500.0,"March 20, 2020",2020-05-20,"April 22, 2020","Clinical Investigation Center Pitié-Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04320017,France,,5.0,2020,Wednesday
2177,2178,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Active, not recruiting",Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,26.0,"April 27, 2020",2021-10-01,"November 30, 2020","Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain",https://ClinicalTrials.gov/show/NCT04366323,Spain,ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,10.0,2021,Friday
2178,2179,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,Recruiting,Drug: Intramuscular injection|Biological: Intramuscular vaccine,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,30612.0,"November 19, 2020",2022-04-30,"November 30, 2020","Manna Research (Mirabel), Mirabel, Quebec, Canada|Diex Research Quebec Inc., Québec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borromée, Quebec, Canada|Q&T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04636697,Canada,Intramuscular injection,4.0,2022,Saturday
2179,2180,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Recruiting,Other: Best Practice|Radiation: Low Dose Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,52.0,"June 12, 2020",2022-05-30,"June 16, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04433949,Georgia,,5.0,2022,Monday
2180,2181,Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19),Not yet recruiting,Drug: Alisporivir|Other: Standard of care (SOC),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,100.0,"November 1, 2020",2021-08-04,"October 29, 2020","Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",https://ClinicalTrials.gov/show/NCT04608214,France,Alisporivir,8.0,2021,Wednesday
2181,2182,Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection,Not yet recruiting,Drug: Human Ezrin Peptide 1 (HEP1)|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,"December 20, 2020",2021-04-01,"November 13, 2020","Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04627233,"Iran, Islamic Republic of",Human Ezrin Peptide 1 (HEP1)|Placebo,4.0,2021,Thursday
2182,2183,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,Recruiting,Biological: VPM1002|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3626.0,"June 24, 2020",2021-07-01,"November 20, 2020","University Health Network, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04439045,Canada,,7.0,2021,Thursday
2183,2184,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Drug: Mavrilimumab|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"May 20, 2020",2021-05-31,"October 6, 2020","Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic Health System, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04399980,United States,Mavrilimumab|Placebos,5.0,2021,Monday
2184,2185,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Recruiting,Drug: AK119|Drug: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,32.0,September 2020,2021-04-01,"September 21, 2020","Christchurch Clinical Studies Trust, Christchurch, New Zealand",https://ClinicalTrials.gov/show/NCT04516564,New Zealand,AK119|Placebo,4.0,2021,Thursday
2185,2186,Perceptions of Undergraduate Students and Teaching Staff on Online Teaching,Not yet recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,9209.0,"October 15, 2020",2021-11-01,"July 28, 2020",,https://ClinicalTrials.gov/show/NCT04466371,Undefined,,11.0,2021,Monday
2186,2187,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults (USA),Not yet recruiting,Drug: Intramuscular injection|Biological: intramuscular accine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,918.0,"December 11, 2020",2022-03-31,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04662697,Undefined,Intramuscular injection,3.0,2022,Thursday
2187,2188,MET-Covid -- Outpatient Metformin Use for Covid-19.,Not yet recruiting,Drug: Metformin|Drug: Placebo,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,70.0,November 2020,2021-09-01,"November 27, 2020",,https://ClinicalTrials.gov/show/NCT04510194,Undefined,Metformin|Placebo,9.0,2021,Wednesday
2188,2189,Anti Infective Agents Impact in COVID-19 Pneumonia,Completed,Drug: favorable outcome,All,"18 Years and older   (Adult, Older Adult)",,132.0,"March 2, 2020",2020-04-25,"July 1, 2020","Benjamin Davido, Garches, France",https://ClinicalTrials.gov/show/NCT04453501,France,favorable outcome,4.0,2020,Saturday
2189,2190,A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE,Not yet recruiting,Biological: Gam-COVID-Vac|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,December 2020,2021-12-01,"December 7, 2020",,https://ClinicalTrials.gov/show/NCT04656613,Undefined,,12.0,2021,Wednesday
2190,2191,Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality,Not yet recruiting,Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality,All,18 Years to 60 Years   (Adult),,874.0,April 2020,2020-07-01,"April 17, 2020",,https://ClinicalTrials.gov/show/NCT04344938,Undefined,,7.0,2020,Wednesday
2191,2192,Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?,Not yet recruiting,Procedure: biopsies of subcutaneous adipose tissue,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5.0,"July 1, 2020",2021-07-09,"June 11, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04427878,France,,7.0,2021,Friday
2192,2193,Telmisartan in Respiratory Failure Due to COVID-19,Recruiting,Drug: Telmisartan,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,August 2020,2021-04-01,"August 12, 2020","Hospital Regional de Alta Especialidad de Zumpango, Zumpango, Estado De Mexico, Mexico",https://ClinicalTrials.gov/show/NCT04510662,Mexico,Telmisartan,4.0,2021,Thursday
2193,2194,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,Recruiting,Drug: Senicapoc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,46.0,"April 24, 2020",2021-12-31,"October 20, 2020","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark",https://ClinicalTrials.gov/show/NCT04594668,Denmark,Senicapoc,12.0,2021,Friday
2194,2195,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,Recruiting,Drug: Ensifentrine Dose 1|Drug: Placebo pMDI,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,45.0,"August 28, 2020",2021-03-01,"September 1, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04527471,United States,Ensifentrine Dose 1|Placebo pMDI,3.0,2021,Monday
2195,2196,Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children,Not yet recruiting,Other: no intervention,All,"Child, Adult, Older Adult",,3000.0,"June 25, 2020",2024-06-01,"June 22, 2020","CHU SAINT Pierre, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04432779,Belgium,,6.0,2024,Saturday
2196,2197,Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP),Available,Biological: Anti-Sars-CoV-2 Convalescent Plasma,All,"Child, Adult, Older Adult",,,,,"November 23, 2020","Naval Hospital Camp Pendleton, Oceanside, California, United States|Navy Medical Center San Diego, San Diego, California, United States|USS Abraham Lincoln CVN 72, San Diego, California, United States|USS Boxer LHD 4, San Diego, California, United States|USS Carl Vinson CVN 70, San Diego, California, United States|USS Essex LHD 2, San Diego, California, United States|USS Makin Island LHD 8, San Diego, California, United States|USS Nimitz CVN 68, San Diego, California, United States|USS Theodore Roosevelt CVN 71, San Diego, California, United States|USS Tripoli LHA 7, San Diego, California, United States|Evans Army Community Hospital, Fort Carson, Colorado, United States|Eglin Air Force Base, Eglin Air Force Base, Florida, United States|Naval Hospital Jacksonville, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Keesler Medical Center, Keesler Air Force Base, Biloxi, Mississippi, United States|Nellis Air Force Base, Las Vegas, Nevada, United States|Naval Medical Center Camp Lejeune, Camp Lejeune, North Carolina, United States|Wright Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|William Beaumont Army Medical Center, El Paso, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Naval Surface Force Atlantic (Fleet Surgical Team), Norfolk, Virginia, United States|USS Dwight D. Eisenhower CVN 69, Norfolk, Virginia, United States|USS Gerald R. Ford CVN 78, Norfolk, Virginia, United States|Naval Medical Center Portsmouth, Portsmouth, Virginia, United States|Madigan Army Medical Center, Lakewood, Washington, United States|Craig Joint Theatre Bagram AFGH, Bagram, Afghanistan|NATO Multinational Kandahar AFG, Kandahar, Afghanistan|EMF Djibouti, Djibouti, Djibouti|Landstuhl Regional Medical Center, Landstuhl, Germany|Naval Hospital Guam, Agaña, Guam|Baghdad Diplomat Support Center Iraq, Baghdad, Iraq|Misawa Air Force Base, 35th Medical Group, Aomori, Japan|Yokota Air Base (374th Medical Group), Fussa, Japan|US Naval Hospital Okinawa, Okinawa, Japan|USS America LHA 6, Yokosuka, Japan|USS Ronald Reagan CVN 76, Yokosuka, Japan|Yokosuka Naval Medical Readiness & Training Command, Yokosuka, Japan|US Military Hospital Camp Arifjan Kuwait, Kuwait, Kuwait",https://ClinicalTrials.gov/show/NCT04360486,Afghanistan,,,n,
2197,2198,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers,Completed,Other: Online Survey,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",,392.0,"June 1, 2020",2020-06-08,"June 11, 2020","Istanbul Okan University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04412278,Turkey,,6.0,2020,Monday
2198,2199,Police COVID-19 Serosurvey,Not yet recruiting,Diagnostic Test: Blood sampling|Other: Online Questionnaire,All,"18 Years to 65 Years   (Adult, Older Adult)",,1000.0,January 2021,2022-06-01,"November 30, 2020","University of Bern, Institute for Infectious Diseases, Bern, BE, Switzerland",https://ClinicalTrials.gov/show/NCT04643444,Switzerland,,6.0,2022,Wednesday
2199,2200,Hydroxy Chloroquine and Covid in RA Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,80.0,"June 15, 2020",2020-11-01,"September 9, 2020","Tanta University Hospital, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04471649,Egypt,,11.0,2020,Sunday
2200,2201,hCT-MSCs for COVID19 ARDS,Recruiting,Biological: human cord tissue mesenchymal stromal cells,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"June 18, 2020",2021-07-31,"June 22, 2020","Duke Hospital, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04399889,United States,,7.0,2021,Saturday
2201,2202,CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19,Not yet recruiting,Drug: DeltaRex-G,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1|Phase 2,18.0,"January 12, 2021",2022-03-12,"November 12, 2020",,https://ClinicalTrials.gov/show/NCT04378244,Undefined,DeltaRex-G,3.0,2022,Saturday
2202,2203,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),Recruiting,Other: Meditation (1 x 20-minute guided audio training),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,624.0,"October 28, 2020",2021-03-01,"November 12, 2020","Health and Behavioural Sciences, Brisbane, Queensland, Australia",https://ClinicalTrials.gov/show/NCT04602312,Australia,,3.0,2021,Monday
2203,2204,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Recruiting,Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo,All,20 Years to 50 Years   (Adult),Phase 4,400.0,"April 15, 2020",2020-06-30,"May 1, 2020","Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04351191,Pakistan,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,6.0,2020,Tuesday
2204,2205,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Recruiting,Diagnostic Test: AAZ Covid-19 rapid test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"April 25, 2020",2020-10-25,"August 25, 2020","Bichat University Hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04525417,France,,10.0,2020,Sunday
2205,2206,COVID-19 in PID Survey,Recruiting,,All,"Child, Adult, Older Adult",,200.0,"March 15, 2020",2022-03-31,"July 7, 2020","Imagine Institute, Paris, France",https://ClinicalTrials.gov/show/NCT04459689,France,,3.0,2022,Thursday
2206,2207,Telemedicine in Outpatient Covid-19 Patients,Recruiting,Device: Withings ScanWatch,All,40 Years to 59 Years   (Adult),Not Applicable,600.0,"September 18, 2020",2021-03-01,"September 22, 2020","LMU Klinikum, Munich, BY, Germany",https://ClinicalTrials.gov/show/NCT04471636,Germany,,3.0,2021,Monday
2207,2208,USZ BioResource COVID,Recruiting,Other: blood sampling for biobank,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 9, 2020",2022-04-30,"June 4, 2020","University Hospital Zurich, Clinical Trials Center, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04414657,Switzerland,,4.0,2022,Saturday
2208,2209,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,Drug: LEAF-4L6715,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,90.0,"April 14, 2020",2020-12-31,"October 29, 2020","Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04378920,France,LEAF-4L6715,12.0,2020,Thursday
2209,2210,Canine COVID-19 Detection,Recruiting,Behavioral: Collection of odour samples,All,"16 Years and older   (Child, Adult, Older Adult)",,16250.0,"July 2, 2020",2020-10-31,"August 12, 2020","ARCTEC, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04509713,United Kingdom,,10.0,2020,Saturday
2210,2211,Estrogen Patch for COVID-19 Symptoms,Recruiting,Drug: Estradiol patch,All,"18 Years and older   (Adult, Older Adult)",Phase 2,110.0,"April 20, 2020",2020-11-15,"April 24, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04359329,United States,Estradiol patch,11.0,2020,Sunday
2211,2212,Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer,Recruiting,Other: mortality,All,"18 Years and older   (Adult, Older Adult)",,600.0,"June 15, 2020",2021-02-15,"July 7, 2020","Centre de lutte contre le Cancer JEAN PERRIN, Clermont-Ferrand, France|Centre Hospitalier Uniersitaire de Clermont-Ferrand, Clermont-Ferrand, France|Centre Leon Berard, Lyon, France|Institut de Cancérologie de la Loire Lucien Neurwirth, Saint-Priest-en-Jarez, France|Centre Hospitalier Universitaire de St Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04457570,France,,2.0,2021,Monday
2212,2213,Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel,Not yet recruiting,Drug: Ivermectin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,550.0,"September 7, 2020",2020-12-16,"August 26, 2020","Pontificia Universidad Javeriana, Cali, Valle Del Cauca, Colombia",https://ClinicalTrials.gov/show/NCT04527211,Colombia,Ivermectin,12.0,2020,Wednesday
2213,2214,Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,400.0,"April 11, 2020",2021-04-11,"September 2, 2020","Medical University of Vienna, Division for Nephrology and Dialysis, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04347694,Austria,,4.0,2021,Sunday
2214,2215,"Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome",Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,200.0,"June 1, 2020",2020-09-01,"June 30, 2020","Faculty of Medicine Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04447144,Egypt,,9.0,2020,Tuesday
2215,2216,Outcomes and Prognostic Factors in COVID-19,Recruiting,,All,70 Years and older   (Older Adult),,4000.0,"March 19, 2020",2021-12-01,"November 4, 2020","Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway",https://ClinicalTrials.gov/show/NCT04321265,Denmark,,12.0,2021,Wednesday
2216,2217,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Recruiting,Drug: Ruxolitinib|Drug: Fostamatinib|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,456.0,"October 2, 2020",2021-07-31,"November 17, 2020","Imperial College Healthcare NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04581954,United Kingdom,Ruxolitinib|Fostamatinib,7.0,2021,Saturday
2217,2218,Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group,Recruiting,Other: Questionnaire-based observational study,All,"18 Years to 100 Years   (Adult, Older Adult)",,100.0,"June 30, 2020",2020-08-31,"July 22, 2020","Centre antituberculeux; Geneva University Hospital, Geneva, Geneva 14, Switzerland",https://ClinicalTrials.gov/show/NCT04477473,Switzerland,,8.0,2020,Monday
2218,2219,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Drug: Anakinra,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 15, 2020",2022-04-15,"October 29, 2020","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|1st Department of InternalMedicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|1st University Departmentof Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseasesof Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION, Athens, Greece|1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO, Athens, Greece|2nd Department of Internal Medicine, 251 Air Force General Hospital, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S., Athens, Greece|5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece|Department of Internal Medicine, General Hospital of Athens ELPIS, Athens, Greece|Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|Department of Internal Medicine, General Hospital of Katerini, Kateríni, Greece|Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece|Department of Internal Medicine, General Hospital of Larisa KOUTLIMBANEIO & ΤΡΙΑΝΤΑFΥLLΕΙΟ, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO, Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",https://ClinicalTrials.gov/show/NCT04357366,Greece,Anakinra,4.0,2022,Friday
2219,2220,Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"November 18, 2020",2021-09-18,"December 7, 2020","Clinique du Parc, Montpellier, France|University Hospitals of Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04619693,France,,9.0,2021,Saturday
2220,2221,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,Recruiting,Drug: Trans Sodium Crocetinate|Drug: Normal saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,224.0,"September 10, 2020",2021-12-14,"October 5, 2020","National Institute of Infectious Diseases- Prof. Dr. Matei Balş, Bucharest, Romania",https://ClinicalTrials.gov/show/NCT04573322,Oman,Trans Sodium Crocetinate|Normal saline,12.0,2021,Tuesday
2221,2222,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Recruiting,Drug: Autophagy inhibitor (GNS651)|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,219.0,"April 15, 2020",2021-08-01,"December 4, 2020","Centre Léon Bérard, Lyon, Rhône, France|CHU Clermont Ferrand, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|AP-HP Hôpital Saint Antoine, Paris, France|AP-HP La Pitié Salpétrière, Paris, France|Hôpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hôpital Bichat Claude Bernard, Paris, France|GH Diaconesses Croix Saint Simon, Paris, France|Institut Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT04333914,France,Autophagy inhibitor (GNS651)|Avdoralimab|Monalizumab,8.0,2021,Sunday
2222,2223,Investigation of Safety and Efficacy of CARDIO Softgels in Former Smokers and Asthma Patients With COVID-19 Infection,Not yet recruiting,Dietary Supplement: Best Standard of Care + CARDIO|Dietary Supplement: Best Standard of Care,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100.0,"August 31, 2020",2021-08-31,"July 10, 2020","KGK Science Inc., London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04465513,Canada,,8.0,2021,Tuesday
2223,2224,Interferon Lambda Therapy for COVID-19,Not yet recruiting,Drug: Peginterferon Lambda-1A,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66.0,September 2020,2021-05-01,"June 16, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04388709,United States,Peginterferon Lambda-1A,5.0,2021,Saturday
2224,2225,COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising,Completed,,All,"4 Years to 80 Years   (Child, Adult, Older Adult)",,130.0,"May 22, 2020",2020-06-14,"June 16, 2020","Faculty of Medicine, University of Alexandria, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT04433039,Egypt,,6.0,2020,Sunday
2225,2226,COVID-19 Seroprevalence Study in French Guiana,Recruiting,Procedure: Blood sample,All,"Child, Adult, Older Adult",Not Applicable,1500.0,"July 15, 2020",2021-07-15,"July 29, 2020","Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Laboratoire de biologie méicale, Institut Pasteur de la Guyane, Cayenne, French Guiana|Laboratoires Eurofins Guyane, Cayenne, French Guiana|Laboratoire de biologie médicale de Kourou, Kourou, French Guiana|Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, Saint-Laurent du Maroni, French Guiana",https://ClinicalTrials.gov/show/NCT04490850,French Guiana,,7.0,2021,Thursday
2226,2227,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Recruiting,Other: Respiratory and psychological rehabilitation,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,108.0,"October 26, 2020",2021-03-30,"December 2, 2020","Hospital Nacional Cayetano Heredia, Lima, Peru",https://ClinicalTrials.gov/show/NCT04649736,Peru,,3.0,2021,Tuesday
2227,2228,COVID-19: Herd Immunity Study in the Czech Republic,Completed,Diagnostic Test: SARS-CoV-2 diagnostic rapid test|Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies,All,"8 Years to 89 Years   (Child, Adult, Older Adult)",,27000.0,"April 23, 2020",2020-05-01,"June 1, 2020","Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia",https://ClinicalTrials.gov/show/NCT04401085,Czech Republic,,5.0,2020,Friday
2228,2229,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Recruiting,Drug: Sargramostim|Other: Normal Saline 0.9%,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2,30.0,"June 2, 2020",2022-06-01,"July 7, 2020","Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04400929,Singapore,Sargramostim,6.0,2022,Wednesday
2229,2230,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Recruiting,Diagnostic Test: Blood sample for serological test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1800.0,"April 17, 2020",2021-08-01,"June 22, 2020","Hôpitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel Hôpital Civil et Hautepierre, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04441684,France,,8.0,2021,Sunday
2230,2231,Outcomes of Covid-19 Protective Measures in Endoscopy,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 27, 2020",2020-07-27,"June 19, 2020","Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain",https://ClinicalTrials.gov/show/NCT04371354,Spain,,7.0,2020,Monday
2231,2232,Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre,Recruiting,Diagnostic Test: Antibody Test,All,"Child, Adult, Older Adult",,300.0,"May 13, 2020",2020-08-01,"June 24, 2020","University Tuebingen, Tuebingen, BW, Germany",https://ClinicalTrials.gov/show/NCT04446338,Germany,,8.0,2020,Saturday
2232,2233,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,Completed,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 19, 2020",2020-10-02,"October 28, 2020","Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04561219,Brazil,Nitazoxanide|Placebo,10.0,2020,Friday
2233,2234,COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX),Recruiting,Diagnostic Test: ABPM|Diagnostic Test: ECG|Diagnostic Test: FMD|Diagnostic Test: PWV|Diagnostic Test: Rarefaction,All,30 Years to 60 Years   (Adult),,70.0,"June 1, 2020",2021-05-31,"August 12, 2020","NHS Greater Glasgow and Clyde, Glasgow, United Kingdom",https://ClinicalTrials.gov/show/NCT04409847,United Kingdom,,5.0,2021,Monday
2234,2235,BCG Vaccination to Protect Healthcare Workers Against COVID-19,Recruiting,Drug: BCG Vaccine|Drug: 0.9%NaCl,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10078.0,"March 30, 2020",2022-03-30,"October 22, 2020","St Vincent's Hospital, Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Noord West Ziekenhuis, Alkmaar, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|St Antonius Hospital, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|University hospital in Utrecht (UMCU), Utrecht, Netherlands|University Hospital German Trias I Pujol, Badalona, Barcelona, Spain|Mutua Terrassa Univeristy Hospital, Terrassa, Barcelona, Spain|University Hospital Cruces, Barakaldo, Bizkaia, Spain|Marqués de Valdecilla University Hospital, Santander, Spain|University Hospital Virgen Macarena, Sevilla, Spain|Lozano Blesa University Hospital, Zaragoza, Spain|Ide Lane Surgery, Alphington, Exeter, United Kingdom|St Leonard's Practice, St Leonards, Exeter, United Kingdom|Travel Clinic, Exeter, United Kingdom",https://ClinicalTrials.gov/show/NCT04327206,Australia,BCG Vaccine|0.9%NaCl,3.0,2022,Wednesday
2235,2236,Coronavirus (COVID-19) ACEi/ARB Investigation,Suspended,Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2414.0,"April 30, 2020",2021-12-01,"June 30, 2020","University Hospital Galway, Galway, Ireland",https://ClinicalTrials.gov/show/NCT04330300,Ireland,Thiazide or Thiazide-like diuretics|Calcium Channel Blockers|ACE inhibitor|Angiotensin receptor blocker,12.0,2021,Wednesday
2236,2237,COVID-19 Infection and Multiple Myeloma,Recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,500.0,"July 1, 2020",2021-07-01,"July 30, 2020","General Hopspital Vienna/Medical University, Vienna, Austria|UCL Saint-Luc, Brussels, Belgium|University Hospital Ostrava, Ostrava, Czechia|University Hospital Würzburg, Würzburg, Germany|Alexandra Clinical Terapeutics, Athens, Greece|AOU Consorziale Policlinico di Bari, Bari, Italy|Amsterdam UMC, Amsterdam, Netherlands|St James's University Hospital, Leeds, United Kingdom",https://ClinicalTrials.gov/show/NCT04492371,Austria,,7.0,2021,Thursday
2237,2238,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Recruiting,Other: Rehabilitation by Eccentric exercises|Other: Rehabilitation by Concentric exercises,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120.0,"June 5, 2020",2021-12-05,"December 2, 2020","CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|Centre Médico-Chirurgical de Réadaptation (CMCR) des Massues, Lyon, France|CHU de Saint-Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04649086,France,,12.0,2021,Sunday
2238,2239,COVID-19 in Liver Transplant Recipients,Recruiting,Other: Observational only,All,"Child, Adult, Older Adult",,200.0,"March 1, 2020",2021-03-01,"April 24, 2020","SETH-affiliated Liver Transplant Programs in Spain, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04361591,Spain,,3.0,2021,Monday
2239,2240,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic,Completed,Other: care modalities|Other: Teleconsultation either by phone or by computer consultation,All,"18 Years and older   (Adult, Older Adult)",,610.0,"May 4, 2020",2020-05-29,"November 10, 2020","Hôpitaux Universitaires de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04370171,France,,5.0,2020,Friday
2240,2241,Ravulizumab and COVID-19,Not yet recruiting,Drug: Ravulizumab,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,32.0,November 2020,2021-11-01,"September 30, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04570397,United States,Ravulizumab,11.0,2021,Monday
2241,2242,Relationship Between Biological Profiles and Clinical Evolutions Within the Same Cluster COVID-19 (COVIDCOLLECT),Not yet recruiting,"Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine",All,"Child, Adult, Older Adult",Not Applicable,100.0,November 2020,2022-02-01,"October 22, 2020","CHU de Clermont-Ferrand, Clermont-Ferrand, France",https://ClinicalTrials.gov/show/NCT04597736,France,,2.0,2022,Tuesday
2242,2243,Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.,Completed,Device: N-95 Respirator|Device: Cloth Face Mask|Diagnostic Test: Graded exercise test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"June 1, 2020",2020-08-01,"August 13, 2020","Cleveland Clinic, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04415879,United States,,8.0,2020,Saturday
2243,2244,Novel Regimens in COVID-19 Treatment,Recruiting,Drug: Nitazoxanide,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160.0,"May 8, 2020",2030-12-01,"December 4, 2020","Tanta University, Assiut University, Tanta, Egypt|Sherief Abd-Elsalam, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04382846,Egypt,Nitazoxanide,12.0,2030,Sunday
2244,2245,Rhu-pGSN for Severe Covid-19 Pneumonia,Recruiting,Drug: Recombinant human plasma gelsolin (Rhu-pGSN)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"July 30, 2020",2020-10-30,"July 31, 2020","Sant Joan de Reus SAM University Hospital, Reus, Spain",https://ClinicalTrials.gov/show/NCT04358406,Spain,Recombinant human plasma gelsolin (Rhu-pGSN),10.0,2020,Friday
2245,2246,Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19,Not yet recruiting,Device: therapeutic plasmaexchnage,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,20.0,December 2020,2021-12-01,"November 3, 2020",,https://ClinicalTrials.gov/show/NCT04613986,Undefined,,12.0,2021,Wednesday
2246,2247,"The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic""",Terminated,,All,"18 Years and older   (Adult, Older Adult)",,4.0,"April 29, 2020",2020-10-09,"October 30, 2020","Mater Misericordiae University Hospital, Dublin, Ireland|University Hospital Limerick, Limerick, Ireland|University Hospital Waterford, Waterford, Ireland",https://ClinicalTrials.gov/show/NCT04581070,Ireland,,10.0,2020,Friday
2247,2248,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,Recruiting,Drug: BCG-10 vaccine|Drug: 0.9% saline,All,"25 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"July 7, 2020",2021-04-01,"December 2, 2020","Department of Anesthesiology and Intensive Care, University Clinical Center, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland|Stefan Żeromski Specialist Hospital, Kraków, Poland|Voivodeship Hospital nr 2 in the Name of The Saint Queen Jadwiga, University of Rzeszów, Poland, Rzeszów, Poland|Saint Jadwiga Śląska Hospital, Trzebnica, Poland|Department of Pediatrics, Bielanski Hospital,, Warsaw, Poland|Praski Hospital, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04648800,Poland,BCG-10 vaccine|0.9% saline,4.0,2021,Thursday
2248,2249,Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,Other: venous ultrasound|Biological: blood sample,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 4, 2020",2020-11-01,"May 8, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04377490,France,,11.0,2020,Sunday
2249,2250,Honey & Nigella Sativa Trial Against COVID-19,Completed,Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 3,313.0,"April 30, 2020",2020-08-30,"November 12, 2020","Federal Post-Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Punjab, Pakistan|Services Institute of Medical Sciences, Services Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04347382,Pakistan,Honey|Nigella Sativa / Black Cumin|Placebos,8.0,2020,Sunday
2250,2251,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),"Active, not recruiting",Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,45.0,"April 24, 2020",2020-12-31,"September 3, 2020","Cleveland Clinic Florida, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04365153,United States,Canakinumab Injection 600mg|Canakinumab Injection 300mg|Placebos,12.0,2020,Thursday
2251,2252,Mouth Rinses for Inactivation of COVID-19,Not yet recruiting,Drug: 1.5-2% w/v Hydrogen Peroxide|Drug: 0.12% Chlorhexidine Gluconate|Drug: 21% Ethanol plus essential oils|Drug: 1% w/v Povidone-iodide|Drug: 0.075% Cetylpyridinium Chloride|Other: Saline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,480.0,December 2020,2023-09-01,"November 6, 2020","General and Oral Health Center, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04584684,United States,1.5-2% w/v Hydrogen Peroxide|0.12% Chlorhexidine Gluconate|21% Ethanol plus essential oils|1% w/v Povidone-iodide|0.075% Cetylpyridinium Chloride,9.0,2023,Friday
2252,2253,SARS-CoV-2 IgG and IgM Serologic Assays,Recruiting,Diagnostic Test: Serologic assays for antibodies to SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,500.0,"August 14, 2020",2021-08-01,"September 24, 2020","Henry Ford Health System, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04562246,United States,,8.0,2021,Sunday
2253,2254,Renin-Angiotensin System Inhibitors and COVID-19,Recruiting,,All,"18 Years to 120 Years   (Adult, Older Adult)",,2000.0,"March 10, 2020",2020-04-30,"April 2, 2020","Spedali Civili di Brescia, Brescia, Italy",https://ClinicalTrials.gov/show/NCT04331574,Italy,,4.0,2020,Thursday
2254,2255,Post Covid Syndrome: Clinical Pattern and Functional Assessment,Not yet recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,85.0,"December 1, 2020",2022-01-01,"September 25, 2020",,https://ClinicalTrials.gov/show/NCT04561141,Undefined,,1.0,2022,Saturday
2255,2256,RAS and Coagulopathy in COVID19,Recruiting,Biological: TRV027|Other: sodium chloride 0.9%,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,60.0,"October 9, 2020",2021-05-01,"December 11, 2020","Imperial College NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04419610,United Kingdom,,5.0,2021,Saturday
2256,2257,COVID 19 Preventive Measures Among Mansoura Nursing Students,Recruiting,,All,"Child, Adult, Older Adult",,215.0,"July 15, 2020",2020-12-01,"July 16, 2020","Faculty of Nursing Mansoura University, Mansoura, Egypt",https://ClinicalTrials.gov/show/NCT04473547,Egypt,,12.0,2020,Tuesday
2257,2258,Bacteriotherapy in the Treatment of COVID-19,"Active, not recruiting",Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",,70.0,"March 1, 2020",2020-07-31,"May 4, 2020","Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",https://ClinicalTrials.gov/show/NCT04368351,Italy,Azithromycin|hydroxychloroquine,7.0,2020,Friday
2258,2259,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic,"Active, not recruiting",Other: PRO-SERO-COV,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,550.0,"June 1, 2020",2021-12-01,"November 30, 2020","Institut Bergonié, Bordeaux, France",https://ClinicalTrials.gov/show/NCT04426006,France,,12.0,2021,Wednesday
2259,2260,The Natural History of Hospitalized COVID-19 Patients,"Active, not recruiting",Other: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.,All,"18 Years and older   (Adult, Older Adult)",,1433.0,"February 23, 2020",2020-12-01,"June 11, 2020","ASST Monza-Ospedale San Gerardo, Monza, Italy",https://ClinicalTrials.gov/show/NCT04424992,Italy,,12.0,2020,Tuesday
2260,2261,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Recruiting,Diagnostic Test: SARS-CoV2 serum antibody testing,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"May 5, 2020",2020-10-30,"May 15, 2020","Hospital for Special Surgery, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04389294,United States,,10.0,2020,Friday
2261,2262,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Dietary Supplement: Vitamins|Drug: Telmisartan|Drug: Ciclesonide,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,615.0,"July 29, 2020",2021-08-31,"December 1, 2020","CH de Bastia, Bastia, France|Bordeaux university Hospital, Bordeaux, France|CHU de Dijon-Bourgogne, Dijon, France|CHRU de Nancy, Nancy, France|CHU de Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04356495,France,Telmisartan|Ciclesonide,8.0,2021,Tuesday
2262,2263,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,Recruiting,Procedure: Conventional oxygen therapy|Procedure: High flow nasal cannula,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,196.0,"August 11, 2020",2021-07-28,"November 2, 2020","Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia",https://ClinicalTrials.gov/show/NCT04609462,Colombia,,7.0,2021,Wednesday
2263,2264,Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19,Not yet recruiting,Drug: ACEIs|Drug: Conventional treatment,All,"Child, Adult, Older Adult",Phase 3,60.0,"April 15, 2020",2029-12-01,"April 14, 2020","Tanta University, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04345406,Egypt,ACEIs|Conventional treatment,12.0,2029,Saturday
2264,2265,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"April 24, 2020",2021-04-01,"December 11, 2020","University of Arizona, Phoenix, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Scripps Health, La Jolla, California, United States|University of Colorado Denver, Aurora, Colorado, United States|MedStar Health Research Institute/MedStar Washington Hospital Center, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore (University of Maryland Medical Center), Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellelsey Hospital, Newton, Massachusetts, United States|Mercy Health Muskegon, Muskegon, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|University at Buffalo/Buffalo General Medical Center, Buffalo, New York, United States|Rochester General Hospital, Rochester, New York, United States|The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Utah Valley Hospital, Provo, Utah, United States|University of Utah Health, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04362176,Israel,,4.0,2021,Thursday
2265,2266,Thromboprophylaxis for Patients in ICU With COVID-19,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,950.0,"March 1, 2020",2020-11-01,"November 10, 2020","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital General de Ciudad Real, Ciudad Real, Castilla La Mancha, Spain|Complejo Asistencial Universitario de León, León, Castilla Y León, Spain|Hospital Universitario Rio Ortega, Valladolid, Castilla Y León, Spain|Hospital Clinic Barcelona, Barcelona, Cataluña, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña, Spain|Hospital de Terrasa, Barcelona, Cataluña, Spain|Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain|Hospital Universitario San Juan de Alicante, Alicante, Comunidad Valenciana, Spain|Complejo Hospitalario de Cáceres, Cáceres, Extramedura, Spain|Hospital Unversitario A Coruña, A Coruña, Galicia, Spain|Complexo Hospitalario Universitario de Ferrol, A Coruña, Galicia, Spain|Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain|Hospital Povisa, Pontevedra, Galicia, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Gran Canaria, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Araba, Álava, País Vasco, Spain|Hospital del Mar, Barcelona, Spain|Hospital Sanitas Cima, Barcelona, Spain|Hospital Sant Joan Despí, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Infanta Sofia, Madrid, Spain|Hospital Rafael Méndez, Murcia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitari La Fe, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04623177,Spain,,11.0,2020,Sunday
2266,2267,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,Diagnostic Test: Ejaculated semen sample,Male,18 Years to 50 Years   (Adult),Not Applicable,20.0,"August 31, 2020",2021-08-31,"October 28, 2020","UZ Brussel, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04391829,Belgium,,8.0,2021,Tuesday
2267,2268,Coagulation Changes Associated With COVID-19 Infection,Enrolling by invitation,Diagnostic Test: Quantra System,All,"18 Years and older   (Adult, Older Adult)",,50.0,"August 14, 2020",2021-02-15,"September 1, 2020","Texas Tech University Health Sciences Center El Paso, El Paso, Texas, United States",https://ClinicalTrials.gov/show/NCT04460664,United States,,2.0,2021,Monday
2268,2269,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 24, 2020",2021-02-28,"June 4, 2020","Intensive Care Unit and Respiratory division ; Groupe hospitalier Pitie-Salpetriere and Universite Pierre et Marie Curie Paris 6, Paris, France",https://ClinicalTrials.gov/show/NCT04413864,France,,2.0,2021,Sunday
2269,2270,Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19),Not yet recruiting,Drug: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,231.0,June 2020,2021-12-01,"May 20, 2020","Hospital San Vicente Fundacion, Medellín, Antioquia, Colombia",https://ClinicalTrials.gov/show/NCT04391101,Colombia,Convalescent plasma,12.0,2021,Wednesday
2270,2271,COVID-19 Pandemic and Female Sexual Behavior,Completed,Behavioral: fsfi survey,Female,"18 Years and older   (Adult, Older Adult)",,58.0,"April 10, 2020",2020-04-12,"May 5, 2020","Haseki Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04374422,Turkey,,4.0,2020,Sunday
2271,2272,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),Completed,,All,"18 Years and older   (Adult, Older Adult)",,1122.0,"March 6, 2020",2020-09-01,"September 22, 2020","Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|St Anna Ziekenhuis, Geldrop, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Leeuwarden Medisch Centrum, Leeuwarden, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|St Antonius Ziekenhuis, Nieuwegein, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard, Netherlands|Isala Ziekenhuis, Zwolle, Netherlands",https://ClinicalTrials.gov/show/NCT04346342,Netherlands,,9.0,2020,Tuesday
2272,2273,Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19),Recruiting,,All,"Child, Adult, Older Adult",,1900.0,"May 29, 2020",2021-12-01,"June 23, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04443712,Egypt,,12.0,2021,Wednesday
2273,2274,Prevalence of Thrombosis in COVID-Patients,Recruiting,Diagnostic Test: duplex sonography,All,"18 Years and older   (Adult, Older Adult)",,400.0,"November 4, 2020",2021-06-30,"November 4, 2020","University Hospital Augsburg, Augsburg, Germany",https://ClinicalTrials.gov/show/NCT04615026,Germany,,6.0,2021,Wednesday
2274,2275,Sero-prevalence COVID-19 Among Belgian Children,Not yet recruiting,,All,8 Years to 14 Years   (Child),,1640.0,"November 20, 2020",2021-08-31,"November 3, 2020",,https://ClinicalTrials.gov/show/NCT04613817,Undefined,,8.0,2021,Tuesday
2275,2276,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Completed,Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"July 20, 2020",2020-10-20,"November 4, 2020","Medical Centre Dinasty, Samara, Russian Federation",https://ClinicalTrials.gov/show/NCT04491240,Russian Federation,EXO 1 inhalation|EXO 2 inhalation|Placebo inhalation,10.0,2020,Tuesday
2276,2277,Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19,Not yet recruiting,Other: Standard of care (SOC)|Drug: Hydroxychloroquine|Drug: Association of diltiazem and niclosamide,All,"18 Years and older   (Adult, Older Adult)",Phase 3,480.0,May 2020,2023-05-01,"May 1, 2020",,https://ClinicalTrials.gov/show/NCT04372082,Undefined,Hydroxychloroquine|Association of diltiazem and niclosamide,5.0,2023,Monday
2277,2278,Influence of COVID-19 on Vascular Endothelial Function,"Active, not recruiting",Diagnostic Test: Carotid Artery Reactivity Testing,All,"16 Years and older   (Child, Adult, Older Adult)",,203.0,"July 14, 2020",2021-09-30,"September 16, 2020","Bernhoven, Uden, Netherlands",https://ClinicalTrials.gov/show/NCT04468412,Netherlands,,9.0,2021,Thursday
2278,2279,The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department,"Active, not recruiting",Diagnostic Test: Blood tests,All,"Child, Adult, Older Adult",,300.0,"March 20, 2020",2020-12-31,"July 21, 2020","Fundacio Puigvert, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04409899,Spain,,12.0,2020,Thursday
2279,2280,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Recruiting,Drug: ArtemiC|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 8, 2020",2021-01-01,"October 1, 2020","Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India|Hillel Yaffe Medical Center, Hadera, Haifa, Israel|Nazareth Hospital EMMS, Nazareth, North, Israel|Rambam Health Care Campus, Haifa, Israel",https://ClinicalTrials.gov/show/NCT04382040,India,ArtemiC|Placebo,1.0,2021,Friday
2280,2281,Prasugrel in Severe COVID-19 Pneumonia,Not yet recruiting,Drug: Prasugrel Hydrochloride 10 MG Oral Tablet|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,128.0,July 2020,2021-01-01,"June 26, 2020","Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy",https://ClinicalTrials.gov/show/NCT04445623,Italy,Prasugrel Hydrochloride 10 MG Oral Tablet|Placebo,1.0,2021,Friday
2281,2282,Characteristics of Neonatal Covid-19 in Turkey,Recruiting,,All,up to 28 Days   (Child),,90.0,"May 1, 2020",2020-12-30,"July 14, 2020","Recep Tayyip Erdogan University Medical School, Rize, Turkey",https://ClinicalTrials.gov/show/NCT04401540,Turkey,,12.0,2020,Wednesday
2282,2283,Symptom-Based Markers for COVID Transmission,Not yet recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,500.0,December 2020,2021-04-01,"December 11, 2020","University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT04665245,United States,,4.0,2021,Thursday
2283,2284,Outpatient Treatment With CoVid-19 With Prexablu,Recruiting,Drug: Sublingual Methylene blue|Other: Control patients,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,"October 12, 2020",2020-12-30,"November 12, 2020","Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico",https://ClinicalTrials.gov/show/NCT04619290,Mexico,Sublingual Methylene blue,12.0,2020,Wednesday
2284,2285,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Drug: Colchicine|Drug: Standard treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,180.0,"April 3, 2020",2020-09-30,"May 8, 2020","AHEPA Hospital, Thessaloniki, Gibraltar",https://ClinicalTrials.gov/show/NCT04326790,Gibraltar,Colchicine|Standard treatment,9.0,2020,Wednesday
2285,2286,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Recruiting,Drug: Anakinra|Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"April 2, 2020",2022-04-01,"April 22, 2020","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",https://ClinicalTrials.gov/show/NCT04339712,Greece,Anakinra|Tocilizumab,4.0,2022,Friday
2286,2287,Transpulmonary Driving Pressure in ARDS COVID19 Patients,Recruiting,,All,"18 Years to 90 Years   (Adult, Older Adult)",,40.0,"April 1, 2019",2021-12-31,"May 12, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04381286,France,,12.0,2021,Friday
2287,2288,Monocytes and NK Cells Activity in Covid-19 Patients,Recruiting,Diagnostic Test: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,150.0,"April 27, 2020",2020-10-31,"May 5, 2020","ATS Insubria, Varese, Italy",https://ClinicalTrials.gov/show/NCT04375176,Italy,,10.0,2020,Saturday
2288,2289,Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study,Not yet recruiting,Device: Breath Biopsy face masks with removable filters and fitted PVA strip|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: oropharyngeal swabs,All,"18 Years and older   (Adult, Older Adult)",,500.0,September 2020,2021-04-01,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04508556,Undefined,,4.0,2021,Thursday
2289,2290,Burden for STaff Working in the NHS,Recruiting,,All,"Child, Adult, Older Adult",,100.0,"June 2, 2020",2022-04-26,"August 10, 2020","Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT04506632,United Kingdom,,4.0,2022,Tuesday
2290,2291,PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort,Recruiting,"Other: Blood tests sputum, nasal lavage and brushing",All,"16 Years and older   (Child, Adult, Older Adult)",,230.0,"June 18, 2020",2022-06-01,"August 19, 2020","Royal Brompton & Harefileld NHS Trusts, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04444609,United Kingdom,,6.0,2022,Wednesday
2291,2292,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,Recruiting,Other: Study A|Other: Study B|Other: Study C|Other: Study D,All,"Child, Adult, Older Adult",,10000.0,"April 9, 2020",2022-04-01,"June 11, 2020","Viollier AG, Allschwil, Switzerland|University Hospital Basel, Basel, Switzerland|Biozentrum University of Basel, Basel, Switzerland|sciCore University of Basel, Basel, Switzerland|Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland|Swiss Institute of Bioinformatics, Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04351503,Switzerland,,4.0,2022,Friday
2292,2293,COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study,Not yet recruiting,Device: Thermography|Device: Tympanic Temperature,All,"16 Years and older   (Child, Adult, Older Adult)",,100.0,"May 20, 2020",2020-07-01,"May 22, 2020","Queen Elizabeth University Hospital, Glasgow, United Kingdom",https://ClinicalTrials.gov/show/NCT04397380,United Kingdom,,7.0,2020,Wednesday
2293,2294,Use of PCR-Sars-CoV-2 in Children,Recruiting,,All,up to 14 Years   (Child),,600.0,"June 3, 2020",2021-05-31,"June 16, 2020","ACTIV network, Créteil, France|PARI network, Créteil, France",https://ClinicalTrials.gov/show/NCT04412317,France,,5.0,2021,Monday
2294,2295,Detecting SARS-CoV-2 in Tears,Not yet recruiting,Diagnostic Test: Tear Collection,All,"18 Years and older   (Adult, Older Adult)",,30.0,September 2020,2021-04-01,"August 26, 2020","University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04526769,United States,,4.0,2021,Thursday
2295,2296,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,11.0,"April 17, 2020",2020-06-26,"July 31, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04335552,United States,Hydroxychloroquine|Azithromycin,6.0,2020,Friday
2296,2297,COVID-19 IgG Formation in Physicians at ALGH and Their Household Members,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,900.0,"August 26, 2020",2021-09-24,"September 9, 2020","Advocate Lutheran General Hospital, Park Ridge, Illinois, United States",https://ClinicalTrials.gov/show/NCT04540484,United States,,9.0,2021,Friday
2297,2298,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,Drug: NK-1R antagonist,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,100.0,"June 15, 2020",2020-08-30,"July 13, 2020","Bahria International Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04468646,Pakistan,NK-1R antagonist,8.0,2020,Sunday
2298,2299,A Study of Quintuple Therapy to Treat COVID-19 Infection,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"June 22, 2020",2021-09-01,"July 20, 2020","ProgenaBiome, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04334512,United States,Hydroxychloroquine|Azithromycin,9.0,2021,Wednesday
2299,2300,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,436.0,"April 13, 2020",2022-01-13,"September 16, 2020","Hôpital Bichat - Service de Pneumologie, Paris, France",https://ClinicalTrials.gov/show/NCT04331054,France,2: Usual practice + SYMBICORT RAPIHALER,1.0,2022,Thursday
2300,2301,Frequency of Perforated Appendicitis in Times of COVID-19,Completed,Other: appendectomy,All,"16 Years and older   (Child, Adult, Older Adult)",,143.0,"March 16, 2020",2020-05-31,"July 15, 2020","University Hospital of Tuebingen, Tuebingen, Germany",https://ClinicalTrials.gov/show/NCT04472052,Germany,,5.0,2020,Sunday
2301,2302,Convalescent Plasma for COVID-19,Not yet recruiting,Biological: Blood plasma,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10.0,"April 27, 2020",2020-06-30,"April 28, 2020",,https://ClinicalTrials.gov/show/NCT04365439,Undefined,,6.0,2020,Tuesday
2302,2303,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,Drug: low-molecular-weight heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"August 1, 2020",2020-12-31,"October 14, 2020","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt",https://ClinicalTrials.gov/show/NCT04584580,Egypt,low-molecular-weight heparin,12.0,2020,Thursday
2303,2304,Prayer in Commbate to Corona Virus - Covid -19,Recruiting,Other: PRAYER,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 1, 2020",2021-01-01,"November 17, 2020","Hospital do Coracao, Sao Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04631380,Brazil,,1.0,2021,Friday
2304,2305,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1517.0,"April 23, 2020",2025-03-20,"December 9, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04362995,United States,,3.0,2025,Thursday
2305,2306,Covid-19 in Lupus Patients,Recruiting,,All,"18 Years to 90 Years   (Adult, Older Adult)",,130.0,"March 1, 2020",2020-12-30,"June 5, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04355702,France,,12.0,2020,Wednesday
2306,2307,Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients,Recruiting,Drug: Nigella Sativa / Black Cumin|Drug: Ivermectin Injectable Solution|Other: Placebo|Drug: Zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"July 14, 2020",2020-09-30,"July 15, 2020","Shaikh Zayed Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04472585,Pakistan,Nigella Sativa / Black Cumin|Ivermectin Injectable Solution|Zinc,9.0,2020,Wednesday
2307,2308,Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection,Recruiting,Diagnostic Test: Lung ultrasound,All,"17 Years and older   (Child, Adult, Older Adult)",,200.0,"July 1, 2020",2025-12-01,"November 25, 2020","Haukeland universitetssykehus, Bergen, Norway|Nordland Hospital, Bodø, Norway|Drammen sykehus, Drammen, Norway|Sørlandet sykehus, Kristiansand, Kristiansand, Norway|Akershus University Hospital, Oslo, Norway|Ullevål University Hospital, Oslo, Norway|Sykehuset Telemark HF, Skien, Norway|Stavanger Universitetssjukehus, Stavanger, Norway|St Olavs Hospital, Trondheim, Norway",https://ClinicalTrials.gov/show/NCT04422691,Norway,,12.0,2025,Monday
2308,2309,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,24.0,"June 30, 2020",2021-06-30,"July 9, 2020","Sacco University Hospital, Milan, MI, Italy",https://ClinicalTrials.gov/show/NCT04463849,Italy,,6.0,2021,Wednesday
2309,2310,Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients,Recruiting,Device: Therapeutic plasma exchange,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,10.0,"September 11, 2020",2021-08-30,"October 19, 2020","Larkin Community Hospital, South Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04592705,United States,,8.0,2021,Monday
2310,2311,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,829.0,"March 31, 2020",2020-10-08,"October 29, 2020","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04328961,United States,Hydroxychloroquine Sulfate|Ascorbic Acid,10.0,2020,Thursday
2311,2312,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Recruiting,Biological: Convalescent anti-SARS-CoV-2 MBT plasma|Other: Control Group,All,"50 Years and older   (Adult, Older Adult)",Phase 2,474.0,"October 30, 2020",2021-10-01,"November 9, 2020","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04621123,Spain,,10.0,2021,Friday
2312,2313,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Active, not recruiting",Biological: BCG vaccine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,908.0,"July 21, 2020",2021-01-01,"November 13, 2020","Hospital Universitario ""José E. González"", Monterrey, Nuevo León, Mexico",https://ClinicalTrials.gov/show/NCT04461379,Mexico,,1.0,2021,Friday
2313,2314,Parental Compliance After Telephone Triage Advice During and After Confinement During the COVID Epidemic in France,Not yet recruiting,,All,up to 17 Years   (Child),,250.0,December 2020,2021-03-01,"December 7, 2020","Hôpitaux Pédiatrique de Nice CHU Lenval, Nice, France",https://ClinicalTrials.gov/show/NCT04656444,France,,3.0,2021,Monday
2314,2315,Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS,Available,Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment,All,"18 Years and older   (Adult, Older Adult)",,,,,"December 8, 2020",,https://ClinicalTrials.gov/show/NCT04657458,Undefined,,,n,
2315,2316,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,Combination Product: Favipiravir and Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,520.0,"May 21, 2020",2021-11-01,"July 28, 2020","King Abdulaziz Hospital - Al Ahsa, Hasa, Eastern Region, Saudi Arabia|AlMadina General Hospital, Al Madīnah, Saudi Arabia|Al-Qatif Central Hospital, Al-Qatif, Saudi Arabia|Imam Abdulrahman Al Faisal Hospital - Dammam, Dammam, Saudi Arabia|King Abdulaziz Medical City, Jeddah, Saudi Arabia|King Abdulaziz Hospital - Makkah, Mecca, Saudi Arabia|King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|Imam Abdulrahman Alfaisal Hospital, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04392973,Saudi Arabia,,11.0,2021,Monday
2316,2317,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,Recruiting,Drug: Colchicine plus symptomatic treatment (paracetamol)|Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations),All,"60 Years and older   (Adult, Older Adult)",Phase 3,954.0,"August 19, 2020",2021-12-31,"November 20, 2020","Atención primaria (Área 2), Laredo, Cantabria, Spain|Gerencia de atención primaria (Área 3), Reinosa, Cantabria, Spain|Atencion primaria (AREA 1), Santander, Cantabria, Spain|Gerencia de atención primaria (área 4), Torrelavega, Cantabria, Spain",https://ClinicalTrials.gov/show/NCT04416334,Spain,Colchicine plus symptomatic treatment (paracetamol)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations),12.0,2021,Friday
2317,2318,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Not yet recruiting,Other: blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"October 15, 2020",2022-10-15,"September 29, 2020","Hôpital Pitié Salpétrière, Paris, France",https://ClinicalTrials.gov/show/NCT04568707,France,,10.0,2022,Saturday
2318,2319,Prognostic Factors of Patients With COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,201.0,"March 1, 2020",2020-03-13,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",https://ClinicalTrials.gov/show/NCT04292964,China,,3.0,2020,Friday
2319,2320,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Recruiting,Drug: Metformin Glycinate|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"July 14, 2020",2021-03-31,"November 12, 2020","The American British Cowdray Medical Center, I.A.P, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04625985,Mexico,Metformin Glycinate|Placebo oral tablet,3.0,2021,Wednesday
2320,2321,SEVERITY SCORE FOR COVID-19 PNEUMONIA,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,248.0,"April 29, 2020",2020-05-27,"May 1, 2020","Massimo Montalto, Roma, Italy",https://ClinicalTrials.gov/show/NCT04372199,Italy,,5.0,2020,Wednesday
2321,2322,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Drug: Methotrexate-LDE phase 1|Drug: Methotrexate-LDE phase 2|Drug: Placebo-LDE phase 2,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,100.0,"October 27, 2020",2021-07-15,"November 4, 2020","Heart Institute (InCor) - University of São Paulo Medical School, São Paulo, Brazil, São Paulo, SP, Brazil|Hospital Santa Marcelina, São Paulo, SP, Brazil|Institute Prevent Senior, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04610567,Brazil,Methotrexate-LDE phase 1|Methotrexate-LDE phase 2|Placebo-LDE phase 2,7.0,2021,Thursday
2322,2323,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Not yet recruiting,Other: Best Practice|Drug: Leflunomide|Drug: Placebo Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"September 18, 2020",2022-09-18,"August 31, 2020","City of Hope Medical Center, Duarte, California, United States",https://ClinicalTrials.gov/show/NCT04532372,United States,Leflunomide|Placebo Administration,9.0,2022,Sunday
2323,2324,HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients,Not yet recruiting,Genetic: Expression of receptors and activating proteases|Genetic: Polymorphism of the HSD3B1,All,"18 Years and older   (Adult, Older Adult)",,500.0,"September 1, 2020",2021-08-31,"August 18, 2020","Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland|Clinica Luganese Moncucco, Lugano, Switzerland",https://ClinicalTrials.gov/show/NCT04516850,Switzerland,,8.0,2021,Tuesday
2324,2325,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Active, not recruiting",Drug: L-ascorbic acid,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"April 16, 2020",2020-10-15,"September 18, 2020","Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT04357782,United States,L-ascorbic acid,10.0,2020,Thursday
2325,2326,Adolescents With COVID-19/MIS-C at HCFMUSP,Enrolling by invitation,Behavioral: Home-based exercise training,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,100.0,"September 24, 2020",2021-04-30,"December 9, 2020","Hospital das Clinicas Faculdade de Medicina USP, Sao Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04659486,Brazil,,4.0,2021,Friday
2326,2327,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,Recruiting,Drug: P2Et (Caesalpinia spinosa extract)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"September 30, 2020",2021-06-01,"October 5, 2020","Hospital Universitario San Ignacio, Bogotá, Colombia",https://ClinicalTrials.gov/show/NCT04410510,Colombia,P2Et (Caesalpinia spinosa extract),6.0,2021,Tuesday
2327,2328,MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009),Withdrawn,Drug: MK-5475|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,0.0,"July 7, 2020",2020-11-10,"August 14, 2020",,https://ClinicalTrials.gov/show/NCT04425733,Undefined,MK-5475|Placebo,11.0,2020,Tuesday
2328,2329,Oropharyngeal Dysphagia in Patients With COVID-19,Recruiting,Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST),All,"Child, Adult, Older Adult",,300.0,"April 14, 2020",2021-01-01,"September 23, 2020","Consorci Sanitari del Maresme (Hospital de Mataró), Mataró, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04346212,Spain,,1.0,2021,Friday
2329,2330,Lung Ultrasound in COVID-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"June 1, 2020",2020-10-01,"July 28, 2020","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands",https://ClinicalTrials.gov/show/NCT04487769,Netherlands,,10.0,2020,Thursday
2330,2331,Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore,Withdrawn,Drug: Hydroxychloroquine,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,0.0,April 2020,2020-08-01,"May 27, 2020","Montefiore Medical Center, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04350450,United States,Hydroxychloroquine,8.0,2020,Saturday
2331,2332,Blood Volume Assessment in COVID-19 ICU Patients - BVAC19,Recruiting,Device: BVA-100,All,"18 Years to 95 Years   (Adult, Older Adult)",,30.0,"August 1, 2020",2021-02-01,"August 18, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04517695,United States,,2.0,2021,Monday
2332,2333,The C3I COVID-19 Project,Recruiting,,All,"Child, Adult, Older Adult",,170000.0,"August 10, 2020",2021-12-31,"August 12, 2020","University of Wisconsin School of Medicine and Public Health Center for Tobacco Research and Intervention, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04506528,United States,,12.0,2021,Friday
2333,2334,Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"March 25, 2020",2020-06-20,"June 23, 2020","Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04438941,France,,6.0,2020,Saturday
2334,2335,Home-based Exercise in COVID-19 Survivors,Recruiting,Other: Exercise training,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60.0,"September 26, 2020",2021-12-21,"November 4, 2020","University of Sao Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04615052,Brazil,,12.0,2021,Tuesday
2335,2336,Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,850.0,"April 10, 2020",2021-09-01,"April 30, 2020","Chu Nantes, Nantes, France",https://ClinicalTrials.gov/show/NCT04344249,France,,9.0,2021,Wednesday
2336,2337,COVID-19 Serology and Immunosenescence,Recruiting,Biological: blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,330.0,"September 18, 2020",2021-11-01,"September 24, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04563650,France,,11.0,2021,Monday
2337,2338,Evaluation of Covid 19 Anxiety in Endometriosis Patients,Completed,,Female,18 Years to 45 Years   (Adult),,80.0,"April 5, 2020",2020-04-25,"May 20, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",https://ClinicalTrials.gov/show/NCT04337346,Turkey,,4.0,2020,Saturday
2338,2339,COVID19-FOIE National Observatory,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,1000.0,"May 11, 2020",2020-12-31,"May 21, 2020","Ganne, Bondy, France",https://ClinicalTrials.gov/show/NCT04375670,France,,12.0,2020,Thursday
2339,2340,"Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.",Recruiting,Other: Patient with SAR-CoV-2 infection,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"March 16, 2020",2023-07-01,"September 17, 2020","Humanitas Research Hospital, Rozzano, Milan, Italy",https://ClinicalTrials.gov/show/NCT04552340,Italy,,7.0,2023,Saturday
2340,2341,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Completed,Drug: Bromhexine Hydrochloride,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"May 14, 2020",2020-08-31,"September 3, 2020","Almazov National Medical Research Centre, Saint Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04405999,Russian Federation,Bromhexine Hydrochloride,8.0,2020,Monday
2341,2342,Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients,Recruiting,Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 1, 2020",2021-02-01,"August 21, 2020","Hôpital de la Croix Rousse / GHN, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital Lyon Sud, Pierre-Bénite, France",https://ClinicalTrials.gov/show/NCT04522037,France,,2.0,2021,Monday
2342,2343,Early Short Course Corticosteroids in COVID-19,Completed,Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",,250.0,"March 12, 2020",2020-04-30,"May 5, 2020","Henry Ford Hospital, Detroit, Michigan, United States",https://ClinicalTrials.gov/show/NCT04374071,United States,Methylprednisolone,4.0,2020,Thursday
2343,2344,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Recruiting,Behavioral: Simha Kriya|Behavioral: Reading a Book,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30000.0,"May 22, 2020",2020-12-31,"October 8, 2020","Beth Israel Deaconess Medical Centre, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04498442,Israel,,12.0,2020,Thursday
2344,2345,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","Active, not recruiting",Biological: Intramuscular Vaccine,All,18 Years to 55 Years   (Adult),Phase 1,180.0,"July 10, 2020",2021-12-31,"October 23, 2020","Syneos Health, Montréal, Quebec, Canada|Syneos Health, Québec, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04450004,Canada,,12.0,2021,Friday
2345,2346,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru",Recruiting,Biological: Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan,All,18 Years to 60 Years   (Adult),Phase 3,6000.0,"September 10, 2020",2021-09-01,"November 3, 2020","Av. Honorio Delgado 430, Urb. Ingeniería, San Martin De Porres, Lima, Peru",https://ClinicalTrials.gov/show/NCT04612972,Peru,,9.0,2021,Wednesday
2346,2347,Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19,"Active, not recruiting",Drug: Corticosteroids and Derivatives,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 1, 2020",2020-12-31,"October 19, 2020","Hopital Central, Service de Reanimation Medicale, Nancy, France",https://ClinicalTrials.gov/show/NCT04586114,France,Corticosteroids and Derivatives,12.0,2020,Thursday
2347,2348,Myeloproliferative Neoplasms (MPN) and COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,80.0,"May 13, 2020",2020-09-01,"July 23, 2020","New York-Presbyterian/Weill Cornell Medical Center, New York, New York, United States|Hopital Saint-Louis, Paris, France|University Medical Center RWTH, Aachen, Germany|University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany|Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy|A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria, Alessandria, Italy|ASST-Papa Giovanni XXIII, Bergamo, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|ASST-Spedali Civili, Brescia, Italy|AOU Ospedale Careggi, Firenze, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy|Ospedale Policlinico ""G.B. Rossi"" Borgo Roma, Verona, Italy|Ospedale San Bortolo, Vicenza, Italy|Sobas Wroclaw Medical University ·, Wrocław, Poland|Hospital Clínic De Barcelona, Barcelona, Barcellona, Spain|Hospital del Mar, Barcelona, Barcellona, Spain|Institut Català d' Oncologia - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO L'Hospitalet - Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital General de La Palma, Breña Alta, Santa Cruz De Tenerife, Spain|Servicio de Hematología Hospital General Universitario de Albacete, Albacete, Spain|Hospital General de Elche, Alicante, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|ICO Girona Hospital Josep Trueta Servei d'hematologia, Girona, Spain|FEA Hematología Hospital Universitario de Móstoles, Madrid, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Moncloa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario, Valencia, Spain|Guy's and St. Thomas' NHS Foundation Trust., London, United Kingdom",https://ClinicalTrials.gov/show/NCT04385160,France,,9.0,2020,Tuesday
2348,2349,Pediatric Acute and Critical Care COVID-19 Registry of Asia,Recruiting,,All,"up to 21 Years   (Child, Adult)",,2000.0,"May 18, 2020",2023-12-31,"October 6, 2020","Chongqing Hospital Children's Medical Center, Chongqing, China|Zhengzhou Children's hospital, Zhengzhou, China|Post Graduate Institute of Medical Education and Research, Chandigarh, India|General Hospital H. Adam Malik, Medan, Indonesia|Murni Teguh Memorial Hospital, Medan, Indonesia|St. Marianna University School of Medicine, Kanagawa, Japan|Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Kuala Lumpur, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Penang General Hospital, Pulau Pinang, Malaysia|Hospital Tuanku Ja'afar, Seremban, Malaysia, Seremban, Malaysia|Aga Khan University Hospital, Karachi, Pakistan|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04395781,China,,12.0,2023,Sunday
2349,2350,Atrium COVID-19 Syndromic and Serologic Surveillance,Enrolling by invitation,Other: daily syndromic surveillance|Diagnostic Test: monthly serologic IgM/G test,All,"18 Years and older   (Adult, Older Adult)",,450000.0,"May 6, 2020",2021-12-01,"July 8, 2020","Atrium Health, Charlotte, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04361123,United States,,12.0,2021,Wednesday
2350,2351,COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking,Recruiting,Other: No Intervention,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 15, 2020",2022-04-14,"June 16, 2020","University Hospital Hamburg Eppendorf, Hamburg, Germany",https://ClinicalTrials.gov/show/NCT04408339,Germany,,4.0,2022,Thursday
2351,2352,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,Not yet recruiting,Behavioral: Lift,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"December 1, 2020",2021-09-30,"November 20, 2020","University of Colorado - Denver, Aurora, Colorado, United States|University of Michigan, Ann Arbor, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health & Sciences University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04581200,United States,,9.0,2021,Thursday
2352,2353,Global Impact of COVID-19 on Pulmonology Special Units,Enrolling by invitation,Other: Survey,All,"Child, Adult, Older Adult",,100.0,"September 1, 2020",2020-12-30,"September 18, 2020","Aliae Mohamed-Hussein, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04554251,Egypt,,12.0,2020,Wednesday
2353,2354,Clinical Characterisation Protocol for COVID-19 in People Living With HIV,Not yet recruiting,Biological: Biological collection (patients co infected HIV Sras-CoV-2)|Other: Auto-questionnaires (patients co infected HIV Sras-CoV-2)|Other: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19),All,"18 Years and older   (Adult, Older Adult)",,270.0,April 2020,2020-10-01,"April 24, 2020","Department of Internal Medicine and Clinical Immunology of Professor Cécile Goujard, Le Kremlin-Bicêtre, France",https://ClinicalTrials.gov/show/NCT04361604,France,,10.0,2020,Thursday
2354,2355,FEnofibRate as a Metabolic INtervention for COVID-19,Enrolling by invitation,Other: Fenofibrate|Other: Placebo|Other: Usual care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"August 18, 2020",2021-08-31,"December 11, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04517396,United States,,8.0,2021,Tuesday
2355,2356,Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers,Not yet recruiting,Other: Prospective observation,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"September 21, 2020",2021-10-31,"September 25, 2020","AOU Mater Domini, Catanzaro, Italy",https://ClinicalTrials.gov/show/NCT04565522,Italy,,10.0,2021,Sunday
2356,2357,COVID-19 Outbreak Consequences for Outpatients Followed in PRM,Completed,,All,"18 Years and older   (Adult, Older Adult)",,467.0,"April 1, 2020",2020-05-09,"May 21, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04384406,France,,5.0,2020,Saturday
2357,2358,Helmet CPAP Versus HFNC in COVID-19,Recruiting,Device: Helmet CPAP|Device: HFNC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"June 3, 2020",2021-05-01,"June 5, 2020","Helsingborg's Hospital, Helsingborg, Region Skane, Sweden",https://ClinicalTrials.gov/show/NCT04395807,Sweden,,5.0,2021,Saturday
2358,2359,Kidney Involvement in COVID-19 Disease (COVKID),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,80.0,"April 15, 2020",2020-07-30,"May 13, 2020","Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04355624,France,,7.0,2020,Thursday
2359,2360,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,Recruiting,Drug: lopinavir/ritonavir|Drug: Losartan|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,4000.0,"April 6, 2020",2021-04-01,"August 20, 2020","Bassett Medical Center, Cooperstown, New York, United States",https://ClinicalTrials.gov/show/NCT04328012,United States,lopinavir/ritonavir|Losartan|Placebos,4.0,2021,Thursday
2360,2361,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Recruiting,Diagnostic Test: Lung impedance technique,All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,50.0,"April 28, 2020",2021-04-28,"May 28, 2020","Hillel Yaffe MC,, Hadera, Israel",https://ClinicalTrials.gov/show/NCT04406493,Israel,,4.0,2021,Wednesday
2361,2362,Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,Recruiting,,All,"Child, Adult, Older Adult",,80.0,"April 9, 2020",2020-07-01,"June 16, 2020","Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Atlantic Health System, Morristown, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04397900,Jersey,,7.0,2020,Wednesday
2362,2363,Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"April 20, 2020",2025-08-31,"May 7, 2020","Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain",https://ClinicalTrials.gov/show/NCT04359927,Spain,,8.0,2025,Sunday
2363,2364,Compassionate Use of REGN-COV2 for the Treatment of COVID-19,Available,Drug: REGN10933+REGN10987 combination therapy,,"Child, Adult, Older Adult",,,,,"November 5, 2020",,https://ClinicalTrials.gov/show/NCT04617535,Undefined,REGN10933+REGN10987 combination therapy,,n,
2364,2365,The COVID-19 Disease and CARdiac Events Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 29, 2020",2020-11-01,"June 19, 2020","University Hospital Hairmyres, Glasgow, Scotland, United Kingdom",https://ClinicalTrials.gov/show/NCT04438993,United Kingdom,,11.0,2020,Sunday
2365,2366,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Recruiting,"Biological: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1040.0,"October 31, 2020",2021-05-31,"November 5, 2020","Dafeng District Center for Disease Prevention and Control, Yancheng, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04617483,China,,5.0,2021,Monday
2366,2367,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,Other: Essential Oil Blend|Other: Control Blend,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,65.0,"October 1, 2020",2021-06-30,"October 19, 2020","Franklin School of Integrative Health Sciences, Franklin, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04495842,United States,,6.0,2021,Wednesday
2367,2368,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Not yet recruiting,Drug: Ivermectin Pill|Drug: Combined ART/hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,80.0,July 2020,2021-11-01,"June 23, 2020","Siriraj Hospital, Bangkok Noi, Bangkok, Thailand",https://ClinicalTrials.gov/show/NCT04435587,Thailand,Ivermectin Pill|Combined ART/hydroxychloroquine,11.0,2021,Monday
2368,2369,A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,Not yet recruiting,Biological: Covigenix VAX-001 placebo|Biological: Covigenix VAX-001,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 1,72.0,December 2020,2021-06-01,"November 24, 2020",,https://ClinicalTrials.gov/show/NCT04591184,Undefined,,6.0,2021,Tuesday
2369,2370,Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study,Not yet recruiting,Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances,All,"18 Years and older   (Adult, Older Adult)",,60.0,May 2020,2020-08-01,"May 14, 2020","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia",https://ClinicalTrials.gov/show/NCT04384042,Malaysia,,8.0,2020,Saturday
2370,2371,Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection,Recruiting,Diagnostic Test: serum NGAL and cystatin c,All,"18 Years to 65 Years   (Adult, Older Adult)",,88.0,"October 30, 2020",2021-03-01,"November 3, 2020","Ainshams hospitals, Cairo, Egypt|Sanaa Wasfy, New Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04603664,Egypt,,3.0,2021,Monday
2371,2372,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,Recruiting,Radiation: Low Dose Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"April 23, 2020",2020-10-23,"June 17, 2020","Emory University Hospital Midtown/Winship Cancer Institute, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04366791,Georgia,,10.0,2020,Friday
2372,2373,Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study,Not yet recruiting,Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances,All,"18 Years and older   (Adult, Older Adult)",,760.0,May 2020,2020-08-01,"May 15, 2020","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia",https://ClinicalTrials.gov/show/NCT04390165,Malaysia,,8.0,2020,Saturday
2373,2374,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",Not yet recruiting,Biological: mRNA-1273|Biological: Placebo,All,12 Years to 17 Years   (Child),Phase 2|Phase 3,3000.0,"November 30, 2020",2022-06-30,"December 4, 2020","Advanced Clinical Research, Meridian, Idaho, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Child Healthcare Associates, Liverpool, New York, United States|Lynn Health Sciences Institute, Oklahoma City, Oklahoma, United States|Kool Kids Pediatrics, Houston, Texas, United States|Tekton Research, San Antonio, Texas, United States|Advanced Clinical Research - Jordan Valley, West Jordan, Utah, United States",https://ClinicalTrials.gov/show/NCT04649151,Jordan,,6.0,2022,Thursday
2374,2375,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Recruiting,Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)|Diagnostic Test: Nasopharyngeal swabs,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2800.0,"April 28, 2020",2021-04-28,"July 30, 2020","Institut Curie, Paris, France|Institut Pasteur, Paris, France",https://ClinicalTrials.gov/show/NCT04369066,France,,4.0,2021,Wednesday
2375,2376,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Biological: mRNA-1273|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,"July 27, 2020",2022-10-27,"October 28, 2020","Ascension St. Vincent Birmingham, Birmingham, Alabama, United States|Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States|Hope Research Institute, Chandler, Arizona, United States|Synexus Clinical Research US, Inc. - Phoenix West, Glendale, Arizona, United States|Hope Research Institute, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Quality of Life Medical and Research Center, Tucson, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Advanced Clinical Research - Rancho Paseo, Banning, California, United States|University of California San Diego, La Jolla, California, United States|eStudySite - La Mesa, La Mesa, California, United States|UCLA Vine Street Clinic CRS, Los Angeles, California, United States|VA Greater Los Angeles Healthcare (veterans only), Los Angeles, California, United States|Paradigm Clinical Research Institute Inc, Redding, California, United States|Benchmark Research - Sacramento, Sacramento, California, United States|Medical Center For Clinical Research - M3 Wake Research, San Diego, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Lynn Institute of The Rockies, Colorado Springs, Colorado, United States|George Washington University, Washington, District of Columbia, United States|Accel Research Site, DeLand, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Synexus - Optimal Research - Melbourne, Melbourne, Florida, United States|Suncoast Research Group, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Synexus Clinical Research US, Inc. - Orlando, Orlando, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Hope Clinic of The Emory Vaccine Center, Decatur, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Synexus Clinical Research US, Inc. - Chicago, Chicago, Illinois, United States|UIC Project WISH CRS, Chicago, Illinois, United States|University of Chicago-Hospital, Chicago, Illinois, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Alliance for Multispecialty Research, Newton, Kansas, United States|Alliance for Multispecialty Research- East Wichita, Wichita, Kansas, United States|Meridian Clinical Research, Baton Rouge, Louisiana, United States|Benchmark Research - Metairie, Metairie, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Synexus - Optimal Research - Rockville, Rockville, Maryland, United States|Meridian Clinical Research, Rockville, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|MediSync Clinical Research Hattiesburg Clinic, Petal, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Meridian Clinical Research, Grand Island, Nebraska, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Jersey Medical School, Newark, New Jersey, United States|Meridian Clinical Research, Binghamton, New York, United States|Weill Cornell Chelsea - (CRS), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Tryon Medical Partners, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research - M3 Wake Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc - M3 Wake, Raleigh, North Carolina, United States|Trial Management Associates, Wilmington, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc. - Cincinnati, Cincinnati, Ohio, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Cincinnati CRS, Cincinnati, Ohio, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Crisor, Medford, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC University Center, Pittsburgh, Pennsylvania, United States|Keystone VitaLink Research, Anderson, South Carolina, United States|Keystone VitaLink Research - Greenville, Greenville, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Keystone VitaLink Research - Spartanburg, Spartanburg, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|WR-ClinSearch, Chattanooga, Tennessee, United States|Alliance for Multispecialty Research, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Medical Arts Building, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Medical Center North, Nashville, Tennessee, United States|Benchmark Research - Austin, Austin, Texas, United States|Synexus - Optimal Research - Austin, Austin, Texas, United States|Tekton Research, Austin, Texas, United States|Advanced Clinical Research - Be Well MD, Cedar Park, Texas, United States|Global Medical Research - M3 Wake Research, Dallas, Texas, United States|Synexus Clinical Research US, Inc. - Dallas, Dallas, Texas, United States|Benchmark Research - Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|DM Clinical Research - Texas Center For Drug Development, Houston, Texas, United States|Laguna Clinical Research, Laredo, Texas, United States|Centex Studies, McAllen, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Synexus Clinical Research US, Inc. - Salt Lake City, Murray, Utah, United States|Foothill Family Clinic - North, Salt Lake City, Utah, United States|Foothill Family Clinic-South Clinic, Salt Lake City, Utah, United States|Kaiser Permanente - Seattle, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04470427,Georgia,,10.0,2022,Thursday
2376,2377,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),"Active, not recruiting",Biological: COVID 19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,350.0,"March 20, 2020",2022-06-01,"November 2, 2020","Houston Methodist Hopsital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04554992,United States,,6.0,2022,Wednesday
2377,2378,Anti-SARS Cov-2 T Cell Infusions for COVID 19,Recruiting,Biological: Dose Finding Phase (MTD)|Biological: Partially HLA-matched SARS-CoVSTs|Other: Routine care (no SARS-CoVSTs),All,"18 Years and older   (Adult, Older Adult)",Phase 1,58.0,"November 4, 2020",2021-08-15,"November 9, 2020","Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04401410,United States,,8.0,2021,Sunday
2378,2379,Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year,Not yet recruiting,Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 2,75.0,"November 1, 2020",2021-11-01,"September 18, 2020","OHSU Knight Cancer Institute, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04455958,United States,Lopinavir/Ritonavir|Placebo Administration,11.0,2021,Monday
2379,2380,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,Recruiting,Diagnostic Test: CTUS examination,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 22, 2020",2020-09-22,"May 4, 2020","CHU de LIMOGES, Limoges, France|CHU de TOULOUSE, Toulouse, France",https://ClinicalTrials.gov/show/NCT04372680,France,,9.0,2020,Tuesday
2380,2381,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,Recruiting,Drug: Janus Kinase Inhibitor (ruxolitinib)|Other: Placebo,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"July 17, 2020",2021-12-31,"July 20, 2020","Hospital das Clínicas, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04477993,Brazil,Janus Kinase Inhibitor (ruxolitinib),12.0,2021,Friday
2381,2382,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 11, 2020",2021-04-01,"September 25, 2020","Hôpital Roger Salengro, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04341792,France,,4.0,2021,Thursday
2382,2383,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,Completed,Other: COVID 19 impact,,"Child, Adult, Older Adult",,998.0,"May 25, 2020",2020-06-21,"June 30, 2020","Mansoura university, Mansoura, Egypt",https://ClinicalTrials.gov/show/NCT04452682,Egypt,,6.0,2020,Sunday
2383,2384,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Recruiting,Drug: Ivermectin|Drug: Placebo,Male,18 Years to 45 Years   (Adult),Early Phase 1,24.0,"September 22, 2020",2021-05-01,"November 17, 2020","MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester, Greater Mancherster, United Kingdom",https://ClinicalTrials.gov/show/NCT04632706,United Kingdom,Ivermectin|Placebo,5.0,2021,Saturday
2384,2385,Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient,Completed,Other: non applicable,All,"18 Years and older   (Adult, Older Adult)",,802.0,"November 11, 2019",2020-05-15,"June 2, 2020","Hôpital E Herriot - Hospices Civils de LYON, Lyon, France",https://ClinicalTrials.gov/show/NCT04412031,France,,5.0,2020,Friday
2385,2386,International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,Recruiting,Other: Tested for SARS-CoV-2 (regardless of the result)|Other: Clinical diagnosis of COVID-19 by a health care professional,Female,"18 Years and older   (Adult, Older Adult)",,25000.0,"June 23, 2020",2024-04-30,"June 25, 2020","Pregistry, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04366986,United States,,4.0,2024,Tuesday
2386,2387,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,Recruiting,Drug: BMS-986253,All,"18 Years and older   (Adult, Older Adult)",Phase 2,138.0,"April 16, 2020",2022-09-01,"October 8, 2020","Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04347226,United States,BMS-986253,9.0,2022,Thursday
2387,2388,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,Recruiting,Behavioral: Informational videos and social media campaigns encouraging cancer screening.,All,"18 Years and older   (Adult, Older Adult)",,100.0,"August 28, 2020",2022-09-01,"October 14, 2020","Blackstone Valley Community Health Center, Pawtucket, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04587258,United States,,9.0,2022,Thursday
2388,2389,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Completed,Other: Standard interface|Device: Double-Trunk Mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12.0,"April 9, 2020",2020-05-01,"June 9, 2020","Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium",https://ClinicalTrials.gov/show/NCT04346420,Belgium,,5.0,2020,Friday
2389,2390,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Recruiting,Biological: Specific anti-SARS-CoV-2 antibodies,All,18 Years to 60 Years   (Adult),,726.0,"June 7, 2020",2020-09-30,"August 11, 2020","ECRRM, Cairo, Egypt|Faculty of Medicine, Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04424017,Egypt,,9.0,2020,Wednesday
2390,2391,Vitamin D Testing and Treatment for COVID 19,Completed,Dietary Supplement: Vitamin D3,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,"May 19, 2020",2020-11-30,"December 2, 2020","Arizona State University, Tempe, Arizona, United States",https://ClinicalTrials.gov/show/NCT04407286,United States,,11.0,2020,Monday
2391,2392,High GRP78 Levels in Covid-19 Infection: A Case-Control Study,Completed,Other: Serum protein level analysis,All,"18 Years and older   (Adult, Older Adult)",,144.0,"April 16, 2020",2020-10-10,"November 13, 2020","Aylin Koseler, Denizli, Outside Of The US, Turkey",https://ClinicalTrials.gov/show/NCT04628637,Turkey,,10.0,2020,Saturday
2392,2393,Early CPAP in COVID-19 Patients With Respiratory Failure.,Suspended,Device: CPAP treatment,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,900.0,October 2020,2020-11-09,"September 2, 2020","Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",https://ClinicalTrials.gov/show/NCT04326075,Italy,,11.0,2020,Monday
2393,2394,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,Recruiting,Other: Postural Positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,"May 25, 2020",2021-05-01,"June 24, 2020","Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04344561,United States,,5.0,2021,Saturday
2394,2395,Immune Changes in Severe COVID-19 Pulmonary Infections,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,15.0,"March 30, 2020",2020-05-30,"May 13, 2020","Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France",https://ClinicalTrials.gov/show/NCT04386395,France,,5.0,2020,Saturday
2395,2396,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,Recruiting,Device: Bedside lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"May 10, 2020",2020-09-10,"May 22, 2020","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04399681,Turkey,,9.0,2020,Thursday
2396,2397,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,Not yet recruiting,Drug: Sitagliptin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,170.0,"December 29, 2020",2021-12-30,"November 3, 2020","ASST FBF Sacco, Milan, Italy",https://ClinicalTrials.gov/show/NCT04365517,Italy,Sitagliptin,12.0,2021,Thursday
2397,2398,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"June 15, 2020",2021-04-14,"July 16, 2020","University Hospital Basel, Basel, Switzerland|Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|University Hospital Bern, Bern, Switzerland|Hôpitaux Universitaires Genève, Geneva, Switzerland|Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Clinica Luganese Moncucco, Lugano, Switzerland|University hospital zurich, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04400799,Switzerland,Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml,4.0,2021,Wednesday
2398,2399,"Endothelial Function, Inflammation and Organ Dysfunction in COVID-19",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,82.0,"August 5, 2020",2021-05-31,"December 1, 2020","Guy's & St Thomas' Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04408365,United Kingdom,,5.0,2021,Monday
2399,2400,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,Not yet recruiting,Behavioral: Biobehavioral Tele-rehabilitation Sessions,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,45.0,"December 15, 2020",2021-08-01,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04663945,Undefined,,8.0,2021,Sunday
2400,2401,Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients,Completed,Procedure: nasopharyngeal and throat swab|Procedure: collection of mucosal lining fluid|Procedure: blood collection via fingerprick,All,"Child, Adult, Older Adult",,187.0,"March 26, 2020",2020-05-13,"October 19, 2020","Radboudumc, Nijmegen, Gelderland, Netherlands",https://ClinicalTrials.gov/show/NCT04590352,Netherlands,,5.0,2020,Wednesday
2401,2402,Characterizing the Immune Response and Neuronal Damage in COVID-19,Recruiting,"Other: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.",All,"18 Years and older   (Adult, Older Adult)",,150.0,"March 5, 2020",2021-03-05,"August 12, 2020","Bern University Hospital, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04510012,Switzerland,,3.0,2021,Friday
2402,2403,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Active, not recruiting",Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,500.0,"September 11, 2020",2021-07-31,"November 13, 2020","Municipal budgetary institution ""Central City Hospital No. 7"", Ekaterinburg, Russian Federation|Federal budgetary institution of science ""Central Research Institute of Epidemiology"" of the Federal Service for Surveillance on Consumer Rights Protectionand Human Welfare, Moscow, Russian Federation|State Budgetary Institution of Healthcare of the City of Moscow ""City Polyclinic No. 2of the Department of Healthcare of the City of Moscow"", Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education ""First MoscowState Medical University named after I.M. Sechenov ""of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Limited Liability Company ""Research Center Eco-safety"", Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""Research Institute of Influenza named after A.A.Smorodintsev ""of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation|Private health care institution ""Clinical hospital 'Russian Railways - Medicine' of the city of Yaroslavl"", Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04540419,Russian Federation,,7.0,2021,Saturday
2403,2404,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,Recruiting,Diagnostic Test: Functional MRI,All,"18 Years and older   (Adult, Older Adult)",,100.0,"July 1, 2020",2023-03-30,"October 19, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04476589,United States,,3.0,2023,Thursday
2404,2405,African Covid-19 Critical Care Outcomes Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"May 1, 2020",2020-12-31,"September 10, 2020","Groote Schuur Hospital, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04367207,South Africa,,12.0,2020,Thursday
2405,2406,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),Recruiting,Diagnostic Test: Pulmonary function tests|Diagnostic Test: Imaging|Biological: Blood sampling,All,"18 Years and older   (Adult, Older Adult)",,130.0,"April 29, 2020",2022-04-28,"December 2, 2020","Medical University of Innsbruck, Innsbruck, Austria",https://ClinicalTrials.gov/show/NCT04416100,Austria,,4.0,2022,Thursday
2406,2407,BAttLe Against COVID-19 Using MesenchYmal Stromal Cells,Not yet recruiting,Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"April 6, 2020",2020-09-30,"April 16, 2020",,https://ClinicalTrials.gov/show/NCT04348461,Undefined,Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells,9.0,2020,Wednesday
2407,2408,Clinical Trial of Sarilumab in Adults With COVID-19,Not yet recruiting,Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120.0,"April 27, 2020",2020-07-27,"April 27, 2020","Hospital Universitario Reina Sofía, Córdoba, Spain",https://ClinicalTrials.gov/show/NCT04357860,Spain,Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment,7.0,2020,Monday
2408,2409,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Recruiting,Drug: CERC-002|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,82.0,"June 9, 2020",2020-11-01,"October 1, 2020","Hoag Memorial Hospital, Newport Beach, California, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Parkview Research Center, Fort Wayne, Indiana, United States|MedPharmics, LLC, Metairie, Louisiana, United States|LSUHSC - Shreveport, Shreveport, Louisiana, United States|Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|AnMed Health Medical Center, Anderson, South Carolina, United States|Lowcountry Infectious Diseases, P.A., Charleston, South Carolina, United States|BRCR Global Texas, McAllen, Texas, United States",https://ClinicalTrials.gov/show/NCT04412057,India,CERC-002|Placebo,11.0,2020,Sunday
2409,2410,Post Intensive Care Syndrome in COVID19 Patients,Recruiting,Diagnostic Test: Questionnaires,All,"18 Years to 90 Years   (Adult, Older Adult)",,100.0,"June 1, 2020",2022-06-01,"June 12, 2020","Corporació Parc Taulí, Sabadell, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04422444,Spain,,6.0,2022,Wednesday
2410,2411,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,142.0,"April 16, 2020",2020-09-03,"October 27, 2020","Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil",https://ClinicalTrials.gov/show/NCT04420247,Brazil,Chloroquine|Hydroxychloroquine,9.0,2020,Thursday
2411,2412,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,Recruiting,"Diagnostic Test: MRI (heart, brain, lungs, liver)|Diagnostic Test: Bloodwork|Other: Cognitive testing|Other: Olfaction testing|Diagnostic Test: Spirometry|Other: Walk Test",All,"18 Years and older   (Adult, Older Adult)",,228.0,"November 12, 2020",2021-09-01,"November 25, 2020","University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04525404,Canada,,9.0,2021,Wednesday
2412,2413,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,Diagnostic Test: CT-scan|Diagnostic Test: EEG|Diagnostic Test: EP|Diagnostic Test: Pulse oximetry|Diagnostic Test: Blood tests,All,18 Years to 60 Years   (Adult),Not Applicable,51.0,"May 22, 2020",2020-10-29,"October 30, 2020","N.I. Pirogov National Medical and Surgical Center, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04405544,Russian Federation,,10.0,2020,Thursday
2413,2414,Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women,Withdrawn,Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet,Female,18 Years to 50 Years   (Adult),Phase 2,0.0,May 2020,2020-05-01,"June 25, 2020",,https://ClinicalTrials.gov/show/NCT04354441,Undefined,hydroxychloroquine sulfate 200 MG|Placebo oral tablet,5.0,2020,Friday
2414,2415,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,Recruiting,Biological: BCG-Denmark|Biological: Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1050.0,"December 3, 2020",2022-03-01,"December 4, 2020","Cape Verde, Praia, Santiago, Cape Verde|Bandim Health Project, Bissau, SAB, Guinea-Bissau|Manhiça Health Research Centre, Manhiça, Maputo, Mozambique",https://ClinicalTrials.gov/show/NCT04641858,Cape Verde,,3.0,2022,Tuesday
2415,2416,"Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection",Recruiting,Other: Hospitalized Patients for COVID-19 Infection,All,"18 Years and older   (Adult, Older Adult)",,15.0,"November 1, 2020",2020-11-15,"November 25, 2020","Centre hospitalier intercommunal de Villeneuve St Georges, Villeneuve St Georges, France",https://ClinicalTrials.gov/show/NCT04432922,France,,11.0,2020,Sunday
2416,2417,"Facial Hair, PPE and COVID-19",Completed,Behavioral: Questionnaire,All,"Child, Adult, Older Adult",,358.0,"May 14, 2020",2020-06-08,"October 8, 2020","Royal Cornwall Hospital, Truro, Cornwall, United Kingdom",https://ClinicalTrials.gov/show/NCT04579627,United Kingdom,,6.0,2020,Monday
2417,2418,The Severity of COVID 19 in Diabetes and Non-diabetes Patients,Not yet recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,1050.0,"November 16, 2020",2021-05-16,"November 18, 2020","Orthomed Hospital, Chennai, Tamil Nadu, India|Medway Hospital, Chennai, Tamil Nadu, India|Venkateswara Hospital, Chennai, Tamil Nadu, India|Dr. Rela Institute & Medical Center, Chennai, Tamil Nadu, India",https://ClinicalTrials.gov/show/NCT04634214,India,,5.0,2021,Sunday
2418,2419,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"April 22, 2020",2020-11-30,"July 15, 2020","Faislabad Medical University, Faisalābad, Pakistan|Gujranwala Medical College, Gujrānwāla, Pakistan|Nawaz Sharif Medical College, Gujrāt, Pakistan|Szabmu-Pims, Islamabad, Pakistan|Akram Medical Complex, Lahore, Pakistan|Fatima Jinnah Medical University, Lahore, Pakistan|King Edward Medical University-Mayo Hospital, Lahore, Pakistan|Lahore General Hospital, Lahore, Pakistan|Khyber Teaching Hospital, Peshawar, Pakistan|Rawalpindi Medical University, Rawalpindi, Pakistan|Sargodha Medical College, Sargodha, Pakistan",https://ClinicalTrials.gov/show/NCT04338698,Pakistan,Hydroxychloroquine|Oseltamivir|Azithromycin,11.0,2020,Monday
2419,2420,Psychological Impact of COVID-19 Outbreak on Caregivers,Not yet recruiting,Other: questionnaire filling,All,"18 Years and older   (Adult, Older Adult)",,5000.0,September 2020,2021-09-01,"August 13, 2020","Intensive Care Unit, CHU d'Amiens, Amiens, France|Intensive Care Unit, CHU d'Angers, Angers, France|CHU de Besançon, Besançon, France|CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France|Intensive care Unit CHU de Brest Hôpital Cavale Blanche, Brest, France|CHU de Caen, Caen, France|CHU de Clermont Ferrand, Clermont-Ferrand, France|AP-HP, Hôpital Henri Mondor, Créteil, France|CHU de dijon, Dijon, France|CHU de Grenoble, Hôpital Michalon, La Tronche, France|AP_HP, Hôpital du Kremlin Bicêtre, Le Kremlin-Bicêtre, France|Intensive Care Unit, CHRU de Lille, Lille, France|Intensive Care Unit, CHU de Limoges, Limoges, France|Hôpitaux civils de Lyon, Hôpital de la Croix Rousse, Lyon, France|Hôpitaux civils de Lyon, Hôpital Louis Pradel, Lyon, France|Hôpitaux civils de Lyon, Hôpital Edouard Herriot, Lyon, France|AP-HM, Hôpital Nord, Marseille, France|AP-HM, Hôpital Timone adultes, Intensive Care Unit, Marseille, France|AP-HM, Hôpital Timone adultes, Neurotraumatology, Marseille, France|AP-HM, Hôpital e la Conception, Marseille, France|CHU de Montpellier, Hôpital Guy de chauliac, Montpellier, France|CHU de Montpellier, Hôpital Lapeyronie, Montpellier, France|CHU de Montpellier, Hôpital St Eloi SAR B, Montpellier, France|CHU De Montpellier, Hôpital St Eloi-DAR B, Montpellier, France|CHU De Montpellier, Hôpital St Eloi, Montpellier, France|Intensive Care Unit, CHU de Mulhouse, Mulhouse, France|Intensive CAre Unit CHRU de Nancy, Hôpital Central, Nancy, France|Intensive Care Unit, CHU de Nantes, Hôtel Dieu, Nantes, France|Intensive Care Unit, CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|Intensive care Unit CHU Nîmes, Nîmes, France|AP-HP, Hôpital de la Pitié, Paris, France|AP-HP, Hôpital Bichât, Paris, France|AP-HP, Hôpital Lariboisière, Paris, France|AP6HP, Hôpital St Loui, Paris, France|AP_HP, Hôpital G Pompidou, Paris, France|AP-HP, Hôpital St Antoine, Paris, France|CH de Perpignan, Perpignan, France|CHU de Bordeaux, Hôpital Haut Leveque, Pessac, France|Intensive care Unit, Hôpitaux civils de Lyon, Lyon Sud, Pierre-Bénite, France|CHU de Poitiers, Poitiers, France|Intensive care Unit CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|Intensive Care Unit, CHU de Nantes, Hôpital Laennec, Saint-Herblain, France|CHU de St Etienne, Hôpital Nord, Saint-Étienne, France|Intesive Care Unit CHRU de Strasbourg, Hôpital civil, Strasbourg, France|Intesive Care Unit CHRU de Strasbourg, Hôpital Hautepierre, Strasbourg, France|CHU de Toulouse, Toulouse, France|Intensive care unit CHU de Tours, Tours, France|Intensive CAre Unit CHRU de Nancy, Hôpital de Brabois, Vandœuvre-lès-Nancy, France|CH de Vesoul, Vesoul, France",https://ClinicalTrials.gov/show/NCT04511780,France,,9.0,2021,Wednesday
2420,2421,Oral Health and Psychosocial Factors During the Covid-19 Pandemic,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"May 8, 2020",2020-07-31,"May 8, 2020","University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany",https://ClinicalTrials.gov/show/NCT04381273,Germany,,7.0,2020,Friday
2421,2422,COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2,Recruiting,Other: Blood sample,All,"18 Years and older   (Adult, Older Adult)",,10.0,"April 29, 2020",2020-07-01,"May 4, 2020","Hôpital de la Croix-Rousse, Lyon, France",https://ClinicalTrials.gov/show/NCT04354766,France,,7.0,2020,Wednesday
2422,2423,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,Recruiting,Biological: BBV152|Biological: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,25800.0,"November 25, 2020",2022-03-01,"November 25, 2020","Pt BD SHARMA,PGIMS/UHS, Rohtak, Haryana, India",https://ClinicalTrials.gov/show/NCT04641481,India,,3.0,2022,Tuesday
2423,2424,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Recruiting,Drug: Cholecalciferol,All,1 Month to 17 Years   (Child),Phase 3,40.0,"July 15, 2020",2021-04-01,"August 6, 2020","Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico",https://ClinicalTrials.gov/show/NCT04502667,Mexico,Cholecalciferol,4.0,2021,Thursday
2424,2425,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women,"Active, not recruiting","Other: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores",Female,18 Years to 45 Years   (Adult),,500.0,"August 1, 2020",2020-11-20,"November 19, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",https://ClinicalTrials.gov/show/NCT04629638,Turkey,,11.0,2020,Friday
2425,2426,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Recruiting,Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,165.0,"May 15, 2020",2021-02-28,"November 30, 2020","University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04311697,United States,Aviptadil by intravenous infusion + standard of care|Normal Saline Infusion + standard of care,2.0,2021,Sunday
2426,2427,Assessment of COVID-19 in Tearfilm,Enrolling by invitation,Procedure: Collection of tears and saliva.,All,"18 Years and older   (Adult, Older Adult)",,500.0,"November 16, 2020",2021-05-09,"October 30, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04579458,United States,,5.0,2021,Sunday
2427,2428,Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure,Completed,Other: Prone position,All,"18 Years and older   (Adult, Older Adult)",,66.0,"July 6, 2020",2020-09-16,"November 23, 2020","Hospital Clinico Red de Salud UC - Christus, Santiago, Region Metropolitana, Chile",https://ClinicalTrials.gov/show/NCT04641182,Chile,,9.0,2020,Wednesday
2428,2429,ACEI or ARB and COVID-19 Severity and Mortality in US Veterans,"Active, not recruiting",Drug: ACEI/ARB|Drug: Non-ACEI/ARB|Drug: ACEI|Drug: ARB,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"January 19, 2020",2020-12-31,"November 3, 2020","University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04467931,United States,ACEI/ARB|Non-ACEI/ARB|ACEI|ARB,12.0,2020,Thursday
2429,2430,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,Other: Prolonged Proned Positioning|Other: Traditional Proning Arm,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,52.0,"November 10, 2020",2021-06-01,"November 13, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04581811,United States,,6.0,2021,Tuesday
2430,2431,The Impact of COVID-19 on Dialysis Users,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,40.0,"June 3, 2020",2021-01-01,"November 5, 2020","School of Sport, Health and Exercise Science, Portsmouth, Outside The United States Or Canada, United Kingdom",https://ClinicalTrials.gov/show/NCT04422873,Canada,,1.0,2021,Friday
2431,2432,Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection,Recruiting,Diagnostic Test: IgG test,All,"18 Years and older   (Adult, Older Adult)",,128.0,"April 15, 2020",2020-12-31,"October 22, 2020","Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Torrejón, Torrejón, Madrid, Spain|Hospital Universitario Son Llàtzer, Palma De Mallorca, Mallorca, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario de A Coruña, A Coruña, Spain|Hospital La Esperanza, A Coruña, Spain|Hospital Universitario de Ferrol, A Coruña, Spain|Hospital Virgen de los Lirios, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Puerto Real, Cadiz, Spain|Hospital General La Mancha Centro, Ciudad Real, Spain|Hospital Universitario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Puerta del Mar, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario de Vinalopó, Elche, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital universitari Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Clínica Universidad de Navarra, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario de Móstoles, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Madrid, Spain|Hospital General Universitario de Málaga, Málaga, Spain|Hospital Costa del Sol, Málaga, Spain|Complejo Hospitalario Universitario de Ourense Santa María Nai, Ourense, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Sant Joan de Reus, Reus, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital de Manises, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Lluís Alcanyís, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Río Ortega, Valladolid, Spain|Complejo Hospitalario Zamora, Zamora, Spain",https://ClinicalTrials.gov/show/NCT04407143,China,,12.0,2020,Thursday
2432,2433,ICU Trial in Critical Ill COVID-19 Patients,Recruiting,"Diagnostic Test: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)",All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 8, 2020",2022-07-31,"October 20, 2020","Medical University of Graz, Graz, Styria, Austria",https://ClinicalTrials.gov/show/NCT04349982,Austria,,7.0,2022,Sunday
2433,2434,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",Biological: Biological: mRNA-1273: 50 mcg|Other: Placebo|Biological: Biological: mRNA-1273: 100 mcg,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"May 29, 2020",2021-08-01,"July 10, 2020","Meridian Clinical Research, Savannah, Georgia, United States|Heartland Research Associates, Newton, Kansas, United States|Heartland Research Associates, Kansas City, Missouri, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Trial Management Associates, Wilmington, North Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Advanced Clinical Research/Velocity, West Jordan, Utah, United States",https://ClinicalTrials.gov/show/NCT04405076,Georgia,,8.0,2021,Sunday
2434,2435,Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic,Recruiting,Other: Serial seroconversion measurements in hospital employees during the COVID-19 pandemic,All,"18 Years and older   (Adult, Older Adult)",,300.0,"March 27, 2020",2025-08-01,"June 16, 2020","Nordsjællands Hospital, Hillerød, Capital Region, Denmark|Nykøbing Falster County Hospital, Nykøbing Falster, Southern Region, Denmark",https://ClinicalTrials.gov/show/NCT04431310,Denmark,,8.0,2025,Friday
2435,2436,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Drug: Camostat Mesilate|Drug: Artemisia Annua Leaf,All,"18 Years and older   (Adult, Older Adult)",Phase 2,360.0,"October 5, 2020",2021-02-01,"October 22, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, None - Non-US/Canada, Mexico",https://ClinicalTrials.gov/show/NCT04530617,Canada,Camostat Mesilate|Artemisia Annua Leaf,2.0,2021,Monday
2436,2437,The Effect of Covid-19 on Patient Outcomes Among Operated Patients,Recruiting,Other: COVID-19 infection status,All,"Child, Adult, Older Adult",,2000.0,"March 1, 2020",2020-12-31,"August 25, 2020","Samtliga akutsjukhus i Region Stockholm, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04525716,Sweden,,12.0,2020,Thursday
2437,2438,Cod Liver Oil for Covid-19 Prevention Study,Recruiting,Dietary Supplement: Cod liver oil|Dietary Supplement: Corn oil (placebo),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,80000.0,"November 10, 2020",2023-05-01,"November 12, 2020","Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04609423,Norway,,5.0,2023,Monday
2438,2439,Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,Completed,Drug: Guduchi Ghan Vati,All,"18 Years to 75 Years   (Adult, Older Adult)",,91.0,"May 12, 2020",2020-07-03,"July 22, 2020","Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India",https://ClinicalTrials.gov/show/NCT04480398,India,Guduchi Ghan Vati,7.0,2020,Friday
2439,2440,COVID-19 in Pain Perspective,Completed,,All,"18 Years to 95 Years   (Adult, Older Adult)",,466.0,"June 3, 2020",2020-06-20,"July 1, 2020","Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04454333,Turkey,,6.0,2020,Saturday
2440,2441,"Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]",Recruiting,Other: Human biological samples,All,"5 Years and older   (Child, Adult, Older Adult)",,2000.0,"November 13, 2020",2023-11-01,"November 27, 2020","Hôpital de Crépy en Valois, Crépy-en-Valois, France|Institut Pasteur, Paris, France",https://ClinicalTrials.gov/show/NCT04644159,France,,11.0,2023,Wednesday
2441,2442,A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19,Withdrawn,Drug: Hydroxychloroquine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"May 5, 2020",2020-09-25,"October 30, 2020","Memorial Sloan - Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04379492,United States,Hydroxychloroquine,9.0,2020,Friday
2442,2443,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Recruiting,Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo,All,20 Years to 50 Years   (Adult),Phase 4,400.0,"April 14, 2020",2021-06-30,"May 1, 2020","Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04346667,Pakistan,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,6.0,2021,Wednesday
2443,2444,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Recruiting,Biological: Cell therapy protocol 1|Biological: Cell therapy protocol 2,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"April 5, 2020",2020-12-10,"April 30, 2020","Royan Institute, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04366063,"Iran, Islamic Republic of",,12.0,2020,Thursday
2444,2445,"Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19",Recruiting,"Diagnostic Test: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19",All,"Child, Adult, Older Adult",,40.0,"September 12, 2020",2020-10-21,"September 16, 2020","Yasin Tire, Konya, Turkey",https://ClinicalTrials.gov/show/NCT04378829,Turkey,,10.0,2020,Wednesday
2445,2446,Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19,Not yet recruiting,Other: Cross-sectional survey,All,"18 Years to 99 Years   (Adult, Older Adult)",,3000.0,December 2020,2021-12-01,"December 8, 2020","Charite University, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04653727,Germany,,12.0,2021,Wednesday
2446,2447,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Recruiting,Behavioral: Therapy Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,"May 19, 2020",2022-04-19,"June 5, 2020","Missouri Orthopedic Institute, Columbia, Missouri, United States",https://ClinicalTrials.gov/show/NCT04385901,United States,,4.0,2022,Tuesday
2447,2448,"Knowledge, Attitudes, and Practices Towards COVID-19 Among Health Care Professionals Among Healthcare Professionals",Not yet recruiting,Other: Survey,All,"22 Years to 75 Years   (Adult, Older Adult)",,200.0,"August 1, 2020",2020-12-10,"July 30, 2020",,https://ClinicalTrials.gov/show/NCT04492202,Undefined,,12.0,2020,Thursday
2448,2449,A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy,Recruiting,Procedure: Tracheostomy,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"August 1, 2020",2021-08-01,"October 1, 2020","University College London NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04572438,United Kingdom,,8.0,2021,Sunday
2449,2450,SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort,Recruiting,Diagnostic Test: SARS-CoV-2 serological assessment (IgG),All,"up to 18 Years   (Child, Adult)",,1000.0,"October 29, 2020",2021-11-01,"November 4, 2020","Ghent University Hospital, Ghent, Belgium",https://ClinicalTrials.gov/show/NCT04615000,Belgium,,11.0,2021,Monday
2450,2451,Automatic Oxygen Titration With O2matic® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure,Completed,Device: Closed-loop control of oxygen supplementation by O2matic,All,"18 Years and older   (Adult, Older Adult)",,16.0,"April 15, 2020",2020-05-31,"September 25, 2020","Hvidovre University Hospital, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04565106,Denmark,,5.0,2020,Sunday
2451,2452,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,Recruiting,Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP),All,"12 Months and older   (Child, Adult, Older Adult)",Phase 3,220.0,"April 30, 2020",2021-12-01,"May 18, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04361253,United States,,12.0,2021,Wednesday
2452,2453,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Recruiting,,All,"Child, Adult, Older Adult",,400.0,"March 14, 2020",2020-12-31,"July 22, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",https://ClinicalTrials.gov/show/NCT04365764,France,,12.0,2020,Thursday
2453,2454,Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,184.0,"April 24, 2020",2020-06-24,"May 19, 2020","Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04394429,France,,6.0,2020,Wednesday
2454,2455,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,Diagnostic Test: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130.0,"April 16, 2020",2020-05-17,"November 5, 2020","Rouen University Hospital, Rouen, France",https://ClinicalTrials.gov/show/NCT04367545,France,,5.0,2020,Sunday
2455,2456,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19,Enrolling by invitation,Device: V/Q Vest,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24.0,"August 11, 2020",2021-04-01,"September 16, 2020","Emory University Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04369599,Georgia,,4.0,2021,Thursday
2456,2457,"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",Recruiting,,All,"18 Years to 89 Years   (Adult, Older Adult)",,100000.0,"April 10, 2020",2099-12-31,"May 7, 2020","Duke Clinical Research Institute, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04342806,United States,,12.0,2099,Thursday
2457,2458,Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients,Enrolling by invitation,Drug: Traditional antirheumatic drugs,All,18 Years to 60 Years   (Adult),,600.0,"March 20, 2020",2020-12-30,"October 6, 2020","Faculty of Medicine, Shibīn Al Kawm, Egypt",https://ClinicalTrials.gov/show/NCT04434118,Egypt,Traditional antirheumatic drugs,12.0,2020,Wednesday
2458,2459,Prone Positioning for Patients on General Medical Wards With COVID19,Recruiting,Other: Prone positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,350.0,"May 15, 2020",2020-12-11,"September 16, 2020","William Osler Health System, Brampton, Ontario, Canada|William Osler Health System, Etobicoke, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|St. Joseph's Health Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04383613,Canada,,12.0,2020,Friday
2459,2460,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,Recruiting,Biological: PLX-PAD,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,40.0,November 2020,2022-03-01,"November 3, 2020","University of hospital Bonn, Bonn, Germany|Hospital Cologne-Merheim, Köln, Germany|Emek Medical Center, Afula, Israel|University Hospital Samson Assuta Ashdod, Ashdod, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Galilee Medical Center, Nahariya, Israel|Baruch Padeh Medical Center, Poriya, Tiberias, Israel",https://ClinicalTrials.gov/show/NCT04614025,Germany,,3.0,2022,Tuesday
2460,2461,Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status,Recruiting,Other: Paraclinical examination|Other: Clinical Examination|Other: Semi-directive interview|Other: quality of life questionnaires,All,"18 Years and older   (Adult, Older Adult)",,500.0,"September 18, 2020",2022-11-01,"November 17, 2020","Chu Dijon Bourgogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04556513,France,,11.0,2022,Tuesday
2461,2462,"Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine","Active, not recruiting",Biological: QazCovid-in® - COVID-19 inactivated vaccine|Other: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1|Phase 2,244.0,"September 19, 2020",2020-12-07,"October 22, 2020","Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstan",https://ClinicalTrials.gov/show/NCT04530357,Kazakhstan,,12.0,2020,Monday
2462,2463,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19,Recruiting,,All,"18 Years to 85 Years   (Adult, Older Adult)",,500.0,"October 1, 2020",2021-10-01,"November 10, 2020","Humanitas Research Hospital, Rozzano, Milan, Italy|Centro Cardiologico Monzino, Milan, Italy|IRCCS Auxologico San Luca, Milan, Italy|IRCCS San Donato, Milan, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy",https://ClinicalTrials.gov/show/NCT04624503,Italy,,10.0,2021,Friday
2463,2464,COVID-19 Stroke Apical Lung Examination Study - A Multi-centre Prospective Study,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"December 1, 2020",2021-04-30,"November 23, 2020",,https://ClinicalTrials.gov/show/NCT04640428,Undefined,,4.0,2021,Friday
2464,2465,Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF),Completed,Other: Experts consensus,All,"18 Years to 70 Years   (Adult, Older Adult)",,40.0,"September 4, 2020",2020-10-06,"October 8, 2020","NMC Specialty Hospital, Dubai, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04534569,United Arab Emirates,,10.0,2020,Tuesday
2465,2466,Efficacy and Safety of Itolizumab in COVID-19 Complications,Completed,"Drug: Itolizumab IV infusion|Drug: Best supportive care"" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,30.0,"May 1, 2020",2020-07-08,"July 17, 2020","Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai, India|Seth GS Medical College and KEM Hospital, Mumbai, India|MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi, India|All India Institute Of Medical Sciences, New Delhi, India",https://ClinicalTrials.gov/show/NCT04475588,India,"Itolizumab IV infusion|Best supportive care"" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy",7.0,2020,Wednesday
2466,2467,"Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects",Not yet recruiting,Drug: HLX71|Other: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,"November 30, 2020",2021-05-31,"October 14, 2020",,https://ClinicalTrials.gov/show/NCT04583228,Undefined,HLX71,5.0,2021,Monday
2467,2468,Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium,Not yet recruiting,Drug: Valproate|Drug: Quetiapine|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20.0,"November 1, 2021",2022-11-01,"November 10, 2020","Jackson Memorial Hospital, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04513314,United States,Valproate|Quetiapine,11.0,2022,Tuesday
2468,2469,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,"Active, not recruiting",Drug: Cannabidiol,All,24 Years to 60 Years   (Adult),Phase 2|Phase 3,120.0,"June 16, 2020",2020-12-16,"November 4, 2020","Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, SP, Brazil",https://ClinicalTrials.gov/show/NCT04504877,Brazil,Cannabidiol,12.0,2020,Wednesday
2469,2470,Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19,Withdrawn,Drug: Chloroquine or hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"May 1, 2020",2021-06-30,"August 18, 2020","Khayelitsha Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04360759,South Africa,Chloroquine or hydroxychloroquine,6.0,2021,Wednesday
2470,2471,"Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship","Active, not recruiting",,Female,18 Years to 50 Years   (Adult),,440.0,"June 1, 2020",2024-06-30,"October 30, 2020","Department of Obstetrics and Gynecology, Hillel-Yaffe Medical Center, Hadera, Israel",https://ClinicalTrials.gov/show/NCT04609501,Israel,,6.0,2024,Sunday
2471,2472,Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease),Not yet recruiting,Device: Ion Mobility Spectrometry (IMS),All,"18 Years and older   (Adult, Older Adult)",,400.0,December 2020,2021-05-01,"December 3, 2020","University Hospital Gießen and Marburg (UKGM), site Marburg, Marburg, Germany",https://ClinicalTrials.gov/show/NCT04649931,Germany,,5.0,2021,Saturday
2472,2473,"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2",Not yet recruiting,Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,November 2020,2022-12-30,"November 30, 2020","Accel Research Sites, Birmingham, Alabama, United States|Centers for American Indian Health, Chinle, Arizona, United States|Synexus Clinical Research US, Inc., Glendale, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|AMR Tempe Clinical Research Consortium, Tempe, Arizona, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Anaheim Clinical Trials, Anaheim, California, United States|Advanced Clinical Research - Rancho Paseo, Banning, California, United States|eStudy Site, Chula Vista, California, United States|eStudySite - Corporate Offices, La Mesa, California, United States|Wr-Pri, Llc, Los Alamitos, California, United States|National Research Institute, Los Angeles, California, United States|Empire Clinical Research, Pomona, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Benchmark Research, Sacramento, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|Woodland Clinic Medical Group, Woodland, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Howard University Hospital Howard/ University College of Medicine, Washington, District of Columbia, United States|University Clinical Research-Deland, LLC dba Accel Research Sites, DeLand, Florida, United States|SIMED Health, LLC / SIMED Research, Gainesville, Florida, United States|M D Clinical, Hallandale Beach, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Meridien Research/Accel Research, Lakeland, Florida, United States|Miami Veterans Affairs Medical Center, Miami, Florida, United States|Suncoast Research Associates, LLC, Miami, Florida, United States|Clinical Neuroscience Solutions Inc, Orlando, Florida, United States|Synexus Clinical Research US, Inc, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Jedidiah Clinical Research, Tampa, Florida, United States|Synexus Clinical Research US, Inc., The Villages, Florida, United States|Comprehensive Clinical Trials, Llc, West Palm Beach, Florida, United States|Ponce de Leon Center, Atlanta, Georgia, United States|Morehouse School Of Medicine, Atlanta, Georgia, United States|Synexus Clinical Research US, Inc., Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Synexus, Chicago, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Providea Health Partners LLC, Mokena, Illinois, United States|Synexus USA, Evansville, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Meridian Clinical Research, Sioux City, Iowa, United States|Johnson County Clin-Trials, Inc., Lenexa, Kansas, United States|Meridian Clinical Research, LLC, Baton Rouge, Louisiana, United States|Med Pharmics, LLC, Metairie, Louisiana, United States|Willis-Knighton Physician Network, Shreveport, Louisiana, United States|University Of Maryland School Of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|VA Medical Center, Ann Arbor, Michigan, United States|Wayne State University/ Children's Hospital of Michigan, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|MedPharmics, LLC-Biloxi, Gulfport, Mississippi, United States|The Curators of University of Missouri, Columbia, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research Associates, LLC, Omaha, Nebraska, United States|University Of Nebraska Medical Center, Omaha, Nebraska, United States|Synexus Clinical Research US, Inc., Henderson, Nevada, United States|Stony Brook Responder Vaccine Program, Commack, New York, United States|Weill Cornell Chelsea CRS, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Womack Army Medical Center, Fort Bragg, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Synexus Clinical Research, US, Inc., Akron, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc., Cincinnati, Ohio, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Synexus Clinical Research US, Inc., Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|CRISOR, LLC - Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|Velocity Clinical Research, Providence, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Medical University of South Carolina, SCTR Research Nexus, Charleston, South Carolina, United States|American Indian Clinical Trials Research Network, Eagle Butte, South Dakota, United States|PMG Research of Bristol, Bristol, Tennessee, United States|WR Clinsearch, LLC, Chattanooga, Tennessee, United States|PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States|Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc, McAllen, Texas, United States|Research Your Health, Plano, Texas, United States|Synexus, US - San Antonio, San Antonio, Texas, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|MultiCare Institute for Research & Innovation, Cheney, Washington, United States|University of Washington VTEU - Seattle and King County Public Health STD clinic, Seattle, Washington, United States|PanAmerican Clinical Research Mexico S.A de C.V, Guadalajara, Jalisco, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico City, Mexico|PanAmerican Clinical Research Mexico, Juriquilla, Queretaro, Mexico|Unidad de Atencion Medica e Investigacion en Salud (UNAMIS), Merida, Yucatan, Mexico|Instituto Nacional de Salud Publica (INSP) - Cuernavaca - Centro de Investigacion en Salud Poblacional (CISP), Cuernavaca, Mexico|CAIMED Investigacion en Salud S.A de C.V, Mexico City, Mexico|Faicic S. de R.L. de C.V., Veracruz, Mexico|Ponce School Of Medicine, Ponce, Puerto Rico|Universidad de Puerto Rico - Recinto de Ciencias Medicas (UPR-MSC) - Centro Mujer y Salud (CMS) ((Women & Health Center) (W&HC)), San Juan, Puerto Rico",https://ClinicalTrials.gov/show/NCT04611802,Georgia,,12.0,2022,Friday
2473,2474,Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,Suspended,Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,300.0,"February 27, 2020",2021-01-01,"May 11, 2020","Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China",https://ClinicalTrials.gov/show/NCT04278963,China,YinHu QingWen Decoction|YinHu QingWen Decoction(low dose),1.0,2021,Friday
2474,2475,Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients,Not yet recruiting,Behavioral: Doctorgram Patient Kit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,January 2021,2021-12-01,"November 25, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04480411,United States,,12.0,2021,Wednesday
2475,2476,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Biological: Convalescent plasma|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"May 18, 2020",2020-10-31,"August 18, 2020","Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia|St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia|Ciputra Hospital CitraRaya, Jakarta, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04380935,Indonesia,Standard of care,10.0,2020,Saturday
2476,2477,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Biological: convalescent plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,90.0,"May 20, 2020",2020-12-01,"June 5, 2020","Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico|Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico|Hospital Central Norte Pemex, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04356482,Mexico,,12.0,2020,Tuesday
2477,2478,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Recruiting,Other: Retrospective data collection,All,"Child, Adult, Older Adult",,500.0,"April 20, 2020",2026-08-31,"December 10, 2020","University Hospital of Cologne, Cologne, Germany",https://ClinicalTrials.gov/show/NCT04351854,Germany,,8.0,2026,Monday
2478,2479,Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin Lymphoma,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,120.0,"December 15, 2020",2021-09-16,"November 24, 2020",,https://ClinicalTrials.gov/show/NCT04641806,Undefined,,9.0,2021,Thursday
2479,2480,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",Recruiting,Biological: PLX-PAD|Biological: Placebo,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,140.0,"October 1, 2020",2022-03-01,"October 29, 2020","University of California Irvine, Irvine, California, United States|University of Southern California (USC) - Keck School of Medicine (KSOM), Los Angeles, California, United States|University Of California Davis,4860 Y Street, Sacramento, California, United States|Baptist Health Medical Center, Jacksonville, Florida, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|Sarah Cannon Research Institute, LLC (Mercer University School of Medicine), Macon, Georgia, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper Research Institute, Camden, New Jersey, United States|Holy Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, New York, New York, United States|Maimonides Medical Center, New York, New York, United States|Mercy Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04389450,Georgia,,3.0,2022,Tuesday
2480,2481,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,Completed,Drug: Dose of Tinzaparin or Dalteparin,All,"Child, Adult, Older Adult",,166.0,"March 6, 2020",2020-05-28,"June 22, 2020","South General Hospital, Stockholm, Stockholms Län, Sweden",https://ClinicalTrials.gov/show/NCT04412304,Sweden,Dose of Tinzaparin or Dalteparin,5.0,2020,Thursday
2481,2482,Methylene Blue Treatment of COVID-19,Not yet recruiting,Drug: Methylene Blue|Drug: Control Test,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64.0,November 2020,2022-12-31,"November 19, 2020","Fondazione Epatocentro Ticino, Lugano, Ticino, Switzerland",https://ClinicalTrials.gov/show/NCT04635605,Switzerland,Methylene Blue|Control Test,12.0,2022,Saturday
2482,2483,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,40000.0,"April 29, 2020",2021-04-01,"October 5, 2020","RSUPN Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia|Istituto Sacro Cuore Don Calabria, Negrar, Negrar Di Valpolicella VR, Italy|Mahosot hospital, Vientiane, Lao People's Democratic Republic|The Aga Khan University Hospital, Karachi, Pakistan|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|University Hospitals Of Morecambe Bay NHS Foundation Trust, Kendal, Cumbria, United Kingdom|Torbay and South Devon NHS Foundation Trust, Torquay, Devon, United Kingdom|The Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom|West Hertfordshire Hospitals NHS Trust, Watford, Hertfordshire, United Kingdom|Lewisham and Greenwich NHS Trust, Woolwich, London, United Kingdom|Sherwood Forest Hospitals NHS Foundation Trust, Sutton In Ashfield, Nottinghamshire, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04303507,Indonesia,Chloroquine or Hydroxychloroquine|Placebo,4.0,2021,Thursday
2483,2484,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,Completed,Procedure: Prone position,All,"18 Years and older   (Adult, Older Adult)",,827.0,"May 1, 2020",2020-07-13,"July 15, 2020","Hospital Materno Celaya, Celaya, Guanajuato, Mexico|Hospital Santo Tomas, Querétaro City, Queretaro, Mexico|Hospital General San Juan del Rio, Querétaro City, Queretaro, Mexico|ISSSTE Hospital Regional Merida, Mérida, Yucatan, Mexico|Hospital General de Zona 48 San PEDRO Xalpa IMSS, Estado De México, Mexico|Hospital Fernando Quiroz Gutierrez, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04407468,Mexico,,7.0,2020,Monday
2484,2485,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Recruiting,Device: Cytokine Adsorption,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"April 17, 2020",2020-07-01,"April 24, 2020","Hospital Clínic de Barcelona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04361526,Spain,,7.0,2020,Wednesday
2485,2486,The Effect of Diabetes Mellitus on Mortality in Patients Hospitalized in the COVID Intensive Care Unit,Completed,Other: no intervention,All,"18 Years and older   (Adult, Older Adult)",,150.0,"March 15, 2020",2020-05-15,"December 11, 2020","SisliHamidiye Etfal Education and Training Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04663659,Turkey,,5.0,2020,Friday
2486,2487,Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden,Completed,Other: Observational study,All,"18 Years and older   (Adult, Older Adult)",,57.0,"March 26, 2020",2020-11-12,"November 13, 2020","Intensive Care Unit, Västerås Hospital, Västerås, Västmanland, Sweden",https://ClinicalTrials.gov/show/NCT04382417,Sweden,,11.0,2020,Thursday
2487,2488,Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection,Recruiting,Procedure: Lateral Position (left and right lateral decubitus),All,"18 Years and older   (Adult, Older Adult)",,12.0,"July 17, 2020",2020-10-01,"September 1, 2020","Hospital Rebagliati, Jesús María, Lima, Peru",https://ClinicalTrials.gov/show/NCT04475068,Peru,,10.0,2020,Thursday
2488,2489,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,Not yet recruiting,"Procedure: Sphenopalatine Ganglion Block with Local Anesthetic|Procedure: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Procedure: ""Sham""-block with Placebo (Isotone NaCl)",All,"18 Years and older   (Adult, Older Adult)",Phase 3,60.0,December 2020,2021-11-01,"December 9, 2020","Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04636034,Denmark,,11.0,2021,Monday
2489,2490,SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir),Recruiting,"Other: Questionnaires, spirometry",All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 3, 2020",2020-12-01,"June 11, 2020","University Hospital Zurich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04365595,Switzerland,,12.0,2020,Tuesday
2490,2491,Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,Completed,,All,"18 Years and older   (Adult, Older Adult)",,950.0,"March 20, 2020",2020-10-31,"November 13, 2020","Hospital Interzonal General de Agudos Gral. San Martín, La Plata, BA, Argentina|Sanatorio Las Lomas, san Isidro, BA, Argentina|Hospital General de Agudos Juan A. Fernández, Buenos Aires, Caba, Argentina|Sanatorio Anchorena Recoleta, Buenos Aires, Caba, Argentina|Sanatorio Otamendi, Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04611269,Argentina,,10.0,2020,Saturday
2491,2492,Mechanisms of Multi-organ Failure in COVID-19,Not yet recruiting,Other: no intervention-mechanistic study,All,"18 Years to 90 Years   (Adult, Older Adult)",,120.0,"May 18, 2020",2021-11-17,"May 22, 2020","Imperial College NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04399603,United Kingdom,,11.0,2021,Wednesday
2492,2493,Rehabilitation for People With COVID-19 in ICU,Not yet recruiting,Other: Pulmonary and Motor Rehabilitation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,92.0,"May 10, 2020",2020-09-30,"May 8, 2020","Teaching Hospital, University of Padova, Padova, Italy|Teaching Hospital, University of Verona, Verona, Italy",https://ClinicalTrials.gov/show/NCT04381338,Italy,,9.0,2020,Wednesday
2493,2494,"Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers",Not yet recruiting,,All,"Child, Adult, Older Adult",,160.0,December 2020,2021-05-01,"November 30, 2020",,https://ClinicalTrials.gov/show/NCT04646642,Undefined,,5.0,2021,Saturday
2494,2495,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Recruiting,Device: Digital oximeter monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"June 22, 2020",2021-06-22,"October 14, 2020","Fundação Zerbini - Instituto do Coração (InCor), São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04587921,Brazil,,6.0,2021,Tuesday
2495,2496,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,Procedure: Prone Positioning|Procedure: Standard of care.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"July 11, 2020",2021-09-11,"August 13, 2020","Galway University Hospital, Galway, Ireland|Galway University Hospital, Galway, Ireland",https://ClinicalTrials.gov/show/NCT04347941,Ireland,,9.0,2021,Saturday
2496,2497,COVID19 Neurological Manifestation,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 13, 2020",2021-03-31,"October 8, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04496128,United States,,3.0,2021,Wednesday
2497,2498,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),Recruiting,Biological: Mesenchymal stromal cells|Other: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,30.0,"July 30, 2020",2021-12-01,"August 14, 2020","University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04466098,United States,,12.0,2021,Wednesday
2498,2499,Association Between BMI and COVID-19,"Active, not recruiting",Other: Patients admitted to Intensive Care Unit with SARS-CoV2,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"February 1, 2020",2020-09-30,"August 4, 2020","Centre Hospitalier Régional & Universitaire de Lille (CHRU), Lille, France",https://ClinicalTrials.gov/show/NCT04391738,France,,9.0,2020,Wednesday
2499,2500,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,Drug: Ivermectin|Drug: Placebo,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,68.0,"August 28, 2020",2021-01-28,"November 19, 2020","Hospital Nacional Cayetano Heredia, Lima, Peru",https://ClinicalTrials.gov/show/NCT04635943,Peru,Ivermectin|Placebo,1.0,2021,Thursday
2500,2501,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b,Recruiting,Other: Human milk donors,All,"Child, Adult, Older Adult",,500.0,"June 21, 2020",2021-02-01,"October 23, 2020","Sinai Health System, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04453982,Canada,,2.0,2021,Monday
2501,2502,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a,Recruiting,Other: COVID-19,All,"Child, Adult, Older Adult",,50.0,"May 24, 2020",2021-01-01,"October 23, 2020","Sinai Health System, Toronto, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04453969,Canada,,1.0,2021,Friday
2502,2503,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,Recruiting,Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo,All,70 Years and older   (Older Adult),Phase 2,100.0,"June 1, 2020",2022-05-01,"June 2, 2020","Bispebjerg Hospital, Copenhagen NV, Denmark",https://ClinicalTrials.gov/show/NCT04407390,Denmark,,5.0,2022,Sunday
2503,2504,Prevalence of COVID-19 Infection Among HCW in a French University Hospital,Not yet recruiting,Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing,All,"18 Years and older   (Adult, Older Adult)",,100.0,April 2020,2020-09-01,"May 1, 2020",,https://ClinicalTrials.gov/show/NCT04371692,Undefined,,9.0,2020,Tuesday
2504,2505,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Recruiting,Drug: Broncho-Vaxom®,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,1000.0,"August 24, 2020",2021-06-30,"September 4, 2020","The Prince Charles Hospital, Brisbane, Queensland, Australia|The Princess Alexandra Hospital, Brisbane, Queensland, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia",https://ClinicalTrials.gov/show/NCT04496245,Australia,Broncho-Vaxom®,6.0,2021,Wednesday
2505,2506,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Recruiting,Other: Solution-Focused Support Program,All,18 Years to 45 Years   (Adult),Not Applicable,60.0,"July 1, 2020",2020-12-30,"November 4, 2020","Online- Data will be collected through the form created with the Google-Forms, Adıyaman, Turkey",https://ClinicalTrials.gov/show/NCT04609722,Turkey,,12.0,2020,Wednesday
2506,2507,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis",Recruiting,Biological: Non applicable,All,"Child, Adult, Older Adult",,110000.0,"May 1, 2020",2020-12-31,"August 5, 2020","Inserm, Paris, France",https://ClinicalTrials.gov/show/NCT04392388,France,,12.0,2020,Thursday
2507,2508,Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,Recruiting,Drug: SARS-CoV-2 plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,90.0,"April 7, 2020",2020-12-31,"June 2, 2020","Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States",https://ClinicalTrials.gov/show/NCT04411602,United States,SARS-CoV-2 plasma,12.0,2020,Thursday
2508,2509,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Recruiting,Device: HCFWO|Other: Standard Care Plus Monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,December 2020,2021-11-01,"December 4, 2020","Mount Sinai Beth Israel, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04654481,Israel,,11.0,2021,Monday
2509,2510,Tomographic Findings in COVID-19 and Influenza,Recruiting,Diagnostic Test: Thoraxic computed tomography,All,"18 Years to 80 Years   (Adult, Older Adult)",,100.0,"June 15, 2020",2022-04-30,"August 6, 2020","Hospital General León-Milenio, León, Guanajuato, Mexico",https://ClinicalTrials.gov/show/NCT04497311,Mexico,,4.0,2022,Saturday
2510,2511,Maraviroc in Patients With Moderate and Severe COVID-19,Recruiting,Drug: Maraviroc,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,16.0,"September 21, 2020",2021-01-01,"September 25, 2020","Rhode Island Hospital, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04435522,United States,Maraviroc,1.0,2021,Friday
2511,2512,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Recruiting,Diagnostic Test: diagnostic,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 7, 2020",2021-08-31,"July 7, 2020","Hôpital Privé de Parly II, Le Chesnay, France",https://ClinicalTrials.gov/show/NCT04460534,France,,8.0,2021,Tuesday
2512,2513,Sofosbuvir in Treatment of COVID 19,Recruiting,Drug: sofosbuvir|Drug: Sofosbuvir ledipsavir|Drug: Daclatasvir,All,"Child, Adult, Older Adult",Phase 2|Phase 3,60.0,"August 1, 2020",2021-08-31,"December 8, 2020","Sherief Abd-Elsalam, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04460443,Egypt,sofosbuvir|Sofosbuvir ledipsavir|Daclatasvir,8.0,2021,Tuesday
2513,2514,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19",Recruiting,Biological: CVnCoV 6 μg|Biological: CVnCoV 12 μg|Biological: Hepatitis A vaccine|Biological: Pneumococcal vaccine|Biological: CVnCoV 12μg,All,"18 Years and older   (Adult, Older Adult)",Phase 2,660.0,"September 28, 2020",2021-11-09,"November 24, 2020","Centro de vacunación internacional - CEVAXIN Panama Clinic, Panama city, Panama|Instituto de Investigación Nutricional, Lima, Peru",https://ClinicalTrials.gov/show/NCT04515147,Panama,,11.0,2021,Tuesday
2514,2515,Head and Neck cancERs International cOviD-19 collabOraTion,Not yet recruiting,Other: non interventional study,All,"18 Years to 100 Years   (Adult, Older Adult)",,750.0,"December 1, 2020",2021-06-30,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04632173,Undefined,,6.0,2021,Wednesday
2515,2516,Stroke Rehabilitation Outcome During COVID-19 Lockdown,Completed,Behavioral: Observation,All,"18 Years and older   (Adult, Older Adult)",,36.0,"April 16, 2020",2020-10-12,"October 20, 2020","University Hospital Zurich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04373109,Switzerland,,10.0,2020,Monday
2516,2517,Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1576.0,"April 22, 2020",2020-07-01,"July 22, 2020","Hôpital Roger Salengro, ICU, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04359693,France,,7.0,2020,Wednesday
2517,2518,The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,Recruiting,Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation,All,"Child, Adult, Older Adult",,20.0,"July 30, 2020",2022-05-01,"August 24, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT04340479,United States,,5.0,2022,Sunday
2518,2519,Evaluation of Physical Activity and Quality of Life of Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic,Recruiting,Other: Online Survey,All,"18 Years to 65 Years   (Adult, Older Adult)",,70.0,"September 18, 2020",2020-12-18,"September 29, 2020","Zeliha ÇELİK, Ankara, Çankaya, Turkey",https://ClinicalTrials.gov/show/NCT04558645,Turkey,,12.0,2020,Friday
2519,2520,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Recruiting,Other: Blood sample and data record,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,270.0,"May 28, 2020",2022-10-28,"November 30, 2020","Damien JOLLY, Reims, France",https://ClinicalTrials.gov/show/NCT04376840,France,,10.0,2022,Friday
2520,2521,Bacillus Calmette-guérin Vaccination to Prevent COVID-19,Recruiting,Biological: BCG vaccine|Biological: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 4,900.0,"May 26, 2020",2021-05-25,"July 14, 2020","General Hospital of Argolida - Nafplion Unit, Náfplio, Argos, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Therapeutics, Alexandra General Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|4th Department of Internal Medicine, ""Attikon"" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|Department of Pulmonary Medicine- General Hospital of Kerkyra, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|Department of Internal Medicine, General Hospital of Karditsa, Kardítsa, Greece|General Hospital of Korinthos, Kórinthos, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Greece|General Hospital of Ptolemaida MPODOSAKEIO, Ptolemaḯda, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece|General Hospital of Imathia - Veria Unit, Véria, Greece",https://ClinicalTrials.gov/show/NCT04414267,Greece,,5.0,2021,Tuesday
2521,2522,"Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers",Recruiting,Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Serum testing,All,"3 Years to 67 Years   (Child, Adult, Older Adult)",,300.0,"November 4, 2020",2021-03-01,"November 6, 2020","Greifswald University Medicine, Greifswald, Germany",https://ClinicalTrials.gov/show/NCT04619407,Germany,,3.0,2021,Monday
2522,2523,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Recruiting,Drug: Bacille Calmette-Guérin (BCG)|Drug: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 4,5200.0,"August 25, 2020",2021-04-01,"September 3, 2020","Meander Medical Center, Amersfoort, Netherlands|Amsterdam University Medical Center, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Amphia hospital, Breda, Netherlands|Hagahospital, Den Haag, Netherlands|Catharina hospital, Eindhoven, Netherlands|Zuyderland Hospital, Geleen, Netherlands|Martini hospital, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|St. Antonius hospital, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Ikazia Hospital, Rotterdam, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Bernhoven hospital, Uden, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04537663,Netherlands,Bacille Calmette-Guérin (BCG)|Placebo,4.0,2021,Thursday
2523,2524,Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo,Not yet recruiting,Diagnostic Test: Serological test|Diagnostic Test: Nasopharyngeal Swab|Diagnostic Test: Oropharyngeal Swab,All,"6 Months to 100 Years   (Child, Adult, Older Adult)",,18901.0,"June 1, 2020",2020-07-30,"May 29, 2020",,https://ClinicalTrials.gov/show/NCT04408014,Undefined,,7.0,2020,Thursday
2524,2525,"""NORPLASMA"" Covid-19 Convalescent Plasma Treatment Monitoring Study",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"July 6, 2020",2025-05-31,"July 9, 2020","Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04463823,Norway,,5.0,2025,Saturday
2525,2526,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,Completed,Diagnostic Test: Tears swab,All,"18 Years and older   (Adult, Older Adult)",,100.0,"February 1, 2020",2020-05-20,"December 3, 2020","ASST Sette Laghi, Varese, Italy",https://ClinicalTrials.gov/show/NCT04402853,Italy,,5.0,2020,Wednesday
2526,2527,Precision Immunology to Determine the Immune Response in Patients With COVID-19,Recruiting,Other: Blood draw,All,"18 Years and older   (Adult, Older Adult)",,200.0,"April 20, 2020",2022-09-01,"April 24, 2020","University Hospital Bonn, Bonn, Germany",https://ClinicalTrials.gov/show/NCT04360733,Germany,,9.0,2022,Thursday
2527,2528,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,Device: Dexcom G6,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,"May 25, 2020",2021-05-25,"June 12, 2020","Nordsjællands Hospital, Hillerød, Denmark",https://ClinicalTrials.gov/show/NCT04430608,Denmark,,5.0,2021,Tuesday
2528,2529,COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM),Recruiting,Other: SARS-CoV-2 and/or MIS-C Exposure,All,"up to 20 Years   (Child, Adult)",,250.0,"November 19, 2020",2022-11-01,"December 10, 2020","Loma Linda University Health, Loma Linda, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital at Montefiore, Bronx, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|NewYork-Presbyterian Queens Hospital, Flushing, New York, United States|Cohen Children's Medical Center - Northwell Health, New Hyde Park, New York, United States|Hassenfeld Children's Hospital at NYU Langone, New York, New York, United States|NewYork-Presbyterian Komansky Children's Hospital, New York, New York, United States|Mount Sinai Kravis Children's Hospital, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Pediatric Rheumatology, Charleston, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Eccles Primary Children's: University of Utah Health, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04588363,Georgia,,11.0,2022,Tuesday
2529,2530,"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications",Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"March 24, 2020",2021-03-30,"September 1, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04535128,United States,,3.0,2021,Tuesday
2530,2531,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Recruiting,Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"May 31, 2020",2021-02-01,"November 25, 2020","North Shore UniversityHealth, Evanston, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04391179,United States,Dipyridamole 100 Milligram(mg)|Placebo oral tablet,2.0,2021,Monday
2531,2532,Acute Encephalopathy in Critically Ill Patients With COVID-19,"Active, not recruiting",Other: Follow up,All,"18 Years and older   (Adult, Older Adult)",,250.0,"March 23, 2020",2020-12-31,"October 22, 2020","Jackson Memorial Health System; University of Miami, Miller School of Medicine, Miami, Florida, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Universidade Federal de São Paulo, São Paulo, Brazil|Fundación Valle del Lili, University Hospital, Cali, Colombia|Cairo University Hospitals, Cairo, Egypt|Centre Hospitalier d'Argenteuil, Argenteuil, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Universitaire Ambroise Paré, Boulogne, France|Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France|Centre Hospitalier Régional Universitaire de Brest, Brest, France|Centre Hospitalier de Brives, Brive-la-Gaillarde, France|Centre Hospitalier Universitaire Beaujon, Clichy, France|Centre Hospitalier Universitaire Louis Mourier, Colombes, France|Centre Hospitalier Universitaire Henri Mondor, Créteil, France|Centre hospitalier de Dieppe, Dieppe, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier d'Etampes, Etampes, France|Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France|Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France|Hôpital privé Jacques Cartier, Massy, France|Groupe Hospitalier Sud Ile-de-France, Melun, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire Cochin, Paris, France|Groupe hospitalier Paris Saint-Joseph, Paris, France|Hôpital Fondation Adolphe de Rothschild, Paris, France|Hopital Privé Claude Galien, Quincy-sous-Sénart, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Centre Hospitalier de Roanne, Roanne, France|Hopital Foch, Suresnes, France|Centre Hospitalier de Toulon, Toulon, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours, France|Gustave-Roussy, Villejuif, France|Hospital Regional De Alta Especialidad Del Bajío, Guanajuato, Mexico|Hospital Clinic Universitari, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04320472,Brazil,,12.0,2020,Thursday
2532,2533,Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"April 27, 2020",2022-04-24,"May 13, 2020","Hôpital Pitié Salpétrière, Paris, France",https://ClinicalTrials.gov/show/NCT04362930,France,,4.0,2022,Sunday
2533,2534,Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2,"Active, not recruiting",Diagnostic Test: PT-PCR test for SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"May 11, 2020",2020-12-31,"November 9, 2020","Instituto Brasileiro de Controle do Cancer - IBCC, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04434261,Brazil,,12.0,2020,Thursday
2534,2535,Risk Factors and Computed Tomography Findings in COVID-19.,Completed,Diagnostic Test: Simple chest tomography,All,"Child, Adult, Older Adult",,233.0,"April 1, 2020",2020-10-01,"October 8, 2020","Instituto Nacional Ignacio Chavez, Ciudad de mexico, Mexico",https://ClinicalTrials.gov/show/NCT04577105,Mexico,,10.0,2020,Thursday
2535,2536,Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study,Recruiting,,All,"Child, Adult, Older Adult",,330.0,"March 1, 2020",2021-06-30,"June 18, 2020","CHR Metz Thionville, Metz, France",https://ClinicalTrials.gov/show/NCT04430322,France,,6.0,2021,Wednesday
2536,2537,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,Drug: Naltrexone|Drug: Ketamine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 29, 2020",2021-08-01,"July 2, 2020","William Beaumont Hospital, Royal Oak, Michigan, United States",https://ClinicalTrials.gov/show/NCT04365985,United States,Naltrexone|Ketamine,8.0,2021,Sunday
2537,2538,Prognostic Factors of COVID19,Recruiting,,All,"1 Year and older   (Child, Adult, Older Adult)",,500.0,"March 27, 2020",2022-03-01,"June 25, 2020","Service de Virologie - Hôpital Civil, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04405726,France,,3.0,2022,Tuesday
2538,2539,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,Recruiting,Diagnostic Test: Vaginal fluid Covid-19 PCR test,Female,"18 Years to 70 Years   (Adult, Older Adult)",,35.0,"June 15, 2020",2020-07-30,"June 18, 2020","Acibadem Maslak Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04437940,Turkey,,7.0,2020,Thursday
2539,2540,Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada,Not yet recruiting,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 1|Phase 2,696.0,"August 1, 2020",2021-12-30,"July 2, 2020","Canadian Center for Vaccinology, Halifax, Canada",https://ClinicalTrials.gov/show/NCT04398147,Canada,,12.0,2021,Thursday
2540,2541,Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases,Enrolling by invitation,,All,"Child, Adult, Older Adult",,1000.0,"June 15, 2020",2021-12-01,"July 7, 2020","Department of Internal Medicine, Medical University of Graz, Graz, Austria",https://ClinicalTrials.gov/show/NCT04420637,Austria,,12.0,2021,Wednesday
2541,2542,COVID-19 and Cancer Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 24, 2020",2022-03-24,"May 21, 2020","Imperial College Healthcare NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04393974,United Kingdom,,3.0,2022,Thursday
2542,2543,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,Recruiting,Biological: Ravulizumab|Other: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,270.0,"May 11, 2020",2021-07-01,"November 16, 2020","Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|LAC/USC Health Center, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Alternative Research Associates, LLC, Hialeah, Florida, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Jupiter Medical Center, Jupiter, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Norton Healthcare, Louisville, Kentucky, United States|Overton Brooks VA Medical Center, Shreveport, Louisiana, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Mayo Clinic Health System in Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|Hôpital Raymond Poincaré, Garches, Hauts De Seine, France|Hôpital Henri Mondor, Créteil, Val De Marne, France|Hôpital Bicêtre, Le Kremlin-Bicêtre cedex, Val De Marne, France|Hôpital Saint-Louis, Paris cedex, France|Medical Hospital, Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo-To, Japan|Jikei University Hospital, Minato-Ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-Ku, Tokyo, Japan|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04369469,France,,7.0,2021,Thursday
2543,2544,Prognositc Factors in COVID-19 Patients Complicated With Hypertension,Withdrawn,,All,"18 Years to 100 Years   (Adult, Older Adult)",,0.0,"January 25, 2020",2020-04-30,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",https://ClinicalTrials.gov/show/NCT04272710,China,,4.0,2020,Thursday
2544,2545,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Recruiting,Diagnostic Test: Point-of-Care Ultrasonography (POCUS),All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 15, 2020",2020-10-01,"September 3, 2020","University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04339998,United States,,10.0,2020,Thursday
2545,2546,Long-term Pulmonary Outcomes After Infection With Sars-CoV-2,Not yet recruiting,Diagnostic Test: Imaging of the lungs,All,"18 Years to 85 Years   (Adult, Older Adult)",,180.0,May 2020,2022-12-01,"May 26, 2020","Aarhus University Hospital, Aarhus, Denmark",https://ClinicalTrials.gov/show/NCT04401163,Denmark,,12.0,2022,Thursday
2546,2547,Emergence of the COVID 19 Epidemic in the City of Nice,Completed,,All,"Child, Adult, Older Adult",,200.0,"February 28, 2020",2020-04-04,"June 26, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04449094,France,,4.0,2020,Saturday
2547,2548,Nasal Photodisinfection COVID Proof of Concept Study,Recruiting,Other: Methylene-Blue Photodisinfection,All,"Child, Adult, Older Adult",Not Applicable,100.0,"July 10, 2020",2021-05-31,"November 4, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04615936,Canada,,5.0,2021,Monday
2548,2549,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,Recruiting,Other: Questionnaire and interview,All,"Child, Adult, Older Adult",,400.0,"July 2, 2020",2020-12-18,"November 9, 2020","Centre Hospitalier Régionale Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire Lille, Lille, France|Centre Hospitalier Universitaire de Marseille, Marseille, France|Centre Hospitalier Universitaire de Nîmes - Caremeau, Nimes, France|Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France|Centre Hospitalier Universitaire de Reims, Reims, France|Centre Hospitalier Universitaire de Rouen, Rouen, France|CHU Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04466839,France,,12.0,2020,Friday
2549,2550,Physical Rehabilitation in ICU in ARDS Patients With COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,35.0,"March 15, 2020",2020-06-11,"June 17, 2020","Koc University School of Medicine, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04435080,Turkey,,6.0,2020,Thursday
2550,2551,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Recruiting,Other: NHANES smell and taste tests,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",,250.0,"June 15, 2020",2020-12-31,"July 10, 2020","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia|prince Mohammed bin Abdulaziz Hospital, Riyadh, Central, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04388618,Saudi Arabia,,12.0,2020,Thursday
2551,2552,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,Completed,Other: Physiotherapy,All,"18 Years and older   (Adult, Older Adult)",,92.0,"March 1, 2020",2020-05-08,"May 20, 2020","UHB NHS Foundation Trust, Birmingham, United Kingdom",https://ClinicalTrials.gov/show/NCT04396197,United Kingdom,,5.0,2020,Friday
2552,2553,Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives,Completed,Other: it is a survey,All,"18 Years and older   (Adult, Older Adult)",,187.0,"April 1, 2020",2020-06-30,"August 3, 2020","URC Ville Evrard, Neuilly-sur-Marne, France",https://ClinicalTrials.gov/show/NCT04357418,France,,6.0,2020,Tuesday
2553,2554,WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19,Recruiting,,All,"18 Years to 120 Years   (Adult, Older Adult)",,100.0,"June 9, 2020",2022-06-01,"December 7, 2020","Tulane University, TRIAD Center, New Orleans, Louisiana, United States|Tulane University, New Orleans, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04605965,United States,,6.0,2022,Wednesday
2554,2555,Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"May 8, 2020",2020-09-01,"August 6, 2020","Hôpital Roger Salengro, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04359706,France,,9.0,2020,Tuesday
2555,2556,Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients,Not yet recruiting,Drug: Pentoxifylline|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,200.0,"December 13, 2020",2020-12-30,"October 6, 2020","Faculty of Medicine, Shibīn Al Kawm, Egypt",https://ClinicalTrials.gov/show/NCT04433988,Egypt,Pentoxifylline|Placebo,12.0,2020,Wednesday
2556,2557,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,86.0,"April 20, 2020",2020-10-01,"April 15, 2020","Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04346329,Colombia,Hydroxychloroquine|Placebo oral tablet,10.0,2020,Thursday
2557,2558,Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19),Recruiting,Procedure: lung ultrasound (LUS),All,"18 Years to 95 Years   (Adult, Older Adult)",,14.0,"March 20, 2020",2020-12-31,"May 19, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04393402,France,,12.0,2020,Thursday
2558,2559,Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,753.0,May 2020,2021-05-01,"May 28, 2020",,https://ClinicalTrials.gov/show/NCT04405362,Undefined,,5.0,2021,Saturday
2559,2560,Measles Vaccine in HCW,Recruiting,Drug: Measles-Mumps-Rubella Vaccine|Drug: Placebos,All,18 Years to 50 Years   (Adult),Phase 3,200.0,"July 13, 2020",2020-11-01,"July 16, 2020","Cairo University Hospital, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04357028,Egypt,Measles-Mumps-Rubella Vaccine|Placebos,11.0,2020,Sunday
2560,2561,Pediatrics HOT COVID-19 Database in NY Tristate,Recruiting,,All,"up to 21 Years   (Child, Adult)",,1500.0,"April 30, 2020",2022-05-01,"June 24, 2020","Connecticut Children's Hospital, Hartford, Connecticut, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Steven Halpern, Morristown, New Jersey, United States|Archana Sharma, New Brunswick, New Jersey, United States|Mount Sinai Beth Israel, Newark, New Jersey, United States|St. Joseph's Regional Medical Center, New Jersey, Paterson, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Maimondes Medical Center, Brooklyn, New York, United States|Mount Sinai, New York, New York, United States|NYU Langone Health, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Stephen Roberts, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Cohen Children's Northwell Health, Queens, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Westchester Medical Center, Valhalla, New York, United States",https://ClinicalTrials.gov/show/NCT04445402,Israel,,5.0,2022,Sunday
2561,2562,Clinical and Haematological Phenotypes in Long COVID,Recruiting,Diagnostic Test: Blood sampling (venesection),All,"18 Years and older   (Adult, Older Adult)",,100.0,December 2020,2021-06-01,"December 9, 2020","The Physicians' Clinic, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04659889,United Kingdom,,6.0,2021,Tuesday
2562,2563,National Survey on the Lockdown of Children With Disabilities,Completed,,All,"up to 18 Years   (Child, Adult)",,2500.0,"April 7, 2020",2020-05-11,"May 20, 2020","CHRU de Brest, Brest, France",https://ClinicalTrials.gov/show/NCT04395833,France,,5.0,2020,Monday
2563,2564,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,18.0,"February 16, 2020",2020-06-01,"May 1, 2020","The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04273763,China,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon α2b Spray,6.0,2020,Monday
2564,2565,Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 1, 2020",2022-04-01,"July 2, 2020","Thoraxklinik at Heidelberg University, Heidelberg, Germany",https://ClinicalTrials.gov/show/NCT04456075,Germany,,4.0,2022,Friday
2565,2566,EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2),Not yet recruiting,Drug: Eicosapentaenoic acid gastro-resistant capsules|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,284.0,"November 9, 2020",2021-07-31,"November 2, 2020",,https://ClinicalTrials.gov/show/NCT04335032,Undefined,Eicosapentaenoic acid gastro-resistant capsules|Placebo,7.0,2021,Saturday
2566,2567,Proactive Care of Ambulatory COVID19 Patients,Not yet recruiting,Other: consultation|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,64.0,"April 29, 2020",2020-07-01,"May 6, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04371107,France,Azithromycin,7.0,2020,Wednesday
2567,2568,Neurologic Manifestations of COVID 19 in Children,Recruiting,Other: Observational study only,All,up to 17 Years   (Child),,500.0,"April 29, 2020",2022-12-31,"May 7, 2020","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04379089,United States,,12.0,2022,Saturday
2568,2569,Study of Famotidine With Vitamins C and D for Pandemic Coronavirus,Not yet recruiting,Drug: Famotidine 20 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 4,216.0,"December 1, 2020",2021-07-31,"September 25, 2020","Pykonsult headquarters, New Fairfield, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04565392,United States,Famotidine 20 MG,7.0,2021,Saturday
2569,2570,Assessment of Safety and Efficacy of CCP,"Active, not recruiting",Biological: COVID Convalescent Plasma,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,136.0,"June 16, 2020",2020-10-31,"September 9, 2020","Mulago Specialised Hospital, Kampala, Uganda",https://ClinicalTrials.gov/show/NCT04542941,Uganda,,10.0,2020,Saturday
2570,2571,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Recruiting,Drug: PLN-74809|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36.0,"October 22, 2020",2021-10-31,"October 29, 2020","Valleywise Health Medical Center, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT04565249,United States,PLN-74809|Placebo,10.0,2021,Sunday
2571,2572,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults,Not yet recruiting,Biological: CVnCoV|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,36500.0,"November 30, 2020",2023-03-04,"December 8, 2020","University Hospital Tübingen Institut für Tropenmedizin, Tübingen, Germany",https://ClinicalTrials.gov/show/NCT04652102,Germany,,3.0,2023,Saturday
2572,2573,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Recruiting,Drug: Placebo|Drug: Ivermectin|Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 2,176.0,"July 23, 2020",2021-02-01,"July 29, 2020","Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04447235,Brazil,Placebo|Ivermectin|Losartan,2.0,2021,Monday
2573,2574,Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed,Completed,Behavioral: Generalized Anxiety Disorder-7 (GAD-7)|Behavioral: Patient Health Questionnaire-9 (PHQ-9),Female,"18 Years and older   (Adult, Older Adult)",,503.0,"April 1, 2020",2020-05-15,"July 28, 2020","IRCCS Ospedale Policlinico San Martino, Genoa, Italy",https://ClinicalTrials.gov/show/NCT04395755,Italy,,5.0,2020,Friday
2574,2575,Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method,Recruiting,Diagnostic Test: Immunfluorescence,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 30, 2020",2020-12-31,"June 25, 2020","University of Szeged, Albert Szent-Györgyi Health Center, Szeged, Hungary",https://ClinicalTrials.gov/show/NCT04429620,Hungary,,12.0,2020,Thursday
2575,2576,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),Recruiting,Biological: Vaccinated with polio vaccine (IPV),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,25.0,"November 15, 2020",2021-01-15,"November 27, 2020","Rac Ii Md, National City, California, United States",https://ClinicalTrials.gov/show/NCT04639375,United States,,1.0,2021,Friday
2576,2577,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,Biological: BCG|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000.0,"August 10, 2020",2023-08-01,"August 7, 2020","Hospital das Clínicas Unicamp, Campinas, SP, Brazil",https://ClinicalTrials.gov/show/NCT04369794,Brazil,,8.0,2023,Tuesday
2577,2578,Thrombosis and Covid-19,Recruiting,Diagnostic Test: TEM-tPA,All,"18 Years and older   (Adult, Older Adult)",,325.0,"May 1, 2020",2020-12-01,"June 17, 2020","Hôpital Louis Pradel, Bron, France",https://ClinicalTrials.gov/show/NCT04366778,France,,12.0,2020,Tuesday
2578,2579,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,Not yet recruiting,Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,374.0,"April 24, 2020",2020-08-24,"April 22, 2020","The New York Center for Travel and Tropical Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04352946,United States,Hydroxychloroquine Pre-Exposure Prophylaxis|Placebo oral tablet,8.0,2020,Monday
2579,2580,Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia,Recruiting,Drug: Favipiravir|Drug: Azithromycin,All,18 Years to 59 Years   (Adult),Phase 3,210.0,"October 15, 2020",2020-12-31,"November 3, 2020","RSJ Soerodjo, Magelang, Central Java, Indonesia|RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia|RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04613271,Indonesia,Favipiravir|Azithromycin,12.0,2020,Thursday
2580,2581,Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study,Recruiting,Diagnostic Test: SARS-CoV-2 IgG,All,"18 Years to 90 Years   (Adult, Older Adult)",,2000.0,"July 1, 2020",2021-12-31,"October 9, 2020","UZ Leuven, Leuven, Vlaams Brabant, Belgium",https://ClinicalTrials.gov/show/NCT04579471,Belgium,,12.0,2021,Friday
2581,2582,Vital Sensor Monitors for CV19 Detection,Enrolling by invitation,Device: ANNE One,All,"18 Years and older   (Adult, Older Adult)",,300.0,"November 5, 2020",2022-10-30,"November 19, 2020","Northwestern Memorial Hospital, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04635787,United States,,10.0,2022,Sunday
2582,2583,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,Recruiting,Procedure: Elective Cancer Surgery,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 30, 2020",2020-12-31,"May 12, 2020","Hospital del Henares, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04384926,Spain,,12.0,2020,Thursday
2583,2584,Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),Completed,,Female,18 Years to 45 Years   (Adult),,720.0,"April 15, 2020",2020-07-15,"September 16, 2020","Hospital San Juan de Dios, Santiago, Chile",https://ClinicalTrials.gov/show/NCT04551690,Chile,,7.0,2020,Wednesday
2584,2585,Analysis of Mortality of Critically Ill Patients With COVID-19,Not yet recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,650.0,"May 11, 2020",2020-05-30,"May 13, 2020",,https://ClinicalTrials.gov/show/NCT04379258,Undefined,,5.0,2020,Saturday
2585,2586,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,Recruiting,Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2),All,"Child, Adult, Older Adult",,2000.0,"April 20, 2020",2022-04-20,"April 29, 2020","Hôpital Pitié Salpétrière, Paris, France",https://ClinicalTrials.gov/show/NCT04355611,France,,4.0,2022,Wednesday
2586,2587,Imaging Feature of SARS-CoV2 Infection,Recruiting,,All,"Child, Adult, Older Adult",,500.0,"April 16, 2020",2020-10-01,"May 19, 2020","Deaprtment of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy",https://ClinicalTrials.gov/show/NCT04394026,Italy,,10.0,2020,Thursday
2587,2588,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Completed,Behavioral: Tele-interventions related to diabetes management and mental well-being,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,149.0,"April 17, 2020",2020-09-20,"October 14, 2020","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04344210,Brazil,,9.0,2020,Sunday
2588,2589,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),Not yet recruiting,Drug: CORVax|Drug: IL-12 plasmid|Device: Cliniporator,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,December 2020,2022-05-01,"November 13, 2020","Providence Portland Medical Center, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04627675,United States,CORVax|IL-12 plasmid,5.0,2022,Sunday
2589,2590,Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Procedure: Study Arm,All,"18 Years to 80 Years   (Adult, Older Adult)",,50.0,"April 9, 2020",2021-12-01,"May 22, 2020","Inselspital Bern, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04397172,Switzerland,,12.0,2021,Wednesday
2590,2591,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Recruiting,Diagnostic Test: Pulmonary function testing,All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,140.0,"May 18, 2020",2025-08-18,"August 24, 2020","CHU Besançon, Besançon, Franche-Comté, France",https://ClinicalTrials.gov/show/NCT04519320,France,,8.0,2025,Monday
2591,2592,Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19,Not yet recruiting,Drug: Lopinavir-Ritonavir|Drug: Hydroxychloroquine,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,6400.0,"November 15, 2020",2026-05-14,"November 5, 2020",,https://ClinicalTrials.gov/show/NCT04386070,Undefined,Lopinavir-Ritonavir|Hydroxychloroquine,5.0,2026,Thursday
2592,2593,Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19),Recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,30.0,"April 1, 2020",2020-09-30,"May 7, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04376905,France,,9.0,2020,Wednesday
2593,2594,The RAPID COVID TRIAGE Algorithm,Not yet recruiting,Diagnostic Test: Spartan Cube Point-of Care Covid-19 test,All,"18 Years and older   (Adult, Older Adult)",,20.0,"April 15, 2020",2021-02-28,"April 20, 2020",,https://ClinicalTrials.gov/show/NCT04353154,Undefined,,2.0,2021,Sunday
2594,2595,"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina","Active, not recruiting",Diagnostic Test: Serological Assay or IgG for SARS-CoV-2,All,"14 Years and older   (Child, Adult, Older Adult)",,873.0,"June 10, 2020",2020-07-18,"July 15, 2020","Hospital de Niños Ricardo Gutierrez, Buenos Aires, Caba, Argentina",https://ClinicalTrials.gov/show/NCT04472078,Argentina,,7.0,2020,Saturday
2595,2596,Impact of COVID-19 Pandemic on Depression and Quality of Life,Completed,Other: Online survey,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",,543.0,"May 6, 2020",2020-05-18,"June 11, 2020","Okan University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04394078,Turkey,,5.0,2020,Monday
2596,2597,COG-UK Project Hospital-Onset COVID-19 Infections Study,Not yet recruiting,Other: Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures,All,"Child, Adult, Older Adult",Not Applicable,2000.0,July 2020,2021-04-01,"June 17, 2020",,https://ClinicalTrials.gov/show/NCT04405934,Undefined,,4.0,2021,Thursday
2597,2598,High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy,Not yet recruiting,Drug: Enoxaparin,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300.0,June 2020,2021-06-01,"May 29, 2020","Azienda Ospedaliero-Universitaria, Modena, Italy",https://ClinicalTrials.gov/show/NCT04408235,Italy,Enoxaparin,6.0,2021,Tuesday
2598,2599,Netizens' Perception of COVID-19 Information & Information Sources.,Recruiting,Other: Electronic Survey questionnaire,All,"19 Years and older   (Adult, Older Adult)",,385.0,"June 10, 2020",2020-08-15,"August 4, 2020","Dr Bugude Shiva Shankar, Ar Rass, Al Qassim, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04497441,Saudi Arabia,,8.0,2020,Saturday
2599,2600,Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population,Recruiting,,All,"50 Years to 89 Years   (Adult, Older Adult)",,800.0,"April 17, 2020",2021-04-20,"May 21, 2020","CHU de Toulouse, Toulouse, Occitanie, France",https://ClinicalTrials.gov/show/NCT04397835,France,,4.0,2021,Tuesday
2600,2601,Zofin (Organicell Flow) for Patients With COVID-19,Recruiting,Biological: Zofin|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"September 8, 2020",2020-12-31,"December 4, 2020","Larkin Community Hospital, Miami, Florida, United States|Larkin Community Hospital, South Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04384445,United States,,12.0,2020,Thursday
2601,2602,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Drug: Valsartan (Diovan)|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 4,651.0,"April 17, 2020",2021-12-01,"June 9, 2020","Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Erasmus MC, Rotterdam, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands",https://ClinicalTrials.gov/show/NCT04335786,Netherlands,Valsartan (Diovan)|Placebo oral tablet,12.0,2021,Wednesday
2602,2603,Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,Completed,Other: questionnaire assesment,All,"18 Years and older   (Adult, Older Adult)",,318.0,"April 27, 2020",2020-05-04,"December 11, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04351399,France,,5.0,2020,Monday
2603,2604,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,180.0,"May 20, 2020",2024-05-01,"December 10, 2020","MedStar Health Research Institute /MedStar Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04401449,United States,,5.0,2024,Wednesday
2604,2605,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Recruiting,Diagnostic Test: biological samples day of delivery,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"May 17, 2020",2020-12-31,"May 27, 2020","Chu Besancon, Besancon, France",https://ClinicalTrials.gov/show/NCT04402918,France,,12.0,2020,Thursday
2605,2606,Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection,Withdrawn,,All,"18 Years and older   (Adult, Older Adult)",,0.0,"August 14, 2020",2020-08-14,"August 18, 2020",,https://ClinicalTrials.gov/show/NCT04409184,Undefined,,8.0,2020,Friday
2606,2607,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Recruiting,Biological: CAStem,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,9.0,"January 27, 2020",2020-12-01,"April 2, 2020","Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China",https://ClinicalTrials.gov/show/NCT04331613,China,,12.0,2020,Tuesday
2607,2608,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,Completed,Other: no intervention,All,"18 Years and older   (Adult, Older Adult)",,617.0,"June 1, 2020",2020-11-17,"November 20, 2020","Valentin Simon, Vandoeuvre Les Nancy, France",https://ClinicalTrials.gov/show/NCT04407169,France,,11.0,2020,Tuesday
2608,2609,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,Recruiting,Dietary Supplement: Omnibiotic AAD|Dietary Supplement: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108.0,"September 24, 2020",2022-12-01,"October 22, 2020","Department of Internal Medicine, Medical University of Graz, Graz, Austria",https://ClinicalTrials.gov/show/NCT04420676,Austria,,12.0,2022,Thursday
2609,2610,"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.",Recruiting,Other: Online Survey,All,18 Years to 35 Years   (Adult),,120.0,"May 27, 2020",2020-12-01,"August 27, 2020","Uskudar University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04453566,Turkey,,12.0,2020,Tuesday
2610,2611,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,Biological: Convalescent Plasma|Other: Placebo,All,65 Years and older   (Older Adult),Not Applicable,165.0,"June 4, 2020",2020-11-02,"November 18, 2020","Hospital Militar Central, Caba, Buenos Aires, Argentina|CEMIC, Caba, Buenos Aires, Argentina|Centro de Investigacion Clinica OSECAC, Caba, Buenos Aires, Argentina|Centro Gallego de Buenos Aires, Caba, Buenos Aires, Argentina|Sanatorio Anchorena, Caba, Buenos Aires, Argentina|Sanatorio de Los Arcos, Caba, Buenos Aires, Argentina|Hospital ""Simplemente Evita"", González Catán, Buenos Aires, Argentina|Hospital Especializado de Agudos y Crónicos ""San Juan de Dios"", La Plata, Buenos Aires, Argentina|Clinica Olivos, Buenos Aires, Argentina|Hospital Central de San Isidro, Buenos Aires, Argentina|Hospital General de Agudos ""Dr. Carlos Bocalandro"", Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04479163,Argentina,,11.0,2020,Monday
2611,2612,Northeast COVID-19 and Pregnancy Study Group,Not yet recruiting,,Female,"Child, Adult, Older Adult",,180.0,"July 1, 2020",2022-12-20,"July 8, 2020","Instituto Materno Infantil Prof. Fernando Figueira, Recife, Pernambuco, Brazil",https://ClinicalTrials.gov/show/NCT04462367,Brazil,,12.0,2022,Tuesday
2612,2613,Long-Term Experience and Health Effects of COVID-19,Recruiting,Other: none - observational,All,"18 Years to 100 Years   (Adult, Older Adult)",,50000.0,"July 1, 2020",2022-07-01,"July 29, 2020","Altura, Mission Viejo, California, United States",https://ClinicalTrials.gov/show/NCT04477902,United States,,7.0,2022,Friday
2613,2614,Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit,Not yet recruiting,Other: Patient management suffering of coronavirus infection,All,"Child, Adult, Older Adult",,100.0,"April 15, 2020",2020-09-01,"April 17, 2020",,https://ClinicalTrials.gov/show/NCT04346810,Undefined,,9.0,2020,Tuesday
2614,2615,COVID-19 in ART: Perception and Experience,Recruiting,Other: Questionnaire,All,18 Years to 60 Years   (Adult),,600.0,"June 1, 2020",2020-07-30,"July 2, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04456010,France,,7.0,2020,Thursday
2615,2616,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,Suspended,Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,116.0,November 2020,2021-06-30,"May 11, 2020","Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04310865,China,Yinhu Qingwen Granula|Yin Hu Qing Wen Granula(low does),6.0,2021,Wednesday
2616,2617,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,Drug: Sevoflurane|Drug: Propofol,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,50.0,"April 16, 2020",2021-04-30,"October 14, 2020","Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04359862,Spain,Sevoflurane|Propofol,4.0,2021,Friday
2617,2618,Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS,Not yet recruiting,Drug: Aviptadil 67μg|Drug: Placebo 0.9% NaCl solution,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,January 2021,2022-03-01,"November 9, 2020","Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St.Gallen, St.Gallen, Switzerland",https://ClinicalTrials.gov/show/NCT04536350,Switzerland,Aviptadil 67μg|Placebo 0.9% NaCl solution,3.0,2022,Tuesday
2618,2619,SPI-1005 Treatment in Severe COVID-19 Patients,Not yet recruiting,Drug: Ebselen|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,December 2020,2021-04-01,"November 10, 2020",,https://ClinicalTrials.gov/show/NCT04483973,Undefined,Ebselen|Placebo,4.0,2021,Thursday
2619,2620,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Recruiting,Other: Psychoeducational intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66.0,"May 1, 2020",2023-04-01,"August 24, 2020","Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark",https://ClinicalTrials.gov/show/NCT04351789,Denmark,,4.0,2023,Saturday
2620,2621,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,Behavioral: e-Psychotherapy,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,80.0,"June 15, 2020",2021-05-01,"July 20, 2020","Hotel Dieu Hospital, Kingston, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04476667,Canada,,5.0,2021,Saturday
2621,2622,SPI-1005 Treatment in Moderate COVID-19 Patients,Not yet recruiting,Drug: Ebselen|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,December 2020,2021-04-01,"November 10, 2020",,https://ClinicalTrials.gov/show/NCT04484025,Undefined,Ebselen|Placebo,4.0,2021,Thursday
2622,2623,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,Drug: Convalescent Plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,100.0,"May 5, 2020",2020-12-31,"May 20, 2020","Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04392232,United States,Convalescent Plasma,12.0,2020,Thursday
2623,2624,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,Other: Questionnaire,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,248.0,"July 21, 2020",2021-08-01,"July 27, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04487171,France,,8.0,2021,Sunday
2624,2625,"Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection",Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"June 1, 2020",2023-06-01,"June 30, 2020","Humanitas reseach hospital (ICH), Rozzano, Milan, Italy",https://ClinicalTrials.gov/show/NCT04451577,Italy,,6.0,2023,Thursday
2625,2626,Long-term Impact of Infection With Novel Coronavirus (COVID-19),"Active, not recruiting",,All,"18 Years to 100 Years   (Adult, Older Adult)",,800.0,"April 21, 2020",2024-12-21,"November 18, 2020","Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04362150,United States,,12.0,2024,Saturday
2626,2627,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Recruiting,Radiation: Low dose radiation 35 cGy|Radiation: High dose radiation 100 cGy,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100.0,"August 28, 2020",2022-12-31,"September 25, 2020","Boca Raton Regional Hospital Lynn Cancer Institute, Boca Raton, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Lowell General Hospital Cancer Center, Lowell, Massachusetts, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Ohio State University James Cancer Hospital, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04466683,India,,12.0,2022,Saturday
2627,2628,Lung Ultrasound for COVID-19 Initial Triage and Monitoring,Recruiting,Other: thoracic lung ultrasound,All,"17 Years and older   (Child, Adult, Older Adult)",,148.0,"May 27, 2020",2021-03-27,"July 16, 2020","University Hospital Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04474236,France,,3.0,2021,Saturday
2628,2629,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,Recruiting,Other: Quality-of-Life Assessment|Other: Questionnaire Administration,All,"Child, Adult, Older Adult",,274.0,"May 26, 2020",2021-07-01,"December 2, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04650178,United States,,7.0,2021,Thursday
2629,2630,COVID-19 and ICU-acquired MDR Bacteria,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,690.0,"May 18, 2020",2021-05-01,"May 28, 2020","Hôpital Roger Salengro, ICU, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04378842,France,,5.0,2021,Saturday
2630,2631,SARS-COV2 Pandemic Serosurvey in a Rare Disease Population,Enrolling by invitation,,All,"up to 89 Years   (Child, Adult, Older Adult)",,5000.0,"December 16, 2020",2023-04-30,"December 11, 2020","National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04609085,United States,,4.0,2023,Sunday
2631,2632,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"June 19, 2020",2023-06-01,"July 9, 2020","Chelsea and Westminster Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04459351,United Kingdom,,6.0,2023,Thursday
2632,2633,Mindfulness During COVID-19,Recruiting,Behavioral: Mindfulness session(s),All,"Child, Adult, Older Adult",Not Applicable,200.0,"March 22, 2020",2020-12-01,"April 24, 2020","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04319445,United States,,12.0,2020,Tuesday
2633,2634,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Not yet recruiting,Other: samling of oropharynx and nasopharynx,All,"Child, Adult, Older Adult",Not Applicable,30.0,"April 20, 2020",2020-05-20,"April 24, 2020","Jessa Hospital, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04361448,Belgium,,5.0,2020,Wednesday
2634,2635,COVID-19 Epidemic Response Study,Not yet recruiting,,All,"60 Years and older   (Adult, Older Adult)",,400.0,"December 20, 2020",2021-11-30,"November 24, 2020",,https://ClinicalTrials.gov/show/NCT04357496,Undefined,,11.0,2021,Tuesday
2635,2636,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50.0,"May 18, 2020",2021-05-01,"May 22, 2020","Wilmer Eye Institute, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04374656,United States,,5.0,2021,Saturday
2636,2637,Convalescent Plasma in the Treatment of COVID 19,Completed,Biological: Convalescent Plasma,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,48.0,"April 10, 2020",2020-08-13,"September 24, 2020","Trinity Health Of New England, Hartford, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04343261,United States,,8.0,2020,Thursday
2637,2638,The McMaster Multi-Regional COVID-19 Hospital Case Registry,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"April 15, 2020",2021-07-01,"November 24, 2020","Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's General Hospital, Kitchener, Ontario, Canada|Niagara Health System, St. Catharines, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04508959,Canada,,7.0,2021,Thursday
2638,2639,COVID-19 in Immunosuppressed Children,Recruiting,,All,"1 Month to 18 Years   (Child, Adult)",,200.0,"June 30, 2020",2021-04-01,"August 13, 2020","Hospital Federal de Bonsucesso, Rio de Janeiro, RJ, Brazil|Hospital Estadual da Criança, Rio De Janeiro, RJ, Brazil",https://ClinicalTrials.gov/show/NCT04511429,Brazil,,4.0,2021,Thursday
2639,2640,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,Recruiting,Biological: Emapalumab|Biological: Anakinra,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,54.0,"April 2, 2020",2020-12-01,"October 22, 2020","Regions hospital, Saint Paul, Minnesota, United States|The Valley hospital, Ridgewood, New Jersey, United States|NewYork-Presbyterian Queens, Flushing, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Utah Health, Salt Lake City, Utah, United States|ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|S.C. Malattie Infettive, Ospedale Galliera, Genova, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Dipartimento di Medicina - DIMED, Azienda Ospedale - Università Padova, Padova, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy|ASL Città di Torino, Unit of Infectious Diseases, Medicine, Rheumatology, Torino, Italy",https://ClinicalTrials.gov/show/NCT04324021,Italy,,12.0,2020,Tuesday
2640,2641,Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City,Recruiting,,All,"Child, Adult, Older Adult",,2000.0,"April 1, 2020",2022-12-31,"April 29, 2020","Hôpital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Hôpital Bellan, Paris, France",https://ClinicalTrials.gov/show/NCT04365530,France,,12.0,2022,Saturday
2641,2642,Mechanisms for Covid-19 Disease Complications,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 18, 2020",2021-12-31,"June 26, 2020","Akershus University Hospital, Lørenskog, Norway",https://ClinicalTrials.gov/show/NCT04314232,Norway,,12.0,2021,Friday
2642,2643,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Recruiting,Biological: Convalescent plasma,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,"June 25, 2020",2021-06-01,"August 5, 2020","Hospital Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aire, Argentina",https://ClinicalTrials.gov/show/NCT04468009,Argentina,,6.0,2021,Tuesday
2643,2644,Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),Recruiting,Diagnostic Test: Blood sample,All,"18 Years and older   (Adult, Older Adult)",,2400.0,"June 8, 2020",2021-06-30,"June 16, 2020","Hospital de Mataró, Mataró, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04425759,Spain,,6.0,2021,Wednesday
2644,2645,STATIN THERAPY AND COVID-19 INFECTION,"Active, not recruiting",Drug: observational,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"May 14, 2020",2020-12-30,"September 17, 2020","Facultat de Medicina i Ciències de la Salut de Reus, Reus, Tarragona, Spain",https://ClinicalTrials.gov/show/NCT04407273,Spain,observational,12.0,2020,Wednesday
2645,2646,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,Recruiting,Drug: Rayaldee 30Mcg Extended-Release (ER) Capsule|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160.0,"October 26, 2020",2021-04-01,"October 29, 2020","OPKO Investigative Site, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04551911,United States,Rayaldee 30Mcg Extended-Release (ER) Capsule|Placebo,4.0,2021,Thursday
2646,2647,Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,Completed,,All,"Child, Adult, Older Adult",,48.0,"February 1, 2020",2020-05-01,"May 12, 2020","Faculty of Medicine, University of Alexandria, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT04382469,Egypt,,5.0,2020,Friday
2647,2648,Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19),Recruiting,Other: Additional biological samples,All,"18 Years and older   (Adult, Older Adult)",,160.0,"April 20, 2020",2025-04-20,"July 14, 2020","CHU Jean Minjoz, Besançon, France",https://ClinicalTrials.gov/show/NCT04365322,France,,4.0,2025,Sunday
2648,2649,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,Drug: Enoxaparin,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,130.0,"June 20, 2020",2020-12-30,"August 11, 2020","Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico City, Ixtapaluca, Mexico",https://ClinicalTrials.gov/show/NCT04508439,Mexico,Enoxaparin,12.0,2020,Wednesday
2649,2650,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,Completed,Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,600.0,"April 1, 2020",2020-07-20,"July 30, 2020","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04492501,Pakistan,Tocilizumab|Remdesivir,7.0,2020,Monday
2650,2651,MSCs in COVID-19 ARDS,Recruiting,Biological: Remestemcel-L|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,"April 30, 2020",2022-04-01,"November 6, 2020","Dignity Health, Gilbert, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Lutheran Hospital, Fort Wayne, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|New York University Langone Health, New York, New York, United States|Mount Sinai Health, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor, Smith & White, Plano, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT04371393,Georgia,Placebo,4.0,2022,Friday
2651,2652,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Enrolling by invitation,Diagnostic Test: qRT-PCR and serology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"September 24, 2020",2021-05-30,"October 19, 2020","Sciensano, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04527614,Belgium,,5.0,2021,Sunday
2652,2653,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Recruiting,Drug: N-acetylcysteine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,"September 23, 2020",2021-05-31,"September 25, 2020","CHA Cambridge Hospital, Cambridge, Massachusetts, United States|CHA Everett Hospital, Everett, Massachusetts, United States|CHA Respiratory Clinic, Somerville, Massachusetts, United States|CHA Somerville campus, Somerville, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04419025,United States,N-acetylcysteine,5.0,2021,Monday
2653,2654,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,"Active, not recruiting",Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline,All,"Child, Adult, Older Adult",Not Applicable,11.0,"August 19, 2020",2020-11-15,"October 5, 2020","Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04570254,Mexico,Vitamin C|Vitamin E|Melatonin|N-acetyl cysteine|Pentoxifylline,11.0,2020,Sunday
2654,2655,Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,67.0,"October 1, 2020",2021-04-01,"September 21, 2020","1. A.H. Juan Ramón Jiménez., Huelva, Andalucia, Spain|5. Hospital Virgen de la Victoria, Málaga, Andalucía, Spain|3. Hospital Universitario. Jerez de la Frontera., Jerez De La Frontera, Cádiz, Spain|4. Hospital Universitario de Álava., Alava, País Vasco, Spain|2. Hospital Universitario Infanta Leonor, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04556864,Spain,,4.0,2021,Thursday
2655,2656,ACCESS A Master Digital Surveillance Protocol for COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000000.0,"April 20, 2020",2031-10-01,"April 28, 2020","Medable Inc., Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT04363268,United States,,10.0,2031,Wednesday
2656,2657,Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Approved for marketing,Drug: Remdesivir,All,"12 Years and older   (Child, Adult, Older Adult)",,,,,"November 13, 2020","University of Alabama- Birmingham, Birmingham, Alabama, United States|Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|Community Regional Medical Centers (CRMC), Fresno, California, United States|St. Jude Medical Center, Fullerton, California, United States|Scripps Memorial Hospital La Jolla, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|Scripps Mercy Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, Medical Center (Parnassus Campus), San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo Medical Center, San Mateo, California, United States|Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Health, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States|Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Swedish Hospital, Chicago, Illinois, United States|Mercy Hospital & Medical Center, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States|Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States|Riverview Health, Noblesville, Indiana, United States|Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|CalvertHealth Medical Center, Prince Frederick, Maryland, United States|University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Charlton Memorial Hospital, Fall River, Massachusetts, United States|Lawrence General Hospital, Lawrence, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Health Care Corporation, Flint, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States|Clara Maass Medical Center, Belleville, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Trinitas Regional Medical Center, Elizabeth, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Ocean Medical Center, Oakhurst, New Jersey, United States|Bayshore Medical Center, Red Bank, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|Virtua Health Voorhees Campus, Voorhees, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Mount Sinai Queens, Astoria, New York, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|Southside Hospital, Bay Shore, New York, United States|Lincoln Medical Center, Bronx, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Montefiore Medical Center, Weiler Campus, Bronx, New York, United States|Montefiore Health System Moses Medical Center, Bronx, New York, United States|The Brooklyn Hospital Center, Brooklyn, New York, United States|Kingsbrook Jewish Medical Center, Brooklyn, New York, United States|University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States|Woodhull Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|New York Harbor VA Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Interfaith Medical Center, Brooklyn, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Brooklyn, Brooklyn, New York, United States|New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States|Kaleida Health System, Buffalo, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|New York Presbyterian- Queens, Flushing, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|NYU Langone Health, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States|NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States|New York City Health + Hospitals / Harlem, New York, New York, United States|New York Presbyterian Lower Manhattan Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States|Samaritan Hospital, Troy, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University College of Medicine, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Francis Hospital, Tulsa, Oklahoma, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|St. Francis Hospital, Greenville, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Texas Department of Criminal Justice Hospital (Hospital Galveston)/University of Texas Medical Branch, Galveston, Texas, United States|HCA Houston Healthcare West, Houston, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|Methodist Mansfield Medical Center, Mansfield, Texas, United States|Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Gold Coast Hospital, Southport, Australia|Landeskrankenhaus Graz West, Graz, Austria|Universitätsklinik für Innere Medizin II, Innsbruck, Austria|Kepler Universitätsklinikum, Linz, Austria|Medical University and General Hospital Vienna, Vienna, Austria|Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Hôpital Civil Marie Curie, Lodelinsart, Belgium|William Osler Health System, Brampton, Ontario, Canada|The Ottowa Hospital, Ottawa, Ontario, Canada|Nicosia General Hospital, Nicosia, Cyprus|Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Bulovce, Praha 8 - Liben, Czechia|Rigshospitalet, Copenhagen, Denmark|Põhja-Eesti Regionaalhaigla, Tallinn, Estonia|Vilnius University, Tartu, Estonia|Hopital Avicenne, Bobigny, France|Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France|Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hôpital Raymond Poincaré, Garches, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hôpital Charles-Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitatsklinikum, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany|Klinikum Würzburg Mitte, Würzburg, Germany|University General Hospital of Patras Panagia I Voithia, Patra, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece|Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary|Landspítali, Reykjavik, Iceland|Kerry University Hospital, Tralee, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Hasharon Hospital, Petah Tikva, Israel|Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera dei Colli, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Italy|Azienda Ospedaliero Universitaria, Turin, Italy|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Vilnius University, Vilnius, Lithuania|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland|Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland|Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal|Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal|Centro Hospitalar Universitário De São João, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania|Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania|Clinical hospital for infectious disease, Timisoara, Romania|Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia|Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia|Univerzitetni Klinicni Center Maribor, Maribor, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Hôpital du Valais -Hôpital de Sion, Sion, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT04323761,Australia,Remdesivir,,n,
2657,2658,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Recruiting,Other: Nasal swab|Other: Taste and olfactory function evaluation,All,"18 Years and older   (Adult, Older Adult)",,24.0,"May 4, 2020",2022-09-15,"May 7, 2020","Hôpital Lariboisière, Policlinique, Paris, France|Hôpital Lariboisière, Service ORL, Paris, France",https://ClinicalTrials.gov/show/NCT04366934,France,,9.0,2022,Thursday
2658,2659,"COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",Recruiting,,All,"up to 18 Years   (Child, Adult)",,350.0,"April 3, 2020",2030-12-31,"April 17, 2020","Akershus universistetssykehus, Lørenskog, Norway",https://ClinicalTrials.gov/show/NCT04335773,Norway,,12.0,2030,Tuesday
2659,2660,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Biological: Convalescent Plasma|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"September 1, 2020",2022-09-01,"September 22, 2020","OLVZ Aalst, Aalst, Belgium|UZ Antwerpen, Antwerp, Belgium|Imelda ZH Bonheiden, Bonheiden, Belgium|AZ Sint-Jan Brugge, Bruges, Belgium|CHU Saint Pierre, Brussels, Belgium|Erasme, Brussels, Belgium|UZ Brussel, Brussel, Belgium|CHU Charleroi Marie Curie, Charleroi, Belgium|AZ Sint Blasius, Dendermonde, Belgium|UZ Gent, Gent, Belgium|AZ Groeningen Kortrijck, Kortrijk, Belgium|CHR Citadelle, Liège, Belgium|CHU Liège, Liège, Belgium|UC Louvain, Louvain, Belgium|AZ Delta, Roeselare, Belgium|CHU UCL Namur-Godinne, Yvoir, Belgium",https://ClinicalTrials.gov/show/NCT04558476,Belgium,,9.0,2022,Thursday
2660,2661,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,Drug: Ivermectin,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50.0,"April 25, 2020",2020-07-25,"May 4, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04373824,India,Ivermectin,7.0,2020,Saturday
2661,2662,Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"October 1, 2020",2021-04-01,"August 14, 2020","International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh",https://ClinicalTrials.gov/show/NCT04441372,Bangladesh,,4.0,2021,Thursday
2662,2663,COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2,Not yet recruiting,Other: Physiology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"October 4, 2020",2023-05-04,"August 24, 2020","Erasme Hospital, Bruxelles, Belgium",https://ClinicalTrials.gov/show/NCT04524156,Belgium,,5.0,2023,Thursday
2663,2664,Evolution of Facial Trauma During COVID Containment Measures,Completed,Procedure: Facial fractures reduction or osteosynthesis,All,"Child, Adult, Older Adult",,300.0,"April 1, 2020",2020-05-30,"July 29, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04355442,France,,5.0,2020,Saturday
2664,2665,Antibodies Responses to COVID-19 Infection in Hospitalized Patients,Not yet recruiting,Diagnostic Test: Testing procedure for Binding antibodies|Diagnostic Test: Neutralizing antibodies,All,"18 Years and older   (Adult, Older Adult)",,158.0,August 2020,2021-02-01,"August 20, 2020","Imam Abdulrahman Bin Faisal University, Dammam, Eastern, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04520880,Saudi Arabia,,2.0,2021,Monday
2665,2666,COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?,Not yet recruiting,Diagnostic Test: Test for SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,20.0,August 2020,2021-02-01,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04444687,Undefined,,2.0,2021,Monday
2666,2667,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Biological: Human Amniotic Fluid,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,"March 20, 2020",2021-03-20,"April 17, 2020","University of Utah Health, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04319731,United States,,3.0,2021,Saturday
2667,2668,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,Suspended,Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C,All,"45 Years and older   (Adult, Older Adult)",Phase 4,13.0,"March 30, 2020",2022-05-27,"September 16, 2020","Portland Providence Medical Center, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04334967,United States,Hydroxychloroquine,5.0,2022,Friday
2668,2669,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,Behavioral: Personalized health education|Behavioral: General health education,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,7576.0,"April 1, 2020",2021-08-21,"June 9, 2020","Institute for Translational Medicine, University of Pécs, Pécs, Hungary",https://ClinicalTrials.gov/show/NCT04321928,Hungary,,8.0,2021,Saturday
2669,2670,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,Recruiting,Biological: CT-P59/Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1020.0,"September 25, 2020",2021-09-01,"October 26, 2020","Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04602000,"Korea, Republic of",,9.0,2021,Wednesday
2670,2671,Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,800.0,"October 1, 2020",2021-09-01,"October 14, 2020","Centre Hospitalier Intercommunal Poissy-Saint Germain en Laye, Poissy, France",https://ClinicalTrials.gov/show/NCT04542512,France,,9.0,2021,Wednesday
2671,2672,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,"Active, not recruiting",Behavioral: Immediate vs. delayed provision of antibody test results,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1700.0,"September 14, 2020",2020-12-01,"November 9, 2020","Indiana University, Bloomington, Indiana, United States",https://ClinicalTrials.gov/show/NCT04620798,India,,12.0,2020,Tuesday
2672,2673,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","Active, not recruiting",Biological: CT-P59,All,18 Years to 60 Years   (Adult),Phase 1,18.0,"September 4, 2020",2020-12-23,"October 20, 2020","Incheon Medical Center, Incheon, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04593641,"Korea, Republic of",,12.0,2020,Wednesday
2673,2674,Functional Recovery of Hospitalised Patients With COVID-19: The COREG Extension Study,Recruiting,,All,"40 Years and older   (Adult, Older Adult)",,211.0,"June 9, 2020",2021-09-01,"October 26, 2020","McMaster University, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04602260,Canada,,9.0,2021,Wednesday
2674,2675,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study,Completed,,,"18 Years and older   (Adult, Older Adult)",,127.0,"October 13, 2020",2020-11-02,"November 6, 2020","Aylin Koseler, Denizli, Outside Of The US, Turkey",https://ClinicalTrials.gov/show/NCT04618861,Turkey,,11.0,2020,Monday
2675,2676,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial),Not yet recruiting,Combination Product: 150 ppm Nitric Oxide delivered through LungFit Delivery System|Combination Product: 80 ppm Nitric Oxide delivered through LungFit Delivery System,All,"22 Years to 75 Years   (Adult, Older Adult)",Phase 2,50.0,"July 15, 2020",2020-12-15,"July 2, 2020",,https://ClinicalTrials.gov/show/NCT04456088,Undefined,,12.0,2020,Tuesday
2676,2677,Cardiac Performance in Mechanically Ventilated COVID-19 Patients,Completed,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 1, 2020",2020-08-01,"November 13, 2020","Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile",https://ClinicalTrials.gov/show/NCT04628195,Chile,,8.0,2020,Saturday
2677,2678,Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus,Recruiting,Other: Questionnaire,All,"Child, Adult, Older Adult",,2500.0,"October 27, 2020",2024-04-01,"December 3, 2020","CHU de Grenoble - Hôpital Nord, La Tronche, France|Hôpital de la Croix Rousse, Lyon, France|Hôpital Henry Gabrielle, Saint-Genis-Laval, France|CHU de Saint Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04441710,France,,4.0,2024,Monday
2678,2679,Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID),Not yet recruiting,Drug: captopril 25mg,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230.0,"May 5, 2020",2020-08-01,"April 28, 2020","CH Victor Dupuy- Argenteuil, Argenteuil, France|Hôpital Avicenne,, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Antoine Béclère, Clamart, France|CH de Compiègne-Noyon, Compiègne, France|Groupe hospitalier Sud Ile de France, Melun, France|Hôpital de la Pitié- Salpêtrière, Paris, France|Hôpital Tenon, Paris, France|CHRU de Tours, Hôpital Bretonneau, Tours, France|Hôpital de Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04355429,France,captopril 25mg,8.0,2020,Saturday
2679,2680,Repeated Employee Testing for Understanding Our Recovery to Normal,Recruiting,Diagnostic Test: SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 11, 2020",2023-12-01,"July 15, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04472793,United States,,12.0,2023,Friday
2680,2681,Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus,Not yet recruiting,Drug: Drug: Isotretinoin plus Tamoxifen|Drug: Aerosolized Isotretinoin plus Tamoxifen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,160.0,June 2020,2020-09-01,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04389580,Undefined,Drug: Isotretinoin plus Tamoxifen|Aerosolized Isotretinoin plus Tamoxifen,9.0,2020,Tuesday
2681,2682,Advanced Endoscopy During COVID-19,Completed,Other: Endoscopic management according to standard of care,All,"Child, Adult, Older Adult",,670.0,"May 18, 2020",2020-07-05,"July 8, 2020","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Al-Azhar Univerisity, Cairo, Egypt|University Medicine Greifswald, Greifswald, Germany|2- Hospital Guillermo Kaelin De la Fuente - EsSalud, Lima, Peru|Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04385147,Egypt,,7.0,2020,Sunday
2682,2683,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10.0,"April 13, 2020",2020-08-01,"April 22, 2020","Centro de Hematología y Medicina Interna, Puebla, Mexico",https://ClinicalTrials.gov/show/NCT04357106,Mexico,,8.0,2020,Saturday
2683,2684,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Enrolling by invitation,Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,152.0,"March 31, 2020",2020-12-31,"April 24, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04338009,United States,,12.0,2020,Thursday
2684,2685,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,Drug: Anluohuaxian,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,750.0,"April 1, 2020",2020-12-01,"April 24, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04334265,China,Anluohuaxian,12.0,2020,Tuesday
2685,2686,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1363.0,"April 22, 2020",2021-01-01,"November 10, 2020","Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of Florida Health Central Florida, Leesburg, Florida, United States|University of Miami Florida, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|Columbia University, Irving Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04334148,United States,Hydroxychloroquine|Placebo oral tablet,1.0,2021,Friday
2686,2687,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,Drug: Favipiravir,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,210.0,"April 1, 2020",2020-09-15,"April 24, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04333589,China,Favipiravir,9.0,2020,Tuesday
2687,2688,Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System,Not yet recruiting,Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",,100.0,"May 13, 2020",2020-12-01,"May 14, 2020","Huashan Hospital of Fudan University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04311398,China,,12.0,2020,Tuesday
2688,2689,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Recruiting,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150.0,"March 8, 2020",2020-05-01,"April 10, 2020","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04310228,China,Favipiravir Combined With Tocilizumab|Favipiravir|Tocilizumab,5.0,2020,Friday
2689,2690,Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells,Not yet recruiting,Biological: Dental pulp mesenchymal stem cells,All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,24.0,"March 5, 2020",2021-07-30,"March 10, 2020",,https://ClinicalTrials.gov/show/NCT04302519,Undefined,,7.0,2021,Friday
2690,2691,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Not yet recruiting,Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80.0,"March 14, 2020",2021-04-14,"March 4, 2020",,https://ClinicalTrials.gov/show/NCT04295551,Undefined,Lopinavir / ritonavir tablets combined with Xiyanping injection|Lopinavir/ritonavir treatment,4.0,2021,Wednesday
2691,2692,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1700.0,"April 27, 2020",2021-06-01,"September 2, 2020","Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04363450,United States,Hydroxychloroquine|Placebo,6.0,2021,Tuesday
2692,2693,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,129.0,"May 8, 2020",2020-07-21,"August 26, 2020","UNIFESP, São Paulo, Sao Paulo, Brazil|HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil|HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil|HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil|HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil|HSL - Hospital Sírio Libanês, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04403685,Brazil,Tocilizumab,7.0,2020,Tuesday
2693,2694,COVID-19 Related Lung Ventilation and Perfusion Injury,Recruiting,Other: V/Q SPECT-CT|Other: St. George's Respiratory Questionnaire (SGRQ)|Other: mMRC (Modified Medical Research Council) Dyspnea Scale|Other: Six-minute walk test (6MWT)|Other: Spirometry|Other: Plethysmography & DLCO|Other: Airwave Oscillometry,All,"18 Years and older   (Adult, Older Adult)",,92.0,"September 18, 2020",2021-12-01,"September 24, 2020","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04549636,Canada,,12.0,2021,Wednesday
2694,2695,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19",Recruiting,Biological: NGM621|Biological: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,48.0,"November 8, 2020",2021-09-01,"November 23, 2020","NGM Clinical Study Site, Brisbane, Australia",https://ClinicalTrials.gov/show/NCT04582318,Australia,,9.0,2021,Wednesday
2695,2696,Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.,Recruiting,Other: PHQ-9 Depression Scale|Other: GAD-7 General anxiety disorder scale|Other: 38-questions questionnaire,Female,"18 Years and older   (Adult, Older Adult)",,200.0,"May 15, 2020",2020-12-01,"June 16, 2020","""Elena Venizelou"" General and Maternity Hospital of Athens, Athens, Attica, Greece",https://ClinicalTrials.gov/show/NCT04432948,Greece,,12.0,2020,Tuesday
2696,2697,Patient Recovery From Heart Surgery During the Covid-19 Pandemic,Recruiting,Other: Cardiac surgery,All,"18 Years to 120 Years   (Adult, Older Adult)",,100.0,"April 18, 2020",2021-12-31,"April 28, 2020","St Bartholomew's Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04366167,United Kingdom,,12.0,2021,Friday
2697,2698,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,Not yet recruiting,Drug: Enoxaparin|Drug: Methylprednisolone|Drug: unfractionated heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,210.0,"September 1, 2020",2021-07-30,"August 27, 2020",,https://ClinicalTrials.gov/show/NCT04528888,Undefined,Enoxaparin|Methylprednisolone|unfractionated heparin,7.0,2021,Friday
2698,2699,COVID-19 Pandemic Burden in Severe Mental Disease Patients,Recruiting,Other: PSS (Perceived Stress Scale)|Other: GAD-7 (7-item Generalized Anxiety Disorder)|Other: PHQ-9 (9-item Patient Health Questionnaire)|Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Other: Zaritt Burden Interview,All,"18 Years to 70 Years   (Adult, Older Adult)",,400.0,"April 10, 2020",2020-04-25,"April 22, 2020","University of Naples ""Federico II"", Napoli, Italy",https://ClinicalTrials.gov/show/NCT04357769,Italy,,4.0,2020,Saturday
2699,2700,Hydroxychloroquine to Prevent SARS-CoV-2 Infection,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,320.0,June 2020,2020-10-01,"June 4, 2020","Centro Médico Naval ""Cirujano Mayor Santiago Távara"", Callao, Peru|Hospital Nacional Hipólito Unanue, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Cayetano Heredia, Lima, Peru",https://ClinicalTrials.gov/show/NCT04414241,Peru,Hydroxychloroquine,10.0,2020,Thursday
2700,2701,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",Recruiting,Drug: Drug: NA-831|Combination Product: NA-831 and Atazanavir|Combination Product: NA-831and Dexamethasone|Combination Product: Atazanavir and Dexamethasone,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,525.0,"October 15, 2020",2021-02-15,"September 7, 2020","Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Institute-Testing Site, Sacramento, California, United States|Coronavirus Research Institute-Testing Site, San Diego, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States|Coronavirus Research Institute-Testing Site, Fort Lauderdale, Florida, United States|Coronavirus Research Institute-Testing Site, Tampa, Florida, United States|Coronavirus Research Institute- Testing Site, Chicago, Illinois, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site, Baltimore, Maryland, United States|Coronavirus Research Institute-Testing Site, Bethesda, Maryland, United States|Coronavirus Research Institute-Testing Site, Boston, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Worcester, Massachusetts, United States|Coronavirus Research Institute-Testing Site, Ann Arbor, Michigan, United States|Coronavirus Research Institute-Testing Site, Detroit, Michigan, United States|Coronavirus Research Institute-Testing Site, Newark, New Jersey, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|Coronavirus Research Institute-Testing Site, New York, New York, United States|Coronavirus Research Institute- Testing Site, Rochester, New York, United States|Coronavirus Research Institute-Testing Site, Durham, North Carolina, United States|Coronavirus Research Institute-Testing Site, Philadelphia, Pennsylvania, United States|Coronavirus Research Institute- Testing Site, Fort Sam Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Galveston, Texas, United States|Coronavirus Research Institute-Testing Site, Houston, Texas, United States|Coronavirus Research Institute-Testing Site, Kirkland, Washington, United States|Coronavirus Research Institute-Testing Site, Seattle, Washington, United States|Coronavirus Research Institute-Testing Site, Tacoma, Washington, United States",https://ClinicalTrials.gov/show/NCT04452565,Jersey,Drug: NA-831,2.0,2021,Monday
2701,2702,Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"December 1, 2020",2021-07-30,"December 10, 2020","Centre hopsitalier universitaire de Montpellier, Montpellier, Occitanie, France",https://ClinicalTrials.gov/show/NCT04655612,France,,7.0,2021,Friday
2702,2703,Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1),Completed,,All,"18 Years and older   (Adult, Older Adult)",,89.0,"May 15, 2020",2020-07-15,"August 7, 2020","CH de Versailles, Le Chesnay, France",https://ClinicalTrials.gov/show/NCT04386512,France,,7.0,2020,Wednesday
2703,2704,Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study),Completed,Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound,All,"18 Years and older   (Adult, Older Adult)",,450.0,"May 11, 2020",2020-06-30,"July 28, 2020","Hospital Rio Hortega, Valladolid, Spain",https://ClinicalTrials.gov/show/NCT04401033,Spain,,6.0,2020,Tuesday
2704,2705,Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,18 Years to 60 Years   (Adult),Not Applicable,374.0,"May 15, 2020",2020-10-15,"May 6, 2020",,https://ClinicalTrials.gov/show/NCT04370015,Undefined,Hydroxychloroquine|Placebo oral tablet,10.0,2020,Thursday
2705,2706,COVID-19 Immune Repertoire Sequencing,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 1, 2020",2020-12-31,"August 6, 2020","Universitairy hospital of Antwerp, Antwerp, Belgium",https://ClinicalTrials.gov/show/NCT04368143,Belgium,,12.0,2020,Thursday
2706,2707,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Recruiting,Other: An auto-questionnaire comprising three psychometric scales,Female,"Child, Adult, Older Adult",,3060.0,"May 11, 2020",2022-10-01,"July 9, 2020","AP-HP Cochin, Paris, France",https://ClinicalTrials.gov/show/NCT04463758,France,,10.0,2022,Saturday
2707,2708,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Recruiting,Drug: Defibrotide,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12.0,"October 1, 2020",2021-10-01,"October 14, 2020","University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04530604,United States,Defibrotide,10.0,2021,Friday
2708,2709,"A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease",Not yet recruiting,Diagnostic Test: Schirmer Test I,All,"18 Years and older   (Adult, Older Adult)",,25.0,"April 14, 2020",2020-04-30,"April 20, 2020","Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy",https://ClinicalTrials.gov/show/NCT04346160,Italy,,4.0,2020,Thursday
2709,2710,Cardiovascular Implications of COVID-19,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,70.0,"September 1, 2020",2020-12-31,"October 8, 2020","University of Texas Southwestern Medical Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04435457,United States,,12.0,2020,Thursday
2710,2711,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,Completed,Diagnostic Test: Diagnostic examination for venous thromboembolism,All,"18 Years and older   (Adult, Older Adult)",,7795.0,"June 8, 2020",2020-09-30,"November 27, 2020","University Hospital Linköping, Linköping, Östergötland, Sweden",https://ClinicalTrials.gov/show/NCT04400877,Sweden,,9.0,2020,Wednesday
2711,2712,Mental Health Outcomes in Healthcare Workers During COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,3852.0,"May 14, 2020",2020-07-03,"November 3, 2020","University Health Network, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04397848,Canada,,7.0,2020,Friday
2712,2713,COVID-19 Vaccine and Impact on Fertility Study,Recruiting,,Male,18 Years to 50 Years   (Adult),,60.0,"December 14, 2020",2021-06-14,"December 11, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04665258,United States,,6.0,2021,Monday
2713,2714,"OD-doxy-PNV-COV Old Drug "" DOXY "" for Prevention of New Virus Virus OD-doxy-PNV",Recruiting,Drug: Doxycyclin,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,1100.0,"November 20, 2020",2021-03-01,"December 10, 2020","Military Hospital of Tunis, Tunis, Montfleury, Tunisia",https://ClinicalTrials.gov/show/NCT04584567,Tunisia,Doxycyclin,3.0,2021,Monday
2714,2715,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,Recruiting,Drug: Hyperbaric oxygen,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"June 3, 2020",2022-12-31,"December 3, 2020","Bergmannsheil und Kinderklinik Buer GmbH, Gelsenkirchen, Germany|Krankenhaus St. Joesf, Regensburg, Germany|Medical Centre Maria Brasov, Braşov, Romania|Blekingesjukhuset, Karlskrona, Blekinge, Sweden|Sahlgrenska University hospital, Östra sjukhuset, Gothenburg, Sweden|Karolinska University Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04327505,Germany,Hyperbaric oxygen,12.0,2022,Saturday
2715,2716,Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19),Not yet recruiting,Drug: Mavrilimumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 22, 2020",2020-11-22,"May 26, 2020","IRCCS Policlinico San Donato, San Donato, MI, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Istituto Ortopedico Galeazzi, Milano, Italy",https://ClinicalTrials.gov/show/NCT04397497,Italy,Mavrilimumab|Placebo,11.0,2020,Sunday
2716,2717,Home Management of Adult Egyptian Mild COVID-19 Cases,Recruiting,,All,"18 Years to 65 Years   (Adult, Older Adult)",,400.0,"July 1, 2020",2021-03-01,"August 17, 2020","Faculty of Medicine Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04515199,Egypt,,3.0,2021,Monday
2717,2718,"""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""",Completed,Behavioral: covid-19 positive pregnant women,Female,18 Years to 45 Years   (Adult),,100.0,"April 25, 2020",2020-08-26,"September 2, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",https://ClinicalTrials.gov/show/NCT04384887,Turkey,,8.0,2020,Wednesday
2718,2719,Impact of COVID-19 on Lung Cancer Patients,Not yet recruiting,Other: questionnaire and optional interview,All,"18 Years and older   (Adult, Older Adult)",,800.0,September 2020,2021-01-01,"September 23, 2020",,https://ClinicalTrials.gov/show/NCT04538456,Undefined,,1.0,2021,Friday
2719,2720,Long Term Outcomes of Patients With COVID-19,Recruiting,Other: Quality of Life|Other: Impact Event Score|Other: Hospital anxiety and depression scale,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 8, 2020",2021-12-30,"April 24, 2020","University of Chicago Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04360538,United States,,12.0,2021,Thursday
2720,2721,The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,"Active, not recruiting",Other: web based survey,All,"18 Years to 100 Years   (Adult, Older Adult)",,300.0,"May 20, 2020",2020-11-20,"August 11, 2020","1Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy",https://ClinicalTrials.gov/show/NCT04448418,Italy,,11.0,2020,Friday
2721,2722,Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),Recruiting,Other: quality of live assessment,All,"18 Years and older   (Adult, Older Adult)",,131.0,"July 24, 2020",2021-07-27,"August 10, 2020","Hôpitaux Universitaires de Strasbourg (Nouvel Hôpital Civil), Strasbourg, France",https://ClinicalTrials.gov/show/NCT04491214,France,,7.0,2021,Tuesday
2722,2723,Cardiac Dysfunction in Critically Ill Patients Infected With COVID-19,Completed,Diagnostic Test: Echocardiography,All,"18 Years to 99 Years   (Adult, Older Adult)",,133.0,"April 20, 2020",2020-09-30,"October 22, 2020","Södersjukhuset, Stockholm, Region Stockholm, Sweden|North Älvsborg County Hospital, Trollhättan, Västra Götalandsregionen, Sweden|Sahlgrenska University Hospital/Mölndal, Gothenburg, Västra Götaland, Sweden|Sahlgrenska University Hospital, Gothenburg, Västra Götaland, Sweden",https://ClinicalTrials.gov/show/NCT04524234,Sweden,,9.0,2020,Wednesday
2723,2724,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,Recruiting,Biological: COVID-19 exposure,All,"18 Years and older   (Adult, Older Adult)",,140.0,"May 14, 2020",2021-11-10,"May 18, 2020","Barts Health Nhs Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04340921,United Kingdom,,11.0,2021,Wednesday
2724,2725,Detection of COVID-19 in Saliva Collection,Completed,,All,"18 Years and older   (Adult, Older Adult)",,501.0,"May 6, 2020",2020-08-05,"December 11, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04386551,France,,8.0,2020,Wednesday
2725,2726,Risk of Air Contamination During Visceral Surgery in COVID19 Patients,Not yet recruiting,"Other: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,May 2020,2020-10-01,"May 20, 2020",,https://ClinicalTrials.gov/show/NCT04395599,Undefined,,10.0,2020,Thursday
2726,2727,Host-pathogen Interactions During SARS-CoV-2 Infection,Recruiting,Biological: Blood sample|Biological: Low or upper respiratory tract sample|Biological: Stool collection or fecal swab|Genetic: Blood sample for whole genome sequencing|Other: phone call,All,"up to 70 Years   (Child, Adult, Older Adult)",Not Applicable,450.0,"May 5, 2020",2021-06-05,"May 8, 2020","Groupement Hospitalier Nord-Daupine, Bourgoin-Jallieu, France|Hôpital femme-mère-enfant, Bron, France|Hôpital Louis Pradel, Bron, France|Hôpital Louis Mourier, Colombes, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Hopital de la Croix-Rousse, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital mère - enfant Nantes, Nantes, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Hôpital Nord de Saint Etienne, Saint-Priest-en-Jarez, France|Hôpital Nord-Ouest, Villefranche-sur-Saône, France|Centre Hospitalier D'Annecy-Genevois, Épagny, France",https://ClinicalTrials.gov/show/NCT04376476,France,,6.0,2021,Saturday
2727,2728,Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children,Not yet recruiting,,All,"up to 18 Years   (Child, Adult)",,500.0,"February 15, 2020",2020-12-31,"February 17, 2020","Beijing Children's Hospital,, Beijing, China",https://ClinicalTrials.gov/show/NCT04270383,China,,12.0,2020,Thursday
2728,2729,One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,150.0,"June 16, 2020",2021-06-15,"September 25, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04401111,France,,6.0,2021,Tuesday
2729,2730,Assessment of the Psycho-social Impact of COVID-19 Outbreak,"Active, not recruiting",Behavioral: COM-COVID anonimous survey,All,"16 Years and older   (Child, Adult, Older Adult)",,56442.0,"March 31, 2020",2021-03-01,"December 9, 2020","Fundació Institut Germans Trias i Pujol, Badalona, Catalonia, Spain|Fundació Lluita contra la Sida (FLS, Fight AIDS Foundation), Badalona, Catalonia, Spain|Anaxomics biotech, Barcelona, Spain|Fundació Privada per a la Recerca i la Docència Sant Joan de Déu, Esplugues De Llobregat, Spain",https://ClinicalTrials.gov/show/NCT04378452,Spain,,3.0,2021,Monday
2730,2731,Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"June 10, 2020",2021-12-30,"October 20, 2020","Chandler Regional Medical Center, Chandler, Arizona, United States",https://ClinicalTrials.gov/show/NCT04595175,United States,,12.0,2021,Thursday
2731,2732,Psychological Impact of the Covid-19 Pandemic on Student Nurses,Completed,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"May 12, 2020",2020-07-31,"November 19, 2020","Versailles hospital, Le Chesnay, France|Toulouse University Hospital, Toulouse, France",https://ClinicalTrials.gov/show/NCT04402229,France,,7.0,2020,Friday
2732,2733,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,Other: Invasive mechanical ventilation,All,"18 Years and older   (Adult, Older Adult)",,470.0,"February 1, 2020",2020-10-16,"October 19, 2020","Ospedale Santa Maria Annunziata - Anestesia e Rianimazione, Bagno A Ripoli, FI, Italy|A.O. SS. Antonio, Biagio e Cesare Arrigo - Anestesia e Rianimazione, Alessandria, Italy|Anestesia e Rianimazione - Ospedale Civile di Baggiovara, Baggiovara, Italy|Anestesia e Rianimazione - Ospedale di Bentivoglio, Bentivoglio, Italy|Azienda Unità Sanitaria Locale, Bologna, Italy|Anestesia e Rianimazione - Ospedale Bellaria, Bologna, Italy|Anestesia e Rianimazione - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia intensiva dei trapianti addominali e chirurgia epatobiliare - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Anestesia e Terapia Intensiva Polivalente - Policlinico Universitario S.Orsola - Malpighi, Bologna, Italy|Ospedale SS. Trinità - Anestesia e Rianimazione, Borgomanero, Italy|Anestesia e Rianimazione - Ospedale M. Bufalini, Cesena, Italy|Anestesia e Rianimazione - Ospedale degli Infermi, Faenza, Italy|Anestesia e Rianimazione Universitaria - Arcispedale Sant'Anna Ferrara, Ferrara, Italy|Anestesia e Rianimazione - Ospedale Morgagni - Pierantoni, Forlì, Italy|Anestesia e Rianimazione - Ospedale di Imola S.Maria della Scaletta, Imola, Italy|Ospedale Santo Stefano - Anestesia e Rianimazione, Prato, Italy|Anestesia e Rianimazione - Ospedale S. Maria delle Croci, Ravenna, Italy|Anestesia e Rianimazione - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Anestesia e Rianimazione - Ospedale di Riccione, Riccione, Italy|Anestesia e Rianimazione - Ospedale Infermi, Rimini, Italy",https://ClinicalTrials.gov/show/NCT04411459,Italy,,10.0,2020,Friday
2733,2734,SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study,Recruiting,,All,"Child, Adult, Older Adult",,500.0,"May 21, 2020",2022-04-02,"July 31, 2020","Hospital do Rim, São Paulo, Aão Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04494776,Brazil,,4.0,2022,Saturday
2734,2735,Rutgers COVID-19 Cohort Study,Recruiting,Other: Non-Interventional,All,"20 Years and older   (Adult, Older Adult)",,750.0,"April 7, 2020",2021-10-21,"April 15, 2020","Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04336215,Jersey,,10.0,2021,Thursday
2735,2736,A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,Completed,Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",,116.0,"May 2, 2020",2020-06-05,"June 16, 2020","Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh",https://ClinicalTrials.gov/show/NCT04434144,Bangladesh,Ivermectin + Doxycycline|Hydroxychloroquine + Azithromycin,6.0,2020,Friday
2736,2737,Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar,Recruiting,Drug: Darunavir/Cobicistat|Drug: Lopinavir/Ritonavir,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 1, 2020",2020-09-01,"June 11, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04425382,Qatar,Darunavir/Cobicistat|Lopinavir/Ritonavir,9.0,2020,Tuesday
2737,2738,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Biological: CONVALESCENT PLASMA,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1.0,"May 1, 2020",2020-09-30,"November 12, 2020","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",https://ClinicalTrials.gov/show/NCT04393727,Italy,,9.0,2020,Wednesday
2738,2739,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"June 20, 2020",2021-05-31,"June 24, 2020","Guy's & St Thomas' Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04445259,United Kingdom,,5.0,2021,Monday
2739,2740,Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital,Recruiting,Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing,All,"18 Years and older   (Adult, Older Adult)",,150.0,"June 15, 2020",2020-09-01,"August 6, 2020","Hôpital Claude Huriez, CHU, Lille, France",https://ClinicalTrials.gov/show/NCT04362267,France,,9.0,2020,Tuesday
2740,2741,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Completed,Device: COViage,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,197.0,"March 24, 2020",2020-05-30,"June 12, 2020","Dascena, Oakland, California, United States",https://ClinicalTrials.gov/show/NCT04390516,United States,,5.0,2020,Saturday
2741,2742,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,Recruiting,Procedure: Prone Positioning (PP),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,596.0,"November 10, 2020",2021-06-01,"November 27, 2020","Peter Lougheed Centre (PLC), Calgary, Alberta, Canada|Foothills Hospital Intensive Care Unit, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04402879,Canada,,6.0,2021,Tuesday
2742,2743,A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction,Recruiting,Combination Product: Respiratory rehabilitation,All,"18 Years to 80 Years   (Adult, Older Adult)",,300.0,"March 10, 2020",2020-12-31,"May 11, 2020","Huarunwugang general hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04382534,China,,12.0,2020,Thursday
2743,2744,Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease,Not yet recruiting,Other: Maintenance or reduction of immunosuppression,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,50.0,"July 1, 2020",2021-12-31,"June 9, 2020",,https://ClinicalTrials.gov/show/NCT04420364,Undefined,,12.0,2021,Friday
2744,2745,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 1, 2020",2021-04-30,"June 30, 2020","Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States",https://ClinicalTrials.gov/show/NCT04378881,United States,,4.0,2021,Friday
2745,2746,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Not yet recruiting,Device: AirFLO2,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"December 4, 2020",2021-06-01,"December 2, 2020",,https://ClinicalTrials.gov/show/NCT04649775,Undefined,,6.0,2021,Tuesday
2746,2747,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Recruiting,Radiation: Low Dose Radiation Therapy (LD-RT)|Other: Sham irradiation,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,22.0,"November 2, 2020",2021-11-01,"November 4, 2020","Department of Radiooncology, University Hospital Basel, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT04598581,Switzerland,,11.0,2021,Monday
2747,2748,Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19),Available,"Biological: IC14, a monoclonal antibody against CD14",All,"18 Years to 70 Years   (Adult, Older Adult)",,,,,"June 24, 2020","IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy",https://ClinicalTrials.gov/show/NCT04346277,Italy,,,n,
2748,2749,Using Whatsapp for the Consultation,Completed,Other: Sending thorax ct video images via smartphone applications,All,"18 Years and older   (Adult, Older Adult)",,144.0,"March 11, 2020",2020-05-31,"November 27, 2020","Ramazan Sabirli, Kars, Outside Of The US, Turkey",https://ClinicalTrials.gov/show/NCT04645563,Turkey,,5.0,2020,Sunday
2749,2750,Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"August 1, 2020",2023-12-01,"June 30, 2020",,https://ClinicalTrials.gov/show/NCT04452604,Undefined,,12.0,2023,Friday
2750,2751,Psychosocial Outcomes in Families of COVID-19 ICU Patients,Completed,Diagnostic Test: HADS questionnaire,All,"18 Years and older   (Adult, Older Adult)",,39.0,"April 16, 2020",2020-10-30,"November 3, 2020","University Hospital of Liège, Liège, Belgium",https://ClinicalTrials.gov/show/NCT04498507,Belgium,,10.0,2020,Friday
2751,2752,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,Recruiting,Device: CT-V,All,"18 Years and older   (Adult, Older Adult)",,25.0,"June 24, 2020",2022-06-01,"July 24, 2020","Beaumont Health, Royal Oak, Michigan, United States",https://ClinicalTrials.gov/show/NCT04320511,United States,,6.0,2022,Wednesday
2752,2753,Electrolyte State in Patients With COVID-19,"Active, not recruiting",Other: electrolytes,All,"18 Years to 80 Years   (Adult, Older Adult)",,52.0,"May 1, 2020",2020-10-01,"September 7, 2020","Zagazig University, Zagazig, Egypt",https://ClinicalTrials.gov/show/NCT04539834,Egypt,,10.0,2020,Thursday
2753,2754,Anti-Androgen Treatment for COVID-19,Recruiting,Drug: Dutasteride|Drug: Nitazoxanide|Drug: Azithromycin|Drug: Proxalutamide,Male,"50 Years and older   (Adult, Older Adult)",Not Applicable,381.0,"July 2, 2020",2021-01-31,"December 11, 2020","Corpometria Institute, Brasilia, Brazil",https://ClinicalTrials.gov/show/NCT04446429,Brazil,Dutasteride|Nitazoxanide|Azithromycin|Proxalutamide,1.0,2021,Sunday
2754,2755,A Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,Other: There is no intervention in this study,All,"18 Years and older   (Adult, Older Adult)",,250.0,"April 16, 2020",2021-07-31,"October 5, 2020","ProgenaBiome, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04359836,United States,,7.0,2021,Saturday
2755,2756,Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic,Recruiting,,All,"Child, Adult, Older Adult",,1500.0,"July 1, 2020",2020-09-01,"July 8, 2020","Faculty of Dentistry, Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04460469,Egypt,,9.0,2020,Tuesday
2756,2757,Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19,Available,Drug: ZofinTM (OrganicellTM Flow),All,"18 Years and older   (Adult, Older Adult)",,,,,"December 8, 2020",,https://ClinicalTrials.gov/show/NCT04657406,Undefined,ZofinTM (OrganicellTM Flow),,n,
2757,2758,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Completed,,All,"18 Years and older   (Adult, Older Adult)",,2878.0,"April 10, 2020",2020-04-21,"April 28, 2020","CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de Fréjus / Saint-Raphael, Fréjus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'Orléans, Orléans, France|Bichat (APHP), Paris, France|Georges Pompidou European Hospital (AP-HP), Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-Étienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04344327,France,,4.0,2020,Tuesday
2758,2759,Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19,Recruiting,Other: pulmonary rehabilitation,All,"18 Years and older   (Adult, Older Adult)",,50.0,"November 25, 2020",2021-03-31,"December 2, 2020","Schön Klinik Berchtesgadener Land, Schönau Am Königssee, Bavaria, Germany",https://ClinicalTrials.gov/show/NCT04649918,Germany,,3.0,2021,Wednesday
2759,2760,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,Behavioral: 1: Prone positioning|Behavioral: 2: No instruction regarding positioning,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,500.0,"June 26, 2020",2021-01-01,"August 19, 2020","Département d'Anesthésie Réanimation - Kremlin Bicêtre, Le Kremlin-Bicêtre, France",https://ClinicalTrials.gov/show/NCT04366856,France,,1.0,2021,Friday
2760,2761,The Prevalence of Pulmonary Hypertension in Patients With COVID-19.,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,80.0,"June 1, 2020",2020-07-10,"July 7, 2020","Karolinska University Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04459364,Sweden,,7.0,2020,Friday
2761,2762,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Recruiting,Diagnostic Test: Blood sample,Female,"up to 45 Years   (Child, Adult)",Not Applicable,20.0,"June 24, 2020",2021-06-15,"September 7, 2020","Uz Brussels, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04425317,Belgium,,6.0,2021,Tuesday
2762,2763,"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19",Recruiting,Drug: Kaletra and beta interferon,All,"18 Years and older   (Adult, Older Adult)",,80.0,"May 22, 2020",2022-05-21,"November 2, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04611243,Hong Kong,Kaletra and beta interferon,5.0,2022,Saturday
2763,2764,Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection,Recruiting,Drug: Immunosuppressive Agents,All,"18 Years to 100 Years   (Adult, Older Adult)",,3000.0,"August 18, 2020",2021-12-31,"September 29, 2020","Sociedad Argentina de Reumatología, Ciudad Autónoma de Buenos Aires, Caba, Argentina",https://ClinicalTrials.gov/show/NCT04568421,Argentina,Immunosuppressive Agents,12.0,2021,Friday
2764,2765,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Active, not recruiting",Drug: Ruxolitinib administration,All,"18 Years and older   (Adult, Older Adult)",Phase 2,15.0,"July 1, 2020",2021-07-01,"December 1, 2020","Andreas Neubauer, Marburg, Germany",https://ClinicalTrials.gov/show/NCT04359290,Germany,Ruxolitinib administration,7.0,2021,Thursday
2765,2766,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,479.0,"April 2, 2020",2020-07-23,"September 2, 2020","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04332991,Israel,Hydroxychloroquine|Placebo,7.0,2020,Thursday
2766,2767,SARS-COV2 Pandemic Serosurvey and Blood Sampling,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,15000.0,"August 26, 2020",2022-03-31,"October 8, 2020","University of Alabama, Birmingham, Alabama, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04334954,United States,,3.0,2022,Thursday
2767,2768,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,Behavioral: General Communication Message|Behavioral: Focused/Targeted Message|Behavioral: Best Message Alone|Behavioral: Best Message + Augmented Message or Implementation Strategy,All,"5 Years to 90 Years   (Child, Adult, Older Adult)",Not Applicable,2500.0,"November 20, 2020",2022-09-21,"November 30, 2020","Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Baltimore, Maryland, United States|University of Missouri, Kansas City, Missouri, United States|Special School District, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04565509,United States,,9.0,2022,Wednesday
2768,2769,COPE - COVID-19 in Pregnancy and Early Childhood,Recruiting,"Other: biological samples, questionnaires and interviews",Female,"18 Years and older   (Adult, Older Adult)",,1200.0,"June 2, 2020",2041-06-02,"June 16, 2020","Falu Hospital, Falun, Dalarna, Sweden|Halmstad lasarett, Halmstad, Halland, Sweden|Varbergs sjukhus, Varberg, Halland, Sweden|Helsingborgs lasarett, Helsingborg, Skåne, Sweden|Skåne Universitetssjukhus, Lund, Skåne, Sweden|Eskiltuna hospital, Eskilstuna, Södermanland, Sweden|Boras hospital, Boras, VGR, Sweden|Sahlgrenska Univeristy Hospital, Gothenburg, VGR, Sweden|Ryhovs sjukhus, Jönköping, Sweden|Kalmar Lasarett, Kalmar, Sweden|Karlstad lasarett, Karlstad, Sweden|Kristiandstad länssjukhus, Kristianstad, Sweden|Skaraborgs sjukhus Skövde, Skövde, Sweden|BB Stockholm, Stockholm, Sweden|Danderyd, Stockholm, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska University Hospital- Huddinge, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden|Södertälje, Stockholm, Sweden|Sundsvall, Sundsvall, Sweden|Umeå University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Västerås, Västerås, Sweden|Ystad, Ystad, Sweden|Örebro University Hospital, Örebro, Sweden|Linköping University Hospital, Linköping, Östergötland, Sweden|Vrinnevisjukhuset, Norrköping, Östergötland, Sweden",https://ClinicalTrials.gov/show/NCT04433364,Sweden,,6.0,2041,Sunday
2769,2770,Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19,Recruiting,Other: Clinical data,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"May 5, 2020",2021-08-24,"May 6, 2020","National Institute of Cardiology, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04374110,Poland,,8.0,2021,Tuesday
2770,2771,Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,150.0,"May 6, 2020",2020-11-30,"August 3, 2020","Groupe Hospitalier Paris Saint-Joseph, Paris, France",https://ClinicalTrials.gov/show/NCT04488510,France,,11.0,2020,Monday
2771,2772,COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia,Not yet recruiting,Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"February 15, 2021",2022-05-15,"November 10, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04381923,United States,,5.0,2022,Sunday
2772,2773,Physical Activity Levels of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic,Recruiting,Behavioral: Questionnaires,All,"18 Years to 65 Years   (Adult, Older Adult)",,32.0,"June 1, 2020",2021-02-01,"October 19, 2020","Hacettepe University, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04583345,Turkey,,2.0,2021,Monday
2773,2774,Pediatric Acute Kidney Injury in COVID-19,Enrolling by invitation,,All,"up to 25 Years   (Child, Adult)",,250.0,"April 15, 2020",2021-07-01,"July 10, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|Arkansas Children's Research Institute, Little Rock, Arkansas, United States|Cedars-Sinai Maxine Dunitz Children's Health Center, Los Angeles, California, United States|UCLA Mattel Children's Hospital, Los Angeles, California, United States|Lucile Packard Children's Hospital Standford, Palo Alto, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|UF Health Shands Children's Hospital, Gainesville, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Comer Children's Hospital - UChicago Medicine, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|Children's Mercy, Kansas City, Kansas, United States|John Hopkins Children's Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Beaumont Children's Hospital, Royal Oak, Michigan, United States|St. Louis Children's Hospital of Washington University, Saint Louis, Missouri, United States|Oishei Children's Hospital of Buffalo, Buffalo, New York, United States|Golisano Children's Hospital - University of Rochester Medicine, Rochester, New York, United States|Stony Brook Children's Hospital, Stony Brook, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke Children's Hospital and Health Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Lifespan Hasbro Children's Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Shawn Jenkins Children's Hospital, Charleston, South Carolina, United States|Seattle Children's Hospital, Seattle, Washington, United States|Stollery Children's Hospital, Edmonton, Alberta, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada|Soroka University Medical Center, Be'er Sheva, Israel|Dana-Dwek Children's Hospital, Tel Aviv, Israel|Shizuoka Children's Hospital, Shizuoka, Japan|Institute for Mother and Child Healthcare, Belgrade, Serbia|University Children's Hospital, Belgrade, Serbia|Hospital 12 de Octubre, Madrid, Spain|Birmingham Children's Hospital NHS, Birmingham, United Kingdom|Alder Hey Children's Hospital NHS, Liverpool, United Kingdom|King's College Hospital NHS, London, United Kingdom|St. George's University Hospital NHS, London, United Kingdom|Great Ormond Street Hospital NHS, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04466306,Canada,,7.0,2021,Thursday
2774,2775,Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2,Recruiting,,All,"3 Months and older   (Child, Adult, Older Adult)",,300.0,"December 2, 2020",2021-08-01,"December 8, 2020","Saarland University, Homburg, Germany",https://ClinicalTrials.gov/show/NCT04655521,Germany,,8.0,2021,Sunday
2775,2776,EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,Completed,Other: Electronic questionnaire,All,"Child, Adult, Older Adult",,1574.0,"June 4, 2020",2020-10-01,"October 22, 2020","Marcelo Rodrigues dos Santos, São Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04396353,Brazil,,10.0,2020,Thursday
2776,2777,Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions,Recruiting,Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Device: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation,All,18 Years to 60 Years   (Adult),,60.0,"September 14, 2020",2021-02-14,"September 28, 2020","Groupement Hospitalier Régional de Mulhouse Sud Alsace, Mulhouse, France",https://ClinicalTrials.gov/show/NCT04517136,France,,2.0,2021,Sunday
2777,2778,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Recruiting,Device: SCD,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,"September 10, 2020",2021-12-01,"December 11, 2020","University of Kentucky, Lexington, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04395911,United States,,12.0,2021,Wednesday
2778,2779,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",Recruiting,Other: Magnetic Resonance Spectroscopy (MRS).,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"September 8, 2020",2022-05-01,"September 17, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04546737,France,,5.0,2022,Sunday
2779,2780,Intravenous Zotatifin in Adults With Mild or Moderate COVID-19,Not yet recruiting,Drug: Zotatifin|Drug: Placebo,All,18 Years to 64 Years   (Adult),Phase 1,36.0,"November 16, 2020",2021-07-01,"November 19, 2020",,https://ClinicalTrials.gov/show/NCT04632381,Undefined,Zotatifin|Placebo,7.0,2021,Thursday
2780,2781,Influence Physical Activity Psychological Responses COVID-19 Pandemic,Recruiting,Other: Online Survey,All,"18 Years and older   (Adult, Older Adult)",,3500.0,"March 16, 2020",2020-09-30,"April 21, 2020","Universidade da Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil|Universidad Autonoma de Chile, Santiago, Región Metropolitana, Chile|Universidad de la República, Rivera, Uruguay",https://ClinicalTrials.gov/show/NCT04352517,Brazil,,9.0,2020,Wednesday
2781,2782,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,"Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine",All,"18 Years and older   (Adult, Older Adult)",Phase 2,152.0,"March 26, 2020",2020-12-31,"April 28, 2020","Francesco Pugliese, Rome, RM, Italy",https://ClinicalTrials.gov/show/NCT04366089,France,Azithromycin|hydroxychloroquine,12.0,2020,Thursday
2782,2783,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,Recruiting,Biological: Convalescent anti-SARS-CoV-2 plasma|Other: Infusion placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1100.0,"May 1, 2020",2021-06-15,"July 31, 2020","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Arhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark",https://ClinicalTrials.gov/show/NCT04345289,Denmark,,6.0,2021,Tuesday
2783,2784,Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease,Not yet recruiting,Dietary Supplement: Lactoferrin (Apolactoferrin)|Drug: Placebo of excipient(s) will be administered,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,516.0,"June 1, 2020",2020-09-30,"June 2, 2020","National Research Center, Egypt (Clinical and Molecular Pharmacology), Cairo, Giza, Egypt|Clinmax CRO (Clinical Research Organization), Cairo, Egypt|Clinical Trial Unit National Research Center, Cairo, Egypt|Egyptian Military Medical Services (Hospitals), Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04412395,Egypt,Placebo of excipient(s) will be administered,9.0,2020,Wednesday
2784,2785,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Recruiting,Biological: Serology SARS-CoV2|Behavioral: Data collection,All,"Child, Adult, Older Adult",Not Applicable,400.0,"June 19, 2020",2021-09-01,"October 6, 2020","Centre d'investigation clinique (CIC) Necker Cochin in Necker Children's Hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04442087,France,,9.0,2021,Wednesday
2785,2786,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,Recruiting,Drug: agenT-797,All,"18 Years and older   (Adult, Older Adult)",Phase 1,55.0,"September 21, 2020",2021-10-15,"October 29, 2020","Weill Cornell Medicine New York Presbyterian, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04582201,United States,agenT-797,10.0,2021,Friday
2786,2787,COVID-19 Convalescent Plasma,"Active, not recruiting",Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,"April 10, 2020",2021-12-31,"November 13, 2020","University of Chicago Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04340050,United States,,12.0,2021,Friday
2787,2788,DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19),Not yet recruiting,Drug: DAS181|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,280.0,July 2020,2022-09-01,"July 9, 2020","Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China",https://ClinicalTrials.gov/show/NCT04298060,China,DAS181|Placebo,9.0,2022,Thursday
2788,2789,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,Recruiting,Device: Doctor Spot,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 10, 2020",2020-07-31,"July 31, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04452695,United States,,7.0,2020,Friday
2789,2790,ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,Recruiting,Other: COVID-19 Serology|Behavioral: Health Care Worker Survey,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 18, 2020",2021-10-01,"April 30, 2020","NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04367857,United States,,10.0,2021,Friday
2790,2791,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,"Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,200.0,"April 16, 2020",2021-04-01,"December 10, 2020","Neuroganics, Northglenn, Colorado, United States",https://ClinicalTrials.gov/show/NCT04348864,United States,,4.0,2021,Thursday
2791,2792,COVID-19 Associated Coagulopathy in Egypt,Recruiting,,All,"Child, Adult, Older Adult",,150.0,"August 7, 2020",2020-10-31,"October 27, 2020","Assiut University Hospitals, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04507230,Egypt,,10.0,2020,Saturday
2792,2793,The RIsk Stratification in COVID-19 Patients in the ICU Registry,Recruiting,Other: ICU treatment,All,"Child, Adult, Older Adult",,10000.0,"March 13, 2020",2022-03-01,"April 22, 2020","University Hospital of Zurich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04357275,Switzerland,,3.0,2022,Tuesday
2793,2794,Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?,Completed,,All,"18 Years and older   (Adult, Older Adult)",,120.0,"March 15, 2020",2020-05-01,"May 15, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04352699,France,,5.0,2020,Friday
2794,2795,"Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients",Not yet recruiting,Procedure: Covid ICU containment measures,All,"18 Years and older   (Adult, Older Adult)",,240.0,"June 22, 2020",2022-01-22,"June 19, 2020","University hospital, Clermont-Ferrand, Clermont-Ferrand, Auvergne, France|CH Aurillac, Aurillac, France|CH Cannes, Cannes, France|Centre Jean Perrin, Clermont-Ferrand, France|CH Grenoble, Grenoble, France|CH Le Puy-en-Velay, Le Puy-en-Velay, France|University hopistal, Lyon, Lyon, France|CH Moulins, Moulins, France|CH Périgueux, Périgueux, France|CH Rodez, Rodez, France|CH Vichy, Vichy, France",https://ClinicalTrials.gov/show/NCT04430049,France,,1.0,2022,Saturday
2795,2796,Double Therapy With IFN-beta 1b and Hydroxychloroquine,Completed,Drug: Interferon Beta-1B|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 9, 2020",2020-07-07,"July 28, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04350281,Hong Kong,Interferon Beta-1B|Hydroxychloroquine,7.0,2020,Tuesday
2796,2797,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2300.0,"May 14, 2020",2021-03-01,"June 2, 2020","Irst Irccs, Meldola, FC, Italy",https://ClinicalTrials.gov/show/NCT04363827,Italy,Hydroxychloroquine,3.0,2021,Monday
2797,2798,Neurocognitive Impairment in Patients With COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,80.0,"April 15, 2020",2021-04-01,"April 24, 2020","Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Vorpommern, Germany",https://ClinicalTrials.gov/show/NCT04359914,Germany,,4.0,2021,Thursday
2798,2799,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),Recruiting,Drug: LSALT peptide|Drug: Placebo,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,60.0,"October 14, 2020",2021-06-30,"December 11, 2020","VA San Diego Healthcare System, San Diego, California, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|LSU Health Shreveport, Shreveport, Louisiana, United States|Ankara City Hospital, Ankara, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04402957,Turkey,LSALT peptide|Placebo,6.0,2021,Wednesday
2799,2800,SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP),Available,Biological: SARSCoV2 Convalescent Plasma,All,"6 Years to 99 Years   (Child, Adult, Older Adult)",,,,,"May 5, 2020","AdventHealth Orlando, Orlando, Florida, United States",https://ClinicalTrials.gov/show/NCT04374370,United States,,,n,
2800,2801,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"Active, not recruiting",Drug: Placebos|Drug: Leronlimab (700mg),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,86.0,"April 1, 2020",2020-08-31,"August 20, 2020","University of California, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|White Plains Hospital, White Plains, New York, United States|Novant Health, Charlotte, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04343651,Georgia,Placebos|Leronlimab (700mg),8.0,2020,Monday
2801,2802,"Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine",Not yet recruiting,Other: Survey,Female,18 Years to 45 Years   (Adult),,100.0,"April 12, 2020",2020-06-10,"April 13, 2020","Istanbul University - Cerrahpaşa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04336787,Turkey,,6.0,2020,Wednesday
2802,2803,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,Recruiting,Behavioral: Daily Coping Toolkit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"May 1, 2020",2021-04-01,"May 21, 2020","Akron Children's Hospital, Akron, Ohio, United States|Summa Health Systems, Akron, Ohio, United States|Kent State University, Kent, Ohio, United States",https://ClinicalTrials.gov/show/NCT04398277,United States,,4.0,2021,Thursday
2803,2804,The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,Withdrawn,Drug: T89,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,0.0,"February 26, 2020",2020-04-20,"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04285190,Undefined,T89,4.0,2020,Monday
2804,2805,"Characteristics of Patients and Healthcare Workers With COVID-19 in Meta State, Colombia",Not yet recruiting,,All,"up to 120 Years   (Child, Adult, Older Adult)",,250.0,July 2020,2020-08-01,"July 2, 2020",,https://ClinicalTrials.gov/show/NCT04456426,Undefined,,8.0,2020,Saturday
2805,2806,Glycine Supplement for Severe COVID-19,Recruiting,Dietary Supplement: Glycine,All,"Child, Adult, Older Adult",Not Applicable,82.0,"August 20, 2020",2021-06-30,"August 24, 2020","Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico",https://ClinicalTrials.gov/show/NCT04443673,Mexico,,6.0,2021,Wednesday
2806,2807,Monovalent Recombinant COVID19 Vaccine,Recruiting,Biological: COVID19 vaccine|Biological: Saline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,"June 30, 2020",2021-07-01,"July 1, 2020","PARC,, Adelaide, South Australia, Australia",https://ClinicalTrials.gov/show/NCT04453852,Australia,,7.0,2021,Thursday
2807,2808,Convalescent Plasma Therapy for COVID-19 Patients,"Active, not recruiting",Biological: convalescent plasma,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,20.0,"May 1, 2020",2020-12-30,"December 8, 2020","Muhammad Irfan Malik, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04565197,Mali,,12.0,2020,Wednesday
2808,2809,"Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and ""Typical""ARDS Patients",Not yet recruiting,Device: Extravascular Lung Water Index|Device: Pulmonary Vascular Permeability Index,All,"18 Years and older   (Adult, Older Adult)",,10.0,"September 1, 2020",2020-12-31,"August 11, 2020","Istanbul University-Cerrahpaşa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04508933,Turkey,,12.0,2020,Thursday
2809,2810,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Drug: Collagen-Polyvinylpyrrolidone,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,90.0,"August 19, 2020",2021-06-19,"September 3, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Cdmx, Mexico",https://ClinicalTrials.gov/show/NCT04517162,Mexico,Collagen-Polyvinylpyrrolidone,6.0,2021,Saturday
2810,2811,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil],All,"20 Years to 79 Years   (Adult, Older Adult)",Not Applicable,33.0,"April 1, 2020",2020-05-31,"August 4, 2020","Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan",https://ClinicalTrials.gov/show/NCT04384380,Undefined,Hydroxychloroquine Sulfate 200 MG [Plaquenil],5.0,2020,Sunday
2811,2812,Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients,Not yet recruiting,Device: Cordio App,All,"18 Years and older   (Adult, Older Adult)",,5000.0,April 2020,2021-09-01,"April 14, 2020",,https://ClinicalTrials.gov/show/NCT04325048,Undefined,,9.0,2021,Wednesday
2812,2813,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption),All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,30.0,"March 27, 2020",2020-11-26,"March 31, 2020","University Clinic Freiburg, Freiburg, Germany",https://ClinicalTrials.gov/show/NCT04324528,Germany,,11.0,2020,Thursday
2813,2814,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Biological: ChAdOx1 nCoV-19|Biological: MenACWY|Biological: ChAdOx1 nCoV-19 full boost|Biological: ChAdOx1 nCoV-19 half boost|Biological: MenACWY boost|Drug: Paracetamol|Biological: ChAdOx1 nCoV-19 0.5mL boost,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,1090.0,"April 23, 2020",2021-10-01,"November 18, 2020","University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04324606,United Kingdom,Paracetamol,10.0,2021,Friday
2814,2815,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Not yet recruiting,Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 14, 2020",2022-04-14,"April 16, 2020","Service de Médecine Intensive Réanimation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de Médecine Intensive Réanimation Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Médecine Intensive Réanimation Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de réanimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de Réanimation Clinique de la Sauvegarde, Lyon, France|Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France|Service de Réanimation Centre hospitalier Annecy Genevois, Pringy, France|Service de Médecine Intensive Réanimation Hôpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France",https://ClinicalTrials.gov/show/NCT04349618,France,,4.0,2022,Thursday
2815,2816,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Suspended,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,122.0,"April 17, 2020",2020-07-15,"June 12, 2020","Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France",https://ClinicalTrials.gov/show/NCT04344379,France,hydroxychloroquine|azithromycin|hydroxychloroquine placebo,7.0,2020,Wednesday
2816,2817,Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia,Available,Drug: Exebacase,All,"18 Years and older   (Adult, Older Adult)",,,,,"October 27, 2020","CF-301-107 Study Site, Butte, Montana, United States",https://ClinicalTrials.gov/show/NCT04597242,United States,Exebacase,,n,
2817,2818,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Recruiting,Other: Questionnary,All,"18 Years and older   (Adult, Older Adult)",,60.0,"April 16, 2020",2021-03-01,"July 21, 2020","Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04385121,France,,3.0,2021,Monday
2818,2819,Echocardiography in Patients With Covid-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 20, 2020",2021-12-31,"June 2, 2020","University Hospital Tubingen, Tubingen, BW, Germany",https://ClinicalTrials.gov/show/NCT04412460,Germany,,12.0,2021,Friday
2819,2820,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,Device: Nitric Oxide delivered via LungFit™ system,All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20.0,"June 13, 2020",2020-09-30,"July 8, 2020","Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04397692,United States,,9.0,2020,Wednesday
2820,2821,MYocardial DOmmages Related to COVID-19,"Active, not recruiting",Biological: Biological data|Other: Clinical data,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 1, 2020",2021-07-01,"August 4, 2020","Chu Dijon Bourgogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04498065,France,,7.0,2021,Thursday
2821,2822,"To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003",Not yet recruiting,Drug: DWRX2003,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24.0,"October 19, 2020",2021-06-30,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04592835,Undefined,DWRX2003,6.0,2021,Wednesday
2822,2823,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,Not yet recruiting,Drug: BAT + Calcifediol|Drug: BAT,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,1008.0,"April 28, 2020",2020-08-28,"April 30, 2020",,https://ClinicalTrials.gov/show/NCT04366908,Undefined,BAT + Calcifediol|BAT,8.0,2020,Friday
2823,2824,Serological Testing for COVID-19 (SARS-CoV-2) in ESKD,Recruiting,Other: dialysis,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 23, 2020",2022-05-01,"May 12, 2020","Jessa Ziekenhuis, Hasselt, Limburg, Belgium|University Hospitals Leuven, Leuven, Belgium",https://ClinicalTrials.gov/show/NCT04378686,Belgium,,5.0,2022,Sunday
2824,2825,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,Not yet recruiting,Biological: BNT162b2|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,960.0,December 2020,2021-12-01,"December 2, 2020","Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04649021,China,,12.0,2021,Wednesday
2825,2826,Impact of COVID19 Outbreak in Cardiac Acute Care,Recruiting,Other: Data collection,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 20, 2020",2020-08-01,"April 28, 2020","Unité de Soins Intensifs de Cardiologie, Pitié Salpêtrière Hospital, AP-HP, Paris, France",https://ClinicalTrials.gov/show/NCT04344912,France,,8.0,2020,Saturday
2826,2827,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: Placebos|Drug: Leronlimab (700mg),All,"18 Years and older   (Adult, Older Adult)",Phase 2,390.0,"April 15, 2020",2021-04-01,"November 16, 2020","Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|St. Jude Medical Center, Fullerton, California, United States|UCLA, Los Angeles, California, United States|James A. Haley Veterans' Hospital, Tampa, Florida, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Barnabas, Livingston, New Jersey, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|New York Community Hospital of Brooklyn, Brooklyn, New York, United States|Novant Health, Winston-Salem, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04347239,Georgia,Placebos|Leronlimab (700mg),4.0,2021,Thursday
2827,2828,"Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Not yet recruiting,Drug: Fostamatinib|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,308.0,December 2020,2021-10-01,"November 23, 2020",,https://ClinicalTrials.gov/show/NCT04629703,Undefined,Fostamatinib|Placebo,10.0,2021,Friday
2828,2829,Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19,Recruiting,Drug: azoximer bromide|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,394.0,"April 29, 2020",2021-04-01,"May 8, 2020","Regional state budgetary institution of public health ""City hospital No. 5 of Barnaul"", Barnaul, Russian Federation|Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation|The state healthcare institution of the city of Moscow ""City Clinical Hospital No. 15 named after OM Filatov"" in ""Moscow City Department of Health"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital No. 24 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State budgetary institution ""Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital No. 40 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region ""Infectious clinical hospital No. 2 of Nizhny Novgorod"", Nizhny Novgorod, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Orenburg State Medical University"" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""First St. Petersburg State Medical University named after Academician I.P. Pavlov, Saint Petersburg, Russian Federation|State budgetary health institution of the Vladimir region ""Regional Clinical Hospital"", Vladimir, Russian Federation|Yaroslavl State Medical University of Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04381377,Russian Federation,azoximer bromide,4.0,2021,Thursday
2829,2830,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Recruiting,Behavioral: Behaviour Change Technique Intervention to Improve Quality of Life,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,969.0,"May 22, 2020",2022-12-31,"August 21, 2020","University of Manchester - online, Manchester, Cheshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04522128,United Kingdom,,12.0,2022,Saturday
2830,2831,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,60.0,"March 1, 2020",2022-12-31,"May 1, 2020","Fuzhou General Hospital, Fuzhou, Fujian, China",https://ClinicalTrials.gov/show/NCT04371601,China,Oseltamivir|hormones,12.0,2022,Saturday
2831,2832,Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection,Recruiting,,Female,"Child, Adult, Older Adult",,200.0,"July 10, 2020",2020-09-30,"August 31, 2020","Hospital Italiano, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04362956,Argentina,,9.0,2020,Wednesday
2832,2833,Community Health Workers Against COVID19,Enrolling by invitation,Other: community health worker support|Other: care as usual,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140.0,"May 21, 2020",2020-10-30,"June 11, 2020","Department of Public Health and Primary Care, Ghent, Belgium",https://ClinicalTrials.gov/show/NCT04426305,Belgium,,10.0,2020,Friday
2833,2834,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Recruiting,Diagnostic Test: CAG length <22|Diagnostic Test: CAG length >=22,Male,"18 Years and older   (Adult, Older Adult)",,200.0,"May 1, 2020",2020-12-01,"July 14, 2020","Hospital Universitario Ramon y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04368897,Spain,,12.0,2020,Tuesday
2834,2835,REassessement After Hospitalization for Sars-COV-2 disordER,Enrolling by invitation,Other: assessment of the sequelae after hospitalization for Sars-COV-2,All,"18 Years and older   (Adult, Older Adult)",,200.0,"July 8, 2020",2021-07-25,"September 16, 2020","University hospital of Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04443257,France,,7.0,2021,Sunday
2835,2836,Obesity and Mortality of Critically Ill Patients With COVID-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,250.0,"May 12, 2020",2020-05-26,"June 16, 2020","Centre hospitalo-universitaire régional de Nancy, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04425213,France,,5.0,2020,Tuesday
2836,2837,Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,3600.0,May 2020,2020-12-01,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04397237,Undefined,,12.0,2020,Tuesday
2837,2838,The Geneva Covid-19 CVD Study,"Active, not recruiting",Other: Covid-19 + patients,All,"18 Years and older   (Adult, Older Adult)",,7000.0,"March 24, 2020",2022-03-31,"May 12, 2020","Geneva University Hospital (HUG), Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04384029,Switzerland,,3.0,2022,Thursday
2838,2839,Sevoflurane in COVID-19 ARDS (SevCov),Recruiting,Drug: Sevoflurane|Drug: Intravenous drug,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,64.0,"April 23, 2020",2021-03-31,"December 4, 2020","Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Stadtspital Triemli, Zurich, Switzerland|University Hospital Zuirch, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04355962,Switzerland,Sevoflurane|Intravenous drug,3.0,2021,Wednesday
2839,2840,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Not yet recruiting,Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS mouthwash|Drug: Distilled water|Drug: Listerine Mouthwash Product,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"December 7, 2020",2021-11-30,"November 20, 2020","University Of California, San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04409873,United States,Oral-B Mouth Sore mouthwash|Crest Pro-Health Multi-Protection mouthwash|CloSYS mouthwash|Distilled water|Listerine Mouthwash Product,11.0,2021,Tuesday
2840,2841,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,"Active, not recruiting",Other: Simulation of Repurposed Drugs for COVID-19,All,"55 Years and older   (Adult, Older Adult)",,12123.0,"April 7, 2020",2021-04-06,"April 14, 2020","Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States",https://ClinicalTrials.gov/show/NCT04339634,United States,,4.0,2021,Tuesday
2841,2842,Intensive Care Therapy of Covid-19 Disease in Germany,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"August 6, 2020",2023-06-01,"November 2, 2020","RWTH Aachen - Department for operative Intensive Care Medicine and intermediate Care, Aachen, Germany|Zollernalbklinikum, Balingen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|UH Bochum - Department for Anesthesiology and Intensive Care Medicine, Bochum, Germany|Universitätsklinikum Bonn, Bonn, Germany|Univerrsitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Hospital Freiburg - Department for Anesthesiology and Intensive Care Medicine, Freiburg, Germany|Universitätsklinikum Greifswald, Greifswald, Germany|Universitätsklinikum Halle, Halle/Saale, Germany|University Hospital Heidelberg - Department for Anesthesiologie and Intensive Care Medicine, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Klinikum der Universität Witten/Herdecke - Köln / Klinik für Anästhesiologie und operative Intensivmedizin, Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|UKSH Campus Lübeck - Department for Anesthesiology and Intensive Care Medicine, Lübeck, Germany|University Hospital Magdeburg - Department for Anesthesiology and Intensive Care Medicine, Magdeburg, Germany|Universitätsklinikum Marburg, Marburg, Germany|Technische Universität München, München, Germany|University Hospital Tübingen - Department for Anesthesiology and Intensive Care Medicine, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany",https://ClinicalTrials.gov/show/NCT04455451,Germany,,6.0,2023,Thursday
2842,2843,Analysis of the Coagulopathy Developed by COVID-19 Infected Patients,Recruiting,Other: Thrombin generation test assay|Other: Fibrin generation markers assays,All,"18 Years and older   (Adult, Older Adult)",,175.0,"April 28, 2020",2022-07-01,"December 2, 2020","CHU de Bordeaux, Bordeaux, France|CHU de Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|CHU de Nimes, Nîmes, France",https://ClinicalTrials.gov/show/NCT04356950,France,,7.0,2022,Friday
2843,2844,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",Recruiting,Biological: SARS-CoV-2 vaccine (inactivated)|Biological: Placebo,All,18 Years to 59 Years   (Adult),Phase 3,1620.0,"August 10, 2020",2021-09-01,"August 21, 2020","Hasan Sadikin Hospital/School of Medicine, Padjadjaran University, Bandung, West Java, Indonesia",https://ClinicalTrials.gov/show/NCT04508075,Indonesia,,9.0,2021,Wednesday
2844,2845,Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption),All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80.0,"September 1, 2020",2021-10-31,"November 4, 2020","University Clinic Freiburg, Freiburg, Germany|Klinikum Ibbenbueren, Ibbenbueren, Germany|Klinikum Ludwigsburg, Ludwigsburg, Germany",https://ClinicalTrials.gov/show/NCT04385771,Germany,,10.0,2021,Sunday
2845,2846,Tocilizumab in COVID-19 Lahore General Hospital,Recruiting,Drug: Tocilizumab,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Phase 1,50.0,"May 1, 2020",2020-12-30,"December 8, 2020","Lahore General Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04560205,Pakistan,Tocilizumab,12.0,2020,Wednesday
2846,2847,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,Recruiting,Device: AirGo Respiratory Monitor,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 15, 2020",2020-12-31,"April 22, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04356443,United States,,12.0,2020,Thursday
2847,2848,Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"March 3, 2020",2021-11-30,"November 27, 2020","Intensive Care Unit, Hospital Clínico Universidad de Chile, Santiago, Chile",https://ClinicalTrials.gov/show/NCT04642703,Chile,,11.0,2021,Tuesday
2848,2849,Effect of COVID-19 Pandemic on Vaccination Compliance,Not yet recruiting,Other: vaccine,All,1 Year to 2 Years   (Child),,100.0,"April 1, 2021",2022-05-01,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04618796,Undefined,,5.0,2022,Sunday
2849,2850,COVID-19 (SARS-CoV-2) in Urine and Semen,"Active, not recruiting",Diagnostic Test: SARS-CoV 2 RNA PCR Urine|Diagnostic Test: SARS-CoV 2 RNA PCR Semen|Diagnostic Test: Semen Qualitative Analysis|Diagnostic Test: IIEF-5 questionnaire|Diagnostic Test: Male Sexual Health Questionnaire (MSHQ)|Diagnostic Test: IPSS questionnaire|Diagnostic Test: SECRET questionnaire|Diagnostic Test: Interleukin assessment in semen,Male,"18 Years to 80 Years   (Adult, Older Adult)",,43.0,"June 27, 2020",2020-12-02,"November 4, 2020","AOU Careggi, Florence, Tuscany, Italy",https://ClinicalTrials.gov/show/NCT04446169,Italy,,12.0,2020,Wednesday
2850,2851,Phase 1 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered as a Single Dose or a Repeat Dose in Healthy Adults,Recruiting,Biological: COVID-HIGIV|Other: Placebo (saline),All,18 Years to 60 Years   (Adult),Phase 1,56.0,December 2020,2021-09-01,"December 10, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04661839,United States,,9.0,2021,Wednesday
2851,2852,The Impact of Camostat Mesilate on COVID-19 Infection,Recruiting,Drug: Camostat Mesilate|Drug: Placebo oral tablet,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 1|Phase 2,580.0,"April 4, 2020",2021-05-01,"April 30, 2020","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark",https://ClinicalTrials.gov/show/NCT04321096,Denmark,Camostat Mesilate|Placebo oral tablet,5.0,2021,Saturday
2852,2853,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",Recruiting,Drug: Hydroxychloroquine Sulfate Tablets|Drug: Lopinavir/ Ritonavir Oral Tablet|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1968.0,"June 3, 2020",2020-11-28,"June 9, 2020","CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil",https://ClinicalTrials.gov/show/NCT04403100,Brazil,Hydroxychloroquine Sulfate Tablets|Lopinavir/ Ritonavir Oral Tablet|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Placebo,11.0,2020,Saturday
2853,2854,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Recruiting,Other: EIT-Group|Other: ARDSNet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,128.0,"May 8, 2020",2021-12-01,"August 4, 2020","USP Instituto do Coração, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04497454,Brazil,,12.0,2021,Wednesday
2854,2855,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,Other: prone position,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,400.0,"August 28, 2020",2022-08-28,"November 6, 2020","CH de DAX, Dax, France|CHD de VENDEE, La Roche sur Yon, France|CH de LA ROCHELLE, La Rochelle, France|CHR d'Orléans - Service Pneumologie, Orléans, France|CHR d'Orleans - Service Maladies Infectieuses, Orléans, France|HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Hopital Lariboisiere - Medecine Interne, Paris, France|Hopital Lariboisiere, Paris, France|CH de PERPIGNAN - Service Maladies infectieuses, Perpignan, France|CH de Perpignan - pneumologie, Perpignan, France|Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau, Quimper, France|CHRU de Tours - Service Médecine interne et immunologie Clinique, Tours, France|CHRU de Tours - Service Pneumologie, Tours, France|CHRU DE TOURS - Service Médecine interne et maladies infectieuses, Tours, France",https://ClinicalTrials.gov/show/NCT04363463,France,,8.0,2022,Sunday
2855,2856,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?,Completed,Other: Case fatality rate,All,"Child, Adult, Older Adult",,32.0,"February 1, 2020",2020-07-01,"July 14, 2020","Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Kucukcekmece, Turkey",https://ClinicalTrials.gov/show/NCT04468802,Turkey,,7.0,2020,Wednesday
2856,2857,T Cells Response to SARS COV 2 Peptides,Recruiting,Diagnostic Test: Savicell's ImmunoBiopsy™,All,"18 Years and older   (Adult, Older Adult)",,400.0,"October 14, 2020",2021-10-10,"November 2, 2020","Carmel Medical Center, Haifa, North, Israel",https://ClinicalTrials.gov/show/NCT04573348,Israel,,10.0,2021,Sunday
2857,2858,Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"May 11, 2020",2022-04-27,"July 28, 2020","St Vincent's Hospital, Darlinghurst, New South Wales, Australia|East Sydney Doctors, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Concord Hospital, Sydney, New South Wales, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|Melanoma Institute Australia, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia",https://ClinicalTrials.gov/show/NCT04354818,Australia,,4.0,2022,Wednesday
2858,2859,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Completed,Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,40.0,"March 29, 2020",2020-05-25,"June 16, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04376814,"Iran, Islamic Republic of",Favipiravir|Hydroxychloroquine|Lopinavir / Ritonavir,5.0,2020,Monday
2859,2860,The Impact of COVID-19 Pandemic on Cancer Care,"Active, not recruiting",Other: survey,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 15, 2020",2020-10-31,"September 9, 2020","EgyBrit Medical Centre, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04382495,Egypt,,10.0,2020,Saturday
2860,2861,COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study,Recruiting,Biological: Collection of blood samples in order to create a biocollection,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 11, 2020",2021-02-01,"May 18, 2020","Hôpital Pierre Wertheimer, Bron, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|Centre hospitalier universitaire de Grenoble Alpes, Grenoble, France|Hôpital Edouard Herriot, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpial de la Croix Rousse, Lyon, France|Hôpital Lyon Sud, Pierre-Bénite, France|CH de St Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04392401,France,,2.0,2021,Monday
2861,2862,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Active, not recruiting",Biological: BNT162b1|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,144.0,"July 28, 2020",2021-08-01,"November 18, 2020","Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04523571,China,,8.0,2021,Sunday
2862,2863,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,Completed,Other: acute kidney injury,All,"18 Years to 110 Years   (Adult, Older Adult)",,724.0,"June 1, 2020",2020-07-20,"September 9, 2020","Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04407156,United Kingdom,,7.0,2020,Monday
2863,2864,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,Other: Pulmonary Rehabilitation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 30, 2020",2021-01-01,"November 24, 2020","Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04642040,Turkey,,1.0,2021,Friday
2864,2865,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,Recruiting,Other: all treatment about COVID-2019,All,"1 Year to 80 Years   (Child, Adult, Older Adult)",,132.0,"February 1, 2020",2020-12-01,"April 15, 2020","the First Hospital of Jilin University, Chang chun, Jilin, China",https://ClinicalTrials.gov/show/NCT04346602,China,,12.0,2020,Tuesday
2865,2866,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Recruiting,Biological: BCG-Denmark|Biological: Saline,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,1500.0,"May 18, 2020",2021-08-01,"November 24, 2020","Hvidovre Hospital, Hvidovre, Denmark",https://ClinicalTrials.gov/show/NCT04373291,Denmark,,8.0,2021,Sunday
2866,2867,A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19,Not yet recruiting,Biological: EQ001|Biological: EQ001 Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,November 2020,2021-06-01,"November 20, 2020","Inv Site CO01, Medellín, Colombia",https://ClinicalTrials.gov/show/NCT04605926,Colombia,,6.0,2021,Tuesday
2867,2868,Prognostic Factors and Outcomes of COVID-19 Cases in Ethiopia,Not yet recruiting,Other: The study does not required,All,"Child, Adult, Older Adult",,6390.0,"October 30, 2020",2021-11-14,"October 14, 2020","Saro Abdella, Addis Ababa, Ethiopia",https://ClinicalTrials.gov/show/NCT04584424,Ethiopia,,11.0,2021,Sunday
2868,2869,Respiratory Mechanics and Gas Exchange Characteristics in Patient With SARS-CoV-2,Recruiting,Other: High PEEP with end inspiratory pause|Other: Low PEEP - FiO2 high|Other: High PEEP without end inspiratory pause|Other: Low PEEP - FiO2 low,All,"18 Years and older   (Adult, Older Adult)",,15.0,"July 1, 2020",2020-10-20,"July 27, 2020","Sanatorio Anchorena San Martin, San Martin, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04486729,Argentina,,10.0,2020,Tuesday
2869,2870,International SARS-CoV-2 (COVID-19) Infection Observational Study,Recruiting,Other: Data Collection,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"June 18, 2020",2021-06-30,"October 19, 2020","Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London Medical School Centre for Sexual Health and HIV Research, London, England, United Kingdom",https://ClinicalTrials.gov/show/NCT04385251,Argentina,,6.0,2021,Wednesday
2870,2871,Solid Organ Transplant Recipients With SARS-CoV-2 French Registry,Recruiting,,All,"1 Year and older   (Child, Adult, Older Adult)",,300.0,"April 8, 2020",2021-04-08,"May 5, 2020","Service de Néphrologie et Transplantation, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04360707,France,,4.0,2021,Thursday
2871,2872,Observational Study of COVID-19 Treatment Efficacy,Enrolling by invitation,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 14, 2020",2021-04-14,"April 30, 2020","OSF HealthCare St Francis Medical Center, Peoria, Illinois, United States",https://ClinicalTrials.gov/show/NCT04369989,United States,,4.0,2021,Wednesday
2872,2873,Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"May 5, 2020",2023-03-31,"July 29, 2020","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|St. Peter's Hospital, Albany, New York, United States|Jacobi Medical Center, New York, New York, United States|Hospital Obrero #2, Cochabamba, Bolivia|Hopital Sacre Coeur & Universite de Montreal, Montreal, Quebec, Canada|Universidad de Los Andes, Santiago, Chile|Postgraduate Institute of Research, Chandigarh, Chandigarh, India|Royal Free Hospital, London, United Kingdom|Guy's & St Thomas's Hospital, London, United Kingdom|University of Nottingham, Nottingham, United Kingdom",https://ClinicalTrials.gov/show/NCT04491227,Canada,,3.0,2023,Friday
2873,2874,Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV,Recruiting,Device: 2019-nCoV IgG/IgM Rapid Test Cassette,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 15, 2020",2020-12-31,"June 16, 2020","Papa Giovanni XXIII Hospital, Bergamo, Italy|Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy|European IO, Division of Early Drug Development for Innovative Therapies, Milan, Italy",https://ClinicalTrials.gov/show/NCT04434417,Italy,,12.0,2020,Thursday
2874,2875,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Recruiting,Other: Physiotherapy,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,34.0,"May 27, 2020",2020-12-01,"August 26, 2020","University of Health Sciences Turkey, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04402983,Turkey,,12.0,2020,Tuesday
2875,2876,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,Behavioral: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|Behavioral: SHG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"May 15, 2020",2020-11-17,"December 1, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04431856,United States,,11.0,2020,Tuesday
2876,2877,Impact of the COVID-19 Pandemic in Gynecological Oncology,Recruiting,Other: modification of the planned therapeutic management,Female,"18 Years and older   (Adult, Older Adult)",,400.0,"May 6, 2020",2020-11-06,"June 9, 2020","Service de Gynécologie, HFME, Hospices Civils de Lyon, Bron, France|Service de Gynécologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France|Service Gynécologie, CHLS, Hospices Civils de Lyon, Pierre-Bénite, France",https://ClinicalTrials.gov/show/NCT04351139,France,,11.0,2020,Friday
2877,2878,Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic,Completed,,All,"18 Years and older   (Adult, Older Adult)",,104.0,"May 1, 2020",2020-06-01,"October 28, 2020","Sisli Hamidiye Etfal Education and Training Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04604119,Turkey,,6.0,2020,Monday
2878,2879,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Active, not recruiting",Drug: TNKase,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,45.0,"September 8, 2020",2022-06-30,"October 27, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04558125,United States,TNKase,6.0,2022,Thursday
2879,2880,SARS-CoV-2 Disguise Study,Recruiting,Diagnostic Test: SARS-CoV-2-test|Other: SARS-CoV-2 questionnaire survey,All,"18 Years and older   (Adult, Older Adult)",,900.0,"May 7, 2020",2020-11-30,"May 20, 2020","Meshalkin National Medical Research Center, Novosibirsk, Russian Federation",https://ClinicalTrials.gov/show/NCT04395794,Russian Federation,,11.0,2020,Monday
2880,2881,MANAGEMENT OF APPENDICITIS DURING THE COVID-19 PANDEMIC,Completed,Procedure: laparoscopic or open appendicectomy,All,"16 Years and older   (Child, Adult, Older Adult)",,207.0,"November 1, 2019",2020-10-06,"November 4, 2020","Addenbrooke's University Hospital, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04615728,United Kingdom,,10.0,2020,Tuesday
2881,2882,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,Drug: Plasma,All,18 Years to 60 Years   (Adult),Phase 2,10.0,"May 1, 2020",2020-07-28,"August 17, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04332380,Colombia,Plasma,7.0,2020,Tuesday
2882,2883,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,Not yet recruiting,Drug: glenzocimab|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,60.0,December 2020,2021-07-01,"December 9, 2020",,https://ClinicalTrials.gov/show/NCT04659109,Undefined,glenzocimab|Placebo,7.0,2021,Thursday
2883,2884,The Containing Coronavirus Disease 19 (COVID-19) Trial,Recruiting,Biological: Peginterferon beta-1a,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1240.0,"December 1, 2020",2021-12-01,"December 2, 2020","Pontificia Universidad Católica de Chile, Santiago, Chile",https://ClinicalTrials.gov/show/NCT04552379,Chile,,12.0,2021,Wednesday
2884,2885,Liver Injury in Patients With COVID-19,Enrolling by invitation,Other: Liver injury,All,"17 Years and older   (Child, Adult, Older Adult)",,320.0,"April 15, 2020",2020-12-31,"July 21, 2020","Universidad Austral, Pilar, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04358380,Argentina,,12.0,2020,Thursday
2885,2886,TARGet Kids! COVID-19 Study of Children and Families,Recruiting,,All,up to 10 Years   (Child),,1082.0,"April 9, 2020",2022-12-31,"June 29, 2020","St Michael's Hospital, Toronto, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04449978,Canada,,12.0,2022,Saturday
2886,2887,Immunoregulatory Therapy for 2019-nCoV,Not yet recruiting,Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"February 10, 2020",2020-10-31,"February 13, 2020",,https://ClinicalTrials.gov/show/NCT04268537,Undefined,PD-1 blocking antibody+standard treatment|Thymosin+standard treatment,10.0,2020,Saturday
2887,2888,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Not yet recruiting,Drug: FX06|Drug: Placebo of FX06,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,November 2020,2021-07-01,"November 5, 2020","Hôpital Pitié Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04618042,France,FX06|Placebo of FX06,7.0,2021,Thursday
2888,2889,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),Recruiting,Biological: NasoVAX|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,96.0,"September 29, 2020",2021-02-01,"October 8, 2020","Miami Dade Medical Research Institute, Miami, Florida, United States|MedPharmics, Metairie, Louisiana, United States|Centex Studies, McAllen, Texas, United States",https://ClinicalTrials.gov/show/NCT04442230,United States,,2.0,2021,Monday
2889,2890,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Recruiting,Device: FFP2|Device: Facial mask|Device: MFS,All,18 Years to 60 Years   (Adult),Not Applicable,10.0,May 2020,2020-05-01,"May 5, 2020","Cliniques Universitaires Saint-Luc, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04375774,Belgium,,5.0,2020,Friday
2890,2891,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Recruiting,Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC),All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 2,270.0,"April 24, 2020",2021-09-28,"November 25, 2020","UCSF Fresno, Fresno, California, United States|MemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|Sutter Institute for Medical Research, Roseville, California, United States|Sutter Medical Foundation, Sacramento, California, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|The Corporation of Mercer University, Macon, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Illinois College of Medicine at Peoria, Peoria, Illinois, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center - Infectious Disease, Newark, New Jersey, United States|SUNY Upstate Medical University, Syracuse, New York, United States|East Carolina University, Greenville, North Carolina, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor All Saints Medical Center at Fort Worth, Fort Worth, Texas, United States|Instituto de infectologia Emilio Ribas, São Paulo, Brazil|Private Healthcare Institution 'Clinical Hospital 'RZD-Medcine' n.a. N.A.Semashko', Moscow, Russian Federation|Clinical Infectious Diseases Hospital n. a. S.P. Botkin, St. Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04380961,Brazil,Sirukumab|Placebo,9.0,2021,Tuesday
2891,2892,M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia,Recruiting,Drug: M5049|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,150.0,"July 29, 2020",2020-11-13,"October 8, 2020","University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States|LAC-USC Medical Center, Los Angeles, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Saint Louis University - Saint Louis University Hospital, Saint Louis, Missouri, United States|Christus Spohn Hospital Corpus Christi-Memorial, Corpus Christi, Texas, United States|Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Leforte Morumbi, Sao Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital Bandeirantes / Hospital Leforte Liberdade, São Paulo, Brazil|Instituto de Infectologia Emílio Ribas, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04448756,Brazil,M5049|Placebo,11.0,2020,Friday
2892,2893,"The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations",Not yet recruiting,Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1080.0,May 2020,2020-12-01,"April 27, 2020",,https://ClinicalTrials.gov/show/NCT04363840,Undefined,Aspirin 81 mg,12.0,2020,Tuesday
2893,2894,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Recruiting,Drug: Selinexor|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230.0,"April 17, 2020",2020-08-31,"May 8, 2020","UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom",https://ClinicalTrials.gov/show/NCT04349098,Austria,Selinexor,8.0,2020,Monday
2894,2895,Pediatric Intensive Care and COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,100.0,"March 26, 2020",2021-06-01,"September 10, 2020","Pediatric Intensive Care and Neonatal Medicine, Bicêtre Hospital, AP-HP PAris Saclay University, Le Kremlin-Bicêtre, France",https://ClinicalTrials.gov/show/NCT04544878,France,,6.0,2021,Tuesday
2895,2896,Nutritional Assessment of Hospitalized Patients With COVID-19,Recruiting,Other: Nutritional assessment,All,"18 Years and older   (Adult, Older Adult)",,50.0,"May 25, 2020",2021-06-30,"August 7, 2020","Saint-Vincent Hospital, Lille, Haut-de-France, France",https://ClinicalTrials.gov/show/NCT04503525,France,,6.0,2021,Wednesday
2896,2897,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19, the REHSCU Study",Not yet recruiting,Drug: Remimazolam,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,30.0,"November 1, 2020",2021-05-01,"November 2, 2020","CHU de Nantes, Nantes, France",https://ClinicalTrials.gov/show/NCT04611425,France,Remimazolam,5.0,2021,Saturday
2897,2898,Tomographic Findings in COVID-19 and Influenza H1N1,Not yet recruiting,Diagnostic Test: Lung CT,All,"18 Years to 80 Years   (Adult, Older Adult)",,200.0,"August 15, 2020",2022-04-30,"August 5, 2020",,https://ClinicalTrials.gov/show/NCT04499378,Undefined,,4.0,2022,Saturday
2898,2899,Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 23, 2020",2020-05-23,"May 29, 2020","CHRU de Brest, Brest, France",https://ClinicalTrials.gov/show/NCT04393233,France,,5.0,2020,Saturday
2899,2900,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Recruiting,Dietary Supplement: Viusid and Asbrip,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80.0,"May 4, 2020",2020-08-07,"July 30, 2020","Hospital de Especialidades Dr. Teodoro Maldonado Carbo, Guayaquil, Ecuador",https://ClinicalTrials.gov/show/NCT04407182,Ecuador,,8.0,2020,Friday
2900,2901,"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",Recruiting,Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,250.0,"April 11, 2020",2020-12-11,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel",https://ClinicalTrials.gov/show/NCT04355052,Israel,hydroxychloroquine in combination with camostat mesylate|Hydroxychloroquine in combination of Azithromycin,12.0,2020,Friday
2901,2902,Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment,Recruiting,,All,up to 17 Years   (Child),,150.0,"May 25, 2020",2020-11-25,"May 29, 2020","CH de Belfort, Belfort, France|CHU de Bordeaux, Bordeaux, France|CHRU de Brest, Brest, France|AP-HP Hôpital Kremlin-Bicêtre, Le Kremlin-Bicêtre, France|CHU de Poitiers, Poitiers, France|CHU de Rennes, Rennes, France|CHU de Strasbourg, Strasbourg, France|CHU de Nancy, Vandœuvre les Nancy, France",https://ClinicalTrials.gov/show/NCT04407923,France,,11.0,2020,Wednesday
2902,2903,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),Recruiting,Other: rapid serological test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"July 21, 2020",2021-03-01,"July 30, 2020","Centre Antoine Lacassagne, Nice, France",https://ClinicalTrials.gov/show/NCT04492410,France,,3.0,2021,Monday
2903,2904,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019,"Active, not recruiting",Other: Severe Acute Respiratory Syndrome CoronaVirus 2 detection,All,"18 Years and older   (Adult, Older Adult)",,8.0,"May 8, 2020",2021-01-01,"November 2, 2020","Hospital Italiano de Buenos Aires, Ciudad autónoma de Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04609774,Argentina,,1.0,2021,Friday
2904,2905,Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Drug: Angiotensin II|Drug: Interleukin-1 receptor antagonist,All,"18 Years and older   (Adult, Older Adult)",,50.0,"June 1, 2020",2021-05-01,"June 5, 2020","Guy's & St Thomas' Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04408326,United Kingdom,Angiotensin II|Interleukin-1 receptor antagonist,5.0,2021,Saturday
2905,2906,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Active, not recruiting",Drug: Cannabidiol|Other: PLACEBO,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"July 6, 2020",2020-12-16,"November 3, 2020","Serviço de Assistência Médica e Social do Pessoal do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, SP, Brazil|Unidade de Pronto Atendimento/UPA - 13 de Maio/Dr. Luis Atílio Losi Viana (UPA Covid), Ribeirão Preto, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04467918,Brazil,Cannabidiol,12.0,2020,Wednesday
2906,2907,Glycaemia and Cardiac Function in Patients With COVID-19,Recruiting,Other: Glycaemic levels,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 20, 2020",2020-11-30,"June 1, 2020","Herlev and Gentofte Hospital, Hellerup, Please Select, Denmark|Hvidovre Hospital, Hvidovre, Please Select, Denmark",https://ClinicalTrials.gov/show/NCT04410718,Denmark,,11.0,2020,Monday
2907,2908,COVID-19 Research in Organ Transplant Recipients,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1100.0,"June 1, 2020",2024-05-01,"May 29, 2020","The Transplant Institute, Gothenburg, Vastra Gotaland, Sweden",https://ClinicalTrials.gov/show/NCT04407221,Sweden,,5.0,2024,Wednesday
2908,2909,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Recruiting,Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,4000.0,"April 15, 2020",2020-12-31,"August 25, 2020","Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Córdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital de Getafe, Getafe, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Reina Sofía, Tudela, Navarra, Spain|Hospital Arnau de Vilanova, Llíria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirón Barcelona, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Universitario de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofía, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain",https://ClinicalTrials.gov/show/NCT04334928,Spain,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Hydroxychloroquine,12.0,2020,Thursday
2909,2910,Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19,Withdrawn,Drug: Selinexor,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"April 30, 2020",2020-08-30,"December 7, 2020",,https://ClinicalTrials.gov/show/NCT04355676,Undefined,Selinexor,8.0,2020,Sunday
2910,2911,Early Intervention in COVID-19: Favipiravir Verses Standard Care,Recruiting,Drug: Favipiravir|Other: Standard of care management,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450.0,"May 1, 2020",2021-03-31,"July 7, 2020","Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04373733,United Kingdom,Favipiravir,3.0,2021,Wednesday
2911,2912,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",Not yet recruiting,Drug: Angiotensin 1-7|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"September 30, 2020",2021-06-15,"August 19, 2020",,https://ClinicalTrials.gov/show/NCT04332666,Undefined,Angiotensin 1-7|Placebos,6.0,2021,Tuesday
2912,2913,Screening of Cancer Patients to Assess Impact of COVID-19,"Active, not recruiting",Diagnostic Test: Nasopharyngeal (NP) swab,All,"Child, Adult, Older Adult",,1000.0,"May 11, 2020",2021-06-30,"September 9, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04373005,Canada,,6.0,2021,Wednesday
2913,2914,In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"August 18, 2020",2022-07-01,"August 24, 2020","Children's Hospital Colorado, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT04431869,United States,,7.0,2022,Friday
2914,2915,Obstructive Sleep Apnea & Covid-19 Outcomes,"Active, not recruiting",Diagnostic Test: Home Sleep Apnea Testing or In-hospital Polysomnography,All,"18 Years and older   (Adult, Older Adult)",,320.0,"April 27, 2020",2020-12-31,"July 23, 2020","Marmara University Hospital, Istanbul, Basibuyuk, Turkey|Koc University, Istanbul, Turkey|Koc Healthcare Istanbul American Hospital, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04363333,Turkey,,12.0,2020,Thursday
2915,2916,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",Recruiting,Biological: INO-4800|Device: CELLECTRA® 2000|Other: Saline-sodium citrate (SSC) buffer,All,19 Years to 64 Years   (Adult),Phase 1|Phase 2,160.0,"July 15, 2020",2022-02-22,"August 19, 2020","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04447781,"Korea, Republic of",,2.0,2022,Tuesday
2916,2917,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,Biological: Intravenous Infusions of Stem Cells,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,20.0,"June 1, 2020",2021-06-30,"June 18, 2020","Jinnah Hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04437823,Pakistan,,6.0,2021,Wednesday
2917,2918,Renal Biomarkers in AKI and COVID-19,Recruiting,"Diagnostic Test: urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic",All,"18 Years to 70 Years   (Adult, Older Adult)",,90.0,"June 1, 2020",2020-09-30,"August 20, 2020","Centro de Investigacion en Enfermedades Infecciosas, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04517630,Mexico,,9.0,2020,Wednesday
2918,2919,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,Procedure: Medical Ozone procedure,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,90.0,"April 8, 2020",2020-10-08,"May 14, 2020","Dott. Amato De Monte, Udine, Italy",https://ClinicalTrials.gov/show/NCT04388514,Italy,,10.0,2020,Thursday
2919,2920,Survival Rates and Longterm Outcomes After COVID-19,Recruiting,Other: ICU treatment,All,"18 Years and older   (Adult, Older Adult)",,250.0,"September 16, 2020",2022-09-01,"October 26, 2020","Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04601090,Norway,,9.0,2022,Thursday
2920,2921,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,Other: risk factors,All,"14 Years to 100 Years   (Child, Adult, Older Adult)",,1589.0,"May 7, 2020",2020-08-05,"August 26, 2020","Hospital das Clínicas -HCFMUSP, Sao Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04378582,Brazil,,8.0,2020,Wednesday
2921,2922,Anakinra in the Management of COVID-19 Infection,Recruiting,Drug: Anakinra|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80.0,"October 30, 2020",2021-10-30,"December 8, 2020","Hamad Medical Corporation, Doha, Qatar",https://ClinicalTrials.gov/show/NCT04643678,Qatar,Anakinra,10.0,2021,Saturday
2922,2923,"The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study.",Completed,Device: Oxygen Hood,All,"Child, Adult, Older Adult",,136.0,"March 6, 2020",2020-05-01,"August 24, 2020","Phelps Hospital, Sleepy Hollow, New York, United States",https://ClinicalTrials.gov/show/NCT04407260,United States,,5.0,2020,Friday
2923,2924,"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",Not yet recruiting,Drug: Hidroxicloroquina|Drug: Control group,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,800.0,"April 6, 2020",2020-11-06,"April 13, 2020",,https://ClinicalTrials.gov/show/NCT04330495,Undefined,Hidroxicloroquina|Control group,11.0,2020,Friday
2924,2925,Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP ),Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,1040.0,"May 28, 2020",2021-07-31,"July 21, 2020","CHI Créteil, Créteil, France|CHU Henri Mondor, Créteil, France|Centre hospitalier de Melun (GHSIF), Melun, France|CHI Villeneuve St Georges, Villeneuve-Saint-Georges, France",https://ClinicalTrials.gov/show/NCT04357639,France,,7.0,2021,Saturday
2925,2926,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Recruiting,Drug: Melatonin 2mg|Drug: Placebo oral tablet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,450.0,"April 20, 2020",2020-12-01,"June 16, 2020","Hospital Universitario La Paz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04353128,Spain,Melatonin 2mg|Placebo oral tablet,12.0,2020,Tuesday
2926,2927,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Recruiting,Dietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG Placebo,All,"1 Year and older   (Child, Adult, Older Adult)",Not Applicable,1000.0,"June 24, 2020",2022-05-25,"July 1, 2020","Duke University, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04399252,United States,,5.0,2022,Wednesday
2927,2928,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Recruiting,Device: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Device: Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,30.0,"November 19, 2020",2021-06-01,"December 7, 2020","Medical University of South Carolina, Charleston, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04638673,United States,,6.0,2021,Tuesday
2928,2929,Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology,Completed,Other: Cross-sectional observational study,All,"18 Years and older   (Adult, Older Adult)",,10084.0,"March 31, 2020",2020-04-07,"April 28, 2020","University of Oslo, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04365881,Norway,,4.0,2020,Tuesday
2929,2930,NOsocomial Dissemination Risk of SARS-Cov2,Completed,,All,"Child, Adult, Older Adult",,2523.0,"April 17, 2020",2020-07-12,"November 23, 2020","Didier Guillemot, Garches, France",https://ClinicalTrials.gov/show/NCT04339881,France,,7.0,2020,Sunday
2930,2931,A Study of Combination Therapies to Treat COVID-19 Infection,Not yet recruiting,Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,200.0,July 2020,2021-12-01,"July 7, 2020","ProgenaBiome, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04459702,United States,hydroxychloroquine|Azithromycin|Ritonavir|Lopinavir,12.0,2021,Wednesday
2931,2932,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Completed,"Other: ""Calm"" is a mindfulness meditation mobile app",Female,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,101.0,"April 13, 2020",2020-11-01,"November 13, 2020","Banner University Medicine Women's Institute, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT04329533,United States,,11.0,2020,Sunday
2932,2933,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study",Not yet recruiting,Drug: Single high dose vitamin D|Drug: Placebo|Drug: Treatment as usual vitamin D,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"December 1, 2020",2021-06-30,"November 9, 2020","Cantonal Hospital Aarau, Aarau, AG, Switzerland|Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St. Gallen, Saint Gallen, SG, Switzerland",https://ClinicalTrials.gov/show/NCT04525820,Switzerland,Single high dose vitamin D|Placebo|Treatment as usual vitamin D,6.0,2021,Wednesday
2933,2934,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,Recruiting,Other: observational,All,"Child, Adult, Older Adult",,50000.0,"March 30, 2020",2021-04-30,"August 11, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04323787,United States,,4.0,2021,Friday
2934,2935,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,Device: Calm Meditation App,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,328.0,"May 15, 2020",2020-10-01,"June 4, 2020","Banner University Medical Center Phoenix, Phoenix, Arizona, United States",https://ClinicalTrials.gov/show/NCT04374786,United States,,10.0,2020,Thursday
2935,2936,Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19,Recruiting,,All,"Child, Adult, Older Adult",,300.0,"April 21, 2020",2020-10-21,"August 31, 2020","Angers University Hospital, Angers, France|Besançon Hospital, Besançon, France|Brest university Hospital, Brest, France|Caen University Hospital, Caen, France|Clermont ferrand University hospital, Clermont-Ferrand, France|APHP Henri Mondor Paris University Hospital, Créteil, France|Dijon University Hospital, Dijon, France|Vendée Hospital, La Roche-sur-Yon, France|Grenoble University Hospital, La Tronche, France|APHP Kremli Bicetre Paris University Hospital, Le Kremlin-Bicêtre, France|Marie Lannelongue Hospital, Le Plessis-Robinson, France|Lens Hospital, Lens, France|Lille University Hospital, Lille, France|Limoges University Hospital, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Lyon University Hospital, Lyon, France|Marseille Européen Hospital, Marseille, France|APHM la Timone- Marseille University Hospital, Marseille, France|Clairval Hospital, Marseille, France|Metz University Hospital, Metz, France|Montpellier University Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy University Hospital, Nancy, France|Nantes University Hospital, Nantes, France|Ambroise Paré Hospital, Neuilly-sur-Seine, France|Nimes University Hospital, Nimes, France|Institut Mutualiste Montsouris, Paris, France|APHP Hopital Européen Georges Pompidou - Paris University Hospital, Paris, France|APHP necker Paris University Hospital, Paris, France|APHP Bichat - Paris University Hospital, Paris, France|APHP La Pitié Salpêtrière Paris University Hospital, Paris, France|Bordeaux University Hospital, Pessac, France|Poitiers University hospital, Poitiers, France|Reims University hospital, Reims, France|Rennes University hospital, Rennes, France|Rouen University Hospital, Rouen, France|Saint brieuc Hospital, Saint brieuc, France|La Réunion University Hospital, Saint-Denis, France|Saint Nazaire Hospital, Saint-Nazaire, France|Saint Etienne University Hospital, Saint-Étienne, France|Strasbourg University Hospital, Strasbourg, France|Toulouse University Hospital - Rangueil Hospital, Toulouse, France|Tours University Hospital, Tours, France|Bretagne Atlantique Hospital, Vannes, France",https://ClinicalTrials.gov/show/NCT04397588,France,,10.0,2020,Wednesday
2936,2937,Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,Recruiting,Diagnostic Test: Specimen Collection|Diagnostic Test: Surveys,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"July 21, 2020",2022-01-01,"August 13, 2020","University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04473183,United States,,1.0,2022,Saturday
2937,2938,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,Recruiting,Drug: Nitazoxanide|Drug: Placebo Nitazoxanide|Drug: Ribavirin|Drug: Placebo Ribavirin|Drug: Hydroxychloroquine|Drug: Placebo Hydroxychloroquine,All,"21 Years and older   (Adult, Older Adult)",Phase 2,70.0,"December 2, 2020",2021-04-01,"December 7, 2020","Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04605588,Jersey,Nitazoxanide|Placebo Nitazoxanide|Ribavirin|Placebo Ribavirin|Hydroxychloroquine|Placebo Hydroxychloroquine,4.0,2021,Thursday
2938,2939,"Feasibility, of Tele-rehabilitation Following COVID-19",Not yet recruiting,Other: Tele-Pulmonary rehabilitation,All,"18 Years and older   (Adult, Older Adult)",,40.0,"August 12, 2020",2022-01-20,"August 13, 2020","Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04511962,United Kingdom,,1.0,2022,Thursday
2939,2940,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Recruiting,Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"July 23, 2020",2021-11-30,"August 13, 2020","Sanford Research, Sioux Falls, South Dakota, United States",https://ClinicalTrials.gov/show/NCT04494386,United States,,11.0,2021,Tuesday
2940,2941,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,Drug: Plasma|Drug: Standard Therapy,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,92.0,"August 8, 2020",2020-11-15,"November 27, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04332835,Colombia,Plasma|Standard Therapy,11.0,2020,Sunday
2941,2942,Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration,Recruiting,Diagnostic Test: IgM and IgG antibodies assay,All,"Child, Adult, Older Adult",,6000.0,"June 22, 2020",2021-04-22,"November 17, 2020","Diagnostyka sp zoo, Katowice, Poland",https://ClinicalTrials.gov/show/NCT04627623,Poland,,4.0,2021,Thursday
2942,2943,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,Enrolling by invitation,,All,up to 13 Years   (Child),,7000.0,"April 22, 2020",2020-05-01,"May 5, 2020","Tine Caroc Warner, Hjørring, Nordjylland, Denmark",https://ClinicalTrials.gov/show/NCT04375410,Denmark,,5.0,2020,Friday
2943,2944,COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey,"Active, not recruiting",Other: No intervention,All,"18 Years to 125 Years   (Adult, Older Adult)",,5000.0,"May 14, 2020",2023-05-01,"July 23, 2020","Department of Haemotology, Odense University Hospital, Odense, Region Of Southern Denmark, Denmark|Department of Oncology, Odense University Hospital, Odense C, Denmark",https://ClinicalTrials.gov/show/NCT04389996,Denmark,,5.0,2023,Monday
2944,2945,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Drug: Part 1 - TL-895|Drug: Part 2 - TL-895|Drug: Part 2 - Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,146.0,"July 9, 2020",2021-07-01,"September 25, 2020","University of Miami, Miami, Florida, United States|Georgia Cancer Center, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Barbara Ann Karmanos Cancer Institute - Wertz Clinic, Detroit, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States|OhioHealth - Riverside Methodist Hospital, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04419623,Georgia,Part 1 - TL-895|Part 2 - TL-895|Part 2 - Placebo,7.0,2021,Thursday
2945,2946,COVID19-hematological Malignancies: the Italian Hematology Alliance,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,250.0,"April 7, 2020",2021-04-30,"May 4, 2020","SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|UOC Ematologia, Ospedali Riuniti, Ancona, Italy|UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy|SC Oncologia Medica, CRO, Aviano, Italy|SC Ematologia, Policlinico Bari, Bari, Italy|UOC Ematologia, I.R.C.C.S Istituto Tumori Giovanni Paolo II, Bari, Italy|SSD Ematologia, Ospedale degli Infermi, Biella, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,, Bologna, Italy|Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Bolzano, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UOC Onco-Ematologia ASST Valle Olona, Busto Arsizio, Italy|SC Ematologia e CTMO AZIENDA OSPEDALIERA ""G. BROTZU"" - OSPEDALE ONCOLOGICO BUSINCO, Cagliari, Italy|UOC Ematologia, AOU Policlinico Vittorio Emanuele, Catania, Italy|Ematologia, Ospedale Valduce, Como, Italy|UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy|UO Ematologia e CTMO, ASST Cremona, Cremona, Italy|SC Ematologia Ospedale S. Croce, Cuneo, Italy|UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy|S.O.D. Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOC Ematologia, Policlinico Ospedali Riuniti, Foggia, Italy|IRST-IRCC di Meldola, Forlì, Italy|UO Ematologia, Ospedale Policlinico S.Martino IRCCS, Genova, Italy|UO Ematologia, Ospedale Policlinico San Martino, Genova, Italy|UOC di Ematologia e Trapianto di Cellule Staminali, P.O. Vito Fazzi, Lecce, Italy|UOC di Ematologia, Ospedale di Legnano, Legnano, Italy|UO Dipartimento di Ematologia, USL 6, Livorno, Italy|UOC Oncologia ASST Lodi, Lodi, Italy|UOC Ematologia Azienda Ospedaliera Universitaria ""G.Martino"", Messina, Italy|UO Ematologia, Ospedale dell'Angelo di Mestre, Mestre, Italy|Ematologia, IEO, Milano, Italy|SC Ematologia, Istituto Nazionale dei Tumori, Milano, Italy|SC Ematologia, Ospedale Niguarda, Milano, Italy|UO Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy|UO Servizio di Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Milano, Italy|UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|UO Ematologia Policlinico di Modena, Modena, Italy|UOC Ematologia, Ospedale S. Gerardo, Monza, Italy|SC Ematologia Istituto Nazionale Tumori - IRCCS ""Fondazione G. Pascale"",, Napoli, Italy|UOC Ematologia e Trapianti di Midollo, AOU Federico II, Napoli, Italy|UOC Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy|Ospedale san Luigi Gonzaga, Orbassano, Italy|Ematologia Azienda Ospedaliera di Padova, Padova, Italy|UO Ematologia, Policlinico Paolo Giaccone, Palermo, Italy|UOC Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|SC Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera di Perugia, Perugia, Italy|UO Ematologia e CTMO, Azienda Ospedaliera Ospedali Riuniti, Pesaro, Italy|UOC di Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy|UO Ematologia e CTMO, Presidio Ospedaliero di Piacenza, Piacenza, Italy|UO Ematologia, AOU Pisana- Santa Chiara, Pisa, Italy|UO Ematologia dell'Ospedale Santa Maria delle Croci, Ravenna, Italy|UOC Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|SC Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|UO Ematologia, Ospedale Infermi, Rimini, Italy|AOU Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy|IFO - Ematologia e Trapianto Cellule -Istituto Nazionale del Cancro di Regina Elena, Roma, Italy|SC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UO Ematologia e Trapianti di Cellule Staminali, A.O. S. Camillo-Forlanini, Roma, Italy|UO Ematologia, Policlinico Tor Vergata, Roma, Italy|UOC Ematologia e trapianto di cellule staminali, Policlinico Universitario Campus Bio-Medico, Roma, Italy|UOC Ematologia Policlinico Umberto I, Roma, Italy|UOC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UOC Ematologia- Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy|UO Ematologia, Istituto Clinico Humanitas, Rozzano, Italy|UOC Ematologia e centro trapianti cellule staminali emopoietiche, AOU San Giovanni Di Dio e Ruggi D'aragona, Salerno, Italy|Ematologia ASL Imperiese, Sanremo, Italy|Medicina Interna ed Ematologia, Asl 1, Savona, Italy|UOC Ematologia, Policlinico Santa Maria alle Scotte, Siena, Italy|UOC Ematologia e Trapianto Midollo Osseo, Ospedale S. G. Moscati, Taranto, Italy|SCDU Ematologia e terapie cellulari, Ospedale Mauriziano Umberto I, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Civili Ca' Foncello, Treviso, Italy|SC Ematologia, Azienda sanitaria universitaria Giuliano Isontina, Trieste, Italy|Clinica Ematologia, Azienda Ospedaliera-Universitaria Santa Maria della Misericordia, Udine, Italy|UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi, Varese, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Ospedale San Bortolo, Vicenza, Italy",https://ClinicalTrials.gov/show/NCT04352556,Italy,,4.0,2021,Friday
2946,2947,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,Diagnostic Test: Rapid detection test|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Stool collection,All,"1 Month and older   (Child, Adult, Older Adult)",Not Applicable,600.0,"June 2, 2020",2020-10-02,"October 26, 2020","Hopital Avicenne, Bobigny, France|Hôpital Jean Verdier - Service de Pédiatrie, Bondy, France|Hôpital Jean Verdier, Bondy, France|Hôpital Antoine béclère, Clamart, France|Hôpital Louis Mourier, Colombes, France|CH intercommunal de Créteil, Créteil, France|Hôpital Andé Mignot, Le Chesnay, France|Hôpital Trousseau, Paris, France|Hôpital Robert debré, Paris, France|CHU de Rouen, Rouen, France|Hôpital Annecy Genevois, Épagny, France",https://ClinicalTrials.gov/show/NCT04413968,France,,10.0,2020,Friday
2947,2948,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,Completed,Other: Questionnaire,All,18 Years to 47 Years   (Adult),,389.0,"May 14, 2020",2020-06-18,"November 18, 2020","Ghent University Hospital, Ghent, Belgium",https://ClinicalTrials.gov/show/NCT04396210,Belgium,,6.0,2020,Thursday
2948,2949,COVID-19 Testing Sample Acquisition Throughput and Efficiency,"Active, not recruiting",Other: Personal Protective Testing Booth,All,"Child, Adult, Older Adult",,25000.0,"March 1, 2020",2020-09-30,"August 31, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04532411,United States,,9.0,2020,Wednesday
2949,2950,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.",Recruiting,Drug: PF-07304814|Drug: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,56.0,"September 9, 2020",2021-04-20,"October 30, 2020","El Camino Health, Mountain View, California, United States|Palo Alto Medical Foundation, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UC Davis Health Investigational Drug Pharmacy, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Iowa, Iowa City, Iowa, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|University of Texas Physicians - Texas Medical Center, Houston, Texas, United States|Multicare Health System-Tacoma General Hospital, Tacoma, Washington, United States",https://ClinicalTrials.gov/show/NCT04535167,United States,PF-07304814|Placebo,4.0,2021,Tuesday
2950,2951,FOUND - Ancillary Study to Smile Protocol NCT03654105,Enrolling by invitation,,All,"50 Years to 75 Years   (Adult, Older Adult)",,960.0,"July 23, 2019",2021-07-01,"June 23, 2020","Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy",https://ClinicalTrials.gov/show/NCT04441814,Italy,,7.0,2021,Thursday
2951,2952,Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly,Recruiting,,All,70 Years and older   (Older Adult),,350.0,"April 15, 2020",2023-04-15,"June 4, 2020","University hospital of Rennes, Rennes, France|Va de Lys-Ramsay Gds group Clinic, Tourcoing, France|Hopsital of Valenciennes, Valenciennes, France|University hospital of Guadeloupe, Les Abymes, Guadeloupe|University hospital of Martinique, Fort-de-France, Martinique",https://ClinicalTrials.gov/show/NCT04414319,France,,4.0,2023,Saturday
2952,2953,Psychological Impact of COVID-19 Pandemic in Healthcare Workers,Completed,Diagnostic Test: Psychological stress and adaptation at work score (PSAS),All,"18 Years to 70 Years   (Adult, Older Adult)",,3000.0,"April 9, 2020",2020-04-30,"August 10, 2020","CHGUV, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04506515,Spain,,4.0,2020,Thursday
2953,2954,Social Media and COVID-19,Completed,Behavioral: Social media & news consumption,All,"21 Years and older   (Adult, Older Adult)",,151.0,"March 17, 2020",2020-05-31,"November 10, 2020","Yale-NUS College, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04367363,Singapore,,5.0,2020,Sunday
2954,2955,"A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1250.0,"October 30, 2020",2021-09-24,"November 2, 2020","Great Lakes Clinical Trials /ID# 224874, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04611230,United States,,9.0,2021,Friday
2955,2956,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,Completed,Diagnostic Test: a specifically designed self-administered questionnaire,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",,3301.0,"May 11, 2020",2020-09-28,"September 30, 2020","Allgemeine Unfallversicherungsanstalt, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04354779,Austria,,9.0,2020,Monday
2956,2957,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Not yet recruiting,Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit,All,"18 Years and older   (Adult, Older Adult)",,340.0,"April 1, 2020",2021-01-01,"April 6, 2020",,https://ClinicalTrials.gov/show/NCT04334876,Undefined,,1.0,2021,Friday
2957,2958,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,"Active, not recruiting",Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,29.0,"May 5, 2020",2021-04-05,"August 21, 2020","University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT04374565,United States,High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma,4.0,2021,Monday
2958,2959,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",Completed,,All,21 Years to 58 Years   (Adult),,30.0,"May 5, 2020",2020-06-18,"June 22, 2020","Ankara Yıldırım Beyazıt University, Faculty of Health Sciences,Department of Physiotherapy and Rehabilitation, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04438954,Turkey,,6.0,2020,Thursday
2959,2960,Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),Withdrawn,Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"April 30, 2020",2020-11-04,"November 19, 2020","Apsen Farmacêutica S.A., São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04361461,Brazil,Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate + Azythromycin,11.0,2020,Wednesday
2960,2961,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",Terminated,Drug: Pemziviptadil (PB1046)|Drug: Low Dose (10 mg) Control,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,54.0,"July 15, 2020",2020-12-02,"December 11, 2020","Baptist Health Research Institute, Jacksonville, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Adventist Healthcare White Oak Medical Center, Silver Spring, Maryland, United States",https://ClinicalTrials.gov/show/NCT04433546,United States,Pemziviptadil (PB1046)|Low Dose (10 mg) Control,12.0,2020,Wednesday
2961,2962,The COVID-ICU Healthcare Professional Study,Recruiting,Behavioral: Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic,All,"20 Years and older   (Adult, Older Adult)",,2200.0,"May 6, 2020",2021-05-06,"August 27, 2020","Oslo university hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04372056,Norway,,5.0,2021,Thursday
2962,2963,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,Completed,Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography,All,"18 Years and older   (Adult, Older Adult)",,230.0,"April 1, 2020",2020-05-01,"May 6, 2020","Vall d´Hebron Research Institute VHIR, Barcelona, Catalunya, Spain|Hospital Germans Trias i Pujol. Universitat Autònoma de Barcelona, Badalona, Spain|Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04374617,Spain,,5.0,2020,Friday
2963,2964,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: vadadustat|Drug: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"August 22, 2020",2022-08-01,"September 10, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04478071,United States,vadadustat|placebo,8.0,2022,Monday
2964,2965,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Recruiting,Other: oxygen treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",,30.0,"February 1, 2020",2021-02-01,"March 18, 2020","Henan Provincial People's Hospital, Zhengzhou, Henan, China",https://ClinicalTrials.gov/show/NCT04312100,China,,2.0,2021,Monday
2965,2966,Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,Recruiting,Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",,120.0,"February 20, 2020",2020-06-20,"March 17, 2020","Tongji Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04306705,China,Tocilizumab,6.0,2020,Saturday
2966,2967,STerOids in COVID-19 Study,Recruiting,Drug: Budesonide dry powder inhaler,All,"18 Years and older   (Adult, Older Adult)",Phase 2,478.0,"July 16, 2020",2020-12-30,"July 24, 2020","Oxford Respiratory Trials Unit, Oxford, Oxfordshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04416399,United Kingdom,Budesonide dry powder inhaler,12.0,2020,Wednesday
2967,2968,The MentalPlus® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,Recruiting,Device: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19,All,"8 Years to 88 Years   (Child, Adult, Older Adult)",Not Applicable,200.0,"November 8, 2020",2023-12-29,"November 17, 2020","Livia Stocco Sanches Valentin, São Paulo, SP, Brazil|Livia Stocco Sanches Valentin, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04632719,Brazil,,12.0,2023,Friday
2968,2969,Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure,"Active, not recruiting",Other: Awake proning,All,"18 Years and older   (Adult, Older Adult)",,29.0,"April 16, 2020",2021-05-01,"May 29, 2020","Columbia University Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04408222,United States,,5.0,2021,Saturday
2969,2970,Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,4800.0,"November 14, 2020",2022-11-14,"October 30, 2020","UCLA, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Yale, New Haven, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04610515,United States,,11.0,2022,Monday
2970,2971,Cyclosporine For The Treatment Of COVID-19(+),Recruiting,Drug: Cyclosporine|Other: Standard of Care Treatment,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,75.0,"November 23, 2020",2025-11-23,"November 27, 2020","Baylor College of Medicine, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04492891,United States,Cyclosporine,11.0,2025,Sunday
2971,2972,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,Completed,Diagnostic Test: Sampling salivary,All,"18 Years to 90 Years   (Adult, Older Adult)",,627.0,"April 13, 2020",2020-10-07,"November 4, 2020","UCH Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04337424,France,,10.0,2020,Wednesday
2972,2973,National Survey of the Impact of COVID-19 Pandemics,Recruiting,Other: Customized questionnaire,All,"18 Years and older   (Adult, Older Adult)",,6000.0,"July 27, 2020",2020-09-27,"July 29, 2020","Lei Li, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04491201,China,,9.0,2020,Sunday
2973,2974,"Covid-19, Acute Myocardial Infarctions and Strokes in France",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"December 1, 2020",2021-06-30,"September 9, 2020","Uh Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04542083,France,,6.0,2021,Wednesday
2974,2975,A Study of ResCure™ to Treat COVID-19 Infection,Not yet recruiting,Biological: ResCure™,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,July 2020,2021-11-01,"July 10, 2020","ProgenaBiome, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04395716,United States,,11.0,2021,Monday
2975,2976,Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,Drug: Losartan|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 13, 2020",2021-04-01,"December 4, 2020","University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Henry Ford Hospital, Detroit, Michigan, United States|M Health Fairview Ridges Hospital, Burnsville, Minnesota, United States|M Health Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|North Memorial Health Hospital, Robbinsdale, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cooper University Hospital, Camden, New Jersey, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04312009,Georgia,Losartan,4.0,2021,Thursday
2976,2977,Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,Recruiting,Behavioral: Remote pulmonary rehabilitation,All,"20 Years to 85 Years   (Adult, Older Adult)",,200.0,"April 6, 2020",2021-12-31,"July 17, 2020","Wuhan Lung Hospital, Wuhan, Hubei, China|Wuhan Central Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04368793,China,,12.0,2021,Friday
2977,2978,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases",Recruiting,,All,"Child, Adult, Older Adult",,13770.0,"April 18, 2020",2020-12-01,"April 22, 2020","Hôpital Huriez, Lille, France",https://ClinicalTrials.gov/show/NCT04353609,France,,12.0,2020,Tuesday
2978,2979,Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers,Recruiting,Diagnostic Test: Nasal swab|Diagnostic Test: Serum testing,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"April 27, 2020",2025-05-01,"April 30, 2020","Greifswald University Medicine, Greifswald, Germany",https://ClinicalTrials.gov/show/NCT04370119,Germany,,5.0,2025,Thursday
2979,2980,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"June 22, 2020",2021-09-01,"July 20, 2020","ProgenaBiome, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04335084,United States,Hydroxychloroquine,9.0,2021,Wednesday
2980,2981,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,Behavioral: MenCare+/Bandebereho fathers'/couples' group education,All,26 Years to 40 Years   (Adult),Not Applicable,1000.0,June 2020,2020-08-01,"June 22, 2020","Rwanda Men's Resource Centre (Rwamrec), Kigali, Rwanda",https://ClinicalTrials.gov/show/NCT04442152,Rwanda,,8.0,2020,Saturday
2981,2982,Randomised Evaluation of COVID-19 Therapy,Recruiting,Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies|Drug: Aspirin|Drug: Colchicine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,20000.0,"March 19, 2020",2031-12-01,"December 1, 2020","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04381936,United Kingdom,Lopinavir-Ritonavir|Corticosteroid|Hydroxychloroquine|Azithromycin|Tocilizumab|Synthetic neutralising antibodies|Aspirin|Colchicine,12.0,2031,Monday
2982,2983,Trial of Treatments for COVID-19 in Hospitalized Adults,Recruiting,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100.0,"March 22, 2020",2023-03-01,"July 22, 2020","Medizinische Universität Innsbruck, Innsbruck, Austria|Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria|Hôpital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium|Hôpital Saint Luc, Brussels, Belgium|Hôpital La Citadelle, Liège, Belgium|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|Centre Hospitalier Andrée Rosemon, Cayenne, France|APHP - hôpital Henri-Mondor, Créteil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|APHP - Hôpital Saint Antoine, Paris, France|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France|APHP - Hôpital Cochin, Paris, France|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP- Hôpital Européen Georges-Pompidou, Paris, France|APHP - Hôpital Bichat Claude Bernard, Paris, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|Centre Hospitalier Annecy Genevois, Épagny, France|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schuman, Luxembourg, Luxembourg",https://ClinicalTrials.gov/show/NCT04315948,Austria,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Hydroxychloroquine,3.0,2023,Wednesday
2983,2984,Losartan for Patients With COVID-19 Not Requiring Hospitalization,"Active, not recruiting",Drug: Losartan|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,580.0,"April 9, 2020",2021-04-01,"November 16, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04311177,United States,Losartan,4.0,2021,Thursday
2984,2985,"COVID-19, Obesity and Lifestyle in Children",Recruiting,Other: Exposure to the Dutch measures due to the Covid-19 pandemic.,All,4 Years to 17 Years   (Child),,4000.0,"May 6, 2020",2021-05-06,"June 2, 2020","Maastricht University Medical Center, Maastricht, Limburg, Netherlands",https://ClinicalTrials.gov/show/NCT04411511,Netherlands,,5.0,2021,Thursday
2985,2986,Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,4500.0,December 2020,2021-03-01,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04513561,Undefined,,3.0,2021,Monday
2986,2987,Serological Study of the Exposure of Personnel to Sars-cov-2,Not yet recruiting,Diagnostic Test: Sars-Cov-2 serology,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,900.0,"June 8, 2020",2020-06-30,"June 9, 2020",,https://ClinicalTrials.gov/show/NCT04422977,Undefined,,6.0,2020,Tuesday
2987,2988,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Drug: EIDD-2801|Drug: Placebo (PB0),All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"June 16, 2020",2021-03-12,"December 10, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cook County Hospital, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Christ Medical Center, Park Ridge, Illinois, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Howard County General Hospital, Columbia, Maryland, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04405739,United States,EIDD-2801|Placebo (PB0),3.0,2021,Friday
2988,2989,Psychiatric Disturbances and COVID-19 Infection,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 8, 2020",2020-09-15,"July 9, 2020","15 Mayo Smart Hospital, Cairo, Egypt|National hepatology and tropical medicine research institute, Cairo, Egypt|Students hospital, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04459403,Egypt,,9.0,2020,Tuesday
2989,2990,Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays,Recruiting,Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images,All,"Child, Adult, Older Adult",,200.0,"March 18, 2020",2020-08-18,"April 27, 2020","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04313946,Italy,,8.0,2020,Tuesday
2990,2991,Physical Activity a Vital Sign? 40 Steps to Safety Test for Patients With COVID-19,Recruiting,Diagnostic Test: 40-Steps-test,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"November 3, 2020",2021-11-03,"November 6, 2020","Ysbyty Gwynedd, Menai Bridge, Gwynedd, United Kingdom",https://ClinicalTrials.gov/show/NCT04618835,United Kingdom,,11.0,2021,Wednesday
2991,2992,Nebulised Rt-PA for ARDS Due to COVID-19,Recruiting,Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA),All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2,24.0,"April 22, 2020",2021-01-14,"April 30, 2020","The Royal Free Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04356833,United Kingdom,nebulised recombinant tissue-Plasminogen Activator (rt-PA),1.0,2021,Thursday
2992,2993,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Recruiting,Drug: Methylprednisolone Injectable Product,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 1, 2020",2020-12-30,"December 8, 2020","Muhammad Irfan Malik, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04559113,Mali,Methylprednisolone Injectable Product,12.0,2020,Wednesday
2993,2994,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Drug: Budesonide Nasal|Other: Physiological serum,All,"18 Years and older   (Adult, Older Adult)",Phase 3,120.0,"May 18, 2020",2021-05-25,"November 25, 2020","Amélie YAvchitz, Paris, France",https://ClinicalTrials.gov/show/NCT04361474,France,Budesonide Nasal,5.0,2021,Tuesday
2994,2995,Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease,Not yet recruiting,Other: telehealth applications,All,75 Years and older   (Older Adult),Not Applicable,200.0,May 2020,2020-09-01,"June 1, 2020",,https://ClinicalTrials.gov/show/NCT04337788,Undefined,,9.0,2020,Tuesday
2995,2996,DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury,Recruiting,Drug: DUR-928|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,80.0,"September 21, 2020",2021-10-01,"September 30, 2020","Site 02, Chicago, Illinois, United States|Site 01, Detroit, Michigan, United States|Site 03, Newark, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04447404,Jersey,DUR-928|Placebo,10.0,2021,Friday
2996,2997,Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19,Recruiting,"Drug: Cannabis, Medical",All,"7 Years and older   (Child, Adult, Older Adult)",Phase 2,200000.0,"December 1, 2018",2025-12-31,"December 9, 2020","OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT03944447,United States,"Cannabis, Medical",12.0,2025,Wednesday
2997,2998,"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","Active, not recruiting",,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",,200.0,"May 20, 2020",2020-07-01,"June 2, 2020","Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust, Hull, United Kingdom",https://ClinicalTrials.gov/show/NCT04411784,United Kingdom,,7.0,2020,Wednesday
2998,2999,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,Behavioral: RECHARGE|Behavioral: Self Study,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"August 28, 2020",2021-06-01,"October 19, 2020","Klinik für Konsiliarpsychiatrie und Psychosomatik, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04531774,Switzerland,,6.0,2021,Tuesday
2999,3000,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",Completed,,All,"18 Years and older   (Adult, Older Adult)",,18251.0,"April 9, 2020",2020-07-10,"July 16, 2020","Penn State College of Medicine, Hershey, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04377581,United States,,7.0,2020,Friday
3000,3001,Mapping COVID-19 Spread in a Tertiary Hospital,Recruiting,Other: no intervention,All,"18 Years to 100 Years   (Adult, Older Adult)",,3000.0,"October 2, 2020",2021-06-15,"October 12, 2020","CHGUV, Valencia, Spain|CHGUV, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04581096,Spain,,6.0,2021,Tuesday
3001,3002,Follow-up of Critical COVID-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"June 25, 2020",2022-12-01,"July 20, 2020","Uppsala University Hospital, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT04474249,Sweden,,12.0,2022,Thursday
3002,3003,The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia,Not yet recruiting,Drug: Intravenous Immunoglobulin|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80.0,"February 10, 2020",2020-06-30,"February 7, 2020",,https://ClinicalTrials.gov/show/NCT04261426,Undefined,Intravenous Immunoglobulin,6.0,2020,Tuesday
3003,3004,COVID-19 Brain Injury,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 2, 2020",2021-03-31,"October 8, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04496076,United States,,3.0,2021,Wednesday
3004,3005,"Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery",Recruiting,Other: Questionnaire Administration,Female,"18 Years and older   (Adult, Older Adult)",,600.0,"May 21, 2019",2022-03-31,"December 9, 2020","MD Anderson in The Woodlands, Conroe, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|MD Anderson League City, League City, Texas, United States|MD Anderson in Sugar Land, Sugar Land, Texas, United States",https://ClinicalTrials.gov/show/NCT04169542,United States,,3.0,2022,Thursday
3005,3006,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,54.0,"May 27, 2020",2020-11-15,"December 3, 2020","Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Paoli Hospital, Paoli, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04652648,United States,Hydroxychloroquine,11.0,2020,Sunday
3006,3007,Trial of Combination Therapy to Treat COVID-19 Infection,Recruiting,Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,300.0,"December 9, 2020",2021-07-01,"December 11, 2020","ProgenaBiome, Ventura, California, United States",https://ClinicalTrials.gov/show/NCT04482686,United States,Ivermectin|Doxycycline Hcl,7.0,2021,Thursday
3007,3008,COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),Enrolling by invitation,Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19,Female,"13 Years and older   (Child, Adult, Older Adult)",,2000.0,"March 20, 2020",2024-03-31,"October 19, 2020","University of California, San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04323839,United States,,3.0,2024,Sunday
3008,3009,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Recruiting,"Diagnostic Test: Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)",All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 9, 2020",2023-12-31,"June 1, 2020","University Hospital Zurich, Zürich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04410263,Switzerland,,12.0,2023,Sunday
3009,3010,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,220.0,"April 3, 2020",2021-04-30,"April 14, 2020","CHU Nimes, Nîmes, France",https://ClinicalTrials.gov/show/NCT04340466,France,,4.0,2021,Friday
3010,3011,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Recruiting,Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"February 1, 2020",2020-07-01,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04255017,China,Abidol hydrochloride|Oseltamivir|Lopinavir/ritonavir,7.0,2020,Wednesday
3011,3012,COVID-19 Persistence in Stool,Enrolling by invitation,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"September 8, 2020",2022-06-01,"September 14, 2020","Quadram Institute Bioscience, Norwich, Norfolk, United Kingdom|Norfolk and Norwich University Hospital Foundation Trust, Norwich, Norfolk, United Kingdom",https://ClinicalTrials.gov/show/NCT04546776,United Kingdom,,6.0,2022,Wednesday
3012,3013,Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects,Recruiting,Diagnostic Test: Multicapillary column coupled ion mobility spectrometry,All,"18 Years and older   (Adult, Older Adult)",,200.0,"September 14, 2020",2021-04-30,"September 14, 2020","Klinikum Bayreuth/ Bayreuth General Hospital, Bayreuth, Germany",https://ClinicalTrials.gov/show/NCT04547114,Germany,,4.0,2021,Friday
3013,3014,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Recruiting,Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,"February 1, 2020",2020-07-01,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04254874,China,Abidol hydrochloride|Abidol Hydrochloride combined with Interferon atomization,7.0,2020,Wednesday
3014,3015,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Recruiting,Drug: Colchicine,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,310.0,"April 20, 2020",2020-12-21,"July 10, 2020","Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy",https://ClinicalTrials.gov/show/NCT04322565,Italy,Colchicine,12.0,2020,Monday
3015,3016,COVID-19 Biological Samples Collection,Recruiting,Other: biological samples collection,All,"up to 100 Years   (Child, Adult, Older Adult)",,2000.0,"April 2, 2020",2023-03-01,"April 3, 2020","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",https://ClinicalTrials.gov/show/NCT04332016,France,,3.0,2023,Wednesday
3016,3017,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Recruiting,Genetic: Complete thrombophilic profile testing by multiplex PCR,All,"18 Years and older   (Adult, Older Adult)",,60.0,"August 18, 2020",2021-08-18,"August 19, 2020","University of Medicine and Pharmacy Gr T. Popa Iasi, Romania, Iasi, Romania",https://ClinicalTrials.gov/show/NCT04519398,Oman,,8.0,2021,Wednesday
3017,3018,COVID-19 Detection Test in Oncology,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"May 23, 2020",2021-05-01,"June 4, 2020","Centre Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Universitaire Pitié Salpêtrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France",https://ClinicalTrials.gov/show/NCT04367870,France,,5.0,2021,Saturday
3018,3019,Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Drug: Ibrutinib|Other: Quality-of-Life Assessment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,134.0,"December 31, 2020",2025-05-01,"December 11, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04665115,United States,Ibrutinib,5.0,2025,Thursday
3019,3020,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Recruiting,Drug: APL-9|Other: Vehicle Control,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,66.0,"May 28, 2020",2020-11-01,"October 19, 2020","University of California at San Francisco - Fresno, Fresno, California, United States|California Pacific Medical Center, San Francisco, California, United States|Westchester General Hospital, Miami, Florida, United States|Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran Health Physicians, Fort Wayne, Indiana, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Audobon Hospital, Louisville, Kentucky, United States|Ascension Providence Hospital, Southfield, Michigan, United States|Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo, Buffalo, New York, United States|Columbia University, New York, New York, United States|Texas A&M College of Medicine - Scott and White, Temple, Texas, United States|Hospital Estadual Mario Covas, Santo André, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clinicos LTDA EPP, São Bernardo Do Campo, Sao Paulo, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, Sao Paulo, Brazil|Hospital Santa Marcelina, São Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04402060,Brazil,APL-9,11.0,2020,Sunday
3020,3021,COPD in the Time of COVID-19,"Active, not recruiting",,All,"40 Years and older   (Adult, Older Adult)",,160.0,"May 1, 2020",2021-06-01,"November 3, 2020","NIHR Leicester Biomedical Research Centre (Respiratory), Glenfield Hospital, Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04407598,United Kingdom,,6.0,2021,Tuesday
3021,3022,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,Enrolling by invitation,Biological: Biological: oral polio vaccine|Biological: Comparable Placebo|Drug: NA-831|Drug: Comparable Placebo of drug|Combination Product: Combination of oral polio vaccine and NA-831|Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3600.0,"November 1, 2020",2022-12-31,"September 9, 2020","Coronavirus Research Institute- Testing Site, Los Angeles, California, United States|Coronavirus Research Institute, Orange, California, United States|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States|Coronavirus Research Testing Site, San Francisco, California, United States|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States|Coronavirus Research Institute, Sunnyvale, California, United States|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States|NeuroActiva-Clinical Research Unit, Auckland, New Zealand|NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand",https://ClinicalTrials.gov/show/NCT04540185,New Zealand,NA-831|Comparable Placebo of drug,12.0,2022,Saturday
3022,3023,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy,Completed,Device: Audio-Visual Triage System (AVT),All,20 Years to 38 Years   (Adult),,60.0,"March 21, 2020",2020-04-28,"November 9, 2020","The University of Lahore, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04621214,Pakistan,,4.0,2020,Tuesday
3023,3024,"COVID-19, bLOod Coagulation and Thrombosis",Recruiting,Diagnostic Test: Echo-Doppler,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 1, 2020",2020-09-01,"May 14, 2020","Hôpital Ambroise Paré, Boulogne-Billancourt, IDF, France|Hôpital Privé Jacques Cartier, Massy, IDF, France|Centre Cardiologique du Nord, Saint-Denis, IDF, France",https://ClinicalTrials.gov/show/NCT04388657,France,,9.0,2020,Tuesday
3024,3025,Neurologic Manifestations of COVID-19,Recruiting,,All,"19 Years and older   (Adult, Older Adult)",,1342.0,"June 10, 2020",2021-03-01,"July 28, 2020","Philippine General Hospital - University of the Philippines Manila, Manila, Philippines",https://ClinicalTrials.gov/show/NCT04386083,Philippines,,3.0,2021,Monday
3025,3026,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Enrolling by invitation,Behavioral: Shared Decision Making,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,800.0,"September 10, 2020",2021-05-30,"September 30, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04548531,United States,,5.0,2021,Sunday
3026,3027,Effects of the COVID-19 Health Emergency on Biopsychosocial Health,"Active, not recruiting",Other: WHOQOL-BREF survey,All,"18 Years to 85 Years   (Adult, Older Adult)",,500.0,"May 7, 2020",2021-03-31,"June 1, 2020","University of New Mexico Department of Pediatrics, Albuquerque, New Mexico, United States",https://ClinicalTrials.gov/show/NCT04409535,Mexico,,3.0,2021,Wednesday
3027,3028,The COGCOV Study in ICU Patients,Recruiting,Behavioral: Neurocognitive assessment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"October 7, 2020",2021-02-28,"October 22, 2020","Ziekenhuis Oost-Limburg, Genk, Belgium",https://ClinicalTrials.gov/show/NCT04593069,Belgium,,2.0,2021,Sunday
3028,3029,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Completed,Other: Pulmonary Physiotherapy Techniques,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40.0,"April 2, 2020",2020-05-30,"June 2, 2020","Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04357340,"Iran, Islamic Republic of",,5.0,2020,Saturday
3029,3030,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,Drug: Ophtamesone,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,250.0,"August 1, 2020",2020-10-15,"September 30, 2020","Raid Muhmid Al-Ani, Ramadi, Anbar, Iraq",https://ClinicalTrials.gov/show/NCT04569825,Iraq,Ophtamesone,10.0,2020,Thursday
3030,3031,OPV as Potential Protection Against COVID-19,Enrolling by invitation,Biological: oral polio vaccine + information|Behavioral: Information,All,"50 Years and older   (Adult, Older Adult)",Phase 4,3400.0,"July 15, 2020",2021-06-01,"July 16, 2020","Bandim Health Project, Bissau, Guinea-Bissau",https://ClinicalTrials.gov/show/NCT04445428,Guinea,,6.0,2021,Tuesday
3031,3032,Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea,Completed,Other: RECOP unit patient,All,"15 Years and older   (Child, Adult, Older Adult)",,1860.0,"March 13, 2020",2020-06-07,"November 5, 2020","University Hospital of Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04422587,France,,6.0,2020,Sunday
3032,3033,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Recruiting,Drug: Linagliptin 5 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"October 1, 2020",2021-09-30,"October 5, 2020","Rabin Medical Center, Petah tikva, Israel",https://ClinicalTrials.gov/show/NCT04371978,Israel,Linagliptin 5 MG,9.0,2021,Thursday
3033,3034,Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19,Not yet recruiting,Drug: RLF-100 (aviptadil)|Drug: Placebo|Device: Nebulized administration of RLF-100 or Placebo,All,"12 Years to 85 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,288.0,"January 10, 2021",2021-09-01,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04360096,Undefined,RLF-100 (aviptadil)|Placebo,9.0,2021,Wednesday
3034,3035,Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients,Recruiting,Diagnostic Test: CLIA of IgG and IgM against SARS-Cov-2,All,"18 Years to 100 Years   (Adult, Older Adult)",,300.0,"May 29, 2020",2021-06-30,"June 2, 2020","Victor Fernandez Alonso, Madrid, Spain|Victor Fernández Alonso, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04410471,Spain,,6.0,2021,Wednesday
3035,3036,Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit,Completed,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"March 15, 2020",2020-05-15,"November 27, 2020","SisliHamidiye Etfal Education and Training Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04645433,Turkey,,5.0,2020,Friday
3036,3037,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,350.0,"March 20, 2020",2020-05-31,"April 7, 2020","University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy",https://ClinicalTrials.gov/show/NCT04316949,Italy,,5.0,2020,Sunday
3037,3038,Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis,Recruiting,Diagnostic Test: microcirculation recording,All,"18 Years and older   (Adult, Older Adult)",,25.0,"February 1, 2020",2021-12-01,"November 30, 2020","University Hospital Hradec Kralove, Hradec Králové, Třebeš, Czechia",https://ClinicalTrials.gov/show/NCT04644302,Undefined,,12.0,2021,Wednesday
3038,3039,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,Recruiting,Diagnostic Test: Venous blood was collected for biochemistry testing.,All,"18 Years to 100 Years   (Adult, Older Adult)",,20.0,"September 1, 2020",2020-12-07,"December 11, 2020","Sabahattin Destek, Fatih, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04659200,Turkey,,12.0,2020,Monday
3039,3040,Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection,"Active, not recruiting",Other: RECOP unit patient,All,"15 Years and older   (Child, Adult, Older Adult)",,1860.0,"March 13, 2020",2021-03-01,"June 9, 2020","University Hospital of Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04371328,France,,3.0,2021,Monday
3040,3041,Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,Completed,,All,"Child, Adult, Older Adult",,1231.0,"April 2, 2020",2020-06-30,"July 1, 2020","Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Hospitalier Métropole Savoie, Chambéry, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|CH Annecy-Genevois, Metz-Tessy, France|Institut de Cancérologie de Montpellier, Montpellier, France|Groupement Hospitalier Porte de Provence, Montélimar, France|Centre Antoine Lacassagne, Nice, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, France|Institut Universitaire du Cancer de Toulouse - IUCT Oncopole, Toulouse, France|CH Valence, Valence, France",https://ClinicalTrials.gov/show/NCT04363632,France,,6.0,2020,Tuesday
3041,3042,Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery,Recruiting,Other: pre-operative screening|Other: telephone consult,All,"18 Years and older   (Adult, Older Adult)",,150.0,"June 25, 2020",2020-09-25,"July 20, 2020","Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom",https://ClinicalTrials.gov/show/NCT04449783,United Kingdom,,9.0,2020,Friday
3042,3043,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,Drug: virgin coconut oil (VCO)|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"June 1, 2020",2020-12-31,"October 20, 2020","Central Public Hospital Dr. Sardjito, Yogyakarta, Indonesia|RSUD Wonosari, Yogyakarta, Indonesia|RSUP Sleman, Yogyakarta, Indonesia|Teaching Hospital of Universitas Gadjah Mada (UGM), Yogyakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04594330,Indonesia,virgin coconut oil (VCO),12.0,2020,Thursday
3043,3044,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Completed,Other: This is an online survey with no intervention.,Female,"18 Years and older   (Adult, Older Adult)",,7000.0,"May 15, 2020",2020-06-20,"June 24, 2020","Pregistry, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04385238,United States,,6.0,2020,Saturday
3044,3045,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,Completed,,All,"18 Years and older   (Adult, Older Adult)",,441.0,"May 1, 2020",2020-09-28,"September 29, 2020","University of Szeged Department of Dermatology and Allergology, Szeged, Hungary",https://ClinicalTrials.gov/show/NCT04426266,Hungary,,9.0,2020,Monday
3045,3046,Menstrual Cycle Characteristics of Healthcare Professionals,Completed,,Female,18 Years to 47 Years   (Adult),,260.0,"April 10, 2020",2020-09-10,"November 19, 2020","University of Health Sciences Turkey, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04413058,Turkey,,9.0,2020,Thursday
3046,3047,Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,Recruiting,Other: Patients received standard of care treatment during hospitalization,All,"18 Years and older   (Adult, Older Adult)",,750.0,"July 10, 2020",2020-12-01,"September 1, 2020","Kansas City Heart Rhythm Institute, Overland Park, Kansas, United States",https://ClinicalTrials.gov/show/NCT04465552,United States,,12.0,2020,Tuesday
3047,3048,"Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19",Recruiting,Diagnostic Test: test,All,"18 Years to 70 Years   (Adult, Older Adult)",,100.0,"July 1, 2020",2021-12-31,"November 17, 2020","University Hospital in Cracow, Kraków, Poland",https://ClinicalTrials.gov/show/NCT04631497,Poland,,12.0,2021,Friday
3048,3049,Appendicitis During the National Lockdown During the COVID-19 Pandemic,Completed,Behavioral: Lock-down and social distancing,All,"Child, Adult, Older Adult",,6000000.0,"March 23, 2017",2020-04-19,"June 19, 2020","Nordsjaellands Hospital, Hillerød, Denmark",https://ClinicalTrials.gov/show/NCT04407117,Denmark,,4.0,2020,Sunday
3049,3050,Tocilizumab for Patients With Cancer and COVID-19 Disease,Suspended,Biological: Tocilizumab,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 2,217.0,"May 28, 2020",2022-04-01,"August 13, 2020","National Cancer Institute, Rockville, Maryland, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Valley Medical Center, Renton, Washington, United States",https://ClinicalTrials.gov/show/NCT04370834,United States,,4.0,2022,Friday
3050,3051,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,Recruiting,Other: During COVID-19 Pandemic|Other: After COVID-19 Pandemic,All,"18 Years to 100 Years   (Adult, Older Adult)",,1000.0,"April 10, 2020",2021-07-30,"May 8, 2020","Dell Medical School, Austin, Texas, United States|CommUnity Care Clinic - Southeast Health and Wellness Clinic, Austin, Texas, United States|CommUnity Care Clinic - Rundberg, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04378595,United States,,7.0,2021,Friday
3051,3052,Effects of DPP4 Inhibition on COVID-19,Not yet recruiting,Drug: Linagliptin|Drug: Insulin regimen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20.0,"January 30, 2021",2021-12-30,"October 8, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04341935,United States,Linagliptin|Insulin regimen,12.0,2021,Thursday
3052,3053,Birth Experience During COVID-19 Confinement,Recruiting,Other: Self-administered questionnaires,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,927.0,"April 16, 2020",2021-10-01,"October 5, 2020","Centre Hospitalier Régional Universitaire de Nancy, Nancy, France",https://ClinicalTrials.gov/show/NCT04348929,France,,10.0,2021,Friday
3053,3054,"National Study ""AEC COVID-19""",Recruiting,,All,"14 Years and older   (Child, Adult, Older Adult)",,1000.0,"March 1, 2020",2020-09-30,"October 5, 2020","Salvador Morales-Conde, Sevilla, Spain",https://ClinicalTrials.gov/show/NCT04573868,Spain,,9.0,2020,Wednesday
3054,3055,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020",Recruiting,Behavioral: Chat-based support|Behavioral: AWARD plus COVID-specific advice|Behavioral: AWARD advice|Behavioral: COVID-19 related health warning leaflet|Behavioral: Health warning leaflet|Behavioral: SMS-based support|Behavioral: Referral card|Behavioral: COSH Self-help smoking cessation booklet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,842.0,"June 13, 2020",2022-06-30,"September 30, 2020","Hong Kong Council on Smoking and Health (COSH), Hong Kong, Hong Kong, China",https://ClinicalTrials.gov/show/NCT04399967,China,,6.0,2022,Thursday
3055,3056,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,Recruiting,Other: non-interventional,All,"18 Years and older   (Adult, Older Adult)",,3500.0,"June 11, 2020",2022-01-15,"August 3, 2020","Eurasian Association of Therapists, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04492384,Russian Federation,,1.0,2022,Saturday
3056,3057,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,Other: Yoga,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"May 20, 2020",2020-12-31,"June 4, 2020","Rutgers University, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04414371,Jersey,,12.0,2020,Thursday
3057,3058,Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic,Completed,,All,"Child, Adult, Older Adult",,706.0,"March 9, 2020",2020-05-20,"October 28, 2020","Akdeniz Üniversitesi, Antalya, Konyaaltı, Turkey",https://ClinicalTrials.gov/show/NCT04605692,Turkey,,5.0,2020,Wednesday
3058,3059,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",Other: SARS-Cov-2 infection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,54.0,"April 8, 2020",2021-06-09,"June 11, 2020","Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy",https://ClinicalTrials.gov/show/NCT04343053,Italy,,6.0,2021,Wednesday
3059,3060,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Not yet recruiting,Biological: Mesenchymal stem cell,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6.0,September 2020,2021-12-01,"August 24, 2020","Osaka University Hospital, Suita, Osaka, Japan",https://ClinicalTrials.gov/show/NCT04522986,Japan,,12.0,2021,Wednesday
3060,3061,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,Recruiting,Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,554.0,"April 9, 2020",2020-08-09,"June 4, 2020","Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04329195,France,1: discontinuation of RAS blocker therapy|2: continuation of RAS blocker therapy,8.0,2020,Sunday
3061,3062,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,Other: Prone position,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,248.0,"May 13, 2020",2021-06-01,"August 18, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04391140,Spain,,6.0,2021,Tuesday
3062,3063,CCP Cancer UK Companion Study,Not yet recruiting,,All,"Child, Adult, Older Adult",,9000.0,"October 31, 2020",2022-10-31,"October 26, 2020",,https://ClinicalTrials.gov/show/NCT04603105,Undefined,,10.0,2022,Monday
3063,3064,Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study),Recruiting,Diagnostic Test: Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|Diagnostic Test: Videofluoroscopy|Other: Dysphagia Handicap Index (DHI)|Other: Voice Symptom Scale (VoiSS),All,"18 Years to 85 Years   (Adult, Older Adult)",,36.0,"September 15, 2020",2021-12-01,"October 19, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",https://ClinicalTrials.gov/show/NCT04584658,United Kingdom,,12.0,2021,Wednesday
3064,3065,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,Recruiting,Biological: CYNK-001,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,86.0,"May 13, 2020",2021-06-30,"November 23, 2020","Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arkansas, Little Rock, Arkansas, United States|UC Irvine, Irvine, California, United States|UC Davis Medical Center, Sacramento, California, United States|Scripps Health, San Diego, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Atlantic Health, Morristown, New Jersey, United States|Atlantic Health, Summit, New Jersey, United States|Multicare Health System, Tacoma, Washington, United States",https://ClinicalTrials.gov/show/NCT04365101,Jersey,,6.0,2021,Wednesday
3065,3066,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Recruiting,Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir,All,18 Years to 55 Years   (Adult),Phase 3,60.0,"February 1, 2020",2020-07-01,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04261270,China,ASC09F+Oseltamivir|Ritonavir+Oseltamivir|Oseltamivir,7.0,2020,Wednesday
3066,3067,"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""",Recruiting,Device: Aerosol Box|Device: Intubation Box,All,"Child, Adult, Older Adult",Not Applicable,30.0,"May 15, 2020",2020-12-30,"May 13, 2020","University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia",https://ClinicalTrials.gov/show/NCT04385576,Malaysia,,12.0,2020,Wednesday
3067,3068,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,"Active, not recruiting",Device: CT-imaging,All,"18 Years and older   (Adult, Older Adult)",,145.0,"April 15, 2020",2021-04-30,"June 9, 2020","Jena University Hospital, Jena, Thuringia, Germany",https://ClinicalTrials.gov/show/NCT04357938,Germany,,4.0,2021,Friday
3068,3069,Brain Health in the Time of COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"June 16, 2020",2020-12-31,"July 7, 2020","Miro Health, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04438967,United States,,12.0,2020,Thursday
3069,3070,COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress,"Active, not recruiting",Other: COVID-19 pandemic,All,"Child, Adult, Older Adult",,342.0,"May 13, 2020",2022-05-01,"September 28, 2020","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",https://ClinicalTrials.gov/show/NCT04379063,Canada,,5.0,2022,Sunday
3070,3071,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,70.0,"March 25, 2020",2020-08-17,"September 22, 2020","University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Eastern Health, Saint John's, Newfoundland and Labrador, Canada|McMaster University, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04421664,Canada,Hydroxychloroquine|Placebo oral tablet,8.0,2020,Monday
3071,3072,Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population,Recruiting,,All,65 Years and older   (Older Adult),,150.0,"June 22, 2020",2020-12-31,"September 14, 2020","Department of Anesthesiology & Intensive Care, Faculty of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04547218,Malaysia,,12.0,2020,Thursday
3072,3073,RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study,Not yet recruiting,Device: Remote Ischemic Conditioning,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,30.0,"December 15, 2020",2021-09-01,"December 9, 2020",,https://ClinicalTrials.gov/show/NCT04659460,Undefined,,9.0,2021,Wednesday
3073,3074,Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),Not yet recruiting,Diagnostic Test: carotid-femoral pulse-wave velocity,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,360.0,September 2020,2032-06-01,"September 22, 2020","CHU Lille, Lille, France|CHRU Nancy, Nancy, France|Hôpital Européen Georges Pompidou - APHP, Paris, France|CHU Rouen, Rouen, France",https://ClinicalTrials.gov/show/NCT04558450,France,,6.0,2032,Tuesday
3074,3075,Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection,Recruiting,,All,"18 Years to 85 Years   (Adult, Older Adult)",,90.0,"July 2, 2020",2022-01-01,"July 13, 2020","Addenbrookes Hospital, Cambridge, United Kingdom|Charing Cross Hospital, London, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",https://ClinicalTrials.gov/show/NCT04466982,United Kingdom,,1.0,2022,Saturday
3075,3076,TOFAcitinib in SARS-CoV2 Pneumonia,Not yet recruiting,Drug: Tofacitinib,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50.0,"April 10, 2020",2020-07-10,"April 2, 2020","Ospedali Riuniti di Ancona, Ancona, Marche, Italy",https://ClinicalTrials.gov/show/NCT04332042,Italy,Tofacitinib,7.0,2020,Friday
3076,3077,The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong,Recruiting,Other: Telephone survey,All,"up to 25 Years   (Child, Adult)",,150.0,"April 24, 2020",2021-12-30,"November 4, 2020","The University of Hong Kong, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04360863,Hong Kong,,12.0,2021,Thursday
3077,3078,The New Silicone N99 Half-Piece Respirator,Completed,Device: Fit test|Device: Filtration Test,All,18 Years to 60 Years   (Adult),Not Applicable,43.0,"May 1, 2020",2020-05-31,"July 1, 2020","Bangkok Metroplitan Administration and Vajira Hospital, Bangkok, Thailand",https://ClinicalTrials.gov/show/NCT04454606,Thailand,,5.0,2020,Sunday
3078,3079,Remdesivir vs Chloroquine in Coronavirus Disease,Recruiting,Drug: Chloroquine or hydroxychloroquine|Drug: Remdesivir,All,"Child, Adult, Older Adult",Phase 2|Phase 3,120.0,"June 16, 2020",2029-12-01,"December 4, 2020","Tanta university hospital, Assuit University, Ainshams University, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04345419,Egypt,Chloroquine or hydroxychloroquine|Remdesivir,12.0,2029,Saturday
3079,3080,Acute Cardiovascular Events Triggered by COVID-19-Related Stress,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,50.0,"May 3, 2020",2020-08-30,"May 5, 2020","Istishari Hospital, Amman, Jordan|Abdelhadi Hospital, Amman, Jordan|Farah Hospital, Amman, Jordan|Jordan Hospital, Amman, Jordan|Specialty Hospital, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04368637,Jordan,,8.0,2020,Sunday
3080,3081,Covid-19 Anxiety and Phobia Levels of the Parents,Completed,"Other: Coronavirus Anxiety Scale , COVID-19 Phobia Scale",All,"18 Years and older   (Adult, Older Adult)",,150.0,"May 1, 2020",2020-10-15,"November 18, 2020","Selcuk University, School of Medicine, Konya, Turkey",https://ClinicalTrials.gov/show/NCT04631172,Turkey,,10.0,2020,Thursday
3081,3082,"This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19",Recruiting,Drug: ADM03820|Other: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,40.0,"December 4, 2020",2021-09-30,"December 10, 2020","PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|ICON Early Phase Services, LLC, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04592549,United States,ADM03820,9.0,2021,Thursday
3082,3083,Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2),Recruiting,Biological: blood sampling,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 3, 2020",2020-12-06,"April 10, 2020","University Hospital Angers, Angers, France",https://ClinicalTrials.gov/show/NCT04337190,France,,12.0,2020,Sunday
3083,3084,University of Utah COVID-19 Hydrochloroquine Trial,Recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"April 4, 2020",2022-04-01,"November 13, 2020","University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04342169,United States,Hydroxychloroquine|Placebo oral tablet,4.0,2022,Friday
3084,3085,The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19,Not yet recruiting,Drug: Adenosine,All,"18 Years to 105 Years   (Adult, Older Adult)",Phase 2,30.0,December 2020,2022-12-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04588441,Undefined,Adenosine,12.0,2022,Thursday
3085,3086,Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,60.0,"May 26, 2020",2021-04-01,"June 11, 2020","The Royal Marden NHS Foundation Trust, Sutton, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT04427280,United Kingdom,,4.0,2021,Thursday
3086,3087,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Recruiting,Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,700.0,"March 28, 2020",2020-11-01,"April 14, 2020","Andreas Barratt-Due, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04321616,Norway,Hydroxychloroquine|Remdesivir,11.0,2020,Sunday
3087,3088,Impact of COVID-19 on Mental Health of Health Care Workers,"Active, not recruiting",Other: Online survey,All,"Child, Adult, Older Adult",,497.0,"April 17, 2020",2022-12-31,"May 11, 2020","Ghent University Hospital, Ghent, Belgium",https://ClinicalTrials.gov/show/NCT04382196,Belgium,,12.0,2022,Saturday
3088,3089,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"May 11, 2020",2021-06-30,"May 28, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",https://ClinicalTrials.gov/show/NCT04382547,Belarus,,6.0,2021,Wednesday
3089,3090,Clinical Use of Stem Cells for the Treatment of Covid-19,Recruiting,Biological: MSC Treatment|Biological: Saline Control,All,40 Years to 60 Years   (Adult),Phase 1|Phase 2,30.0,"April 1, 2020",2020-09-01,"May 19, 2020","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04392778,Turkey,,9.0,2020,Tuesday
3090,3091,Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Not yet recruiting,Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,March 2020,2020-11-01,"March 20, 2020","Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy",https://ClinicalTrials.gov/show/NCT04316728,Italy,,11.0,2020,Sunday
3091,3092,Immune Response and Risk of Serious Infection to SARS-Cov2,Recruiting,Biological: Blood sample collection,All,"18 Years and older   (Adult, Older Adult)",,63.0,"September 29, 2020",2021-08-01,"November 13, 2020","Chu Dijon Bourogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04410432,France,,8.0,2021,Sunday
3092,3093,"Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2",Not yet recruiting,Drug: metformin glycinate|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"November 30, 2020",2021-03-31,"November 12, 2020","Hospital Juárez de México, OPD, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04626089,Mexico,metformin glycinate|Placebo oral tablet,3.0,2021,Wednesday
3093,3094,Evaluation of Immune Response in COVID-19 Patients,Recruiting,Drug: COVID-19 treatment,All,"18 Years to 90 Years   (Adult, Older Adult)",,80.0,"March 26, 2020",2020-11-26,"June 22, 2020","Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy",https://ClinicalTrials.gov/show/NCT04438629,Italy,COVID-19 treatment,11.0,2020,Thursday
3094,3095,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,Biological: Convalescent Plasma,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30.0,"March 28, 2020",2020-09-30,"March 31, 2020","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04327349,"Iran, Islamic Republic of",,9.0,2020,Wednesday
3095,3096,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","Active, not recruiting",Behavioral: Brief educational video,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2500.0,"May 8, 2020",2021-03-01,"October 14, 2020","University of California, Los Angeles, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04373135,United States,,3.0,2021,Monday
3096,3097,Telerehabilitation After Coronavirus,Recruiting,Other: Aerobic Exercise Training|Behavioral: Patient Education|Other: Respiratory Exercise Training,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,36.0,"June 19, 2020",2020-12-19,"July 27, 2020","KTO Karatay University, Konya, Karatay, Turkey",https://ClinicalTrials.gov/show/NCT04473898,Turkey,,12.0,2020,Saturday
3097,3098,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Recruiting,Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,"February 1, 2020",2020-07-01,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04263402,China,Methylprednisolone,7.0,2020,Wednesday
3098,3099,Respiratory Syncytial Virus Infection May be More Dangerous in Neonate,"Active, not recruiting",,All,up to 1 Month   (Child),,28.0,"March 1, 2020",2020-08-31,"August 28, 2020","Behçet Uz Children's Hospital, İzmirli, Izmir, Turkey|İzmir Dr. Behcet Uz Training and Research Hospital, İzmir, Turkey",https://ClinicalTrials.gov/show/NCT04531735,Turkey,,8.0,2020,Monday
3099,3100,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Recruiting,Drug: Alteplase 50 MG [Activase],All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"May 14, 2020",2021-11-01,"November 19, 2020","Scripps Memorial Hospital La Jolla, La Jolla, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Miami Hospital, Miami, Florida, United States|St. Mary's Medical Center, West Palm Beach, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Long Island Jewish Medical Center, New York, New York, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Ben Taub Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04357730,Israel,Alteplase 50 MG [Activase],11.0,2021,Monday
3100,3101,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"April 9, 2020",2020-04-22,"April 24, 2020","Intensive care unit CHU Nimes, Nîmes, France",https://ClinicalTrials.gov/show/NCT04358640,France,,4.0,2020,Wednesday
3101,3102,Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,Other: venous ultrasound|Other: blood sample,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 22, 2020",2020-09-22,"April 29, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04366752,France,,9.0,2020,Tuesday
3102,3103,Effect of Tele-consultation in Addition With Psychiatric Follow-up During COVID-19 in Women Who Have Medical History of Post-partum Depression,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,250.0,November 2020,2020-11-01,"October 6, 2020",,https://ClinicalTrials.gov/show/NCT04516668,Undefined,,11.0,2020,Sunday
3103,3104,COVID-19 Risk Stratification,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1326.0,"March 1, 2020",2020-04-26,"November 30, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04339387,United States,,4.0,2020,Sunday
3104,3105,Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19),Not yet recruiting,Drug: Tissue plasminogen activator|Drug: Ringer solution,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,"October 15, 2020",2021-02-15,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04453371,Undefined,Tissue plasminogen activator|Ringer solution,2.0,2021,Monday
3105,3106,Convalescent Plasma Therapy in Patients With COVID-19,Completed,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,"May 1, 2020",2020-06-22,"June 30, 2020","Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia",https://ClinicalTrials.gov/show/NCT04407208,Indonesia,,6.0,2020,Monday
3106,3107,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Recruiting,Procedure: Human biological samples,All,"Child, Adult, Older Adult",Not Applicable,1300.0,"March 23, 2020",2022-03-23,"September 23, 2020","Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana|Institut Pasteur de Guadeloupe, Les Abymes, Guadeloupe|Institut Pasteur de Nouvelle-Calédonie, Nouméa, New Caledonia",https://ClinicalTrials.gov/show/NCT04328129,French Guiana,,3.0,2022,Wednesday
3107,3108,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Recruiting,"Diagnostic Test: Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples",All,"18 Years to 75 Years   (Adult, Older Adult)",,150.0,"June 2, 2020",2020-09-25,"July 13, 2020","Laboratorio Neurognos, Santiago, Providencia, Chile",https://ClinicalTrials.gov/show/NCT04468217,Chile,,9.0,2020,Friday
3108,3109,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,Recruiting,Drug: Therapeutic anticoagulation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,462.0,"July 4, 2020",2020-12-31,"August 19, 2020","Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04444700,Brazil,Therapeutic anticoagulation,12.0,2020,Thursday
3109,3110,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",Recruiting,Biological: SAB-185|Other: Normal saline,All,18 Years to 60 Years   (Adult),Phase 1,28.0,"August 5, 2020",2020-12-01,"August 27, 2020","Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States|SUNY Upstate Medical University, Syracuse, New York, United States|ICON Early Phase Services, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04468958,United States,,12.0,2020,Tuesday
3110,3111,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Recruiting,Biological: BCG-Denmark|Biological: Saline,All,65 Years to 110 Years   (Older Adult),Phase 3,1900.0,"September 15, 2020",2022-03-01,"November 24, 2020","Seniorhuset, Odense, Denmark",https://ClinicalTrials.gov/show/NCT04542330,Denmark,,3.0,2022,Tuesday
3111,3112,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Recruiting,Other: NaCl Solution,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,405.0,"June 23, 2020",2020-10-31,"September 2, 2020","NHS Lothian, Edinburgh, United Kingdom",https://ClinicalTrials.gov/show/NCT04382131,United Kingdom,,10.0,2020,Saturday
3112,3113,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,Not yet recruiting,Behavioral: psychological assessment,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,April 2020,2020-06-01,"April 29, 2020","Service médecine foetale-Hôpital Trousseau, Paris, France",https://ClinicalTrials.gov/show/NCT04366817,France,,6.0,2020,Monday
3113,3114,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",Not yet recruiting,Drug: Ibudilast|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,40.0,November 2020,2021-12-01,"October 20, 2020",,https://ClinicalTrials.gov/show/NCT04429555,Undefined,Ibudilast|Placebo,12.0,2021,Wednesday
3114,3115,Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era,Recruiting,Diagnostic Test: COVID-19 testing,All,"Child, Adult, Older Adult",,1000.0,"August 1, 2020",2022-06-30,"November 19, 2020","UPMC Pinnacle Harrisburg, Harrisburg, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04636021,United States,,6.0,2022,Thursday
3115,3116,Efficacy and Safety of Ozonised Oil (HOO) in COVID-19 Patients,Not yet recruiting,Dietary Supplement: Ozonized oil (HOO,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,74.0,January 2021,2021-08-01,"December 3, 2020",,https://ClinicalTrials.gov/show/NCT04651387,Undefined,,8.0,2021,Sunday
3116,3117,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Not yet recruiting,Drug: Nebulised heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,September 2020,2022-01-01,"August 13, 2020","Galway University Hospital, Galway, Ireland",https://ClinicalTrials.gov/show/NCT04511923,Ireland,Nebulised heparin,1.0,2022,Saturday
3117,3118,COVIDAR - Arrhythmias in COVID-19,Not yet recruiting,,All,"Child, Adult, Older Adult",,10000.0,June 2020,2021-12-01,"June 18, 2020","Antwerp University Hospital, Antwerpen, Belgium|Istituto Auxologico Italiano, IRCCS, Milan, Italy|Amsterdam UMC, Amsterdam, AZ, Netherlands|Hospital Clinic of Barcelona, Barcelona, Spain|St. Georges University Hospitals, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04437901,Belgium,,12.0,2021,Wednesday
3118,3119,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,Recruiting,Drug: Nintedanib 150 MG [Ofev]|Other: Placebo,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 3,250.0,"October 29, 2020",2021-12-01,"November 23, 2020","Pneumologie, Paris, France",https://ClinicalTrials.gov/show/NCT04541680,France,Nintedanib 150 MG [Ofev],12.0,2021,Wednesday
3119,3120,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,Procedure: Robot Assisted Percutaneous Cardiovascular Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"April 27, 2020",2020-04-27,"May 8, 2020","Hospital Israelita Albert Einstein, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04379453,Brazil,,4.0,2020,Monday
3120,3121,Investigating a Vaccine Against COVID-19,Recruiting,Biological: ChAdOx1 nCoV-19 (Abs 260)|Biological: MenACWY vaccine|Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|Biological: Two dose MenACWY vaccine|Biological: ChAdOx1 nCoV-19 (qPCR)|Biological: ChAdOx1 nCoV-19 0.5mL prime plus boost|Biological: Two dose MenACWY vaccine min. 4 weeks apart|Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,12390.0,"May 28, 2020",2021-09-01,"December 10, 2020","University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Castle Hill Hospital, Cottingham, Hull, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, Tooting, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|NIHR Cambridge Clinical Research Facility, Cambridge, United Kingdom|NHS Lothian, Western General Hospital, Edinburgh, United Kingdom|Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital, Glasgow, United Kingdom|Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator, LIverpool, United Kingdom|London North West University Healthcare Trust (LNWUH), Northwick Park Hospital, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|Public Health Wales, Newport, United Kingdom|University of Nottingham Health Service, Cripps Health Centre, University Park, Nottingham, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Sheffield Teaching Hospitals, Royal Hallamshire Hospital, Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT04400838,United Kingdom,,9.0,2021,Wednesday
3121,3122,Endothelial Damage and Angiogenesis Biomarkers During COVID-19,Recruiting,Diagnostic Test: Endothelial damage and angiogenic biomarkers,All,"18 Years and older   (Adult, Older Adult)",,40.0,"November 10, 2020",2021-11-01,"November 13, 2020","Hospital Clínico de la Universidad de Chile, Independencia, Santiago, Chile",https://ClinicalTrials.gov/show/NCT04609332,Chile,,11.0,2021,Monday
3122,3123,Pregnancy Outcomes During the Pandemic: Using Placental Pathology and Gene Expression to Understand Fetal Risk,Recruiting,Biological: SARS-CoV-2,Female,"18 Years and older   (Adult, Older Adult)",,100.0,"August 4, 2020",2021-09-30,"October 14, 2020","Prisma Health Upstate, Greenville, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04585945,United States,,9.0,2021,Thursday
3123,3124,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),Recruiting,Biological: MultiStem|Biological: Placebo,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,400.0,"April 28, 2020",2022-08-01,"September 29, 2020","Athersys Investigational Site 103, Akron, Ohio, United States|Athersys Investigational Site 101, Cleveland, Ohio, United States|Athersys Investigational Site 102, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04367077,United States,,8.0,2022,Monday
3124,3125,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,Other: EPIC risk score display,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1200.0,"May 15, 2020",2021-05-15,"October 14, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04570488,United States,,5.0,2021,Saturday
3125,3126,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,47.0,"April 6, 2020",2022-04-06,"December 4, 2020","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",https://ClinicalTrials.gov/show/NCT04333368,France,,4.0,2022,Wednesday
3126,3127,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Recruiting,Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d,All,"18 Years and older   (Adult, Older Adult)",Phase 4,600.0,"June 21, 2020",2020-12-01,"October 6, 2020","Centro de Estudos Clínicos do Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Instituto de Ensino e Pesquisa do Hospital da Bahia, Salvador, Bahia, Brazil|Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel, Salvador, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Centro de Ensino e Aperfeiçoamento em Pesquisa - CEAP, Serra, Espirito Santo, Brazil|Centro de Pesquisas Cardiológicas de Goiânia do Hospital das Clínicas (UFG), Goiânia, Goiás, Brazil|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Hospital Universitário da Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Agamenon Magalhães, Recife, Pernambuco, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - Unesp, Botucatu, São Paulo, Brazil|Praxis Pesquisa Médica, Santo André, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil|BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil|Hcor - Hospital do Coração, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Samaritano Paulista, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Hospital São Paulo, São Paulo, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil|Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04394377,Brazil,Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Group 2: control group with enoxaparin 40mg/d,12.0,2020,Tuesday
3127,3128,A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19,Suspended,Drug: SNDX-6352|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,186.0,"May 30, 2020",2020-11-15,"August 11, 2020","HonorHealth, Scottsdale, Arizona, United States|Montefiore Medical Center, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04415073,United States,SNDX-6352|Placebo,11.0,2020,Sunday
3128,3129,Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use,Not yet recruiting,Behavioral: Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|Behavioral: Internet Cognitive Behavioral Therapy plus CHAMindWell|Behavioral: CHAMindWell,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,240.0,"November 1, 2020",2022-11-01,"October 20, 2020",,https://ClinicalTrials.gov/show/NCT04595084,Undefined,,11.0,2022,Tuesday
3129,3130,Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19),Recruiting,Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148),All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,75.0,"January 7, 2019",2022-10-01,"April 15, 2020","Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom",https://ClinicalTrials.gov/show/NCT03042143,Ireland,,10.0,2022,Saturday
3130,3131,The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19,"Active, not recruiting",Drug: Chemotherapy,Female,"18 Years to 80 Years   (Adult, Older Adult)",,305.0,"July 1, 2020",2021-01-10,"October 8, 2020","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04341480,China,Chemotherapy,1.0,2021,Sunday
3131,3132,In-depth Immunological Investigation of COVID-19.,Recruiting,Other: Patient sampling,All,"18 Years and older   (Adult, Older Adult)",,100.0,"March 27, 2020",2020-09-30,"May 29, 2020","UZ Leuven, Leuven, Belgium",https://ClinicalTrials.gov/show/NCT04327570,Belgium,,9.0,2020,Wednesday
3132,3133,Biomarkers of Trained Immunity Following MMR Vaccination,Not yet recruiting,Diagnostic Test: Heterologous stimuli,All,"18 Years and older   (Adult, Older Adult)",,80.0,December 2020,2021-04-01,"December 3, 2020",,https://ClinicalTrials.gov/show/NCT04646239,Undefined,,4.0,2021,Thursday
3133,3134,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Recruiting,Other: Best Practice|Drug: Ibrutinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,72.0,"July 22, 2020",2022-12-31,"August 19, 2020","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04439006,United States,Ibrutinib,12.0,2022,Saturday
3134,3135,Improving Thinking in Everyday Life After Covid-19,Recruiting,Behavioral: Speed of Processing Training|Behavioral: Instrumental Activities of Daily Living Shaping|Behavioral: Transfer Package from CI Therapy|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"November 1, 2020",2024-11-01,"November 25, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04644172,United States,,11.0,2024,Friday
3135,3136,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,106.0,"June 5, 2020",2021-07-01,"June 18, 2020","Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04380818,China,Hydroxychloroquine Sulfate|Ritonavir/lopinavir|Tocilizumab Injection [Actemra]|Azithromycin|Corticosteroid|Low molecular weight heparin,7.0,2021,Thursday
3136,3137,Survey on COVID-19 Airway Management,Recruiting,Other: Survey,All,"Child, Adult, Older Adult",,5000.0,"April 22, 2020",2020-09-30,"July 27, 2020","Consorcio Hospital General Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04487977,Spain,,9.0,2020,Wednesday
3137,3138,Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19,Completed,Other: mobile internet survey on self-test,All,"Child, Adult, Older Adult",,102456.0,"February 1, 2020",2020-07-01,"July 7, 2020","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04256395,China,,7.0,2020,Wednesday
3138,3139,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,140.0,"May 11, 2020",2020-08-20,"May 13, 2020","National Institute of Rehabilitation, Mexico City, Cdmx, Mexico",https://ClinicalTrials.gov/show/NCT04340349,Mexico,Hydroxychloroquine Sulfate|Bromhexine 8 MG,8.0,2020,Thursday
3139,3140,Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants,Recruiting,Other: questionnaire assesment,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"August 18, 2020",2020-12-01,"December 11, 2020","Lille University Hospital, Lille, France",https://ClinicalTrials.gov/show/NCT04426279,France,,12.0,2020,Tuesday
3140,3141,Immunogenetics Predictors With COVID-19,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"September 10, 2020",2022-05-09,"September 2, 2020","Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt",https://ClinicalTrials.gov/show/NCT04390269,Egypt,,5.0,2022,Monday
3141,3142,RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,Recruiting,Drug: Doxycycline|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"June 22, 2020",2021-07-01,"June 24, 2020","Temple University Hospital, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04433078,United States,Doxycycline|Placebo,7.0,2021,Thursday
3142,3143,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Drug: Darunavir and Cobicistat,All,"Child, Adult, Older Adult",Phase 3,30.0,"January 30, 2020",2020-12-31,"April 13, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04252274,China,Darunavir and Cobicistat,12.0,2020,Thursday
3143,3144,Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation,"Active, not recruiting",Other: Transplant patient,All,"18 Years and older   (Adult, Older Adult)",,3602.0,"May 11, 2020",2020-12-11,"June 18, 2020","Hopital Pellegrin, Bordeaux, France",https://ClinicalTrials.gov/show/NCT04376775,France,,12.0,2020,Friday
3144,3145,Remote Monitoring of Cancer Patients With Suspected Covid-19,Not yet recruiting,Device: Patient Status Engine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,June 2020,2020-10-01,"May 21, 2020","The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04397705,United Kingdom,,10.0,2020,Thursday
3145,3146,BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization,Recruiting,Drug: Bromhexine and Spironolactone|Drug: Base therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,80.0,"May 16, 2020",2020-08-23,"June 9, 2020","Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation",https://ClinicalTrials.gov/show/NCT04424134,Russian Federation,Bromhexine and Spironolactone|Base therapy,8.0,2020,Sunday
3146,3147,Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,170.0,"February 24, 2020",2021-06-17,"March 30, 2020","Prince of Wales Hospital, Sha Tin, Hong Kong",https://ClinicalTrials.gov/show/NCT04325919,Hong Kong,,6.0,2021,Thursday
3147,3148,COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,175.0,"May 22, 2020",2022-06-30,"September 17, 2020","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04401436,United States,,6.0,2022,Thursday
3148,3149,Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS,Recruiting,Other: PEEP trial,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 18, 2020",2020-12-31,"April 17, 2020","CHU, Angers, France",https://ClinicalTrials.gov/show/NCT04350710,France,,12.0,2020,Thursday
3149,3150,Cardiovascular Complications and COVID-19 (CovCardioVasc-Study),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"February 28, 2020",2021-08-31,"November 24, 2020","Centre Hospitalier de Cannes, Cannes, France|CHU de Dijon, Dijon, France|Centre Hospitalier de Draguignan, Draguignan, France|Centre Hospitalier de Grasse, Grasse, France|Clinique Ambroise-Paré, Neuilly, France|CHU de Nice, Nice, France|Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France|CHU de REIMS, Reims, France",https://ClinicalTrials.gov/show/NCT04335162,France,,8.0,2021,Tuesday
3150,3151,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,"Active, not recruiting",Drug: Nitric Oxide-Sessions|Drug: Nitric Oxide-Continuous and Sessions,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"July 24, 2020",2021-09-17,"September 16, 2020","Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation",https://ClinicalTrials.gov/show/NCT04476992,Russian Federation,Nitric Oxide-Sessions|Nitric Oxide-Continuous and Sessions,9.0,2021,Friday
3151,3152,Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19),Completed,,All,"Child, Adult, Older Adult",,5.0,"April 27, 2020",2020-06-30,"July 2, 2020","Minia university Hospital, Minya, Minia, Egypt",https://ClinicalTrials.gov/show/NCT04456556,Egypt,,6.0,2020,Tuesday
3152,3153,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,Recruiting,Diagnostic Test: nasopharyngeal swab,All,"up to 18 Years   (Child, Adult)",,914.0,"April 15, 2020",2021-01-01,"August 5, 2020","CH Louis MOURIER, Colombes, France|Hôpital Jeanne de Flandres, CHU, Lille, France|Hôpital Mère Enfant CHU, Nantes, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France|Hôpital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04336761,France,,1.0,2021,Friday
3153,3154,Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy,Not yet recruiting,Diagnostic Test: Nasopharyngeal swab,All,"18 Years to 75 Years   (Adult, Older Adult)",,300.0,"April 1, 2020",2020-12-01,"March 27, 2020",,https://ClinicalTrials.gov/show/NCT04324866,Undefined,,12.0,2020,Tuesday
3154,3155,The Use of Lung Ultrasonography in COVID-19 Patients,Recruiting,Behavioral: mechanical ventilator settings and position,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 26, 2020",2020-08-10,"August 7, 2020","Gazoosmanpasa Education and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04432051,Turkey,,8.0,2020,Monday
3155,3156,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,"Active, not recruiting",Other: Questionnaire by phone call,All,"18 Years and older   (Adult, Older Adult)",,572.0,"April 17, 2020",2020-11-30,"September 28, 2020","Fondation Adolphe de Rothschild, Paris, France",https://ClinicalTrials.gov/show/NCT04345159,France,,11.0,2020,Monday
3156,3157,Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,Recruiting,,All,"1 Year and older   (Child, Adult, Older Adult)",,92.0,"May 5, 2020",2020-06-15,"June 12, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04393142,Mexico,,6.0,2020,Monday
3157,3158,Assessment of Chilbains Occuring During Covid-19 Infection,Recruiting,,All,"up to 90 Years   (Child, Adult, Older Adult)",,30.0,"April 9, 2020",2020-06-30,"May 13, 2020","CHU de Nice, Nice, France",https://ClinicalTrials.gov/show/NCT04344119,France,,6.0,2020,Tuesday
3158,3159,Innovative Tool to Limit Spread of SARS-CoV-2 (COVID 19) in Residential Aged Care Facilities,Terminated,Behavioral: Gamification|Behavioral: Newsfeed function,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,34.0,"May 6, 2020",2020-08-26,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04377165,Undefined,,8.0,2020,Wednesday
3159,3160,Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,Completed,"Other: Serum zinc, vitamin d vitamin b12 levels .",Female,18 Years to 45 Years   (Adult),,44.0,"April 20, 2020",2020-06-14,"June 23, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",https://ClinicalTrials.gov/show/NCT04407572,Turkey,,6.0,2020,Sunday
3160,3161,AKI Biomarkers in Coronavirus(COVID)-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"August 20, 2020",2021-06-30,"December 7, 2020","Guy's & St Thomas' Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04408248,United Kingdom,,6.0,2021,Wednesday
3161,3162,COVID-19 and Lactating Mothers,Recruiting,,All,"Child, Adult, Older Adult",,100.0,"July 2, 2020",2021-04-01,"September 22, 2020","University of Rochester Medical Center, Rochester, New York, United States",https://ClinicalTrials.gov/show/NCT04558320,United States,,4.0,2021,Thursday
3162,3163,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Recruiting,Drug: Nitric Oxide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,"March 21, 2020",2022-04-01,"November 17, 2020","Providence HealthCare Network, Anchorage, Alaska, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04305457,United States,Nitric Oxide,4.0,2022,Friday
3163,3164,Registry of Patients With Hematologic Disease and COVID-19 in Russia,Recruiting,Other: Non-interventional study,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 22, 2020",2021-07-22,"November 13, 2020","Regional Clinical Hospital No1, Ekaterinburg, Russian Federation|Republican Clinical Hospital of Tatarstan, Kazan, Russian Federation|City Hospital n.a. V.V. Veresaev, Moscow, Russian Federation|Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|National Research Center for Hematology, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russian Federation|Regional Hospital, Novosibirsk, Russian Federation|Regional Clinical Hospital, Omsk, Russian Federation|Republican Clinical Hospital No4, Saransk, Russian Federation|Republic Clinical Hospital n.a. N.A. Semashko, Ulan-Ude, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Regional Clinical Hospital No2, Vladivostok, Russian Federation|Republican Hospital No1, Yakutsk, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation",https://ClinicalTrials.gov/show/NCT04422470,Russian Federation,,7.0,2021,Thursday
3164,3165,Electrocardiogram Analysis in COVID-19 Patients,Recruiting,Diagnostic Test: ECG,All,"18 Years to 100 Years   (Adult, Older Adult)",,1000.0,"April 14, 2020",2021-12-01,"April 29, 2020","Arcispedale S. Anna, Ferrara, Italy",https://ClinicalTrials.gov/show/NCT04367129,Italy,,12.0,2021,Wednesday
3165,3166,RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE),Available,Drug: RLF-100 (aviptadil),All,"12 Years to 100 Years   (Child, Adult, Older Adult)",,,,,"December 10, 2020","Dignity Health-Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Honor Health Shea Medical Center, Scottsdale, Arizona, United States|Kaiser Permanente, Baldwin Park, California, United States|University of California - Irvine, Irvine, California, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Lakeland Regional Health, Lakeland, Florida, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Baycare St. Joseph Hospital, Tampa, Florida, United States|Southeast Georgia Health system, Brunswick, Georgia, United States|Maui Health Systems, Wailuku, Hawaii, United States|St. Anthony Regional Hospital, Carroll, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|St. Tammany Parish Hospital, Covington, Louisiana, United States|Our Ladies of Lourdes Regional Hospital, Lafayette, Louisiana, United States|St. Joseph Heritage Healthcare, Saint Joseph, Missouri, United States|Great Plains Health, North Platte, Nebraska, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Hendrick Medical Center, Abilene, Texas, United States|Baptist Hospitals of Southeast Texas, Beaumont, Texas, United States|Medical City Denton, Denton, Texas, United States|HR Health Institute for Research & Development, Edinburg, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Hospital Houston, Houston, Texas, United States|Medical City McKinney, McKinney, Texas, United States",https://ClinicalTrials.gov/show/NCT04453839,Georgia,RLF-100 (aviptadil),,n,
3166,3167,HFNC and NIV for COVID-19 Complicated by Respiratory Failure,Recruiting,Device: HFNC,All,"18 Years and older   (Adult, Older Adult)",,15.0,"June 11, 2020",2021-06-10,"June 30, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04452708,Hong Kong,,6.0,2021,Thursday
3167,3168,COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"August 12, 2020",2021-12-31,"August 28, 2020","Institute of Human Virology, Nigeria (IHVN), Abuja, Nigeria",https://ClinicalTrials.gov/show/NCT04371835,Niger,,12.0,2021,Friday
3168,3169,Impact of COVID-19 Pandemic in Perinatal Mental Health (RISEUP-PPD-COVID-19),Recruiting,,Female,"18 Years and older   (Adult, Older Adult)",,3900.0,"June 15, 2020",2021-06-15,"October 27, 2020","Beder College University, Tirana, Albania|Universidade Presbiteriana Mackenzie, São Paulo, Brazil|Sofia University, Sofia, Bulgaria|Universidad de Concepción, Concepción, Chile|European University Cyprus, Nicosia, Cyprus|Groupe Hospitalier du Havre, Le Havre, France|University of Athens, Athens, Greece|Bar-Ilan University, Ramat Gan, Israel|University of Malta, Imsida, Malta|Universidade do Minho, Braga, Portugal|Universidad Loyola Andalucia, Sevilla, Spain|Kırklareli Üniversitesi, Kırklareli, Turkey|King'S College London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04595123,Albania,,6.0,2021,Tuesday
3169,3170,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Recruiting,Other: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4000.0,"May 20, 2020",2020-10-30,"July 28, 2020","Institut Paoli-Calmettes, Marseille, France",https://ClinicalTrials.gov/show/NCT04401046,France,,10.0,2020,Friday
3170,3171,The Covid-19 HEalth caRe wOrkErS (HEROES) Study,Recruiting,Other: Exposure to the SARS-CoV-2 and its consequences,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"April 26, 2020",2021-12-31,"July 14, 2020","Columbia University, New York, New York, United States|Universidad del Chubut, Rawson, Chubut, Argentina|National Institute of Health Named After Academician S. Avdalbekyan, Yerevan, Armenia|University of Sydney, Sidney, New South Wales, Australia|Salud Global, Sucre, Chuquisaca, Bolivia|University of Chile, Santiago, Chile|Universidad Nacional de Costa Rica, Heredia, Costa Rica|Society for Emergecy and Disaster Medicine CzMA JEP, Kladno, Bohemia, Czechia|Hochschule Emden/Leer, Emden, Niedersachsen, Germany|Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias Médicas Universidad de San Carlos de Guatemala -USAC-, Guatemala City, Guatemala|University of Cagliari, Cagliari, CA, Italy|University of Cagliari, Cagliari, Italy|The Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon|Logotipo del comercio Instituto Jalisciense De Salud Mental (SALME), Guadalajara, Jalisco, Mexico|Maastricht University, Maastricht, Limburg, Netherlands|University of Ibadan, Ibadan, Oyo State, Nigeria|Ponce Health Sciences University, Ponce, Puerto Rico|King Abdullah International medical research center, Riyadh, Central, Saudi Arabia|Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain|Razi Hospital La Manouba, Tunis, La Manouba, Tunisia|Koc University, Istanbul, Sariyer, Turkey|PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon, Maracay, Aragua, Venezuela",https://ClinicalTrials.gov/show/NCT04352634,Argentina,,12.0,2021,Friday
3171,3172,Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents,Recruiting,Procedure: Questionnaire|Other: Data collection up to 1 year,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"May 27, 2020",2021-12-01,"June 23, 2020","Centre Pôle Vision du val d'Ouest, Ecully, France|Fondation Adolphe de Rothschild, Paris, France|Hôpital Lariboisière, Paris, France|Centre ophtalmologique Maison Rouge, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04395859,France,,12.0,2021,Wednesday
3172,3173,Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention,Withdrawn,Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe|Device: Ultrasound of the lower limbs,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"May 2, 2020",2020-07-10,"August 20, 2020","Groupement Hospitalier des portes de Province, Montélimar, France|Centre Hospitalier de Roanne, Roanne, France|CHU de Saint-Etienne, Saint-Étienne, France|Clinique Mutualiste, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04520620,France,Lovenox 40 MG in 0.4 mL Prefilled Syringe,7.0,2020,Friday
3173,3174,Mental Health Consequences of COVID19 Infection in the French RMD Cohort,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1313.0,January 2021,2021-08-01,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04510467,Undefined,,8.0,2021,Sunday
3174,3175,COVID-19 Ad Intervention,Not yet recruiting,Behavioral: Social Distancing Advertisements,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,52500.0,"September 29, 2020",2022-07-28,"September 23, 2020","UC Irvine, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04555122,United States,,7.0,2022,Thursday
3175,3176,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Drug: Ruxolitinib plus simvastatin|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,94.0,"April 12, 2020",2020-05-13,"April 17, 2020","Hospital Universitario Madrid Sanchinarro, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04348695,China,Ruxolitinib plus simvastatin,5.0,2020,Wednesday
3176,3177,Understanding Reactions to Emotional Material in the Media During COVID-19,Recruiting,Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,66.0,"October 28, 2020",2021-01-15,"October 29, 2020","Uppsala University, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT04608097,Sweden,,1.0,2021,Friday
3177,3178,"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.",Not yet recruiting,Drug: Baricitinib,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"May 16, 2020",2020-07-30,"April 22, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",https://ClinicalTrials.gov/show/NCT04320277,Italy,Baricitinib,7.0,2020,Thursday
3178,3179,Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.,Not yet recruiting,Diagnostic Test: Generalized Anxiety Disorder-7 (GAD 7)|Diagnostic Test: Background questionnaire|Diagnostic Test: Impact of COVID-19 questionnaire|Diagnostic Test: Confinement and Communication During the COVID-19 Pandemic|Diagnostic Test: Mental Health questionnaire|Diagnostic Test: Patient Health Questionnaire (PHQ-9)|Diagnostic Test: Post Traumatic Stress Disorder questionnaire (PTSD-8)|Diagnostic Test: Experiences in Close Relationship Scale questionnaire (ECR-S),All,"18 Years and older   (Adult, Older Adult)",,405.0,September 2020,2020-12-01,"September 23, 2020","Centre Hospitalier Universitaire de Saint-Etienne, Saint-Étienne, France|Centre de Recherche et d'Innovation Clinique, Glasgow, United Kingdom",https://ClinicalTrials.gov/show/NCT04491071,France,,12.0,2020,Tuesday
3179,3180,Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals,Withdrawn,Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0.0,"April 28, 2020",2020-07-15,"August 28, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Tunis, Tunisia",https://ClinicalTrials.gov/show/NCT04349228,Tunisia,Hydroxychloroquine (HCQ)|Placebo oral tablet,7.0,2020,Wednesday
3180,3181,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes,Recruiting,Other: no intervention,All,"18 Years and older   (Adult, Older Adult)",,700.0,July 2020,2020-09-01,"July 24, 2020","University Regional Hospital of Nancy, Nancy, France",https://ClinicalTrials.gov/show/NCT04485351,France,,9.0,2020,Tuesday
3181,3182,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,Recruiting,Behavioral: Remote Cognitive Behavioral Therapy for Insomnia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"June 7, 2020",2021-11-01,"December 11, 2020","Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT04409743,United States,,11.0,2021,Monday
3182,3183,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Enrolling by invitation,Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,520.0,"April 8, 2020",2021-04-30,"August 14, 2020","Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04342728,United States,,4.0,2021,Friday
3183,3184,Profiling Recovery of Those Discharged Into the Community With COVID-19,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"January 4, 2021",2021-12-17,"December 2, 2020","University of Derby, Derby, United Kingdom",https://ClinicalTrials.gov/show/NCT04649957,United Kingdom,,12.0,2021,Friday
3184,3185,Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study,Enrolling by invitation,,All,"45 Years to 75 Years   (Adult, Older Adult)",,200.0,"June 9, 2020",2021-06-30,"December 7, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04432870,United States,,6.0,2021,Wednesday
3185,3186,COVID-19 Wellness Survey,Terminated,Other: Survey,All,"18 Years and older   (Adult, Older Adult)",,593.0,"May 27, 2020",2020-05-31,"December 7, 2020","Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04394104,Jersey,,5.0,2020,Sunday
3186,3187,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms,Recruiting,Other: Nil intervention,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"May 26, 2020",2022-05-01,"August 12, 2020","London North West University Healthcare NHS Trust, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Imperial College London (Hammersmith campus), London, United Kingdom|St Mary's Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04510441,United Kingdom,,5.0,2022,Sunday
3187,3188,Cardiac COVID-19 Health Care Workers,Completed,Other: Passed infection of SARS-CoV-2,All,"18 Years to 71 Years   (Adult, Older Adult)",,142.0,"May 25, 2020",2020-06-12,"June 16, 2020","University Hospital of Salamanca, Salamanca, Spain",https://ClinicalTrials.gov/show/NCT04413071,Spain,,6.0,2020,Friday
3188,3189,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Recruiting,Behavioral: HADS|Behavioral: a survey,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 18, 2020",2021-01-01,"June 1, 2020","universitair Ziekenhuis Brussel, Jette, Vlaams Brabant, Belgium",https://ClinicalTrials.gov/show/NCT04406181,Belgium,,1.0,2021,Friday
3189,3190,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",Recruiting,Drug: ACE inhibitor|Drug: ARB,All,"Child, Adult, Older Adult",,2574.0,"March 1, 2020",2023-08-31,"August 21, 2020","Hospital de Terrassa, Terrassa, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04367883,Spain,ACE inhibitor|ARB,8.0,2023,Thursday
3190,3191,Thromboembolic Events in Severe COVID-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"April 29, 2020",2021-04-01,"May 29, 2020","Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04405869,France,,4.0,2021,Thursday
3191,3192,Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt,Not yet recruiting,Other: Follow up,All,"Child, Adult, Older Adult",,200.0,"May 1, 2020",2020-07-30,"April 9, 2020",,https://ClinicalTrials.gov/show/NCT04339322,Undefined,,7.0,2020,Thursday
3192,3193,"Knowledge, Attitude and Practice of Dental Students About COVID-19",Completed,"Behavioral: Knowledge, Attitude, Practice, Awareness, Preference",All,18 Years to 30 Years   (Adult),,215.0,"April 25, 2020",2020-06-20,"September 2, 2020","Faculty of Dentistry, Melaka-Manipal Medical College, Melaka Tengah, Melaka, Malaysia",https://ClinicalTrials.gov/show/NCT04449081,Malaysia,,6.0,2020,Saturday
3193,3194,Characteristics of COVID-19 Infection Among PREGnant Women,Recruiting,Other: COVID-19 positive via testing,Female,"18 Years and older   (Adult, Older Adult)",,100.0,"July 22, 2020",2021-03-31,"July 29, 2020","INOVA Health System, Falls Church, Virginia, United States",https://ClinicalTrials.gov/show/NCT04398264,United States,,3.0,2021,Wednesday
3194,3195,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Recruiting,Biological: blood tests|Biological: Nasopharyngeal swabs|Biological: Stools,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"June 11, 2020",2023-12-01,"October 14, 2020","Cochin hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04584541,France,,12.0,2023,Friday
3195,3196,Timing of Tracheotomy in Covid-19 Patients,Recruiting,Procedure: Tracheotomy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"June 4, 2020",2021-02-01,"June 9, 2020","Sahlgrenska University Hospital, Gothenburg, Sweden",https://ClinicalTrials.gov/show/NCT04412356,Sweden,,2.0,2021,Monday
3196,3197,Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic,Recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,350.0,"May 11, 2020",2022-06-30,"November 20, 2020","University Hospital, Nantes, France",https://ClinicalTrials.gov/show/NCT04389463,France,,6.0,2022,Thursday
3197,3198,"Hydroxychloroquine, Azithromycin and Zinc for the Treatment of COVID-19 in the Outpatient Setting",Not yet recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo,All,"30 Years and older   (Adult, Older Adult)",Phase 4,750.0,November 2020,2021-05-01,"November 9, 2020","St. Francis Hospital - The Heart Center, Roslyn, New York, United States",https://ClinicalTrials.gov/show/NCT04621461,United States,Hydroxychloroquine|Azithromycin|Placebo,5.0,2021,Saturday
3198,3199,"Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19",Not yet recruiting,,All,"19 Years and older   (Adult, Older Adult)",,1000.0,"December 1, 2020",2021-06-30,"November 19, 2020",,https://ClinicalTrials.gov/show/NCT04637295,Undefined,,6.0,2021,Wednesday
3199,3200,Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic,Enrolling by invitation,"Other: ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.",All,"18 Years to 65 Years   (Adult, Older Adult)",,45.0,"April 1, 2020",2020-06-15,"May 27, 2020","IstanbulU, Istanbul, Bakırköy, Turkey",https://ClinicalTrials.gov/show/NCT04403438,Turkey,,6.0,2020,Monday
3200,3201,Effect of a Nss to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Not yet recruiting,Dietary Supplement: Nutritional support system (NSS)|Other: Control,All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,240.0,August 2020,2020-12-01,"August 11, 2020",,https://ClinicalTrials.gov/show/NCT04507867,Undefined,,12.0,2020,Tuesday
3201,3202,COVID-19 Prevalence and Cognitive Deficits in Neurological Patients,Withdrawn,Diagnostic Test: COVID-19 swap test PCR,All,"18 Years and older   (Adult, Older Adult)",,0.0,"May 7, 2020",2022-06-30,"September 3, 2020","Aalborg University Hospital, Aalborg, DK, Denmark|Aarhus University Hospital, Aarhus, DK, Denmark|Regional Hospital West Jutland, Hostebro, Holstebro, DK, Denmark|Regional Hospital Central Jutland, Viborg, Viborg, DK, Denmark",https://ClinicalTrials.gov/show/NCT04377425,Denmark,,6.0,2022,Thursday
3202,3203,Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes,Completed,Other: antidiabetic treatment,All,"18 Years to 85 Years   (Adult, Older Adult)",,114.0,"March 11, 2020",2020-06-30,"August 6, 2020","University of Pisa, Pisa, Italy",https://ClinicalTrials.gov/show/NCT04501991,Italy,,6.0,2020,Tuesday
3203,3204,Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19,Withdrawn,Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,0.0,April 2020,2020-10-01,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04342156,Undefined,Hydroxychloroquine Sulfate 200 milligram (mg) Tab,10.0,2020,Thursday
3204,3205,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,Completed,Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,152.0,"April 8, 2020",2020-06-08,"July 7, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",https://ClinicalTrials.gov/show/NCT04342650,Brazil,Chloroquine Diphosphate|Placebo oral tablet,6.0,2020,Monday
3205,3206,COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,700.0,"December 16, 2020",2024-12-31,"December 11, 2020","NIAAA Section on Human Psychopharmacology, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04391816,United States,,12.0,2024,Tuesday
3206,3207,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Completed,Behavioral: Ultra Brief Online Mindfulness-based Intervention|Behavioral: Control,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,161.0,"April 1, 2020",2020-06-30,"September 2, 2020","Universiti Tunku Abdul Rahman, Kampar, Perak, Malaysia",https://ClinicalTrials.gov/show/NCT04536441,Malaysia,,6.0,2020,Tuesday
3207,3208,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",Enrolling by invitation,Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2,All,"18 Years to 99 Years   (Adult, Older Adult)",,10000.0,"April 28, 2020",2021-04-01,"June 17, 2020","Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04367740,United States,,4.0,2021,Thursday
3208,3209,"Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients",Completed,,All,"18 Years and older   (Adult, Older Adult)",,77.0,"June 1, 2020",2020-08-10,"September 30, 2020","Fatih Sultan Mehmet Training and Research Hospital, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04560413,Turkey,,8.0,2020,Monday
3209,3210,Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19,Not yet recruiting,Diagnostic Test: Laboratory tests,All,"Child, Adult, Older Adult",,200.0,July 2020,2020-09-01,"July 29, 2020",,https://ClinicalTrials.gov/show/NCT04490772,Undefined,,9.0,2020,Tuesday
3210,3211,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,Recruiting,Other: Tele-medicine platform,All,"Child, Adult, Older Adult",Not Applicable,200.0,"March 31, 2020",2020-10-01,"April 1, 2020","Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania",https://ClinicalTrials.gov/show/NCT04325867,Oman,,10.0,2020,Thursday
3211,3212,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),Recruiting,,All,"Child, Adult, Older Adult",,120.0,"March 13, 2020",2021-04-13,"November 24, 2020","Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04458337,Canada,,4.0,2021,Tuesday
3212,3213,"COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff""",Recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,20000.0,"June 12, 2020",2020-12-31,"September 22, 2020","Assistance Publique - Hôpitaux de Paris, Paris, Ile De France, France",https://ClinicalTrials.gov/show/NCT04558437,France,,12.0,2020,Thursday
3213,3214,Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,Recruiting,Other: Data record,All,"18 Years and older   (Adult, Older Adult)",,300.0,"June 2, 2020",2022-03-02,"June 11, 2020","Damien JOLLY, Reims, France",https://ClinicalTrials.gov/show/NCT04356378,France,,3.0,2022,Wednesday
3214,3215,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1900.0,"March 30, 2020",2020-04-20,"May 1, 2020","University Hospital Munich (LMU Klinikum), Munich, Germany",https://ClinicalTrials.gov/show/NCT04361877,Germany,,4.0,2020,Monday
3215,3216,Experience of Orthopaedic and Spine Center Pakistan During COVID-19,Completed,Procedure: Orthopaedic Surgical Procedures,All,"18 Years to 70 Years   (Adult, Older Adult)",,2160.0,"March 19, 2020",2020-08-15,"August 18, 2020","Ghurki trust hospital, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04516824,Pakistan,,8.0,2020,Saturday
3216,3217,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Recruiting,Other: ICU Recovery + Physical Therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"May 1, 2020",2021-05-01,"June 24, 2020","University of Kentucky, Lexington, Kentucky, United States",https://ClinicalTrials.gov/show/NCT04412330,United States,,5.0,2021,Saturday
3217,3218,CT Scores Predict Mortality in 2019-nCoV Pneumonia,Completed,Other: CT score,All,"Child, Adult, Older Adult",,39.0,"January 31, 2020",2020-02-18,"February 25, 2020","Wuhan third hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04284046,China,,2.0,2020,Tuesday
3218,3219,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",Recruiting,Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab|Drug: Vitamin C|Drug: Therapeutic anticoagulation|Drug: Simvastatin|Biological: Convalescent plasma|Other: Protocolised mechanical ventilation strategy|Drug: Eritoran|Drug: Apremilast|Drug: Aspirin|Drug: Clopidogrel|Drug: Prasugrel|Drug: Ticagrelor,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100.0,"April 11, 2016",2023-12-01,"October 12, 2020","University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",https://ClinicalTrials.gov/show/NCT02735707,Australia,Fixed-duration Hydrocortisone|Shock-dependent hydrocortisone|Ceftriaxone|Moxifloxacin or Levofloxacin|Piperacillin-tazobactam|Ceftaroline|Amoxicillin-clavulanate|Macrolide administered for 3-5 days|Macrolide administered for up to 14 days|Five-days oseltamivir|Ten-days oseltamivir|Lopinavir/ritonavir|Hydroxychloroquine|Hydroxychloroquine + lopinavir/ritonavir|Interferon-β1a|Anakinra|Fixed-duration higher dose Hydrocortisone|Tocilizumab|Sarilumab|Vitamin C|Therapeutic anticoagulation|Simvastatin|Eritoran|Apremilast|Aspirin|Clopidogrel|Prasugrel|Ticagrelor,12.0,2023,Friday
3219,3220,Yoga Pranayama Adjuvant to Treat Burden COVID-19,Not yet recruiting,Behavioral: morning Yoga-based breathing support|Behavioral: pre_lunch Yoga-based breathing support|Behavioral: pre_dinner Yoga-based breathing support,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,1000.0,"August 15, 2020",2021-09-30,"August 7, 2020","Ambulatorio Telemedicina Giardino St Lucia, Massa Lombarda, Ravenna, Italy",https://ClinicalTrials.gov/show/NCT04413747,Italy,,9.0,2021,Thursday
3220,3221,The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs,Recruiting,Diagnostic Test: Physical examination,All,1 Year to 16 Years   (Child),,300.0,"October 1, 2020",2021-02-01,"November 30, 2020","Selcuk University, Konya, Selcuklu, Turkey",https://ClinicalTrials.gov/show/NCT04646525,Turkey,,2.0,2021,Monday
3221,3222,Spanish Registry of Pregnant Women With COVID-19,Recruiting,,Female,"18 Years and older   (Adult, Older Adult)",,3000.0,"March 1, 2020",2021-03-31,"September 22, 2020","Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04558996,Spain,,3.0,2021,Wednesday
3222,3223,Plasma Adsorption in Patients With Confirmed COVID-19,Recruiting,Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"May 20, 2020",2021-12-01,"August 17, 2020","UNM Health Science Center, Albuquerque, New Mexico, United States|Providence Portland Medical Center, Portland, Oregon, United States|UT Southwestern/Clements Hospital, Dallas, Texas, United States|UTMB, Galveston, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States",https://ClinicalTrials.gov/show/NCT04358003,Mexico,,12.0,2021,Wednesday
3223,3224,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Completed,Device: Intravenous access|Device: Intraosseous access,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,41.0,"January 12, 2020",2020-02-25,"April 28, 2020","Lazarski Univeristy, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04366297,Poland,,2.0,2020,Tuesday
3224,3225,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",Enrolling by invitation,Other: global survey,All,"Child, Adult, Older Adult",,1200.0,"April 2, 2020",2020-04-15,"April 14, 2020","Tor Vergata Hospital, Rome, Italy",https://ClinicalTrials.gov/show/NCT04344197,Italy,,4.0,2020,Wednesday
3225,3226,Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic,Completed,Diagnostic Test: Questionnaire forms,All,"18 Years and older   (Adult, Older Adult)",,85.0,"May 15, 2020",2020-05-31,"June 16, 2020","Sungai Buloh Hospital, Sungai Buloh, Selangor, Malaysia",https://ClinicalTrials.gov/show/NCT04362319,Malaysia,,5.0,2020,Sunday
3226,3227,CBD Oil for Reducing Emotional Impact of COVID-19,Recruiting,Dietary Supplement: CBD Isolate|Dietary Supplement: Full Spectrum CBD Oil|Dietary Supplement: Placebo Oil,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"December 4, 2020",2021-12-31,"December 8, 2020","University of Texas at Austin, Laboratory for the Study of Anxiety Disorders, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04603781,United States,,12.0,2021,Friday
3227,3228,Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"April 7, 2020",2022-04-01,"November 25, 2020","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04339790,United States,,4.0,2022,Friday
3228,3229,Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,250.0,"June 29, 2020",2020-12-31,"September 28, 2020","Eastern Colorado Veterans Affairs Health Care System, University Of Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Brigham and Women's Medical Center, Boston, Massachusetts, United States|South Shore Medical Center, Weymouth, Massachusetts, United States|Columbia Milstein and Allen Hospitals, New York, New York, United States|Penn State Hershey Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04476914,United States,,12.0,2020,Thursday
3229,3230,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),"Active, not recruiting",Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,60.0,"May 1, 2020",2021-05-31,"May 15, 2020","GENKOK, Kayseri, Melikgazi, Turkey",https://ClinicalTrials.gov/show/NCT04389385,Turkey,,5.0,2021,Monday
3230,3231,Fostamatinib for Hospitalized Adults With COVID-19,Recruiting,Drug: Placebo|Drug: fostamatinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"October 8, 2020",2020-12-15,"December 4, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|INOVA Health Systems, Falls Church, Virginia, United States",https://ClinicalTrials.gov/show/NCT04579393,United States,Placebo|fostamatinib,12.0,2020,Tuesday
3231,3232,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,15.0,"April 21, 2020",2021-04-21,"May 19, 2020","Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04394182,Spain,Lopinavir/ritonavir|Hydroxychloroquine|Azithromycin|Piperacillin/tazobactam|Low molecular weight heparin|Corticosteroid injection|Tocilizumab,4.0,2021,Wednesday
3232,3233,Mental Health Impact of the COVID-19 Pandemic Among Migrants in Chile,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1092.0,"July 3, 2020",2021-01-31,"August 4, 2020","Pontificia Universidad Catolica de Chile, Santiago, RM, Chile",https://ClinicalTrials.gov/show/NCT04497636,Chile,,1.0,2021,Sunday
3233,3234,COVID-19 and Pregnancy Outcomes,Recruiting,Diagnostic Test: RT PCR SARS-CoV-2,Female,"16 Years to 55 Years   (Child, Adult)",,300.0,"March 22, 2020",2023-12-01,"June 4, 2020","Nova Medical School - UNL, Lisbon, Portugal",https://ClinicalTrials.gov/show/NCT04416373,Portugal,,12.0,2023,Friday
3234,3235,Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study,"Active, not recruiting",Other: Training load,Male,"Child, Adult, Older Adult",,3.0,"December 15, 2019",2021-01-15,"October 26, 2020","KINÉ kinesiología deportiva y funcional, Caba, Argentina",https://ClinicalTrials.gov/show/NCT04602637,Argentina,,1.0,2021,Friday
3235,3236,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,"Active, not recruiting",Diagnostic Test: pulmonary anomalies 4 months after documented COVID-19 pneumonia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,73.0,"May 28, 2020",2022-05-01,"November 5, 2020","University Hospital of Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04422613,France,,5.0,2022,Sunday
3236,3237,COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial,Recruiting,Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,"May 8, 2020",2020-08-23,"May 27, 2020","Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation",https://ClinicalTrials.gov/show/NCT04403243,Russian Federation,Colchicine|Ruxolitinib 5 MG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX],8.0,2020,Sunday
3237,3238,A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic,Completed,"Other: Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail",All,"18 Years and older   (Adult, Older Adult)",,442.0,"February 1, 2020",2020-04-15,"May 20, 2020","Barts Health NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04375501,United Kingdom,,4.0,2020,Wednesday
3238,3239,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",Behavioral: Peer Resilience Champion|Behavioral: Enriched Survey Feedback,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,882.0,"July 27, 2020",2022-02-01,"November 5, 2020","Sinai Health System, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04373382,Canada,,2.0,2022,Tuesday
3239,3240,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Recruiting,Other: Collection of samples,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"June 16, 2020",2021-06-01,"December 3, 2020","CH Victor Dupouy, Argenteuil, France|CH Intercommunal, Créteil, France|Department of General and Digestive Surgery, Hospital René Dubos, Pontoise, France|Department of Gynecology-Obstetrics, Hospital René Dubos, Pontoise, France|CH Delafontaine, Saint-Denis, France",https://ClinicalTrials.gov/show/NCT04361396,France,,6.0,2021,Tuesday
3240,3241,Health Behavior Change During COVID-19 Pandemic,"Active, not recruiting",Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,6079.0,"March 25, 2020",2021-03-24,"August 24, 2020","the University of Melbourne, Melbourne, Australia|University of New Brunswick, Fredericton, Canada|Peking University, Beijing, China|University of Bordeaux, Bordeaux, France|London School of Hygiene and Tropical Medicine (in collaboration with MRC Unit The Gambia at LSHTM), Fajara, Gambia|Freie Universität Berlin, Berlin, Germany|Bar-Ilan University, Ramat Gan, Israel|University of Padova, Padova, Italy|Perdana University, Serdang, Malaysia|SWPS University of Social Sciences and Humanities, Wroclaw, Lower Silezia, Poland|University of Lisbon, Lisbon, Portugal|Babes-Bolyai Unversity, Cluj-Napoca, Romania|Nanyang Technological University, Singapore, Singapore|University of Zurich, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04367337,Australia,,3.0,2021,Wednesday
3241,3242,Psychological Impact of Admission With Covid-19 During the SARS-CoV-2 Pandemic: Naturalistic Cohort Study With a Digital Intervention,Not yet recruiting,Other: Feeling Good Digital App,All,"18 Years and older   (Adult, Older Adult)",,125.0,"August 31, 2020",2021-01-31,"August 28, 2020",,https://ClinicalTrials.gov/show/NCT04449627,Undefined,,1.0,2021,Sunday
3242,3243,Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device,Not yet recruiting,Device: Hemopurifier,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,October 2020,2021-08-01,"October 30, 2020","Hoag Hospital - Irvine, Irvine, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",https://ClinicalTrials.gov/show/NCT04595903,United States,,8.0,2021,Sunday
3243,3244,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,299.0,"April 13, 2020",2020-07-22,"August 7, 2020","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04327401,Brazil,Dexamethasone,7.0,2020,Wednesday
3244,3245,Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19,Not yet recruiting,Drug: Nintedanib 150 MG|Other: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,96.0,"April 2, 2020",2020-08-01,"April 8, 2020",,https://ClinicalTrials.gov/show/NCT04338802,Undefined,Nintedanib 150 MG,8.0,2020,Saturday
3245,3246,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Terminated,Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,7.0,"April 11, 2020",2020-06-08,"June 11, 2020","Montpellier University hospital, Montpellier, France",https://ClinicalTrials.gov/show/NCT04345861,France,Hydroxychloroquine + placebo|hydroxychloroquine + azithromycin,6.0,2020,Monday
3246,3247,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,Recruiting,Drug: XAV-19|Drug: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,414.0,"September 1, 2020",2021-12-01,"December 7, 2020","CHU Angers, Angers, France|Hospices Civils Lyon, Lyon, France|CHU Nantes, Nantes, France|Hôpital Saint Antoine, Paris, France",https://ClinicalTrials.gov/show/NCT04453384,France,XAV-19|Placebo,12.0,2021,Wednesday
3247,3248,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Recruiting,Drug: Canakinumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,116.0,"October 23, 2020",2023-09-01,"November 4, 2020","University Medical Clinic Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|University Hospital Geneva, Geneva, Switzerland|University Hospital Lausanne, Lausanne, Switzerland|Cantonal Hospital Lucerne, Luzern, Switzerland|Cantonal Hospital St Gallen, St. Gallen, Switzerland|University Hospital Zürich, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04510493,Switzerland,Canakinumab|Placebo,9.0,2023,Friday
3248,3249,Seroprevalence of SARS-Cov-2 Antibodies in Children,Recruiting,Diagnostic Test: Covid-19 Antibody testing (IgG and IgM),All,2 Years to 15 Years   (Child),,1000.0,"May 6, 2020",2020-12-13,"June 16, 2020","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04347408,United Kingdom,,12.0,2020,Sunday
3249,3250,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","Active, not recruiting",Biological: Gam-COVID-Vac,All,"60 Years to 111 Years   (Adult, Older Adult)",Phase 2,110.0,"October 22, 2020",2020-12-31,"November 19, 2020","Federal state budgetary institution ""Central clinical hospital with polyclinic"" Of the office Of the President of the Russian Federation, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04587219,Russian Federation,,12.0,2020,Thursday
3250,3251,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,Recruiting,Drug: Nintedanib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120.0,November 2020,2021-07-01,"November 9, 2020","Mount Sinai Beth Israel, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04619680,Israel,Nintedanib|Placebo,7.0,2021,Thursday
3251,3252,Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic,Recruiting,,All,"6 Years and older   (Child, Adult, Older Adult)",,100000.0,"April 26, 2020",2022-06-01,"May 14, 2020","Aristotle University of Thessaloniki, Thessaloníki, Greece",https://ClinicalTrials.gov/show/NCT04383470,Greece,,6.0,2022,Wednesday
3252,3253,Serology to Covid for Recording Exposures and Evaluating Needs,Recruiting,Diagnostic Test: SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,230.0,"August 18, 2020",2023-12-31,"September 28, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04566965,United States,,12.0,2023,Sunday
3253,3254,"Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas",Recruiting,Other: MRI,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 20, 2020",2021-11-20,"December 7, 2020","Fondation A De Rothschild, Paris, France",https://ClinicalTrials.gov/show/NCT04448054,France,,11.0,2021,Saturday
3254,3255,Remdesivir in COVID-19 Lahore General Hospital,Recruiting,Drug: Remdesivir,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,30.0,"June 1, 2020",2020-11-30,"September 25, 2020","Muhammad Irfan Malik, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04560231,Mali,Remdesivir,11.0,2020,Monday
3255,3256,Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,400.0,"May 1, 2020",2021-03-01,"December 10, 2020","Egypt, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04613245,Egypt,,3.0,2021,Monday
3256,3257,COVID-19 Quarantine on Musculoskeletal Status in Hemophilia,Recruiting,Other: Observational,Male,"18 Years to 65 Years   (Adult, Older Adult)",,27.0,"July 1, 2020",2020-07-29,"July 29, 2020","European University of Madrid, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04491318,Spain,,7.0,2020,Wednesday
3257,3258,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Drug: Bevacizumab Injection,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,27.0,"February 15, 2020",2020-05-02,"September 14, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy",https://ClinicalTrials.gov/show/NCT04275414,China,Bevacizumab Injection,5.0,2020,Saturday
3258,3259,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",Recruiting,Diagnostic Test: COVID 19 diagnostic test by PCR,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,3600.0,"April 17, 2020",2022-04-01,"April 24, 2020","University Hospital of Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04360811,France,,4.0,2022,Friday
3259,3260,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,Procedure: Therapeutic Plasma Exchange,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,280.0,"April 1, 2020",2020-07-31,"September 28, 2020","Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04485169,Pakistan,,7.0,2020,Friday
3260,3261,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,Recruiting,Biological: Otilimab|Biological: Placebo|Drug: Standard of care,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,800.0,"May 28, 2020",2020-12-21,"November 17, 2020","GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Loma Linda, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Winfield, Illinois, United States|GSK Investigational Site, Portland, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Germantown, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Doylestown, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Roanoke, Virginia, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Munro, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Yvoir, Belgium|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Montréal, Quebec, Canada|GSK Investigational Site, QC, Quebec, Canada|GSK Investigational Site, St-Jerome, Quebec, Canada|GSK Investigational Site, Talca, Región Del Maule, Chile|GSK Investigational Site, Quillota, Valparaíso, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Amiens Cedex 1, France|GSK Investigational Site, Angers Cedex 9, France|GSK Investigational Site, Argenteuil, France|GSK Investigational Site, Ars-Laquenexy, France|GSK Investigational Site, La Roche-Sur-Yon, France|GSK Investigational Site, La Tronche, France|GSK Investigational Site, Limoges Cedex, France|GSK Investigational Site, Melun, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pierre-Bénite, France|GSK Investigational Site, Strasbourg cedex, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Valenciennes Cedex, France|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Mexico City, Ciudad De Mexico, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, DF, Mexico|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Den Bosch, Netherlands|GSK Investigational Site, Enschede, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Ufa, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Benoni, Gauteng, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Middelburg, Mpumalanga, South Africa|GSK Investigational Site, Muckleneuk Pretoria, South Africa|GSK Investigational Site, Panorama,, South Africa|GSK Investigational Site, Tygerberg, South Africa|GSK Investigational Site, Worcester, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Logroño, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, San Sebastián De Los Reyes/Madrid, Spain|GSK Investigational Site, Manchester, Greater Manchester, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Middlesbrough, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT04376684,Argentina,Standard of care,12.0,2020,Monday
3261,3262,"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",Completed,Behavioral: Telephonic interview during the Italian lockdown.,All,"18 Years to 65 Years   (Adult, Older Adult)",,116.0,"March 9, 2020",2020-05-30,"July 1, 2020","Michela Campanelli, Rome, RM, Italy",https://ClinicalTrials.gov/show/NCT04453579,Italy,,5.0,2020,Saturday
3262,3263,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,Enrolling by invitation,Behavioral: Cognitive Behavioral Brief-Telepsychotherapy|Behavioral: Brief Interpersonal Telepsychotherapy|Behavioral: Telepsychoeducation,All,"Child, Adult, Older Adult",Not Applicable,999.0,"November 5, 2020",2021-07-20,"November 19, 2020","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04635618,Brazil,,7.0,2021,Tuesday
3263,3264,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Recruiting,Procedure: Awake Prone Positioning|Procedure: Standard care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,346.0,"May 15, 2020",2020-12-31,"August 11, 2020","Hôpital de Verdun, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04395144,Canada,,12.0,2020,Thursday
3264,3265,Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"June 23, 2020",2020-09-23,"June 30, 2020","Service Unité Neurovasculaire, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04452422,France,,9.0,2020,Wednesday
3265,3266,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Not yet recruiting,Behavioral: Phone-call screening and management by a medical student/general practitioner tandem,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,22000.0,April 2020,2020-12-01,"April 24, 2020","Dibao-Dina, Tours, France",https://ClinicalTrials.gov/show/NCT04359875,France,,12.0,2020,Tuesday
3266,3267,Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure,Recruiting,Other: Maternal stress,All,up to 12 Months   (Child),,600.0,"May 6, 2020",2023-05-31,"September 7, 2020","IRCCS Mondino Foundation, Pavia, PV, Italy",https://ClinicalTrials.gov/show/NCT04540029,Italy,,5.0,2023,Wednesday
3267,3268,"Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients",Recruiting,Genetic: COVID-19 Diagnostic and Assessment Tests,All,"18 Years to 80 Years   (Adult, Older Adult)",,40.0,"October 4, 2020",2022-10-03,"October 14, 2020","Tanta University Hospital, Tanta, El Gharbia, Egypt|Center of Excellence in Cancer Research, Tanta University Hospital., Tanta, Gharbia, Egypt",https://ClinicalTrials.gov/show/NCT04583566,Egypt,,10.0,2022,Monday
3268,3269,Tele-health Enabled Clinical Trial for COVID-19,Not yet recruiting,Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,110.0,"August 1, 2020",2021-08-01,"July 31, 2020","Northwestern University, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04489628,United States,Vitamin D3 or Placebo,8.0,2021,Sunday
3269,3270,"SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)",Recruiting,Procedure: blood sample for seroepidemiological investigation,All,"18 Years and older   (Adult, Older Adult)",,300.0,"July 15, 2020",2021-01-15,"August 4, 2020","IRCCS San Raffaele, Milan, Italy",https://ClinicalTrials.gov/show/NCT04487197,Italy,,1.0,2021,Friday
3270,3271,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns",Recruiting,Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,2200.0,"May 4, 2020",2021-08-31,"September 9, 2020","Tsastaris Vassillis, Paris, France",https://ClinicalTrials.gov/show/NCT04355234,France,,8.0,2021,Tuesday
3271,3272,High Flow Nasal Cannula HFNC In Covid-19 Patients,Recruiting,Device: High flow nasal cannula HFNC,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,"May 1, 2020",2020-12-30,"December 8, 2020","Muhammad Irfan Malik, Lahore, Punjab, Pakistan",https://ClinicalTrials.gov/show/NCT04560257,Mali,,12.0,2020,Wednesday
3272,3273,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,Completed,Diagnostic Test: Respiratory mechanics measurement|Diagnostic Test: Gas exchange measurement,All,"18 Years to 90 Years   (Adult, Older Adult)",,117.0,"May 1, 2020",2020-08-14,"August 27, 2020","Sechenov University Clinic #1, Moscow, Russian Federation|Sechenov University Clinic #3, Moscow, Russian Federation|Sechenov University Clinic #4, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04445961,Russian Federation,,8.0,2020,Friday
3273,3274,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,Drug: Methylprednisolone|Other: standard care,All,"18 Years to 80 Years   (Adult, Older Adult)",,173.0,"March 23, 2020",2020-05-10,"June 24, 2020","Marco Confalonieri, Trieste, TS, Italy",https://ClinicalTrials.gov/show/NCT04323592,Italy,Methylprednisolone,5.0,2020,Sunday
3274,3275,The Global PCHF-COVICAV Registry,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"April 30, 2020",2021-07-01,"May 15, 2020","Zurich Heart Center, Unispital Zurich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04390555,Switzerland,,7.0,2021,Thursday
3275,3276,COVID-19 Health Messaging to Underserved Communities,Completed,Behavioral: Messaging,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15475.0,"May 13, 2020",2020-05-24,"June 19, 2020","JPAL North America, Cambridge, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04371419,United States,,5.0,2020,Sunday
3276,3277,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,Recruiting,Behavioral: Intervention program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,102.0,"May 25, 2020",2021-03-25,"July 14, 2020","Tomás Cuñat, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04394169,Spain,,3.0,2021,Thursday
3277,3278,PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis,Completed,,All,"Child, Adult, Older Adult",,661.0,"August 13, 2020",2020-10-06,"October 8, 2020","Dermatrials Research, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04513847,Canada,,10.0,2020,Tuesday
3278,3279,Short Term Corticosteroids in SARS-CoV2 Patients,Completed,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 1, 2020",2020-05-31,"June 24, 2020","The Miriam Hospital, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04445506,United States,Dexamethasone,5.0,2020,Sunday
3279,3280,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,"Active, not recruiting",Behavioral: eHealth +counselling contacts|Behavioral: eHealth|Behavioral: Usual care,All,"20 Years to 69 Years   (Adult, Older Adult)",Not Applicable,122.0,"March 6, 2019",2020-10-31,"October 14, 2020","North Karelia Hospital District, Joensuu, Finland",https://ClinicalTrials.gov/show/NCT04587414,Finland,,10.0,2020,Saturday
3280,3281,Cardiovascular Manifestations of COVID-19,Recruiting,"Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values",All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 30, 2020",2022-03-01,"April 7, 2020","Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04335630,United States,,3.0,2022,Tuesday
3281,3282,COVID-19 in People With Primary Ciliary Dyskinesia,Recruiting,,All,"Child, Adult, Older Adult",,1000.0,"May 31, 2020",2025-05-31,"October 26, 2020","Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04602481,Switzerland,,5.0,2025,Saturday
3282,3283,"Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients",Completed,Other: Practice details,All,"18 Years to 90 Years   (Adult, Older Adult)",,644.0,"May 4, 2020",2020-05-18,"June 22, 2020","IRCCS San Raffaele, Milano, Italy",https://ClinicalTrials.gov/show/NCT04377776,Italy,,5.0,2020,Monday
3283,3284,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Recruiting,Drug: Povidone-Iodine|Drug: Normal saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,May 2020,2020-08-01,"May 19, 2020","Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04393792,United Kingdom,Povidone-Iodine|Normal saline,8.0,2020,Saturday
3284,3285,"General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19",Not yet recruiting,Behavioral: Medical Music|Behavioral: Narrative Writing|Behavioral: Prolonged Exposure Therapy|Behavioral: Interpersonal Psychotherapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,November 2020,2021-09-01,"November 12, 2020","Weill Cornell Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04626050,United States,,9.0,2021,Wednesday
3285,3286,"Simple, Safe, Same: Lung Ultrasound for COVID-19",Recruiting,Diagnostic Test: Lung ultrasound,All,"Child, Adult, Older Adult",,100.0,"April 8, 2020",2021-01-15,"April 17, 2020","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy",https://ClinicalTrials.gov/show/NCT04322487,Italy,,1.0,2021,Friday
3286,3287,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,Not yet recruiting,Drug: CM4620-IE (Injectable Emulsion)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36.0,December 2020,2021-04-01,"December 10, 2020","Northwestern Memorial Hospital, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04661540,United States,CM4620-IE (Injectable Emulsion)|Placebo,4.0,2021,Thursday
3287,3288,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Drug: Auxora|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"April 8, 2020",2021-04-01,"November 23, 2020","Long Beach Memorial, Long Beach, California, United States|University of Southern California / LA County, Los Angeles, California, United States|Sharp Memorial San Diego, San Diego, California, United States|Baton Rouge General, Baton Rouge, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai Grace, Detroit, Michigan, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Texas Tech University Medical Center, El Paso, Texas, United States|John Peter Smith Hospital, Fort Worth, Texas, United States|Ben Taub (Baylor), Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital San Cristobal, Ponce, Puerto Rico",https://ClinicalTrials.gov/show/NCT04345614,Puerto Rico,Auxora|Placebo,4.0,2021,Thursday
3288,3289,GERAS Frailty Rehabilitation at Home During COVID-19,Recruiting,Behavioral: Socialization|Behavioral: Virtual Group Exercise|Combination Product: Nutrition Consult and Protein Supplementation|Behavioral: Medication Review,All,65 Years and older   (Older Adult),Not Applicable,70.0,"August 26, 2020",2021-05-01,"November 10, 2020","McMaster University - Hamilton Health Sciences (St. Peter's Site), Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04500366,Canada,,5.0,2021,Saturday
3289,3290,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Recruiting,Drug: Dornase Alfa Inhalation Solution,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20.0,"June 19, 2020",2022-05-31,"June 26, 2020","University of Missouri Hospital and Clinics, Columbia, Missouri, United States",https://ClinicalTrials.gov/show/NCT04402970,United States,Dornase Alfa Inhalation Solution,5.0,2022,Tuesday
3290,3291,Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic,Recruiting,,All,"24 Years to 80 Years   (Adult, Older Adult)",,310.0,"June 27, 2020",2020-10-01,"August 5, 2020","Dokuz Eylul University, Izmir, Turkey",https://ClinicalTrials.gov/show/NCT04500652,Turkey,,10.0,2020,Thursday
3291,3292,COVID-19 and the Healthy Minds Program for Educators,Recruiting,Behavioral: Healthy Minds Program Foundations Training,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"June 14, 2020",2022-06-30,"November 27, 2020","University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04426318,United States,,6.0,2022,Thursday
3292,3293,W-SUDs for COVID-19,Recruiting,Other: Woebot Substance Use Disorder,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,160.0,"June 22, 2020",2020-08-31,"August 17, 2020","Stanford University, Palo Alto, California, United States",https://ClinicalTrials.gov/show/NCT04460027,United States,,8.0,2020,Monday
3293,3294,French Single Centre Experience of Critically Ill Patients With Covid 19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"July 1, 2020",2021-08-01,"September 11, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04354558,France,,8.0,2021,Sunday
3294,3295,COVID-19 Related Lockdown Effects On Chronic Diseases,"Active, not recruiting",Other: life questionnaires|Other: questionnaire,All,"4 Years and older   (Child, Adult, Older Adult)",,1200.0,"April 20, 2020",2021-11-07,"June 16, 2020","CHU Dijon Bourgogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04390126,France,,11.0,2021,Sunday
3295,3296,Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis,Not yet recruiting,Drug: hydroxychloroquine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,93.0,"October 27, 2020",2021-01-31,"October 22, 2020",,https://ClinicalTrials.gov/show/NCT04597775,Undefined,hydroxychloroquine,1.0,2021,Sunday
3296,3297,Insomnia After the COVID-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04443361,Undefined,,7.0,2020,Monday
3297,3298,Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.,Recruiting,Diagnostic Test: Thoracic CT Scan,All,"18 Years to 100 Years   (Adult, Older Adult)",,56000.0,"April 20, 2020",2020-11-01,"April 28, 2020","Chu de Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04339686,France,,11.0,2020,Sunday
3298,3299,Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19,Completed,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,27.0,"July 14, 2020",2020-10-24,"December 3, 2020","Institute of Sports Medicine, Prevention and Rehabilitation, Salzburg, Austria",https://ClinicalTrials.gov/show/NCT04501432,Austria,,10.0,2020,Saturday
3299,3300,Serological Diagnostics of COVID-19 in Health Care Workers,Not yet recruiting,Diagnostic Test: SARS-CoV2 nasal swab,All,"18 Years to 70 Years   (Adult, Older Adult)",,300.0,November 2020,2021-01-31,"November 20, 2020","University Medical Centre Ljubljana, Ljubljana, Slovenia",https://ClinicalTrials.gov/show/NCT04635592,Slovenia,,1.0,2021,Sunday
3300,3301,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,Behavioral: Emotion Regulation Training via Telehealth,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 1, 2020",2023-01-01,"November 4, 2020","Teachers College, Columbia University, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04615416,United States,,1.0,2023,Sunday
3301,3302,Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS),Recruiting,,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",,300.0,"May 1, 2020",2024-05-01,"August 6, 2020","Region Skåne, Lund, Skåne Län, Sweden",https://ClinicalTrials.gov/show/NCT04503057,Sweden,,5.0,2024,Wednesday
3302,3303,Italian Web-based Cross-sectional Survey on COVID-19,Recruiting,Behavioral: Environmental exposure and clinical features,All,"18 Years and older   (Adult, Older Adult)",,200000.0,"April 13, 2020",2020-08-31,"July 16, 2020","Institute of Biomedical Technologies-National Research Council, Segrate, MI, Italy",https://ClinicalTrials.gov/show/NCT04471701,Italy,,8.0,2020,Monday
3303,3304,Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,Recruiting,Other: Observation only,All,"18 Years and older   (Adult, Older Adult)",,105.0,"April 23, 2020",2020-12-01,"May 11, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04379544,United States,,12.0,2020,Tuesday
3304,3305,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Recruiting,Procedure: Direct laryngoscopy|Procedure: Vie Scope laryngoscopy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"March 20, 2020",2020-05-20,"April 29, 2020","Emergency Medical Service, Poznan, Poland|Emergency Medical Service, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04365608,Poland,,5.0,2020,Wednesday
3305,3306,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,Enrolling by invitation,Behavioral: Telepsychoeducation with personalized videos|Behavioral: Telepsychoeducation without personalized videos,All,"Child, Adult, Older Adult",Not Applicable,2200.0,"November 5, 2020",2021-07-20,"November 20, 2020","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04632082,Brazil,,7.0,2021,Tuesday
3306,3307,COVID-19-Related Health and Practices Among Dental Hygienists,Not yet recruiting,Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,5000.0,September 2020,2021-10-01,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04542915,Undefined,,10.0,2021,Friday
3307,3308,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,Not yet recruiting,Device: MejoraCare,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,96.0,"December 9, 2020",2021-12-09,"December 11, 2020","Hospital Regional de Encarnación, Encarnación, Itapúa, Paraguay",https://ClinicalTrials.gov/show/NCT04659746,Paraguay,,12.0,2021,Thursday
3308,3309,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Drug: Lopinavir/ritonavir,All,"18 Months and older   (Child, Adult, Older Adult)",Phase 3,1220.0,"April 17, 2020",2022-03-31,"April 21, 2020","St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04321174,Canada,Lopinavir/ritonavir,3.0,2022,Thursday
3309,3310,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,602.0,"May 13, 2020",2021-11-01,"November 23, 2020","Amiens Academic Hospital, Amiens, France|Besançon Academic Hospital, Besançon, France|Brest Academic Hospital, Brest, France|Civil Hospital, Colmar, France|Dijon Academic Hospital, Dijon, France|Kremlin Bicêtre Academic Hospital, Le Kremlin-Bicêtre, France|Lille Academic Hospital, Lille, France|Groupe Hospitalier Unéos, Metz, France|Metz-Thionville Regional Hospital, Metz, France|Montpellier Academic Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy Academic Hospital, Nancy, France|George Pompidou European Hospital, Paris, France|Lariboisière Academic Hospital, Paris, France|St Etienne Academic Hospital, Saint-Étienne, France|Strasbourg Academic Hospital, Strasbourg, France|Toulouse Academic Hospital, Toulouse, France",https://ClinicalTrials.gov/show/NCT04373707,France,Enoxaparin,11.0,2021,Monday
3310,3311,Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period,Recruiting,,Female,18 Years to 43 Years   (Adult),,700.0,"May 20, 2020",2020-07-01,"June 11, 2020","Service Clinico biologique d'Assistance Médicale à La Procréation, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04415359,France,,7.0,2020,Wednesday
3311,3312,Assocation Between In-person Instruction and COVID-19 Risk,Not yet recruiting,Behavioral: Online instruction|Behavioral: In-person instruction,All,"18 Years and older   (Adult, Older Adult)",,70000.0,September 2020,2020-12-01,"September 1, 2020","Oslo Metropolitan University, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04529421,Norway,,12.0,2020,Tuesday
3312,3313,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,Diagnostic Test: COPAN swabbing and blood sample collection,All,"18 Years and older   (Adult, Older Adult)",,400.0,"March 18, 2020",2021-12-31,"May 21, 2020","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04318314,United Kingdom,,12.0,2021,Friday
3313,3314,Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia,"Active, not recruiting",Other: Telephone interview,All,"55 Years and older   (Adult, Older Adult)",,200.0,"May 4, 2020",2020-12-31,"December 4, 2020","Instituto de Investigacion Biomedica de Malaga-IBIMA, Málaga, Spain",https://ClinicalTrials.gov/show/NCT04385797,Spain,,12.0,2020,Thursday
3314,3315,Serology COVID-19 From the Cornwall Hospital Union,Completed,Biological: Serological test|Biological: Serum test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2587.0,"May 4, 2020",2020-11-16,"December 10, 2020","CH de Cornouaille, Quimper, France",https://ClinicalTrials.gov/show/NCT04363593,France,,11.0,2020,Monday
3315,3316,Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;,Recruiting,Other: quesionnair,All,18 Years to 60 Years   (Adult),,874.0,"April 1, 2020",2020-08-01,"June 2, 2020","Assiut, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04351568,Egypt,,8.0,2020,Saturday
3316,3317,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,Not yet recruiting,Drug: Immunoglobulin of cured patients|Drug: γ-Globulin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"March 17, 2020",2020-05-31,"March 17, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04264858,China,Immunoglobulin of cured patients|γ-Globulin,5.0,2020,Sunday
3317,3318,Health cAre woRkers exposeD to COVID-19,Recruiting,Behavioral: EMDR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,900.0,"November 20, 2020",2022-08-20,"November 24, 2020","Centre Investigation Clinique 1415, Tours, Centre Val De Loire, France|Bretonneau Regional Universitary Hospital, Tours, France",https://ClinicalTrials.gov/show/NCT04570202,France,,8.0,2022,Saturday
3318,3319,COVID-19 - Implications on Surgeons' Burnout and Career Satisfaction,Not yet recruiting,Other: Questionnaire,All,"Child, Adult, Older Adult",,1000.0,"June 15, 2020",2020-08-31,"June 16, 2020","Faculty of Medicine Mansoura University, Mansoura, Egypt",https://ClinicalTrials.gov/show/NCT04433286,Egypt,,8.0,2020,Monday
3319,3320,Provider Burnout During COVID-19,Recruiting,Behavioral: Coping strategies video,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250.0,"April 29, 2020",2020-10-29,"May 1, 2020","UPMC, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04370938,United States,,10.0,2020,Thursday
3320,3321,Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis,Not yet recruiting,Biological: MMR vaccine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,60.0,"August 17, 2020",2021-12-01,"July 20, 2020",,https://ClinicalTrials.gov/show/NCT04475081,Undefined,,12.0,2021,Wednesday
3321,3322,Perceived Stress Among ICU Medical Staff During COVID-19 Crisis,Completed,,All,"18 Years and older   (Adult, Older Adult)",,60.0,"June 26, 2019",2020-09-01,"October 27, 2020","University of Liège, Liège, Province De Liège, Belgium",https://ClinicalTrials.gov/show/NCT04604769,Belgium,,9.0,2020,Tuesday
3322,3323,Neuro-COVID-19: Neurological Complications of COVID-19,Recruiting,Other: further processing of health data,All,"18 Years and older   (Adult, Older Adult)",,30.0,"May 1, 2020",2022-05-30,"June 5, 2020","University Hospital Zurich, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04418609,Switzerland,,5.0,2022,Monday
3323,3324,Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry,Completed,Behavioral: Questionnaires,All,7 Years to 12 Years   (Child),,247.0,"May 4, 2020",2020-06-04,"July 2, 2020","Centre Hospitalier René Dubos, Pontoise, France",https://ClinicalTrials.gov/show/NCT04370210,France,,6.0,2020,Thursday
3324,3325,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Recruiting,Drug: Colchicine|Drug: Interferon-Beta|Drug: Aspirin|Drug: Rivaroxaban,All,"18 Years and older   (Adult, Older Adult)",Phase 3,4000.0,"April 21, 2020",2021-06-30,"October 8, 2020","Prodal Saude S/A, Salvador, BA, Brazil|Hospital das Clinicas de Vitoria (Hospital Universitario Cassiano Antonio Moraes), Vitoria, ES, Brazil|Hospital das Clinicas da Universidade Federal de Goias, Goiania, GO, Brazil|Ubermed Serviços em Saúde Eireli - Hospital São Domingos, Uberaba, MG, Brazil|Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, MG, Brazil|Hospital Universitario Julio Muller, Cuiabá, Mount, Brazil|Hospital Universitario da UFPI - Filial EBSERH, Teresina, PI, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, Brazil|Hospital Universitario Prof. Dr. Horacio Carlos Panepucci da Universidade Federal de Sao Carlos (HU-UFSCar), São Carlos, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital de Doencas Tropicais - HDT/UFT, Araguaina, TO, Brazil|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|CIUSSS de L'est-de-l'ile de Montreal, Hopital Maisonneuve-Rosemont, Montreal, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|Halton Healthcare/Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada|Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada|Toronto Western Hospital Family Health Team, Toronto, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Woodstock Hospital, Woodstock, Ontario, Canada|Estudios Clinicos Barros Luco Spa, Santiago, Region Metropolitana, Chile|Hospital El Pino, Santiago, Region Metropolitana, Chile|Biomelab SAS, Barranquilla, Atlantico, Colombia|Clinica de la Costa LTDA, Barranquilla, Atlantico, Colombia|Hospital Universidad del Norte, Barranquilla, Atlantico, Colombia|Centro de Diagnostico Cardiologico, Cartagena, Bolivar, Colombia|Clinica de Marly - Sede UniMarly, Bogota, Cundinamarca, Colombia|Fundacion Cometa, Pasto, Narino, Colombia|Fundacion Cardiomet CEQUIN, Armenia, Quindio, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Bucaramanga, Santander, Colombia|Fundacion Centro de Investigaciones Biomedicas Riescard, El Espinal, Tolima, Colombia|Clinica Internacional La Misericordia, Barranquilla, Colombia|Unicormed, Guayaquil, Guayas, Ecuador|Hospital de Especialidades Eugenio Espejo, Quito, Pichincha, Ecuador|Hospital Enrique Garces, Quito, Pichincha, Ecuador|Hospital General Docente de Calderon, Quito, Pichincha, Ecuador|Hospital General Pablo Arturo Suarez, Quito, Pichincha, Ecuador|Giza Chest Hospital, Giza, Cairo, Egypt|Al Rajhi University Hospital, Assiut, Egypt|Abbasia Chest Hospital, Cairo, Egypt|Abbasia Fever Hospital, Cairo, Egypt|National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt|Fayoum General Hospital, Fayoum, Egypt|Fayoum University Hospital, Fayoum, Egypt|CIMS Hospital, Ahmedabad, Gujarat, India|City Plus Hospital, Ahmedabad, Gujarat, India|Sanjivani Hospital, Ahmedabad, Gujarat, India|GMERS Medical College & Hospital, Vadodara, Gujarat, India|Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India|Mazumdar Shaw Medical Centre a Unit of Narayana, Bangalore, Karnataka, India|Bharathi Hospital and Research Center, Pune, Maharashtra, India|Sidhu Hospital Pvt.Ltd, Doraha, Punjab, India|Vijaya Medical & Educational Trust, Chennai, Tamil Nadu, India|SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India|AIG Hospital, Hyderabad, Telangana, India|KIMS, Hyderabad, Telangana, India|Mahavir Hospital & Research Centre, Hyderabad, Telangana, India|Jinnah Postgraduate Medical Center, Karachi, Pakistan|Tabba Heart Institute, Karachi, Pakistan|Philippine General Hospital, Manila, Metro Manila, Philippines|Altai Regional Center for Medical Prevention, Barnaul, Russian Federation|Altai Regional Hospital for War Veterans, Barnaul, Russian Federation|City Clinical Hospital No. 15 named after O.M. Filatova, Moscow, Russian Federation|National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital No. 10, Nizhny Novgorod, Russian Federation|City Clinical Hospital No. 3, Nizhny Novgorod, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|King Saud Medical City, Riyadh, Saudi Arabia|Thumbay Hospital Dubai, Al Qusais, Dubai, United Arab Emirates|Hatta Hospital, Hatta, Dubai, United Arab Emirates|Rashid Hospital, Dubai Health Authority, Umm Hurair, Dubai, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04324463,Armenia,Colchicine|Interferon-Beta|Aspirin|Rivaroxaban,6.0,2021,Wednesday
3325,3326,"Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",Enrolling by invitation,Other: Online survey,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"April 1, 2020",2020-11-30,"October 29, 2020","Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina|Pontificia Universidad Católica de Chile, Santiago, Chile|Universidad de Santander, Bucaramanga, Santander, Colombia|Universidad Católica de Santiago de Guayaquil, Guayaquil, Guayas, Ecuador|Universidad Miguel Hernández de Elche, Elche, Alicante, Spain",https://ClinicalTrials.gov/show/NCT04486404,Argentina,,11.0,2020,Monday
3326,3327,ARDS Caused by COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 12, 2020",2020-12-31,"April 30, 2020","Ricard Mellado, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04368975,Spain,,12.0,2020,Thursday
3327,3328,Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,400.0,"May 1, 2020",2021-03-01,"September 10, 2020","UZ Brussel, Brussel, Belgium",https://ClinicalTrials.gov/show/NCT04544072,Belgium,,3.0,2021,Monday
3328,3329,Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuébec Sub-study,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,2465.0,"April 16, 2020",2020-05-07,"May 1, 2020","Université Laval, Québec, Canada",https://ClinicalTrials.gov/show/NCT04371848,Canada,,5.0,2020,Thursday
3329,3330,Active Pregnancy Against COVID-19,Recruiting,Other: Exercise program|Other: Healthy lifestyle advise,Female,18 Years to 50 Years   (Adult),Not Applicable,280.0,"August 1, 2020",2023-12-31,"September 28, 2020","Facultad de Ciencias de la Actividad Física y el Deporte (INEF), Madrid, Spain|Facultad de Ciencias de la Actividad Física y el Deporte - INEF, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04563065,Spain,,12.0,2023,Sunday
3330,3331,"The Psychological, Social, and Economic Impacts of COVID-19",Recruiting,,All,"12 Years and older   (Child, Adult, Older Adult)",,1000.0,"April 3, 2020",2021-04-03,"April 30, 2020","Southlake Regional Health Centre, Newmarket, Ontario, Canada|CHEO Research Institute, Ottawa, Ontario, Canada|The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|The Centre for Addiction and Mental Health, Ottawa, Ontario, Canada|The University of Ottawa Heart Institute, Ottawa, Ontario, Canada|The Royal's Institute of Mental Health Research, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hôpital en santé mentale Rivière-des-Prairies (CIUSSS du Nord-de-l'Île-de-Montréal), Montréal, Quebec, Canada|McGill University, Montréal, Quebec, Canada|University of Montréal, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04369690,Canada,,4.0,2021,Saturday
3331,3332,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,Recruiting,Other: Assembled mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"July 15, 2020",2025-05-01,"July 1, 2020","Oklahoma City VA Health Care System, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT04416919,United States,,5.0,2025,Thursday
3332,3333,Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak,Completed,,All,"18 Years and older   (Adult, Older Adult)",,1778.0,"March 31, 2020",2020-04-07,"May 6, 2020","University of Oslo, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04374097,Norway,,4.0,2020,Tuesday
3333,3334,Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers,Not yet recruiting,,All,"18 Years to 65 Years   (Adult, Older Adult)",,2700.0,"January 31, 2021",2023-12-31,"November 23, 2020","Cambodian Center for Communicable Disease (CCDC), Ministry of Health (MOH), Phnom Penh, Cambodia|National Malaria Center (CNM), Ministry of Health (MOH), Phnom Penh, Cambodia",https://ClinicalTrials.gov/show/NCT04594395,Cambodia,,12.0,2023,Sunday
3334,3335,Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety,Completed,,All,"18 Years and older   (Adult, Older Adult)",,2880.0,"March 31, 2020",2020-04-07,"May 6, 2020","University of Oslo, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04377074,Norway,,4.0,2020,Tuesday
3335,3336,Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer,Recruiting,Other: Data record,All,"18 Years and older   (Adult, Older Adult)",,700.0,"April 1, 2020",2022-04-01,"May 28, 2020","Damien JOLLY, Reims, France",https://ClinicalTrials.gov/show/NCT04406571,France,,4.0,2022,Friday
3336,3337,"Behavior, Environment And Treatments for Covid-19",Recruiting,"Other: Observation of patients with known, suspected, or at risk for COVID-19 infection",All,"18 Years and older   (Adult, Older Adult)",,100000.0,"March 21, 2020",2022-03-20,"April 2, 2020","BEAT19.org, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04321811,United States,,3.0,2022,Sunday
3337,3338,The COVID-19 and Healthcare Workers: An Active Intervention,Recruiting,Other: Video-Based intervention,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1200.0,"October 21, 2020",2021-01-30,"October 23, 2020","New York State Psychiatric Institute, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04497415,United States,,1.0,2021,Saturday
3338,3339,Addressing COVID-19 Mental Health Problems Among US Veterans,Recruiting,Other: A short video intervention|Other: A vignette intervention,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200.0,"July 6, 2020",2020-10-26,"October 14, 2020","New York State Psychiatric Institute, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04484207,United States,,10.0,2020,Monday
3339,3340,Physical Activity in University Students Around COVID-19 Confinement,Recruiting,Other: On-Line Survey,All,"Child, Adult, Older Adult",,25000.0,"April 16, 2020",2020-10-20,"July 27, 2020","Basque Country University (UPV-EHU),, Bilbao, Bizkaia, Spain",https://ClinicalTrials.gov/show/NCT04361019,Spain,,10.0,2020,Tuesday
3340,3341,COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry,Not yet recruiting,Other: Transthoracic echocardiogram (TTE)|Other: Cardiovascular Magnetic Resonance (CMR) Imaging,All,"18 Years and older   (Adult, Older Adult)",,70.0,December 2020,2022-09-30,"December 10, 2020","Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04661657,United States,,9.0,2022,Friday
3341,3342,COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases,Recruiting,Other: COVID-19 infection,All,"18 Years and older   (Adult, Older Adult)",,333.0,"April 23, 2020",2021-09-01,"May 29, 2020","Aalborg University Hospital, Aalborg, Denmark",https://ClinicalTrials.gov/show/NCT04335747,Denmark,,9.0,2021,Wednesday
3342,3343,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Completed,Other: Exercise Group,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,170.0,"April 1, 2020",2020-06-10,"July 1, 2020","Clinical Exercise Physiology and Rehabilitation Laboratory, Lamia, Sterea Ellada, Greece",https://ClinicalTrials.gov/show/NCT04381000,Greece,,6.0,2020,Wednesday
3343,3344,Reducing Burnout Among Frontline Healthcare Workers During COVID-19,Not yet recruiting,Behavioral: Virtual Peer Support Platform|Behavioral: Control Period,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1080.0,"January 15, 2021",2021-07-01,"October 22, 2020","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04474080,Canada,,7.0,2021,Thursday
3344,3345,Determinants of COVID-19 Pneumonia (MC-19),Completed,Diagnostic Test: Serology for Covid-19,All,"18 Years to 100 Years   (Adult, Older Adult)",,520.0,"May 13, 2020",2020-06-17,"June 19, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",https://ClinicalTrials.gov/show/NCT04387799,Italy,,6.0,2020,Wednesday
3345,3346,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,Recruiting,Diagnostic Test: Testing of SARS-CoV-2 antibodies,All,"18 Years and older   (Adult, Older Adult)",,800.0,"August 6, 2020",2021-12-01,"August 4, 2020","VU medical center, Amsterdam, Netherlands",https://ClinicalTrials.gov/show/NCT04498286,Netherlands,,12.0,2021,Wednesday
3346,3347,"Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic",Completed,Other: Survey administration,All,"18 Years and older   (Adult, Older Adult)",,394.0,"March 30, 2020",2020-09-18,"September 25, 2020","University Hospital Gent, Gent, Belgium",https://ClinicalTrials.gov/show/NCT04340219,Belgium,,9.0,2020,Friday
3347,3348,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),Not yet recruiting,Behavioral: Simulation Intervention|Behavioral: Control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84.0,"December 15, 2020",2022-11-15,"December 2, 2020","Yale New Haven Hospital, New Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04614844,United States,,11.0,2022,Tuesday
3348,3349,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,Other: specific exercise rehabilitation treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 7, 2020",2022-05-07,"September 29, 2020","Groupe Hospitalier Paris Saint Joseph, Paris, Ile-de-France, France",https://ClinicalTrials.gov/show/NCT04569266,France,,5.0,2022,Saturday
3349,3350,Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM),Not yet recruiting,Drug: Hydroxychloroquine Only Product in Oral Dose Form,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1930.0,September 2020,2021-04-01,"September 29, 2020",,https://ClinicalTrials.gov/show/NCT04400019,Undefined,Hydroxychloroquine Only Product in Oral Dose Form,4.0,2021,Thursday
3350,3351,Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic,Recruiting,Other: Pandemic control measures,Female,"18 Years and older   (Adult, Older Adult)",,8500.0,"May 1, 2020",2020-10-31,"May 6, 2020","Wayne State University, Detroit, Michigan, United States|University of Medicine Tirana, Tirana, Albania|Royal Prince Alfred Hospital, Sydney, Australia|Charles University, Prague, Czechia|Université de Paris, Paris, France|Charité - University Medicine Berlin, Berlin, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Meir Medical Center, Kafr Saba, Israel|University of Brescia, Brescia, Italy|American University of Beirut, Beirut, Lebanon|The Arctic University of Norway, Tromsø, Norway|Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland|Pomeranian Medical University, Szczecin, Poland|Centre of Postgraduate Medical Education, Warsaw, Poland|11. Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal ""iMaterna"", Madrid, Spain|Karolinska Institutet, Stockholm, Sweden|Taiji Clinic, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04377412,Albania,,10.0,2020,Saturday
3351,3352,Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf,Recruiting,Other: No interverntion,All,"Child, Adult, Older Adult",,100.0,"June 2, 2020",2020-12-31,"June 26, 2020","Hamad Medical Corporation, Doha, Unlisted (UL), Qatar",https://ClinicalTrials.gov/show/NCT04430374,Qatar,,12.0,2020,Thursday
3352,3353,The Change of Critical Patient Managements and Subsequent Influences Under Epidemic of Coronavirus Disease 19 (COVID-19),Not yet recruiting,Procedure: Tracheal intubation and cardiopulmonary resuscitation,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,334.0,"August 1, 2020",2022-07-31,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04479332,Undefined,,7.0,2022,Sunday
3353,3354,Exercise Influence on COVID-19,Not yet recruiting,Diagnostic Test: COVID-19 survey,All,"17 Years to 85 Years   (Child, Adult, Older Adult)",,30000.0,"December 4, 2020",2021-04-04,"November 12, 2020",,https://ClinicalTrials.gov/show/NCT04624048,Undefined,,4.0,2021,Sunday
3354,3355,Moral Judgements and Choices of Caregivers in the Time of COVID-19 Pandemic,Not yet recruiting,Behavioral: Choices and judgements,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,500.0,"September 3, 2020",2021-08-02,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04542122,Undefined,,8.0,2021,Monday
3355,3356,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Recruiting,"Diagnostic Test: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)",All,"3 Years and older   (Child, Adult, Older Adult)",Not Applicable,500.0,"July 12, 2020",2020-11-30,"August 17, 2020","Christine KATLAMA, Paris, Ile De France, France",https://ClinicalTrials.gov/show/NCT04511949,France,,11.0,2020,Monday
3356,3357,"COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor",Recruiting,,Female,"18 Years and older   (Adult, Older Adult)",,300.0,"October 1, 2020",2021-07-31,"September 29, 2020","University Hospital of Halle, Halle, Saxony Anhalt, Germany",https://ClinicalTrials.gov/show/NCT04568551,Germany,,7.0,2021,Saturday
3357,3358,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Not yet recruiting,Behavioral: Virtual-Care Cognitive Behavioural Therapy,All,12 Years to 17 Years   (Child),Not Applicable,20.0,"June 1, 2020",2021-06-01,"May 29, 2020","The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04408027,Canada,,6.0,2021,Tuesday
3358,3359,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),"Active, not recruiting",Behavioral: HOPE intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"March 20, 2020",2021-09-01,"November 3, 2020","UC Irvine, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04376515,United States,,9.0,2021,Wednesday
3359,3360,LIBERATE Trial in COVID-19,Recruiting,Drug: Ibuprofen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,230.0,"May 26, 2020",2021-09-25,"October 23, 2020","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04334629,United Kingdom,Ibuprofen,9.0,2021,Saturday
3360,3361,COVID-19 Health Professional Impact Study,Not yet recruiting,Other: Survey|Diagnostic Test: SARS-CoV-2 antibody test,All,"Child, Adult, Older Adult",Not Applicable,3000.0,"November 1, 2020",2020-12-31,"October 8, 2020","The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom",https://ClinicalTrials.gov/show/NCT04527432,United Kingdom,,12.0,2020,Thursday
3361,3362,Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK,Recruiting,Other: Non-interventional,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"May 25, 2020",2021-06-25,"July 31, 2020","Imperial College Healthcare NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04405232,United Kingdom,,6.0,2021,Friday
3362,3363,Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan,Completed,Other: service of questionnaire,All,"Child, Adult, Older Adult",,390.0,"November 1, 2020",2020-11-18,"November 19, 2020","The Islamia University of Bahawalpur, Bahāwalpur, Punjab, Pakistan|GC University Faisalabad, Faisalabad, Punjab, Pakistan|University of Veterinary and Animal Sciences, Lahore, Lahore, Punjab, Pakistan|Bahauddin Zakriya University Multan, Multan, Punjab, Pakistan|Quaid-i-Azam University Islamabad, Islamabad, Pakistan",https://ClinicalTrials.gov/show/NCT04604080,Pakistan,,11.0,2020,Wednesday
3363,3364,Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19,Recruiting,Other: Follow up calls,All,"18 Years and older   (Adult, Older Adult)",,100.0,"July 27, 2020",2022-07-01,"November 6, 2020","University Hospital of Toulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04619368,France,,7.0,2022,Friday
3364,3365,Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19),Recruiting,Drug: Intravenous sedation|Drug: Inhaled sedation,All,"18 Years and older   (Adult, Older Adult)",,400.0,"June 26, 2020",2020-12-31,"December 1, 2020","Beth Israel Deaconess Medical Center, Inc., Boston, Massachusetts, United States|CHU, Clermont-Ferrand, France|Centre Hospitalier, Dunkerque, France|Pitié-Salpêtrière Hospital - APHP, Paris, France|CH Privé de la Loire, Saint-Étienne, France|University Medical Center Schleswig-Holstein, Kiel, Germany|Universitätsklinikum, Oldenburg, Germany|Hospital Clínico Universitario de Valencia, Valencia, Spain|Cantonal Hospital, Münsterlingen, Switzerland|Universitätsspital, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04383730,France,Intravenous sedation|Inhaled sedation,12.0,2020,Thursday
3365,3366,COVID-19 and Psychotic Symptoms in France,Recruiting,,All,"18 Years to 65 Years   (Adult, Older Adult)",,600.0,"April 1, 2020",2020-08-01,"May 7, 2020","UH Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04356885,France,,8.0,2020,Saturday
3366,3367,Percutaneous Tracheostomy With COVID-19,Completed,Procedure: Tracheostomy with aerosol box in COVID-19 positive patients,All,"18 Years to 90 Years   (Adult, Older Adult)",,24.0,"March 20, 2020",2020-06-01,"September 24, 2020","Canakkale Onsekiz Mart University, Canakkale, Turkey",https://ClinicalTrials.gov/show/NCT04447638,Turkey,,6.0,2020,Monday
3367,3368,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"Active, not recruiting",Biological: VPM1002|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,59.0,"May 25, 2020",2021-05-01,"September 30, 2020","Ludwig-Maximilians-Universität München, München, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|SocraTec R&D GmbH, Erfurt, Thüringen, Germany",https://ClinicalTrials.gov/show/NCT04387409,Germany,,5.0,2021,Saturday
3368,3369,3D Telemedicine During COVID-19: Cohort Study,Not yet recruiting,Other: 3D Telemedicine,All,"1 Year to 95 Years   (Child, Adult, Older Adult)",Not Applicable,50.0,"September 1, 2020",2021-01-01,"July 7, 2020","Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom",https://ClinicalTrials.gov/show/NCT04444323,United Kingdom,,1.0,2021,Friday
3369,3370,Surgical Consent During the COVID-19 Pandemic,Completed,Behavioral: Educational meetings and visual prompts,All,"18 Years and older   (Adult, Older Adult)",,45.0,"April 10, 2020",2020-08-14,"September 21, 2020","Medway NHS Foundation Trust, Gillingham, United Kingdom",https://ClinicalTrials.gov/show/NCT04556604,United Kingdom,,8.0,2020,Friday
3370,3371,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,Recruiting,Dietary Supplement: Chinese Herbal Medicine,All,"18 Years to 114 Years   (Adult, Older Adult)",,500.0,"April 11, 2020",2025-04-11,"May 8, 2020","Seattle Intstitute of East Asian Medicine, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04380870,United States,,4.0,2025,Friday
3371,3372,Self-sampling for the Study of COVID-19,Not yet recruiting,Diagnostic Test: iAMP test,All,"18 Years and older   (Adult, Older Adult)",,500.0,"July 1, 2020",2020-12-31,"June 25, 2020",,https://ClinicalTrials.gov/show/NCT04447495,Undefined,,12.0,2020,Thursday
3372,3373,Cerebral Compliance Impairment in COVID-19,Completed,Device: Cerebral compliance and hemodynamics monitoring,All,"1 Year and older   (Child, Adult, Older Adult)",,50.0,"May 1, 2020",2020-07-31,"September 22, 2020","Hospital das Clínicas da Faculdade de Medicina da USP., São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04429477,Brazil,,7.0,2020,Friday
3373,3374,HFNC Treatment in COVID-19 Pneumonia,Completed,Device: high flow nasal cannula device,All,"18 Years and older   (Adult, Older Adult)",,43.0,"May 15, 2020",2020-06-05,"July 16, 2020","Sisli Etfal Research and Training Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04424836,Turkey,,6.0,2020,Friday
3374,3375,COVID-19 Psychological Wellbeing for Healthcare Students,Not yet recruiting,Other: COVID-19 e-package: Psychological wellbeing for healthcare workers,All,"Child, Adult, Older Adult",Not Applicable,45.0,"June 13, 2020",2020-12-30,"June 12, 2020",,https://ClinicalTrials.gov/show/NCT04429828,Undefined,,12.0,2020,Wednesday
3375,3376,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),Recruiting,Drug: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"October 8, 2020",2021-07-01,"December 9, 2020","Penrose Hospital, Colorado Springs, Colorado, United States|St. Francis Health Services, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|Saint Anthony North Health Campus, Westminster, Colorado, United States|Washington VA Medical Center, Washington, District of Columbia, United States|Redmond Regional Medical Center, Rome, Georgia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Hennepin Healthcare Research Institute/HCMC, Minneapolis, Minnesota, United States|University of Missouri, Columbia, Missouri, United States|Cox Medical Centers, Springfield, Missouri, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|Hendrick Medical Center, Abilene, Texas, United States|CHRISTUS Spohn Shoreline Hospital, Corpus Christi, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|CJW Chippenham Medical Center, Richmond, Virginia, United States|Henrico Doctors' Hospital (HCA), Richmond, Virginia, United States|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|CHIP, Department of Infectious Diseases, Section 2100, Copenhagen, Denmark|Herlev-Gentofte Hospital, Hellerup, Denmark|Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Kolding Sygehus, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Democritus University of Thrace, Alexandroupoli, Thrace, Greece|3rd Dept of Medicine, Medical School, NKUA, Athens, Greece|1st Respiratory Medicine Dept, Athens University Medical School, Athens, Greece|Attikon University General Hospital, Athens, Greece|Dept. of Critical Care & Pulmonary Medicine, Evangelismos General Hospital, Athens, Greece|NCGM, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|Institute of Human Virology-Nigeria (IHVN), Abuja, Nigeria|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Royal Free Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04546581,Denmark,Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Remdesivir,7.0,2021,Thursday
3376,3377,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Drug: Conestat alfa,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120.0,"August 6, 2020",2021-07-01,"December 8, 2020","University Hospital Basel, Division of Internal Medicine, Basel, Switzerland",https://ClinicalTrials.gov/show/NCT04414631,Switzerland,Conestat alfa,7.0,2021,Thursday
3377,3378,The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's),Completed,Other: Cross-sectional study investigating the association of NPIs with mental health,All,"18 Years and older   (Adult, Older Adult)",,10084.0,"March 31, 2020",2020-04-07,"April 24, 2020","University of Oslo, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04356365,Norway,,4.0,2020,Tuesday
3378,3379,Impact of COVID-19 Lockdown on Obesity and Eating Behaviors,Recruiting,Other: Questionnaires,All,"18 Years and older   (Adult, Older Adult)",,46.0,"June 16, 2020",2021-06-23,"November 24, 2020","Centre Intégré de l'obésité de Lyon / HCL, Pierre-Bénite, France",https://ClinicalTrials.gov/show/NCT04431284,France,,6.0,2021,Wednesday
3379,3380,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Enrolling by invitation,Other: SCH Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"April 21, 2020",2021-05-31,"July 9, 2020","Huntsman Cancer Institute, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04464486,United States,,5.0,2021,Monday
3380,3381,"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19",Completed,Other: Description of groups caracteristics,All,"18 Years and older   (Adult, Older Adult)",,94.0,"May 1, 2020",2020-06-30,"July 29, 2020","University hospital, Montpellier, France",https://ClinicalTrials.gov/show/NCT04417374,France,,6.0,2020,Tuesday
3381,3382,"Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods.",Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,2000.0,June 2020,2022-08-28,"May 14, 2020",,https://ClinicalTrials.gov/show/NCT04366219,Undefined,,8.0,2022,Sunday
3382,3383,How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?,"Active, not recruiting",Behavioral: Enhanced hygiene measures,All,"Child, Adult, Older Adult",,120.0,"January 1, 2019",2021-02-04,"April 17, 2020","Department of anesthesia and intensive care, Fattouma Bourguiba Hospital, Monastir, Tunisia",https://ClinicalTrials.gov/show/NCT04348227,Tunisia,,2.0,2021,Thursday
3383,3384,Reducing Food Insecurity During COVID-19,Not yet recruiting,Other: Produce prescription program|Other: Grocery store gift cards,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250.0,January 2021,2022-10-01,"December 3, 2020","Boston Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04652596,United States,,10.0,2022,Saturday
3384,3385,CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.,Not yet recruiting,Other: Community popular opinion leader (POL) based intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"January 6, 2021",2021-10-31,"December 2, 2020","Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04646616,United States,,10.0,2021,Sunday
3385,3386,Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff,Recruiting,Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,2944.0,"January 21, 2020",2020-06-01,"March 31, 2020","Taihe Hospital, Shiyan, Hubei, China",https://ClinicalTrials.gov/show/NCT04320238,China,recombinant human interferon Alpha-1b|thymosin alpha 1,6.0,2020,Monday
3386,3387,Renal Outcome in Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,40.0,"April 21, 2020",2021-03-31,"September 30, 2020","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany",https://ClinicalTrials.gov/show/NCT04353583,Germany,,3.0,2021,Wednesday
3387,3388,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,Drug: Aspirin 100mg,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,128.0,"February 10, 2020",2020-06-01,"April 28, 2020","Cai Yue, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT04365309,China,Aspirin 100mg,6.0,2020,Monday
3388,3389,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Completed,Other: SPIN-CHAT Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,172.0,"April 9, 2020",2020-07-24,"November 30, 2020","Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04335279,Canada,,7.0,2020,Friday
3389,3390,Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,Recruiting,Diagnostic Test: Collection of breath sample,All,"18 Years and older   (Adult, Older Adult)",,120.0,"September 10, 2019",2021-12-31,"April 13, 2020","Mayo Clinic Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04341012,United States,,12.0,2021,Friday
3390,3391,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,Diagnostic Test: Low-dose Chest CT,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,230.0,"April 25, 2020",2020-05-22,"June 12, 2020","Victor Gombolevskiy, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04379531,Russian Federation,,5.0,2020,Friday
3391,3392,3D Telemedicine During COVID-19: Non-clinical Validation,Not yet recruiting,Other: 3D Telemedicine|Other: 2D Telemedicine,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,40.0,"July 31, 2020",2021-01-31,"July 7, 2020","Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom",https://ClinicalTrials.gov/show/NCT04444297,United Kingdom,,1.0,2021,Sunday
3392,3393,IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT,Enrolling by invitation,Other: Hydroxychloroquine/Chloroquine,All,"18 Years and older   (Adult, Older Adult)",,500.0,September 2020,2021-04-01,"June 4, 2020","University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04347798,Canada,,4.0,2021,Thursday
3393,3394,Cross Sectional CFAR HIV/COVID Study,Recruiting,,All,"3 Years to 25 Years   (Child, Adult)",,100.0,"August 12, 2020",2021-03-31,"August 14, 2020","Batchelor's Children's Research Institute, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04514016,United States,,3.0,2021,Wednesday
3394,3395,Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India,Recruiting,,All,"18 Years to 90 Years   (Adult, Older Adult)",,1300.0,"May 18, 2020",2020-09-30,"July 14, 2020","Max Super Speciality Hospital Saket, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04469660,India,,9.0,2020,Wednesday
3395,3396,COVID-19 Risk Reduction Among African American Parishioners,Not yet recruiting,"Behavioral: Change in knowledge, motivation, skills, resources",All,65 Years and older   (Older Adult),Not Applicable,265.0,"October 1, 2020",2021-09-30,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04542343,Undefined,,9.0,2021,Thursday
3396,3397,COVID-19 and Rare Skin Diseases European Observational Study During an Epidemic,Not yet recruiting,,All,"Child, Adult, Older Adult",,80.0,"June 30, 2020",2021-06-30,"June 30, 2020",,https://ClinicalTrials.gov/show/NCT04451902,Undefined,,6.0,2021,Wednesday
3397,3398,Fibromyalgia During the COVID-19 Pandemic,"Active, not recruiting",,All,"19 Years and older   (Adult, Older Adult)",,45.0,"March 15, 2020",2020-06-30,"June 11, 2020","Al-Azhar Faculty of medicine, Rheumatology Department, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04422522,Egypt,,6.0,2020,Tuesday
3398,3399,CMR Findings in COVID-19 Patients Presenting With Myocardial Infarction,Not yet recruiting,Radiation: cardiac magnetic resonance,All,"18 Years to 80 Years   (Adult, Older Adult)",,60.0,"January 1, 2021",2023-10-01,"November 16, 2020",,https://ClinicalTrials.gov/show/NCT04628104,Undefined,,10.0,2023,Sunday
3399,3400,ASCO Survey on COVID-19 in Oncology (ASCO) Registry,Recruiting,,All,"Child, Adult, Older Adult",,2000.0,"April 19, 2020",2022-12-01,"December 9, 2020","Anchorage Oncology Center, Anchorage, Alaska, United States|AIS Cancer Center, Bakersfield, California, United States|Long Beach Memorial Medical Center, Fountain Valley, California, United States|Orange Coast Medical Center, Fountain Valley, California, United States|Saddleback Memorial Medical Center, Fountain Valley, California, United States|Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|PIH Health, Whittier, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Hartford HealthCare Cancer Institute, Hartford, Connecticut, United States|Bayhealth Medical Center, Dover, Delaware, United States|Florida Precision Oncology, A Division of 21st Centry Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, LLC, Sarasota, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Hawaii Cancer Care, Honolulu, Hawaii, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|Edward-Elmhurst Healthcare, Naperville, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Michiana Hematology Oncology, Mishawaka, Indiana, United States|MidAmerica Oncology Associates, Overland Park, Kansas, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Baptist Health Madisonville, Madisonville, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|LifeBridge Health, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Great Lakes Cancer Management Specialists, Grosse Pointe Woods, Michigan, United States|Lakeland Hospitals, Saint Joseph, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mosaic Cancer Care, Saint Joseph, Missouri, United States|Nebraska Hematology Oncology, Lincoln, Nebraska, United States|Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Bayonne Medical Center, Bayonne, New Jersey, United States|CarePoint Health - Christ Hospital, Jersey City, New Jersey, United States|Penn Medicine, Princeton Health, Plainsboro, New Jersey, United States|Hematology Oncology Associates of Central New York, East Syracuse, New York, United States|Northwell Health Cancer Institute, Lake Success, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Levine Cancer Institute Atrium Health, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Carteret Health Care, Morehead City, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Florida Cancer Specialists, Massillon, Ohio, United States|Columbia Memorial Hospital, Astoria, Oregon, United States|Samaritan Health Services Corvallis, Corvallis, Oregon, United States|Penn Medicine, Lancaster General Health, Lancaster, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Monument Health, Rapid City, South Dakota, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|BSA Harrington Cancer Center, Amarillo, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT04659135,Georgia,,12.0,2022,Thursday
3400,3401,Distress in Crisis Situations During COVID-19,Completed,Other: questionnaire assesment,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"March 31, 2020",2020-05-03,"May 5, 2020","Wefight, Montpellier, France",https://ClinicalTrials.gov/show/NCT04337047,France,,5.0,2020,Sunday
3401,3402,Clinical and Radiomic Model of COVID-19,Completed,Diagnostic Test: Machine learning model,All,"Child, Adult, Older Adult",,300.0,"December 23, 2019",2020-03-03,"April 7, 2020","The central hospital of Wuhan, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04337502,China,,3.0,2020,Tuesday
3402,3403,Treating COVID-19 With a Bidirectional Oxygenation Valve,Recruiting,Device: bidirectional oxygenation mouthpiece,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"March 27, 2020",2021-03-27,"October 6, 2020","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04326452,Georgia,,3.0,2021,Saturday
3403,3404,Inhaled Ibuprofen to Treat COVID-19,Recruiting,Drug: Inhaled Hypertonic ibuprofen,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 1, 2020",2021-01-01,"June 11, 2020","Centro de Excelencia en Productos y Procesos Córdoba, Córdoba, Argentina",https://ClinicalTrials.gov/show/NCT04382768,Argentina,Inhaled Hypertonic ibuprofen,1.0,2021,Friday
3404,3405,Surfactant Protein Genetic Variants in COVID-19 Infection,Recruiting,Other: Identification of genetic variants,All,"up to 90 Years   (Child, Adult, Older Adult)",,300.0,"March 1, 2020",2021-12-01,"December 2, 2020","Milton S. Hershey Medical center, Hershey, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04650191,United States,,12.0,2021,Wednesday
3405,3406,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,Recruiting,Other: Exercise|Behavioral: Psychological and Behaviour Change Support|Other: Nutrition,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1100.0,"May 29, 2020",2022-11-30,"June 11, 2020","University Hospital Southampton NHS FT, Southampton, United Kingdom",https://ClinicalTrials.gov/show/NCT04425616,United Kingdom,,11.0,2022,Wednesday
3406,3407,NO Prevention of COVID-19 for Healthcare Providers,Recruiting,Drug: Inhaled nitric oxide gas,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,470.0,"April 7, 2020",2022-04-07,"June 16, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04312243,United States,Inhaled nitric oxide gas,4.0,2022,Thursday
3407,3408,Sequencing and Tracking of Phylogeny in COVID-19 Study,Recruiting,,All,"7 Years and older   (Child, Adult, Older Adult)",,500.0,May 2020,2022-09-01,"April 24, 2020","Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04359849,United Kingdom,,9.0,2022,Thursday
3408,3409,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5.0,"April 6, 2020",2020-04-23,"April 29, 2020","L. Sacco Hospital, Milano, Lombardia, Italy",https://ClinicalTrials.gov/show/NCT04368377,Italy,Tirofiban Injection|Clopidogrel|Acetylsalicylic acid|Fondaparinux,4.0,2020,Thursday
3409,3410,UVA Light Device to Treat COVID-19,Recruiting,Device: UV Light Treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5.0,"October 30, 2020",2020-12-01,"November 13, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04572399,United States,,12.0,2020,Tuesday
3410,3411,Mechanisms for Organ Dysfunction in Covid-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"March 12, 2020",2021-12-31,"March 20, 2020","Uppsala University Hospital, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT04316884,Sweden,,12.0,2021,Friday
3411,3412,Viral Specific T-cells for Treatment of COVID-19,Not yet recruiting,Biological: Viral Specific T-cells (VSTs),All,"Child, Adult, Older Adult",Phase 2,100.0,January 2021,2025-06-01,"November 4, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04406064,United States,,6.0,2025,Sunday
3412,3413,Capturing MultiORgan Effects of COVID-19,Recruiting,Diagnostic Test: Magnetic Resonance Imaging,All,"18 Years to 100 Years   (Adult, Older Adult)",,616.0,"May 13, 2020",2023-05-01,"August 18, 2020","University of Oxford, Oxford, United Kingdom",https://ClinicalTrials.gov/show/NCT04510025,United Kingdom,,5.0,2023,Monday
3413,3414,Prognostic Factors Keeping Track for COVID-19 Pneumonia,Completed,,All,"18 Years to 100 Years   (Adult, Older Adult)",,198.0,"March 31, 2020",2020-05-07,"May 14, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",https://ClinicalTrials.gov/show/NCT04324684,Italy,,5.0,2020,Thursday
3414,3415,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,Biological: Blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"May 28, 2020",2021-01-27,"May 29, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, Paca, France",https://ClinicalTrials.gov/show/NCT04408131,France,,1.0,2021,Wednesday
3415,3416,Can the Prediction Market Improve Predictions of COVID-19?,Completed,Other: Prediction Market,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,560.0,"May 15, 2020",2020-05-17,"June 2, 2020","National University of Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04410692,Singapore,,5.0,2020,Sunday
3416,3417,Scaling Mental Healthcare in COVID-19 With Voice Biomarkers,Not yet recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,50.0,"September 1, 2020",2021-06-30,"August 13, 2020",,https://ClinicalTrials.gov/show/NCT04510519,Undefined,,6.0,2021,Wednesday
3417,3418,"COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being","Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 17, 2020",2021-04-01,"June 5, 2020","Clinical Nutrition Research Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04357041,United States,,4.0,2021,Thursday
3418,3419,COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector,Not yet recruiting,Other: Health Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"August 15, 2020",2021-01-15,"July 22, 2020","CH Argenteuil - Service de Réanimation, Argenteuil, France|Ch Belfort, Belfort, France|CHU Dijon - Serve de Réanimation, Dijon, France|CHU de Limoges, Limoges, France",https://ClinicalTrials.gov/show/NCT04481529,France,,1.0,2021,Friday
3419,3420,Predictors of Mental Well-being During the COVID-19 Pandemic,Not yet recruiting,Behavioral: Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04443699,Undefined,,7.0,2020,Monday
3420,3421,COVID-19 Infection in Patients Infected With HIV and/or on PrEP,Completed,"Other: Data research, database analysis",All,"18 Years and older   (Adult, Older Adult)",,4200.0,"April 30, 2020",2020-05-04,"May 7, 2020","Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France",https://ClinicalTrials.gov/show/NCT04379245,France,,5.0,2020,Monday
3421,3422,Registry of COVID-19 Patients at AOUI Verona,Recruiting,Other: not applicable (observational study),All,"Child, Adult, Older Adult",,500.0,"March 1, 2020",2020-09-30,"August 4, 2020","University Hospital of Verona, Verona, Italy",https://ClinicalTrials.gov/show/NCT04497194,Italy,,9.0,2020,Wednesday
3422,3423,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Enrolling by invitation,Biological: Flu shot,All,18 Years to 64 Years   (Adult),,100.0,"October 29, 2020",2022-12-01,"November 25, 2020","Stanford University, Hospital, and Clinics, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04579588,United States,,12.0,2022,Thursday
3423,3424,Handling Oxygenation Targets in COVID-19,Recruiting,Drug: Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,780.0,"August 25, 2020",2024-03-01,"September 14, 2020","Dept. of Intensive Care, Aalborg University Hospital, Aalborg, Denmark|Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Herlev Hospital, Herlev, Denmark|Dept. of Intensive Care, Hillerød Hospital, Hillerød, Denmark|Dept. of Intensive Care, Holbæk Hospital, Holbæk, Denmark|Dept. of Intensive Care, Kolding Hospital, Kolding, Denmark|Dept. of Intensive Care, Køge Hospital, Køge, Denmark|Dept. of Intensive Care, Slagelse Hospital, Slagelse, Denmark",https://ClinicalTrials.gov/show/NCT04425031,Denmark,Oxygen,3.0,2024,Friday
3424,3425,Blood Donor Recruitment During Epidemic of COVID-19,Completed,Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information,All,18 Years to 60 Years   (Adult),Not Applicable,19491.0,"March 13, 2020",2020-04-03,"April 13, 2020","Guangzhou Blood Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04306055,China,,4.0,2020,Friday
3425,3426,Taste and Smell Impairment in Critically Ill COVID-19 Patients,Completed,,All,"18 Years to 80 Years   (Adult, Older Adult)",,40.0,"September 1, 2020",2020-10-09,"November 10, 2020","Sisli Etfal Research and Training Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04532632,Turkey,,10.0,2020,Friday
3426,3427,Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study,Recruiting,Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL,All,"Child, Adult, Older Adult",Phase 3,250.0,"May 23, 2019",2021-12-28,"October 27, 2020","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|University of California Davis Health System, Sacramento, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Universtiy of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health, Winston-Salem, North Carolina, United States|The Lindner Center- The Christ Hospital, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Mercy Health, Youngstown, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Kent Hospital, Warwick, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|Texas Health, Fort Worth, Texas, United States|Therapeutic Concepts, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert Medical College Pulmonary Clinic, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Wesley Hospital, Auchenflower, Queensland, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Shanghai Pulmonary Hospital, Yangpu, Shanghai, China|West China Hospital, Nanchong, Sichuan, China|Shulan(Hangzhou)Hospital co., LTD, Hangzhou, Zhejiang, China|Rigshospitalet, Copenhagen, Denmark|Hôpital Henri Mondor, Créteil, Ile-de-France, France|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan",https://ClinicalTrials.gov/show/NCT03808922,Australia,DAS181|Placebo|DAS181 COVID-19|DAS181 OL,12.0,2021,Tuesday
3427,3428,Impact of COVID-19 on Mental Health of Patients With Skin Picking,Enrolling by invitation,Behavioral: Internet-based Cognitive Behavioral Therapy|Other: Quality of life promotion,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"August 11, 2020",2021-03-01,"August 21, 2020","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04522492,Brazil,,3.0,2021,Monday
3428,3429,Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era,Not yet recruiting,Other: Remote Automated Monitoring System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,January 2021,2022-06-01,"December 10, 2020","Anesthesia Department, Central Hospital, Nancy, France|Anesthesia, Critical Care & Perioperative Medicine, Hautepierre, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04661423,France,,6.0,2022,Wednesday
3429,3430,Ozone Therapy in the Prevention of COVID-19 Infection,Completed,,All,"18 Years to 90 Years   (Adult, Older Adult)",,71.0,"May 6, 2020",2020-05-17,"May 22, 2020","Kardelen Gencer Atalay, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04400006,Turkey,,5.0,2020,Sunday
3430,3431,BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,Drug: BIO 300 Oral Suspension|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66.0,"November 11, 2020",2022-05-01,"November 17, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04482595,United States,BIO 300 Oral Suspension|Placebo,5.0,2022,Sunday
3431,3432,The Psychological Impact of the COVID-19 on Students.,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,300.0,"April 26, 2020",2021-03-31,"May 19, 2020","LAI Agnes, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04365361,Hong Kong,,3.0,2021,Wednesday
3432,3433,Parental Burnout During the COVID-19 Pandemic: Risk Factors and Predictors,Not yet recruiting,Other: Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04442386,Undefined,,7.0,2020,Monday
3433,3434,IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.,Not yet recruiting,Drug: Experimental drug,All,70 Years and older   (Older Adult),Phase 2,99.0,"September 1, 2020",2021-12-01,"August 7, 2020","CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France",https://ClinicalTrials.gov/show/NCT04357613,France,Experimental drug,12.0,2021,Wednesday
3434,3435,"REmotely Monitored, Mobile Health Supported High Intensity Interval Training for Survivors of COVID-19",Not yet recruiting,"Behavioral: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"January 1, 2021",2023-02-01,"December 11, 2020","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04664101,United States,,2.0,2023,Wednesday
3435,3436,Determining the Reproductive Health of Men Post-COVID-19 Infection,Withdrawn,Other: Exposure: Covid-19 infection,Male,18 Years to 50 Years   (Adult),,0.0,"June 10, 2020",2020-06-10,"November 24, 2020","Channa Jayasena, London, Outside U.S./Canada, United Kingdom",https://ClinicalTrials.gov/show/NCT04414904,Canada,,6.0,2020,Wednesday
3436,3437,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Completed,Behavioral: blood donation SMS,All,18 Years to 60 Years   (Adult),Not Applicable,456517.0,"April 30, 2020",2020-05-10,"June 1, 2020","Guangzhou Blood Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04370886,China,,5.0,2020,Sunday
3437,3438,Risk Factors for Community- and Workplace Transmission of COVID-19,Recruiting,Behavioral: Observation of behavior and COVID-19 infection will be conducted.,All,"18 Years and older   (Adult, Older Adult)",,250000.0,"March 27, 2020",2030-03-20,"June 25, 2020","Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04320732,Norway,,3.0,2030,Wednesday
3438,3439,Obstetric and Perinatal Outcomes of Women With COVID-19,Recruiting,Behavioral: Examine the impact of COVID-19 during pregnancy,Female,"18 Years and older   (Adult, Older Adult)",,1300.0,"April 23, 2020",2021-04-22,"May 4, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, Paca, France",https://ClinicalTrials.gov/show/NCT04369859,France,,4.0,2021,Thursday
3439,3440,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Recruiting,Behavioral: Anxiety Reduction Training|Behavioral: Kundalini Yoga and Anxiety Reduction Training|Behavioral: Meditation and Anxiety Reduction Training,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,360.0,"May 25, 2020",2022-01-30,"July 1, 2020","ProofPilot (Virtual Study: https://proofpilot.com/covid-anxiety/), New York, New York, United States|Columbia University Department of Psychiatry, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04386291,United States,,1.0,2022,Sunday
3440,3441,An Approach to Screening for COVID-19 at Vancouver Airport,Recruiting,Diagnostic Test: Rapid Antigen Test,All,"19 Years to 80 Years   (Adult, Older Adult)",Not Applicable,900.0,"November 23, 2020",2021-04-30,"December 11, 2020","Vancouver International Airport, WestJet Domestic Terminal, Level 3, Richmond, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04665193,Canada,,4.0,2021,Friday
3441,3442,Impact of Colchicine in Hospitalized Colombian Patients With COVID-19,Not yet recruiting,Drug: Colchicine 0.5 MG|Combination Product: CONTROL GROUP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,128.0,"November 30, 2020",2021-03-01,"December 1, 2020","Fundación Universitaria de Ciencias de La Salud, Bogota, Cundinamarca, Colombia",https://ClinicalTrials.gov/show/NCT04539873,Colombia,Colchicine 0.5 MG,3.0,2021,Monday
3442,3443,Effects of Fuzheng Huayu Tablets on COVID-19,Completed,Drug: Fuzheng Huayu tablet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,66.0,"February 1, 2020",2020-04-15,"November 27, 2020","Shuguang Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04645407,China,Fuzheng Huayu tablet,4.0,2020,Wednesday
3443,3444,Improving Activity Engagement Among Persons With SCI During COVID-19,Not yet recruiting,Other: WebEx Physical Activity Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"September 15, 2020",2021-10-31,"September 3, 2020","St. Josephs Parkwood Institute, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04408287,Canada,,10.0,2021,Sunday
3444,3445,Assessment of Mortality Rates in SARS-CoV-2 Infected Populations Treated With Repurposed Medications,Not yet recruiting,,All,"Child, Adult, Older Adult",,50000.0,"June 15, 2020",2021-05-31,"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04432350,Undefined,,5.0,2021,Monday
3445,3446,Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology,Completed,,All,18 Years to 35 Years   (Adult),,1008.0,"April 22, 2020",2020-05-11,"June 19, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04440098,United States,,5.0,2020,Monday
3446,3447,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults",Recruiting,Biological: CVnCoV Vaccine|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,284.0,"June 18, 2020",2021-10-01,"October 20, 2020","Universitair Ziekenhuis Ghent, Ghent, Belgium|Ludwig-Maximilians-Universität München, München, Bavaria, Germany|Medical University Hannover (MHH), Hannover, Germany|University Hospital Tübingen Institut für Tropenmedizin, Tübingen, Germany",https://ClinicalTrials.gov/show/NCT04449276,Belgium,Placebo,10.0,2021,Friday
3447,3448,Correlation Between Oxidative Stress Status and COVID-19 Severity,Recruiting,Diagnostic Test: Oxidative Stress ELISA Kit,All,"18 Years and older   (Adult, Older Adult)",,90.0,"April 20, 2020",2020-09-30,"July 28, 2020","Nooshin Dalili, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04375137,"Iran, Islamic Republic of",,9.0,2020,Wednesday
3448,3449,Living With Sickle Cell Disease in the COVID-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"December 16, 2020",2024-12-31,"December 11, 2020","National Human Genome Research Institute (NHGRI), Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04417673,United States,,12.0,2024,Tuesday
3449,3450,Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers,Not yet recruiting,Drug: Apo-Hydroxychloroquine|Drug: Matched Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1100.0,"May 1, 2020",2020-08-30,"May 1, 2020","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04371523,Canada,Apo-Hydroxychloroquine|Matched Placebo,8.0,2020,Sunday
3450,3451,Recovery of Exertion Ability Following COVID-19 Infection in Military Staff,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,October 2020,2023-03-01,"October 8, 2020","Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France",https://ClinicalTrials.gov/show/NCT04548505,France,,3.0,2023,Wednesday
3451,3452,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",Recruiting,Other: There is no intervention,All,"2 Years and older   (Child, Adult, Older Adult)",,1000.0,"April 8, 2020",2022-04-30,"November 16, 2020","Stanford University, Hospital, and Clinics, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT04373148,United States,,4.0,2022,Saturday
3452,3453,Acupressure for COVID-19 Related Quality of Life and Stress,Not yet recruiting,Behavioral: Self-acupressure,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"December 25, 2020",2021-02-25,"November 4, 2020",,https://ClinicalTrials.gov/show/NCT04472559,Undefined,,2.0,2021,Thursday
3453,3454,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","Active, not recruiting",Drug: REGN10933+REGN10987|Drug: Placebo,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,974.0,"July 26, 2020",2021-10-25,"December 2, 2020","Regeneron Study Site, Tempe, Arizona, United States|Regeneron Study Site, Rogers, Arkansas, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04519437,United States,REGN10933+REGN10987|Placebo,10.0,2021,Monday
3454,3455,Mental Health and Academic Performance in COVID-19,Recruiting,Other: Survey,All,"18 Years and older   (Adult, Older Adult)",,720.0,"April 1, 2020",2020-07-30,"July 28, 2020","Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico",https://ClinicalTrials.gov/show/NCT04420416,Mexico,,7.0,2020,Thursday
3455,3456,Psychological Symptoms and Families of COVID-19 Patients,Recruiting,Behavioral: Written Summary of Rounds,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 14, 2020",2021-09-15,"October 8, 2020","Rush University Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04501445,United States,,9.0,2021,Wednesday
3456,3457,Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),Completed,Drug: Opaganib|Drug: Standard of Care,All,"18 Years to 80 Years   (Adult, Older Adult)",,23.0,"April 3, 2020",2020-05-15,"June 17, 2020","Shaare-Zedek Medical Center, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04435106,Israel,Opaganib|Standard of Care,5.0,2020,Friday
3457,3458,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,"Active, not recruiting",,Male,74 Years to 95 Years   (Older Adult),,21.0,"June 10, 2020",2020-12-31,"November 13, 2020","Institute of Medical Physics, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Bavaria, Germany",https://ClinicalTrials.gov/show/NCT04444661,Germany,,12.0,2020,Thursday
3458,3459,EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19,"Active, not recruiting",Biological: Biological data|Other: Clinical data,All,"18 Years and older   (Adult, Older Adult)",,35.0,"March 15, 2020",2021-07-01,"August 4, 2020","Chu Dijon Bourgogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04498091,France,,7.0,2021,Thursday
3459,3460,Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases,Recruiting,Diagnostic Test: Serological test,All,"18 Years and older   (Adult, Older Adult)",,200.0,"June 1, 2020",2021-01-31,"September 22, 2020","Military Hospital of Tunis, Tunis, Tunisia",https://ClinicalTrials.gov/show/NCT04530461,Tunisia,,1.0,2021,Sunday
3460,3461,Hydroxychloroquine in Outpatient Adults With COVID-19,Terminated,Drug: Hydroxychloroquine SAR321068|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,8.0,"April 12, 2020",2020-05-26,"July 14, 2020","Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 0561001, Bruxelles, Belgium|Investigational Site Number 0561002, Lodelinsart, Belgium|Investigational Site Number 2501001, Bordeaux Cedex, France|Investigational Site Number 2501002, Paris, France|Investigational Site Number 5281001, Groningen, Netherlands|Investigational Site Number 5281002, Harderwijk, Netherlands",https://ClinicalTrials.gov/show/NCT04333654,Belgium,Hydroxychloroquine SAR321068|Placebo,5.0,2020,Tuesday
3461,3462,VRQOL in Cataract Patients During the COVID-19 Pandemic,Recruiting,Other: Questionnaire,All,"50 Years and older   (Adult, Older Adult)",,116.0,"September 8, 2020",2021-03-01,"September 23, 2020","Medical University Innsbruck, Innsbruck, Tyrol, Austria",https://ClinicalTrials.gov/show/NCT04468308,Austria,,3.0,2021,Monday
3462,3463,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,Not yet recruiting,Other: Mindfulness Rounds,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30.0,January 2021,2022-06-01,"December 10, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04431297,United States,,6.0,2022,Wednesday
3463,3464,Mental Health in Communities Affected by COVID-19 in Uganda,Not yet recruiting,Behavioral: Psycho-education|Behavioral: Comparator,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,840.0,"November 1, 2020",2021-07-30,"November 9, 2020",,https://ClinicalTrials.gov/show/NCT04616989,Undefined,,7.0,2021,Friday
3464,3465,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,Other: HIT-exercise|Other: Sham intervention,Female,48 Years to 60 Years   (Adult),Not Applicable,21.0,"March 14, 2020",2020-10-30,"November 13, 2020","Institute of Medical Physics, Friedrich-Alexanden University Erlangen-Nürnberg, Erlangen, Germany",https://ClinicalTrials.gov/show/NCT04420806,Germany,,10.0,2020,Friday
3465,3466,Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19,Not yet recruiting,Diagnostic Test: Serological test for COVID-19.,All,"18 Years and older   (Adult, Older Adult)",,489.0,"July 1, 2020",2021-04-01,"June 12, 2020",,https://ClinicalTrials.gov/show/NCT04429815,Undefined,,4.0,2021,Thursday
3466,3467,External Dead Space in Ventilated COVID-19 Patients,Recruiting,Other: Removal of dead space filter,All,"Child, Adult, Older Adult",Not Applicable,40.0,"June 9, 2020",2020-11-07,"November 12, 2020","Karolinska University Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04424082,Sweden,,11.0,2020,Saturday
3467,3468,Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus),Not yet recruiting,Device: SensiumVitals wearable sensor,All,"18 Years to 95 Years   (Adult, Older Adult)",,200.0,"July 28, 2020",2021-04-01,"July 31, 2020",,https://ClinicalTrials.gov/show/NCT04337489,Undefined,,4.0,2021,Thursday
3468,3469,The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study,Completed,Procedure: Thyroidectomy,All,"Child, Adult, Older Adult",,3800.0,"March 10, 2020",2020-11-12,"November 19, 2020","AOU Cagliari, Cagliari, CA, Italy",https://ClinicalTrials.gov/show/NCT04635813,Italy,,11.0,2020,Thursday
3469,3470,Medical Masks vs N95 Respirators for COVID-19,Recruiting,Device: Medical Mask|Device: N95 respirator,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,576.0,"April 1, 2020",2021-04-01,"November 18, 2020","Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Brantford General Hospital, Brantford, Ontario, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Hopital Montfort, Ottawa, Ontario, Canada|Niagara Health Services, St. Catherines, Ontario, Canada|St. Joe's Unity Health, Toronto, Ontario, Canada|St. Mike's Unity Health, Toronto, Ontario, Canada|Montreal University Health Centre, Montréal, Quebec, Canada|The Jewish General Hospital, Montréal, Quebec, Canada|Golden Care LTCF, Tzrifin, Israel",https://ClinicalTrials.gov/show/NCT04296643,Canada,,4.0,2021,Thursday
3470,3471,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",Other: No intervention,All,"18 Years and older   (Adult, Older Adult)",,5220.0,"April 1, 2020",2022-08-01,"November 6, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04343898,United States,,8.0,2022,Monday
3471,3472,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy,Recruiting,Other: pregnant women with laboratory-confirmed 2019-n-CoV,Female,"Child, Adult, Older Adult",,200.0,"January 1, 2020",2020-05-01,"April 28, 2020","Gabriele Saccone, Napoli, Italy",https://ClinicalTrials.gov/show/NCT04319016,Italy,,5.0,2020,Friday
3472,3473,MRI Changes of Acute Kidney Injury in COVID-19,Recruiting,Procedure: MRI scans,All,"18 Years to 90 Years   (Adult, Older Adult)",,60.0,"October 7, 2020",2023-09-01,"October 20, 2020","University Hospitals of Derby and Burton NHS Foundation Trust, Derby, Derbyshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04594291,United Kingdom,,9.0,2023,Friday
3473,3474,Accurate Classification System for Patients With COVID-19 Pneumonitis,Completed,,All,"Child, Adult, Older Adult",,669.0,"December 10, 2019",2020-03-04,"March 10, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04302688,China,,3.0,2020,Wednesday
3474,3475,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Completed,"Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|Other: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|Other: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.",All,"5 Years and older   (Child, Adult, Older Adult)",,167.0,"May 1, 2020",2020-08-30,"October 19, 2020","Hospital Eurnekian, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04425863,Argentina,"Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets",8.0,2020,Sunday
3475,3476,Impact of Isolation in Patients With IBD During the COVID-19 Crisis,Recruiting,,All,"16 Years and older   (Child, Adult, Older Adult)",,232.0,"June 30, 2020",2022-06-30,"July 28, 2020","Sheffield Teaching Hospitals NHS FT, Sheffield, United Kingdom",https://ClinicalTrials.gov/show/NCT04488471,United Kingdom,,6.0,2022,Thursday
3476,3477,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,Drug: Hydroxychloroquine|Drug: Ivermectin,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,400.0,"July 20, 2020",2021-04-01,"October 6, 2020","Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil",https://ClinicalTrials.gov/show/NCT04384458,Brazil,Hydroxychloroquine|Ivermectin,4.0,2021,Thursday
3477,3478,Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak,Recruiting,,All,"21 Years and older   (Adult, Older Adult)",,1000.0,"June 22, 2020",2020-12-31,"November 27, 2020","EXPO, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04448704,Singapore,,12.0,2020,Thursday
3478,3479,FilmArray and Management of ICU Patients With Pneumonia in the Covid-19 Context,Not yet recruiting,Diagnostic Test: FilmArray PCR on respiratory samples,All,"18 Years to 100 Years   (Adult, Older Adult)",,150.0,"July 1, 2020",2020-08-30,"July 1, 2020",,https://ClinicalTrials.gov/show/NCT04453540,Undefined,,8.0,2020,Sunday
3479,3480,The Impact of Information Sources on Mental Health During the COVID-19 Pandemic,Not yet recruiting,Behavioral: Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04442360,Undefined,,7.0,2020,Monday
3480,3481,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic,Not yet recruiting,Other: Bereavement Virtual Support Group,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"November 1, 2020",2022-01-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04588415,Undefined,,1.0,2022,Saturday
3481,3482,C-reactive Protein Levels Among Individuals With COVID-19,Recruiting,Diagnostic Test: C-reactive protein,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"May 4, 2020",2020-11-30,"June 11, 2020","The Parker Institute, Frederiksberg Hospital, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04373798,Denmark,,11.0,2020,Monday
3482,3483,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Recruiting,Drug: Nitazoxanide 500Mg Oral Tablet,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,150.0,"May 21, 2020",2020-12-31,"May 28, 2020","Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico",https://ClinicalTrials.gov/show/NCT04406246,Mexico,Nitazoxanide 500Mg Oral Tablet,12.0,2020,Thursday
3483,3484,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Recruiting,Diagnostic Test: NG test|Diagnostic Test: Blood test|Behavioral: Self-questionnary,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,13000.0,"May 29, 2020",2020-10-10,"July 8, 2020","CENTRE HOSPITALIER de VITRE_ Saint Jean (La Guerche), La Guerche de Bretagne, La Guerche-de-Bretagne, France|Centre Hospitalier de Fougeres, Fougères, France|Centre Hospitalier Grand Fougeray, Grand-Fougeray, France|Centre Hospitalier de La Roche Aux Fees, Janzé, France|Centre Hospitalier Montfort-Sur-Meu, Montfort sur Meu, France|Centre Hospitalier de Redon Carentoir, Redon, France|Chu Rennes, Rennes, France|Centre Hospitalier St Meen Le Grand, Saint-Méen-le-Grand, France|CENTRE HOSPITALIER VITRE_Simone Veil, Vitré, France",https://ClinicalTrials.gov/show/NCT04416308,France,,10.0,2020,Saturday
3484,3485,Evaluation of Novel Diagnostic Tests for COVID-19,Recruiting,Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection,All,"16 Years and older   (Child, Adult, Older Adult)",,200.0,"April 6, 2020",2021-10-07,"May 18, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04326387,United Kingdom,,10.0,2021,Thursday
3485,3486,Surfactant Levels in the Lungs of COVID-19 Patients,Not yet recruiting,Diagnostic Test: Surfactant assessment,All,"19 Years and older   (Adult, Older Adult)",,30.0,"November 1, 2020",2022-10-01,"October 30, 2020",,https://ClinicalTrials.gov/show/NCT04609488,Undefined,,10.0,2022,Saturday
3486,3487,Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic,Not yet recruiting,Other: Prospective study across two time-points examining the impact of viral mitigation protocols on mental health,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04442204,Undefined,,7.0,2020,Monday
3487,3488,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Recruiting,Other: Online questionnaire,All,"6 Years to 18 Years   (Child, Adult)",,30000.0,"June 10, 2020",2020-12-31,"July 17, 2020","hôpital Femme Mère Enfant, Bron, France",https://ClinicalTrials.gov/show/NCT04475484,France,,12.0,2020,Thursday
3488,3489,Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study,Completed,,All,"18 Years and older   (Adult, Older Adult)",,6332.0,"March 1, 2020",2020-05-31,"August 19, 2020","Hôpital Universitaire Carémeau, Nîmes, France",https://ClinicalTrials.gov/show/NCT04357314,France,,5.0,2020,Sunday
3489,3490,Hesperidin and Diosmin for Treatment of COVID-19,Not yet recruiting,Drug: Hesperidin and Diosmin mixture,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,100.0,"July 1, 2020",2020-10-30,"June 30, 2020",,https://ClinicalTrials.gov/show/NCT04452799,Undefined,Hesperidin and Diosmin mixture,10.0,2020,Friday
3490,3491,"1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study",Not yet recruiting,Other: Data collection,All,"18 Years to 100 Years   (Adult, Older Adult)",,93.0,May 2020,2020-12-01,"May 20, 2020",,https://ClinicalTrials.gov/show/NCT04395742,Undefined,,12.0,2020,Tuesday
3491,3492,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,Recruiting,Other: measurement of circulating sFlt1 concentration,All,"18 Years and older   (Adult, Older Adult)",,200.0,"March 25, 2020",2020-09-01,"May 19, 2020","Chu Reims, Reims, France",https://ClinicalTrials.gov/show/NCT04394195,France,,9.0,2020,Tuesday
3492,3493,Impact Nerium Oleander on Symptoms and Mortality: A Feasibility Study,Enrolling by invitation,Other: Proprietary extract of Nerium oleander,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"May 20, 2020",2020-09-01,"July 24, 2020","KDunn and Associates, PA, dba Healthquilt, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04486144,United States,,9.0,2020,Tuesday
3493,3494,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Not yet recruiting,Behavioral: Transcendental Meditation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,November 2020,2021-04-01,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04632368,Undefined,,4.0,2021,Thursday
3494,3495,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,,All,70 Years and older   (Older Adult),,132.0,"March 25, 2020",2020-05-11,"July 20, 2020","Angers University Hospital, Angers, France",https://ClinicalTrials.gov/show/NCT04333849,France,,5.0,2020,Monday
3495,3496,Intravascular Access in Suspected/Confirmed COVID-19 Patient,"Active, not recruiting",Device: NIO® (Intraosseous access)|Device: Standard of Care (Intravenous access),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 14, 2020",2020-05-20,"April 29, 2020","Lazarsku University, Warsaw, Masovian, Poland",https://ClinicalTrials.gov/show/NCT04366947,Poland,,5.0,2020,Wednesday
3496,3497,Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke,Completed,Other: exposure,All,"18 Years and older   (Adult, Older Adult)",,198.0,"May 10, 2020",2020-06-30,"September 1, 2020","Galit Yogev-Seligmann, Haifa, Please Select..., Israel",https://ClinicalTrials.gov/show/NCT04535297,Israel,,6.0,2020,Tuesday
3497,3498,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,Recruiting,Behavioral: Emotional Support Plan|Behavioral: Daily Monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"August 12, 2020",2021-03-31,"September 9, 2020","Rutgers University, Piscataway, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04460677,Jersey,,3.0,2021,Wednesday
3498,3499,The Investigation of the Neonates With or With Risk of COVID-19,Recruiting,,All,up to 28 Days   (Child),,100.0,"February 1, 2020",2020-12-31,"February 21, 2020","Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04279899,China,,12.0,2020,Thursday
3499,3500,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Recruiting,Behavioral: Computer task questionnaires,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3000.0,"December 16, 2020",2021-02-28,"December 11, 2020","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04377100,United States,,2.0,2021,Sunday
3500,3501,Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units,Recruiting,Other: Non interventional study,All,"18 Years and older   (Adult, Older Adult)",,200.0,"April 1, 2020",2020-11-01,"July 7, 2020","Intensive care units attached to the Hospices Civils de Lyon (HCL), Lyon, France",https://ClinicalTrials.gov/show/NCT04459975,France,,11.0,2020,Sunday
3501,3502,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,80.0,"May 29, 2020",2020-12-01,"June 9, 2020","Servicio de Anestesia, Hospital General Universitario Gregorio Marañon, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04422535,Spain,,12.0,2020,Tuesday
3502,3503,Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.,Withdrawn,Drug: Nitric Oxide Gas,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"March 23, 2020",2022-03-01,"March 24, 2020",,https://ClinicalTrials.gov/show/NCT04290871,Undefined,Nitric Oxide Gas,3.0,2022,Tuesday
3503,3504,Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial）,Enrolling by invitation,Behavioral: blood donation SMS,All,18 Years to 60 Years   (Adult),Not Applicable,506517.0,"May 31, 2020",2020-06-12,"June 1, 2020","Guangzhou Blood Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04410458,China,,6.0,2020,Friday
3504,3505,The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families,Recruiting,,All,"18 Years to 100 Years   (Adult, Older Adult)",,300.0,"April 27, 2020",2021-06-30,"May 19, 2020","Agnes, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04365348,Hong Kong,,6.0,2021,Wednesday
3505,3506,Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment,Recruiting,Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test,All,"Child, Adult, Older Adult",,100.0,April 2020,2021-03-01,"April 7, 2020","Royal National Orthopaedic Hospital, Stanmore, United Kingdom",https://ClinicalTrials.gov/show/NCT04337151,United Kingdom,,3.0,2021,Monday
3506,3507,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,Behavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"August 19, 2020",2020-10-15,"October 20, 2020","Stony Brook University, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04459455,United States,,10.0,2020,Thursday
3507,3508,Health Care Workers' Perception of Patient Safety During COVID-19 Pandemic,"Active, not recruiting",Other: Group 1,All,"18 Years and older   (Adult, Older Adult)",,800.0,"September 1, 2020",2020-12-15,"October 6, 2020","Pontificia Universidad Católica de Chile, Santiago, Chile|Universidad de Santander, Bucaramanga, Santander, Colombia|Universidad Católica de Santiago de Guayaquil, Guayaquil, Guayas, Ecuador|Miguel Hernández University, Elche, Alicante, Spain",https://ClinicalTrials.gov/show/NCT04576299,Chile,,12.0,2020,Tuesday
3508,3509,Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients,Not yet recruiting,Other: Bacterial species isolated,All,"18 Years to 100 Years   (Adult, Older Adult)",,10000.0,June 2020,2020-12-01,"June 2, 2020",,https://ClinicalTrials.gov/show/NCT04344509,Undefined,,12.0,2020,Tuesday
3509,3510,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Not yet recruiting,Behavioral: VR for psychoeducation and relaxation|Behavioral: Text material for psychoeducation and audio for relaxation techniques,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90.0,"November 1, 2020",2021-11-01,"November 2, 2020","Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy",https://ClinicalTrials.gov/show/NCT04611399,Italy,,11.0,2021,Monday
3510,3511,Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19),Completed,Other: Survey,All,"Child, Adult, Older Adult",,1051.0,"May 20, 2020",2020-06-10,"July 28, 2020","Treviso Regional Hospital, Treviso, Italy",https://ClinicalTrials.gov/show/NCT04488549,Italy,,6.0,2020,Wednesday
3511,3512,Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,218.0,"July 11, 2020",2020-11-30,"August 28, 2020","Ain shams Univesrity, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04524754,Egypt,,11.0,2020,Monday
3512,3513,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Recruiting,Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine,All,"5 Years and older   (Child, Adult, Older Adult)",Phase 4,86.0,"April 6, 2020",2020-12-30,"April 24, 2020","Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico",https://ClinicalTrials.gov/show/NCT04341493,Mexico,Nitazoxanide 500 MG|Hydroxychloroquine,12.0,2020,Wednesday
3513,3514,Clinical Characteristics of Critically Ill Patients With COVID-19,Recruiting,Other: File Scanning,All,"18 Years and older   (Adult, Older Adult)",,105.0,"October 30, 2020",2020-12-25,"September 16, 2020","Konya Trainig and Research Hospital, Konya, Turkey",https://ClinicalTrials.gov/show/NCT04413435,Turkey,,12.0,2020,Friday
3514,3515,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Drug: Tocilizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,38.0,"March 12, 2020",2020-05-01,"April 13, 2020","Università Politecnica delle Marche, Ancona, AN, Italy",https://ClinicalTrials.gov/show/NCT04315480,Italy,Tocilizumab,5.0,2020,Friday
3515,3516,A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial,Not yet recruiting,Other: Learning running subcuticular sutures on the Gamified Educational Network,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,June 2020,2020-06-01,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04425499,Undefined,,6.0,2020,Monday
3516,3517,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Enrolling by invitation,Behavioral: blood donation SMS,All,18 Years to 60 Years   (Adult),Not Applicable,403535.0,"June 13, 2020",2020-06-30,"June 16, 2020","Guangzhou Blood Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04431180,China,,6.0,2020,Tuesday
3517,3518,Distance Learning for Dental Student During COVID-19 Pandemic,Completed,,All,"Child, Adult, Older Adult",,418.0,"May 1, 2020",2020-05-10,"May 26, 2020","Faculty of Dentistry, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04401371,Egypt,,5.0,2020,Sunday
3518,3519,Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic,Recruiting,,All,"Child, Adult, Older Adult",,1200000.0,"August 1, 2020",2020-12-31,"August 4, 2020","National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04497467,Undefined,,12.0,2020,Thursday
3519,3520,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,Behavioral: Reward Re-Training|Behavioral: Supportive Therapy,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60.0,"December 1, 2020",2022-03-30,"December 10, 2020","Drexel University, Stratton Hall, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04661410,United States,,3.0,2022,Wednesday
3520,3521,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,Recruiting,Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"April 15, 2020",2020-08-01,"June 9, 2020","IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italy",https://ClinicalTrials.gov/show/NCT04346589,Italy,,8.0,2020,Saturday
3521,3522,Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis,Not yet recruiting,Drug: topical steroids and cyclosporin-A,All,"Child, Adult, Older Adult",Not Applicable,12.0,"June 30, 2020",2020-07-01,"June 30, 2020","Farawanyia hospital, Kuwait, Farawanyia, Kuwait",https://ClinicalTrials.gov/show/NCT04451239,Kuwait,topical steroids and cyclosporin-A,7.0,2020,Wednesday
3522,3523,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,Diagnostic Test: Serological tests will be applied on patients blood sampling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,550.0,"April 9, 2020",2024-04-09,"July 31, 2020","Hôpital Lyon Sud,Sainte Eugénie bat 4M,5, Chemin du Grand Revoyet, Pierre-Bénite cedex, France",https://ClinicalTrials.gov/show/NCT04341142,France,,4.0,2024,Tuesday
3523,3524,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Recruiting,Device: Freestyle Libre 14 day CGM system|Device: Accuchek Inform II platform,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 12, 2020",2020-12-31,"November 27, 2020","Lenox Hill Hospital, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04417270,United States,,12.0,2020,Thursday
3524,3525,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Recruiting,Drug: Vitamin D|Drug: PLACEBO,All,"Child, Adult, Older Adult",Phase 3,108.0,"November 9, 2020",2021-11-09,"November 12, 2020","Joaquín Durán Cantolla, Vitoria-Gasteiz, Alava, Spain",https://ClinicalTrials.gov/show/NCT04621058,Spain,Vitamin D|PLACEBO,11.0,2021,Tuesday
3525,3526,Clinical Characteristics and Prognostic Factors of Patients With COVID-19,Recruiting,Other: retrospective analysis,All,"18 Years and older   (Adult, Older Adult)",,120.0,"January 30, 2020",2020-04-15,"March 31, 2020","Shanghai 10th People's Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04328454,China,,4.0,2020,Wednesday
3526,3527,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Recruiting,Behavioral: Trauma-informed yoga video recording,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"July 21, 2020",2020-10-01,"July 24, 2020","National University of Natural Medicine, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04453514,United States,,10.0,2020,Thursday
3527,3528,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,Device: COVSurf Drug Delivery System|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24.0,"June 18, 2020",2021-11-16,"September 9, 2020","University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04362059,United Kingdom,,11.0,2021,Tuesday
3528,3529,Yoga in NHS Health Care Workers With COVID-19 Related Stress,Recruiting,Other: Yoga,All,"18 Years and older   (Adult, Older Adult)",,30.0,"July 1, 2020",2021-02-01,"July 22, 2020","Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, South Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04481516,United Kingdom,,2.0,2021,Monday
3529,3530,COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection,Not yet recruiting,Diagnostic Test: Novel laser inferometry test for CORONA virus,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,250.0,June 2020,2021-12-01,"May 26, 2020","Somerset NHS Foundation Trust, Taunton, Somerset, United Kingdom",https://ClinicalTrials.gov/show/NCT04401644,United Kingdom,,12.0,2021,Wednesday
3530,3531,Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Recruiting,Other: observation of covid 19 pneumonia,All,"18 Years to 70 Years   (Adult, Older Adult)",,156.0,"June 5, 2020",2020-08-20,"May 29, 2020","Gaziosmanpaşa TREH, Istanbul, Gaziosmanpaşa, Turkey",https://ClinicalTrials.gov/show/NCT04408378,Turkey,,8.0,2020,Thursday
3531,3532,"Knowledge, Attitude and Practice of Gastrointestinal Endoscopists Toward PPE in COVID-19 Era",Not yet recruiting,Other: Questionnaire,All,"25 Years and older   (Adult, Older Adult)",,100.0,July 2020,2020-09-01,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04479345,Undefined,,9.0,2020,Tuesday
3532,3533,Patient Preference Trial for COVID-19 (PPT-COVID),Recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,100.0,"April 6, 2020",2020-09-01,"June 9, 2020","Centre Hospitalier Princesse Grace, Monaco, Monaco",https://ClinicalTrials.gov/show/NCT04418193,Monaco,,9.0,2020,Tuesday
3533,3534,Impact of Cancellation of Non-urgent Surgical Cases on Patients During the COVID-19 Pandemic,Not yet recruiting,Other: Questionnaire,All,"Child, Adult, Older Adult",,10000.0,"July 1, 2020",2020-12-01,"June 24, 2020","Mansoura Faculty of Medicine, Mansoura, Egypt",https://ClinicalTrials.gov/show/NCT04433312,Egypt,,12.0,2020,Tuesday
3534,3535,Evaluation of Aerosol in a Dental Clinic,Not yet recruiting,Device: High volume evacuation (HVE)|Device: Extraoral vacuum aspirator (EVA)|Device: External evacuation device (EED)|Drug: Hydrogen Peroxide,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"December 1, 2020",2022-12-01,"December 9, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04659928,United States,Hydrogen Peroxide,12.0,2022,Thursday
3535,3536,The Doctors for Coronavirus Prevention Project Thanksgiving Messaging Campaign,Not yet recruiting,Behavioral: Facebook Ads on the importance of staying safe during the Thanksgiving holiday,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20000000.0,"November 14, 2020",2021-11-26,"November 25, 2020","JPAL North America, Cambridge, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04644328,United States,,11.0,2021,Friday
3536,3537,Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study,Recruiting,Other: data record,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 1, 2020",2020-12-01,"June 29, 2020","Chu Reims, Reims, France",https://ClinicalTrials.gov/show/NCT04445870,France,,12.0,2020,Tuesday
3537,3538,Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial,Not yet recruiting,Drug: Baricitinib,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,13.0,"May 15, 2020",2020-11-15,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04399798,Undefined,Baricitinib,11.0,2020,Sunday
3538,3539,Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix (NanoDx-CoV-19),Recruiting,Device: sample of blood and saliva,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,200.0,"October 15, 2020",2021-12-31,"October 22, 2020","olivier EPAULARD, Grenoble, France",https://ClinicalTrials.gov/show/NCT04597216,France,,12.0,2021,Friday
3539,3540,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Completed,Other: Farmalarm,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"March 31, 2020",2020-05-18,"June 9, 2020","Vall d'Hebron Hospital Universitari, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04423289,Spain,,5.0,2020,Monday
3540,3541,Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic,Recruiting,Behavioral: online survey,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"April 24, 2020",2025-10-01,"April 28, 2020","University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04360850,United States,,10.0,2025,Wednesday
3541,3542,A Clinical Study to Evaluate MW33 Injection,"Active, not recruiting",Combination Product: MW33 injection|Combination Product: MW33 injection placebo,All,18 Years to 45 Years   (Adult),Phase 1,42.0,"August 7, 2020",2020-12-01,"September 3, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04533048,China,,12.0,2020,Tuesday
3542,3543,Impact of Spectacles on Compliance to Mask-wearing Directives,Completed,Behavioral: Questionnaire completion,All,"18 Years to 85 Years   (Adult, Older Adult)",,1214.0,"June 25, 2020",2020-08-14,"September 16, 2020","University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece",https://ClinicalTrials.gov/show/NCT04501172,Greece,,8.0,2020,Friday
3543,3544,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers,Completed,Drug: inhaled hydroxychloroquine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12.0,"September 15, 2020",2020-11-01,"November 10, 2020","University Medical Center Groningen, Groningen, Netherlands",https://ClinicalTrials.gov/show/NCT04497519,Netherlands,inhaled hydroxychloroquine,11.0,2020,Sunday
3544,3545,Intranasal Heparin Tolerability Study,"Active, not recruiting",Drug: Intranasal heparin sodium (porcine),All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,6.0,"October 9, 2020",2020-11-01,"October 14, 2020","The University of Mississippi National Center for Natural Products Research, University, Mississippi, United States",https://ClinicalTrials.gov/show/NCT04490239,United States,Intranasal heparin sodium (porcine),11.0,2020,Sunday
3545,3546,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Completed,Drug: Polyoxidonium,All,"18 Years and older   (Adult, Older Adult)",,81.0,"March 31, 2020",2020-10-30,"December 9, 2020","Healthcare Institution ""Grodno Regional Infectious Clinical Hospital"", Grodno, Belarus|State-Funded Healthcare Institution ""Emergency Hospital"" of Ministry of Health of Chuvash Republic, Cheboksary, Chuvashia, Russian Federation|State-Funded Healthcare Institution ""Infectious Disease Hospital No.3"" of Ministry of Health of Krasnodar Krai, Novorossiysk, Krasnodar Krai, Russian Federation|State-Funded Institution of Mari El Republic ""Yoshkar-Ola City Hospital"", Yoshkar-Ola, Mari El Republic, Russian Federation|State-Funded Healthcare Institution of Voronezh Region ""Novaya Usman District Hospital"", Novaya Usman, Voronezh Region, Russian Federation",https://ClinicalTrials.gov/show/NCT04542226,Belarus,Polyoxidonium,10.0,2020,Friday
3546,3547,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Recruiting,Drug: Colchicine|Drug: Usual Care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,70.0,"April 26, 2020",2020-06-14,"May 8, 2020","Maimonides Medical Center, Brooklyn, New York, United States",https://ClinicalTrials.gov/show/NCT04363437,United States,Colchicine|Usual Care,6.0,2020,Sunday
3547,3548,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Completed,Other: Chiropractic care (one visit)|Other: Chiropractic care (more than one visit),All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,723.0,"May 2, 2020",2020-05-27,"October 5, 2020","Real Centro Universitario María Cristina, San Lorenzo De El Escorial, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04573361,Spain,,5.0,2020,Wednesday
3548,3549,Status of Management of Surgery in Beijing During COVID-19,Not yet recruiting,Other: no intervention,All,"Child, Adult, Older Adult",,500.0,"May 25, 2020",2020-06-07,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04401124,Undefined,,6.0,2020,Sunday
3549,3550,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,Recruiting,Diagnostic Test: Odd/Even birth year intervention groups,All,"Child, Adult, Older Adult",,120.0,"March 25, 2020",2020-04-10,"April 14, 2020","Everett Clinic, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04327804,United States,,4.0,2020,Friday
3550,3551,The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.,Recruiting,Other: no intervention,All,"18 Years to 70 Years   (Adult, Older Adult)",,1000.0,"April 10, 2020",2020-12-31,"September 3, 2020","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04345640,India,,12.0,2020,Thursday
3551,3552,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Recruiting,Diagnostic Test: Assessment of ventilator-associated pneumonia criteria,All,"18 Years and older   (Adult, Older Adult)",,30.0,"April 16, 2020",2020-08-01,"May 4, 2020","Semmelweis University, Budapest, Hungary",https://ClinicalTrials.gov/show/NCT04372576,Hungary,,8.0,2020,Saturday
3552,3553,Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.,Not yet recruiting,Other: Questionnaire,All,"18 Years to 100 Years   (Adult, Older Adult)",,1200.0,"April 30, 2020",2020-09-30,"May 1, 2020","Saint Joseph University, Beirut, Lebanon",https://ClinicalTrials.gov/show/NCT04372043,Lebanon,,9.0,2020,Wednesday
3553,3554,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Recruiting,Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,346.0,"April 2, 2020",2020-12-31,"October 6, 2020","Rush University Medical Center, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04325906,United States,,12.0,2020,Thursday
3554,3555,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Not yet recruiting,Device: Personal protective equipment (PPE)|Device: No Personal protective equipment (PPE),All,18 Years to 60 Years   (Adult),Not Applicable,28.0,"September 13, 2020",2020-12-31,"September 16, 2020",,https://ClinicalTrials.gov/show/NCT04548934,Undefined,,12.0,2020,Thursday
3555,3556,Endoscopy-related Phone Consultation During the COVID-19 Outbreak,Completed,Other: None - NA,All,"18 Years and older   (Adult, Older Adult)",,186.0,"April 15, 2020",2020-07-03,"July 9, 2020","Austin Health, Melbourne, Victoria, Australia",https://ClinicalTrials.gov/show/NCT04344964,Australia,,7.0,2020,Friday
3556,3557,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Completed,Biological: Anti-SARS-CoV-2 IgT seropositivity,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,2006.0,"June 26, 2020",2020-07-24,"August 19, 2020","Chru Nancy, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04448769,France,,7.0,2020,Friday
3557,3558,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Enrolling by invitation,Dietary Supplement: PreserVision AREDS formulation gel tabs|Dietary Supplement: Centrum Adult (under 50) multivitamin,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,4500.0,"September 28, 2020",2021-05-14,"September 29, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04551339,United States,,5.0,2021,Friday
3558,3559,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Recruiting,Device: Limbix Spark|Other: Psychoeducation,All,"13 Years to 21 Years   (Child, Adult)",Not Applicable,410.0,"July 20, 2020",2020-12-31,"September 18, 2020","Limbix Health, Inc., San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04524598,United States,,12.0,2020,Thursday
3559,3560,Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers,Not yet recruiting,Drug: HLX70|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,24.0,"December 9, 2020",2021-09-18,"September 24, 2020",,https://ClinicalTrials.gov/show/NCT04561076,Undefined,HLX70,9.0,2021,Saturday
3560,3561,Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia,Not yet recruiting,,All,"4 Years and older   (Child, Adult, Older Adult)",,10000.0,"August 1, 2020",2020-12-31,"July 22, 2020","dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04343664,Indonesia,,12.0,2020,Thursday
3561,3562,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,"Active, not recruiting",Other: Non invasive visual acuity testing,All,"18 Years to 90 Years   (Adult, Older Adult)",,150.0,"May 20, 2020",2022-05-01,"July 30, 2020","Vanderbilt Eye Institute, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04391166,United States,,5.0,2022,Sunday
3562,3563,Status and Predictors of Mental Health Symptoms Among Migrants and Refugees During the COVID-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,287.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04443764,Undefined,,7.0,2020,Monday
3563,3564,Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19,Recruiting,Other: nutritional intervention,All,"16 Years and older   (Child, Adult, Older Adult)",,800.0,"April 1, 2020",2020-11-30,"June 30, 2020","Quilliot, VANDOEUVRE LES Nancy, France",https://ClinicalTrials.gov/show/NCT04451694,France,,11.0,2020,Monday
3564,3565,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,Enrolling by invitation,Other: Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,350.0,"October 14, 2020",2020-12-01,"November 4, 2020","University of British Columbia, Kelowna, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04602832,Canada,,12.0,2020,Tuesday
3565,3566,One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"May 8, 2020",2021-05-31,"July 7, 2020","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital General de Cataluña, Sant Cugat Del Vallès, Barcelona, Spain|Hospital Infanta Margarita de Cabra, Cabra, Córdoba, Spain|Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain|Hospital Son Llatzer, Palma De Mallorca, Mallorca, Spain|Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|Hospital Universitario Sant Joan d'Alacant, Alicante, Spain|Clínica Sagrada Família, Barcelona, Spain|Hospital Sagrat Cor, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Burgos, Burgos, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Hospital de León, León, Spain|Hospital Arnau de Vilanova Lleida, Lleida, Spain|Hospital Infanta Leonor de Madrid, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Complexo Hospitalario Universitario de Ourense, Ourense, Spain|Complejo Asistencial Universitario de Palencia, Palencia, Spain|Hospital Montecelo, Pontevedra, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitari Virgen de Valme, Sevilla, Spain|Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain|Hospital Clínic Universitari de València, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Hospital Universitario Valladolid, Valladolid, Spain|Hospital Nuestra Señora de Gracia, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT04457505,Spain,,5.0,2021,Monday
3566,3567,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",Recruiting,Device: Virtual Reality,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,40.0,"August 1, 2020",2021-01-01,"August 24, 2020","Radboud university medical center, Nijmegen, Gelderland, Netherlands",https://ClinicalTrials.gov/show/NCT04505761,Netherlands,,1.0,2021,Friday
3567,3568,ChulaCov19 mRNA Vaccine in Healthy Adults,Not yet recruiting,Biological: ChulaCov19 mRNA vaccine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,96.0,January 2021,2021-06-01,"October 6, 2020","Chula Vaccine Research Center (ChulaCRC) Faculty of Medicine Chulalongkorn University, Bangkok, Thailand|Center of Excellence for Vaccine Trial (Vaccine Trial Centre), Faculty of Tropical Medicine Mahidol University, Bangkok, Thailand",https://ClinicalTrials.gov/show/NCT04566276,Thailand,,6.0,2021,Tuesday
3568,3569,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,Recruiting,"Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"May 12, 2020",2022-11-01,"May 29, 2020","CAMH, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04384965,Canada,,11.0,2022,Tuesday
3569,3570,Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP,Recruiting,Device: Low flow ECMO driving by CVVH machine,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,10.0,"February 20, 2020",2020-10-15,"June 16, 2020","Yun Long, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04340414,China,,10.0,2020,Thursday
3570,3571,Renin Angiotensin System - CoronaVirus,Recruiting,Other: blood draw,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 3, 2020",2020-07-31,"April 24, 2020","ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE, Marseille, France",https://ClinicalTrials.gov/show/NCT04337008,France,,7.0,2020,Friday
3571,3572,An Observational Study of Patients With Coronavirus Disease 2019,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"April 13, 2020",2021-03-01,"May 14, 2020","University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04331886,United States,,3.0,2021,Monday
3572,3573,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure,Not yet recruiting,Procedure: Plasma exchange and convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,220.0,"November 16, 2020",2022-06-30,"November 18, 2020",,https://ClinicalTrials.gov/show/NCT04634422,Undefined,,6.0,2022,Thursday
3573,3574,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Recruiting,Other: Staff Wellbeing Centres,All,"Child, Adult, Older Adult",Not Applicable,45.0,"May 25, 2020",2020-11-30,"June 12, 2020","Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04410016,United Kingdom,,11.0,2020,Monday
3574,3575,Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients,Not yet recruiting,Drug: Recombinant human interferon α1β,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,328.0,"March 1, 2020",2020-06-30,"March 3, 2020",,https://ClinicalTrials.gov/show/NCT04293887,Undefined,Recombinant human interferon α1β,6.0,2020,Tuesday
3575,3576,Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia,Available,Other: Phage Therapy,All,"18 Years and older   (Adult, Older Adult)",,,,,"November 19, 2020",,https://ClinicalTrials.gov/show/NCT04636554,Undefined,,,n,
3576,3577,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",Recruiting,Behavioral: Dialectical Behavioral Therapy (DBT) Skills,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"September 12, 2020",2020-12-15,"September 22, 2020","Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04558411,Jersey,,12.0,2020,Tuesday
3577,3578,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,Not yet recruiting,Drug: SIR1-365|Drug: Matching Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,60.0,"December 15, 2020",2021-12-15,"November 9, 2020",,https://ClinicalTrials.gov/show/NCT04622332,Undefined,SIR1-365|Matching Placebo,12.0,2021,Wednesday
3578,3579,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Not yet recruiting,Other: EXTRA-CVD Virtual Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75.0,February 2021,2022-08-01,"December 10, 2020","Duke Health, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04661813,United States,,8.0,2022,Monday
3579,3580,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Recruiting,Other: Caring Contacts,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"August 4, 2020",2021-03-01,"August 31, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04456062,Canada,,3.0,2021,Monday
3580,3581,Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19,Not yet recruiting,Other: COVID-19,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"June 15, 2020",2021-09-15,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04376658,Undefined,,9.0,2021,Wednesday
3581,3582,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,Terminated,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,259.0,"April 1, 2020",2020-06-18,"October 6, 2020","CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Auxerre, Auxerre, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Chalon Sur Saône, Chalon Sur Saône, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|CH Compiègne, Compiègne, France|APHP Henri Mondor, Créteil, France|CH Intercommunal Créteil, Créteil, France|CHU Dijon, Dijon, France|APHP Joffre Dupuytren, Draveil, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CH Emile Roux, Le Puy-en-Velay, France|APHP Emile ROUX, Limeil-Brevannes, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|Hôpital Européen - Marseille, Marseille, France|Hôpital Saint-Joseph, Marseille, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|GH Croix Saint Simon, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco",https://ClinicalTrials.gov/show/NCT04325893,France,Hydroxychloroquine|Placebo,6.0,2020,Thursday
3582,3583,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,Biological: BCG GROUP|Other: PLACEBO GROUP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1120.0,"May 20, 2020",2021-02-20,"August 18, 2020","I-REIVAC/CIC 1417 Cochin Hospital, APHP, Paris, France",https://ClinicalTrials.gov/show/NCT04384549,France,,2.0,2021,Saturday
3583,3584,Sarilumab COVID-19,Completed,Drug: Sarilumab SAR153191|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,420.0,"March 28, 2020",2020-09-02,"September 29, 2020","Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, São José Do Rio Preto, Brazil|Investigational Site Number 0760005, São Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational site number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid / Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04327388,Argentina,Sarilumab SAR153191|Placebo,9.0,2020,Wednesday
3584,3585,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,Recruiting,"Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"June 9, 2020",2022-12-01,"June 23, 2020","CAMH, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04427137,Canada,,12.0,2022,Thursday
3585,3586,Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index,Not yet recruiting,Diagnostic Test: Pleth variability index,All,"18 Years and older   (Adult, Older Adult)",,30.0,"May 5, 2020",2020-06-15,"May 4, 2020","Erzincan University, Erzincan, Turkey",https://ClinicalTrials.gov/show/NCT04373213,Turkey,,6.0,2020,Monday
3586,3587,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,Recruiting,Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,44.0,"September 4, 2020",2021-09-04,"November 25, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT04379518,United States,Rintatolimod,9.0,2021,Saturday
3587,3588,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19.,Recruiting,Diagnostic Test: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",,2400.0,"September 15, 2020",2020-10-15,"September 28, 2020","Hôpital d'Instruction des Armées Percy, Clamart, France|Hôpital d'Instruction des Armées Laveran, Marseille, France|Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France|Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France",https://ClinicalTrials.gov/show/NCT04550390,France,,10.0,2020,Thursday
3588,3589,Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic,Recruiting,Other: Satisfaction evaluation,All,"18 Years and older   (Adult, Older Adult)",,450.0,"March 16, 2020",2020-06-15,"May 27, 2020","Department of Neuro- Urology, Hôpital Tenon, Paris, France",https://ClinicalTrials.gov/show/NCT04341714,France,,6.0,2020,Monday
3589,3590,Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,"Active, not recruiting",Drug: Plaquenil 200Mg Tablet,All,"20 Years to 90 Years   (Adult, Older Adult)",,80.0,"March 20, 2020",2020-09-01,"July 28, 2020","Istinye University Medical School, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04326725,Turkey,Plaquenil 200Mg Tablet,9.0,2020,Tuesday
3590,3591,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,Completed,Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals,All,"Child, Adult, Older Adult",,533.0,"March 9, 2020",2020-03-23,"April 13, 2020","Everett Clinic, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04321369,United States,,3.0,2020,Monday
3591,3592,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,Behavioral: Online Intervention Mental Health COVID-19,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,128.0,"May 20, 2020",2021-01-15,"November 4, 2020","Universidad Autónoma de Ciudad Juárez, Juarez, Chihuahua, Mexico",https://ClinicalTrials.gov/show/NCT04468893,Mexico,,1.0,2021,Friday
3592,3593,"Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff",Not yet recruiting,Other: COVID visitation restrictions,All,"18 Years to 100 Years   (Adult, Older Adult)",,1000.0,September 2020,2021-12-01,"September 4, 2020",,https://ClinicalTrials.gov/show/NCT04538469,Undefined,,12.0,2021,Wednesday
3593,3594,A Study on the Prospective Cohort Library of COVID-19 in Southeran,"Active, not recruiting",,All,"Child, Adult, Older Adult",,504.0,"March 16, 2020",2021-03-01,"May 5, 2020","Wenzhou Medical University, Wenzhou, Zhejiang, China|The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04342702,China,,3.0,2021,Monday
3594,3595,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,Other: blood sample,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,115.0,"April 22, 2020",2020-10-22,"May 1, 2020","Lyon Univerity Hospital, Lyon, France|APHM, Marseille, France|Montpellier University Hospital, Montpellier, France|University Nice Hospital, Nice, France|APHP, Paris, France|Saint Etienne University Hospital, Saint-Étienne, France|Strasbourg Univeristy Hospital, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04369456,France,,10.0,2020,Thursday
3595,3596,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,Biological: Plasma exchange|Drug: Standar medical treatmen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,116.0,"April 29, 2020",2021-08-29,"July 7, 2020","Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04374539,Spain,Standar medical treatmen,8.0,2021,Sunday
3596,3597,The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19,Recruiting,Other: no intervention,All,"20 Years to 100 Years   (Adult, Older Adult)",,100.0,"February 1, 2020",2020-06-20,"May 27, 2020","The First Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China|Hankou Hospital, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04403009,China,,6.0,2020,Saturday
3597,3598,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,Recruiting,Other: Exercise training group,All,"10 Years to 19 Years   (Child, Adult)",Not Applicable,140.0,July 2020,2021-06-01,"July 7, 2020","Univsersity of Sao Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04458246,Brazil,,6.0,2021,Tuesday
3598,3599,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,"Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)",All,"14 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,150.0,"January 22, 2020",2021-01-22,"May 5, 2020","The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04251871,China,"Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)",1.0,2021,Friday
3599,3600,PTSD Symptoms Among Health Workers and Public Service Providers After the COVID-19 Outbreak: A 3 Month Follow up,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,889.0,"June 22, 2020",2020-07-13,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04442243,Undefined,,7.0,2020,Monday
3600,3601,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,Recruiting,,All,"Child, Adult, Older Adult",,15.0,"February 1, 2020",2020-12-31,"March 3, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04292340,China,,12.0,2020,Thursday
3601,3602,Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak,Not yet recruiting,Behavioral: online mindfulness group,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"August 1, 2020",2021-07-30,"July 15, 2020","School of public health and primary care, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04346082,Hong Kong,,7.0,2021,Friday
3602,3603,Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19,Not yet recruiting,Device: Inspiratory training device|Device: Expiratory training device,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240.0,"July 26, 2020",2020-12-20,"June 2, 2020",,https://ClinicalTrials.gov/show/NCT04326114,Undefined,,12.0,2020,Sunday
3603,3604,Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors,Recruiting,Other: Psycho-Social Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,120.0,"May 27, 2020",2021-07-27,"July 17, 2020","MOULIN Valérie, La Rochelle, France|BOURGEOIS Hugues, Le Mans, France|RANDRIAN Violaine, Poitiers, France",https://ClinicalTrials.gov/show/NCT04389684,France,,7.0,2021,Tuesday
3604,3605,Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19,Completed,Other: Pulmonary Rehabilitation,All,"18 Years to 88 Years   (Adult, Older Adult)",,100.0,"March 20, 2020",2020-03-27,"May 14, 2020","Nippon Gases Portugal Unipessoal Lda, Maia, Porto, Portugal|Universidade de Lisboa, Faculdade de Medicina, Instituto de Saúde Ambiental (ISAMB), Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Hospital Pulido Valente, Unidade de Reabilitação Respiratória, Lisboa, Portugal",https://ClinicalTrials.gov/show/NCT04388579,Portugal,,3.0,2020,Friday
3605,3606,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,49.0,"April 3, 2020",2020-06-01,"June 23, 2020","Akarkh Healt hdirectorate, Baghdad, Iraq",https://ClinicalTrials.gov/show/NCT04441424,Iraq,Hydroxychloroquin with Azithromycin,6.0,2020,Monday
3606,3607,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Completed,Device: non-contact magnetically-controlled capsule endoscopy,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40.0,"March 26, 2020",2020-05-20,"July 21, 2020","Changhai Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04389333,China,,5.0,2020,Wednesday
3607,3608,A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19,Not yet recruiting,Behavioral: Usual Care|Behavioral: online KKH Sports Singapore Program with Usual Care,All,4 Years to 6 Years   (Child),Not Applicable,40.0,"September 1, 2020",2021-10-01,"August 5, 2020",,https://ClinicalTrials.gov/show/NCT04395430,Undefined,,10.0,2021,Friday
3608,3609,Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic,Recruiting,,All,"12 Years to 98 Years   (Child, Adult, Older Adult)",,150.0,"May 9, 2020",2021-06-30,"July 22, 2020","Max Superspeciality hospital, A Unit of Balaji Medical and Diagnostic Centre, New Delhi, India",https://ClinicalTrials.gov/show/NCT04406844,India,,6.0,2021,Wednesday
3609,3610,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",Recruiting,,All,"up to 24 Years   (Child, Adult)",,400.0,"April 27, 2020",2022-06-30,"June 29, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04371315,United States,,6.0,2022,Thursday
3610,3611,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Recruiting,Other: physiological effects of awake prone position in COVID 19 patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 4, 2020",2021-01-31,"November 17, 2020","Assistance Publique Höpitaux de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04632602,France,,1.0,2021,Sunday
3611,3612,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,Completed,Diagnostic Test: Venous blood was collected for biochemistry testing,All,"18 Years to 100 Years   (Adult, Older Adult)",,150.0,"September 10, 2020",2020-12-09,"December 10, 2020","Bezmialem VU, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04662437,Turkey,,12.0,2020,Wednesday
3612,3613,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic,Not yet recruiting,Behavioral: Self-focused acts|Behavioral: Prosocial acts,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1542.0,January 2021,2021-03-01,"November 6, 2020",,https://ClinicalTrials.gov/show/NCT04517006,Undefined,,3.0,2021,Monday
3613,3614,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,Not yet recruiting,Behavioral: Behavioral: OCAT-sham|Behavioral: Behavioral: OCAT|Other: psycho-education video,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"April 20, 2020",2020-08-01,"April 29, 2020","Ghent University, Gent, Oost-Vlaanderen, Belgium",https://ClinicalTrials.gov/show/NCT04367636,Belgium,,8.0,2020,Saturday
3614,3615,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Recruiting,Behavioral: Mindfulness intervention|Behavioral: Non-Mindfulness intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,"August 26, 2020",2020-12-01,"September 2, 2020","Monash University Malaysia, Subang Jaya, Selangor, Malaysia",https://ClinicalTrials.gov/show/NCT04394013,Malaysia,,12.0,2020,Tuesday
3615,3616,Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation,Completed,Diagnostic Test: Asynchronies detection,All,"18 Years and older   (Adult, Older Adult)",,32.0,"March 9, 2020",2020-06-30,"July 14, 2020","Candelaria de Haro, Sabadell, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04448782,Spain,,6.0,2020,Tuesday
3616,3617,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630.0,"April 1, 2020",2020-08-30,"June 1, 2020","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil",https://ClinicalTrials.gov/show/NCT04322123,Brazil,Hydroxychloroquine Oral Product|Hydroxychloroquine + azithromycin,8.0,2020,Sunday
3617,3618,Improving Wellbeing and Health for Care Home Residents During COVID-19,Not yet recruiting,Other: COVID WHELD,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,2880.0,"November 20, 2020",2022-01-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04590469,Undefined,,1.0,2022,Saturday
3618,3619,Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients,Not yet recruiting,Drug: Dexmedetomidine Injectable Product,All,"18 Years to 99 Years   (Adult, Older Adult)",,80.0,"April 15, 2020",2020-06-30,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04358627,Undefined,Dexmedetomidine Injectable Product,6.0,2020,Tuesday
3619,3620,Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,Recruiting,,Female,"18 Years and older   (Adult, Older Adult)",,11000.0,"April 21, 2020",2022-09-01,"May 15, 2020","University of California, San Francisco, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04388605,United States,,9.0,2022,Thursday
3620,3621,Impact of Social Distancing on Bariatric Versus Non-Surgical Obese Patients During COVID-19 Pandemic,Completed,Other: Standard Care,All,"18 Years to 65 Years   (Adult, Older Adult)",,272.0,"June 1, 2020",2020-07-30,"November 20, 2020","Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04633941,Singapore,,7.0,2020,Thursday
3621,3622,Difficulties in Emotion-regulation and Interpersonal Problems During and After the COVID-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5041.0,"June 22, 2020",2020-07-13,"June 22, 2020",,https://ClinicalTrials.gov/show/NCT04442282,Undefined,,7.0,2020,Monday
3622,3623,Factors Associated With Adherence to Hygiene-related Behaviors and Viral Mitigation Protocols During the COVID-19 Pandemic,Not yet recruiting,Behavioral: Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04442217,Undefined,,7.0,2020,Monday
3623,3624,"Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19",Recruiting,Diagnostic Test: SARS-CoV-2 PCR,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 2, 2020",2023-12-31,"May 11, 2020","Vestre Viken Drammen Hospital, Drammen, Viken, Norway|Haukeland University Hospital, Bergen, Norway|Østfold Hospital Trust, Fredrikstad, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway|University Hospital North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway",https://ClinicalTrials.gov/show/NCT04381819,Norway,,12.0,2023,Sunday
3624,3625,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,Other: CHEST CT SCAN,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 8, 2020",2021-11-08,"July 23, 2020","Hôpital Marie Lannelongue, Le Plessis-Robinson, France|Hôpital Saint Joseph, Paris, France|Institut Gustave Roussy (IGR), Villejuif, France",https://ClinicalTrials.gov/show/NCT04483752,France,,11.0,2021,Monday
3625,3626,Influence of the COVId-19 Pandemic on STRESS of Occupational Health Workers,Recruiting,Behavioral: Occupational health workers,All,"10 Years and older   (Child, Adult, Older Adult)",,1000.0,"June 1, 2020",2025-12-21,"November 6, 2020","Clermont-Ferrand University Hospital, Clermont-Ferrand, Aura, France",https://ClinicalTrials.gov/show/NCT04619576,France,,12.0,2025,Sunday
3626,3627,Information Sources and Their Relationship to Depressive and Anxiety Symptoms During the COVID-19 Pandemic: A Network Study,Not yet recruiting,Behavioral: Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"June 22, 2020",2020-07-13,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04444336,Undefined,,7.0,2020,Monday
3627,3628,Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments,Completed,Other: survey,All,"18 Years and older   (Adult, Older Adult)",,900.0,"July 8, 2020",2020-09-18,"September 23, 2020","CHU Angers, Angers, France|CH Le Mans, Le Mans, France",https://ClinicalTrials.gov/show/NCT04460196,France,,9.0,2020,Friday
3628,3629,Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19),Not yet recruiting,Behavioral: Video based exercise,All,40 Years to 60 Years   (Adult),Not Applicable,128.0,"August 20, 2020",2020-11-30,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04346953,Undefined,,11.0,2020,Monday
3629,3630,Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in México During the COVID-19 Pandemic,Recruiting,Other: COVID-19 survey|Other: RAPID-3|Other: WHOQOL-BREF|Other: DASS-21 instrument (depression and anxiety)|Other: IER-R (posttraumatic stress),All,"18 Years and older   (Adult, Older Adult)",,346.0,"July 1, 2020",2020-12-31,"September 21, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Tlalpan, Mexico",https://ClinicalTrials.gov/show/NCT04557358,Mexico,,12.0,2020,Thursday
3630,3631,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 27, 2020",2021-12-31,"April 1, 2020","Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France",https://ClinicalTrials.gov/show/NCT04324047,France,,12.0,2021,Friday
3631,3632,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,Not yet recruiting,"Behavioral: Intervention, TBN",All,15 Years to 17 Years   (Child),Not Applicable,4.0,"January 1, 2021",2023-06-30,"October 27, 2020","University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04604743,United States,,6.0,2023,Friday
3632,3633,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),Recruiting,Drug: Eltrombopag|Drug: rhTPO,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,"August 31, 2020",2022-08-01,"September 1, 2020","Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04516837,China,Eltrombopag|rhTPO,8.0,2022,Monday
3633,3634,Upper Limb Robotic Rehabilitation During COVID-19 Outbreak,Not yet recruiting,Device: Robotic therapy,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40.0,May 2020,2020-12-01,"May 18, 2020",,https://ClinicalTrials.gov/show/NCT04392453,Undefined,,12.0,2020,Tuesday
3634,3635,Breastfeeding Education in the Time of COVID-19,Recruiting,Behavioral: Telesimulation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39.0,"July 31, 2020",2021-09-30,"August 19, 2020","University of California - Davis, Sacramento, California, United States",https://ClinicalTrials.gov/show/NCT04519216,United States,,9.0,2021,Thursday
3635,3636,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.,Recruiting,Other: pregnant women with laboratory-confirmed 2019-n-CoV,Female,18 Years to 50 Years   (Adult),,20.0,"January 1, 2020",2020-04-30,"March 20, 2020","University of Naples Federico II, Napoli, Italy",https://ClinicalTrials.gov/show/NCT04315870,Italy,,4.0,2020,Thursday
3636,3637,Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection,Not yet recruiting,Drug: Nitric Oxide-Releasing Drug,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,January 2021,2021-07-01,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04443868,Undefined,Nitric Oxide-Releasing Drug,7.0,2021,Thursday
3637,3638,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting","Behavioral: Transitional Online Peer Support Group (n=20)|Other: Control Group (pharmacotherapy and/or psychotherapy, n=10)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"August 25, 2020",2020-12-01,"November 23, 2020","CR-IUSMM, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04445324,Canada,,12.0,2020,Tuesday
3638,3639,Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders,Recruiting,Diagnostic Test: Online Survey,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"April 28, 2020",2021-04-28,"June 11, 2020","Medical University Graz, Department of Psychiatry and Psychotherapeutic Medicine, Graz, Styria, Austria",https://ClinicalTrials.gov/show/NCT04410835,Austria,,4.0,2021,Wednesday
3639,3640,Covid-19 Pandemic and Pancreatic Surgery in Italy,Completed,Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer,All,"18 Years and older   (Adult, Older Adult)",,730.0,"January 1, 2019",2020-07-31,"August 3, 2020","Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma, Roma, Lazio, Italy",https://ClinicalTrials.gov/show/NCT04380766,Italy,,7.0,2020,Friday
3640,3641,Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons (COVISTRESS - Dental Surgery),Recruiting,,All,"16 Years and older   (Child, Adult, Older Adult)",,1000.0,"May 1, 2020",2020-12-01,"September 9, 2020","University Hospital, Clermont Ferrand, Clermont-Ferrand, France",https://ClinicalTrials.gov/show/NCT04541472,France,,12.0,2020,Tuesday
3641,3642,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Completed,Drug: SAR443122|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,68.0,"July 17, 2020",2020-10-23,"November 13, 2020","Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, São José Do Rio Preto, Brazil|Investigational Site Number 0760002, São Paulo, Brazil|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Talca, Chile|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04469621,Argentina,SAR443122|Placebo,10.0,2020,Friday
3642,3643,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,Recruiting,Behavioral: Assigned Strategies: Opt-in|Behavioral: Assigned Strategies: Active Choice|Behavioral: Assigned Strategies: Enhanced Active Choice|Behavioral: Choice of Assignment: Opt-in|Behavioral: Choice of Assignment: Active Choice|Behavioral: Choice of Assignment: Enhanced Active Choice,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,145.0,"September 7, 2020",2020-12-01,"September 23, 2020","University of Western Ontario, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04488796,Canada,,12.0,2020,Tuesday
3643,3644,Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic,Completed,Behavioral: Assessment of work-related stress|Biological: Saliva sample collection|Other: Cardiac and electrodermal recordings|Behavioral: Assessment of behavioral response to emotional stimulation,All,18 Years to 60 Years   (Adult),,50.0,"April 25, 2020",2020-06-12,"August 17, 2020","Elément Militaire de Réanimation (EMR), Mulhouse, France",https://ClinicalTrials.gov/show/NCT04365335,France,,6.0,2020,Friday
3644,3645,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,Completed,"Behavioral: Training for Awareness, Resilience, and Action (TARA)",All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,21.0,"October 18, 2019",2020-05-20,"September 14, 2020","UCSF, San Francisco, California, United States",https://ClinicalTrials.gov/show/NCT04548544,United States,,5.0,2020,Wednesday
3645,3646,The Validity of Modern Mobile Applications in Management of COVID-19 Home Isolation Patients: a Survey for Health Care Professionals,Not yet recruiting,Other: Survey,All,"35 Years and older   (Adult, Older Adult)",,175.0,"September 14, 2020",2021-01-01,"September 14, 2020",,https://ClinicalTrials.gov/show/NCT04548492,Undefined,,1.0,2021,Friday
3646,3647,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Drug: Ruconest,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120.0,"November 30, 2020",2021-11-30,"December 10, 2020","The Valley Hospital, Ridgewood, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04530136,Jersey,Ruconest,11.0,2021,Tuesday
3647,3648,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Recruiting,Biological: Anti-SARS-CoV-2 Human Convalescent Plasma,All,"1 Month to 18 Years   (Child, Adult)",Phase 1,30.0,"May 28, 2020",2022-05-28,"June 2, 2020","Johns Hopkins Hospitals, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04377672,United States,,5.0,2022,Saturday
3648,3649,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Device: ECCO2R,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"May 3, 2020",2021-10-01,"September 30, 2020","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany",https://ClinicalTrials.gov/show/NCT04351906,Germany,,10.0,2021,Friday
3649,3650,An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies,Not yet recruiting,Other: Quality of life assessment,All,"18 Years and older   (Adult, Older Adult)",,400.0,October 2020,2024-10-01,"October 9, 2020",,https://ClinicalTrials.gov/show/NCT04581187,Undefined,,10.0,2024,Tuesday
3650,3651,COVID-19 Burnout Study,Not yet recruiting,Behavioral: Mindfulness Based Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"November 1, 2020",2021-07-01,"November 3, 2020",,https://ClinicalTrials.gov/show/NCT04594278,Undefined,,7.0,2021,Thursday
3651,3652,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,Recruiting,Drug: NORS (Nitric Oxide Releasing Solution),All,"19 Years and older   (Adult, Older Adult)",Phase 2,200.0,"May 8, 2020",2020-09-30,"June 25, 2020","BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche Québec, Québec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-Borromée, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04337918,Canada,NORS (Nitric Oxide Releasing Solution),9.0,2020,Wednesday
3652,3653,COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,Not yet recruiting,Behavioral: COMPASS|Behavioral: Standard charity resources,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"September 28, 2020",2021-06-01,"September 2, 2020","Health Psychology Section, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04535778,United Kingdom,,6.0,2021,Tuesday
3653,3654,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Recruiting,Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use,All,"18 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,10.0,"March 25, 2020",2021-12-31,"October 12, 2020","Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States",https://ClinicalTrials.gov/show/NCT04326036,United States,Liberase Enzyme (Roche)|Sterile Normal Saline for Intravenous Use,12.0,2021,Friday
3654,3655,Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19,Recruiting,Behavioral: Data registry,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 14, 2020",2022-12-31,"August 12, 2020","Chu Angers, Angers, France|CHU Jean Minjoz - Hématologie, Besançon, France|Hôpital Avicenne - Centre de Recherche Clinique, Bobigny, France|CHU Estaing - Hématologie Clinique Adulte, Clermont-Ferrand, France|Chu Creteil, Créteil, France|CHU Grenoble - Hématologie, Grenoble, France|Chd Vendee, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|Hôpital Saint Vicent de Paul, Lille, France|Centre Léon Bérard - Hématologie, Lyon, France|Institut Paoli Calmette, Marseille, France|Hopital E.Muller, Mulhouse, France|CHU DE NANTES - Hematologie clinique, Nantes, France|Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire, Poitiers, France|Hôpital Robert Debré - Hématologie Clinique, Reims, France|Centre Henri Becquerel - Service Hématologie Clinique, Rouen, France|Hôpital Hautepierre - Hématologie, Strasbourg, France|IUCT ONCOPOLE - Hématologie, Toulouse, France|Hôpital Bretonneau - Hématologie et Thérapie Cellulaire, Tours, France|CHU Nancy Brabois, Vandœuvre-lès-Nancy, France",https://ClinicalTrials.gov/show/NCT04391946,France,,12.0,2022,Saturday
3655,3656,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Not yet recruiting,Behavioral: Online Intervention Grief COVID-19,All,18 Years to 60 Years   (Adult),Not Applicable,42.0,"December 15, 2020",2021-06-01,"November 20, 2020","Universidad Autónoma de Ciudad Juárez, Juárez, Chihuahua, Mexico",https://ClinicalTrials.gov/show/NCT04638842,Mexico,,6.0,2021,Tuesday
3656,3657,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,Recruiting,Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,164.0,"September 30, 2020",2021-08-01,"October 5, 2020","Hospital units across Sweden (e.g. FO Akut, Karolinska University Hospital Huddinge), Huddinge, Sweden",https://ClinicalTrials.gov/show/NCT04460014,Sweden,,8.0,2021,Sunday
3657,3658,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,Recruiting,"Biological: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|Drug: Normal Saline",All,65 Years to 100 Years   (Older Adult),Early Phase 1,250.0,"September 1, 2020",2021-09-01,"November 10, 2020","Fran and Earl Ziegler College of Nursing, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT04523246,United States,Normal Saline,9.0,2021,Wednesday
3658,3659,Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.,"Active, not recruiting",Other: Survey and Questionnaire,All,18 Years to 25 Years   (Adult),,800.0,"April 30, 2020",2020-12-30,"June 30, 2020","Erasme University Hospital, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04371250,Belgium,,12.0,2020,Wednesday
3659,3660,Convalescent Antibodies Infusion in COVID 19 Patients,Not yet recruiting,Biological: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,June 2020,2020-09-01,"June 5, 2020","ASST - Papa Giovanni XXIII - Unit of Nephrology, Bergamo, BG, Italy|Asst Hpg23 - Eas, Bergamo, BG, Italy|ASST HPG23 - Intensive Care Unit, Bergamo, BG, Italy|ASST HPG23 - Microbioly and Virology Unit, Bergamo, BG, Italy|Sst Hpg23 - S.I.M.T., Bergamo, BG, Italy|IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy",https://ClinicalTrials.gov/show/NCT04418531,Italy,,9.0,2020,Tuesday
3660,3661,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440.0,"March 28, 2020",2020-06-14,"July 2, 2020","Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Hospital e Clínica São Roque, Ipiaú, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil|Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil|Hospital São Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Hospital Nereu Ramos, Florianópolis, SC, Brazil|Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saude Santa Marcelina, São Paulo, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital Moriah, São Paulo, SP, Brazil|Hospital Nove de Julho, São Paulo, SP, Brazil|Hospital Santa Paula, São Paulo, SP, Brazil|Hospital São Camilo Pompeia, São Paulo, SP, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04321278,Brazil,Hydroxychloroquine + azithromycin|Hydroxychloroquine,6.0,2020,Sunday
3661,3662,A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole,Recruiting,Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D,All,18 Years to 55 Years   (Adult),Phase 1,40.0,"October 12, 2020",2020-11-30,"October 22, 2020","Research Site, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04564040,Germany,Acalabrutinib Treatment A|Acalabrutinib Treatment B|Acalabrutinib Treatment C|Acalabrutinib Treatment D,11.0,2020,Monday
3662,3663,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,"Active, not recruiting",Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320.0,"April 8, 2020",2020-12-01,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04346693,Russian Federation,,12.0,2020,Tuesday
3663,3664,Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.,Recruiting,Diagnostic Test: Susceptibility to infection,All,"18 Years to 65 Years   (Adult, Older Adult)",,60.0,"August 1, 2020",2021-01-30,"August 25, 2020","Hospital Ramon y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04402827,Spain,,1.0,2021,Saturday
3664,3665,ASC Therapy for Patients With Severe Respiratory COVID-19,Withdrawn,Drug: Stem Cell Product,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,0.0,"April 20, 2020",2021-04-30,"May 27, 2020","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",https://ClinicalTrials.gov/show/NCT04341610,Denmark,Stem Cell Product,4.0,2021,Friday
3665,3666,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Recruiting,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"Child, Adult, Older Adult",Phase 2,226.0,"April 6, 2020",2021-03-31,"May 11, 2020","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark",https://ClinicalTrials.gov/show/NCT04322396,Denmark,Azithromycin|Hydroxychloroquine|Placebo oral tablet,3.0,2021,Wednesday
3666,3667,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,Behavioral: Digital Health Online Platform,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 20, 2020",2021-01-01,"November 18, 2020","Behavioural Medicine Lab, University of Victoria, Victoria, British Columbia, Canada|University of Victoria, Victoria, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04400305,Canada,,1.0,2021,Friday
3667,3668,"Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19",Recruiting,Drug: bovhyaluronidase azoxymer,All,"18 Years and older   (Adult, Older Adult)",,160.0,"July 1, 2020",2021-07-01,"November 27, 2020","Federal State Budgetary Educational Institution of Higher Education ""Astrakhan State Medical University"" of the Ministry of Health of the Russian Federation, Astrakhan, Astrakhan Region, Russian Federation|Municipal autonomous health care institution ""City Clinical Polyclinic No. 8"", Chelyabinsk, Chelyabinsk Region, Russian Federation|State Budgetary Healthcare Institution ""Regional Clinical Hospital No. 3"", Chelyabinsk, Chelyabinsk Region, Russian Federation|Municipal budgetary institution ""Central city clinical hospital number 6 "", Ekaterinburg, Ekaterinburg Region, Russian Federation|Medical center ""Clinic South"", Krasnodar, Krasnodar Region, Russian Federation|Federal State Budgetary Scientific Institution ""Federal Research Center"" Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences "" Scientific Research Institute of Medical Problems of the North, Krasnoyarsk, Krasnoyarsk Region, Russian Federation|Institute of Clinical Immunology LLC, Krasnoyarsk, Krasnoyarsk Region, Russian Federation|St. Petersburg State Budgetary Healthcare Institution ""City Consultative and Diagnostic Center No. 1"", Saint Petersburg, Leningrad Region, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Novosibirsk Region, Russian Federation|CJSC ""Medical Center"" Philosophy of Beauty and Health "", Perm, Perm Region, Russian Federation|State budgetary institution of health care Republican clinical hospital named after G.G. Kuvatova, Ufa, Ufa Region, Russian Federation|State health care institution ""Clinical Hospital No. 4"", Volgograd, Volgograd Region, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Volgograd State Medical University"" of the Ministry of Health of the Russian Federation Volgograd State Medical University of the Ministry of Health of Russia, Volgograd, Volgograd Region, Russian Federation|FSBI ""Main Military Clinical Hospital named after Academician N.N.Burdenko"" of the Ministry of Defense of the Russian Federation, Moscow, Russian Federation|State Budgetary Institution of Healthcare of the City of Moscow ""City Polyclinic No. 180 of the Department of Healthcare of the City of Moscow"", Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04645368,Russian Federation,bovhyaluronidase azoxymer,7.0,2021,Thursday
3668,3669,Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine,Recruiting,Biological: Flucelvax|Biological: Fluvirin|Biological: Fluzone High Dose,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"October 2, 2019",2025-12-31,"November 13, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04025580,United States,,12.0,2025,Wednesday
3669,3670,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers",Recruiting,Behavioral: PTSD|Behavioral: Burnout,All,"18 Years and older   (Adult, Older Adult)",,1464.0,"April 6, 2020",2021-12-31,"October 6, 2020","Saint-Louis Hospital, Paris, Ile De France, France|Cochin, Paris, France|Pitié Salpetrière, Paris, France",https://ClinicalTrials.gov/show/NCT04341519,France,,12.0,2021,Friday
3670,3671,Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Recruiting,Device: Electrical Impedance tomography,All,"18 Years and older   (Adult, Older Adult)",,15.0,"October 26, 2020",2022-04-01,"November 9, 2020","Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France",https://ClinicalTrials.gov/show/NCT04603755,France,,4.0,2022,Friday
3671,3672,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,"Active, not recruiting",Other: Nutrition support,All,"18 Years and older   (Adult, Older Adult)",,117.0,"February 19, 2020",2020-07-01,"April 8, 2020","Peking University Third Hospital, Beijing, China",https://ClinicalTrials.gov/show/NCT04274322,China,,7.0,2020,Wednesday
3672,3673,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,Behavioral: Patient-centred advice on Telephone Consultation in TB Patients:,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 20, 2020",2020-12-20,"November 18, 2020","Dhq Bannu Kpk, Bannu, KPK, Pakistan|District Bannu TB Control Center, Bannu, KPK, Pakistan",https://ClinicalTrials.gov/show/NCT04412239,Pakistan,,12.0,2020,Sunday
3673,3674,Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic,Not yet recruiting,Behavioral: Therapist Guided E-Therapy|Behavioral: Self-Help Therapy,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,70.0,"June 1, 2020",2020-10-20,"May 8, 2020",,https://ClinicalTrials.gov/show/NCT04378257,Undefined,,10.0,2020,Tuesday
3674,3675,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,Recruiting,Drug: Pioglitazone 30 mg|Other: standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,76.0,"September 18, 2020",2021-04-10,"November 17, 2020","Hospital Ramón y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04535700,Spain,Pioglitazone 30 mg,4.0,2021,Saturday
3675,3676,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",Drug: Sarilumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,239.0,"March 27, 2020",2021-12-31,"April 15, 2020","Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France",https://ClinicalTrials.gov/show/NCT04324073,France,Sarilumab,12.0,2021,Friday
3676,3677,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,"Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU",All,65 Years and older   (Older Adult),Phase 3,260.0,"April 15, 2020",2021-05-01,"October 5, 2020","CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France",https://ClinicalTrials.gov/show/NCT04344041,France,"cholecalciferol 200,000 IU|cholecalciferol 50,000 IU",5.0,2021,Saturday
3677,3678,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,Recruiting,Biological: Plasma|Other: Best Available Therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 27, 2020",2021-05-30,"May 19, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04358783,Mexico,,5.0,2021,Sunday
3678,3679,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,Drug: Amlodipine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000.0,"October 23, 2020",2021-07-31,"November 13, 2020","Queen Mary University London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04559074,United Kingdom,Amlodipine,7.0,2021,Saturday
3679,3680,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,Recruiting,Biological: ARCT-021 Dose 1|Biological: ARCT-021 Dose 2|Biological: ARCT-021 Dose 3|Biological: ARCT-021 Dose 4|Biological: ARCT-021 Dose Regimen 1|Biological: ARCT-021 Dose Regimen 2|Other: Placebo,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,92.0,"August 4, 2020",2021-01-01,"August 17, 2020","SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04480957,Singapore,,1.0,2021,Friday
3680,3681,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,Recruiting,Drug: Camostat Mesilate|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,264.0,"July 28, 2020",2022-09-15,"September 25, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04470544,United States,Camostat Mesilate,9.0,2022,Thursday
3681,3682,Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy,"Active, not recruiting",Procedure: Colorectal resections,All,"Child, Adult, Older Adult",,100.0,"March 23, 2020",2020-10-22,"October 19, 2020","Sher i Kashmir Institute of Medical Sciences, Srinagar, J&K, India",https://ClinicalTrials.gov/show/NCT04588909,India,,10.0,2020,Thursday
3682,3683,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",Enrolling by invitation,Device: FamilyChildCare (provisional name of app),All,"3 Years to 99 Years   (Child, Adult, Older Adult)",Not Applicable,270.0,December 2020,2021-09-01,"November 3, 2020","Johns Hopkins School of Nursing, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04453657,United States,,9.0,2021,Wednesday
3683,3684,Physical Activity Level in Patients With OSAS During Covid-19 Pandemic,Recruiting,,All,"19 Years to 70 Years   (Adult, Older Adult)",,60.0,"June 25, 2020",2020-12-31,"July 1, 2020","Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital, Trabzon, Turkey",https://ClinicalTrials.gov/show/NCT04451993,Turkey,,12.0,2020,Thursday
3684,3685,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,Not yet recruiting,Drug: Alteplase|Procedure: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,270.0,"December 7, 2020",2022-09-01,"December 4, 2020",,https://ClinicalTrials.gov/show/NCT04640194,Undefined,Alteplase,9.0,2022,Thursday
3685,3686,Sparing in Neuromuscular Blockade in COVID 19 ICU,Completed,Device: TOF protocol,All,"18 Years and older   (Adult, Older Adult)",,250.0,"June 1, 2020",2020-06-01,"July 7, 2020","Department of Anesthesiology and Intensive Care Medicine, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France",https://ClinicalTrials.gov/show/NCT04459533,France,,6.0,2020,Monday
3686,3687,SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida,Enrolling by invitation,Diagnostic Test: SARS-CoV-2 Antibody Analysis|Diagnostic Test: Weck-cel Swab Collection|Behavioral: Web Based Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"October 9, 2020",2022-10-09,"October 23, 2020","Moffitt Cancer Center, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT04596579,United States,,10.0,2022,Sunday
3687,3688,Somerset and South Essex Coronavirus Antigen Testing,Not yet recruiting,Diagnostic Test: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,June 2020,2021-08-01,"May 27, 2020","Musgrove Park Hospital, Taunton, Somerset, United Kingdom",https://ClinicalTrials.gov/show/NCT04403906,United Kingdom,,8.0,2021,Sunday
3688,3689,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,Recruiting,Drug: L-Citrulline|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60.0,"October 15, 2020",2021-12-28,"November 12, 2020","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",https://ClinicalTrials.gov/show/NCT04570384,United States,L-Citrulline|Placebo,12.0,2021,Tuesday
3689,3690,An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic,Available,Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC),All,"18 Years and older   (Adult, Older Adult)",,,,,"November 23, 2020","Beverly Hills Cancer Center, Beverly Hills, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Stanford Univ School of Med; Oncology, Stanford, California, United States|MedStar Washington Hosp Center, Washington, District of Columbia, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Levine Cancer Institute, Charlotte, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04395508,United States,Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC),,n,
3690,3691,"Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near",Completed,Other: Telemedicine to remote outpatient visit in bariatric patient,All,"18 Years and older   (Adult, Older Adult)",,138.0,"March 3, 2020",2020-05-04,"May 29, 2020","University of Campania ""Luigi Vanvitelli"", Naples, Italy",https://ClinicalTrials.gov/show/NCT04407663,Italy,,5.0,2020,Monday
3691,3692,Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19,Completed,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 1, 2020",2020-04-15,"June 29, 2020","Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04343404,France,,4.0,2020,Wednesday
3692,3693,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,Recruiting,,All,18 Years to 40 Years   (Adult),,230.0,"May 22, 2020",2021-02-28,"November 17, 2020","IRCCS Istituto Ortopedico Galeazzi, Milan, Italy",https://ClinicalTrials.gov/show/NCT04632615,Italy,,2.0,2021,Sunday
3693,3694,Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure,Recruiting,Radiation: thoracic CT-scan,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"September 1, 2020",2021-01-15,"September 3, 2020","GHR MULHOUSE-SUD ALSACE, Hôpital Emile Muller, Service de Radiologie, Mulhouse, France|HÔPITAUX UNIVERSITAIRES DE STRASBOURG, Hôpital de Hautepierre, Service de Réanimation Médicale, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04534400,France,,1.0,2021,Friday
3694,3695,Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East,Completed,Other: Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East,,"Child, Adult, Older Adult",,104.0,"March 1, 2020",2020-08-31,"September 9, 2020","OTC, MOH , Kuwait, Kuwait, Kuwait",https://ClinicalTrials.gov/show/NCT04542954,Kuwait,,8.0,2020,Monday
3695,3696,European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO,Recruiting,,All,"Child, Adult, Older Adult",,150.0,"April 10, 2020",2021-04-01,"April 29, 2020","Universitätskliniken Innsbruck, Innsbruck, Austria|Landesklinikum Sankt Polten, St.Pölten, Austria|Medical University of Vienna, Vienna, Austria|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|University Hospital, Antwerp, Antwerp, Belgium|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Chirec, Brussels, Belgium|Erasme University Hospital, Brussel, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|Hôpital Civil Marie Curie de Charleroi, Charleroi, Belgium|University Hospital, Ghent, Ghent, Belgium|La Louvière Hopital, La Louvière, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU de Liege, Liège, Belgium|Charles University, Czech Republic, Praha, Czechia|General University Hospital, Prague, Praha, Czechia|Copenhagen University Hospital at Herlev, Copenhagen, Denmark|University Hospital, Bordeaux, Bourdeaux, France|Hospices Civils de Lyon, Lyon, France|University Hospital, Montpellier, Montpellier, France|Henri Mondor University Hospital, Paris, France|Paris South University Hospitals, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Rennes University Hospital, Rennes, France|University Hospital, Aachen, Aachen, Germany|German Heart Center, Berlin, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Children's Medical Hospital, University of Essen, Essen, Germany, Essen, Germany|University Hospital, Essen, Essen, Germany|University Heart Center Freiburg - Bad Krozingen, Freiburg, Germany|Hannover Medical School, Hannover, Germany|Klinikum Kassel, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Heart Center Leipzig - University Hospital, Leipzig, Germany|Klinikum Nürnberg, Nürnberg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Tuebingen, Tuebingen, Germany|University Hospital, Alexandroupolis, Alexandroupolis, Greece|Heim Pal Children's Hospital, Budapest, Hungary|ECMO Centers Israel, Jerusalem, Israel|San Giorgio Clinic, Alessandria, Italy|Ospedali Riuniti Ancona, Ancona, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|St. Orsola Hospital, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Ospedale Maurizio Bufalini, Cesena, Italy|Gaslini Children's Hospital, Genua, Italy|G. Pasquinucci Heart Hospital, Massa, Massa, Italy|Policlinico Hospital Milan, Milano, Italy|Niguarda Hospital, Milan, Italy|Ospedale San Donato, Milan, Italy|San Raffaele University Hospital, Italy, Milan, Italy|San Gerardo Hospital, Monza, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy|GVM Care & Research, Puglia, Italy|Bambino Gesù Hospital and Research Institute, Roma, Italy|San Camillo Hospital, Rome, Roma, Italy|A.O.U. Città della Salute e della Scienza - Molinette Hospital, Turin, Italy|Mauriziano Umberto I Hospital, Turin, Italy|Ospedale S. Giovanni Bosco, Turin, Italy|University Hospital, Udine, Italy, Udine, Italy|Ospedale dell'Angelo, Venezia-Mestre, Venice, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|University of Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Medical University of Warsaw, Warsaw, Poland|Hospital Sao Joao, Porto, Portugal|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|City Hospital No 41, Ekaterinburg, Russia, Ekaterinburg, Russian Federation|Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, Kemerovo, Russian Federation|Krasnodar Regional Hospital no 1, Krasnodar, Russian Federation|City Clinical Hospital No. 67, Moscow, Russia, Moscow, Russian Federation|Novosibirsk City Hospital #2, Novosibirsk, Russian Federation|City Hospital No 40, Saint Petersburg, Russia, Saint Petersburg, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Miguel Servet, Zaragoza, Spain|Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Basel, Switzerland, Basel, Switzerland|University of Bern, Bern, Switzerland|University Hospital, Geneva, Geneva, Switzerland|University of Lausanne Hospitals, Lausanne, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|Klinik Hirslanden, Zurich, Zürich, Switzerland|University of Zurich, Zürich, Switzerland|Royal Brompton & Harefield NHS Foundation Trust, Brompton, United Kingdom|Paediatric Intensive Care Glasgow, Glasgow, United Kingdom|Leicester Children's Hospital, Leicester, United Kingdom|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom",https://ClinicalTrials.gov/show/NCT04366921,Austria,,4.0,2021,Thursday
3696,3697,Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI,Recruiting,,All,"Child, Adult, Older Adult",,200.0,"January 24, 2019",2021-07-24,"June 11, 2020","Beijing Friendship Hospital, Capital Medical University, Beijing, China",https://ClinicalTrials.gov/show/NCT04427735,China,,7.0,2021,Saturday
3697,3698,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,Recruiting,Drug: VIB7734|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,48.0,"August 28, 2020",2021-03-01,"September 2, 2020","Research Site, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04526912,United States,VIB7734|Placebo,3.0,2021,Monday
3698,3699,COVID-19 - Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c (Infusion),Not yet recruiting,Biological: human monoclonal antibody DZIF-10c (Group 1A-2D)|Other: Placebo (NaCl 0.9%) (Group 2D),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,69.0,"November 23, 2020",2021-06-30,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04631666,Undefined,,6.0,2021,Wednesday
3699,3700,COVID-19 - Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c (Inhalation),Not yet recruiting,Biological: human monoclonal antibody DZIF-10c (Group 1A-2D)|Other: Placebo (NaCl 0.9%) (Group 2D),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,69.0,"November 23, 2020",2021-06-30,"November 17, 2020",,https://ClinicalTrials.gov/show/NCT04631705,Undefined,,6.0,2021,Wednesday
3700,3701,Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19,Available,Device: Toraymyxin PMX-20R (PMX Cartridge),All,"18 Years and older   (Adult, Older Adult)",,,,,"August 28, 2020","University of Connecticut Health Center, Farmington, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|Stony Brook University Hospital, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04352985,United States,,,n,
3701,3702,The COVID-19 Pandemic and Exercise Study,"Active, not recruiting",Behavioral: Yoga group|Behavioral: High Intensity Interval Training group|Behavioral: Combination,All,18 Years to 64 Years   (Adult),Not Applicable,334.0,"June 1, 2020",2020-11-01,"August 20, 2020","University of British Columbia, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04400279,Canada,,11.0,2020,Sunday
3702,3703,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,Recruiting,Drug: Group A HCQ|Drug: Group B Control,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,850.0,"April 7, 2020",2021-06-15,"April 24, 2020","ProHealth New York, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04353037,United States,Group A HCQ|Group B Control,6.0,2021,Tuesday
3703,3704,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,Drug: Tocilizumab|Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,69.0,"March 1, 2020",2020-08-05,"August 25, 2020","Qena faculty medicine, Qinā, Egypt",https://ClinicalTrials.gov/show/NCT04519385,Egypt,Tocilizumab|Dexamethasone,8.0,2020,Wednesday
3704,3705,Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19),Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,300.0,"August 17, 2020",2021-04-01,"November 9, 2020","San Gerardo Hospital, Monza, MB, Italy",https://ClinicalTrials.gov/show/NCT04435327,Italy,,4.0,2021,Thursday
3705,3706,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,Recruiting,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80.0,"May 20, 2020",2020-12-20,"September 29, 2020","Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04405310,Mexico,,12.0,2020,Sunday
3706,3707,Extracellular Water in Covid 19 Pneumonia,Recruiting,Device: NİCaS,All,"18 Years to 80 Years   (Adult, Older Adult)",,52.0,"July 5, 2020",2021-02-20,"June 4, 2020","Gaziosmanpaşa TREH, Istanbul, Gaziosmanpaşa, Turkey",https://ClinicalTrials.gov/show/NCT04416009,Turkey,,2.0,2021,Saturday
3707,3708,Immunity and Infections in the Psychiatric Population,Not yet recruiting,Diagnostic Test: COVID19 immunization testing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"December 10, 2020",2021-03-10,"October 26, 2020",,https://ClinicalTrials.gov/show/NCT04381845,Undefined,,3.0,2021,Wednesday
3708,3709,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,Recruiting,Drug: Colchicine|Drug: Placebo oral tablet,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,174.0,"May 27, 2020",2021-04-27,"May 28, 2020","Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04367168,Mexico,Colchicine|Placebo oral tablet,4.0,2021,Tuesday
3709,3710,"Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection",Recruiting,Diagnostic Test: EasyCov POC,All,"18 Years and older   (Adult, Older Adult)",,160.0,October 2020,2021-03-01,"October 20, 2020","Istanbul University Istanbul Faculty of Medicine (ITF), Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04583319,Turkey,,3.0,2021,Monday
3710,3711,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Recruiting,Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,216.0,"April 20, 2020",2021-10-31,"April 21, 2020","Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04320056,Canada,,10.0,2021,Sunday
3711,3712,The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients,"Active, not recruiting",,All,"18 Years and older   (Adult, Older Adult)",,1509.0,"April 3, 2020",2021-04-01,"November 3, 2020","Ch D'Abbeville, Abbeville, France|CHU - Hôpital Sud, Amiens, France|CHU - Hôtel Dieu, Angers, France|Hôpital Privé, Antony, France|CH Victor Dupouy, Argenteuil, France|CH - Metz Thionville Mercy, Ars-Laquenexy, France|Hôpital Général d'Auch, Auch, France|Ch-Ght Unyon Auxerre, Auxerre, France|CH - Henri Duffaut, Avignon, France|PRIVE - Sainte Catherine, Avignon, France|CH, Bayeux, France|CH - Côte Basque, Bayonne, France|CH, Beauvais, France|CHU - Jean Minjoz, Besançon, France|PRIVE - Franche Comté, Besançon, France|PRIVE - Centre Pierre Curie, Beuvry, France|CH, Blois, France|PRIVE - Tivoli, Bordeaux, France|CH - Duchenne, Boulogne-sur-Mer, France|CHU - Ambroise Paré, Boulogne, France|CH - Fleyriat, Bourg-en-Bresse, France|CHU - Morvan, Brest, France|CHU - Pierre Wertheimer, Bron, France|CH - Germon et Gauthier - Service de Gastroentérologie, Béthune, France|CH, Béziers, France|CHU - Côte de Nacre, Caen, France|PRIVE - François Baclesse, Caen, France|CH, Calais, France|PRIVE - Infirmerie protestante, Caluire-et-Cuire, France|CH, Cannes, France|PRIVE - Médipole de Savoie, Challes-les-Eaux, France|PRIVE - Pôle Santé Léonard de Vinci, Chambray-lès-Tours, France|CH, Charleville-Mézières, France|CH, Chauny, France|CHP du Cotentin, Cherbourg, France|CH, Cholet, France|CH, Châlons-en-Champagne, France|CH - HIA Percy, Clamart, France|CHU - Estaing, Clermont-Ferrand, France|PRIVE - CAC Jean PERRIN, Clermont-Ferrand, France|CHU - Beaujon, Clichy, France|CH - Hôpitaux civils de Colmar, Colmar, France|CHU - Louis MOURIER, Colombes, France|CH - Compiegne, Compiègne, France|PRIVE - Saint Côme, Compiègne, France|CH - Sud Francilien, Corbeil-Essonnes, France|PRIVE - Cédres, Cornebarrieu, France|PRIVE - Clinique de Flandre, Coudekerque-Branche, France|CH - GHPSO Site de Creil, Creil, France|Ch - C.H.I.C., Créteil, France|CHU - Henri Mondor, Créteil, France|PRIVE - Centre Léonard de Vinci, Dechy, France|CHU - Hôpital François Mitterand, Dijon, France|PRIVE - CAC GF Leclerc, Dijon, France|PRIVE - Institut de Cancérologie de Bourgogne GRReCC, Dijon, France|CH - Louis Pasteur, Dole, France|CH, Douai, France|CH - Victor Jousselin, Dreux, France|PRIVE - Clinique Claude Bernard, Ermont, France|CH - Frejus Saint Raphael, Fréjus, France|PRIVE - Forcilles, Férolles-Attilly, France|CH, Grasse, France|CHU - Grenoble Alpes, Grenoble, France|PRIVE - GHM Daniel Hollard, Grenoble, France|CH - Marne La Vallée/Jossigny, Jossigny, France|CH - CHD Vendée, La Roche-sur-Yon, France|CH - Louis Pasteur, Le Coudray, France|PRIVE - L'Estuaire, Le Havre, France|PRIVE - Centre Jean Bernard, Le Mans, France|CH - Docteur Schaffner, Lens, France|CH - Saint Vincent, Lille, France|CHU - Claude Huriez, Lille, France|PRIVE - CAC Oscar Lambret, Lille, France|PRIVE - La Louvière Institut de Cancérologie Lille Métropole, Lille, France|CH - Robert Bisson, Lisieux, France|PRIVE - Teissier, Liévin, France|CH - GH Nord Essone, Longjumeau, France|CH - CHBS Hôpital du Scrorff, Lorient, France|CHU - Edouard Herriot, Lyon, France|CHU - La Croix Rousse, Lyon, France|PRIVE - La Sauvegarde Lyon, Lyon, France|CH - La Conception, Marseille, France|CH - Saint Joseph, Marseille, France|CHU - La Timone, Marseille, France|CH - GHI de l'Est Francilien Site de Meaux, Meaux, France|CH - Layné, Mont-de-Marsan, France|CH - Site du Mittan, Montbéliard, France|CH, Montélimar, France|CH - Emile Muller, Mulhouse, France|CH - Les Chanaux, Mâcon, France|PRIVE - Oncologie Gentilly, Nancy, France|PRIVE - Confluent SAS, Nantes, France|PRIVE - Hartmann, Neuilly-sur-Seine, France|CH - Pierre Beregovoy, Nevers, France|CH, Niort, France|CHU - Caremeau, Nîmes, France|CHR - Centre Hospitalier Régional La Source, Orléans, France|AP - HP - Pitié Salpêtrière, Paris, France|Bichat, Paris, France|CHU - Cochin, Paris, France|CHU - Lariboisière, Paris, France|CHU - Saint Antoine, Paris, France|CHU - Saint Louis, Paris, France|CHU - Tenon, Paris, France|Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|PRIVE - Saint Joseph, Paris, France|Privé - Montsouris, Paris, France|PRIVE - Centre Oncologie Catalan, Perpignan, France|CHU - Haut Lévêque, Pessac, France|CHU - Lyon Sud, Pierre-Bénite, France|PRIVE - Centre Cario HPCA, Plérin, France|CHU - La Miletrie, Poitiers, France|CH - René Dubos, Pontoise, France|CH, Périgueux, France|PRIVE - Clinique La Croix du Sud, Quint-Fonsegrives, France|CHU - Robert Debré, Reims, France|PRIVE - Polyclinique Courlancy, Reims, France|PRIVEE - Jean Godinot, Reims, France|PRIVEE - Polyclinique Courlancy, Reims, France|CHU - Charles Nicolle, Rouen, France|CAC - Institut Curie R. Huguenin, Saint-Cloud, France|PRIVE - Saint Grégoire, Saint-Grégoire, France|CH - Centre Hospitalier de Saint Malo, Saint-Malo, France|CH - Begin, Saint-Mandé, France|PRIVE - Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France|CHU - Hôpital Nord CHU Saint Etienne, Saint-Priest-en-Jarez, France|PRIVE - Ramsay Sainte Loire, Saint-Étienne, France|PRIVE - Trenel, Sainte-Colombe, France|CHU - Hautepierre, Strasbourg, France|ICAN - Institut de Cancérologie de Strasbourg Europe, Strasbourg, France|PRIVE - Strasbourg Oncologie Libérale, Strasbourg, France|CH - Foch, Suresnes, France|CH - Maison Santé Protestante, Talence, France|CH - Birgorre, Tarbes, France|CH - Leman, Thonon-les-Bains, France|CH - Sainte Musse, Toulon, France|CAC - Oncopole, Toulouse, France|CHU - Rangueil, Toulouse, France|CH - Gustave Dron, Tourcoing, France|CHU - Bretonneau, Tours, France|CH, Valence, France|CH, Valenciennes, France|PRIVE - Dentellières, Valenciennes, France|CHU - Brabois, Vandœuvre-lès-Nancy, France|PRIVE - Robert Schuman, Vantoux, France|CH - Paul Morel, Vesoul, France|CAC - Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT04397575,France,,4.0,2021,Thursday
3712,3713,HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440.0,April 2020,2020-08-01,"April 7, 2020",,https://ClinicalTrials.gov/show/NCT04336748,Undefined,Hydroxychloroquine,8.0,2020,Saturday
3713,3714,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,Not yet recruiting,Drug: Arbidol|Other: basic treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,380.0,"February 7, 2020",2020-12-30,"February 7, 2020",,https://ClinicalTrials.gov/show/NCT04260594,Undefined,Arbidol,12.0,2020,Wednesday
3714,3715,Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia,Completed,Other: PHQ-9 (Patient Health Questionnaire) Depression Scale|Other: GAD-7 (General Anxiety Disorder) scale|Other: 38 questions questionnaire|Other: EPDS (Edinburgh Postnatal Depression Scale),Female,"18 Years and older   (Adult, Older Adult)",,330.0,"June 30, 2020",2020-10-27,"October 28, 2020","""Elena Venizelou"" General and Maternity Hospital of Athens, Athens, Attica, Greece|Aretaieio University Hospital, Athens, Attica, Greece|Alexandra Genaral Hospital Athens, Athens, Greece|University of Ioannina Health Science, Ioannina, Greece|University of Ioannina, Medical School, Ioannina, Greece|University of Thessaly Medical School, Larisa, Greece",https://ClinicalTrials.gov/show/NCT04437342,Greece,,10.0,2020,Tuesday
3715,3716,SARS-CoV-2 (COVID-19) and Surgery,Recruiting,Other: No intervention (survey study for medical doctors).,All,"25 Years and older   (Adult, Older Adult)",,350.0,"March 30, 2020",2020-12-01,"July 29, 2020","2nd Department of General Surgery, Jagiellonian University Medical College, Cracovia, Małopolska, Poland",https://ClinicalTrials.gov/show/NCT04368026,Poland,,12.0,2020,Tuesday
3716,3717,Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression,Recruiting,Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery,Female,18 Years to 50 Years   (Adult),,900.0,"April 29, 2020",2020-12-14,"July 20, 2020","Bertrand GACHON, Poitiers, France",https://ClinicalTrials.gov/show/NCT04368208,France,,12.0,2020,Monday
3717,3718,Clinical Characteristics and Outcomes of Pediatric COVID-19,Recruiting,Other: Exposure (not intervention) - SARS-CoV-2 infection,All,"up to 18 Years   (Child, Adult)",,12500.0,"March 18, 2020",2022-03-17,"April 1, 2020","University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04330261,Canada,,3.0,2022,Thursday
3718,3719,COVID19 and Physical and Emotional Wellbeing of HCP,Recruiting,"Other: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|Other: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Other: Informed consent",All,"18 Years and older   (Adult, Older Adult)",,1050.0,"July 25, 2020",2021-09-01,"September 16, 2020","Ajay K Gupta, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04433260,United Kingdom,,9.0,2021,Wednesday
3719,3720,Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial,Not yet recruiting,Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine,All,"6 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,60.0,"May 5, 2020",2020-10-30,"May 13, 2020",,https://ClinicalTrials.gov/show/NCT04383717,Undefined,Levamisole and isoprinosine|Azithromycin and hydroxychloroquine,10.0,2020,Friday
3720,3721,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,Device: VibroLUNG,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,200.0,"March 22, 2020",2021-02-01,"June 17, 2020","Mukatova Irina, Astana, Nur-Sultan, Kazakhstan|Center of pulmonology Astana, Astana, Kazakhstan",https://ClinicalTrials.gov/show/NCT04435353,Kazakhstan,,2.0,2021,Monday
3721,3722,Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Completed,,All,"18 Years to 99 Years   (Adult, Older Adult)",,70.0,"June 8, 2020",2020-07-20,"September 23, 2020","Vital Hospital, Bahcelievler, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04423315,Turkey,,7.0,2020,Monday
3722,3723,Covid-19 Epidemic on Acute Stroke Management,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,300.0,"March 3, 2020",2020-04-30,"April 30, 2020","Service de Neuroradiologie Interventionnelle, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04370197,France,,4.0,2020,Thursday
3723,3724,Virtual Pain Care Management (COVID-19),Recruiting,Other: VCPM,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"October 1, 2020",2021-06-30,"November 2, 2020","Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04539821,United States,,6.0,2021,Wednesday
3724,3725,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Recruiting,Dietary Supplement: Probiotics|Other: Placebo,All,18 Years to 60 Years   (Adult),Not Applicable,300.0,"August 19, 2020",2021-01-31,"September 3, 2020","Hospital General Dr. Manuel Gea Gonzalez, Mexico city, Mexico",https://ClinicalTrials.gov/show/NCT04517422,Mexico,,1.0,2021,Sunday
3725,3726,Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 9, 2020",2021-08-31,"November 3, 2020","Rouen University Hospital, Rouen, France",https://ClinicalTrials.gov/show/NCT04357847,France,,8.0,2021,Tuesday
3726,3727,Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement,Recruiting,Diagnostic Test: laboratory biomarkers|Diagnostic Test: muscle ultrasound,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 20, 2020",2022-03-31,"April 29, 2020","University Hospital Tuebingen, Tuebingen, Germany",https://ClinicalTrials.gov/show/NCT04367350,Germany,,3.0,2022,Thursday
3727,3728,The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients,Recruiting,Other: COVID-19 Pandemic,All,"18 Years and older   (Adult, Older Adult)",,10000.0,"April 5, 2020",2022-04-01,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel",https://ClinicalTrials.gov/show/NCT04338672,Israel,,4.0,2022,Friday
3728,3729,Acute kIDnEy Injury in coviD-19,Not yet recruiting,Other: No intervention,All,"18 Years to 90 Years   (Adult, Older Adult)",,220.0,November 2020,2022-10-01,"October 22, 2020",,https://ClinicalTrials.gov/show/NCT04583293,Undefined,,10.0,2022,Saturday
3729,3730,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,670.0,"May 9, 2020",2021-09-10,"October 19, 2020","Karolinska Institutet, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04341922,Sweden,,9.0,2021,Friday
3730,3731,WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,20.0,"October 13, 2020",2021-08-13,"December 1, 2020","CHU, Clermont-Ferrand, France",https://ClinicalTrials.gov/show/NCT04643548,France,,8.0,2021,Friday
3731,3732,Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital,Completed,Procedure: Surgical procedures performed under general anesthesia,All,"Child, Adult, Older Adult",,14.0,"May 1, 2020",2020-05-30,"June 16, 2020","Ospedale di Lodi - ASST Lodi, Lodi, Lombardia, Italy",https://ClinicalTrials.gov/show/NCT04430062,Italy,,5.0,2020,Saturday
3732,3733,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Not yet recruiting,Other: Telerehabilitation,All,65 Years and older   (Older Adult),Not Applicable,30.0,"August 20, 2020",2020-12-31,"July 30, 2020","Istanbul university Cerrahpasa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04334434,Turkey,,12.0,2020,Thursday
3733,3734,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,450.0,"June 15, 2020",2020-08-15,"July 31, 2020","Yasmine Dudoit, Paris, France",https://ClinicalTrials.gov/show/NCT04402905,France,,8.0,2020,Saturday
3734,3735,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,"Active, not recruiting",,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",,1500.0,"May 22, 2020",2020-08-01,"June 4, 2020","Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust, Hull, United Kingdom",https://ClinicalTrials.gov/show/NCT04410484,United Kingdom,,8.0,2020,Saturday
3735,3736,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"May 8, 2020",2021-12-30,"October 22, 2020","AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AHN West Penn Hospital, Pittsburgh, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04382391,United States,,12.0,2021,Thursday
3736,3737,Influence of the COVId-19 Pandemic on STRESS and Eating Habits,Recruiting,Behavioral: Eating habits,All,"10 Years and older   (Child, Adult, Older Adult)",,1000.0,"April 1, 2020",2025-12-31,"November 9, 2020","Clermont-Ferrand University Hospital, clermont-Ferrand, Aura, France",https://ClinicalTrials.gov/show/NCT04621084,France,,12.0,2025,Wednesday
3737,3738,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,Enrolling by invitation,Drug: Tradipitant|Drug: Placebo,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,300.0,"April 13, 2020",2020-08-31,"April 20, 2020","Lenox Hill Hospital Northwell Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04326426,United States,Tradipitant|Placebo,8.0,2020,Monday
3738,3739,COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,5000.0,"October 20, 2020",2024-07-01,"August 28, 2020","Centre hopsitalier universitaire de Montpellier, Montpellier, Occitanie, France",https://ClinicalTrials.gov/show/NCT04530682,France,,7.0,2024,Monday
3739,3740,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Recruiting,Drug: Ivermectin|Other: Standard treatment for COVID-19,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64.0,"July 1, 2020",2021-07-01,"September 2, 2020","Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil|Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04431466,Brazil,Ivermectin,7.0,2021,Thursday
3740,3741,PREdiction of DIagnosed Covid-19 infecTion in IUC Patients,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 30, 2020",2021-09-01,"April 6, 2020","Hôpital Roger Salengro, ICU, CHU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04327180,France,,9.0,2021,Wednesday
3741,3742,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,Enrolling by invitation,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,988.0,"April 30, 2020",2022-01-30,"May 8, 2020","University Health Network, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04374942,Canada,Hydroxychloroquine|Placebo oral tablet,1.0,2022,Sunday
3742,3743,GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection,Not yet recruiting,Drug: GLS-1027|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,132.0,November 2020,2021-11-01,"October 19, 2020",,https://ClinicalTrials.gov/show/NCT04590547,Undefined,GLS-1027|Placebo,11.0,2021,Monday
3743,3744,Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.,Completed,"Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA",All,"Child, Adult, Older Adult",,70.0,"July 20, 2020",2020-08-16,"September 9, 2020","Assiut university, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04479280,Egypt,,8.0,2020,Sunday
3744,3745,Health Care Use During the Covid19 Crisis,Not yet recruiting,Other: Online questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10000.0,"May 1, 2020",2021-10-31,"May 1, 2020",,https://ClinicalTrials.gov/show/NCT04372030,Undefined,,10.0,2021,Sunday
3745,3746,Epigenetic Tools as Prognostic Predictors in Covid19,Recruiting,Other: Taking biological samples,All,"18 Years to 65 Years   (Adult, Older Adult)",,105.0,"May 21, 2020",2020-12-01,"June 2, 2020","Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04411563,Turkey,,12.0,2020,Tuesday
3746,3747,Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry,"Active, not recruiting",Device: Percutaneous Coronary Revascularization for STEMI,All,"Child, Adult, Older Adult",,6609.0,"May 5, 2020",2020-06-02,"June 11, 2020","Giuseppe De Luca, Novara, Italy",https://ClinicalTrials.gov/show/NCT04412655,Italy,,6.0,2020,Tuesday
3747,3748,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,Not yet recruiting,Behavioral: insurance navigation,All,"4 Years to 64 Years   (Child, Adult)",Not Applicable,430.0,"November 2, 2020",2023-01-31,"November 3, 2020",,https://ClinicalTrials.gov/show/NCT04613739,Undefined,,1.0,2023,Tuesday
3748,3749,Incidence of Covid-19 in School Children,Withdrawn,Diagnostic Test: RT-PCR Covid-19,All,3 Years to 10 Years   (Child),Not Applicable,0.0,"May 15, 2020",2020-09-01,"May 27, 2020","Hôpitaux Pédiatrique de Nice CHU Lenval, Nice, France",https://ClinicalTrials.gov/show/NCT04377737,France,,9.0,2020,Tuesday
3749,3750,Evaluation of Newborns Presenting With Suspected COVID 19,"Active, not recruiting",,All,up to 1 Month   (Child),,72.0,"March 1, 2020",2020-08-31,"August 19, 2020","İzmir Dr. Behcet Uz Training and Research Hospital, İzmir, Turkey",https://ClinicalTrials.gov/show/NCT04519307,Turkey,,8.0,2020,Monday
3750,3751,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Recruiting,,All,"18 Years to 80 Years   (Adult, Older Adult)",,50.0,"May 20, 2020",2020-12-31,"June 2, 2020","Falun Hospital, Falun, Sweden",https://ClinicalTrials.gov/show/NCT04412551,Sweden,,12.0,2020,Thursday
3751,3752,COVID-19 Prevalence in HIV-infected Patients,Not yet recruiting,Other: Blood Sample,All,"18 Years and older   (Adult, Older Adult)",,500.0,"September 15, 2020",2020-09-15,"August 17, 2020",,https://ClinicalTrials.gov/show/NCT04515225,Undefined,,9.0,2020,Tuesday
3752,3753,Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19,Not yet recruiting,Drug: Inactivated convalescent plasma|Drug: Support treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"June 20, 2020",2020-12-30,"June 2, 2020","Clínica Antioquía, Medellín, Antioquía, Colombia|Clínica Sagrado Corazón, Medellín, Antioquía, Colombia|IPS Universitaria, Medellín, Antioquía, Colombia|Universidad de Antioquía, Medellín, Antioquía, Colombia|National Blood Center Foundation, Hemolife/Fundación Banco Nacional de Sangre Hemolife, Bogotá, Cundinamarca, Colombia|Clínica Rosales, Pereira, Risaralda, Colombia|Clinica Nuestra, Cali, Valle, Colombia|Clínica Corpas, Bogotá, Colombia|E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia|Clínica la Estancia, Popayán, Colombia",https://ClinicalTrials.gov/show/NCT04385186,Colombia,Inactivated convalescent plasma|Support treatment,12.0,2020,Wednesday
3753,3754,COVID-19 Pandemic Response Network,Recruiting,,All,"Child, Adult, Older Adult",,200000.0,"April 3, 2020",2021-12-31,"April 27, 2020","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04320862,United States,,12.0,2021,Friday
3754,3755,Covid-19 and Diabetes in West of Algeria,Recruiting,Drug: MANAGEMENT OF COVID-19,All,"16 Years and older   (Child, Adult, Older Adult)",,100.0,"April 1, 2020",2020-06-30,"June 2, 2020","Department of Internal Medicine, Acedemic Hospital of Tlemcen, Tlemcen, Algeria",https://ClinicalTrials.gov/show/NCT04412746,Algeria,MANAGEMENT OF COVID-19,6.0,2020,Tuesday
3755,3756,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Recruiting,"Diagnostic Test: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics",Male,18 Years to 60 Years   (Adult),Not Applicable,250.0,"July 10, 2020",2021-07-01,"July 27, 2020","AP-Hôpitaux de Paris - Hôpital Jean Verdier - Service de Biologie de la reproduction, Bondy, France|AP-Hôpitaux de Paris - Hôpital Antoine Béclére - Service de Biologie de la reproduction et AMP DPI CECOS, Clamart, France|CHU de Clermont-Ferrand - Laboratoire de Virologie, Clermont-Ferrand, France|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Dijon - Laboratoire de Biologie de la Reproduction-CECOS, Dijon, France|CHU de Grenoble - Laboratoire d'Aide à la Procréation CECOS, Grenoble, France|Hospices Civils de Lyon - Service AMP-CECOS, Lyon, France|Hôpital de la Conception - AP-Hôpitaux de Marseille - Service AMP-CECOS, Marseille, France|CHU de Nancy - Laboratoire de biologie de la reproduction - CECOS, Nancy, France|AP-Hôpitaux de Paris - Hôpital Tenon - Service de Biologie de la reproduction - CECOS, Paris, France|AP-Hôpitaux de Paris - Hôpital Cochin - Service d'Histologie-Embryologie-Biologie de la reproduction, Paris, France|Centre Hospitalier intercommunal (CHI) de Poissy Saint Germain en Laye, Poissy, France|CHU de Reims - Service de Biologie de la Reproduction - CECOS Champagne-Ardenne de Reims, Reims, France|CHU de Rouen Normandie - Service Biologie de la Reproduction-CECOS, Rouen, France|CHU de Strasbourg - Service de Biologie de la reproduction, Strasbourg, France|CHU de Toulouse - CECOS Midi-Pyrénées, Toulouse, France",https://ClinicalTrials.gov/show/NCT04487639,France,,7.0,2021,Thursday
3756,3757,Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health,Not yet recruiting,Diagnostic Test: Online questionnaire,All,"Child, Adult, Older Adult",,300.0,May 2020,2020-10-01,"April 15, 2020",,https://ClinicalTrials.gov/show/NCT04344834,Undefined,,10.0,2020,Thursday
3757,3758,"Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT",Recruiting,Drug: [18F]FP-R01-MG-F2,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30.0,"November 8, 2017",2023-04-14,"November 27, 2020","Stanford University, Stanford, California, United States",https://ClinicalTrials.gov/show/NCT03183570,United States,[18F]FP-R01-MG-F2,4.0,2023,Friday
3758,3759,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,Other: Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,26.0,"October 1, 2020",2021-09-01,"October 22, 2020","University Hospital Southampton NHS Foundation Trust, Southampton, Hamphsire, United Kingdom",https://ClinicalTrials.gov/show/NCT04455360,United Kingdom,,9.0,2021,Wednesday
3759,3760,Surgery and Lung Ultrasound in SARS-CoV-2 Infection,Recruiting,Diagnostic Test: Lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",,451.0,"May 8, 2020",2021-11-30,"December 10, 2020","Fundación Valle del Lili, Cali, Valle Del Cauca, Colombia",https://ClinicalTrials.gov/show/NCT04661631,Colombia,,11.0,2021,Tuesday
3760,3761,Maternal Telemental Health Interventions in Response to Covid-19*,Not yet recruiting,Other: Low-Intensity Psychosocial Interventions through Telemental health,Female,18 Years to 49 Years   (Adult),Not Applicable,58.0,November 2020,2022-02-01,"October 20, 2020",,https://ClinicalTrials.gov/show/NCT04594525,Undefined,,2.0,2022,Tuesday
3761,3762,Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients,Recruiting,Other: Prone positioning,All,"18 Years to 80 Years   (Adult, Older Adult)",,16.0,"April 27, 2020",2021-01-31,"June 2, 2020","University Hospitals of Geneva, Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04359407,Switzerland,,1.0,2021,Sunday
3762,3763,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Completed,Other: Individualised Ayurveda,All,18 Years to 60 Years   (Adult),Not Applicable,18.0,"February 26, 2020",2020-03-30,"April 14, 2020","Aarogyam, Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04345549,United Kingdom,,3.0,2020,Monday
3763,3764,Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients,Recruiting,Diagnostic Test: Global Longitudinal Strain,All,"18 Years and older   (Adult, Older Adult)",,50.0,"April 4, 2020",2020-11-04,"April 24, 2020","UHToulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04358952,France,,11.0,2020,Wednesday
3764,3765,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection,Withdrawn,Drug: Nitric Oxide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"March 1, 2020",2022-02-01,"March 24, 2020",,https://ClinicalTrials.gov/show/NCT04290858,Undefined,Nitric Oxide,2.0,2022,Tuesday
3765,3766,Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).,Completed,Device: ARFC mask,All,"18 Years and older   (Adult, Older Adult)",,15.0,"April 29, 2020",2020-05-28,"June 29, 2020","CHU Saint-Etienne, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04427176,France,,5.0,2020,Thursday
3766,3767,"Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic",Recruiting,Behavioral: Questionnaire|Behavioral: Interview,All,"14 Years and older   (Child, Adult, Older Adult)",,1200.0,"May 15, 2020",2021-06-30,"July 9, 2020","Intercommunal hospital of Créteil, Creteil, IDF, France|TROUSSEAU Hospital, Paris, IDF, France|FOCH Hospital, Suresnes, IDF, France",https://ClinicalTrials.gov/show/NCT04463628,France,,6.0,2021,Wednesday
3767,3768,COVID-19 and SARS-CoV-2 Detection in Saliva,Enrolling by invitation,Diagnostic Test: RT-PCR,All,"18 Years and older   (Adult, Older Adult)",,300.0,"May 21, 2020",2020-12-30,"August 25, 2020","Ambry Genetics, Aliso Viejo, California, United States",https://ClinicalTrials.gov/show/NCT04517682,United States,,12.0,2020,Wednesday
3768,3769,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Behavioral: Intervention App,All,"18 Years and older   (Adult, Older Adult)",Phase 3,560.0,"May 5, 2020",2020-08-24,"September 10, 2020","Ignacio Ricci-Cabello, Palma De Mallorca, Balearic Islands, Spain",https://ClinicalTrials.gov/show/NCT04393818,Spain,,8.0,2020,Monday
3769,3770,"""COVID-19 and Diabetes Outcomes""","Active, not recruiting",Other: no interventional study,All,"Child, Adult, Older Adult",,5309.0,"March 10, 2020",2020-12-31,"November 4, 2020","CHU Nantes, Nantes, France",https://ClinicalTrials.gov/show/NCT04324736,France,,12.0,2020,Thursday
3770,3771,The Provider Insurance Revenue Study in Healthcare Providers in the United States of America,Recruiting,Other: Online questionnaire and interviews,All,"Child, Adult, Older Adult",,100.0,"October 1, 2020",2021-10-15,"October 19, 2020","University of California Irvine Beall Applied Innovation, Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04587245,United States,,10.0,2021,Friday
3771,3772,Covid-19 and Vitamin D in Nursing-home,Completed,,All,70 Years and older   (Older Adult),,96.0,"March 15, 2020",2020-05-15,"June 17, 2020","Angers University Hospital, Angers, France",https://ClinicalTrials.gov/show/NCT04435119,France,,5.0,2020,Friday
3772,3773,Covid-19 Triage Using Camera-based AI,Completed,Device: RIA-device (Remote Investigation and Assessment),All,"18 Years and older   (Adult, Older Adult)",,214.0,"June 15, 2020",2020-10-08,"December 1, 2020","Östra Sjukhuset, Gothenburg, Sweden",https://ClinicalTrials.gov/show/NCT04383457,Sweden,,10.0,2020,Thursday
3773,3774,Feasibility of a Telematics Pre-operative Assessment in a Bariatric Surgery During Covid-19,Recruiting,,All,"18 Years to 65 Years   (Adult, Older Adult)",,20.0,"June 1, 2020",2020-07-31,"July 24, 2020","Gianfranco Silecchia, Latina, Italy",https://ClinicalTrials.gov/show/NCT04486417,Italy,,7.0,2020,Friday
3774,3775,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Recruiting,Other: Interview by psychologists,All,6 Years to 17 Years   (Child),Not Applicable,40.0,"May 5, 2020",2021-01-01,"June 4, 2020","University hospital of Toulouse, Toulouse, Occitanie, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Esquirol, Limoges, France|Hôpital Robert-Debré (AP-HP), Paris, France|Maison de Solenn (Hôpital Cochin AP-HP), Paris, France",https://ClinicalTrials.gov/show/NCT04416360,France,,1.0,2021,Friday
3775,3776,Finding Wellness in the Pandemic,Recruiting,Behavioral: Trauma Informed Yoga|Behavioral: Trauma Informed Psychotherapy,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,200.0,"November 1, 2020",2021-04-30,"November 10, 2020","University of Lethbridge, Lethbridge, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04615741,Canada,,4.0,2021,Friday
3776,3777,Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases,Recruiting,Diagnostic Test: Performing routine care (clinical and paraclinical tests)|Diagnostic Test: Examinations for the research:,All,"Child, Adult, Older Adult",,400.0,"April 15, 2020",2021-10-15,"November 23, 2020","Cardiology, Aix-en-Provence, France|Reanimation, Amiens, France|Cardiology, Angers, France|Reanimation, Angers, France|Cardiology, Avignon, France|Cardiology, Bordeaux, France|Pediatric cardiology, Bordeaux, France|Reanimation, Bordeaux, France|Cardiology, Brest, France|Cardiology, Caen, France|Pediatric Cardiology, Caen, France|Cardiology, Clermont-Ferrand, France|Pediatric cardilogy, Clermont-Ferrand, France|Reanimation, Clermont-Ferrand, France|Pediatric cardiology, Dijon, France|Cardiology, Grenoble, France|Pediatric cardiology, Grenoble, France|Reanimation, Grenoble, France|Cardiology, Lille, France|Pediatric cardiology, Lille, France|Pediatric cardiology, Limoges, France|Cardiology, Lyon, France|Pediatric cardiology, Lyon, France|Cardiology, Marseille, France|Pediatric cardiology, Marseille, France|Cardiology, Metz, France|Cardiology, Montpellier, France|Millénaire Clinical - Cardiology, Montpellier, France|Pediatric cardiology, Montpellier, France|Reanimation, Montpellier, France|Cardiology, Nancy, France|Cardiology, Nancy, France|Pediatric cardiology, Nancy, France|Cardiology, Nantes, France|Pediatric cardiology, Nantes, France|Cardiology, Nice, France|Pediatric cardiology, Nice, France|Cardiology, Nîmes, France|Cardiology, Henri Mondor Hospital, Paris, France|Cardiology, Paris, France|Cardiology, Paris, France|Henri Mondor Hospital Reanimation, Paris, France|Marie Lannelongue Hospital - Pediatric Cardiology, Paris, France|Marie Lannelongue Hospital Cardiology, Paris, France|Reanimation, Paris, France|Reanimation, Paris, France|Robert Debré Hospital - Pediatric cardiology, Paris, France|Saint Antoine Hospital - Cardiology, Paris, France|Cardiology, Poitiers, France|Reanimation, Poitiers, France|Pediatric cardiology, Reims, France|Cardiology, Rennes, France|Pediatric reanimation, Rennes, France|Cardiology, Rouen, France|Pediatric cardiology, Rouen, France|Pédiatric cardiology, Strasbourg, France|Reanimation, Strasbourg, France|CHU de TOULOUSE, Toulouse, France|Croix du Sud Clinical, Toulouse, France|Pasteur Clinical - Cardiology, Toulouse, France|Pasteur Clinical - Pediatric cardiology, Toulouse, France|Pediatric Cardiology, Toulouse, France|Cardiolgy, Tours, France|Pediatric Cardiology, Tours, France|Cardiology, Valenciennes, France|Cardiology, Martinique, Martinique|Cardiology, Mamoudzou, Mayotte|Pédiatric cardiology, Réunion, Réunion",https://ClinicalTrials.gov/show/NCT04375748,France,,10.0,2021,Friday
3777,3778,Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit During Covid-19 Pandemic,Not yet recruiting,Diagnostic Test: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,145.0,"May 1, 2020",2020-06-30,"May 5, 2020",,https://ClinicalTrials.gov/show/NCT04371302,Undefined,,6.0,2020,Tuesday
3778,3779,Asymptomatic COVID-19 Infection Among Healthcare Workers,Completed,Diagnostic Test: Serum SARs COV 2 IGg screening in health care workers,All,25 Years to 60 Years   (Adult),,500.0,"May 1, 2020",2020-06-10,"June 17, 2020","Cairo University Hospital, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04354792,Egypt,,6.0,2020,Wednesday
3779,3780,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study",Recruiting,Diagnostic Test: Covid-19 presto test,All,"18 Years to 65 Years   (Adult, Older Adult)",,5000.0,"August 24, 2020",2021-03-24,"December 9, 2020","Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole, Orléans, France|Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole, Orléans, France",https://ClinicalTrials.gov/show/NCT04387968,France,,3.0,2021,Wednesday
3780,3781,Effectiveness of a Novel Respirator With Chitosan Nanoparticles,Not yet recruiting,Device: VESTA respirator|Device: Conventional N95 respirator,All,20 Years to 59 Years   (Adult),Not Applicable,1000.0,"November 30, 2020",2021-07-31,"October 5, 2020",,https://ClinicalTrials.gov/show/NCT04490200,Undefined,,7.0,2021,Saturday
3781,3782,Eculizumab (Soliris) in Covid-19 Infected Patients,Available,Drug: Eculizumab,All,"18 Years and older   (Adult, Older Adult)",,,,,"March 30, 2020",,https://ClinicalTrials.gov/show/NCT04288713,Undefined,Eculizumab,,n,
3782,3783,NK Cells Treatment for COVID-19,Recruiting,Biological: NK Cells,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30.0,"February 15, 2020",2020-12-30,"April 14, 2020","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China",https://ClinicalTrials.gov/show/NCT04280224,China,,12.0,2020,Wednesday
3783,3784,COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus,Recruiting,Other: nosocomial infection/hospital acquired infection,All,"Child, Adult, Older Adult",,300.0,"March 9, 2020",2020-12-31,"November 3, 2020","Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France",https://ClinicalTrials.gov/show/NCT04290780,France,,12.0,2020,Thursday
3784,3785,Exploring Interventions for Glue Ear During Covid-19,Not yet recruiting,Device: Bone conduction headphones,All,3 Years to 11 Years   (Child),Not Applicable,20.0,"June 22, 2020",2021-06-01,"June 11, 2020","Peacock Children's centre. Brookfields Hospital, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04427631,United Kingdom,,6.0,2021,Tuesday
3785,3786,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Recruiting,,All,"16 Years and older   (Child, Adult, Older Adult)",,50.0,"March 12, 2020",2021-04-01,"July 8, 2020","Hospital Universitario Virgen del Rocio, Seville, Spain",https://ClinicalTrials.gov/show/NCT04319172,Spain,,4.0,2021,Thursday
3786,3787,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,Recruiting,Drug: Veru-111,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"June 18, 2020",2021-01-18,"December 3, 2020","HonorHealth, Scottsdale, Arizona, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|WC-CRCN at North Vista Hospital, Las Vegas, Nevada, United States|Inspira Medical Center, Vineland, New Jersey, United States|Memorial Hermann Memorial City Hospital, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04388826,Jersey,Veru-111,1.0,2021,Monday
3787,3788,Antimalarial and Covid 19 in Rheumatoid Arthritis,Completed,Drug: Hydroxychloroquine,All,"20 Years to 70 Years   (Adult, Older Adult)",,60.0,"March 15, 2020",2020-05-01,"May 15, 2020","Manal Hassanien, Assiut, Yes, Egypt",https://ClinicalTrials.gov/show/NCT04389320,Egypt,Hydroxychloroquine,5.0,2020,Friday
3788,3789,Biomarkers for Identification of COVID-19 Infection,Recruiting,Diagnostic Test: Biomarkers expression,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",,110.0,"March 24, 2020",2020-12-30,"September 16, 2020","Luca Gallelli, Catanzaro, Italy",https://ClinicalTrials.gov/show/NCT04322513,Italy,,12.0,2020,Wednesday
3789,3790,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Recruiting,"Other: Collection of blood, salivary and nasopharyngeal samples.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"November 23, 2020",2021-11-01,"December 11, 2020","hopital Edouard Herriot, Lyon, France",https://ClinicalTrials.gov/show/NCT04637867,France,,11.0,2021,Monday
3790,3791,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor",Recruiting,Other: Observational Study,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 19, 2020",2022-03-19,"June 19, 2020","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy",https://ClinicalTrials.gov/show/NCT04318366,Italy,,3.0,2022,Saturday
3791,3792,Pharmacy Education During Covid-19 Outbreak,Not yet recruiting,,All,"16 Years to 40 Years   (Child, Adult)",,100.0,November 2020,2021-09-01,"July 22, 2020","Damanhour university, Beheira, Damanhour, Egypt",https://ClinicalTrials.gov/show/NCT04409951,Egypt,,9.0,2021,Wednesday
3792,3793,Use of Angiotensin-(1-7) in COVID-19,Recruiting,Drug: Angiotensin-(1-7)|Drug: Placebo,All,"17 Years to 81 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,130.0,"August 5, 2020",2021-02-28,"November 23, 2020","Hospital Eduardo de Menezes, Belo Horizonte, Minas Gerais, Brazil|Hospital Mater Dei, Belo Horizonte, Minas Gerais, Brazil",https://ClinicalTrials.gov/show/NCT04633772,Brazil,Angiotensin-(1-7)|Placebo,2.0,2021,Sunday
3793,3794,Effect of COVID19-related COntainment in ChildreN,Recruiting,Other: cries 13 questionnaire,All,8 Years to 15 Years   (Child),,1000.0,"June 10, 2020",2020-11-30,"November 4, 2020","UHToulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04615195,France,,11.0,2020,Monday
3794,3795,Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19),Withdrawn,Other: Olfactory retraining|Drug: corticosteroid nasal irrigation|Other: smell household Items|Other: Nasal Irrigation,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"January 10, 2021",2022-03-10,"August 27, 2020","St. Joseph's Health Care, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04374474,Canada,corticosteroid nasal irrigation,3.0,2022,Thursday
3795,3796,Knowledge About Covid-19 Infection in Pregnant Women,Recruiting,Other: labs,Female,18 Years to 42 Years   (Adult),,30.0,"June 1, 2020",2020-08-20,"July 21, 2020","Aljazeera( Al Gazeera) hospital, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04423692,Egypt,,8.0,2020,Thursday
3796,3797,Covid-19 Lockdown and Deviant Sexual Fantasies,Recruiting,Behavioral: Questionnaire for evaluation of confinement on deviant sexual fantasies,All,"18 Years and older   (Adult, Older Adult)",,100.0,"June 18, 2020",2020-10-30,"July 7, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04448405,France,,10.0,2020,Friday
3797,3798,Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures,Completed,,All,"Child, Adult, Older Adult",,840.0,"March 16, 2020",2020-05-31,"July 22, 2020","Aga Khan University Hospital, Karachi, Sindh, Pakistan",https://ClinicalTrials.gov/show/NCT04482205,Pakistan,,5.0,2020,Sunday
3798,3799,Spironolactone in Covid-19 Induced ARDS,Not yet recruiting,Drug: Spironolactone 100mg|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60.0,"April 21, 2020",2020-10-21,"April 15, 2020","Istanbul University-Cerrahpaşa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04345887,Turkey,Spironolactone 100mg|Placebo oral tablet,10.0,2020,Wednesday
3799,3800,Non-contact Endoscopy at Covid-19 Outbreak,Completed,Device: Non-contact MCE system,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5.0,"March 16, 2020",2020-04-09,"April 17, 2020","Changhai Hospital, Shanghai, China",https://ClinicalTrials.gov/show/NCT04320953,China,,4.0,2020,Thursday
3800,3801,COVID 19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals,Not yet recruiting,,All,18 Years to 50 Years   (Adult),,31.0,June 2020,2021-06-01,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04409574,Undefined,,6.0,2021,Tuesday
3801,3802,Social Media and Covid19 Pandemic,Enrolling by invitation,Behavioral: survey,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,212.0,"May 1, 2020",2020-05-08,"May 7, 2020","Bahar Yuksel, Istanbul, Turkey|Haseki Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04378738,Turkey,,5.0,2020,Friday
3802,3803,Characteristics in Post Covid-19 Patients,Recruiting,Other: Exercise,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,"August 11, 2020",2021-12-31,"August 17, 2020","Universidade do Estado do Pará, Belém, Pará, Brazil",https://ClinicalTrials.gov/show/NCT04514705,Brazil,,12.0,2021,Friday
3803,3804,Psychological Impairment Due to Covid-19,Not yet recruiting,Other: No intervention,All,"Child, Adult, Older Adult",,100.0,"May 6, 2020",2020-05-30,"April 29, 2020",,https://ClinicalTrials.gov/show/NCT04368312,Undefined,,5.0,2020,Saturday
3804,3805,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Biological: ChAdOx1 nCoV-19|Biological: Normal saline 0.9%,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,2130.0,"June 24, 2020",2021-12-01,"November 27, 2020","PHRU Kliptown, Johannesburg, Gauteng, South Africa|Soweto Clinical Trials Centre, Johannesburg, Gauteng, South Africa|Wits RHI Shandukani Research Centre, Johannesburg, Gauteng, South Africa|Setshaba Research Centre (SRC), Soshanguve, Gauteng, South Africa|Chris Hani Baragwanath Academic Hospital - DST/NRF VPD RMPRU, Soweto, Gauteng, South Africa|FAMCRU, Cape Town, Western Cape, South Africa|Groote Schuur hospital, Lung infection and immunity unit, UCT, Cape Town, Western Cape, South Africa",https://ClinicalTrials.gov/show/NCT04444674,South Africa,,12.0,2021,Wednesday
3805,3806,The Seniors COvid-19 Pandemic and Exercise Study,Completed,Behavioral: Virtual Group Intervention|Behavioral: Personal Exercise Intervention,All,65 Years and older   (Older Adult),Not Applicable,241.0,"May 23, 2020",2020-10-05,"November 3, 2020","University of British Columbia, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04412343,Canada,,10.0,2020,Monday
3806,3807,CoViD-19 Patient in Reims University Hospital in March to April 2020,Recruiting,Biological: serology,All,"Child, Adult, Older Adult",,499.0,"September 25, 2020",2022-09-01,"October 5, 2020","Chu Reims, Reims, France",https://ClinicalTrials.gov/show/NCT04553575,France,,9.0,2022,Thursday
3807,3808,Acute Respiratory Failure and COVID-19 in Real Life,Recruiting,Other: standard operating procedures,All,"18 Years and older   (Adult, Older Adult)",,50.0,"March 19, 2020",2020-12-31,"May 13, 2020","Luigi Sacco University Hospital, Milan, Lombardia, Italy",https://ClinicalTrials.gov/show/NCT04307459,Italy,,12.0,2020,Thursday
3808,3809,Sexual Function During COVID 19 Pandemic,Completed,Other: Electronic questionnaire,All,18 Years to 40 Years   (Adult),,306.0,"June 1, 2020",2020-09-15,"October 6, 2020","Ahmed Abbas, Assiut, Cairo, Egypt|Assiut Faculty of Medicine, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04395885,Egypt,,9.0,2020,Tuesday
3809,3810,Hemodynamic Characteristics of Patients With SARS-CoV-2,Recruiting,Device: Transpulmonary thermodilution|Device: Echocardiography,All,"Child, Adult, Older Adult",,200.0,"March 13, 2020",2021-04-01,"July 9, 2020","Bicetre Hospital, Paris, Val-de-Marne, France",https://ClinicalTrials.gov/show/NCT04337983,France,,4.0,2021,Thursday
3810,3811,Regional COVID Epidemiology in England (RECEDE),Not yet recruiting,Other: No intervention,All,"18 Years to 110 Years   (Adult, Older Adult)",,5000.0,"November 1, 2020",2021-10-31,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04579562,Undefined,,10.0,2021,Sunday
3811,3812,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Recruiting,Other: blood sampling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"July 28, 2020",2025-12-31,"October 19, 2020","University Nice Hospital, Nice, France",https://ClinicalTrials.gov/show/NCT04429594,France,,12.0,2025,Wednesday
3812,3813,Parental Stress After the Covid-19 Pandemic,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1440.0,"June 22, 2020",2020-07-13,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04442308,Undefined,,7.0,2020,Monday
3813,3814,Role of Children in Transmission of COVID-19 to Immunocompromised Patients,Recruiting,,All,"Child, Adult, Older Adult",,300.0,"May 27, 2020",2023-05-28,"July 23, 2020","University of California at Los Angeles, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04407546,United States,,5.0,2023,Sunday
3814,3815,"Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study",Not yet recruiting,Other: Rehabilitation exercise protocol,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,30.0,"July 13, 2020",2021-12-31,"July 15, 2020",,https://ClinicalTrials.gov/show/NCT04471831,Undefined,,12.0,2021,Friday
3815,3816,Covid-19 and Prevention of Malnutrition After Confinement by Dentists,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 11, 2020",2021-05-11,"May 13, 2020","University Nice Hospital, Nice, France",https://ClinicalTrials.gov/show/NCT04386460,France,,5.0,2021,Tuesday
3816,3817,Outcomes in Hospitalized Older Patients With COVID-19,Completed,,All,65 Years and older   (Older Adult),,230.0,"March 13, 2020",2020-04-14,"May 12, 2020","Department of Rehabilitation and Geriatrics, Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04385212,Switzerland,,4.0,2020,Tuesday
3817,3818,Etiology of Lymphopenia in Covid19 Infection,Not yet recruiting,"Diagnostic Test: Complete blood picture, bone marrow aspiration cytology",All,"Child, Adult, Older Adult",,90.0,June 2020,2021-12-01,"May 27, 2020",,https://ClinicalTrials.gov/show/NCT04404608,Undefined,,12.0,2021,Wednesday
3818,3819,Influence of the COvid-19 Epidemic on STRESS,Not yet recruiting,,All,"Child, Adult, Older Adult",,50000.0,"March 11, 2020",2022-03-01,"March 13, 2020","University Hospital, Clermont-Ferrand, Clermont-Ferrand, France",https://ClinicalTrials.gov/show/NCT04308187,France,,3.0,2022,Tuesday
3819,3820,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,Recruiting,Behavioral: Telehealth coaching sessions,All,65 Years and older   (Older Adult),Not Applicable,75.0,"July 28, 2020",2021-07-31,"July 31, 2020","University of British Columbia, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04492527,Canada,,7.0,2021,Saturday
3820,3821,Technology-enabled Collaborative Care for Diabetes Management During COVID-19,Not yet recruiting,Behavioral: Intervention for TECC Model,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"November 30, 2020",2021-03-31,"October 29, 2020",,https://ClinicalTrials.gov/show/NCT04607915,Undefined,,3.0,2021,Wednesday
3821,3822,Convalescent Plasma to Stem Coronavirus (CSSC-001),Recruiting,Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"June 10, 2020",2023-01-01,"November 9, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami, Coral Gables, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States",https://ClinicalTrials.gov/show/NCT04323800,India,,1.0,2023,Sunday
3822,3823,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Recruiting,Biological: 2019-nCoV PCR,All,"Child, Adult, Older Adult",,345.0,"February 4, 2020",2021-02-04,"May 22, 2020","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont-Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre Investigation Clinique 1433 CHRU de NANCY, Nancy, France|Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Département maladie infectieux CHU Saint Etienne, Saint-Étienne, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana",https://ClinicalTrials.gov/show/NCT04259892,France,,2.0,2021,Thursday
3823,3824,Escin in Patients With Covid-19 Infection,Recruiting,Drug: Escin|Drug: standard therapy,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"March 23, 2020",2020-12-30,"September 16, 2020","Luca Gallelli, Catanzaro, Italy",https://ClinicalTrials.gov/show/NCT04322344,Italy,Escin|standard therapy,12.0,2020,Wednesday
3824,3825,Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"April 21, 2020",2022-04-21,"May 14, 2020","Percy Military Teaching Hospital, Clamart, France|Bégin Military Teaching Hospital, Saint-Mandé, France",https://ClinicalTrials.gov/show/NCT04365166,France,,4.0,2022,Thursday
3825,3826,Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19,Not yet recruiting,Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis,All,18 Years to 60 Years   (Adult),Phase 2,20.0,"November 10, 2020",2021-11-10,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04299152,Undefined,,11.0,2021,Wednesday
3826,3827,Functional Exhaustion of T Cells in COVID19 Patients,Recruiting,Diagnostic Test: Flow cytometry,All,"Child, Adult, Older Adult",,100.0,"July 22, 2020",2020-11-01,"August 6, 2020","Faculty of Medicine, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04470323,Egypt,,11.0,2020,Sunday
3827,3828,Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19,Not yet recruiting,Behavioral: Remote Problem Management Plus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,November 2020,2021-09-01,"November 9, 2020",,https://ClinicalTrials.gov/show/NCT04617262,Undefined,,9.0,2021,Wednesday
3828,3829,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Drug: Nitric Oxide Gas,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200.0,"March 21, 2020",2022-03-21,"July 14, 2020","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04306393,Israel,Nitric Oxide Gas,3.0,2022,Monday
3829,3830,Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals,Not yet recruiting,Other: maslach burnout inventory questionnair,All,"22 Years and older   (Adult, Older Adult)",,250.0,July 2020,2021-06-01,"July 8, 2020",,https://ClinicalTrials.gov/show/NCT04363229,Undefined,,6.0,2021,Tuesday
3830,3831,Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19,Not yet recruiting,Other: COVID-19 Pneumonia,All,"18 Years and older   (Adult, Older Adult)",,230.0,"June 15, 2020",2022-10-01,"June 17, 2020","Centro Hospitalar Universitário do Algarve, Faro, Algarve, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário de São João, Porto, Portugal|Centro Hospitalar Universitário do Porto - Hospital de Santo António, Porto, Portugal",https://ClinicalTrials.gov/show/NCT04416464,Portugal,,10.0,2022,Saturday
3831,3832,Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19,Completed,Other: Ultrasonography,All,"18 Years and older   (Adult, Older Adult)",,80.0,"March 3, 2020",2020-05-28,"September 29, 2020","Ospedale Regionale di Bellinzona e Valli, Bellinzona, Ticino, Switzerland",https://ClinicalTrials.gov/show/NCT04567927,Switzerland,,5.0,2020,Thursday
3832,3833,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,Dietary Supplement: Vitamin D3,All,"30 Years to 66 Years   (Adult, Older Adult)",Not Applicable,100.0,"October 5, 2020",2021-02-20,"December 8, 2020","Mahmoud S Abu-Samak, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04476745,Jordan,,2.0,2021,Saturday
3833,3834,At Home Monitoring for Patients With Covid19,Not yet recruiting,Device: Covidfree@home,All,"Child, Adult, Older Adult",Not Applicable,1000.0,"October 16, 2020",2023-04-01,"October 12, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04453774,Canada,,4.0,2023,Saturday
3834,3835,Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),Withdrawn,Other: Best Practice|Biological: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"April 7, 2020",2020-06-02,"June 18, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04361552,Georgia,,6.0,2020,Tuesday
3835,3836,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Terminated,Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"April 5, 2020",2020-10-08,"October 9, 2020","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark",https://ClinicalTrials.gov/show/NCT04322773,Denmark,RoActemra iv|RoActemra sc|Kevzara sc,10.0,2020,Thursday
3836,3837,Psychological Impact of COVID19 Among Women Undergoing Infertility Treatment,Not yet recruiting,Other: Online questionnaire,Female,18 Years to 43 Years   (Adult),,600.0,July 2020,2020-12-01,"August 3, 2020","Hôpital Femme Mère Enfant, Bron, France",https://ClinicalTrials.gov/show/NCT04496869,France,,12.0,2020,Tuesday
3837,3838,A Comparison of 3D and 2D Telemedicine During Covid 19,Not yet recruiting,Other: 3D Telemedicine|Other: 2D Telemedicine,All,"1 Year to 95 Years   (Child, Adult, Older Adult)",Not Applicable,80.0,"June 30, 2020",2021-12-31,"April 28, 2020","Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom",https://ClinicalTrials.gov/show/NCT04359225,United Kingdom,,12.0,2021,Friday
3838,3839,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,Biological: Mesenchymal stromal cells,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"June 12, 2020",2022-09-30,"June 24, 2020","CHU de Liège, Liège, Belgium",https://ClinicalTrials.gov/show/NCT04445454,Belgium,,9.0,2022,Friday
3839,3840,Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study,Completed,Other: Beck Depression Inventory (BDI),All,"18 Years and older   (Adult, Older Adult)",,97.0,"April 17, 2020",2020-05-01,"June 23, 2020","Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04444557,Turkey,,5.0,2020,Friday
3840,3841,"Evaluation of Systemic and Oral Conditions of Pregnant Women and Their Babies, With Exposure to COVID-19 Infection",Not yet recruiting,Other: congenital malformation,Female,"16 Years to 40 Years   (Child, Adult)",,260.0,January 2021,2022-12-01,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04492449,Undefined,,12.0,2022,Thursday
3841,3842,Orthopaedic Conservative Treatment in the Time of Covid-19 Pandemic,"Active, not recruiting",Procedure: Observation for study group,All,85 Years and older   (Older Adult),,262.0,"March 11, 2020",2020-12-01,"November 16, 2020","SBU Prof. Cemil Tascioglu City Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04623346,Turkey,,12.0,2020,Tuesday
3842,3843,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Drug: INO-4800|Device: CELLECTRA® 2000,All,"18 Years and older   (Adult, Older Adult)",Phase 1,120.0,"April 3, 2020",2021-07-01,"September 21, 2020","Central Kentucky Research Associates, Lexington, Kentucky, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04336410,United States,INO-4800,7.0,2021,Thursday
3843,3844,Evaluation of Dental Emergency Treatments During COVID19 Crisis,Not yet recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",,840.0,"April 13, 2020",2020-06-20,"April 21, 2020",,https://ClinicalTrials.gov/show/NCT04354272,Undefined,,6.0,2020,Saturday
3844,3845,Mask Usage and Exercise During the COVİD-19 Pandemic,Recruiting,,All,"18 Years to 65 Years   (Adult, Older Adult)",,60.0,"July 20, 2020",2021-09-30,"August 6, 2020","KTO Karatay University, Konya, Karatay, Turkey",https://ClinicalTrials.gov/show/NCT04498546,Turkey,,9.0,2021,Thursday
3845,3846,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,Biological: Blood sample|Biological: Serum tube collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"June 5, 2020",2020-12-15,"June 17, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, Paca, France",https://ClinicalTrials.gov/show/NCT04420338,France,,12.0,2020,Tuesday
3846,3847,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Drug: Inhaled budesonide,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,300.0,"April 21, 2020",2020-10-18,"July 23, 2020","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04355637,Spain,Inhaled budesonide,10.0,2020,Sunday
3847,3848,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Completed,Dietary Supplement: Ayurveda|Other: Usual Care,All,18 Years to 60 Years   (Adult),Not Applicable,32.0,"March 6, 2020",2020-04-12,"April 17, 2020","Aarogyam, Leicester, United Kingdom",https://ClinicalTrials.gov/show/NCT04351542,United Kingdom,,4.0,2020,Sunday
3848,3849,The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection,Completed,Other: biochemical analysis,All,"18 Years and older   (Adult, Older Adult)",,500.0,"March 1, 2020",2020-06-12,"June 16, 2020","Usak University Training and Research Hospital, Usak, Turkey",https://ClinicalTrials.gov/show/NCT04433754,Turkey,,6.0,2020,Friday
3849,3850,SARS-CoV 2 in Personal Protective Equipment,Not yet recruiting,,All,"16 Years and older   (Child, Adult, Older Adult)",,16.0,"May 15, 2020",2020-07-30,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04398043,Undefined,,7.0,2020,Thursday
3850,3851,The Impact of Covid-19 Pandemic on Colorectal Cancer Prevention Due to Delays in Diagnosis: a Global Study,Not yet recruiting,Other: Colonoscopy,All,"Child, Adult, Older Adult",,1000.0,"December 16, 2020",2021-03-31,"November 20, 2020",,https://ClinicalTrials.gov/show/NCT04637893,Undefined,,3.0,2021,Wednesday
3851,3852,Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital,Not yet recruiting,Other: COVID positive via testing,Female,18 Years to 50 Years   (Adult),,200.0,May 2020,2020-12-01,"May 13, 2020",,https://ClinicalTrials.gov/show/NCT04385914,Undefined,,12.0,2020,Tuesday
3852,3853,imPROving prenaTal carE During ConfinemenT,"Active, not recruiting",Other: Remote consultation,Female,"18 Years and older   (Adult, Older Adult)",,108.0,"April 25, 2020",2021-09-30,"July 29, 2020","Maternité Régionale Universitaire de Nancy, Nancy, France",https://ClinicalTrials.gov/show/NCT04368832,France,,9.0,2021,Thursday
3853,3854,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults",Recruiting,Drug: HFB30132A|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,24.0,October 2020,2021-07-01,"October 19, 2020","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04590430,United States,HFB30132A,7.0,2021,Thursday
3854,3855,Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study,Recruiting,"Other: Dietary counselling on Food Groups according to IYC Feeding practices, WHO",All,6 Months to 6 Years   (Child),,300.0,"June 6, 2020",2021-05-31,"June 25, 2020","University of Malaya Medical Center, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04447209,Malaysia,,5.0,2021,Monday
3855,3856,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,Recruiting,Diagnostic Test: conjunctival RT PCR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,68.0,"May 15, 2020",2020-11-15,"August 18, 2020","Centre Hospitalier de versailles, Le Chesnay, France",https://ClinicalTrials.gov/show/NCT04397666,France,,11.0,2020,Sunday
3856,3857,A Survey to Assess Effects of Covid-19 on Cardiovascular Patients,Recruiting,"Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)",All,"18 Years to 80 Years   (Adult, Older Adult)",,76.0,"May 15, 2019",2021-07-15,"August 11, 2020","Centro de Insuficiencia Cardiaca Instituto Nacional de Cardiologia, Mexico City, Mexico",https://ClinicalTrials.gov/show/NCT04508920,Mexico,,7.0,2021,Thursday
3857,3858,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,Drug: Tocilizumab|Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"July 16, 2020",2021-12-31,"August 18, 2020","CH Andrée Rosemon, Cayenne, French Guiana",https://ClinicalTrials.gov/show/NCT04476979,French Guiana,Tocilizumab|Dexamethasone,12.0,2021,Friday
3858,3859,Turkish of the SARS-CoV-2 Anxiety Scale,Recruiting,Other: survey work,All,18 Years to 60 Years   (Adult),Not Applicable,300.0,"July 24, 2020",2020-12-24,"July 29, 2020","Eskisehir Osmangazi University, Eskisehir, Turkey",https://ClinicalTrials.gov/show/NCT04490473,Turkey,,12.0,2020,Thursday
3859,3860,GlobalSurg-CovidSurg Week,Not yet recruiting,,All,"Child, Adult, Older Adult",,1000.0,"October 1, 2020",2020-12-01,"August 12, 2020",,https://ClinicalTrials.gov/show/NCT04509986,Undefined,,12.0,2020,Tuesday
3860,3861,Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital,Not yet recruiting,Device: CT of the chest,All,"18 Years to 99 Years   (Adult, Older Adult)",,100.0,August 2020,2021-09-01,"July 22, 2020",,https://ClinicalTrials.gov/show/NCT04481360,Undefined,,9.0,2021,Wednesday
3861,3862,"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","Active, not recruiting",Drug: ACE inhibitor,All,"18 Years and older   (Adult, Older Adult)",,1302508.0,"January 1, 1998",2021-03-31,"November 13, 2020",,https://ClinicalTrials.gov/show/NCT04322786,Undefined,ACE inhibitor,3.0,2021,Wednesday
3862,3863,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",Completed,Drug: Aerolized Hydroxychloroquine Sulfate|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,"June 25, 2020",2020-08-17,"October 8, 2020","The Rockefeller University, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04461353,United States,Aerolized Hydroxychloroquine Sulfate,8.0,2020,Monday
3863,3864,Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak,Not yet recruiting,,All,"18 Years to 65 Years   (Adult, Older Adult)",,500.0,"April 10, 2020",2020-07-01,"April 10, 2020",,https://ClinicalTrials.gov/show/NCT04342208,Undefined,,7.0,2020,Wednesday
3864,3865,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Recruiting,Other: Home-based exercise,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,70.0,"May 10, 2020",2021-02-01,"June 11, 2020","Univsersity of Sao Paulo, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04425005,Brazil,,2.0,2021,Monday
3865,3866,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Recruiting,Procedure: Prone positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25.0,"April 1, 2020",2020-05-01,"April 14, 2020","CHI Aix-Pertuis, Aix-en-Provence, France",https://ClinicalTrials.gov/show/NCT04344106,France,,5.0,2020,Friday
3866,3867,Evaluation of Lymphedema Patients Status During Covid-19 Pandemic,Completed,,All,"18 Years and older   (Adult, Older Adult)",,60.0,"June 1, 2020",2020-08-01,"October 8, 2020","Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Ataşehir, Turkey",https://ClinicalTrials.gov/show/NCT04568005,Turkey,,8.0,2020,Saturday
3867,3868,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,Recruiting,Biological: VPM1002|Biological: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 3,2038.0,"June 18, 2020",2021-09-30,"December 1, 2020","Hautarztpraxis Dres. Leitz & Kollegen, Stuttgart, Baden-Württemberg, Germany|MECS Cottbus GmbH, Cottbus, Brandenburg, Germany|Studienzentrum Dr. Keller, Frankfurt, Hessen, Germany|Klinische Forschung Hannover Mitte GmbH, Hannover, Niedersachsen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Medizentrum Essen Borbeck, Essen, Nordrhein-Westfalen, Germany|BAG Dres. med. Quist PartG, Mainz, Rheinland-Pfalz, Germany|SIBAmed GmbH & Co. KG, Leipzig, Sachsen, Germany|SocraTec R&D GmbH, Erfurt, Thüringen, Germany|emovis GmbH, Berlin, Germany|Klinische Forschung Berlin GbR, Berlin, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany",https://ClinicalTrials.gov/show/NCT04435379,Germany,,9.0,2021,Thursday
3868,3869,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Recruiting,Other: Questionnaires|Biological: blood test|Other: Maximal effort test|Device: actigraphy|Device: Neuromuscular evaluation,All,"35 Years to 80 Years   (Adult, Older Adult)",Not Applicable,82.0,"May 27, 2020",2021-12-01,"October 8, 2020","CHU de Grenoble, Grenoble, France|Clinique de la Sauvegarde - Lyon, Lyon, France|Hôpital Croix Rousse - HCL, Lyon, France|Centre Hospitalier de Lyon Sud, Pierre-benite, France|Chu Saint-Etienne, Saint Etienne, France|Clinique Mutualiste Saint Etienne, Saint Etienne, France|Hôpital Henry Gabrielle, Saint-Genis-Laval, France|Hôpital privé de la Loire, Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04363606,France,,12.0,2021,Wednesday
3869,3870,Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center,Completed,Biological: Screening test for covid ( RT PCR and CT Chest),All,"18 Years and older   (Adult, Older Adult)",,112.0,"March 19, 2020",2020-04-25,"May 7, 2020","Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France",https://ClinicalTrials.gov/show/NCT04379232,France,,4.0,2020,Saturday
3870,3871,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Completed,Other: Tele-yoga therapy|Other: Primary care,All,18 Years to 60 Years   (Adult),Not Applicable,64.0,"March 30, 2020",2020-07-06,"July 10, 2020","NMP Medical Research Institute, Jaipur, Rajasthan, India",https://ClinicalTrials.gov/show/NCT04466605,India,,7.0,2020,Monday
3871,3872,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Not yet recruiting,Behavioral: Increasing Willingness and Uptake of COVID-19 Testing and Vaccination,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,310.0,"December 1, 2020",2022-11-30,"September 9, 2020",,https://ClinicalTrials.gov/show/NCT04542395,Undefined,,11.0,2022,Wednesday
3872,3873,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Recruiting,Behavioral: Training session adressing information and health literacy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1230.0,"July 1, 2020",2021-12-31,"August 27, 2020","Jacobs University Bremen gGmbH, Bremen, Germany",https://ClinicalTrials.gov/show/NCT04453475,Germany,,12.0,2021,Friday
3873,3874,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Recruiting,Behavioral: exercise group|Other: control group,Male,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40.0,"November 19, 2020",2021-03-01,"November 20, 2020","Faculty of Physical Therapy Cairo University, Giza, Dokki, Egypt",https://ClinicalTrials.gov/show/NCT04639349,Egypt,,3.0,2021,Monday
3874,3875,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Recruiting,Behavioral: Internet-based self-help|Behavioral: Internet-based self-help after 3 weeks,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"May 6, 2020",2021-04-01,"May 8, 2020","Universität Bern, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04380909,Switzerland,,4.0,2021,Thursday
3875,3876,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,Behavioral: Meditation app usage,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 19, 2020",2021-04-30,"November 13, 2020","LECOM, Erie, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04369378,United States,,4.0,2021,Friday
3876,3877,Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection,Recruiting,Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors,All,"18 Years and older   (Adult, Older Adult)",,728.0,"March 26, 2020",2026-03-25,"April 27, 2020","University Hospital Essen, Essen, NRW, Germany",https://ClinicalTrials.gov/show/NCT04327479,Germany,,3.0,2026,Wednesday
3877,3878,Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders,Recruiting,Other: Semi-structured telephone questionnaire,All,"16 Years and older   (Child, Adult, Older Adult)",,75.0,"September 11, 2020",2020-12-17,"October 9, 2020","Royal Brompton Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04581577,United Kingdom,,12.0,2020,Thursday
3878,3879,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Recruiting,Behavioral: Brief Behavioral Activation with Mental Imagery|Behavioral: Minimal Attention Control Intervention,All,65 Years and older   (Older Adult),Not Applicable,154.0,"August 17, 2020",2021-07-01,"August 19, 2020","Adult Psychiatric Clinic, Västerås, Västmanland, Sweden",https://ClinicalTrials.gov/show/NCT04508868,Sweden,,7.0,2021,Thursday
3879,3880,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Recruiting,Drug: Symptomatic drugs|Drug: Bridge therapy|Behavioral: Mindfulness program,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,25.0,"June 15, 2020",2022-07-01,"October 9, 2020","Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit, Milano, Italy",https://ClinicalTrials.gov/show/NCT04410536,Italy,Symptomatic drugs|Bridge therapy,7.0,2022,Friday
3880,3881,"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study",Enrolling by invitation,Other: Colgate periogard mouthwash|Other: Colgate Peroxyl mouthwash|Other: Colgate Total mouthwash|Other: Placebo mouthwash (water),All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,70.0,"June 11, 2020",2021-08-30,"September 3, 2020","Hospital israelita Albert Einstein, Sao Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04537962,Brazil,,8.0,2021,Monday
3881,3882,Social Media Use During COVID-19,Completed,Behavioral: Use of social media during COVID-19,All,"21 Years and older   (Adult, Older Adult)",,1145.0,"March 7, 2020",2020-04-21,"July 7, 2020","Yale-NUS College, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04305574,Singapore,,4.0,2020,Tuesday
3882,3883,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,Other: Video Dance classes|Other: Unsupervised physical activities,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60.0,"May 1, 2020",2024-12-30,"June 11, 2020","Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil",https://ClinicalTrials.gov/show/NCT04422353,Brazil,,12.0,2024,Monday
3883,3884,Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure,Completed,Device: patients receiving nasal high flow,All,"18 Years and older   (Adult, Older Adult)",,62.0,"March 1, 2020",2020-05-04,"May 13, 2020","Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris, Colombes, France",https://ClinicalTrials.gov/show/NCT04385823,France,,5.0,2020,Monday
3884,3885,Experience of Lock Down Related to the Covid-19 Epidemic and Its Impact on the Project of Parenthood,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,360.0,October 2020,2020-12-01,"September 21, 2020",,https://ClinicalTrials.gov/show/NCT04556630,Undefined,,12.0,2020,Tuesday
3885,3886,"Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic",Recruiting,,All,"2 Months and older   (Child, Adult, Older Adult)",,200.0,"December 16, 2020",2025-05-01,"December 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04419870,United States,,5.0,2025,Thursday
3886,3887,CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid),Not yet recruiting,Other: n/a - samples collected along routine care samples only,All,"21 Years and older   (Adult, Older Adult)",,70.0,"January 15, 2021",2021-10-01,"December 9, 2020",,https://ClinicalTrials.gov/show/NCT04659252,Undefined,,10.0,2021,Friday
3887,3888,"Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"May 29, 2020",2021-06-01,"July 29, 2020","UH Montpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04384419,France,,6.0,2021,Tuesday
3888,3889,A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis,Not yet recruiting,Procedure: Bone Marrow Harvest,All,18 Years to 40 Years   (Adult),,10.0,May 2020,2021-12-01,"May 21, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04397471,United Kingdom,,12.0,2021,Wednesday
3889,3890,Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic,Recruiting,Diagnostic Test: Serology test for COVID-19,All,"18 Years and older   (Adult, Older Adult)",,250.0,"July 7, 2020",2021-04-30,"October 6, 2020","Hôpital Saint Joseph Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04465656,France,,4.0,2021,Friday
3890,3891,Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"July 1, 2020",2020-12-31,"November 3, 2020","Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates|Mediclinic, Abu Dhabi, United Arab Emirates|Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates|Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04422418,United Arab Emirates,,12.0,2020,Thursday
3891,3892,"Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network",Completed,,All,"18 Years and older   (Adult, Older Adult)",,4789.0,"May 8, 2020",2020-07-11,"August 28, 2020","CHU Grenoble Alpes, Grenoble, France",https://ClinicalTrials.gov/show/NCT04409197,France,,7.0,2020,Saturday
3892,3893,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"Active, not recruiting",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,320.0,"April 8, 2020",2020-08-01,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04347031,Russian Federation,Mefloquine|Hydroxychloroquine,8.0,2020,Saturday
3893,3894,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Recruiting,,All,"Child, Adult, Older Adult",,20.0,"January 20, 2020",2021-02-28,"February 21, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04279795,China,,2.0,2021,Sunday
3894,3895,HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital,Recruiting,Other: research specific blood sample,All,"18 Years and older   (Adult, Older Adult)",,500.0,"June 17, 2020",2021-07-01,"July 17, 2020","Centre Hospitalier Universitaire Réunion, Saint-Denis, France|Centre Hospitalier Universitaire de la Réunion, Saint-Pierre, France",https://ClinicalTrials.gov/show/NCT04384705,France,,7.0,2021,Thursday
3895,3896,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Recruiting,Biological: BCG Vaccine|Biological: Placebo Vaccine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,1800.0,"April 20, 2020",2021-11-01,"May 27, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Texas A&M Family Care Clinic, Bryan, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04348370,United States,,11.0,2021,Monday
3896,3897,Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic,Not yet recruiting,Behavioral: Online cognitive behavioral therapy (CBT)|Behavioral: Online bibliotherapy programme,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120.0,"May 1, 2020",2021-10-01,"April 24, 2020",,https://ClinicalTrials.gov/show/NCT04362358,Undefined,,10.0,2021,Friday
3897,3898,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Not yet recruiting,"Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,September 2020,2021-07-01,"July 9, 2020","BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia",https://ClinicalTrials.gov/show/NCT04390152,Colombia,"Wharton's jelly derived Mesenchymal stem cells.|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)",7.0,2021,Thursday
3898,3899,Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,20.0,"May 25, 2020",2021-05-25,"May 27, 2020","HOPITAL HAUT-LEVEQUE - Service Réanimation thoracique, Pessac, France",https://ClinicalTrials.gov/show/NCT04386720,France,,5.0,2021,Tuesday
3899,3900,Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis,"Active, not recruiting",Other: Questionnaires|Other: psychological and sociological interviews,All,"18 Years and older   (Adult, Older Adult)",,3000.0,"April 21, 2020",2020-11-01,"June 22, 2020","Chu Dijon Bourgogne, Dijon, France",https://ClinicalTrials.gov/show/NCT04441476,France,,11.0,2020,Sunday
3900,3901,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,Diagnostic Test: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus,All,"Child, Adult, Older Adult",Not Applicable,80.0,"May 23, 2020",2021-07-23,"June 9, 2020","CHU de Poitiers, Poitiers, France",https://ClinicalTrials.gov/show/NCT04387253,France,,7.0,2021,Friday
3901,3902,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Recruiting,Other: Comprehensive treatment,All,"Child, Adult, Older Adult",,100.0,"January 20, 2020",2021-02-28,"February 24, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04279782,China,,2.0,2021,Sunday
3902,3903,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Recruiting,Other: Doppler Echo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 24, 2020",2020-10-30,"August 4, 2020","Centre Hospitalier de Versailles, Le Chesnay, France",https://ClinicalTrials.gov/show/NCT04363528,France,,10.0,2020,Friday
3903,3904,Anosmia and / or Ageusia and Early Corticosteroid Use,Recruiting,Drug: Early-Dexamethasone|Drug: Late dexamethazone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,300.0,"August 30, 2020",2020-12-15,"September 16, 2020","Asalam, Maadi, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04528329,Egypt,Early-Dexamethasone|Late dexamethazone,12.0,2020,Tuesday
3904,3905,Coping With 2020 - No Health Without Mental Health,Recruiting,Behavioral: Co-mestring (co-coping),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"April 2, 2020",2021-12-31,"October 14, 2020","Haukeland University Hospital, Bergen, Norway",https://ClinicalTrials.gov/show/NCT04421612,Norway,,12.0,2021,Friday
3905,3906,Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19),Not yet recruiting,Biological: Respiratory infections,All,"18 Years and older   (Adult, Older Adult)",,100.0,"December 7, 2020",2021-06-30,"December 11, 2020","Imperial College London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04664075,United Kingdom,,6.0,2021,Wednesday
3906,3907,Stay Well at Home: a Text-messaging Study Social Distancing,Recruiting,Behavioral: Uniform random message delivery|Behavioral: Reinforcement learning message delivery,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 17, 2020",2021-04-01,"July 28, 2020","University of California Berkeley, Berkeley, California, United States",https://ClinicalTrials.gov/show/NCT04473599,United States,,4.0,2021,Thursday
3907,3908,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Active, not recruiting",Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,416.0,"April 18, 2020",2020-09-01,"July 1, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",https://ClinicalTrials.gov/show/NCT04343729,Brazil,Methylprednisolone Sodium Succinate|Placebo solution,9.0,2020,Tuesday
3908,3909,Emotional Freedom Technique (EFT) Effect on Nurses,Completed,Behavioral: Emotional Freedom Technique,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80.0,"May 10, 2020",2020-05-20,"November 24, 2020","Medeniyet University, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04393077,Turkey,,5.0,2020,Wednesday
3909,3910,Mask Adhesive Institutional Study,Not yet recruiting,Device: Mask with Mask Adhesive/Arm 1|Device: Mask without Mask Adhesive / Arm 2,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30.0,"November 17, 2020",2020-12-17,"November 25, 2020","Sleep Disorder Center of Alabama, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04644276,United States,,12.0,2020,Thursday
3910,3911,A Research Platform to Screen Healthcare Workers,Recruiting,Diagnostic Test: Nasopharyngeal swab|Other: Questionnaire collection|Other: Optional blood completion|Other: Optional questionnaire completion,All,"18 Years and older   (Adult, Older Adult)",,100000.0,"April 16, 2020",2021-04-16,"October 5, 2020","University Health Network, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04574765,Canada,,4.0,2021,Friday
3911,3912,Study of Descartes-30 in Acute Respiratory Distress Syndrome,Recruiting,Biological: Descartes 30,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"September 15, 2020",2022-09-25,"October 22, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT04524962,United States,,9.0,2022,Sunday
3912,3913,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,Procedure: Awake Proning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,350.0,"June 10, 2020",2021-08-30,"October 22, 2020","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Hamilton General Hospital, Hamilton, Canada|Juravinski Hospital, Hamilton, Canada|St. Catharine's General -, St. Catharines, Canada|King Fahad Hospital of the University, Khobar, Eastern Province, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04350723,Canada,,8.0,2021,Monday
3913,3914,Containment Measures and Eating Disorders,Completed,,All,"18 Years and older   (Adult, Older Adult)",,40.0,"April 1, 2020",2020-06-30,"July 30, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04492189,France,,6.0,2020,Tuesday
3914,3915,Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population,Recruiting,Other: Slef questionnaires fulfilment,All,"18 Years and older   (Adult, Older Adult)",,500.0,"April 1, 2020",2020-11-01,"July 1, 2020","University hospital, Montpellier, France",https://ClinicalTrials.gov/show/NCT04374643,France,,11.0,2020,Sunday
3915,3916,Inflammatory Bowel Disease (IBD) and Covid-19 Infection,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,700.0,"July 7, 2020",2021-01-07,"July 30, 2020","Service Hépato-Gastroentérologie et Assistance Nutritive Hôpitaux Univesitaires de Strasbourg, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04492267,France,,1.0,2021,Thursday
3916,3917,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Not yet recruiting,Drug: Anakinra,All,"18 Years and older   (Adult, Older Adult)",Phase 2,240.0,April 2020,2020-12-31,"April 14, 2020",,https://ClinicalTrials.gov/show/NCT04341584,Undefined,Anakinra,12.0,2020,Thursday
3917,3918,Haemoglobin Concentration on COVID-19,Recruiting,Other: File scanning,All,"Child, Adult, Older Adult",,200.0,"November 1, 2020",2020-12-30,"September 16, 2020","Konya Training and Research Hospital, Konya, Turkey",https://ClinicalTrials.gov/show/NCT04377607,Turkey,,12.0,2020,Wednesday
3918,3919,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Biological: Ad26.COV2.S|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1045.0,"July 15, 2020",2024-02-02,"November 27, 2020","Optimal Research, San Diego, California, United States|Optimal Research, Melbourne, Florida, United States|Optimal Research, Peoria, Illinois, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Optimal Research, Rockville, Maryland, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States|Optimal Research, Austin, Texas, United States|SGS Life Science Services, Antwerpen, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|ATC Pharma, Luik, Belgium|Clinical Pharmacology Unit, Merksem, Belgium|Universiteit Antwerpen, Wilrijk, Belgium",https://ClinicalTrials.gov/show/NCT04436276,Belgium,,2.0,2024,Friday
3919,3920,Neurological Features During COVID19,Recruiting,Other: Observation,All,"18 Years and older   (Adult, Older Adult)",,30.0,"March 8, 2020",2020-09-30,"July 9, 2020","Hopital Raymond Poincare, Garches, France",https://ClinicalTrials.gov/show/NCT04460599,France,,9.0,2020,Wednesday
3920,3921,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,"Active, not recruiting",,All,"18 Years to 75 Years   (Adult, Older Adult)",,400.0,"January 1, 2020",2020-07-31,"March 3, 2020","Fujian Provincial Hospital, Fuzhou, Fujian, China",https://ClinicalTrials.gov/show/NCT04292327,China,,7.0,2020,Friday
3921,3922,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Recruiting,Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,"March 27, 2020",2020-12-31,"June 2, 2020","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04340557,United States,Losartan,12.0,2020,Thursday
3922,3923,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Recruiting,Biological: UC-MSCs,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,16.0,"February 6, 2020",2020-12-30,"July 1, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04269525,China,,12.0,2020,Wednesday
3923,3924,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Recruiting,Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care,All,"31 Days and older   (Child, Adult, Older Adult)",Phase 3,240.0,"April 16, 2020",2021-03-30,"May 6, 2020","WVU Medicine, Morgantown, West Virginia, United States",https://ClinicalTrials.gov/show/NCT04376034,United States,,3.0,2021,Tuesday
3924,3925,"Body Weight Regulation, Disordered Eating Behaviour, and Experiences of Sexual Harassment in Female Martial Art Athletes",Recruiting,,Female,"16 Years to 40 Years   (Child, Adult)",,200.0,"September 10, 2020",2020-12-31,"September 23, 2020","Norwegian school of sport sciences, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04559542,Norway,,12.0,2020,Thursday
3925,3926,Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations,Recruiting,Behavioral: Motivational social support from nurse|Behavioral: Motivational social support from nurse with additional support from significant other|Behavioral: Attention control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,225.0,"August 1, 2019",2023-05-01,"October 30, 2020","Spectrum Health, Grand Rapids, Michigan, United States",https://ClinicalTrials.gov/show/NCT03907891,United States,,5.0,2023,Monday
3926,3927,Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic,Completed,Biological: blood sample,All,"18 Years and older   (Adult, Older Adult)",,1680.0,"May 12, 2020",2020-06-30,"August 18, 2020","Centre Georges-François LECLERC, Dijon, France",https://ClinicalTrials.gov/show/NCT04517097,France,,6.0,2020,Tuesday
3927,3928,Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome,Not yet recruiting,Other: Blood sampling|Other: Skin biopsy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25.0,October 2020,2020-12-01,"October 19, 2020","Department of Dermatology, Tarnier hospital, AP-HP, Paris, France",https://ClinicalTrials.gov/show/NCT04590209,France,,12.0,2020,Tuesday
3928,3929,Tocilizumab in Coronavirus-19 Positive Patients,Not yet recruiting,Biological: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30.0,"July 30, 2020",2021-06-01,"July 22, 2020",,https://ClinicalTrials.gov/show/NCT04423042,Undefined,,6.0,2021,Tuesday
3929,3930,Convalescent Plasma to Limit Coronavirus Associated Complications,Withdrawn,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"April 1, 2020",2022-12-31,"April 8, 2020",,https://ClinicalTrials.gov/show/NCT04325672,Undefined,,12.0,2022,Saturday
3930,3931,Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions,Not yet recruiting,Biological: anti-SARS-CoV-2 human convalescent plasma,All,1 Month to 17 Years   (Child),Phase 1,30.0,August 2020,2024-12-01,"July 8, 2020","University of California, Los Angeles (UCLA), Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04462848,United States,,12.0,2024,Sunday
3931,3932,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,Recruiting,Device: Breath Biopsy face masks with removable filters and fitted PVA strip,All,"16 Years and older   (Child, Adult, Older Adult)",,100.0,"July 30, 2020",2020-12-01,"August 18, 2020","Cambridge University Hospital NHS, Cambridge, United Kingdom",https://ClinicalTrials.gov/show/NCT04467112,United Kingdom,,12.0,2020,Tuesday
3932,3933,A Study of a Candidate COVID-19 Vaccine (COV003),Recruiting,Biological: ChAdOx1 nCoV-19 single dose + paracetamol|Biological: MenACWY single dose + paracetamol|Biological: ChAdOx1 nCoV-19 two dose + paracetamol|Biological: MenACWY prime & saline placebo boost + paracetamol,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10300.0,"June 2, 2020",2021-09-01,"November 27, 2020","Instituto D'Or de Pesquisa e Ensino - I'Dor, Salvador, Bahia, Brazil|Centro de Pesquisas Clinicas de Natal (CPCLIN), Natal, Rio Grande Do Norte, Brazil|Hospital das Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Santa Maria (UFSM), Santa Maria, Rio Grande Do Sul, Brazil|Instituto D'Or de Pesquisa e Ensino - I'Dor, Rio de Janeiro, Brazil|CRIE, Universidade Federal de São Paulo, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04536051,Brazil,,9.0,2021,Wednesday
3933,3934,Viral Infections in Healthy and Immunocompromised Hosts,Recruiting,,All,"Child, Adult, Older Adult",,1000.0,"March 5, 2011",,"October 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT01306084,United States,,,n,
3934,3935,The PREPARE for COVID Trial,Not yet recruiting,Behavioral: The PREPARE program,All,65 Years and older   (Older Adult),Not Applicable,372.0,"June 15, 2020",2021-09-15,"May 18, 2020",,https://ClinicalTrials.gov/show/NCT04392115,Undefined,,9.0,2021,Wednesday
3935,3936,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,Recruiting,Diagnostic Test: Serology|Genetic: Sequencing,All,"Child, Adult, Older Adult",,300.0,"March 9, 2020",2021-06-01,"May 22, 2020","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Hôpital Cochin CIC 1417 Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Département maladie infectieux CHU Saint Etienne, Saint Etienne, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Centre Investigation Clinique 1433 CHRU de NANCY, Vandœuvre-lès-Nancy, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana",https://ClinicalTrials.gov/show/NCT04322279,France,,6.0,2021,Tuesday
3936,3937,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Not yet recruiting,Drug: L-ascorbic acid|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,January 2021,2021-05-01,"December 9, 2020","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",https://ClinicalTrials.gov/show/NCT04344184,United States,L-ascorbic acid,5.0,2021,Saturday
3937,3938,Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP),Recruiting,Other: attendance by ambulance crew,All,"Child, Adult, Older Adult",,55000.0,"March 23, 2019",2021-03-23,"July 16, 2020","University of Lincoln, Lincoln, United Kingdom",https://ClinicalTrials.gov/show/NCT04474444,United Kingdom,,3.0,2021,Tuesday
3938,3939,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,Not yet recruiting,Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,160.0,"February 7, 2020",2020-06-30,"February 10, 2020",,https://ClinicalTrials.gov/show/NCT04261907,Undefined,ASC09/ritonavir group|lopinavir/ritonavir group,6.0,2020,Tuesday
3939,3940,Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From an Asymptomatic Population,Enrolling by invitation,Diagnostic Test: Diagnostic test for detection of SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"September 11, 2020",2020-12-31,"September 23, 2020","Rollins College Alfonds Sports Center, Winter Park, Florida, United States",https://ClinicalTrials.gov/show/NCT04561102,United States,,12.0,2020,Thursday
3940,3941,Evaluation of the COVIDSeq Test in Saliva Specimens From Illumina Personnel,Enrolling by invitation,Diagnostic Test: COVIDSeq Test,All,"18 Years and older   (Adult, Older Adult)",,2000.0,"July 13, 2020",2020-12-31,"September 23, 2020","Illumina Laboratory Services, Foster City, California, United States|Illumina Hayward, Hayward, California, United States|Illumina Laboratory Services, San Diego, California, United States",https://ClinicalTrials.gov/show/NCT04561089,United States,,12.0,2020,Thursday
3941,3942,Using PRP and Cord Blood in Treatment of Covid -19,Recruiting,Combination Product: stem cells,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 25, 2020",2020-09-01,"July 27, 2020","Aljazeera( Al Gazeera) hospital, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04393415,Egypt,,9.0,2020,Tuesday
3942,3943,Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome,Recruiting,Diagnostic Test: Cytokines measurement|Diagnostic Test: Cellular response|Diagnostic Test: TLRs activation measurement|Diagnostic Test: KIR phenotype evaluation,All,"18 Years to 100 Years   (Adult, Older Adult)",,80.0,"May 22, 2020",2020-09-30,"May 27, 2020","Hospital Ramon y Cajal, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04403061,Spain,,9.0,2020,Wednesday
3943,3944,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Drug: VC|Drug: Sterile Water for Injection,All,"18 Years and older   (Adult, Older Adult)",Phase 2,56.0,"February 14, 2020",2020-03-29,"October 12, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04264533,China,VC|Sterile Water for Injection,3.0,2020,Sunday
3944,3945,Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,20.0,"May 11, 2020",2020-08-31,"July 16, 2020","Osaka University Hospital, Suita, Osaka, Japan",https://ClinicalTrials.gov/show/NCT04473300,Japan,,8.0,2020,Monday
3945,3946,Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,Recruiting,Drug: REGN10933 + REGN10987|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,2000.0,"July 13, 2020",2021-08-15,"November 10, 2020","Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Northridge, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Eatonton, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 2, Chicago, Illinois, United States|Regeneron Study Site 3, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site 1, Boston, Massachusetts, United States|Regeneron Study Site 2, Boston, Massachusetts, United States|Regeneron Study Site 3, Boston, Massachusetts, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Gulfport, Mississippi, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Hazelwood, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Fayetteville, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Gaffney, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Yakima, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucharest, Romania",https://ClinicalTrials.gov/show/NCT04452318,Georgia,REGN10933 + REGN10987|Placebo,8.0,2021,Sunday
3946,3947,Sero-epidemiological Survey of England in 2019/2020,Recruiting,Procedure: Venepuncture|Procedure: Oral fluid swab,All,"up to 24 Years   (Child, Adult)",,3500.0,"October 15, 2019",2021-06-30,"August 7, 2020","Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04061382,United Kingdom,,6.0,2021,Wednesday
3947,3948,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,Other: HOME-CoV rule implementation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3133.0,"April 9, 2020",2020-06-17,"September 23, 2020","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco",https://ClinicalTrials.gov/show/NCT04338841,Belgium,,6.0,2020,Wednesday
3948,3949,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Drug: Chloroquine diphosphate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,278.0,"March 23, 2020",2020-06-07,"July 7, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",https://ClinicalTrials.gov/show/NCT04323527,Brazil,Chloroquine diphosphate,6.0,2020,Sunday
3949,3950,MR-Evaluation of Renal Function In Septic Patients,Recruiting,Other: Plasma expansion with Ringer's Acetate,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,April 2016,2025-10-01,"June 17, 2020","Uppsala University Hospital, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT02765191,Sweden,,10.0,2025,Wednesday
3950,3951,"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",Recruiting,Drug: CT-P59|Drug: Placebo,All,19 Years to 55 Years   (Adult),Phase 1,32.0,"July 18, 2020",2020-11-30,"August 25, 2020","Chungnam National University Hospital, Daejeon, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04525079,"Korea, Republic of",CT-P59|Placebo,11.0,2020,Monday
3951,3952,Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.,Completed,Other: Questionnaire,All,"Child, Adult, Older Adult",,280.0,"May 10, 2020",2020-06-25,"September 23, 2020","CHU, Angers, France",https://ClinicalTrials.gov/show/NCT04349163,France,,6.0,2020,Thursday
3952,3953,Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments (COVID-19-LAT),Recruiting,Behavioral: decisions of limitations and stop processing,All,"18 Years and older   (Adult, Older Adult)",,2500.0,"June 1, 2020",2021-06-01,"June 30, 2020","CHU de Clermont-Ferrand, Clermont-Ferrand, France|Hospices Civiles de Lyon, Lyon, France|CH de Vichy, Vichy, France",https://ClinicalTrials.gov/show/NCT04452487,France,,6.0,2021,Tuesday
3953,3954,Expanded Access Remdesivir (RDV; GS-5734™),Available,Drug: Remdesivir,All,"Child, Adult, Older Adult",,,,,"April 10, 2020",,https://ClinicalTrials.gov/show/NCT04302766,Undefined,Remdesivir,,n,
3954,3955,Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,Not yet recruiting,"Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride",All,"up to 100 Years   (Child, Adult, Older Adult)",,426.0,"May 15, 2020",2021-12-14,"May 20, 2020",,https://ClinicalTrials.gov/show/NCT04275388,Undefined,"Xiyanping injection|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride",12.0,2021,Tuesday
3955,3956,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,Recruiting,Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,456.0,"April 23, 2020",2020-11-01,"September 11, 2020","Contract Research Organization, Berlin, Germany|Contract Research Organization, Mannheim, Germany",https://ClinicalTrials.gov/show/NCT04380701,Germany,,11.0,2020,Sunday
3956,3957,Less Frequency Hemodialysis and COVID-19,"Active, not recruiting",Other: less-frequency hemodialysis,All,"18 Years to 85 Years   (Adult, Older Adult)",,50.0,"March 20, 2020",2021-03-01,"May 5, 2020","Dialisis Madariaga, General Juan Madariaga, Buenos Aires, Argentina",https://ClinicalTrials.gov/show/NCT04374058,Argentina,,3.0,2021,Monday
3957,3958,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",Recruiting,Diagnostic Test: Recombinase aided amplification (RAA) assay,All,"1 Year to 90 Years   (Child, Adult, Older Adult)",,50.0,"January 1, 2020",2020-12-31,"April 10, 2020","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04245631,China,,12.0,2020,Thursday
3958,3959,Evaluation of the Physical Activity Level of the Elderly in Social Isolation,Not yet recruiting,Behavioral: Home exercise program,All,65 Years to 80 Years   (Older Adult),Not Applicable,88.0,"August 1, 2020",2020-11-20,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04480606,Undefined,,11.0,2020,Friday
3959,3960,"Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU",Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,320.0,"April 27, 2020",2020-07-01,"May 28, 2020","Service Reanimation Medicale, Strasbourg, France",https://ClinicalTrials.gov/show/NCT04385004,France,,7.0,2020,Wednesday
3960,3961,Covid Radiographic Images Data-set for A.I,Recruiting,Diagnostic Test: Neural network diagnosis algorithm,All,"Child, Adult, Older Adult",,2500.0,"March 24, 2020",2021-03-31,"June 5, 2020","Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Turin, Italy",https://ClinicalTrials.gov/show/NCT04419545,Italy,,3.0,2021,Wednesday
3961,3962,Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,November 2007,2025-02-01,"September 10, 2020","Carolina BioOncology Institute, Huntersville, North Carolina, United States",https://ClinicalTrials.gov/show/NCT00571389,United States,,2.0,2025,Saturday
3962,3963,Nurse Leadership for Hospital Infection Control,Not yet recruiting,Behavioral: Intervention for COVID-19 preventive protocols,Female,"Child, Adult, Older Adult",Not Applicable,200.0,"November 1, 2020",2021-03-01,"October 26, 2020",,https://ClinicalTrials.gov/show/NCT04603079,Undefined,,3.0,2021,Monday
3963,3964,Sequelae of Sars-CoV-2 Infections,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,30.0,"May 20, 2020",2023-12-31,"June 24, 2020","Department of Internal Medicine II, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig-University, Giessen, Germany",https://ClinicalTrials.gov/show/NCT04442789,Germany,,12.0,2023,Sunday
3964,3965,"imPulse™ Una Full-spectrum, Over Clothing E-stethoscope",Recruiting,Device: imPulse™ Una e-stethoscope|Device: Philips Lumify Ultrasound System,All,"18 Years to 90 Years   (Adult, Older Adult)",,30.0,"October 1, 2020",2021-01-31,"December 8, 2020","Johns Hopkins School of Medicine, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04556149,United States,,1.0,2021,Sunday
3965,3966,Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections,Recruiting,Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation,All,"19 Years and older   (Adult, Older Adult)",Phase 2,20.0,"October 24, 2017",2021-03-31,"September 9, 2020","Nitric Solutions-Mobile Unit, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT03331445,Canada,Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation,3.0,2021,Wednesday
3966,3967,Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children,Recruiting,Other: Diagnostic test,All,"1 Year to 18 Years   (Child, Adult)",,2380.0,"July 2, 2020",2021-12-01,"October 14, 2020","Institute of Tropical Medicine, Tübingen, Deutschland, Germany",https://ClinicalTrials.gov/show/NCT04581889,Germany,,12.0,2021,Wednesday
3967,3968,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,Drug: Colchicine|Drug: Placebo oral tablet,All,"40 Years and older   (Adult, Older Adult)",Phase 3,6000.0,"March 23, 2020",2020-12-01,"November 17, 2020","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|University of Arkansas for medical Sciences, Little Rock, Arkansas, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Prisma Health, Greenville, South Carolina, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, São Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04322682,Brazil,Colchicine|Placebo oral tablet,12.0,2020,Tuesday
3968,3969,The COVID-19 ICU PRAYER Study,Recruiting,Behavioral: prayer,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,1000.0,"June 1, 2020",2020-08-31,"June 4, 2020","Research Medical Center, Kansas City, Missouri, United States",https://ClinicalTrials.gov/show/NCT04361838,United States,,8.0,2020,Monday
3969,3970,2019-nCoV Outbreak and Cardiovascular Diseases,Recruiting,,All,"Child, Adult, Older Adult",,12000.0,"January 20, 2020",2020-04-30,"February 5, 2020","Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China",https://ClinicalTrials.gov/show/NCT04255940,China,,4.0,2020,Thursday
3970,3971,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Recruiting,Radiation: Angiography scanner,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"May 26, 2020",2021-08-31,"September 10, 2020","Hôpital Foch, Suresnes, France",https://ClinicalTrials.gov/show/NCT04479540,France,,8.0,2021,Tuesday
3971,3972,COV2Base-A Rare Disease by COVID Study,Recruiting,,All,"1 Month and older   (Child, Adult, Older Adult)",,120000.0,"December 16, 2020",2021-09-01,"December 11, 2020","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04564274,United States,,9.0,2021,Wednesday
3972,3973,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,Completed,Diagnostic Test: MCC IMS,All,"18 Years and older   (Adult, Older Adult)",,76.0,"February 15, 2020",2020-06-30,"July 14, 2020","Klinikum Bayreuth, Bayreuth, Germany",https://ClinicalTrials.gov/show/NCT04282135,Germany,,6.0,2020,Tuesday
3973,3974,Sexual Health and Problems During the Covid -19 Infection,Not yet recruiting,Behavioral: questionaire to husband and wife,All,18 Years to 60 Years   (Adult),,400.0,"June 11, 2020",2020-07-12,"June 11, 2020","Algazeerah, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04427813,Egypt,,7.0,2020,Sunday
3974,3975,LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION,Recruiting,,All,"18 Years to 90 Years   (Adult, Older Adult)",,500.0,"May 21, 2020",2021-07-31,"June 11, 2020","Pulmonary Department. Hospital Clinico., Valencia, Spain",https://ClinicalTrials.gov/show/NCT04409275,Spain,,7.0,2021,Saturday
3975,3976,A New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy,All,"Child, Adult, Older Adult",Not Applicable,230.0,February 2020,2020-03-01,"February 24, 2020","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04281693,China,,3.0,2020,Sunday
3976,3977,Needle Stick Injuries in Emergency Medical Service Practice,Completed,Procedure: double gloves,,"Child, Adult, Older Adult",,300.0,"February 28, 2020",2020-04-24,"April 28, 2020","Lazarski Univeristy, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04363788,Poland,,4.0,2020,Friday
3977,3978,COVID-19 - SARS-CoV-2 Community Contamination in Children and Adults (Dyn3CEA_Nosocor),Not yet recruiting,Other: Review of medical patient file|Other: Phone call interview,All,"Child, Adult, Older Adult",,75.0,"January 1, 2021",2021-04-04,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04664296,Undefined,,4.0,2021,Sunday
3978,3979,Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.,Recruiting,Other: Coronavirus Disease 2019,Male,18 Years to 60 Years   (Adult),,200.0,"May 10, 2020",2021-05-01,"May 18, 2020","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04388631,China,,5.0,2021,Saturday
3979,3980,Evaluation of Self-Collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing Via RT-PCR,Not yet recruiting,Diagnostic Test: SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600.0,October 2020,2021-02-01,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04604145,Undefined,,2.0,2021,Monday
3980,3981,Behavior During and After COVID-19 Crisis,Recruiting,Behavioral: Covid19,All,"18 Years to 65 Years   (Adult, Older Adult)",,1000.0,"April 1, 2020",2022-12-31,"August 10, 2020","Bern University of Applied Sciences, Department of Health Professions, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04502108,Switzerland,,12.0,2022,Saturday
3981,3982,Clinical Outcome of Anti-IL6 vs Anti-IL6 Corticosteroid Combination in Patients With SARS-CoV-2 Cytokine Release Syndrome,Recruiting,Drug: Interleukin 6 (IL6) Antagonist|Drug: Interleukin 6 (IL6) Antagonist and corticosteroids,All,"14 Years and older   (Child, Adult, Older Adult)",,11000.0,"July 22, 2020",2021-07-22,"July 24, 2020","King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04486521,Saudi Arabia,Interleukin 6 (IL6) Antagonist|Interleukin 6 (IL6) Antagonist and corticosteroids,7.0,2021,Thursday
3982,3983,A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia,Recruiting,,All,"Child, Adult, Older Adult",,30000.0,"February 3, 2020",2020-04-20,"February 7, 2020","Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China",https://ClinicalTrials.gov/show/NCT04260308,China,,4.0,2020,Monday
3983,3984,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,Behavioral: Mindfulness-Based Cognitive Therapy|Behavioral: Muscle Relaxation Therapy,All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,60.0,"October 19, 2020",2021-12-01,"November 2, 2020","University of Michigan, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04540939,United States,,12.0,2021,Wednesday
3984,3985,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,Drug: alpha one antitrypsin inhalation,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,150.0,"June 1, 2020",2020-09-01,"May 13, 2020","Ministry of Health, Mecca, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04385836,Saudi Arabia,alpha one antitrypsin inhalation,9.0,2020,Tuesday
3985,3986,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Recruiting,Drug: Meplazumab for Injection,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"February 3, 2020",2020-12-31,"February 19, 2020","Tangdu Hospital, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT04275245,China,Meplazumab for Injection,12.0,2020,Thursday
3986,3987,First Responder Resiliency Program During COVID-19,Not yet recruiting,Behavioral: Resilience Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"January 1, 2021",2021-12-31,"December 1, 2020",,https://ClinicalTrials.gov/show/NCT04536376,Undefined,,12.0,2021,Friday
3987,3988,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Biological: Ad26.COV2.S|Biological: Placebo,All,"20 Years and older   (Adult, Older Adult)",Phase 1,250.0,"August 11, 2020",2021-12-08,"November 25, 2020","Souseikai Hakata Clinic, Fukuoka, Japan|SOUSEIKAI PS Clinic, Fukuoka, Japan|Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan",https://ClinicalTrials.gov/show/NCT04509947,Japan,,12.0,2021,Wednesday
3988,3989,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Completed,Drug: EIDD-2801|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,130.0,"April 10, 2020",2020-08-11,"August 17, 2020","Covance Leeds Clinical Research Unit, Leeds, United Kingdom",https://ClinicalTrials.gov/show/NCT04392219,United Kingdom,EIDD-2801|Placebo,8.0,2020,Tuesday
3989,3990,Variation in Acute Appendicitis During COVID-19 Pandemic in Italy,Completed,Procedure: Appendectomy,All,"Child, Adult, Older Adult",,532.0,"September 1, 2020",2020-11-30,"December 4, 2020","Policlinico San Pietro, Ponte San Pietro, BG, Italy|Ospedale Manzoni, Lecco, LC, Italy|ASST Monza, Monza, MB, Italy|Ospedale San Raffaele, Milano, Mi, Italy|ASST Lodi, Lodi, Italy|Azienda ospedaliero-universitaria Pisana,Ospedale Cisanello, Pisa, Italy",https://ClinicalTrials.gov/show/NCT04649996,Italy,,11.0,2020,Monday
3990,3991,The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,142.0,June 2020,2020-12-01,"June 11, 2020","Lawson Health Research Institute, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04426071,Canada,,12.0,2020,Tuesday
3991,3992,Effect of Positive Attitudes on Behavior and Wellness,Completed,Behavioral: Positive feedback,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24.0,"June 15, 2020",2020-07-30,"August 12, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04441632,United States,,7.0,2020,Thursday
3992,3993,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",Suspended,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"April 4, 2020",2021-08-01,"June 4, 2020","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04341727,United States,Hydroxychloroquine Sulfate|Azithromycin|Chloroquine Sulfate,8.0,2021,Sunday
3993,3994,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Recruiting,Behavioral: Internet-based guided self-help based on CBT principles,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"May 14, 2020",2021-06-30,"October 22, 2020","Hebrew University of Jerusalem, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04394403,Israel,,6.0,2021,Wednesday
3994,3995,"Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19",Enrolling by invitation,Other: 40ml blood sample,All,"18 Years and older   (Adult, Older Adult)",,125.0,"October 1, 2020",2021-05-01,"November 5, 2020","Universit of Manchester, Manchester, Greater Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04363047,United Kingdom,,5.0,2021,Saturday
3995,3996,Implementation of the Integrated Care of Older People App and ICOPE Monitor in Primary Care (ICOPE),Not yet recruiting,,All,65 Years and older   (Older Adult),,600.0,October 2020,2021-11-01,"June 4, 2020",,https://ClinicalTrials.gov/show/NCT04413877,Undefined,,11.0,2021,Monday
3996,3997,An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,Recruiting,,All,"18 Years to 99 Years   (Adult, Older Adult)",,150.0,"April 24, 2020",2020-12-31,"July 2, 2020","Sourou Sanon University Hospital, Bobo-Dioulasso, Burkina Faso|Tingadogo University Hospital, Ouagadougou, Burkina Faso",https://ClinicalTrials.gov/show/NCT04445441,Burkina Faso,,12.0,2020,Thursday
3997,3998,Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.,Recruiting,Other: evaluation of skin microvascular flow and reactivity,All,"18 Years to 80 Years   (Adult, Older Adult)",,25.0,"May 15, 2020",2020-11-01,"June 1, 2020","National Institute of Cardiology, Rio de Janeiro, Brazil",https://ClinicalTrials.gov/show/NCT04406545,Brazil,,11.0,2020,Sunday
3998,3999,Psychological Impact of Institutional Quarantine as a Precautionary Measure Against COVID-19,Not yet recruiting,Other: No intervention,All,18 Years to 60 Years   (Adult),,100.0,"September 20, 2020",2020-10-20,"September 17, 2020","ITBP Chawala, Delhi, India",https://ClinicalTrials.gov/show/NCT04552392,India,,10.0,2020,Tuesday
3999,4000,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Completed,Other: Deep Breathing training|Other: Compassion focused intervention,All,20 Years to 40 Years   (Adult),Not Applicable,69.0,"May 2, 2020",2020-05-31,"September 25, 2020","Sapienza University of Rome, Rome, Italy",https://ClinicalTrials.gov/show/NCT04382560,Italy,,5.0,2020,Sunday
4000,4001,QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,200.0,"May 26, 2020",2020-08-31,"July 23, 2020","Don Gnocchi Foundation, Rome, Italy",https://ClinicalTrials.gov/show/NCT04408196,Italy,,8.0,2020,Monday
4001,4002,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19","Active, not recruiting",Behavioral: Supportive Therapy SSI|Behavioral: Behavioral Activation SSI|Behavioral: Growth Mindset SSI,All,13 Years to 16 Years   (Child),Not Applicable,2409.0,"November 19, 2020",2021-07-31,"December 8, 2020","Stony Brook University, Stony Brook, New York, United States",https://ClinicalTrials.gov/show/NCT04634903,United States,,7.0,2021,Saturday
4002,4003,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,"Active, not recruiting",Behavioral: SSE educational intervention|Other: Home sample collection of concerning mole with physician supervision|Behavioral: Active control:Healthy Living,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"July 2, 2020",2021-12-30,"September 4, 2020","Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04420273,United States,,12.0,2021,Thursday
4003,4004,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',Not yet recruiting,Behavioral: Brief Skills for Safer Living,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75.0,August 2020,2021-08-01,"August 3, 2020","St. Michael's Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04495543,Canada,,8.0,2021,Sunday
4004,4005,Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention,Recruiting,,All,"20 Years to 65 Years   (Adult, Older Adult)",,300.0,"February 20, 2020",2020-05-30,"May 14, 2020","Branch of Chinese Medicine, Taipei City Hospital, Taipei, Taiwan|Branch of Linsen Chinese Medicine and Kunming, Taipei City Hospital, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04388644,Undefined,,5.0,2020,Saturday
4005,4006,"To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19",Not yet recruiting,Drug: DWRX2003|Drug: Placebo,All,18 Years to 45 Years   (Adult),Phase 1,32.0,August 2020,2020-12-01,"August 24, 2020",,https://ClinicalTrials.gov/show/NCT04524052,Undefined,DWRX2003|Placebo,12.0,2020,Tuesday
4006,4007,Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey,Not yet recruiting,,All,"15 Years and older   (Child, Adult, Older Adult)",,1000.0,May 2020,2020-06-01,"April 24, 2020","Istanbul University-Cerrahpasa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04357886,Turkey,,6.0,2020,Monday
4007,4008,Physiotherapist-led Exercise Within Cardiac Rehabilitation and Paroxysmal Atrial Fibrillation and COVID-19.,Not yet recruiting,Other: PT-X and IMT,All,"40 Years to 85 Years   (Adult, Older Adult)",Not Applicable,180.0,January 2021,2025-10-01,"October 23, 2020",,https://ClinicalTrials.gov/show/NCT04600713,Undefined,,10.0,2025,Wednesday
4008,4009,The Professional Peer Resilience Initiative,Enrolling by invitation,Behavioral: MinnRAP Peer Support Program,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"June 8, 2020",2022-05-25,"September 4, 2020","University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04396600,United States,,5.0,2022,Wednesday
4009,4010,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,Recruiting,Biological: T memory cells and NK cells,All,"up to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,58.0,"September 4, 2020",2021-03-01,"October 19, 2020","Hospital Universitario La Paz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04578210,Spain,,3.0,2021,Monday
4010,4011,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,Recruiting,Other: Sudarshan Kriya Yoga (SKY)|Other: Health Enhancement Program,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,60.0,"June 25, 2020",2021-06-30,"September 3, 2020","London Health Sciences Centre, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04368676,Canada,,6.0,2021,Wednesday
4011,4012,Post-Pandemic Perception of Public Space in Singapore,Not yet recruiting,Other: Public space exposure,All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,34.0,"June 1, 2020",2020-12-31,"May 19, 2020","Institute for Health Innovation & Technology (iHealthtech), Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04394039,Singapore,,12.0,2020,Thursday
4012,4013,CoCo-20: a Longitudinal Follow-up Study of the French Paediatric Population During and After the Coronavirus Pandemic COVID-19,Recruiting,Diagnostic Test: Quantitative and qualitative assessments of mental health,All,up to 17 Years   (Child),,70.0,"April 27, 2020",2020-12-01,"October 6, 2020","Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France",https://ClinicalTrials.gov/show/NCT04498416,France,,12.0,2020,Tuesday
4013,4014,Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures,Completed,Behavioral: Change in preference to surgery under COVID-19 pandemic.,All,"18 Years and older   (Adult, Older Adult)",,79.0,"April 17, 2020",2020-04-24,"May 7, 2020","Zealand University Hospital, Køge, Zealand Region, Denmark",https://ClinicalTrials.gov/show/NCT04370678,Denmark,,4.0,2020,Friday
4014,4015,A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study,Not yet recruiting,Other: Museum virtual guided tours,All,65 Years and older   (Older Adult),Not Applicable,40.0,"January 4, 2021",2021-07-04,"October 22, 2020","Jewish General Hospital, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04593433,Canada,,7.0,2021,Sunday
4015,4016,Obesity Surgery During 2020 Italian Pandemic,Recruiting,Procedure: Bariatric procedures,All,18 Years to 60 Years   (Adult),,1600.0,"July 15, 2020",2021-05-30,"November 5, 2020","University La Sapienza of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Latina, LT, Italy",https://ClinicalTrials.gov/show/NCT04480034,Italy,,5.0,2021,Sunday
4016,4017,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome,Recruiting,Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,9.0,"June 17, 2020",2025-06-30,"June 25, 2020","Uppsala University Hospital, Uppsala, Sweden",https://ClinicalTrials.gov/show/NCT04447833,Sweden,Mesenchymal Stromal Stem Cells - KI-MSC-PL-205,6.0,2025,Monday
4017,4018,A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device,Not yet recruiting,Diagnostic Test: RBA-2,All,"18 Years and older   (Adult, Older Adult)",,300.0,April 2020,2020-12-01,"April 22, 2020","Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT04357977,United States,,12.0,2020,Tuesday
4018,4019,Vitamin D3 Supplementation to Prevent Respiratory Tract Infections,Recruiting,Dietary Supplement: Vitamin D supplementation,All,"52 Years and older   (Adult, Older Adult)",Not Applicable,2099.0,"October 27, 2020",2021-11-01,"November 20, 2020","Cooper University Hospital, Camden, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04596657,Jersey,,11.0,2021,Monday
4019,4020,RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study,Recruiting,Diagnostic Test: Rapid Pathogen Detection,All,up to 16 Years   (Child),,250.0,"April 6, 2020",2025-02-28,"June 5, 2020","Addenbrooke's Hospital, Cambridge, Cambs, United Kingdom",https://ClinicalTrials.gov/show/NCT04233268,United Kingdom,,2.0,2025,Friday
4020,4021,Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects,Enrolling by invitation,Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination|Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy,Male,18 Years to 51 Years   (Adult),Not Applicable,3350.0,"December 20, 2019",2021-02-15,"October 14, 2020","Harvard University, Cambridge, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04160975,United States,,2.0,2021,Monday
4021,4022,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),Recruiting,Other: Meditation (1 x 20-minute guided audio training),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,292.0,"October 28, 2020",2021-03-01,"November 12, 2020","Health and Behavioural Sciences, Brisbane, Queensland, Australia",https://ClinicalTrials.gov/show/NCT04602286,Australia,,3.0,2021,Monday
4022,4023,"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: TAK-981|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,242.0,"October 1, 2018",2023-10-01,"December 3, 2020","University of California San Diego Moores Cancer Center, La Jolla, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT03648372,United States,TAK-981|Standard of care,10.0,2023,Sunday
4023,4024,A Patient-Centered PaTH to Addressing Diabetes,"Active, not recruiting",Other: Weight Counseling|Other: Telemedicine,All,"18 Years and older   (Adult, Older Adult)",,2000000.0,March 2016,2021-02-01,"July 23, 2020",,https://ClinicalTrials.gov/show/NCT02788903,Undefined,,2.0,2021,Monday
4024,4025,CoV-PICS: A Virtual Post-ICU Clinic,Recruiting,Other: Medical Record Review - Inpatient Treatment|Other: Online Questionnaires,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80.0,"September 29, 2020",2021-07-30,"October 5, 2020","Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04490278,United States,,7.0,2021,Friday
4025,4026,Brief Video Interventions for Depression,Recruiting,Behavioral: Entrée: Cognitive skills|Behavioral: Entrée: Behavioral skills|Behavioral: Entrée: Interpersonal skills|Behavioral: Sampler skills,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,501.0,November 2020,2020-11-01,"November 25, 2020","Department of Psychology, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04643964,United States,,11.0,2020,Sunday
4026,4027,Mindfulness Training for Seniors,Completed,Behavioral: Mindfulness training (MT) Connect,All,"60 Years to 95 Years   (Adult, Older Adult)",Not Applicable,53.0,"May 13, 2020",2020-08-04,"August 17, 2020","University of Miami, Coral Gables, Florida, United States",https://ClinicalTrials.gov/show/NCT04378803,United States,,8.0,2020,Tuesday
4027,4028,"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",Recruiting,Other: COVICU,All,"18 Years to 100 Years   (Adult, Older Adult)",,100.0,"June 15, 2020",2020-08-31,"June 12, 2020","Bursa Yüksek Ihtisas Training and Research Hospital, Bursa, Yildirim, Turkey",https://ClinicalTrials.gov/show/NCT04383483,Turkey,,8.0,2020,Monday
4028,4029,Sleep Quality Among HCWs,Completed,Other: PSQI,All,25 Years to 60 Years   (Adult),,217.0,"May 19, 2020",2020-09-05,"September 21, 2020","Zagazig University, Zagazig, Egypt",https://ClinicalTrials.gov/show/NCT04549350,Egypt,,9.0,2020,Saturday
4029,4030,A Clinical Study of Online Active Play Program With Adolescents,Completed,,All,11 Years to 17 Years   (Child),,32.0,"March 30, 2020",2020-07-28,"November 5, 2020","Revival Active, Leicester, Leicestershire, United Kingdom",https://ClinicalTrials.gov/show/NCT04618341,United Kingdom,,7.0,2020,Tuesday
4030,4031,Needs of Persons With Spinal Cord Injury (SCI),Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,250.0,"May 22, 2020",2020-12-31,"September 25, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04422769,United States,,12.0,2020,Thursday
4031,4032,Music Therapy in Frontline Healthcare Workers,Not yet recruiting,Behavioral: Music Therapy,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"October 1, 2020",2020-11-30,"September 16, 2020","Simon Fraser University, Burnaby, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04551274,Canada,,11.0,2020,Monday
4032,4033,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Recruiting,Device: TAPE-Software,All,"Child, Adult, Older Adult",Not Applicable,100.0,"April 20, 2020",2020-11-30,"August 19, 2020","RWTH Aachen University Hospital, Aachen, Germany",https://ClinicalTrials.gov/show/NCT04518514,Germany,,11.0,2020,Monday
4033,4034,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Recruiting,Other: Pulmonary tele-rehabilitation,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,December 2020,2022-01-01,"December 10, 2020","Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04658979,Canada,,1.0,2022,Saturday
4034,4035,Effects of a Face Mask on Oxygenation During Exercise,Completed,Other: Progressive cycling exercise test to exhaustion,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14.0,"September 14, 2020",2020-10-15,"October 20, 2020","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",https://ClinicalTrials.gov/show/NCT04557605,Canada,,10.0,2020,Thursday
4035,4036,Video-Based Exercises and Well-Being During Social Isolation,Completed,Other: Video based aerobic exercise,All,18 Years to 35 Years   (Adult),Not Applicable,68.0,"April 6, 2020",2020-06-03,"June 9, 2020","Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04335851,Turkey,,6.0,2020,Wednesday
4036,4037,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Completed,Other: after-each-case room disinfection|Other: daily room disinfection,All,"Child, Adult, Older Adult",Not Applicable,240.0,"May 25, 2020",2020-06-10,"June 25, 2020","First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04399005,China,,6.0,2020,Wednesday
4037,4038,Effectiveness of Convalescent Immune Plasma Therapy,Completed,Other: Convalescent Immune Plasma,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60.0,"May 15, 2020",2020-06-17,"July 1, 2020","Istanbul Bagcılar Training and Research Hospital, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04442958,Turkey,,6.0,2020,Wednesday
4038,4039,Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019,Recruiting,Other: Questionnaire,All,"Child, Adult, Older Adult",,200.0,"September 30, 2020",2020-11-30,"June 11, 2020","HOPITAL PELLEGRIN, Service des maladies infectieuses et tropicales, Bordeaux, France|HOPITAL PELLEGRIN, service des maladies intensives et réanimation, Bordeaux, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Limoges, Limoges, France|Hôpital St Louis, Paris, France|HEGP, Paris, France|Hôpital Robert Debré, Paris, France|CHU de Rouen, Rouen, France",https://ClinicalTrials.gov/show/NCT04383899,France,,11.0,2020,Monday
4039,4040,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Enrolling by invitation,Behavioral: self-care tools|Behavioral: lay telephone coaching,All,65 Years and older   (Older Adult),Not Applicable,176.0,"October 21, 2020",2021-05-01,"November 18, 2020","St Mary's Hospital Research Centre, Montréal, Canada",https://ClinicalTrials.gov/show/NCT04609371,Canada,,5.0,2021,Saturday
4040,4041,Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease,Not yet recruiting,Dietary Supplement: Vitamin D 1000 IU|Drug: Placebo,All,18 Years to 30 Years   (Adult),Not Applicable,4400.0,"September 1, 2020",2021-04-28,"July 20, 2020","Headingley and City campuses, Leeds Beckett University, Leeds, Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04476680,United Kingdom,Placebo,4.0,2021,Wednesday
4041,4042,The Impact of Lifestyle Changes on Non-COVID Deaths,Recruiting,,All,"Child, Adult, Older Adult",,80000.0,September 2020,2020-10-01,"September 16, 2020","Xuzhou Medical University affiliated Hospital, Xuzhou, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04550312,China,,10.0,2020,Thursday
4042,4043,Telemedicine in HIV Care in Buenos Aires,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,4000.0,"September 1, 2020",2022-07-01,"August 14, 2020",,https://ClinicalTrials.gov/show/NCT04513496,Undefined,,7.0,2022,Friday
4043,4044,Telerehabilitation for Patients Diagnosed With Coronavirus,Not yet recruiting,Other: Telerehabilitation|Other: exercise brochure,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30.0,"August 10, 2020",2020-11-30,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04346927,Undefined,,11.0,2020,Monday
4044,4045,Chat-based Support for Preventing Smoking Relapse,"Active, not recruiting",Behavioral: Chat-based instant messaging support|Behavioral: SMS message support|Behavioral: Self-help booklet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108.0,"June 2, 2020",2021-06-30,"November 27, 2020","Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04409496,Hong Kong,,6.0,2021,Wednesday
4045,4046,French COVID Cohort,Recruiting,,All,"Child, Adult, Older Adult",,5000.0,"February 8, 2020",2023-08-07,"May 7, 2020","CHG Agen, Agen, France|Centre Hospitalier Du Pays D'aix, Aix-en-Provence, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Annecy Genevois, Annecy, France|Hopital privé d'Antony, Antony, France|Hôpital de Mercy. CHR METZ-THIONVILLE, Ars-Laquenexy, France|Centre Hospitalier Henri Duffaut, Avignon, France|Chu Jean Minjoz, Besançon, France|Hôpital Avicenne AP-HP, Bobigny, France|CHU Pellegrin, Bordeaux, France|CHU Ambroise Paré, Boulogne-Billancourt, France|Ch Fleyriat, Bourg-en-Bresse, France|Chru Hopital Cavale Blanche, Brest, France|CHU Brest, Brest, France|Centre hospitalier de Béziers, Béziers, France|CH Cahors, Cahors, France|Chms Chambery Nh, Chambéry, France|Centre Hospitalier De Cholet, Cholet, France|CHU Gabriel Montpied, Clermont-Ferrand, France|CH Colmar - Hopital Pasteur, Colmar, France|Centre hospitalier Alpes Leman, Contamine-sur-Arve, France|Centre hospitalier Intercommunal de Créteil, Créteil, France|Hôpital Henri Mondor, Créteil, France|Centre Hospitalier Dax, Dax, France|CHU Dijon Bourgogne, Dijon, France|Hopital Raymond Poincare, Garches, France|CHU Grenoble, Grenoble, France|Grand Hopital de l'Est Francilien site Marne-la-Vallée, Jossigny, France|Chd Les Oudairies, La Roche-sur-Yon, France|Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France|Centre Hospitalier Emile Roux, Le Puy-en-Velay, France|Centre Hospitalier Universitaire de Lille, Lille, France|CHRU Lille, Hôpital Salengro, Lille, France|CHU de Lille, Lille, France|Hôpital de la Croix-Rousse, Lyon, France|Hôpital Louis Raffalli, Manosque, France|Assistance publique hopitaux de Marseille, hopital Nord, Marseille, France|Hôpital Conception, Marseille, France|Groupe Hospitalier Sud Ile De France, Melun, France|CH de Mont Marsan, Mont de Marsan, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hopital Américain de Paris, Neuilly-sur-Seine, France|CHU de Nice, Nice, France|CHU Caremeau, Nîmes, France|APHP Bichat, Paris, France|APHP Tenon, Paris, France|CH Lariboisière, Paris, France|Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France|Hopital Cochin-CIC1417, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Saint Louis, Paris, France|La pitié salpetrière, Paris, France|Centre Hospitalier de Pau, Pau, France|CH de Perpignan, Perpignan, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de Périgueux, Périgueux, France|Ch Cornouaille, Quimper, France|Chu Reims, Reims, France|Hôpital Pontchaillou, Rennes, France|CHU Rouen Normandie, Rouen, France|Hopital d'instruction des armées Begin 69, Saint-Mandé, France|Centre hospitalier Louis Constant Fleming, Saint-Martin, France|CHU de Saint-Etienne, Saint-Étienne, France|CH de Saintonge, Saintes, France|Centre Hospitalier de Soissons, Soissons, France|N.H.C. - Nouvel Hopital Civil, Strasbourg, France|Hopital Foch, Suresnes, France|CHR Metz-Thionville -Hopital Bel Air, Thionville, France|Hopitaux du Leman, Thonon-les-Bains, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU Toulouse IUCT Institut Universitaire de Cancer de Toulouse, Toulouse, France|Hôpital Gustave Dron, Tourcoing, France|Centre Hospitalier Régional Universitaire de Tours, Tours, France|CHRU de Tours, Tours, France|CHU Nancy, Vandœuvre-lès-Nancy, France|Centre Hospitalier Intercommunal, Villeneuve Saint Georges, France|CH Annecy Genevois, Épagny, France",https://ClinicalTrials.gov/show/NCT04262921,France,,8.0,2023,Monday
4046,4047,Telemedicine for Follow-up of Systemic Lupus Erythematosus,Recruiting,Other: Telemedicine|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"May 1, 2020",2021-12-31,"July 15, 2020","The Chinese University of Hong Kong, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04368299,Hong Kong,,12.0,2021,Friday
4047,4048,Specimen Collection Study Protocol,"Active, not recruiting",,All,"21 Years and older   (Adult, Older Adult)",,40.0,"July 7, 2020",2020-09-30,"September 2, 2020","Biomerica, Inc., Irvine, California, United States",https://ClinicalTrials.gov/show/NCT04468386,United States,,9.0,2020,Wednesday
4048,4049,Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions,Not yet recruiting,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,980.0,"October 7, 2020",2023-12-30,"September 17, 2020","Hospital Universitario Mutua Terrassa (ICU), Terrassa, Barcelona, Spain|Hospital General La Mancha Centro (ICU), Alcazar de San Juan, Ciudad Real, Spain|Complejo Hospitalario Universitario de Santiago (Anesthesia), Santiago De Compostela, La Coruña, Spain|Hospital General El Bierzo (ICU), Ponferrada, León, Spain|Hospital Universitario del Henares (ICU), Coslada, Madrid, Spain|Hospital Universitario de Getafe (ICU), Getafe, Madrid, Spain|Hospital Universitario Puerta de Hierro (ICU), Majadahonda, Madrid, Spain|Hospital Nuestra Señora del Prado (ICU), Talavera De La Reina, Toledo, Spain|Hospital Universitario de Cruces (Anesthesia), Barakaldo, Vizcaya, Spain|Hospital Universitario de Cruces (ICU), Barakaldo, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete (ICU), Albacete, Spain|Hospital Clinic de Barcelona (AVI), Barcelona, Spain|Hospital Clinic de Barcelona (Cardiac ICU), Barcelona, Spain|Hospital Clínic (Hepatic ICU), Barcelona, Spain|Hospital Clínic de Barcelona (Anesthesia), Barcelona, Spain|Hospital General de Ciudad Real (ICU), Ciudad Real, Spain|Hospital Virgen de la Luz (ICU), Cuenca, Spain|Hospital Universitario de A Coruña (ICU), La Coruña, Spain|Complejo Asistencial Universitario de León (ICU), León, Spain|Hospital Universitario La Princesa (ICU), Madrid, Spain|Hospital Universitario Ramón y Cajal (Anesthesia), Madrid, Spain|Hospital Clínico Universitario San Carlos (ICU), Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz (ICU), Madrid, Spain|Hospital Universitario Doce de Octubre (ICU), Madrid, Spain|Hospital Universitario La Paz (Anesthesia), Madrid, Spain|Hospital Universitario La Paz (ICU), Madrid, Spain|Hospital Universitario Virgen de Arrixaca (Anesthesia), Murcia, Spain|Hospital Universitario Virgen de Arrixaca (ICU), Murcia, Spain|Hospital Universitario Regional de Malaga Carlos Haya (ICU), Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Montecelo (Anesthesia), Pontevedra, Spain|Hospital Universitario Nuestra Señora de Candelaria (ICU), Santa Cruz De Tenerife, Spain|Hospital General de Segovia (ICU), Segovia, Spain|Hospital Clinico Universitario de Valencia (Anesthesia), Valencia, Spain|Hospital Clinico Universitario de Valencia (ICU), Valencia, Spain|Hospital Clínico Universitario de Valladolid (Anesthesia), Valladolid, Spain|Hospital Universitario Río Hortega (Anesthesia), Valladolid, Spain|Hospital Universitario Río Hortega (ICU), Valladolid, Spain|Hospital Virgen de la Concha (ICU), Zamora, Spain|Hospital Universitario Severo Ochoa (ICU), Leganés, ´Madrid, Spain",https://ClinicalTrials.gov/show/NCT04545242,Spain,Dexamethasone,12.0,2023,Saturday
4049,4050,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Drug: Hydroxychloroquine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"April 6, 2020",2020-08-01,"May 27, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04328467,United States,Hydroxychloroquine,8.0,2020,Saturday
4050,4051,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,Recruiting,Drug: Niclosamide|Drug: Placebo,All,18 Years to 45 Years   (Adult),Phase 1,28.0,"November 2, 2020",2021-05-31,"November 25, 2020","Charité Research Organisation GmbH, Berlin, Germany",https://ClinicalTrials.gov/show/NCT04644705,Germany,Niclosamide|Placebo,5.0,2021,Monday
4051,4052,Virtual Parental Presence on Induction,Not yet recruiting,Other: Use of Facetime with child and parents during induction,All,4 Years to 12 Years   (Child),Not Applicable,184.0,October 2020,2022-12-01,"October 5, 2020","Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Hospital for Sick Children, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04574219,Canada,,12.0,2022,Thursday
4052,4053,Determining the Physical Activity Level of Healthy Adults During Pandemic,Completed,Other: surveys and questionnaires,All,"Child, Adult, Older Adult",,205.0,"April 11, 2020",2020-08-20,"September 21, 2020","Afyonkarahisar Health Science University, Afyonkarahisar, Turkey",https://ClinicalTrials.gov/show/NCT04555954,Turkey,,8.0,2020,Thursday
4053,4054,"Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress",Not yet recruiting,"Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.",All,18 Years to 55 Years   (Adult),,200.0,"March 25, 2020",2020-07-20,"March 24, 2020","Istanbul University Cerrahpasa, Istanbul, Turkey",https://ClinicalTrials.gov/show/NCT04319211,Turkey,,7.0,2020,Monday
4054,4055,Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Vent,Not yet recruiting,Device: Mechanical ventilation with the automated BVM compressor,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30.0,May 2020,2020-11-01,"April 30, 2020",,https://ClinicalTrials.gov/show/NCT04369274,Undefined,,11.0,2020,Sunday
4055,4056,Online Culture for Mental Health in People Aged 16-24,Not yet recruiting,Other: WofB|Other: Ashmolean Website,All,"16 Years to 24 Years   (Child, Adult)",Not Applicable,400.0,"December 4, 2020",2021-03-01,"December 11, 2020",,https://ClinicalTrials.gov/show/NCT04663594,Undefined,,3.0,2021,Monday
4056,4057,Project Resurgence Communication Trial,Completed,Other: Communication type,All,"Child, Adult, Older Adult",Not Applicable,11120.0,"June 15, 2020",2020-07-17,"July 31, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04418947,United States,,7.0,2020,Friday
4057,4058,TRACERx Renal CAPTURE Sub-study,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,360.0,"February 5, 2012",2023-09-01,"August 25, 2020","Edinburgh Western General Hospital, Edinburgh, Scotland, United Kingdom|Guy's & St Thomas Hospital, London, UK, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT03226886,United Kingdom,,9.0,2023,Friday
4058,4059,Point of Care Artificial Intelligence Tool for Heart Failure Diagnosis,Not yet recruiting,Diagnostic Test: ECG from handheld device,All,"18 Years and older   (Adult, Older Adult)",,1500.0,"February 1, 2021",2022-10-01,"October 23, 2020",,https://ClinicalTrials.gov/show/NCT04601415,Undefined,,10.0,2022,Saturday
4059,4060,Self-compassion for Chronic Pain Virtual Group Treatment Program,Recruiting,Behavioral: Self-Compassion for Chronic Pain Virtual Group Treatment Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28.0,"May 25, 2020",2021-03-31,"June 2, 2020","University of Manitoba, Winnipeg, Manitoba, Canada",https://ClinicalTrials.gov/show/NCT04413006,Canada,,3.0,2021,Wednesday
4060,4061,PH94B in the Treatment of Adjustment Disorder With Anxiety,Not yet recruiting,Drug: PH94B,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30.0,November 2020,2021-09-01,"May 27, 2020","The Medical Research Network, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04404192,United States,PH94B,9.0,2021,Wednesday
4061,4062,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Enrolling by invitation,Other: impliminting Online Distance Learning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"September 1, 2020",2021-02-28,"November 3, 2020","Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04372693,Egypt,,2.0,2021,Sunday
4062,4063,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228.0,"March 30, 2020",2021-12-31,"April 28, 2020","APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Pitié Salpêtrière, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",https://ClinicalTrials.gov/show/NCT04331808,France,Tocilizumab,12.0,2021,Friday
4063,4064,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Enrolling by invitation,Behavioral: Brief cognitive behavioral therapy|Behavioral: Crisis intervention therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,236.0,"June 30, 2020",2020-12-30,"July 2, 2020","Universidad Nacional Autónoma de Honduras, Tegucigalpa, Francisco Morazán, Honduras",https://ClinicalTrials.gov/show/NCT04394455,Honduras,,12.0,2020,Wednesday
4064,4065,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Active, not recruiting",Drug: Opaganib|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,40.0,"July 2, 2020",2020-12-01,"November 17, 2020","HonorHealth Research Institute, Scottsdale, Arizona, United States|Miami Cancer Institute, Miami, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Albany Medical Center, Albany, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Memorial Herman Southeast Hospital, Houston, Texas, United States|Memorial Hermann, Memorial City Medical Center, Houston, Texas, United States|Ziv Medical Center, Safed, Israel",https://ClinicalTrials.gov/show/NCT04414618,Israel,Opaganib|Placebo,12.0,2020,Tuesday
4065,4066,Evaluation of Six-month HIV Treatment Dispensing in South Africa,Not yet recruiting,Other: Six-month ARV dispensing,All,"18 Years and older   (Adult, Older Adult)",,150945.0,April 2021,2022-12-01,"December 2, 2020","Health Economics and Epidemiology Research Office, Johannesburg, Gauteng, South Africa",https://ClinicalTrials.gov/show/NCT04468789,South Africa,,12.0,2022,Thursday
4066,4067,Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,Completed,Drug: Ketotifen 1 MG,Female,30 Years to 60 Years   (Adult),,111.0,"January 14, 2019",2019-08-13,"June 17, 2020","Horus University, Damietta, Damiete Governonate, Egypt",https://ClinicalTrials.gov/show/NCT04435028,Egypt,Ketotifen 1 MG,8.0,2019,Tuesday
4067,4068,Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols?,Not yet recruiting,,All,"18 Years and older   (Adult, Older Adult)",,10084.0,"June 22, 2020",2020-07-13,"June 23, 2020",,https://ClinicalTrials.gov/show/NCT04444713,Undefined,,7.0,2020,Monday
4068,4069,International Lung UltraSound Analysis (ILUSA) Study,Recruiting,Diagnostic Test: standardized Lung Ultrasound (LUS) examination,Female,"Child, Adult, Older Adult",,1850.0,"April 28, 2020",2020-12-31,"May 7, 2020","University Hospitals Leuven, Leuven, Belgium|University of Brescia, Brescia, Italy|University of Foggia, Foggia, Italy|University of Milan, Milan, Italy|University of Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Queen Charlotte's & Chelsea Hospital, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04353141,Belgium,,12.0,2020,Thursday
4069,4070,A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy,Recruiting,Drug: Anakinra,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"October 30, 2019",2022-10-01,"November 17, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04148430,United States,Anakinra,10.0,2022,Saturday
4070,4071,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,Recruiting,Device: MakAir,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,117.0,"July 20, 2020",2020-12-01,"November 27, 2020","CHRU Brest, Brest, Finistère, France|CHU Nantes, Nantes, Loire-Atlantique, France",https://ClinicalTrials.gov/show/NCT04475185,France,,12.0,2020,Tuesday
4071,4072,Corona Virus Infection Among Liver Transplant Recipients,Recruiting,,All,"Child, Adult, Older Adult",,150.0,"September 15, 2020",2020-12-31,"September 25, 2020","Assiut University, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04565782,Egypt,,12.0,2020,Thursday
4072,4073,Brain Imaging in Babies Study,Recruiting,,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",,790.0,"April 5, 2013",2023-12-01,"June 24, 2020","King's College London, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04443179,United Kingdom,,12.0,2023,Friday
4073,4074,Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.,Recruiting,Diagnostic Test: Chest MRI,All,"18 Years and older   (Adult, Older Adult)",,115.0,"May 19, 2020",2021-12-20,"December 10, 2020","Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department, Moscow, Russian Federation",https://ClinicalTrials.gov/show/NCT04424355,Russian Federation,,12.0,2021,Monday
4074,4075,Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System,Not yet recruiting,Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM,All,"18 Years and older   (Adult, Older Adult)",,130.0,"June 1, 2020",2021-09-30,"April 20, 2020","Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04353245,Brazil,,9.0,2021,Thursday
4075,4076,OUR Stress/ Emotion Management for Black/African American Women With Hypertension,Not yet recruiting,Behavioral: Stress and emotion management,Female,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30.0,"September 14, 2020",2022-01-30,"August 25, 2020",,https://ClinicalTrials.gov/show/NCT04526145,Undefined,,1.0,2022,Sunday
4076,4077,Clinical Outcomes of Patients With COVID19,Withdrawn,Other: retrospective analysis,All,"Child, Adult, Older Adult",,0.0,"February 22, 2020",2020-03-31,"March 19, 2020","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04280913,China,,3.0,2020,Tuesday
4077,4078,Study Testing Convalescent Plasma vs Best Supportive Care,Not yet recruiting,Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,115.0,"April 1, 2020",2022-12-31,"April 6, 2020",,https://ClinicalTrials.gov/show/NCT04333251,Undefined,,12.0,2022,Saturday
4078,4079,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),Not yet recruiting,Drug: CUROSURF® (poractant alfa),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,85.0,"September 1, 2020",2020-11-30,"August 6, 2020",,https://ClinicalTrials.gov/show/NCT04502433,Undefined,CUROSURF® (poractant alfa),11.0,2020,Monday
4079,4080,Telerehabilitation in Oncology Patients,Enrolling by invitation,Other: Therapeutic Exercise and Education,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30.0,"July 1, 2020",2020-12-01,"September 14, 2020","Antonio Cuesta Vargas, Málaga, Spain",https://ClinicalTrials.gov/show/NCT04547634,Spain,,12.0,2020,Tuesday
4080,4081,Psychological Impact of the Health Measures Generated by the COVID19 in Adolescents,Recruiting,Other: Questionnaire,All,"11 Years to 18 Years   (Child, Adult)",,400.0,"May 27, 2020",2020-11-01,"May 28, 2020","Camille JUNG, Creteil, France",https://ClinicalTrials.gov/show/NCT04406558,France,,11.0,2020,Sunday
4081,4082,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Enrolling by invitation,Behavioral: Technology based social interactions|Other: No research related technology based social interactions,All,"Child, Adult, Older Adult",Not Applicable,150.0,"June 2, 2020",2021-05-01,"September 4, 2020","Boston University Alzheimer Disease Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04480112,United States,,5.0,2021,Saturday
4082,4083,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100.0,"May 28, 2020",2021-09-01,"July 1, 2020","Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom",https://ClinicalTrials.gov/show/NCT04453527,United Kingdom,,9.0,2021,Wednesday
4083,4084,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,Enrolling by invitation,Dietary Supplement: 300 mg of omega3-FA,All,"30 Years to 66 Years   (Adult, Older Adult)",Not Applicable,100.0,"October 2, 2020",2021-02-10,"December 8, 2020","Mahmoud S Abu-Samak, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04483271,Jordan,,2.0,2021,Wednesday
4084,4085,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"Active, not recruiting",Other: DIG Axial|Other: DIG Tilted|Other: CIG Axial|Other: CIG Tilted,All,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,56.0,"July 11, 2018",2020-08-01,"July 17, 2020","OctoberUMSA, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04475913,Egypt,,8.0,2020,Saturday
4085,4086,Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial,"Active, not recruiting",Other: Virtual Care and Remote Automated Monitoring,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,905.0,"April 23, 2020",2021-01-01,"November 23, 2020","University of Alberta Hospital, Edmonton, Alberta, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Hamilton General Hospital, Hamilton, Canada|Juravinski Hospital, Hamilton, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Kingston Health Sciences Centre, Kingston, Canada|London Health Sciences Centre, London, Canada",https://ClinicalTrials.gov/show/NCT04344665,Canada,,1.0,2021,Friday
4086,4087,Tele-Yoga Therapy for Chronic Pain,Completed,Other: Tele-Yoga Therapy,All,18 Years to 60 Years   (Adult),Not Applicable,18.0,"March 25, 2020",2020-06-15,"July 8, 2020","Aarogyam UK, Leicester, Leicestershire, United Kingdom",https://ClinicalTrials.gov/show/NCT04457388,United Kingdom,,6.0,2020,Monday
4087,4088,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,"Active, not recruiting",Behavioral: Video Chat +Personalized Feedback|Behavioral: Video Chat + Basic Feedback|Behavioral: Discussion Board for Social Support +Basic Feedback|Behavioral: Discussion Board for Social Support+Personalized Feedback,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"September 23, 2020",2021-09-15,"October 22, 2020","University of South Carolina, Columbia, South Carolina, United States",https://ClinicalTrials.gov/show/NCT04514900,United States,,9.0,2021,Wednesday
4088,4089,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults,Recruiting,Drug: Icosapent ethyl,All,"50 Years and older   (Adult, Older Adult)",Phase 4,16500.0,"August 7, 2020",2023-02-28,"October 5, 2020","Kaiser Permanente Northern California, Oakland, California, United States",https://ClinicalTrials.gov/show/NCT04505098,United States,Icosapent ethyl,2.0,2023,Tuesday
4089,4090,Mobile Mental Health Apps for Suicide Prevention,Not yet recruiting,Behavioral: Mobile Mental Health App - 1|Behavioral: Mobile Mental Health App - 2|Behavioral: Mobile Mental Health App - 3|Behavioral: Mobile Mental Health App - 4|Behavioral: Mobile Mental Health App - 5|Behavioral: Mobile Mental Health App - 6|Behavioral: Mobile Mental Health App - 7|Behavioral: Mobile Mental Health App - 8|Behavioral: Mobile Mental Health App - 9|Behavioral: Mobile Mental Health App - 10,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,September 2020,2020-12-01,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04536935,Undefined,,12.0,2020,Tuesday
4090,4091,Feasibility and Quality of TeleConsultation in Pediatric Anesthesia,"Active, not recruiting",Other: teleconsultation,All,"1 Month to 18 Years   (Child, Adult)",,400.0,"October 7, 2020",2022-03-14,"October 12, 2020","UHToulouse, Toulouse, France",https://ClinicalTrials.gov/show/NCT04583865,France,,3.0,2022,Monday
4091,4092,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,Other: Digital cardiac Counseling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,394.0,"June 5, 2020",2022-12-31,"June 9, 2020","Maastricht University Medical Center, Maastricht, Netherlands",https://ClinicalTrials.gov/show/NCT04393636,Netherlands,,12.0,2022,Saturday
4092,4093,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Recruiting,Behavioral: Mindfulness,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50.0,"March 15, 2020",2021-12-01,"May 18, 2020","UOC Neurologia 3, Milano, Italy",https://ClinicalTrials.gov/show/NCT04389372,Italy,,12.0,2021,Wednesday
4093,4094,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Recruiting,Behavioral: Mindfulness,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,25.0,"September 15, 2020",2021-12-01,"October 27, 2020","Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit, Milano, Italy",https://ClinicalTrials.gov/show/NCT04604977,Italy,,12.0,2021,Wednesday
4094,4095,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,Completed,Behavioral: brief mindfulness based intervention|Behavioral: Progressive muscle relaxation,All,"22 Years and older   (Adult, Older Adult)",Not Applicable,146.0,"July 7, 2020",2020-09-05,"December 10, 2020","Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04656626,Saudi Arabia,,9.0,2020,Saturday
4095,4096,DigiVis: Self-testing Vision App for Telephone Consultations,Not yet recruiting,Device: DigiVis visual acuity app,All,"5 Years to 85 Years   (Child, Adult, Older Adult)",Not Applicable,250.0,"July 24, 2020",2021-01-01,"July 22, 2020","Cambridge University Hospitals NHS Trust, Cambridge, Cambs, United Kingdom",https://ClinicalTrials.gov/show/NCT04482387,United Kingdom,,1.0,2021,Friday
4096,4097,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,Behavioral: Lifestyle change promotion program|Behavioral: Mindfullness based cognitive program|Behavioral: Written Information,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,186.0,"January 13, 2020",2022-07-12,"June 11, 2020","Universitat Illes Balears, Palma de Mallorca, Illes Balears, Spain",https://ClinicalTrials.gov/show/NCT04428099,Spain,,7.0,2022,Tuesday
4097,4098,Prednisolone in Early Diffuse Systemic Sclerosis,Recruiting,Drug: Prednisolone 5 mg|Drug: Placebo oral capsule; From August 2020 'no additional treatment',All,"18 Years and older   (Adult, Older Adult)",Phase 2,72.0,"December 21, 2017",2021-09-01,"November 6, 2020","Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, Aberdeenshire, United Kingdom|Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom|Glasgow Royal Infirmary -, Glasgow, Lanarkshire, United Kingdom|Aintree University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Royal National Hospital For Rheumatic Diseases - Royal United Hospitals Bath NHS Foundation Trust, Bath, Somerset, United Kingdom|Royal Hallamshire Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom|Freeman Hospital - The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom|Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, United Kingdom|Southmead Hospital Bristol - North Bristol NHS Trust, Bristol, United Kingdom|Ninewells Hospital and Medical School - NHS Tayside, Dundee, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT03708718,United Kingdom,Prednisolone 5 mg|Placebo oral capsule; From August 2020 'no additional treatment',9.0,2021,Wednesday
4098,4099,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,Enrolling by invitation,Other: Aerobic Exercises,Female,18 Years to 25 Years   (Adult),Not Applicable,40.0,"December 10, 2020",2021-02-25,"December 10, 2020","Marwa Eid, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04662021,Egypt,,2.0,2021,Thursday
4099,4100,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"Active, not recruiting",Combination Product: Insulin film|Device: Fast dissolving film,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,40.0,"December 1, 2020",2021-01-15,"December 9, 2020","Soad, Minya, Egypt",https://ClinicalTrials.gov/show/NCT04657809,Egypt,,1.0,2021,Friday
4100,4101,Effectiveness of Basic Body Awareness Therapy in Post-traumatic Stress Disorders: A Randomized Clinical Trial,Not yet recruiting,Behavioral: Basic Body Awareness Therapy|Behavioral: Psychological treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,54.0,"January 1, 2021",2021-09-30,"November 24, 2020",,https://ClinicalTrials.gov/show/NCT04396314,Undefined,,9.0,2021,Thursday
4101,4102,The Effect of Clear Masks in Improving Patient Relationships,Recruiting,Behavioral: Transparent mask|Behavioral: Typical surgical covered mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 3, 2020",2020-12-01,"October 20, 2020","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04595695,United States,,12.0,2020,Tuesday
4102,4103,A Smartphone Intervention for Relational and Mental Well Being,Completed,Behavioral: Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1765.0,"April 4, 2020",2020-08-03,"November 19, 2020","University of Washington, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04629755,United States,,8.0,2020,Monday
4103,4104,Intracorporeal Anastomosis in Laparoscopic Left Colectomy. Cohort Comparative Study,Recruiting,Procedure: Extracorporeal left hemicolectomy anastomosis|Procedure: Intracorporeal left hemicolectomy anastomosis,All,"18 Years and older   (Adult, Older Adult)",,148.0,"June 29, 2020",2022-02-28,"July 17, 2020","Hospital Universitario Parc Tauli de Sabadel, Sabadell, Barceelona, Spain",https://ClinicalTrials.gov/show/NCT04456933,Spain,,2.0,2022,Monday
4104,4105,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Recruiting,Other: Phone call,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130.0,"June 12, 2020",2021-10-12,"July 14, 2020","University Hospital Toulouse, Toulouse, Occitanie, France",https://ClinicalTrials.gov/show/NCT04470869,France,,10.0,2021,Tuesday
4105,4106,Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids,Not yet recruiting,Other: Storage of operating waste,All,"Child, Adult, Older Adult",,40.0,December 2020,2021-09-01,"November 23, 2020","Hôpital Mondor, Créteil, France|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Lariboisière, Paris, France|Hôpital Armand Trousseau, Paris, France|Hôpital Pitié Salpêtrière, Paris, France|HEGP, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Bichat, Paris, France|Hôpital Tenon, Paris, France",https://ClinicalTrials.gov/show/NCT04640610,France,,9.0,2021,Wednesday
4106,4107,Proper Nutrition And Its Relation To Oral Diseases In Covid -19 Era,Recruiting,Dietary Supplement: proper diet,All,20 Years to 60 Years   (Adult),,300.0,"June 8, 2020",2020-06-28,"June 16, 2020","October university of modern sciences and arts, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04434014,Egypt,,6.0,2020,Sunday
4107,4108,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old),Recruiting,Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,"August 19, 2020",2021-12-31,"September 16, 2020","Hunan Provincial Center for Disease Control and Prevention, Xiangtan, Changsha, China",https://ClinicalTrials.gov/show/NCT04550351,China,,12.0,2021,Friday
4108,4109,"A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults",Withdrawn,Drug: TAK-671|Drug: TAK-671 Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,0.0,"September 25, 2020",2020-10-30,"October 8, 2020",,https://ClinicalTrials.gov/show/NCT04464460,Undefined,TAK-671|TAK-671 Placebo,10.0,2020,Friday
4109,4110,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Recruiting,Drug: Sodium bicarbonate|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"October 5, 2020",2021-03-01,"October 19, 2020","WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States",https://ClinicalTrials.gov/show/NCT04530448,United States,Sodium bicarbonate,3.0,2021,Monday
4110,4111,Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,Recruiting,Drug: Methylprednisolone|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"December 2, 2019",2022-07-01,"April 22, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT03852537,United States,Methylprednisolone,7.0,2022,Friday
4111,4112,The Effectiveness of Telerehabilitation-Based Exercises in Elderly People,Not yet recruiting,Other: Telerehabilitation|Other: Exercise brochure,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"August 10, 2020",2020-11-30,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04346940,Undefined,,11.0,2020,Monday
4112,4113,Telerehabilitation in Lung Surgery Patients,Recruiting,"Other: Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|Other: Exercise booklet",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"October 1, 2020",2021-05-01,"October 1, 2020","Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine Thoracic Surgery Clinic, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04568564,Turkey,,5.0,2021,Saturday
4113,4114,Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress,Recruiting,Device: faecal sample collector,All,18 Years to 50 Years   (Adult),,180.0,"June 24, 2020",2020-08-30,"August 4, 2020","First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT04443075,China,,8.0,2020,Sunday
4114,4115,Lockdown Impact on Spontaneous Premature Birth in a Level III NICU,Not yet recruiting,Other: hospitalization for premature birth,All,up to 28 Days   (Child),,1000.0,November 2020,2021-05-01,"October 27, 2020",,https://ClinicalTrials.gov/show/NCT04605172,Undefined,,5.0,2021,Saturday
4115,4116,Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections,Recruiting,Diagnostic Test: Thrombin Generation Assay (TGA)|Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM),All,"18 Years and older   (Adult, Older Adult)",,60.0,"April 15, 2020",2020-12-01,"May 5, 2020","Medical University Vienna, Vienna, Austria",https://ClinicalTrials.gov/show/NCT04356144,Austria,,12.0,2020,Tuesday
4116,4117,First Level Socio-geriatric Evaluation: ESOGER Databank,Recruiting,Other: ESOGER,All,70 Years and older   (Older Adult),,20000.0,"April 20, 2020",2021-04-19,"May 20, 2020","Jewish General Hospital, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04393649,Canada,,4.0,2021,Monday
4117,4118,Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis,"Active, not recruiting",Device: TAVR or SAVR,All,"18 Years and older   (Adult, Older Adult)",,71.0,"March 20, 2020",2020-12-01,"May 4, 2020","Department of Cardiology, Bern University Hospital, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04333875,Switzerland,,12.0,2020,Tuesday
4118,4119,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Drug: Hydroxychloroquine Sulfate,All,"18 Years and older   (Adult, Older Adult)",Phase 4,53.0,"March 25, 2020",2025-03-03,"June 5, 2020","Akershus University Hospital, Lørenskog, Norway",https://ClinicalTrials.gov/show/NCT04316377,Norway,Hydroxychloroquine Sulfate,3.0,2025,Monday
4119,4120,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B,All,"18 Years and older   (Adult, Older Adult)",Phase 2,127.0,"February 10, 2020",2020-03-31,"April 15, 2020","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04276688,Hong Kong,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,3.0,2020,Tuesday
4120,4121,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Not yet recruiting,Drug: Botulinum Neurotoxin|Drug: Placebo,All,"10 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1,45.0,"July 15, 2020",2020-10-15,"July 22, 2020","DeNova Research, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04439825,United States,Botulinum Neurotoxin|Placebo,10.0,2020,Thursday
4121,4122,Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,100000.0,"November 4, 2020",2021-12-08,"December 11, 2020","Boston Children's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04663776,United States,,12.0,2021,Wednesday
4122,4123,Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation,Not yet recruiting,Drug: Propranolol Hydrochloride,All,"19 Years and older   (Adult, Older Adult)",Phase 3,108.0,December 2020,2021-03-01,"November 13, 2020",,https://ClinicalTrials.gov/show/NCT04467086,Undefined,Propranolol Hydrochloride,3.0,2021,Monday
4123,4124,Virtual White Boards for Patient Satisfaction,Not yet recruiting,Device: e-ink screen|Behavioral: Treatment as usual,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"August 20, 2020",2021-04-17,"August 5, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04497922,United States,,4.0,2021,Saturday
4124,4125,Global Mental Health of Urban Mothers,Not yet recruiting,Behavioral: Web-based psychosocial peer-to-peer support,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"November 1, 2020",2023-06-01,"October 26, 2020","Shanghai Women's and Children's Health Center, Shanghai, Shanghai, China|Chinese University Hong Kong, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04363177,China,,6.0,2023,Thursday
4125,4126,Lessening Organ Dysfunction With VITamin C,Recruiting,Drug: Vitamin C|Other: Control,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,"November 8, 2018",2022-12-31,"April 10, 2020","Research Center of the CHUS, Sherbrooke, Quebec, Canada",https://ClinicalTrials.gov/show/NCT03680274,Canada,Vitamin C,12.0,2022,Saturday
4126,4127,Inhaled NO for the Treatment of Viral Pneumonia in Adults,Recruiting,Device: LungFit™,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,90.0,"November 25, 2020",2021-09-07,"December 3, 2020","Shaare Zedek Medical Center, Jerusalem, Israel",https://ClinicalTrials.gov/show/NCT04606407,Israel,,9.0,2021,Tuesday
4127,4128,Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of Medical University of Warsaw,Recruiting,Other: Vacciantion status in health care workers,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"September 1, 2020",2022-07-01,"September 29, 2020","Warsaw Medical Uniwerity, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04569019,Poland,,7.0,2022,Friday
4128,4129,"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",Recruiting,Drug: Drug: NA-831 - 0.10 mg/kg|Drug: Placebo- 0.10 mg/kg|Drug: Drug: NA-831 - 0.20 mg/kg|Drug: Placebo- 0.20 mg/kg|Drug: Drug: GS-5734 - 1.00 mg/kg|Drug: Placebo- 1.00 mg/kg|Drug: Drug: GS-5734 - 2.00 mg/kg|Drug: Placebo- 2.00 mg/kg|Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|Combination Product: Placebo 0.10 mg + 1.00 mg/kg|Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|Combination Product: Placebo 0.20 mg + 2.00 mg/kg,All,21 Years to 50 Years   (Adult),Phase 1,45.0,"September 15, 2020",2021-03-31,"July 21, 2020","Coronavirus Research Institute, Sunnyvale, California, United States",https://ClinicalTrials.gov/show/NCT04480333,United States,Drug: NA-831 - 0.10 mg/kg|Placebo- 0.10 mg/kg|Drug: NA-831 - 0.20 mg/kg|Placebo- 0.20 mg/kg|Drug: GS-5734 - 1.00 mg/kg|Placebo- 1.00 mg/kg|Drug: GS-5734 - 2.00 mg/kg|Placebo- 2.00 mg/kg,3.0,2021,Wednesday
4129,4130,Advance Care Planning: Communicating With Outpatients for Vital Informed Decision,Recruiting,Other: VitalTalk communication skills training|Other: ACP Decisions Video Program|Other: Intervention training:|Other: Medical Record Review,All,65 Years and older   (Older Adult),,13150.0,February 2021,2021-04-30,"December 9, 2020","Northwell Health, New Hyde Park, New York, United States",https://ClinicalTrials.gov/show/NCT04660422,United States,,4.0,2021,Friday
4130,4131,Universal Anti-Viral Vaccine for Healthy Elderly Adults,Not yet recruiting,Drug: AlloStim,All,65 Years and older   (Older Adult),Phase 1|Phase 2,40.0,"January 6, 2021",2021-12-31,"November 20, 2020","Medical Oncology and Hematology, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04441047,United States,AlloStim,12.0,2021,Friday
4131,4132,The Effectiveness of Video-Based Exercises in Young Adults,Not yet recruiting,Other: Study Group,All,18 Years to 40 Years   (Adult),Not Applicable,128.0,"August 20, 2020",2020-11-20,"July 22, 2020",,https://ClinicalTrials.gov/show/NCT04346966,Undefined,,11.0,2020,Friday
4132,4133,Audio Data Collection for Identification and Classification of Coughing,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1000.0,"March 25, 2020",2022-09-25,"March 30, 2020","Virtual Facility, Bronx, New York, United States",https://ClinicalTrials.gov/show/NCT04326309,United States,,9.0,2022,Sunday
4133,4134,Characteristics of TraceTogether Users,"Active, not recruiting",Behavioral: Use of mobile application,All,"21 Years and older   (Adult, Older Adult)",,500.0,"March 8, 2020",2020-07-31,"July 13, 2020","Yale NUS, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04468581,Singapore,,7.0,2020,Friday
4134,4135,Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device,Not yet recruiting,Device: Sensbiosys,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"May 1, 2020",2020-06-01,"May 8, 2020","University and hospital Fribourg, Fribourg, Switzerland",https://ClinicalTrials.gov/show/NCT04379986,Switzerland,,6.0,2020,Monday
4135,4136,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,1200.0,"December 16, 2020",2024-12-31,"December 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04573062,United States,,12.0,2024,Tuesday
4136,4137,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Enrolling by invitation,Other: Questionnaire,,"Child, Adult, Older Adult",,1500.0,"March 22, 2020",2021-03-21,"May 20, 2020","University Hospital Southampton NHS FT, Southampton, Hampshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04382508,United Kingdom,,3.0,2021,Sunday
4137,4138,PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock,Recruiting,"Other: Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"March 15, 2019",2024-03-15,"November 25, 2020","Cliniques Universitaires St Luc, Bruxelles, Belgium",https://ClinicalTrials.gov/show/NCT04107402,Belgium,,3.0,2024,Friday
4138,4139,SELF-BREATHE RCT for Chronic Breathlessness,Not yet recruiting,Other: SELF-BREATHE,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"December 3, 2020",2022-06-30,"October 5, 2020",,https://ClinicalTrials.gov/show/NCT04574050,Undefined,,6.0,2022,Thursday
4139,4140,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,Drug: Pioglitazone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10.0,"May 21, 2020",2020-12-01,"December 4, 2020","Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States",https://ClinicalTrials.gov/show/NCT04473274,United States,Pioglitazone,12.0,2020,Tuesday
4140,4141,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",Recruiting,"Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",All,"up to 20 Years   (Child, Adult)",,5000.0,"March 5, 2020",2024-04-24,"October 14, 2020","Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|University of California, Los Angeles, California, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas-Southwestern Medical Center, Dallas, Texas, United States|University of Texas--Memorial Hermann Texas Medical Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04278404,Canada,"The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",4.0,2024,Wednesday
4141,4142,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Drug: Hydroxychloroquine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1309.0,"March 17, 2020",2020-05-20,"July 17, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04308668,Canada,Hydroxychloroquine,5.0,2020,Wednesday
4142,4143,Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study,Recruiting,"Other: Primary care professionals reports of potential patient safety incidents, non-COVID-19 related",All,"Child, Adult, Older Adult",,1000.0,"April 28, 2020",2020-06-28,"June 29, 2020","University Hospital, Nantes, France",https://ClinicalTrials.gov/show/NCT04348552,France,,6.0,2020,Sunday
4143,4144,Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis,Completed,"Other: GPs reports of potential patient safety incidents, non-COVID-19 related",All,"Child, Adult, Older Adult",,132.0,"April 28, 2020",2020-06-29,"October 19, 2020","University Hospital, Nantes, France",https://ClinicalTrials.gov/show/NCT04346121,France,,6.0,2020,Monday
4144,4145,Coronavirus Smell Therapy for Anosmia Recovery,Not yet recruiting,Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,200.0,"June 1, 2021",2023-12-31,"June 11, 2020","Washington University, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04422275,United States,Budesonide|Placebo,12.0,2023,Sunday
4145,4146,Acceptance and Commitment Therapy Delivered by Automated Software Messaging,Completed,Behavioral: Software Messaging,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"April 5, 2020",2020-06-01,"July 16, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",https://ClinicalTrials.gov/show/NCT04329897,United States,,6.0,2020,Monday
4146,4147,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Not yet recruiting,Other: revised HOME-CoV score,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1300.0,"December 8, 2020",2021-06-08,"December 10, 2020",,https://ClinicalTrials.gov/show/NCT04657471,Undefined,,6.0,2021,Tuesday
4147,4148,Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness,Recruiting,Behavioral: Mindfulness Alone (MO) Intervention|Behavioral: Mindfulness + Compassion Intervention (MC),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120.0,"May 25, 2020",2021-05-01,"June 4, 2020","Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04414826,United States,,5.0,2021,Saturday
4148,4149,Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions,Completed,Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT,Male,18 Years to 40 Years   (Adult),Phase 1,30.0,"June 5, 2020",2020-06-13,"November 30, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey",https://ClinicalTrials.gov/show/NCT04444986,Turkey,FAVIR 200 MG FT|AVIGAN 200 mg FT,6.0,2020,Saturday
4149,4150,Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions,Completed,Device: The standard Macintosh laryngoscope|Device: The Vie Scope laryngoscope,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35.0,"January 20, 2020",2020-02-25,"April 28, 2020","Lazarski Univeristy, Warsaw, Poland",https://ClinicalTrials.gov/show/NCT04363775,Poland,,2.0,2020,Tuesday
4150,4151,Care in Patients Hospitalized for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic (QUALICOVID),Not yet recruiting,,All,"Child, Adult, Older Adult",,18.0,"May 14, 2020",2020-06-08,"May 14, 2020",,https://ClinicalTrials.gov/show/NCT04387708,Undefined,,6.0,2020,Monday
4151,4152,SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry,Recruiting,Other: Clinical Trial Matching,All,"Child, Adult, Older Adult",,1500.0,"January 1, 2018",2022-12-01,"April 28, 2020","Massive Bio, Inc, New York, New York, United States",https://ClinicalTrials.gov/show/NCT03452774,United States,,12.0,2022,Thursday
4152,4153,Healthy Lifestyle or Pro-health Obsession During the Pandemic,Recruiting,,All,"18 Years and older   (Adult, Older Adult)",,50000.0,"June 19, 2020",2021-06-30,"September 17, 2020","Gdansk University of Physical Education and Sport, Gdańsk, Poland",https://ClinicalTrials.gov/show/NCT04432038,Poland,,6.0,2021,Wednesday
4153,4154,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,Recruiting,Behavioral: Intervention group CoronaCope,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"June 10, 2020",2021-08-01,"June 11, 2020","Linköping University, Linköping, Östergötland, Sweden",https://ClinicalTrials.gov/show/NCT04424212,Sweden,,8.0,2021,Sunday
4154,4155,Telehealth Intervention Program for Older Adults,Not yet recruiting,Behavioral: Telehealth phone calls|Other: Volunteer of TIP-OA Program|Other: Stakeholder of TIP-OA Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,258.0,October 2020,2022-10-01,"September 3, 2020",,https://ClinicalTrials.gov/show/NCT04523610,Undefined,,10.0,2022,Saturday
4155,4156,Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation,Not yet recruiting,Other: Telerehabilitation-Based|Other: Video-Based,Female,"45 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50.0,"August 1, 2020",2020-11-01,"July 21, 2020",,https://ClinicalTrials.gov/show/NCT04346979,Undefined,,11.0,2020,Sunday
4156,4157,Responsible Gambling Telephone Intervention to High-risk Gamblers by a State-owned Gambling Operator in Sweden.,Recruiting,Behavioral: Motivational telephone intervention,All,"18 Years and older   (Adult, Older Adult)",,3626.0,"November 30, 2020",2021-11-30,"November 30, 2020","Lund University, Lund, Sweden",https://ClinicalTrials.gov/show/NCT04646421,Sweden,,11.0,2021,Tuesday
4157,4158,Using Telemedicine to Optimize Teamwork and Infection Control of Critical and Highly-infectious Patients in an Emergency Department,Not yet recruiting,Other: telemedicine|Other: traditional communication tools,All,"20 Years to 99 Years   (Adult, Older Adult)",,100.0,"October 10, 2020",2021-10-30,"October 19, 2020","National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04591873,Undefined,,10.0,2021,Saturday
4158,4159,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions","Active, not recruiting",Drug: AVICOD 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets,Male,18 Years to 55 Years   (Adult),Phase 1,30.0,"November 13, 2020",2020-12-20,"December 3, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04651959,Turkey,AVICOD 200 MG Film Tablet|AVIGAN 200 MG Film Tablets,12.0,2020,Sunday
4159,4160,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Completed,Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets,Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"May 14, 2020",2020-06-19,"August 14, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",https://ClinicalTrials.gov/show/NCT04406194,Turkey,FAVICOVIR 200 mg Film Tablet|AVIGAN 200 mg Film Tablets,6.0,2020,Friday
4160,4161,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Completed,Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets,Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"May 28, 2020",2020-06-18,"August 11, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",https://ClinicalTrials.gov/show/NCT04400682,Turkey,FAVIRA 200 MG Film Tablet|AVIGAN 200 MG Film Tablets,6.0,2020,Thursday
4161,4162,The Cognitive and spOrt Virtual EPIC Training Study for Cardiovascular Diseases,Recruiting,Behavioral: Physical exercise training|Behavioral: Cognitive training,All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,118.0,"May 18, 2020",2022-12-01,"December 10, 2020","Preventive medicine and physical activity centre (centre EPIC), Montreal Heart Institute, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04661189,Canada,,12.0,2022,Thursday
4162,4163,Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients,Recruiting,Procedure: Fiberoptic Bronchoscopy (FOB)|Procedure: Bronchoalveolar Lavage (BAL)|Diagnostic Test: Electrical Impedance Tomography (EIT)|Diagnostic Test: Arterial Blood Gas test (ABG),All,"18 Years and older   (Adult, Older Adult)",,15.0,"August 6, 2020",2020-09-30,"August 10, 2020","Erasme University Hospital - Intensive Care Unit, Brussels, Belgium",https://ClinicalTrials.gov/show/NCT04502368,Belgium,,9.0,2020,Wednesday
4163,4164,Careful Ventilation in Acute Respiratory Distress Syndrome,Not yet recruiting,Other: Respiratory Mechanics|Other: Standard Ventilation Strategy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,740.0,November 2020,2022-11-01,"November 2, 2020",,https://ClinicalTrials.gov/show/NCT03963622,Undefined,,11.0,2022,Tuesday
4164,4165,Eating Habits of Adults During the Quarantine,Completed,Other: Assessment of Dietary Changes in Adults in the Quarantine,All,"18 Years to 80 Years   (Adult, Older Adult)",,673.0,"April 10, 2020",2020-05-31,"July 22, 2020","Online, Nicosia, Cyprus",https://ClinicalTrials.gov/show/NCT04339842,Cyprus,,5.0,2020,Sunday
4165,4166,"The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions","Active, not recruiting",Drug: ATAFENOVIR 200 MG KAPSUL|Drug: ARBIDOL 100 MG KAPSUL,Male,20 Years to 40 Years   (Adult),Phase 1,18.0,"July 9, 2020",2020-08-20,"July 20, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",https://ClinicalTrials.gov/show/NCT04476719,Turkey,ATAFENOVIR 200 MG KAPSUL|ARBIDOL 100 MG KAPSUL,8.0,2020,Thursday
4166,4167,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions",Completed,Drug: Test: Favipiravir 200 mg (LOQULAR)|Drug: Reference: Favipiravir 200 mg (Avigan),Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"June 23, 2020",2020-08-08,"August 11, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",https://ClinicalTrials.gov/show/NCT04407000,Turkey,Test: Favipiravir 200 mg (LOQULAR)|Reference: Favipiravir 200 mg (Avigan),8.0,2020,Saturday
4167,4168,Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes,Recruiting,Behavioral: Mindfulness Based Intervention,All,"21 Years and older   (Adult, Older Adult)",,1000.0,"September 20, 2019",2022-06-30,"June 9, 2020","National University Singapore, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04417153,Singapore,,6.0,2022,Thursday
4168,4169,The VISION-Acute Study,Not yet recruiting,Device: Lifelight® Data Collect Blood Pressure Group|Device: Lifelight® Data Collect Oxygen Saturation Group,All,"18 Years and older   (Adult, Older Adult)",,200.0,October 2020,2021-01-01,"October 19, 2020","Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom",https://ClinicalTrials.gov/show/NCT04589923,United Kingdom,,1.0,2021,Friday
4169,4170,Azithromycin-Prevention in Labor Use Study (A-PLUS),Recruiting,Drug: Azithromycin|Drug: Placebo,Female,18 Years to 45 Years   (Adult),Phase 3,34000.0,"September 1, 2020",2023-09-01,"September 16, 2020","ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belagavi, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia",https://ClinicalTrials.gov/show/NCT03871491,Bangladesh,Azithromycin|Placebo,9.0,2023,Friday
4170,4171,"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions","Active, not recruiting",Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Test|Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Reference,Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"April 30, 2020",2020-06-20,"May 15, 2020","Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey",https://ClinicalTrials.gov/show/NCT04386876,Turkey,Lopinavir 200Mg/Ritonavir 50Mg FT Test|Lopinavir 200Mg/Ritonavir 50Mg FT Reference,6.0,2020,Saturday
4171,4172,Virtual Simulation for Woven EndoBridge Device Sizing,Completed,Device: WEB embolization,All,"18 Years and older   (Adult, Older Adult)",,186.0,"January 1, 2015",2020-10-30,"November 10, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04621552,France,,10.0,2020,Friday
4172,4173,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Completed,Biological: MSCs-derived exosomes,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,24.0,"February 15, 2020",2020-07-31,"September 7, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04276987,China,,7.0,2020,Friday
4173,4174,Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients,Recruiting,Drug: Crizanlizumab,All,6 Months to 17 Years   (Child),Phase 2,100.0,"October 1, 2018",2024-11-20,"December 7, 2020","University of Alabama 1600 7th ave, Birmingham, Alabama, United States|Phoenix Childrens Hospital CVAL489A2302, Phoenix, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|Children s National Hospital, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States|Childrens Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H Lurie Childrens Hospital of Chicago CTBM100C2407, Chicago, Illinois, United States|University of Chicago Hospital, Chicago, Illinois, United States|Childrens Hospital Boston, Boston, Massachusetts, United States|Institute for Pediatric Cancer and Blood Disorders, Hackensack, New Jersey, United States|UMDNJ, New Brunswick, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Duke University Medical Center Oncology, Durham, North Carolina, United States|East Carolina University SC, Greenville, North Carolina, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Medical Uni of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hosptial, Memphis, Tennessee, United States|Cook Childrens Medical Center Oncology, Fort Worth, Texas, United States|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Laeken, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Heidelberg, Baden Wuerttemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Vellore, India|Novartis Investigative Site, Modena, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Padova, Italy|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Aarau, Aargau, Switzerland|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",https://ClinicalTrials.gov/show/NCT03474965,Belgium,Crizanlizumab,11.0,2024,Wednesday
